(54) Title: RECEPTOR FINGERPRINTING, SENSORY PERCEPTION, AND BIOSENSORS OF CHEMICAL SENSANTS

(57) Abstract: The use of sensory G protein-coupled receptors that recognize chemical sensants, particularly those involving olfactory and taste receptors; polypeptide fragments and mutants thereof; classes of such receptors; polynucleotides encoding such receptors, fragments and mutants thereof, and representatives of receptor classes; genetic vectors including such polynucleotides; and cells and non-human organisms engineered to express such receptor complexes, fragments and mutants of an olfactory or taste receptor, and representatives of receptor classes to simulate sensory perception of odorants and tastants is described. The use of such products as a biosensor or a components thereof to detect, identify, measure, or otherwise process the event of binding between the receptor and its cognate ligand (i.e., chemical sensant) is also described. The invention has application, for example, in the design and formulation of odorant and tastant compositions.

RECEPTOR FINGERPRINTING, SENSORY PERCEPTION, AND BIOSENSORS OF CHEMICAL SENSANTS

Cross Reference to Related Application

This application is related to U.S. Provisional Serial No. 60/213,812, filed June 22, 2000, and U.S. Serial No. 09/804,291, filed March 13, 2001, which are incorporated by reference in their entirety.

Background of the Invention

Field of the Invention

The invention relates to the use of sensory G protein-coupled receptor complexes that recognize chemical sensants, particularly those involving olfactory and taste receptors; polypep-tide fragments and mutants thereof; classes of such receptors; polynucleotides encoding such receptors, fragments and mutants thereof, and representatives of receptor classes; genetic vectors including such polynucleotides; and cells and non-human organisms engineered to express such receptor complexes, fragments and mutants of an olfactory or taste receptor, and representatives of receptor classes to simulate sensory perception of odorants and tastants. The invention also relates to the use of such products as a biosensor or component thereof to detect, to identify, to measure, or otherwise process the event of binding between the receptor and its cognate ligand (*i.e.*, chemical sensant). The invention has application, for example, in the design and formu-lation of odorant and tastant compositions.

Description of the Related Art

The olfactory and taste systems provide sensory information about the chemical environ-ment. Olfactory receptors and taste receptors recognize, respectively, "odorants" and "tastants," collectively referred to as "sensants" or "sensory receptor ligands" herein. A "primary" sensant is an odorant or tastant ligand that substantially binds to sensory receptors with a ligand-binding site of a single amino acid sequence. Olfactory and taste receptors belong to the superfamily of seven-transmembrane guanyl nucleotide-binding proteins: such receptors are, however, also recognized as distinct families, or sub-genuses, of olfactory or taste

receptors (see Raming *Nature* 361:353, 1993). These receptors control diverse physiological functions such as media-ting signaling from an external chemical stimulus across the membrane containing the receptor into a cell, endocrine function, exocrine function, heart rate, lipolysis, and carbohydrate metabolism. Thus, the

5   dissection of these diverse functions into component signals is needed.

But the complexities of sensory perception of chemical sensants prevent easy translation of the olfaction and taste systems to a machine sensor. For example, U.S. Patent Nos. 5,675,070; 5,918,257; 5,928,609; and 6,085,576 disclose machine sensors that use various chemistries, but they do not take advantage of the specificity of

10   olfactory and taste receptors for their cognate ligands to produce a biosensor.

WO 00/15269 discloses methods and apparatus for odor reproduction. The total affinities of a specific odorant with a group of receptors was called the affinity fingerprint of the odorant. This odorant fingerprint was represented by a vector of affinity values. It was proposed to repro-duce an arbitrary odor by inputting its sensed

15   odorant fingerprint into a device, which has a palate of predetermined odorants and produces a composite odor using predetermined odorant finger-prints by minimizing the difference between vectors representing the sensed odorant fingerprint and the predetermined odorant fingerprints. This reference, however, does not teach or suggest the human olfactory receptors disclosed herein.

20   WO 00/70343 discloses biosensors and sense replication systems using G-protein coupled receptors (GPCR). It was proposed to mimic the response of the G-protein signal transduction system by detecting the affinity of a stimulus to a plurality of GPCR, codifying such information into electronic signals, and reproducing the stimulus by converting the codified information into a combination of stimulant

25   entities. But this reference also does not teach or suggest the human olfactory receptors disclosed herein.

WO 01/27158 discloses olfactory receptors and their use to determine the correspondence between individual odorant receptors and particular odors. It was proposed that the interactions between an odor and olfactory receptors can be used to

30   represent the odor and to re-create it. This reference, however, does not teach or suggest the human olfactory receptors disclosed herein.

Dissecting the function of sensory receptors by binding sensory receptors of a clone of cells expressing a single sensory receptor gene, fragmentation of sensory

receptors to provide ligand-binding or signal-transducing domains thereof, and construction of fusion sensory recep-tor proteins will separate the diverse physiological functions associated with sensory perception at the level of ligand-receptor binding. Furthermore, novel "primary sensants" that are identified and

5   isolated by the methods described herein may be used to further define the function of the cognate sensory receptor by uniquely enhancing or, in the alternative, blocking stimulation of sensory receptors with a single ligand-binding domain.

The present invention addresses the need for better understanding of these ligand-receptor interactions by using a large set of identified sensory receptors. Even

10   if the receptor set used is incomplete (*i.e.*, a partial set of all sensory receptors encoded in the genome), a large number of sensants will be detected. Moreover, redundancy in the chemical structures recognized by the sensory receptors or combinatorial processing of signals from different sensory receptors would allow broad coverage of chemically diverse sensants (*e.g.*, by selection of a representative class of sensory

15   receptors). Also provided are, *inter alia*, methods for utilizing such sensory receptors and biosensors to simulate sensory perception. To analyze ligand-receptor interactions and their effects on cell signaling and the processing of those signals in sensory perception, specific sensants and their cognate receptor complexes are detected, identified, and measured under binding conditions. Fragrances and

20   flavorings can be detected, identified, measured, and/or custom designed by the methods herein described. In addition, drugs that incorporate artificial odors and/or tastes can be formulated.

Summary of the Invention

25   Large gene families encoding mammalian olfactory G-protein-coupled receptors (OLFR) and mammalian taste G-protein-coupled receptors (TASR) are known in the prior art or are disclosed herein. An object of the invention to provide fragments and variants of such OLFRs and TASRs which retain odorant- or tastant-binding activity, respectively. The large number of sensory receptors that are made

30   available herein and now amendable to manipulation raises the confidence that a substantially complete, or at least functional, repertoire of sensory receptors is provided.

It is an object of the invention to provide nucleic acid sequences or molecules that encode such sensory receptors, or fragments or variants thereof. Another object is to provide expression vectors which include nucleic acid sequences that encode such sensory receptors, or fragments or variants thereof. It is yet another object of the

5   invention to provide human or non-human cells which functionally express at least one of such sensory receptors, or fragments or variants thereof. Still another object is to provide sensory receptor fusion proteins or other polypeptides which include at least a fragment of at least one of such sensory receptors. In particular, fusions with reporter molecules or other heterologous amino acid sequences may maintain the

10   original ligand-properties while changing the signaling properties to allow easier detection of sensant binding to the receptor (*e.g.*, change in fluorescent signal). Moreover, chimeric proteins or other polypeptides with altered ligand-binding and/or signaling properties can be made from two or more different sensory receptors by mixing domains.

15   The invention provides methods for representing the sensory perception of one or more chemicals (*e.g.*, a primary sensant or mixture thereof) and/or for predicting the sensory percep-tion of one or more chemicals in a mammal (*e.g.*, human) using the aforementioned products. Given a known member of a ligand-receptor binding pair, one or both members of the pair (*i.e.*, ligand, receptor, or both) may be detected,

20   identified, and/or measured under binding conditions.

             Novel molecules or combinations of molecules which elicit a desired and predetermined sensory perception in a mammal (*e.g.*, human) can be generated by determining a value of sensory perception in a mammal for a known molecule or combination thereof; determining a value of sensory perception in a mammal for one

25   or more unknown molecules or combinations thereof; comparing the value of sensory perception in a mammal for one or more unknown com-positions to the value of sensory perception in a mammal for one or more known compositions; selecting a molecule or combination of molecules that elicits a predetermined sensory perception in a mammal; and mixing two or more unknown molecules or combinations thereof to

30   form a molecule or combination thereof that elicits a predetermined sensory perception in a mammal. The combining step yields a single molecule or a combination thereof that elicits a predetermined sensory perception in a mammal. In particular, primary odorants that uniquely bind to olfactory receptors with a single

ligand-binding domain may be such novel molecules. Variants thereof may be used (1) to enhance stimulation of a limited response by olfactory receptors with a single ligand-binding domain or (2) to block stimulation of olfactory receptors with a single ligand-binding domain to reduce or inhibit olfactory perception. An alternative

5   method for identifying primary odorants is to identify the mutated receptors in genetic anosmias because that odorant would be expected to be recognized by only one or a few olfactory receptors affected by the mutation.

Detailed Description of the Invention

10   Perception of Chemical Sensants

U.S. Patent No. 5,691,188 describes how upon binding of ligand to receptor, the receptor presumably undergoes a conformational change leading to activation of the G protein. The G proteins are comprised of three subunits: a guanyl nucleotide binding α subunit, a β subunit, and a γ subunit. G proteins cycle between two forms,

15   depending on whether GDP or GTP is bound to the α subunit. When GDP is bound, the G protein exists as a heterotrimer: the Gαβγ complex. When GTP is bound, the α subunit dissociates from the heterotrimer, leaving a Gβγ complex. When a Gαβγ complex operatively associates with an activated G protein coupled receptor in a cell membrane, the rate of exchange of GTP for bound GDP is increased and the rate of

20   disso-ciation of the bound Gα subunit from the Gαβγ complex increases. The free Gα subunit and Gβγ complex are thus capable of transmitting a signal to downstream elements of a variety of signal transduction pathways. These events from the basis for a multiplicity of different cell signaling phenomena, including for example the signaling phenomena that are identified as neurological sensory perceptions such as

25   taste and/or smell. A high-resolution X-ray crystal structure is available for rhodopsin, a guanyl nucleotide binding protein, has been solved (Palczewski *et al.*, *Science* 289:739, 2000). Using this structure, the portions of the amino acid sequence of sensant receptors that are responsible for ligand binding can be identified.

30

Sensory Perception - Olfaction

Genes encoding the olfactory receptors are active primarily in olfactory neurons (Axel *Sci. Amer.* 273:154, 1995). Individual olfactory receptor types are expressed in subsets of cells distributed in distinct zones of the olfactory epithelium (Breer *Semin. Cell Biol.* 5:25, 1994). The human genome contains thousands of genes

5   that encode a diverse repertoire of olfactory receptors (Rouquier *Nat. Genet.* 18:243, 1998; Trask *Hum. Mol. Genet.* 7:2007, 1998). An understanding of an animal's ability to detect and discriminate among the thousands of distinct odorants or tastants, and more particularly to distinguish, for example beneficial tastants or odorants from toxic tastants or odorants, is complicated by the fact that sensory receptors belong to a

10 multigene family with over a thousand members, and the odorant receptors number at least 500 to 1,000. Moreover, each sensory receptor neuron may express only one or a few of these receptors. With respect to odorant receptors, any given olfactory neuron can respond to a small set of odorant ligands. In addition, odorant discrimination for a given neuron may depend on the ligand specificity of the one or few receptors it

15 expresses.

Sensory Perception - Taste

Mammals are believed to have five basic taste modalities: sweet, bitter, sour, salty, and umami (the taste of monosodium glutamate). *See, e.g.,* Kawamura *et al.,*

20 *Introduction to Umami: A Basic Taste* (1987); Kinnamon *et al., Ann. Rev. Physiol.,* 54:715, 1992; Lindemann, *Physiol. Rev.,* 76:718, 1996; Stewart *et al., Am. J. Physiol.,* 272:1, 1997. Numerous physiological studies in animals have shown that taste receptor cells may selectively respond to different chemical stimuli. *See, e.g.,* Akabas *et al., Science,* 242:1047, 1988; Gilbertson *et al., J. Gen. Physiol.,* 100:803, 1992;

25 Bernhardt *et al., J. Physiol.,* 490:325, 1996; Cummings *et al., J. Neurophysiol.,* 75:1256, 1996.

In mammals, taste receptor cells are assembled into taste buds that are distributed into different papillae in the tongue epithelium. Circumvallate papillae, found at the very back of the tongue, contain hundreds, *e.g.,* mice, to thousands, *e.g.,*

30 human, of taste buds. By contrast, foli-ate papillae, localized to the posterior lateral edge of the tongue, only contain dozens to hundreds of taste buds. Moreover, fungiform papillae contain only a single or a few taste buds, and are at the front of the tongue.

AC010814, AC018700, AC021304, AC008620, AC011537, AC010760, AC027641, AC017103, AC024729, AC024257, AC025115, AP001524, AP000916, AC010814, AL162254, AC025234, AP001521, AC026090, AC019088, AC016856, AC016787, AC009594, AC026038, AQ628489, AC025942, AL163152, AC026975, AC024654,

5   AP001803, AP001804, AL353767, AP001884, AC026083, AC018793, AP000818, AL353894, AL049734, AL355366, AC011464, AC037472, AC036111, AC019093, AC027239, AC027522, AC009545, AC021333, AC036216, AC021935, AC022762, AL356019, AC055861, AC018375, AC072059, AC068339, AC022891, AL357039, AP002345, AC044810, AC073113, AC024399, AC023564, AL390860, AC074365,

10 AP002826, AL359636, AL391534, AC055731, AC076959, AP002826, AC019088, AC009779, AL445307, AP002512, AP000818, AC079190) by virtue of their sequence homology to some of the known human and other mammalian olfactory receptor genes. Similarly, genes encoding five and thirty-six (36) distinct, novel human T1R and T2R taste receptors, respectively, have been identified in genome

15 sequence databases.

    Alternatively, nucleic acids encoding the sensory receptors and other related polypep-tides can be isolated from a variety of sources, genetically engineered, amplified, synthesized, and/or expressed recombinantly according to the methods disclosed in WO 00/35374, which is herein incorporated by reference in its entirety.

20 These nucleic acids provide probes for the identification of cells expressing sensory receptors, as the nucleic acids are specifically expressed in such cells. They can also serve as tools for the generation of sensory topographical maps that elucidate the relationship between cells expressing sensory receptors and sensory neurons leading to particular regions of the brain. Furthermore, the nucleic acids and the

25 polypeptides they encode can be used as probes to elucidate olfactant- or tastant-induced behaviors.

    Nucleic acid molecules encoding a sensory receptor comprising a nucleic acid sequence that is at least 75%, 85%, 90%, 95%, or 99% identical to a nucleic acid sequence selected from those known in the prior art or disclosed herein are considered

30 variants. Other nucleic acid molecules comprising a nucleic acid sequence that encodes a polypeptide having an amino acid sequence at least 75%, 85%, 90%, 95%, or 99% identical to an amino acid sequence selected from those known in the prior art or disclosed herein are also considered variants. Further variants contain amino acid

sequence differences in at most ten, five, four, three, two, or one amino acid
residue(s).

Exemplary nucleic acid sequences may be selected from the group consisting
of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10,

5   SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20,
SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30,
SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40,
SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50,
SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60,

10   SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70,
SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80,
SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90,
SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID
NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108,

15   SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID
NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, SEQ ID NO: 126,
SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID
NO: 136, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 142, SEQ ID NO: 144,
SEQ ID NO: 146, SEQ ID NO: 148, SEQ ID NO: 150, SEQ ID NO: 152, SEQ ID

20   NO: 154, SEQ ID NO: 156, SEQ ID NO: 158, SEQ ID NO: 160, SEQ ID NO: 162,
SEQ ID NO: 164, SEQ ID NO: 166, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID
NO: 172, SEQ ID NO: 174, SEQ ID NO: 176, SEQ ID NO: 178, SEQ ID NO: 180,
SEQ ID NO: 182, SEQ ID NO: 184, SEQ ID NO: 186, SEQ ID NO: 188, SEQ ID
NO: 190, SEQ ID NO: 192, SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198,

25   SEQ ID NO: 200, SEQ ID NO: 202, SEQ ID NO: 204. SEQ ID NO: 206, SEQ ID
NO: 208, SEQ ID NO: 210, SEQ ID NO: 212, SEQ ID NO: 214, SEQ ID NO: 216,
SEQ ID NO: 218, SEQ ID NO: 220, SEQ ID NO: 222, SEQ ID NO: 224, SEQ ID
NO: 226, SEQ ID NO: 228, SEQ ID NO: 230, SEQ ID NO: 232, SEQ ID NO: 234,
SEQ ID NO: 236, SEQ ID NO: 238, SEQ ID NO: 240, SEQ ID NO: 242, SEQ ID

30   NO: 244, SEQ ID NO: 246, SEQ ID NO: 248, SEQ ID NO: 250, SEQ ID NO: 252,
SEQ ID NO: 254, SEQ ID NO: 256, SEQ ID NO: 258, SEQ ID NO: 260, SEQ ID
NO: 262, SEQ ID NO: 264, SEQ ID NO: 266, SEQ ID NO: 268, SEQ ID NO: 270,
SEQ ID NO: 272, SEQ ID NO: 274, SEQ ID NO: 276, SEQ ID NO: 278, SEQ ID

NO: 280, SEQ ID NO: 282, SEQ ID NO: 284, SEQ ID NO: 286, SEQ ID NO: 288, SEQ ID NO: 290, SEQ ID NO: 292, SEQ ID NO: 294, SEQ ID NO: 296, SEQ ID NO: 298, SEQ ID NO: 300, SEQ ID NO: 302, SEQ ID NO: 304, SEQ ID NO: 306,

5   SEQ ID NO: 308, SEQ ID NO: 310, SEQ ID NO: 312, SEQ ID NO: 314, SEQ ID NO: 316, SEQ ID NO: 318, SEQ ID NO: 320, SEQ ID NO: 322, SEQ ID NO: 324, SEQ ID NO: 326, SEQ ID NO: 328, SEQ ID NO: 330, SEQ ID NO: 332, SEQ ID NO: 334, SEQ ID NO: 336, SEQ ID NO: 338, SEQ ID NO: 340, SEQ ID NO: 342, SEQ ID NO: 344, SEQ ID NO: 346, SEQ ID NO: 348, SEQ ID NO: 350, SEQ ID NO: 352, SEQ ID NO: 354, SEQ ID NO: 356, SEQ ID NO: 358, SEQ ID NO: 360,

10   SEQ ID NO: 362, SEQ ID NO: 364, SEQ ID NO: 366, SEQ ID NO: 368, SEQ ID NO: 370, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 376, SEQ ID NO: 378, SEQ ID NO: 380, SEQ ID NO: 382, SEQ ID NO: 384, SEQ ID NO: 386, SEQ ID NO: 388, SEQ ID NO: 390, SEQ ID NO: 392, SEQ ID NO: 394, SEQ ID NO: 396, SEQ ID NO: 398, SEQ ID NO: 400, SEQ ID NO: 402, SEQ ID NO: 404, SEQ ID

15   NO: 406, SEQ ID NO: 408, SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414, SEQ ID NO: 416, SEQ ID NO: 418, SEQ ID NO: 420, SEQ ID NO: 422, SEQ ID NO: 424, SEQ ID NO: 426, SEQ ID NO: 428, SEQ ID NO: 430, SEQ ID NO: 432, SEQ ID NO: 434, SEQ ID NO: 436, SEQ ID NO: 438, SEQ ID NO: 440, SEQ ID NO: 442, SEQ ID NO: 444, SEQ ID NO: 446, SEQ ID NO: 448, SEQ ID NO: 450,

20   SEQ ID NO: 452, SEQ ID NO: 454, SEQ ID NO: 456, SEQ ID NO: 458, SEQ ID NO: 460, SEQ ID NO: 462, SEQ ID NO: 464, SEQ ID NO: 466, SEQ ID NO: 468, SEQ ID NO: 470, SEQ ID NO: 472, SEQ ID NO: 474, SEQ ID NO: 476, SEQ ID NO: 478, SEQ ID NO: 480, SEQ ID NO: 482, SEQ ID NO: 484, SEQ ID NO: 486, SEQ ID NO: 488, SEQ ID NO: 490, SEQ ID NO: 492, SEQ ID NO: 494, SEQ ID

25   NO: 496, SEQ ID NO: 498, SEQ ID NO: 500, SEQ ID NO: 502, SEQ ID NO: 504, SEQ ID NO: 506, SEQ ID NO: 508, SEQ ID NO: 510; and SEQ ID NO: 512.

Nucleic acid molecule comprising a nucleic acid sequence that encodes a fragment of a polypeptide having an amino acid sequence selected from those known in the prior art or dis-closed herein; wherein the fragment is at least ten, 20, 30, 50, 70,

30   100, or 150 amino acid resi-dues in length, are useful as probes, primers, and to construct hybrids or chimerae.

Polypeptides comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from those

known in the prior art or disclosed herein are considered variants. Further variants contain amino acid sequence differ-ences in at most ten, five, four, three, two, or one amino acid residue(s). Other polypeptides comprising a fragment of a polypeptide having an amino acid sequence selected from those known in the prior art or disclosed

5   herein; wherein the fragment is at least 40, 60, 80, 100, 150, 200, or 250 amino acid residues in length, are useful as specific binders of sensants, competitive binders, antigens, and to construct hybrids or chimerae.

Exemplary amino acid sequences may be selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ

10   ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ
ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ
ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ
ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ
ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ

15   ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ
ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ
ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ
ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ
ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109,

20   SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID
NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127,
SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID
NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145,
SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 153, SEQ ID

25   NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 161, SEQ ID NO: 163,
SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169, SEQ ID NO: 171, SEQ ID
NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID NO: 179, SEQ ID NO: 181,
SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID
NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID NO: 197, SEQ ID NO: 199,

30   SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205, SEQ ID NO: 207, SEQ ID
NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID NO: 215, SEQ ID NO: 217,
SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223, SEQ ID NO: 225, SEQ ID
NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID NO: 233, SEQ ID NO: 235,

SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241, SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259, SEQ ID NO: 261, SEQ ID NO:, 263, SEQ ID NO:, 265, SEQ ID NO: 267, SEQ ID NO: 269, SEQ ID NO: 271,

5　SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295, SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313, SEQ ID NO: 315, SEQ ID

10　NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331, SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349, SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 361,

15　SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID

20　NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439, SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 449, SEQ ID NO: 451,

25　SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475, SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493, SEQ ID NO: 495, SEQ ID

30　NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO: 511.

Also provided are methods of screening for modulators, *e.g.*, activators, inhibitors, stimu-lators, enhancers, agonists, and antagonists, of the sensory receptors,

or fragments or variants thereof. Such modulators of signal transduction are useful for pharmacological or genetic modu-lation of signaling pathways. These methods of screening can be used to identify high affinity agonists and antagonists of sensory cell activity. These modulator compounds can then be used in the pharmaceutical, food,

5   and cosmetic industries to customize odorants or tastants.

Thus, the invention provides assays for sensory modulation, where the sensory receptors, or fragments or variants thereof, act as direct or indirect reporter molecules for the effect of modulators on signal transduction. Sensory receptors, or fragments or variants thereof, can be used in assays, *e.g.*, to measure changes in ion concentration,

10   membrane potential, current flow, ion flux, transcription, signal transduction, receptor-ligand interaction, second messenger concen-trations, *in vitro, in vivo*, and *ex vivo*. In one embodiment, sensory receptors, or fragments or variants thereof, can be used as an indirect reporters via attachment to second reporter molecules, such as green fluorescent protein (*see, e.g.*, Mistili *et al., Nature Biotech.*, 15:961, 1997). In

15   another embodiment, the sensory receptors, or fragments or variants thereof, can be expressed in host cells, and modulation of signal transduction via sensory receptor activity can be assayed by measuring changes in Ca^{2+} levels.

Methods of assaying for modulators of signal transduction include *in vitro* ligand binding assays using the sensory receptors, or fragments or variants thereof.

20   More particularly, such assays can use the sensory receptors; portions thereof such as the extracellular or transmembrane domains; chimeric proteins comprising one or more of such domains; oocyte receptor expression; tissue culture cell receptor expression; transcriptional activation of the receptor; G-protein binding to the receptor; ligand binding assays; voltage, membrane potential and conductance

25   changes; ion flux assays; changes in intracellular second messengers such as cAMP and inositol triphosphate; changes in intracellular Ca^{2+} levels; and neurotransmitter release.

The invention also provides for methods of detecting sensory receptor nucleic acid and protein expression, allowing for the investigation of taste transduction

30   regulation and specific identification of sensory receptor cells. The sensory receptors, fragments, and variants of the invention can also be used to generate monoclonal and polyclonal antibodies useful for identi-fying a sensory receptor cells. Sensory receptor cells can be identified using techniques such as reverse transcription and amplification

of mRNA, isolation of total RNA or poly A$^+$ RNA, Northern blotting, dot blotting, *in situ* hybridization, RNase protection, S1 digestion, probing DNA microchip arrays, Western blots, and the like.

A. Identification and Characterization of Sensory Receptors

5　　　　The amino acid sequences of the sensory receptors and polypeptides of the invention can be identified by putative translation of the coding nucleic acid sequences. These various amino acid sequences and the coding nucleic acid sequences may be compared to one another or to other sequences according to a number of methods.

10　　　　For example, in sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, as

15　described below for the BLASTN and BLASTP programs, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

　　　　A "comparison window," as used herein, includes reference to a segment of

20　any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment

25　of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482, 1981, by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443, 1970, by the search for similarity method of Pearson & Lipman, Proc. *Natl. Acad Sci. USA* 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and

30　TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g., Current Protocols in Molecular Biology* (Ausubel *et al.*, eds. 1995 supplement)).

A preferred example of an algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nucl. Acids Res.* 25:3389, 1977 and Altschul *et al.*, *J Mol. Biol.* 215:403, 1990, respectively. Software for performing BLAST

5   analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to

10   as the neighborhood word score threshold (Altschul *et al.*, Altschul *et al.*, *Nucl. Acids Res.* 25:3389, 1977 and Altschul *et al.*, *J. Mol. Biol.* 215:403, 1990). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are

15   calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved

20   value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison of both

25   strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff, *Proc. Natl. Acad Sci. USA* 89:10915, 1989) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

Another example of a useful algorithm is PILEUP. PILEUP creates a multiple

30   sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a so-called "tree" or "dendogram" showing the clustering relationships used to create the alignment (*see, e.g.,* Figure 2). PILEUP uses a simplification of the progressive

alignment method of Feng & Doolittle, *J Mol. Evol.* 35:351, 1987. The method used is similar to the method described by Higgins & Sharp, CABIOS 5:151, 1989. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the

5   pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by

10 designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can

15 be obtained from the GCG sequence analysis software package, *e.g.,* version 7. 0 (Devereaux *et al., Nucl. Acids Res.* 12:387, 1984) encoded by the genes were derived by conceptual translation of the corresponding open reading frames. Comparison of these protein sequences to all known proteins in the public sequence databases using BLASTP algorithm revealed their strong homology to the members of the mammalian

20 olfactory receptor family, each of the olfactory receptor sequences having at least 50%, and preferably at least 55%, at least 60%, at least 65%, and most preferably at least 70%, amino acid identity to at least one known member of the family.

The nucleic acid molecules of the present invention are typically intronless and encode putative sensory receptor proteins generally having lengths of about 300 to

25 about 400 amino acid residues that contain seven transmembrane domains, as predicted by hydrophobicity plotting analysis, indicating that they belong to the G protein-coupled receptor superfamily, which includes the subset of taste and olfactory receptors. In addition to the overall structural similarity, each of the 256 sensory receptors identified herein has a characteristic sequence signature of an olfactory

30 receptor. In particular, all 256 sequences contain very close matches to the following consensus amino acid motifs (Mombaerts, 1999; Pilpel, 1999): LHTPMY in intracellular loop 1, MAYDRYVAIC at the end of transmembrane domain 3 and the beginning of intracellular loop 2 , SY at the end of transmembrane domain 5,

FSTCSSH in the beginning of transmembrane domain 6, and PMLNPF in transmembrane domain 7. Combination of all the above mentioned structural features of the 256 genes and encoded proteins strongly suggests that they represent novel members of the human olfactory receptor family.

5   As noted above, complete or partial sequences of numerous human and other eukaryotic sensory receptors are currently known. The novel human receptors have amino acid sequences distinctly different from the previously known human sensory receptors, which suggests their different specificity in sensant recognition. Therefore, these novel sensory receptors and their genes can be used, alone or in combination

10   with known sensory receptors, in developing detec-tion systems and assays for chemically distinct types of sensants not recognized by the known sensory receptors, as well as for diagnostic and research purposes.

B.   <u>Definitions</u>

      The terms "purified," "substantially purified," and "isolated" as used herein

15   refer to the state of being free of other, dissimilar compounds with which the compound of the invention is normally associated in its natural state, so that the "purified," "substantially purified," and "isolated" subject comprises at least 0.5%, 1%, 5%, 10%, or 20%, and most preferably at least 50% or 75% of the mass, by weight, of a given sample. In one preferred embodiment, these terms refer to the

20   compound of the invention comprising at least 95% of the mass, by weight, of a given sample. As used herein, the terms "purified," "substantially purified," and "isolated" "isolated," when referring to a nucleic acid or protein, of nucleic acids or proteins, also refers to a state of purification or concentration different than that which occurs naturally in the mammalian, especially human, body. Any degree of purification or

25   concentration greater than that which occurs naturally in the mammalian, especially human, body, including (1) the purification from other associated structures or compounds or (2) the association with structures or compounds to which it is not normally associated in the mammalian, especially human, body, are within the meaning of "isolated." The nucleic acid or protein or classes of nucleic acids or

30   proteins, described herein, may be isolated, or otherwise associated with structures or compounds to which they are not normally associated in nature, according to a variety of methods and processes known to those of skill in the art.

The terms "amplifying" and "amplification" refer to the use of any suitable amplification methodology for generating or detecting recombinant or naturally expressed nucleic acid, as described in detail, below. For example, the invention provides methods and reagents (*e.g.*, specific degenerate oligonucleotide primer pairs)

5 for amplifying (*e.g.*, by polymerase chain reaction, PCR) naturally expressed (*e.g.*, genomic or mRNA) or recombinant (*e.g.*, cDNA) nucleic acids of the invention (*e.g.*, sensant-binding sequences of the invention) *in vivo* or *in vitro*.

The term "7- transmembrane receptor" means a polypeptide belonging to a superfamily of transmembrane proteins that have seven domains that span the plasma

10 membrane seven times (thus, the seven domains are called "transmembrane" or "TM" domains TM I to TM VII). The families of olfactory and taste receptors each belong to this super-family. Seven-transmembrane receptor polypeptides have similar and characteristic primary, secondary and tertiary structures, as discussed in further detail below.

15 The term "expression vector" refers to any recombinant expression system for the purpose of expressing a nucleic acid sequence of the invention *in vitro* or *in vivo*, constitutively or inducibly, in any cell, including prokaryotic, yeast, fungal, plant, insect or mammalian cell. The term includes linear or circular expression systems. The term includes expression systems that remain episomal or integrate into the host

20 cell genome. The expression systems can have the ability to self-replicate or not, *i.e.*, drive only transient expression in a cell. The term includes recombinant expression "cassettes which contain only the minimum elements needed for transcription of the recombinant nucleic acid.

The term "library" means a preparation that is a mixture of different nucleic

25 acid or polypeptide molecules, such as the library of recombinantly generated sensory, particularly olfactory or taste, receptor ligand-binding domains generated by amplification of nucleic acid with degenerate primer pairs, or an isolated collection of vectors that incorporate the amplified sensant-binding domains, or a mixture of cells each randomly transfected with at least one vector encoding a sensory receptor.

30 The term "nucleic acid" or "nucleic acid sequence" refers to a deoxy-ribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogs of natural nucleotides. The term also encompasses nucleic-acid-like

structures with synthetic backbones, *see e.g.*, *Oligonucleo-tides and Analogues, a Practical Approach*, ed. F. Eckstein, Oxford Univ. Press (1991); *Anti-sense Strategies*, Annals of the N.Y. Academy of Sciences, Vol. 600, Eds. Baserga *et al.* (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; *Antisense Research and*

5   *Applications* (1993, CRC Press), WO 97/03211; WO 96/39154; Mata (1997) *Toxicol. Appl. Pharmacol.* 144:189-197; Strauss-Soukup (1997) *Biochemistry* 36:8692-8698; Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156.

The term sensory receptor "ligand-binding region" refers to sequences derived from a sensory receptor that substantially incorporates transmembrane domains II to

10   VII (TM II to VII). The domain may be capable of binding a sensant.

The terms "conservative variant" or "analog" or "mimetic" refer to a polypeptide which has a modified amino acid sequence, such that the change(s) do not substantially alter the poly-peptide's (the conservative variant's) structure and/or activity, as defined herein. These include conservatively modified variations of an

15   amino acid sequence, *i.e.*, amino acid substitutions, additions or deletions of those residues that are not critical for protein activity, or substitution of amino acids with residues having similar properties (*e.g.*, acidic, basic, positively or negatively charged, polar or non-polar, etc.) such that the substitutions of even critical amino acids does not substantially alter structure and/or activity. Conservative substitution tables

20   providing function-ally similar amino acids are well known in the art.

For example, one exemplary guideline to select conservative substitutions includes (original residue followed by exemplary substitution): Ala/Gly or Ser; Arg/Lys; Asn/Gln or His; Asp/Glu; Cys/Ser; Gln/Asn; Gly/Asp; Gly/Ala or Pro; His/Asn or Gln; Ile/Leu or Val; Leu/Ile or val; Lys/Arg or Gln or Glu; Met/Leu or Tyr

25   or Ile; Phe/Met or Leu or Tyr; Ser/Thr; Thr/Ser; Trp/Tyr; Tyr/Trp or Phe; Val/Ile or Leu. An alternative exemplary guideline uses the following six groups, each containing amino acids that are conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (I); 5) Isoleucine (I), Leucine (L),

30   Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); (*see also, e.g.*, Creighton, *Proteins*, W.H. Freeman, 1984; Schultz & Schimer, *Principles of Protein Structure*, Springer-Verlag, 1979). One of skill in the art will appreciate that the above-identified substitutions are not the only possible

conservative substitutions. For example, for some purposes, one may regard all charged amino acids as conservative substitutions for each other whether they are positive or negative. In addition, individual substitutions, deletions or additions that alter, add or delete a single amino acid or a small percentage of amino acids in an

5   encoded sequence can also be considered "conservatively modified variations."

The terms "mimetic" and "peptidomimetic" refer to a synthetic chemical compound that has substantially the same structural and/or functional characteristics of the polypeptides, e.g., translocation domains or sensant-binding domains or chimeric receptors of the invention. The mimetic can be either entirely composed of

10   synthetic, non-natural analogs of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids. The mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetic's structure and/or activity. As with polypeptides of the invention which are

15   conservative variants, routine experi-mentation will determine whether a mimetic is within the scope of the invention, i.e., that its structure and/or function is not substantially altered. Polypeptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages;

20   b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like. A polypeptide can be characterized as a mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds.

25   Individual peptidomimetic residues can be joined by peptide bonds, other chemical bonds or coupling means, such as, e.g., glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIC). Linking groups that can be an alternative to the traditional amide bond ("peptide bond") linkages include, e.g., ketomethylene (e.g.,

30   -C(=O)-CH$_2$- for -C(=O)-NH-), aminomethylene (CH$_2$-NH), ethylene, olefin (CH=CH), ether (CH$_2$-O), thioether (CH$_2$-S), tetrazole (CN$_4$), thiazole, retroamide, thioamide, or ester (see, e.g., Spatola (1983) in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. 7, pp 267-357, "Peptide Backbone Modifications,"

Marcell Dekker, NY). A polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues; non-natural residues are well described in the scientific and patent literature.

As used herein, "recombinant" refers to a polynucleotide synthesized or

5   otherwise manipulated *in vitro* (*e.g.*, "recombinant polynucleotide"), to methods of using recombinant polynucleotides to produce gene products in cells or other biological systems, or to a polypeptide ("recombinant protein") encoded by a recombinant polynucleotide. "Recombinant means" also encompass the ligation of nucleic acids having various coding regions or domains or promoter sequences from

10   different sources into an expression cassette or vector for expression of, *e.g.*, inducible or constitutive expression of a fusion protein comprising a translocation domain of the invention and a nucleic acid sequence amplified using a primer of the invention.

The term "transmembrane domain" means a polypeptide domain that can completely span the plasma membrane. The general secondary and tertiary structure

15   of transmembrane domains, in particular the seven transmembrane domains of 7-transmembrane receptors such as olfactory receptors, are well known in the art. Thus, primary structure sequence can be designed or predicted based on known transmembrane domain sequences, as described in detail below.

C.   Isolation and Expression of Olfactory Receptors

20   Isolation and expression of the sensory receptors, or fragments or variants thereof, of the invention can be performed as described below. PCR primers can be used for the amplification of nucleic acids encoding olfactory receptor ligand binding regions and libraries of these nucleic acids can thereby be generated. Libraries of expression vectors can then be used to infect or transfect host cells for the functional

25   expression of these libraries. These genes and vectors can be made and expressed *in vitro* or *in vivo*. One of skill will recognize that desired phenotypes for altering and controlling nucleic acid expression can be obtained by modulating the expression or activity of the genes and nucleic acids (*e.g.*, promoters, enhancers and the like) within the vectors of the invention. Any of the known methods described for increasing or

30   decreasing expression or activity can be used. The invention can be practiced in conjunction with any method or protocol known in the art, which are well described in the scientific and patent literature.

The nucleic acid sequences of the invention and other nucleic acids used to practice this invention, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed recombinantly. Any recombinant expression system can be used, including, in addition to mammalian cells, *e.g.*, bacterial, yeast, insect or plant systems.

Alternatively, these nucleic acids can be synthesized *in vitro* by well-known chemical synthesis techniques, as described in, *e.g.*, Carruthers, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982); Adams, *Am. Chem. Soc.* 105:661 (1983); Belousov, *Nucleic Acids Res.* 25:3440-3444 (1997); Frenkel, *Free Radic. Biol. Med.* 19:373-380 (1995); Blommers, *Biochemistry* 33:7886-7896 (1994); Narang, *Meth. Enzymol.* 68:90 (1979); Brown, *Meth. Enzymol.* 68:109 (1979); Beaucage, *Tetra. Lett.* 22:1859 (1981); U.S. Patent No. 4,458,066. Double-stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence..

Techniques for the manipulation of nucleic acids, such as, for example, for generating mutations in sequences, subcloning, labeling probes, sequencing, hybridization and the like are well described in the scientific and patent literature. *See, e.g.*, Sambrook, ed., *Molecular Cloning: a Laboratory manual* (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory (1989); *Current Protocols in Molecular Biology*, Ausubel, ed. John Wiley & Sons, Inc., New York (1997); *Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I, Theory and Nucleic Acid Preparation*, Tijssen, ed. Elsevier, N.Y. (1993).

Nucleic acids, vectors, capsids, polypeptides, and the like can be analyzed and quantified by any of a number of general means well known to those of skill in the art. These include, *e.g.*, analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromato-graphy (TLC), and hyperdiffusion chromatography, various immunological methods, *e.g.*, fluid or gel precipitin reactions, immunodiffusion, immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), immunofluorescent assay, Southern analysis, Northern analysis, dot-blot analysis, gel electrophoresis (*e.g.*, SDS-PAGE),

RT-PCR, quantita-tive PCR, other nucleic acid or target or signal amplification methods, radiolabeling, scintillation counting, and affinity chromatography.

Oligonucleotide primers are used to amplify nucleic acid encoding an olfactory receptor ligand-binding region. The nucleic acids described herein can also be cloned

5   or measured quan-titatively using amplification techniques. Using exemplary degenerate primer pair sequences, (see below), the skilled artisan can select and design suitable oligonucleotide amplification primers. Amplification methods are also well known in the art, and include, *e.g.*, polymerase chain reaction, PCR (*PCR Protocols, a Guide to Methods and Applications*, ed. Innis. Academic Press, NY, 1990

10 and *PCR Strategies*, ed. Innis, Academic Press, NY, 1995), ligase chain reaction (LCR) (*see, e.g.*, Wu, *Genomics* 4:560, 1989; Landegren, *Science* 241:1077, 1988; Barringer, *Gene* 89:117, 1990); transcription amplification (*see, e.g.*, Kwoh, *Proc. Natl. Acad. Sci. USA* 86:1173, 1989); and, self-sustained sequence replication (*see, e.g.*, Guatelli, *Proc. Natl. Acad. Sci. USA* 87:1874, 1990); Q Beta replicase

15 amplification (*see, e.g.*, Smith, *J. Clin. Microbiol.* 35:1477, 1997); automated Q-beta replicase amplification assay (*see, e.g.*, Burg, *Mol. Cell. Probes* 10:257, 1996) and other RNA polymerase mediated techniques (*e.g.*, NASBA, Cangene, Mississauga, Ontario); see also Berger, *Methods Enzymol.* 152:307, 1987; Sambrook; Ausubel; U.S. Patent Nos. 4,683,195 and 4,683,202; Sooknanan, *Biotechnology* 13:563, 1995.

20 Once amplified, the nucleic acids, either individually or as libraries, may be cloned according to methods known in the art, if desired, into any of a variety of vectors using routine molecular biological methods; methods for cloning *in vitro* amplified nucleic acids are described, *e.g.*, U.S. Patent No. 5,426,039. To facilitate cloning of amplified sequences, restriction enzyme sites can be "built into" the PCR

25 primer pair. For example, Pst I and Bsp E1 sites were designed into the exemplary primer pairs of the invention. These particular restriction sites have a sequence that, when ligated, are "in-frame" with respect to the 7-membrane receptor "donor" coding sequence into which they are spliced (the sensant-binding region-coding sequence is internal to the 7-membrane polypeptide, thus, if it is desired that the construct be

30 translated downstream of a restriction enzyme splice site, out of frame results should be avoided; this may not be necessary if the inserted sensant-binding domain comprises substantially most of the transmembrane VII region). The primers can be designed to retain the original sequence of the "donor" 7-membrane receptor (the Pst I

22

and Bsp E1 sequence in he primers of the invention generate an insert that, when ligated into the Pst I/Bsp E1 cut vector, encode residues found in the "donor" mouse olfactory receptor M4 sequence). Alternatively, the primers can encode amino acid residues that are conservative substitutions (*e.g.*, hydrophobic for hydrophobic

5   residue, see above discussion) or functionally benign substitutions (*e.g.*, do not prevent plasma membrane insertion, cause cleavage by peptidase, cause abnormal folding of receptor, and the like).

The primer pairs are designed to selectively amplify sensant-binding regions of olfactory receptor proteins. These domain regions may vary for different sensnants,

10   and more particularly odorants; thus, what may be a minimal binding region for one sensant, and more particularly odorants, may be too limiting for a second potential ligand. Thus, domain regions of different sizes comprising different domain structures may be amplified; for example, transmembrane (TM) domains II through VII, III through VII, III through VI or II through VI, or variations thereof (*e.g.*, only a

15   subsequence of a particular domain, mixing the order of the domains, and the like), of a 7-transmembrane sensory receptor.

As domain structures and sequence of many 7-membrane proteins, particularly olfactory receptors, are known, the skilled artisan can readily select domain-flanking and internal domain sequences as model sequences to design degenerate amplification

20   primer pairs. For example, a nucleic acid sequence encoding domain regions II through VII can be generated by PCR ampli-fication using a primer pair. To amplify a nucleic acid comprising transmembrane domain I (TM I) sequence, a degenerate primer can be designed from a nucleic acid that encodes the amino acid sequence LFLLYL. Such a degenerate primer can be used to generate a binding domain

25   incorpo-rating TM I through TM III, TM I through TM IV, TM I through TM V, TM I through TM VI or TM I through TM VII.

To amplify a nucleic acid comprising a transmembrane domain III (TM III) sequence, a degenerate primer (of at least about 17 residues) can be designed from a nucleic acid that encodes the amino acid sequence M(A/G)(Y/F)DRYVAI (encoded

30   by a nucleic acid sequence such as 5'-ATGG(G/C)CT(A/T)TGACCG(C/A/T)T(AT)(C/T)GT- 3'). Such a degenerate primer can be used to generate a binding domain incorporating TM III through TM IV, TM III through TM V, TM III through TM VI or TM III through TM VII.

To amplify a transmembrane domain VI (TM VI) sequence, a degenerate primer (of at least about 17 residues) can be designed from nucleic acid encoding an amino acid sequence TC(G/A)SHL, encoded by a sequence such as 5'-AG(G/A)TGN(G/C)(T/A)N(G/C)C(G/A)CA-NGT-3'. Such a degenerate primer can
5   be used to generate a binding domain incorporating TM I through TM VI, TM II through TM VI, TM III through TM VI or TM IV through TM VI).

Paradigms to design degenerate primer pairs are well known in the art. For example, a COnsensus-DEgenerate Hybrid Oligonucleotide Primer (CODEHOP) strategy computer program is accessible as http://blocks.fhcrc.org/codehop.html, and
10   is directly linked from the BlockMaker multiple sequence alignment site for hybrid primer prediction beginning with a set of related protein sequences, as known olfactory receptor ligand-binding regions (*see, e.g.,* Rose, *Nucl. Acids Res.* 26:1628, 1998; Singh, *Biotechniques* 24:318, 1998).

Means to synthesize oligonucleotide primer pairs are well known in the art.
15   "Natural" base pairs or synthetic base pairs can be used. For example, use of artificial nucleobases offers a versatile approach to manipulate primer sequence and generate a more complex mixture of amplification products. Various families of artificial nucleobases are capable of assuming multiple hydrogen bonding orientations through internal bond rotations to provide a means for degenerate molecular recognition.
20   Incorporation of these analogs into a single position of a PCR primer allows for generation of a complex library of amplification products. *See, e.g.,* Hoops, *Nucleic Acids Res.* 25:4866, 1997. Nonpolar molecules can also be used to mimic the shape of natural DNA bases. A non-hydrogen-bonding shape mimic for adenine can replicate efficiently and selectively against a nonpolar shape mimic for thymine (*see,*
25   *e.g.,* Morales, *Nat. Struct. Biol.* 5:950, 1998). For example, two degenerate bases can be the pyrimidine base 6H, 8H-3,4-dihydropyrimido[4,5-c][1,2]oxazin-7-one or the purine base N6-methoxy-2,6-diaminopurine (*see, e.g.,* Hill, *Proc. Natl. Acad. Sci. USA* 95:4258, 1998). Exemplary degenerate primers of the invention incorporate the nucleobase analog 5'-Dimethoxytrityl-N-benzoyl-2'-deoxy-Cytidine, 3'-[(2-
30   cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (the term "P" in the sequences, see above). This pyrimidine analog hydrogen bonds with purines, including A and G residues.

Exemplary primer pairs for amplification of olfactory receptor transmembrane domains II through VII include:

(a)   5'-GGGGTCCGGAG(A/G)(C/G)(A/G)TA(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-3' and

5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-3'.

(b)   5'-GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-3' and

5'-GGGGCTGCAGACACC(AC/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-3'.

(c)   5'-GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT(A/G/C/T)A(A/G/C/T)(A/G/C/T)GG-3' and

5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-3'.

Nucleic acids that encode ligand-binding regions of olfactory receptors are generated by amplification (*e.g.*, PCR) of appropriate nucleic acid sequences using degenerate primer pairs. The amplified nucleic acid can be genomic DNA from any cell or tissue or mRNA or cDNA derived from olfactory receptor-expressing cells, *e.g.*, olfactory neurons or olfactory epithelium.

Isolation from olfactory receptor-expressing cells is well known in the art (cells expressing naturally or inducibly expressing olfactory receptors can be used to express the hybrid olfactory receptors of the invention to screen for potential odorants and odorant effect on cell physiology, as described below). For example, cells can be identified by olfactory marker protein (OMP), an abundant cytoplasmic protein expressed almost exclusively in mature olfactory sensory neurons (*see, e.g.*, Buiakova, *Proc. Natl. Acad. Sci. USA* 93:9858, 1996). Shirley, *Eur. J. Biochem.* 32:485, 1983), describes a rat olfactory preparation suitable for biochemical studies *in vitro* on olfactory mechanisms. Cultures of adult rat olfactory receptor neurons are described by Vargas, *Chem. Senses* 24:211, 1999). Because these cultured neurons exhibit typical voltage-gated currents and are responsive to application of odorants, they can also be used to express the hybrid olfactory receptors of the invention for odorant screening (endogenous olfactory receptor can be initially blocked, if desired, by, *e.g.*,

antisense, knockout, and the like). U.S. Patent No. 5,869,266 describes culturing human olfactory neurons for neurotoxicity tests and screening. Murrell, *J. Neurosci.* 19:8260, 1999), describes differentiated olfactory receptor-expressing cells in culture that respond to odorants, as measured by an influx of calcium.

5   Hybrid protein-coding sequences comprising nucleic acids sensory receptors fused to the translocation sequences described herein may be constructed. Also provided are hybrid receptors comprising the translocation motifs and ligand-binding domains of sensory receptors. These nucleic acid sequences can be operably linked to transcriptional or translational control elements, *e.g.*, transcription and translation

10   initiation sequences, promoters and enhancers, transcription and translation terminators, polyadenylation sequences, and other sequences useful for transcribing DNA into RNA. In construction of recombinant expression cassettes, vectors, transgenics, and a promoter fragment can be employed to direct expression of the desired nucleic acid in all tissues. Olfactory cell-specific transcriptional elements can

15   also be used to express the fusion polypeptide receptor, including, *e.g.*, a 6.7 kb region upstream of the M4 olfactory receptor coding region. This region was sufficient to direct expression in olfactory epithelium with wild type zonal restriction and distributed neuronal expression for endogenous olfactory receptors (Qasba, *J. Neurosci.* 18:227, 1998). Receptor genes are normally expressed in a small subset of

20   neurons throughout a zonally restricted region of the sensory epithelium. The transcriptional or translational control elements can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods.

          Fusion proteins, either having C-terminal or, more preferably, N-terminal

25   translocation sequences, may also comprise the translocation motif described herein. However, these fusion proteins can also comprise additional elements for, *e.g.*, protein detection, purification, or other applications. Detection and purification facilitating domains include, *e.g.*, metal chelating peptides such as polyhistidine tracts or histidine-tryptophan modules or other domains that allow purification on immobilized

30   metals; maltose binding protein; protein A domains that allow purification on immobilized immunoglobulin; or the domain utilized in the FLAGS extension/ affinity purification system (Immunex Corp, Seattle WA).

The inclusion of a cleavable linker sequences such as Factor Xa (*see, e.g.,* Ottavi, *Biochi-mie* 80:289, 1998), subtilisin protease recognition motif (*see, e.g.,* Polyak, *Protein Eng.* 10:615, 1997); enterokinase (Invitrogen, San Diego, CA), and the like, between the translocation domain (for efficient plasma membrane

5   expression) and the rest of the newly translated polypeptide may be useful to facilitate purification. For example, one construct can include a nucleic acid sequence encoding a polypeptide linked to six histidine residues followed by a thioredoxin, an enterokinase cleavage site (*see, e.g.,* Williams, *Biochemistry* 34:1787, 1995), and an amino terminal translocation domain. The histidine residues facilitate detection and

10   purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, *see, e.g.,* Kroll, *DNA Cell. Biol.* 12:441, 1993).

Expression vectors, either as individual expression vectors or as libraries of

15   expression vectors, comprising the olfactory binding domain-encoding sequences may be introduced into a genome or into the cytoplasm or a nucleus of a cell and expressed by a variety of conventional techniques, well described in the scientific and patent literature. *See, e.g.,* Roberts, *Nature* 328:731, 1987; Berger *supra*; Schneider, *Protein Expr. Purif.* 6435:10, 1995; Sambrook; Tijssen; Ausubel. Product information from

20   manufacturers of biological reagents and experimental equipment also provide information regarding known biological methods. The vectors can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods.

The nucleic acids can be expressed in expression cassettes, vectors or viruses

25   which are stably or transiently expressed in cells (*e.g.,* episomal expression systems). Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences. For example, selection markers can code for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode antibiotic

30   resistance (*e.g.,* chloramphenicol, kanamycin, G418, bleomycin, hygromycin) or herbicide resistance (*e.g.,* chlorosulfuron or Basta) to permit selection of those cells transformed with the desired DNA sequences (*see, e.g.,* Blondelet-Rouault, *Gene* 190:315, 1997; Aubrecht, *J. Pharmacol. Exp. Ther.* 281:992, 1997). Because

selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo.*

5   A chimeric nucleic acid sequence may encode a sensant-binding domain within any 7-transmembrane polypeptide. Seven-transmembrane receptors belong to a superfamily of trans-membrane (TM) proteins having seven domains that traverse a plasma membrane seven times. Each of the seven domains spans the plasma membrane (TM I to TM VII). Because 7-trans-membrane receptor polypeptides have similar primary sequences and secondary and tertiary structures, structural domains

10   (*e.g.*, TM domains) can be readily identified by sequence analysis. For example, homology modeling, Fourier analysis and helical periodicity detection can identify and characterize the seven domains with a 7-transmembrane receptor sequence. Fast Fourier Transform (FFT) algorithms can be used to assess the dominant periods that characterize profiles of the hydrophobicity and variability of analyzed sequences. To

15   predict TM domains and their boundaries and topology, a "neural network algorithm" by "PHD server" can be used, as done by Pilpel, *Protein Science* 8:969, 1999; Rost, *Protein Sci.* 4:521, 1995. Periodicity detection enhancement and alpha helical periodicity index can be done as by, *e.g.*, Donnelly, *Protein Sci.* 2:55-70 (1993). Other alignment and modeling algorithms are well known in the art, *see, e.g.*, Peitsch,

20   *Receptors Channels* 4:161, 1996; Cronet, *Protein Eng.* 6:59, (1993) (homology and "discover modeling"); http://bioinfo.weizmann.ac.il/.

       The library sequences include receptor sequences that correspond to TM ligand-binding domains, including, *e.g.*, TM II to VII, TM II to VI, TM III to VII, and TM III to VII, that have been amplified (*e.g.*, PCR) from mRNA of or cDNA derived

25   from, *e.g.*, olfactory receptor-expressing neurons or genomic DNA.

       Libraries of sensory receptor ligand-binding TM domain sequences can include a various TM domains or variations thereof, as described above. These sequences can be derived from any 7-transmembrane receptor. Because these polypeptides have similar primary sequences and secondary and tertiary structures, the

30   seven domains can be identified by various analyses well known in the art, including, *e.g.*, homology modeling, Fourier analysis and helical periodicity (*see, e.g.*, Pilpel *supra*), as described above. Using this information sequences flanking the seven

domains can be identified and used to design degenerate primers for amplification of various combinations of TM regions and subsequences.

The present invention also includes not only the DNA and proteins having the specified amino acid sequences, but also DNA fragments, particularly fragments of,

5 for example, 40, 60, 80, 100, 150, 200, or 250 nucleotides, or more, as well as protein fragments of, for example, 10, 20, 30, 50, 70, 100, or 150 amino acids, or more.

Also contemplated are chimeric proteins, comprising at least 10, 20, 30, 50, 70, 100, or 150 amino acids, or more, of one of at least one of the sensory receptors described herein, coupled to additional amino acids representing all or part of another

10 G protein receptor, preferably a member of the 7-transmembrane superfamily. These chimerae can be made from the instant receptors and a G protein receptor described herein, or they can be made by combining two or more of the present proteins. In one preferred embodiment, one portion of the chimera corresponds to and is derived from one or more of the domains of the 7-transmembrane protein described herein, and the

15 remaining portion or portions come from another G protein-coupled receptor. Chimeric receptors are well known in the art, and the techniques for creating them and the selection and boundaries of domains or fragments of G protein-coupled receptors for incorpo-ration therein are also well known. Thus, this knowledge of those skilled in the art can readily be used to create such chimeric receptors. The use of such

20 chimeric receptors can provide, for example, an olfactory selectivity characteristic of one of the receptors specifically disclosed herein, coupled with the signal transduction characteristics of another receptor, such as a well known receptor used in prior art assay systems.

For example, a domain such as a ligand binding domain, an extracellular

25 domain, a transmembrane domain (e.g., one comprising seven transmembrane regions and corresponding extracellular and cytosolic loops), the transmembrane domain and a cytoplasmic domain, an active site, a subunit association region, etc., can be covalently linked to a heterologous protein. For instance, an extracellular domain can be linked to a heterologous GPCR transmembrane domain, or a heterologous CGPCR

30 extracellular domain can be linked to a transmembrane domain. Other heterologous proteins of choice can include, e.g., green fluorescent protein, β-gal, glutamtate receptor, and the rhodopsin presequence.

Polymorphic variants, alleles, and interspecies homologs that are substantially identical to a sensory receptor disclosed herein can be isolated using the nucleic acid probes described above. Alternatively, expression libraries can be used to isolate sensory receptors and polymorphic variants, alleles, and interspecies homologs

5   thereof, by detecting expressed homologs immunologically with antisera or purified antibodies made against a sensory receptor-derived polypeptide, which also recognize and selectively bind to the sensory receptor homolog.

Also within the scope of the invention are host cells for expressing the sensory receptors, fragments, or variants of the invention. To obtain high levels of expression

10   of a cloned gene or nucleic acid, such as cDNAs encoding the sensory receptors, fragments, or variants thereof, the nucleic acid sequence of interest is subcloned into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable prokaryotic and eukaryotic

15   expression systems are well known in the art and described, e.g., in Sambrook et al.

Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasmid vectors, viral vectors and any of the other well known methods for

20   introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al.). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at lest one gene into the host cell capable of expressing the olfactory receptor, fragment, or variant of interest.

25   After the expression vector is introduced into the cells, the transfected cells are cultured under conditions favoring expression of the receptor, fragment, or variant of interest, which is then recovered from the culture using standard techniques. Examples of such techniques are well known in the art. See, e.g., WO 00/06593, which is incorporated by reference in a manner consistent with this disclosure.

30   D.   Immunological Detection of Sensory Receptor Polypeptides

In addition to the detection of sensory receptor genes and gene expression using nucleic acid hybridization technology, one can also use immunoassays to detect

sensory receptors, *e.g.*, to identify olfactory receptor cells, and variants of sensory receptor family members. Immunoassays can be used to qualitatively or quantitatively analyze the sensory receptors. A general overview of the applicable technology can be found in Harlow & Lane, *Antibodies: A Laboratory Manual* (1988).

5   1.   Antibodies to sensory receptor family members

Methods of producing polyclonal and monoclonal antibodies that react specifically with a sensory receptor family member are known to those of skill in the art (*see, e.g.*, Coligan, *Current Protocols in Immunology*, 1991; Goding, *Monoclonal Antibodies: Principles and Practice*, 2d ed., 1986; Harlow & Lane, supra; and Kohler

10   & Milstein, *Nature*, 256:495, 1975). Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors, as well as preparation of polyclonal and monoclonal antibodies by immunizing rabbits or mice (*see, e.g.*, Huse *et al.*, *Science*, 246:1275, 1989; Ward *et al.*, *Nature*, 341:544, 1989).

15   A number of sensory receptor-comprising immunogens may be used to produce antibody specifically reactive with a sensory receptor family member. For example, a recombinant sensory receptor protein, or an antigenic fragment thereof, can be isolated as described herein. Suitable antigenic regions include, *e.g.*, the conserved motifs that are used to identify members of the sensory receptor family.

20   Recombinant proteins can be expressed in eukaryotic or prokaryotic cells as described above, and purified as generally described above. Recombinant protein is the preferred immunogen for the production of monoclonal or polyclonal antibodies. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used an immunogen. Naturally occurring

25   protein may also be used either in pure or impure form. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein.

Methods of production of polyclonal antibodies are known to those of skill in

30   the art. Mice, hamsters, rats, guinea pigs, rabbits, goats, or chickens is immunized with the protein using an adjuvant (*e.g.*, Freund's adjuvant) and a standard immunization protocol with periodic boosts. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of

reactivity to the sensory receptor. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired (see Harlow & Lane, *supra*).

5   Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (see Kohler & Milstein, *Eur. J. Immunol.*, 6:511, 1976). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, retroviruses, or other

10   methods well known in the art. Colonies arising from single clones of immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a

15   monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse *et al.*, *Science*, 246:1275, 1989.

          Monoclonal antibodies or polyclonal sera are collected and titered against antigen in an immunoassay, for example, a solid phase immunoassay with the antigen

20   immobilized on a solid support. Typically, polyclonal antisera with a titer of 10^4 or greater are selected and tested for their cross reactivity against non-sensory receptor proteins, or even other sensory receptor family members or other related proteins from other organisms, using a competitive binding immuno-assay. Specific polyclonal antisera and monoclonal antibodies will usually bind with a Kd of at least about 0.1

25   mM, more usually at least about 1 pM, optionally at least about 0.1 p.M or better, and optionally 0.01 pM or better.

          Once sensory receptor family member specific antibodies are available, individual sensory receptor proteins can be detected by a variety of immunoassay methods. For a review of immu-nological and immunoassay procedures, see *Basic*

30   *and Clinical Immunology* (Stites & Terr eds., 7th ed., 1991). Moreover, the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in *Enzyme Immunoassay* (Maggio, ed., 1980); and Harlow & Lane, *supra*.

2.   Immunological binding assays

Sensory receptor proteins can be detected and/or quantified using any of a number of well recognized immunological binding assays (see, e.g., U.S. Patent Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general

5   immunoassays, see also *Methods in Cell Biology: Antibodies in Cell Biology*, volume 37 (Asai, ed. 1993); *Basic and Clinical Immunology* (Stites & Terr, eds., 7th ed., 1991). Immunological binding assays (or immunoassays) typically use an antibody that specifically binds to a protein or antigen of choice (in this case a sensory receptor family member or an antigenic subsequence thereof). The antibody (*e.g.*, anti-sensory

10   receptor) may be produced by any of a number of means well known to those of skill in the art and as described above.

Immunoassays also often use a labeling agent to specifically bind to and label the complex formed by the antibody and antigen. The labeling agent may itself be one of the moieties comprising the antibody/antigen complex. Thus, the labeling agent

15   may be a labeled sensory receptor polypeptide or a labeled anti-sensory receptor antibody. Alternatively, the labeling agent may be a third moiety, such a secondary antibody, that specifically binds to the antibody/sensory receptor complex (a secondary antibody is typically specific to antibodies of the species from which the first antibody is derived). Other proteins capable of specifically binding

20   immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (*see, e.g.*, Kronval *et al., J. Immunol.*, 111:1401, 1973; Akerstrom *et al., J. Immunol.*, 135:2589, 1985). The labeling agent can be modified with a detectable moiety, such as biotin, to which

25   another molecule can specifically bind, such as streptavidin. A variety of detectable moieties are well known to those skilled in the art.

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, optionally from about 5 minutes to about 24 hours. However, the

30   incubation time will depend upon the assay format, antigen, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

a.   Non-competitive assay formats

Immunoassays for detecting a sensory receptor protein in a sample may be either competi-tive or noncompetitive. Noncompetitive immunoassays directly measure the amount of antigen. In one preferred "sandwich" assay, for example, the

5   anti-sensory receptor antibodies are bound directly to a solid substrate on which they are immobilized. These immobilized antibodies then capture the sensory receptor protein present in the test sample. The sensory receptor protein thus immobilized is then bound by a labeling agent, such as a second anti-sensory receptor antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in

10   turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second or third antibody is typically modified with a detectable moiety, such as biotin, to which another molecule specifically binds, e.g., streptavidin, to provide a detectable moiety.

b.   Competitive assay formats

15   In competitive assays, the amount of sensory receptor protein present in the sample is measured indirectly by measuring the amount of a known, added (exogenous) sensory receptor protein displaced (competed away) from an anti-sensory receptor antibody by the unknown sensory receptor protein present in a sample. In one competitive assay, a known amount of sensory receptor protein is added to a

20   sample and the sample is then contacted with an antibody that specifically binds to the sensory receptor. The amount of exogenous sensory receptor protein bound to the antibody is inversely proportional to the concentration of sensory receptor protein present in the sample. In a particularly preferred embodiment, the antibody is immobilized on a solid substrate. The amount of sensory receptor protein bound to

25   the antibody may be determined either by measuring the amount of sensory receptor protein present in a sensory receptor/antibody complex, or alternatively by measuring the amount of remaining uncomplexed protein. The amount of sensory receptor protein may be detected by providing a labeled sensory receptor molecule.

A hapten inhibition assay is another preferred competitive assay. In this assay

30   the known sensory receptor protein is immobilized on a solid substrate. A known amount of anti-sensory receptor antibody is added to the sample, and the sample is then contacted with the immobilized sensory receptor. The amount of anti-sensory receptor antibody bound to the known immobilized sensory receptor protein is

inversely proportional to the amount of sensory receptor protein present in the sample. Again, the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the

5   subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

c.   Cross-reactivity determinations

Immunoassays in the competitive binding format can also be used for cross-reactivity determinations. For example, a protein at least partially encoded by the

10   nucleic acid sequences disclosed herein can be immobilized to a solid support. Proteins (e.g., sensory receptor proteins and homologs) are added to the assay that compete for binding of the antisera to the immobilized antigen. The ability of the added proteins to compete for binding of the antisera to the immobi-lized protein is compared to the ability of the sensory receptor polypeptide encoded by the nucleic

15   acid sequences disclosed herein to compete with itself. The percentage cross-reactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with each of the added proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorption with the added considered proteins,

20   e.g., distantly related homologs. In addition, peptides comprising amino acid sequences representing conserved motifs that are used to identify members of the sensory receptor family can be used in cross-reactivity determinations.

The immunoabsorbed and pooled antisera are then used in a competitive binding immu-noassay as described above to compare a second protein, thought to be

25   perhaps an allele or poly-morphic variant of a sensory receptor family member, to the immunogen protein (i.e., sensory receptor protein encoded by the nucleic acid sequences disclosed herein). In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is

30   determined. If the amount of the second protein required to inhibit 50% of binding is less than 10 times the amount of the protein encoded by nucleic acid sequences disclosed herein required to inhibit 50% of binding, then the second protein is said to

specifically bind to the polyclonal antibodies generated to a sensory receptor immunogen.

Antibodies raised against sensory receptor conserved motifs can also be used to prepare antibodies that specifically bind only to GPCRs of the sensory receptor

5   family, but not to GPCRs from other families. Polyclonal antibodies that specifically bind to a particular member of the sensory receptor family, can be make by subtracting out cross-reactive antibodies using other sensory receptor family members. Species-specific polyclonal antibodies can be made in a similar way. For example, antibodies specific to human T2R01 can be made by, subtracting out antibodies that

10   are cross-reactive with orthologous sequences, *e.g.*, rat OLFR1 or mouse OLFR1.

d.   Other assay formats

Western blot (immunoblot) analysis is used to detect and quantify the presence of sensory receptor protein in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight,

15   transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind the sensory receptor protein. The anti-sensory receptor polypeptide antibodies specifically bind to the sensory receptor poly-peptide on the solid support. These antibodies may be directly labeled or alternatively may be

20   subsequently detected using labeled antibodies (*e.g.*, labeled sheep anti-mouse antibodies) that specifically bind to the anti-sensory receptor antibodies.

Other assay formats include liposome immunoassays (LIA) using liposomes designed to bind specific molecules (*e.g.*, antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard

25   techniques (*see* Monroe *et al.*, *Amer. Clin. Prod. Rev.*, 5:34, 1986).

e.   Reduction of non-specific binding

One of skill in the art will appreciate that it is often desirable to minimize non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immo-bilized on a solid substrate it is desirable to minimize the

30   amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well known to those of skill in the art. Typically, this technique involves coating the substrate with a proteinaceous composition. In particular, protein

compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used with powdered milk being most preferred.

f.   Labels

The particular label or detectable group used in the assay is not a critical aspect of the invention, as long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immuno-assays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, bio-chemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (e.g., DYNABEADS^{TM}, fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g., ^{3}H, ^{125}I, ^{35}S, ^{14}C, or ^{32}P), enzymes (e.g., horseradish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic beads (e.g., polystyrene, polypropylene, latex, etc.).

The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (e.g., biotin) is covalently bound to the molecule. The ligand then binds to another molecules (e.g., streptavidin) molecule, which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. The ligands and their targets can be used in any suitable combination with antibodies that recognize a sensory receptor protein, or secondary antibodies that recognize anti-sensory receptor.

The molecules can also be conjugated directly to signal generating compounds, e.g., by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidotases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone,

37

etc. Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol. For a review of various labeling or signal producing systems that may be used, see U.S. Patent No. 4,391,904.

5   Methods for detecting labels are well known. Thus, for example, where the label is a radioactive label, it may be detected using a scintillation counter or with photographic film as in autoradiography. Where the label is a fluorescent label, it may be detected by exciting the fluoro-chrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, with photographic film, or using electronic detectors such as charge coupled devices

10   (CCDs) or photomultipliers. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally, simple colorimetric labels may be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color

15   of the bead.

Some assay formats do not require the use of labeled components. For instance, aggluti-nation assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be

20   labeled and the presence of the target antibody is detected by simple visual inspection.

E.   Detection of Olfactory Modulators

Methods and compositions for determining whether a test compound specifically binds to a mammalian sensory, and more particularly, olfactory receptor of the invention, both *in vitro* and *in vivo* are described below, as are methods and

25   compositions for determining whether a test compound is neurotoxic to an olfactory neuron expressing an olfactory transmembrane receptor polypeptide. Any aspect of cell physiology can be monitored to assess the effect of sensant-binding to a naturally-occurring or chimeric olfactory receptor. These assays may be performed on intact cells expressing an olfactory receptor, on permeabilized cells or on membrane

30   fractions produced by standard methods.

Olfactory receptors are normally located on the specialized cilia of olfactory neurons. These receptors bind odorants and initiate the transduction of chemical

stimuli into electrical signals. An activated or inhibited G-protein will in turn alter the properties of target enzymes, channels, and other effector proteins. The classic examples are the activation of cGMP phosphodiesterase by transducin in the visual system, adenylate cyclase by the stimulatory G-protein, phospholipase C by Gq and

5   other cognate G-proteins, and modulation of diverse channels by Gi and other G-proteins. Downstream consequences can also be examined such as generation of diacyl glycerol and IP3 by phospholipase C, and in turn, for calcium mobilization by IP3.

        The sensory receptor protein of the assay will typically be selected from a

10   natural poly-peptide or conservatively modified variant thereof. Generally, the amino acid sequence identity will be at least 75%, 85%, 90%, 95%, or 99%. Optionally, the polypeptide of the assays can comprise a domain of a sensory receptor protein, such as an extracellular domain, transmembrane region, transmembrane domain, cytoplasmic domain, ligand binding domain, subunit association domain, active site, and the like.

15   Either the sensory receptor protein or a domain thereof can be covalently linked to a heterologous protein to create a chimeric protein used in the assays described herein.

        Modulators of sensory receptor activity can be tested using sensory receptor polypeptides as described above, either recombinant or naturally occurring. Protein can be isolated, expressed in a cell, expressed in a membrane derived from a cell,

20   expressed in tissue or in an animal, either recombinant or naturally occurring. Modulation can be tested using one of the *in vitro* or *in vivo* assays described herein.

        1.   *In vitro* binding assays

        Sensory perception can also be examined *in vitro* with soluble or solid state reactions, using a full-length sensory receptor-GPCR or a chimeric molecule such as

25   an extracellular domain or transmembrane region, or combination thereof, of a sensory receptor covalently linked to a heterologous signal transduction domain, or a heterologous extracellular domain and/or transmembrane region covalently linked to the transmembrane and/or cytoplasmic domain of a sensory receptor. Furthermore, ligand-binding domains of the protein of interest can be used *in vitro* in soluble or

30   solid state reactions to assay for ligand binding. In numerous embodiments, a chimeric receptor will be made that comprises all or part of a sensory receptor polypeptide, as well an additional sequence that facilitates the localization of the

sensory receptor to the membrane, such as a rhodopsin, *e.g.*, an N-terminal fragment of a rhodopsin protein.

Ligand binding to a sensory receptor protein, a domain, or chimeric protein can be tested in solution, in a bilayer membrane, attached to a solid phase, in a lipid

5 monolayer, or in vesicles. Binding of a modulator can be tested using, *e.g.*, changes in spectroscopic characteristics (*e.g.*, fluorescence, absorbence, refractive index) hydrodynamic (*e.g.*, shape), chromatographic, or solubility properties. Sensory receptors with large (*e.g.*, approximately 600 amino acid residues) extracellular N-terminal segments. These N-terminal segments are thought to form ligand-binding

10 domains, and are therefore useful in biochemical assays to identify sensory receptor agonists and antagonists. Similar assays have been used with other GPCRs, such as the metabo-tropic glutamate receptors (*e.g.*, Han &Hampson, *J. Biol. Chem.* 274:10008, 1999). These assays might involve displacing a radioactively or fluorescently labeled ligand, and measuring changes in intrinsic fluorescence or

15 changes in proteolytic susceptibility, *etc.*

Receptor-G-protein interactions can also be examined. For example, binding of the G-protein to the receptor or its release from the receptor can be examined. For example, in the absence of GTP, an activator will lead to the formation of a tight complex of a G protein (all three subunits) with the receptor. This complex can be

20 detected in a variety of ways, as noted above. Such an assay can be modified to search for inhibitors, *e.g.*, by adding an activator to the receptor and G protein in the absence of GTP, which form a tight complex, and then screen for inhibitors by looking at dissociation of the receptor-G protein complex. In the presence of GTP, release of the alpha subunit of the G protein from the other two G protein subunits

25 serves as a criterion of activation.

An activated or inhibited G-protein will in turn alter the properties of target enzymes, channels, and other effector proteins. The classic examples are the activation of cGMP phosphodiesterase by transducin in the visual system, adenylate cyclase by the stimulatory G-protein, phospholipase C by Gq and other cognate G

30 proteins, and modulation of diverse channels by Gi and other G proteins. Downstream consequences can also be examined such as generation of diacyl glycerol and IP3 by phospholipase C, and in turn, for calcium mobilization by IP3.

2.   Fluorescence Polarization Assays

In another embodiment, Fluorescence Polarization ("FP") based assays may be used to detect and monitor sensant binding. Fluorescence polarization is a versatile laboratory technique for measuring equilibrium binding, nucleic acid hybridization, and enzymatic activity. Fluores-cence polarization assays are homogeneous in that they do not require a separation step such as centrifugation, filtration, chromatography, precipitation, or electrophoresis. These assays are done in real time, directly in solution and do not require an immobilized phase. Polarization values can be measured repeatedly and after the addition of reagents since measuring the polari-zation is rapid and does not destroy the sample. Generally, this technique can be used to measure polarization values of fluorophores from low picomolar to micromolar levels. This section describes how fluorescence polarization can be used in a simple and quantitative way to measure the binding of odorants to the sensory receptors of the invention.

When a fluorescently labeled molecule is excited with plane polarized light, it emits light that has a degree of polarization that is inversely proportional to its molecular rotation. Large fluorescently labeled molecules remain relatively stationary during the excited state (4 nano-seconds in the case of fluorescein) and the polarization of the light remains relatively constant between excitation and emission. Small fluorescently labeled molecules rotate rapidly during the excited state and the polarization changes significantly between excitation and emission. There-fore, small molecules have low polarization values and large molecules have high polarization values. For example, a single-stranded fluorescein-labeled oligonucleotide has a relatively low polarization value but when it is hybridized to a complementary strand, it has a higher polariza-tion value. When using FP to detect and monitor odorant-binding which may activate or inhibit the sensory receptors of the invention, fluorescence-labeled sensants or auto-fluorescent sensants may be used. Fluorescence polarization (P) is defined as:

$$P = \frac{Int_{\text{II}} - Int_{\perp}}{Int_{\text{II}} + Int_{\perp}}$$

Where $\prod$ is the intensity of the emission light parallel to the excitation light plane and Int $\perp$ is the intensity of the emission light perpendicular to the excitation light plane. P, being a ratio of light intensities, is a dimensionless number. For

example, the Beacon® and Beacon 2000™ System may be used in connection with these assays. Such systems typically express polarization in millipolarization units (1 Polarization Unit =1000 mP Units).

The relationship between molecular rotation and size is described by the Perrin equation and the reader is referred to Jolley *J. Anal. Toxicol.* 5, 236, 1981 which gives a thorough expla-nation of this equation. Summarily, the Perrin equation states that polarization is directly propor-tional to the rotational relaxation time, the time that it takes a molecule to rotate through an angle of approximately 68.5°. Rotational relaxation time is related to viscosity (η), absolute tempera-ture (T), molecular volume (V), and the gas constant (R) by the following equation:

$$Rotational \, Re\,laxation Time = \frac{3\eta V}{RT}$$

The rotational relaxation time is small ($\approx$ 1 nanosecond) for small molecules (*e.g.*, fluorescein) and large ($\approx$ 100 nanoseconds) for large molecules (*e.g.*, immunoglobulins). If viscosity and temperature are held constant, rotational relaxation time, and therefore polarization, is directly related to the molecular volume. Changes in molecular volume may be due to inter-actions with other molecules, dissociation, polymerization, degradation, hybridization, or confor-mational changes of the fluorescently labeled molecule. For example, fluorescence polarization has been used to measure enzymatic cleavage of large fluorescein labeled polymers by proteases, DNases, and RNases. It also has been used to measure equilibrium binding for protein/protein interactions, antibody/antigen binding, and protein/DNA binding.

3.   Soluble and solid state high throughput assays

In yet another embodiment, the invention provides soluble assays using molecules such as a domain such as ligand binding domain, an extracellular domain, a transmembrane domain (*e.g.*, one comprising seven transmembrane regions and cytosolic loops), the transmembrane domain and a cytoplasmic domain, an active site, a subunit association region, *etc.*; a domain that is covalently linked to a heterologous protein to create a chimeric molecule; a sensory receptor protein; or a cell or tissue expressing a sensory receptor protein, either naturally occurring or recombinant. In another embodiment, the invention provides solid phase based *in vitro* assays in a high throughput format, where the domain, chimeric molecule, sensory receptor protein, or cell or tissue expressing the sensory receptor is attached to a solid phase substrate.

In the high throughput assays of the invention, it is possible to screen up to
several thousand different modulators or ligands in a single day. In particular, each
well of a microtiter plate can be used to run a separate assay against a selected
potential modulator, or, if concentra-tion or incubation time effects are to be observed,

5   every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate
can assay about 100 (e.g., 96) modulators. If 1536 well plates are used, then a single
plate can easily assay from about 1000 to about 1500 different compounds. It is
possible to assay several different plates per day; assay screens for up to about
6,000-20,000 different compounds is possible using the integrated systems of the

10   invention. More recently, microfluidic approaches to reagent manipulation have been
developed.

The molecule of interest can be bound to the solid state component, directly or
indirectly, via covalent or non covalent linkage, e.g., via a tag. The tag can be any of a
variety of compo-nents. In general, a molecule which binds the tag (a tag binder) is

15   fixed to a solid support, and the tagged molecule of interest (e.g., the taste
transduction molecule of interest) is attached to the solid support by interaction of the
tag and the tag binder.

A number of tags and tag binders can be used, based upon known molecular
interactions well described in the literature. For example, where a tag has a natural

20   binder, for example, biotin, protein A, or protein G, it can be used in conjunction with
appropriate tag binders (avidin, streptavidin, neutravidin, the Fc region of an
immunoglobulin, etc.). Antibodies to molecules with natural binders such as biotin
are also widely available and appropriate tag binders (see, SIGMA Immunochemicals
1998 catalogue SIGMA, St. Louis MO).

25   Similarly, any haptenic or antigenic compound can be used in combination
with an appro-priate antibody to form a tag/tag binder pair. Thousands of specific
antibodies are commercially available and many additional antibodies are described in
the literature. For example, in one common configuration, the tag is a first antibody
and the tag binder is a second antibody which recognizes the first antibody. In

30   addition to antibody-antigen interactions, receptor-ligand inter-actions are also
appropriate as tag and tag-binder pairs. For example, agonists and antagonists of cell
membrane receptors (e.g., cell receptor-ligand interactions such as transferrin, c-kit,
viral receptor ligands, cytokine receptors, chemokine receptors, interleukin receptors,

describing arrays of biopolymers fixed to solid substrates). Non-chemical approaches for fixing tag binders to substrates include other common methods, such as heat, cross-linking by UV radiation, and the like.

4.   Computer-based assays

5   Yet another assay for compounds that modulate sensory receptor protein activity involves computer assisted drug design, in which a digital or analog processing system is used to generate a three-dimensional structure of a sensory receptor protein based on the structural information encoded by its amino acid sequence. The input amino acid sequence interacts directly and actively with a

10   preestablished algorithm in a computer program to yield secondary, tertiary, and quaternary structural models of the protein. The models of the protein structure are then examined to identify regions of the structure that have the ability to bind, *e.g.*, ligands. These regions are then used to identify ligands that bind to the protein.

The three-dimensional structural model of the protein is generated by entering

15   protein amino acid sequences of at least 10 amino acid residues or corresponding nucleic acid sequences encoding a sensory receptor polypeptide into the computer system. The nucleotide sequence encoding the polypeptide, or the amino acid sequence thereof, can be any of those described herein, or fragments or variants thereof.

20   The amino acid sequence represents the primary sequence or subsequence of the protein, which encodes the structural information of the protein. At least 10 residues of the amino acid sequence (or a nucleotide sequence encoding 10 amino acids) are entered into the computer system from computer keyboards, computer readable substrates that include, but are not limited to, electronic storage media (e.g.,

25   magnetic diskettes, tapes, cartridges, and chips), optical media (*e.g.*, CD ROM), information distributed by internet sites, and by RAM. The three-dimensional structural model of the protein is then generated by the interaction of the amino acid sequence and the computer system, using software known to those of skill in the art.

The amino acid sequence represents a primary structure that encodes the

30   information necessary to form the secondary, tertiary and quaternary structure of the protein of interest. The software looks at certain parameters encoded by the primary sequence to generate the structural model. These parameters are referred to as "energy terms," and primarily include electrostatic potentials, hydrophobic potentials, solvent

accessible surfaces, and hydrogen bonding. Secon-dary energy terms include van der Waals potentials. Biological molecules form the structures that minimize the energy terms in a cumulative fashion. The computer program is therefore using these terms encoded by the primary structure or amino acid sequence to create the secon-dary

5 structural model.

The tertiary structure of the protein encoded by the secondary structure is then formed on the basis of the energy terms of the secondary structure. The user at this point can enter addi-tional variables such as whether the protein is membrane bound or soluble, its location in the body, and its cellular location, *e.g.*, cytoplasmic, surface,

10 or nuclear. These variables along with the energy terms of the secondary structure are used to form the model of the tertiary structure. In modeling the tertiary structure, the computer program matches hydrophobic faces of secondary structure with like, and hydrophilic faces of secondary structure with like.

Once the structure has been generated, potential ligand binding regions are

15 identified by the computer system. Three-dimensional structures for potential ligands are generated by entering amino acid or nucleotide sequences or chemical formulas of compounds, as described above. The three-dimensional structure of the potential ligand is then compared to that of the sensory receptor protein to identify ligands that bind to the protein. Binding affinity between the protein and ligands is determined

20 using energy terms to determine which ligands have an enhanced probability of binding to the protein.

Computer systems are also used to screen for mutations, polymorphic variants, alleles and interspecies homologs of sensory receptor genes. Such mutations can be associated with disease states or genetic traits. As described above, GeneChip™ and

25 related technology can also be used to screen for mutations, polymorphic variants, alleles and interspecies homologs. Once the variants are identified, diagnostic assays can be used to identify patients having such mutated genes. Identification of the mutated sensory receptor genes involves receiving input of a first nucleic acid or amino acid sequence of a sensory receptor gene, or conservatively modified versions

30 thereof. The sequence is entered into the computer system as described above. The first nucleic acid or amino acid sequence is then compared to a second nucleic acid or amino acid sequence that has substantial identity to the first sequence. The second sequence is entered into the computer system in the manner described above. Once

odorant dependent activation monitored. Control samples (untreated with activators or inhibitors) are assigned a relative sensory receptor activity value of 100. Inhibition of a sensory receptor protein is achieved when the sensory receptor activity value relative to the control is about 90%, optionally 50%, optionally 25-0%. Activation of

5 a sensory receptor protein is achieved when the sensory receptor activity value relative to the control is 110%, optionally 150%, 200-500%, or 1000-2000%.

Changes in ion flux may be assessed by determining changes in polarization (*i.e.*, electri-cal potential) of the cell or membrane expressing a sensory receptor protein. One means to deter-mine changes in cellular polarization is by measuring

10 changes in current, and thereby measuring changes in polarization, with voltage-clamp and patch-clamp techniques, *e.g.*, the "cell-attached" mode, the "inside-out" mode, and the "whole cell" mode (*see, e.g.*, Ackerman *et al.*, *New Engl. J Med.*, 336:1575, 1997). Whole cell currents are conveniently determined using the standard. Other known assays include: assays to measure ion flux using radiolabeled or fluorescent

15 probes such as voltage-sensitive dyes (*see, e.g.*, Vestergarrd-Bogind *et al.*, *J. Membrane Biol.*, 88:67, 1988; Gonzales & Tsien, *Chem. Biol.*, 4:269, 1997; Daniel *et al.*, *J. Pharmacol. Meth.*, 25:185, 1991; Holevinsky *et al.*, *J. Membrane Biology*, 137:59, 1994). Generally, the compounds to be tested are present in the range from 1 pM to 100 mM.

20 The effects of the test compounds upon the function of the polypeptides can be measured by examining any of the parameters described above. Any suitable physiological change that affects GPCR activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a

25 variety of effects such as transmitter release, hormone release, transcriptional changes to both known and uncharacterized genetic markers (*e.g.*, Northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as Ca^{2+}, IP3, cGMP, or cAMP.

Preferred assays for G-protein coupled receptors include cells that are loaded

30 with ion or voltage sensitive dyes to report receptor activity. Assays for determining activity of such receptors can also use known agonists and antagonists for other G-protein coupled receptors as negative or positive controls to assess activity of tested compounds. In assays for identifying modulatory compounds (*e.g.*, agonists,

antagonists), changes in the level of ions in the cytoplasm or membrane voltage will be monitored using an ion sensitive or membrane voltage fluorescent indicator, respectively. Among the ion-sensitive indicators and voltage probes that may be employed are those disclosed in the Molecular Probes 1997 Catalog. For G-protein

5   coupled receptors, promiscuous G-proteins such as Gα15 and Gα16 can be used in the assay of choice (Wilkie *et al., Proc. Natl. Acad. Sci.*, 88:10049, 1991). Such promiscuous G-proteins allow coupling of a wide range of receptors.

Receptor activation typically initiates subsequent intracellular events, *e.g.*, increases in second messengers such as IP3, which releases intracellular stores of

10   calcium ions. Activation of some G-protein coupled receptors stimulates the formation of inositol triphosphate (IP3) through phospholipase C-mediated hydrolysis of phosphatidylinositol (Berridge & Irvine, *Nature* 312:315, 1984). IP3 in turn stimulates the release of intracellular calcium ion stores. Thus, a change in cytoplasmic calcium ion levels, or a change in second messenger levels such as IP3

15   can be used to assess G-protein coupled receptor function. Cells expressing such G-protein coupled receptors may exhibit increased cytoplasmic calcium levels as a result of contribution from both intracellular stores and via activation of ion channels, in which case it may be desirable although not necessary to conduct such assays in calcium-free buffer, optionally supplemented with a chelating agent such as EGTA, to

20   distinguish fluorescence response resulting from calcium release from internal stores.

Other assays can involve determining the activity of receptors which, when activated, result in a change in the level of intracellular cyclic nucleotides, *e.g.*, cAMP or cGMP, by activating or inhibiting enzymes such as adenylate cyclase. There are cyclic nucleotide-gated ion channels, *e.g.*, rod photoreceptor cell channels and

25   olfactory neuron channels that are permeable to cations upon activation by binding of cAMP or cGMP (see, *e.g.*, Altenhofen *et al., Proc. Natl. Acad. Sci.*, 88:9868, 1991 and Dhallan *et al., Nature* 347:184, 1990). In cases where activation of the receptor results in a decrease in cyclic nucleotide levels, it may be preferable to expose the cells to agents that increase intracellular cyclic nucleotide levels, *e.g.*, forskolin, prior

30   to adding a receptor-activating compound to the cells in the assay. Cells for this type of assay can be made by co-transfection of a host cell with DNA encoding a cyclic nucleotide-crated ion channel, GPCR phosphatase and DNA encoding a receptor (*e.g.*, certain glutamate receptors, muscarinic acetylcholine receptors, dopamine receptors,

serotonin receptors, and the like), which, when activated, causes a change in cyclic nucleotide levels in the cytoplasm.

In a preferred embodiment, sensory receptor protein activity is measured by expressing a sensory receptor gene in a heterologous cell with a promiscuous

5   G-protein that links the receptor to a phospholipase C signal transduction pathway (see Offermanns & Simon, *J. Biol. Chem.*, 270:15175, 1995). Optionally the cell line is HEK-293 (which does not naturally express sensory receptor genes) and the promiscuous G-protein is Gal 5 (Offermanns & Simon, *supra*). Modu-lation of olfactory transduction is assayed by measuring changes in intracellular Ca^{2+} levels,

10   which change in response to modulation of the sensory receptor signal transduction pathway via administration of a molecule that associates with a sensory receptor protein. Changes in Ca^{2+} levels are optionally measured using fluorescent Ca^{2+} indicator dyes and fluorometric imaging.

In one embodiment, the changes in intracellular cAMP or cGMP can be

15   measured using immunoassays. The method described in Offermanns & Simon, *J. Biol. Chem.*, 270:15175, 1995, may be used to determine the level of cAMP. Also, the method described in Felley-Bosco *et al.*, *Am. J. Resp. Cell and Mol. Biol.*, 11:159, 1994, may be used to determine the level of cGMP. Further, an assay kit for measuring cAMP and/or cGMP is described in U.S. Patent No. 4,115,538, herein

20   incorporated by reference.

In another embodiment, phosphatidyl inositol (PI) hydrolysis can be analyzed according to U.S. Patent No. 5,436,128, herein incorporated by reference. Briefly, the assay involves labeling of cells with 3H-myoinositol for 48 or more hrs. The labeled cells are treated with a test compound for one hour. The treated cells are lysed and

25   extracted in chloroform-methanol-water after which the inositol phosphates were separated by ion exchange chromatography and quantified by scintillation counting. Fold stimulation is determined by calculating the ratio of cpm in the presence of agonist, to cpm in the presence of buffer control. Likewise, fold inhibition is determined by calculating the ratio of cpm in the presence of antagonist, to cpm in the

30   presence of buffer control (which may or may not contain an agonist).

In another embodiment, transcription levels can be measured to assess the effects of a test compound on signal transduction. A host cell containing a sensory receptor protein of interest is contacted with a test compound for a sufficient time to

effect any interactions, and then the level of gene expression is measured. The amount of time to effect such interactions may be empiri-cally determined, such as by running a time course and measuring the level of transcription as a function of time. The amount of transcription may be measured by using any method known to those of

5　skill in the art to be suitable. For example, mRNA expression of the protein of interest may be detected using northern blots or their polypeptide products may be identified using immunoassays. Alternatively, transcription based assays using reporter gene may be used as described in U.S. Patent No. 5,436,128, herein incorporated by reference. The reporter genes can be, *e.g.*, chloramphenicol

10　acetyltransferase, luciferase, '3-galactosidase and alkaline phosphatase. Furthermore, the protein of interest can be used as an indirect reporter via attachment to a second reporter such as green fluorescent protein (see, *e.g.*, Mistili & Spector, *Nature Biotech*. 15:961, 1997).

The amount of transcription is then compared to the amount of transcription in

15　either the same cell in the absence of the test compound, or it may be compared with the amount of transcription in a substantially identical cell that lacks the sensory receptor protein of interest. A substantially identical cell may be derived from the same cells from which the recombinant cell was prepared but which had not been modified by introduction of heterologous DNA. Any difference in the amount of

20　transcription indicates that the test compound has in some manner altered the activity of the sensory receptor protein of interest.

6.　　<u>Transgenic non-human animals expressing sensory receptors</u>

Non-human animals expressing one or more sensory receptor sequences of the invention, particularly human olfactory receptor sequences, can also be used for

25　receptor assays. Such expression can be used to determine whether a test compound specifically binds to a mammalian olfactory transmembrane receptor polypeptide *in vivo* by contacting a non-human animal stably or transiently transfected with a nucleic acid encoding an olfactory receptor or ligand binding region thereof with a test compound and determining whether the animal reacts to the test compound by

30　specifically binding to the receptor polypeptide.

Use of translocation domains in the fusion polypeptides generates a cell expressing high levels of olfactory receptor. Animals transfected or infected with the vectors of the invention are particularly useful for assays to identify and characterize

odorants/ligands that can bind to a specific or sets of receptors. Such vector-infected animals expressing libraries of human olfactory sequences can be used for *in vivo* screening of odorants and their effect on, *e.g.*, cell physiology (*e.g.*, on olfactory neurons), on the CNS (*e.g.*, olfactory bulb activity), or behavior.

5   Means to infect/express the nucleic acids and vectors, either individually or as libraries, are well known in the art. A variety of individual cell, organ or whole animal parameters can be measured by a variety of means. For example, recording of stimulant-induced waves (bulbar responses) from the main olfactory bulb or accessory olfactory bulb is a useful tool for measuring quantitative stable olfactory responses.

10   When electrodes are located on the olfactory bulb surface it is possible to record stable responses over a period of several days (*see, e.g.*, Kashiwayanagi, *Brain Res. Protoc.* 1:287, 1997). In this study, electroolfactogram recordings were made with a four-electrode assembly from the olfactory epithelium overlying the endoturbinate bones facing the nasal septum. Four electrodes were fixed along the dorsal-to-ventral axis of

15   one turbinate bone or were placed in corresponding positions on four turbinate bones and moved together up toward the top of the bone. *See also*, Scott, *J. Neurophysiol.* 77:1950, 1997; Scott, *J. Neuro-physiol.* 75:2036, 1996; Ezeh, *J. Neurophysiol.* 73:2207, 1995. In other systems, fluorescence changes in nasal epithelium can be measured using the dye di-4-ANEPPS, which is applied on the rat's nasal septum and

20   medial surface of the turbinates (*see, e.g.*, Youngentob, *J. Neuro-physiol.* 73:387, 1995). Extracellular potassium activity (aK) measurements can also be carried out in *in vivo*. An increase in aK can be measured in the mucus and the proximal part of the nasal epithelium (*see, e.g.*, Khayari, *Brain Res.* 539:1, 1991).

      The sensory receptor sequences of the invention can be for example expressed

25   in animal nasal epithelium by delivery with an infecting agent, *e.g.*, adenovirus expression vector. Recom-binant adenovirus-mediated expression of a recombinant gene in olfactory epithelium using green fluorescent protein as a marker is described by, *e.g.*, Touhara, *Proc. Natl. Acad. Sci. USA* 96:4040, 1999.

      The endogenous olfactory receptor genes can remain functional and wild-type

30   (native) activity can still be present. In other situations, where it is desirable that all olfactory receptor activity is by the introduced exogenous hybrid receptor, use of a knockout line is preferred. Methods for the construction of non-human transgenic

animals, particularly transgenic mice, and the selection and preparation of recombinant constructs for generating transformed cells are well known in the art.

Construction of a "knockout" cell and animal is based on the premise that the level of expression of a particular gene in a mammalian cell can be decreased or
5   completely abrogated by introducing into the genome a new DNA sequence that serves to interrupt some portion of the DNA sequence of the gene to be suppressed. Also, "gene trap insertion" can be used to disrupt a host gene, and mouse embryonic stem (ES) cells can be used to produce knockout transgenic animals (see, e.g., Holzschu, Transgenic Res 6:97, 1997). The insertion of the exogenous is typically by
10   homologous recombination between complementary nucleic acid sequences. The exogenous sequence is some portion of the target gene to be modified, such as exonic, intronic or transcriptional regulatory sequences, or any genomic sequence which is able to affect the level of the target gene's expression; or a combination thereof. Gene targeting via homologous recombi-nation in pluripotential embryonic stem (ES) cells
15   allows one to modify precisely the genomic sequence of interest. Any technique can be used to create, screen for, propagate, a knockout animal, e.g., see Bijvoet, Hum. Mol. Genet. 7:53, 1998); Moreadith, J. Mol. Med. 75:208, 1997; Tojo, Cytotechnology 19:161, 1995; Mudgett, Methods Mol. Biol. 48:167, 1995; Longo, Transgenic Res. 6:321, 1997; U.S. Patents Nos. 5,616,491; 5,464,764; 5,631,153; 5,487,992;
20   5,627,059; 5,272,071; WO 91/09955; WO93/09222; WO 96/29411; WO 95/31560; WO 91/12650.

The nucleic acid libraries can also be used as reagents to produce "knockout" human cells and their progeny.

F.   Modulators
25   The compounds tested as modulators of a sensory receptor family member can be any small chemical compound, or a biological entity, such as a protein, sugar, nucleic acid or lipid. Alternatively, modulators can be genetically altered versions of a sensory receptor gene. Typically, test compounds will be small chemical molecules and peptides. Essentially any chemical compound can be used as a potential
30   modulator or ligand in the assays of the invention, although most often compounds-can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by

automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (*e.g.*, in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, MO), Aldrich (St. Louis, MO),

5   Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland) and the like.

In one preferred embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such

10   "combinatorial chemical libraries" or "ligand libraries" are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired charac-teristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

15   A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a

20   given compound length (*i.e.*, the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing. of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not

25   limited to, peptide libraries (see, *e.g.*, U.S. Patent No. 5,010,175; Furka, *Int. J. Pept. Prot. Res.* 37:487, 1991; and Houghton *et al.*, *Nature* 354:84, 1991). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (*e.g.*, WO 91/19735), encoded peptides (*e.g.*, WO 93/20242), random bio-oligomers (*e.g.*, WO 92/00091),

30   benzodiazepines (*e.g.*, U.S. Patent No. 5,288,514), diversomers such as hydantoins, benzodiaze-pines and dipeptides (Hobbs *et al.*, *Proc. Nat. Acad. Sci.* 90:6909, 1993), vinylogous polypep-tides (Hagihara *et al.*, *J. Amer. Chem. Soc.* 114:6568, 1992), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann *et al.*, *J. Amer.*

Moreover, a method is provided for simulating a fragrance or flavor sensed by a mammal (*e.g.*, human), comprising: for each of a plurality of sensory receptors, or fragments or variants thereof, ascertaining the extent to which the sensory receptor interacts with the fragrance and/or flavor; and combining a plurality of compounds,

5   each having a previously-determined interaction with one or more of the sensory receptors, in amounts that together provide a stimulation profile that mimics the profile for the fragrance and/or flavor. Interaction of a fragrance and/or flavor with a sensory receptor can be determined using any of the binding or reporter assays described herein. The interactions can be aggregated or a profile generated using

10   known signal processing techniques (*e.g.*, a neural network) as described below. The sensory receptor, or fragments or variants thereof (*e.g.*, fusion proteins with reporters, chimeric proteins) may be expressed in cells; otherwise, ligand-binding domain(s) may be fixed to a substrate (*e.g.*, planar, bead, or fiber) that is solid or porous. The plurality of compounds may then be combined to form a mixture. If desired, one or

15   more of the plurality of the compounds can be combined covalently. The combined compounds substantially stimulate at least 50%, 60%, 70%, 75%, 80%, 90%, 95%, 99% or all of the receptors that are substantially stimulated by the fragrance or flavor.

In yet another aspect of the invention, a method is provided in which a plurality of standard compounds are tested against a plurality of sensory receptors, or

20   fragments or variants thereof, to ascertain the extent to which the sensory receptors each interact with each standard compound, thereby generating a receptor stimulation profile for each standard compound. These receptor stimulation profiles may then be stored in a relational database on data storage medium. The method may further comprise providing a desired receptor-stimulation profile for an odor and/or taste;

25   comparing the desired receptor stimulation profile to the relational database; and ascertaining one or more combinations of standard compounds that most closely match the desired receptor-stimulation profile. The method may further comprise combining standard compounds in one or more of the ascertained combinations to simulate the odor and/or taste.

30   A further aspect of the invention is to provide a method for representing sensory percep-tion of a particular odor and/or taste in a mammal (*e.g.*, human), comprising: providing values X_1 to X_n representative of the quantitative stimulation of each of n sensory receptors of the mammal; where n is greater than or equal to 5, n is

greater than or equal to 10, n is greater than or equal to 20, n is greater than or equal to 50, n is greater than or equal to 75, n is greater than or equal to 100, n is greater than or equal to 125, n is greater than or equal to 150, n is greater than or equal to 175, n is greater than or equal to 200, n is greater than or equal to 225, n is greater than or equal

5   to 250, n is greater than or equal to 275, n is greater than or equal to 300, n is greater than or equal to 325, or n is greater than or equal to 350; and generating from the values a quantitative representation of sensory perception. The sensory receptors may be a receptor disclosed herein, or fragments or variants thereof. The representation may constitute a point or a volume in n-dimensional space, may constitute a graph or a

10   spectrum, or may constitutes a matrix of quantita-tive representations. Also, the providing step may comprise contacting a plurality of recombi-nantly-produced sensory receptors, or fragments or variants thereof, with a composition and quantitatively measuring the interaction of the composition with the receptors. The maximum number of taste receptors that are needed to mimic the native repertoire

15   (e.g., about 50) may be less than the maximum number of olfactory receptors that are needed (e.g., about 350). But the number of sensory receptors that need to be represented in an assay to provide useful results may be much less.

It is yet another aspect of the invention to provide a method for predicting the sensory perception in a mammal (e.g., human) generated by one or more molecules or

20   combinations of molecules yielding unknown olfactory perception in the mammal, comprising: providing values X_1 to X_n representative of the quantitative stimulation of each of n sensory receptors of the mammal; where n is greater than or equal to 5, n is greater than or equal to 10, n is greater than or equal to 20, n is greater than or equal to 50, n is greater than or equal to 75, n is greater than or equal to 100, n is greater than

25   or equal to 125, n is greater than or equal to 150, n is greater than or equal to 175, n is greater than or equal to 200, n is greater than or equal to 225, n is greater than or equal to 250, n is greater than or equal to 275, n is greater than or equal to 300, n is greater than or equal to 325, or n is greater than or equal to 350; for one or more molecules or combinations of molecules yielding known sensory perception in a mammal; and

30   generating from the values a quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding known sensory perception in a mammal, providing values X_1 to X_n representative of the quantitative stimulation of each of n sensory receptors of the mammal; where n is

greater than or equal to 5, n is greater than or equal to 10, n is greater than or equal to 20, n is greater than or equal to 50, n is greater than or equal to 75, n is greater than or equal to 100, n is greater than or equal to 125, n is greater than or equal to 150, n is greater than or equal to 175, n is greater than or equal to 200, n is greater than or equal

5   to 225, n is greater than or equal to 250, n is greater than or equal to 275, n is greater than or equal to 300, n is greater than or equal to 325, or n is greater than or equal to 350; for one or more mole-cules or combinations of molecules yielding unknown sensory perception in a mammal; and generating from the values a quantitative representation of sensory perception in a mammal for the one or more molecules or

10 combinations of molecules yielding unknown sensory perception in a mammal, and predicting the olfactory perception in a mammal generated by one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal by comparing the quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding unknown sensory

15 perception in a mammal to the quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding known sensory perception in a mammal. The sensory receptors used in this method may include a receptor disclosed herein, or fragment or variant thereof. The maximum number of taste receptors that are needed to mimic the native repertoire (*e.g.*, about

20 50) may be less than the maximum number of olfactory receptors that are needed (*e.g.*, about 350). But the number of sensory receptors that need to be represented in an assay to provide useful results may be much less.

Assaying for ligand-receptor binding in a large set of sensory receptors is envisioned to mimic the function of the nose or tongue in sensory perception of

25 chemical sensants. For a set of sensory receptors with a redundancy of ligand-binding domains, the resultant signal is a summa-tion of the interactions of all sensory receptors in the set: none, one, or a few of which have ligand-binding domains that are a perfect fit for the sensant; some of which have ligand-binding domains that are only an imperfect fit for the sensant; and most of which do not significantly bind to the

30 sensant. The individual sensory receptor's binding affinity for sensant varies accor-dingly. Thus, a suitably large set of ligand-binding domains from sensory receptors will be analogous to any ability of the native repertoire of olfactory or taste receptors to tolerate varying degrees of mismatch between ligand and ligand-binding domain.

The complication of desensiti-zation of sensory receptor signaling will also be
avoided by using the invention instead of prepa-rations of nasal or tongue epithelium
containing native sensory receptors. For example, the event of binding between
ligand and receptor can be separated from more complicated downstream signaling
5   events in the epithelial cells. But the latter events can be reconstituted in the invention
by transferring the sensory receptor of interest into appropriate host cells containing
an intact and functional signaling pathway.

H.   Administration of Novel Sensant Compositions

     Sensory modulators can be administered directly to a mammal (*e.g.*, human)
10   for modu-lation of sensory perception *in vivo*. Administration is by any of the routes
normally used for introducing a modulator compound into ultimate contact with the
tissue to be treated (*e.g.*, nose or tongue). The olfactory modulators are administered
in any suitable manner, optionally with acceptable carriers. Suitable methods of
administering such modulators are available and well known to those of skill in the
15   art, and, although more than one route can be used to administer a particular
composition, a particular route can often provide a more immediate and more
effective reaction than another route. Acceptable carriers are determined at least in
part by the particular components of the composition to be administered (*e.g.*,
stabilizing the sensants), as well as by the particular method used to administer the
20   composition. Accordingly, there is a wide variety of suitable formulations of
pharmaceutical compositions of the present invention (*see, e.g.*, *Remington's
Pharmaceutical Sciences*, 17th ed. 1985).

     The sensory modulators, alone or in combination with other suitable
components, can be made into aerosol formulations (*i.e.*, they can be "nebulized") to
25   be administered via inhalation. Aerosol formulations can be placed into pressurized
acceptable propellants, such as dichloro-difluoromethane, propane, nitrogen, and the
like that may or may not contribute to sensory perception. Other possible formulation
include dry or liquid forms, powders or tablets, solutions of polar (*e.g.*, water) or
nonpolar (*e.g.*, alcohol) solvents, emulsions or suspensions, creams, gels, lotions, and
30   syrups.

     Formulations suitable for administration include aqueous and non-aqueous
solutions, isotonic sterile solutions, which can contain antioxidants; buffers,

bacteriostats, and solutes that render the formulation isotonic, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by orally, topically, intravenously,

5   intraperitoneally, intravesically, or intrathecally. Optionally, the compositions are administered orally or nasally. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials. Solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The modu-lators can also be administered as part a of prepared

10   drug, food, or cosmetic. In particular, an un-pleasant odor or taste (*e.g.*, sulfur or bitter, respectively) may not be perceived as such and/or its effects reduced by blocking the binding between sensant ligand and sensory receptor by adding a competitor ligand that blocks binding between cognate ligand and receptor, or inhibiting or reducing signal transduction. In contrast, a pleasant odor or taste can be

15   mimicked or enhanced. Primary sensants are preferred because the subset of activated cells is kept small and the effects limited to projection into a specific region of the brain. But novel olfactants or combinations thereof that bind only a few olfactory receptors (*e.g.*, having less than five different ligand-binding domains) would also be useful.

20   The dose administered to a mammal (*e.g.*, human) should be sufficient to effect a bene-ficial response in the subject over time. The dose will be determined by the efficacy of the parti-cular sensory modulators employed and the condition of the subject, as well as the body weight or surface area of the area to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse

25   side-effects that accompany the administration of a particular compound or vector in a particular subject. In determining the effective amount of the modulator to be administered in a physician may evaluate circulating plasma levels of the sensory modulator, modulator toxicities,, and the production of anti-modulator antibodies. In general, the dose equivalent of a modulator is from about 1 ng/kg to 10 mg/kg for the

30   typical mammal. For administration, sensory modulators can be administered at a rate determined by the ED_{50} of the modulator, and the side-effects of the inhibitor at various concentrations, as applied to the mass and overall health of the mammal. Administration can be accomplished via single or divided doses.

I.   Kits

Sensory receptor genes, or fragments or variants thereof are useful tools for identifying cells expressing sensory receptors, for forensics and paternity determinations, and for examining signal transduction in isolated cells. Sensory

5   receptor family member-specific reagents that specifically hybridize to sensory receptor nucleic acids, such AOFLF1 probes and primers, and sensory receptor specific reagents that specifically bind to a sensory receptor protein, *e.g.*, anti-sensory receptor antibodies are used to examine expression in cells and regulation of signal trans-duction. For example, one or more family member-specific reagents may be

10   used to detect poly-morphisms that are linked to genetic anosmia or to detect allelic exclusion.

Nucleic acid assays for the presence of DNA and RNA for a sensory receptor family member in a sample include numerous techniques are known to those skilled in the art, such as Southern analysis, Northern analysis, dot blots, RNase protection, S1

15   analysis, amplification techniques such as PCR, and *in situ* hybridization. In *in situ* hybridization, for example, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybrid-ization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the art of *in situ* hybridization: Singer *et al.*,

20   *Biotechniques*, 4:230-250 (1986); Haase *et al.*, *Methods in Virology*, vol. VII, pp. 189-226 (1984); and *Nucleic Acid Hybridization: A Practical Approach* (Names *et al.*, eds. 1987). In addition, a sensory receptor protein can be detected with the various immunoassay techniques described above. The test sample is typically compared to both a positive control (*e.g.*, a sample expressing a recombinant sensory

25   receptor protein) and a negative control.

The present invention also provides for kits for screening for novel modulators of sensory receptor family members. Such kits can be prepared from readily available materials and reagents, as well as any of the aforementioned products. For example, such kits can comprise any one or more of the following materials: sensory receptor

30   nucleic acids or proteins, reaction tubes, and instructions for testing sensory receptor activity. Optionally, the kit contains a biologically active sensory receptor. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user.

Examples

AOLFR1 sequences:

MKTFSSFLQIGRNMHQGNQTTITEFILLGFFKQDEHQNLLFVLFLGMYLVTVIGNGLIIVAISLD
TYLHTPMYLFLANLSFADISSISNSVPKMLVNIQTKSQSISYESCITQMYFSIVFVVIDNLLLGTM
AYDHFVAICHPLNYTILMRPRFGILLTVISWFLSNIIALTHTLLLIQLLFCNHNTLPHFFCDLAPLL
KLSCSDTLINELVLFIVGLSVIIFPFTLSFFSYVCIIRAVLRVSSTQGKWKAFSTCGSHLTVVLLFY
GTIVGVYFFPSSTHPEDTDKIGAVLFTVVTPMINPFIYSLRNKDMKGALRKLINRKISSL (SEQ ID
NO: 1)

ATGAAGACTTTTAGTTCCTTTCTTCAGATCGGCAGAAATATGCATCAAGGAAACCAAACCA
CCATCACTGAATTCATTCTCCTGGGATTTTTCAAGCAGGATGAGCATCAAAACCTCCTCTTT
GTGCTTTTCTTGGGTATGTACCTGGTCACTGTGATTGGGAACGGGCTCATCATTGTGGCTA
TCAGCTTGGATACGTACCTTCATACCCCCATGTATCTCTTCCTTGCCAATCTATCCTTTGCT
GATATTTCCTCCATTTCCAACTCAGTCCCCAAAATGCTGGTGAATATTCAAACCAAGAGTC
AATCCATCTCTTATGAGAGCTGCATCACACAGATGTACTTTTCTATTGTGTTTGTCGTCATT
GACAATTTGCTCTTGGGGACCATGGCCTATGACCACTTTGTGGCGATCTGCCACCCTCTGA
ATTATACAATTCTCATGCGGCCCAGGTTCGGCATTTTGCTCACAGTCATCTCATGGTTCCTC
AGTAATATTATTGCTCTGACACACACCCTTCTGCTCATTCAATTGCTCTTCTGTAACCACAA
CACTCTCCCACACTTCTTCTGTGACTTGGCCCCTCTGCTCAAACTGTCCTGTTCAGATACAT
TGATCAATGAGCTTGTGTTGTTTATTGTGGGTTTATCAGTTATCATCTTCCCCTTTACACTC
AGCTTCTTTTCCTATGTCTGCATCATCAGAGCTGTCCTGAGAGTATCTTCCACACAGGGAA
AGTGGAAAGCCTTCTCCACTTGTGGCTCTCACCTGACAGTTGTATTACTGTTCTACGGAAC
CATTGTAGGCGTGTACTTTTTCCCCTCCTCCACTCACCCTGAGGACACTGATAAGATTGGT
GCTGTCCTATTCACTGTGGTGACACCCATGATAAACCCCTTCATCTACAGCTTGAGGAATA
AGGATATGAAAGGTGCCCTGAGAAAGCTCATCAATAGAAAAATTTCTTCCCTTTGA (SEQ
ID NO: 2)

AOLFR2 sequences:

MMMVLRNLSMEPTFALLGFTDYPKLQIPLFLVFLLMYVITVVGNLGMIIIIKINPKFHTPMYFFL
SHLSFVDFCYSSIVTPKLLENLVMADKSIFYFSCMMQYFLSCTAVVTESFLLAVMAYDRFVAIC
NPLLYTVAMSQRLCALLVAGSYLWGMFGPLVLLCYALRLNFSGPNVINHFFCEYTALISVSGS
DILIPHLLLFSFATFNEMCTLLIILTSYVFIFVTVLKIRSVSGRHKAFSTWASHLTAITIFHGTILFL
YCVPNSKNSRQTVKVASVFYTVVNPMLNPPIYSLRNKDVKDAFWKLIHTQVPFH (SEQ ID NO:
3)

ATGATGATGGTTTTAAGGAATCTGAGCATGGAGCCCACCTTTGCCCTTTTAGGTTTCACAG
ATTACCCAAAGCTTCAGATTCCTCTCTTCCTTGTGTTTCTGCTCATGTATGTTATCACAGTG
GTAGGAAACCTTGGGATGATCATAATAATCAAGATTAACCCCAAATTTCACACTCCTATGT
ACTTTTTCCTTAGTCACCTCTCTTTTGTTGATTTTTGTTACTCTTCCATTGTCACTCCCAAGC
TGCTTGAGAACTTGGTAATGGCAGATAAAAGCATCTTCTACTTTAGCTGCATGATGCAGTA
CTTCCTGTCCTGCACTGCTGTGGTGACAGAGTCTTTCTTGCTGGCAGTGATGGCCTATGAC
CGCTTTGTGGCCATCTGCAATCCTCTGCTTTATACAGTGGCCATGTCACAGAGGCTCTGTG
CCCTGCTGGTGGCTGGGTCATATCTCTGGGGCATGTTTGGCCCCTTGGTACTCCTTTGTTAT
GCTCTCCGGTTAAACTTCTCTGGACCTAATGTAATCAACCACTTCTTTTGTGAGTATACTGC
TCTCATCTCTGTGTCTGGCTCTGATATACTCATCCCCCACCTGCTGCTTTTCAGCTTCGCCA
CCTTCAATGAGATGTGTACACTACTGATCATCCTCACTTCCTATGTTTTCATTTTTGTGACT
GTACTAAAAATCCGTTCTGTTAGTGGGCGCCACAAAGCCTTCTCCACCTGGGCCTCCCACC
TGACTGCTATCACCATCTTCCATGGGACCATCCTTTTCCTTTACTGTGTACCCAACTCCAAA
AACTCTCGGCAAACAGTCAAAGTGGCCTCTGTATTTTACACAGTTGTCAACCCCATGCTGA
ACCCTCCGATCTACAGCCTAAGGAATAAAGACGTGAAGGATGCTTTCTGGAAGTTAATACA
TACACAAGTTCCATTTCACTGA (SEQ ID NO: 4)

AOLFR3 sequences:

MLLTDRNTSGTTFTLLGFSDYPELQVPLFLVFLAIYNVTVLGNIGLIVIIKINPKLHTPMYFFLSQ
LSFVDFCYSSIIAPKMLVNLVVKDRTISFLGCVVQFFFFCTFVVTESFLLAVMAYDRFVAICNPL
LYTVDMSQKLCVLLVVGSYAWGVSCSLELTCSALKLCFHGFNTINHFFCEFSSLLSLSCSDTYI

NQWLLFFFLATFNEISTLLIVLTSYAFIVVTILKMRSVSGRRKAFSTCASHLTAITIFHGTILFLYCV
PNSKNSRHTVKVASVFYTVVIPMLNPLIYSLRNKDVKDTVTEILDTKVFSY (SEQ ID NO: 5)

ATGCTGCTGACAGATAGAAATACAAGTGGGACCACGTTCACCCTCTTGGGCTTCTCAGATT
ACCCAGAACTGCAAGTCCCACTCTTCCTGGTTTTTCTGGCCATCTACAATGTCACTGTGCTA
GGGAATATTGGGTTGATTGTGATCATCAAAATCAACCCCAAACTGCATACCCCCATGTACT
TTTTCCTCAGCCAACTCTCCTTTGTGGATTTCTGCTATTCCTCCATCATTGCTCCCAAGATG
TTGGTGAACCTTGTTGTCAAAGACAGAACCATTTCATTTTTAGGATGCGTAGTACAATTCT
TTTTCTTCTGTACCTTTGTGGTCACTGAATCCTTTTTATTAGCTGTGATGGCCTATGACCGC
TTCGTGGCCATTTGCAACCCTCTGCTCTACACAGTTGACATGTCCCAGAAACTCTGCGTGC
TGCTGGTTGTGGGATCCTATGCCTGGGGAGTCTCATGTTCCTTGGAACTGACGTGCTCTGC
TTTAAAGTTATGTTTTCATGGTTTCAACACAATCAATCACTTCTTCTGTGAGTTCTCCTCAC
TACTCTCCCTTTCTTGCTCTGATACTTACATCAACCAGTGGCTGCTATTCTTTCTTGCCACC
TTTAATGAAATCAGCACACTACTCATCGTTCTCACATCTTATGCGTTCATTGTTGTAACCAT
CCTCAAGATGCGTTCAGTCAGTGGGCGCCGCAAAGCCTTCTCCACCTGTGCCTCCCACCTG
ACTGCCATCACCATCTTCCATGGCACCATCCTCTTCCTTTACTGTGTGCCCAACTCCAAAAA
CTCCAGGCACACAGTCAAAGTGGCCTCTGTGTTTTACACCGTGGTGATCCCCATGTTGAAT
CCCCTGATCTACAGTCTGAGAAATAAAGATGTCAAGGATACAGTCACCGAGATACTGGAC
ACCAAAGTCTTCTCTTACTGA (SEQ ID NO: 6)

AOLFR4 sequences:
MENQNNVTEFILLLGLTENLELWKIFSAVFLVMYVATVLENLLIVVTIITSQSLRSPMYFFLTFLS
LLDVMFSSVVAPKVIVDTLSKSTTISLKGCLTQLFVEHFFGGVGIILLTVMAYDRYVAICKPLHY
TIIMSPRVCCLMVGGAWVGGFMHAMIQLLFMYQIPFCGPNIIDHFICDLFQLLTLACTDTHILGL
LVTLNSGMMCVAIFLILIASYTVILCSLKSYSSKGRHKALSTCSSHLTVVVLFFVPCIFLYMRPV
VTHPIDKAMAVSDSIITPMLNPLIYTLRNAEVKSAMKKLWMKWEALAGK (SEQ ID NO: 7)

ATGGAAAATCAAAACAATGTGACTGAATTCATTCTTCTGGGTCTCACAGAGAACCTGGAGC
TGTGGAAAATATTTTCTGCTGTGTTTCTTGTCATGTATGTAGCCACAGTGCTGGAAAATCT
ACTTATTGTGGTAACTATTATCACAAGTCAGAGTCTGAGGTCACCTATGTATTTTTTTCTTA
CCTTCTTGTCCCTTTTGGATGTCATGTTCTCATCTGTCGTTGCCCCCAAGGTGATTGTAGAC
ACCCTCTCCAAGAGCACTACCATCTCTCTCAAAGGCTGCCTCACCCAGCTGTTTGTGGAGC
ATTTCTTTGGTGGTGTGGGGATCATCCTCCTCACTGTGATGGCCTATGACCGCTACGTGGC
CATCTGTAAGCCCCTGCACTACACGATCATCATGAGTCCACGGGTGTGCTGCCTAATGGTA
GGAGGGGCTTGGGTGGGGGGATTTATGCACGCAATGATACAACTTCTCTTCATGTATCAAA
TACCCTTCTGTGGTCCTAATATCATAGATCACTTTATATGTGATTTGTTTCAGTTGTTGACA
CTTGCCTGCACGGACACCCACATCCTGGGCCTCTTAGTTACCCTCAACAGTGGGATGATGT
GTGTGGCCATCTTTCTTATCTTAATTGCGTCCTACACGGTCATCCTATGCTCCCTGAAGTCT
TACAGCTCTAAAGGGCGGCACAAAGCCCTCTCTACCTGCAGCTCCCACCTCACGGTGGTTG
TATTGTTCTTTGTCCCCTGTATTTTCTTGTACATGAGGCCTGTGGTCACTCACCCCATAGAC
AAGGCAATGGCTGTGTCAGACTCAATCATCACACCCATGTTAAATCCCTTGATCTATACAC
TGAGGAATGCAGAGGTGAAAAGTGCCATGAAGAAACTCTGGATGAAATGGGAGGCTTTGG
CTGGGAAATAA (SEQ ID NO: 8)

AOLFR5 sequences:
MGKENCTTVAEFILLGLSDVPELRVCLFLLFLLIYGVTLLANLGMIALIQVSSRLHTPMYFFLSH
LSSVDFCYSSIIVPKMLANIFNKDKAISFLGCMVQFYLFCTCVVTEVFLLAVMAYDRFVAICNPL
LYTVTMSWKVRVELASCCYFCGTVCSLIHLCLALRIPFYRSNVINHFFCDLPPVLSLACSDITVN
ETLLFLVATLNESVTIMIILTSYLLILTTILKMGSAEGRHKAFSTCASHLTAITVFHGTVLSIYCRP
SSGNSGDADKVATVFYTVVIPMLNSVIYSLRNKDVKEALRKVMGSKIHS (SEQ ID NO: 9)

ATGGGCAAGGAAAACTGCACCACTGTGGCTGAGTTCATTCTCCTTGGACTATCAGATGTCC
CTGAGTTGAGAGTCTGCCTCTTCCTGCTGTTCCTTCTCATCTATGGAGTCACGTTGTTAGCC
AACCTGGGCATGATTGCACTGATTCAGGTCAGCTCTCGGCTCCACACCCCCATGTACTTTT
TCCTCAGCCACTTGTCCTCTGTAGATTTCTGCTACTCCTCAATAATTGTGCCAAAAATGTTG
GCTAATATCTTTAACAAGGACAAAGCCATCTCCTTCCTAGGGTGCATGGTGCAATTCTACT

TGTTTTGCACTTGTGTGGTCACTGAGGTCTTCCTGCTGGCCGTGATGGCCTATGACCGCTTT
GTGGCCATCTGTAACCCTTTGCTATACACAGTCACCATGTCTTGGAAGGTGCGTGTGGAGC
TGGCTTCTTGCTGCTACTTCTGTGGGACGGTGTGTTCTCTGATTCATTTGTGCTTAGCTCTT
AGGATCCCCTTCTATAGATCTAATGTGATTAACCACTTTTTCTGTGATCTACCTCCTGTCTT
5   AAGTCTTGCTTGCTCTGATATCACTGTGAATGAGACACTGCTGTTCCTGGTGGCCACTTTG
AATGAGAGTGTTACCATCATGATCATCCTCACCTCCTACCTGCTAATTCTCACCACCATCCT
GAAGATGGGCTCTGCAGAGGGCAGGCACAAAGCCTTCTCCACCTGTGCTTCCCACCTCACA
GCTATCACTGTCTTCCATGGAACAGTCCTTTCCATTTATTGCAGGCCCAGTTCAGGCAATA
GTGGAGATGCTGACAAAGTGGCCACCGTGTTCTACACAGTCGTGATTCCTATGCTGAACTC
10   TGTGATCTACAGCCTGAGAAATAAAGATGTGAAAGAAGCTCTCAGAAAAGTGATGGGCTC
CAAAATTCACTCCTAG (SEQ ID NO: 10)

AOLFR6 sequences:

MMASERNQSSTPTFILLGFSEYPEIQVPLFLVFLFVYTVTVVGNLGMIIIRLNSKLHTIMYFFLS
15   HLSLTDFCFSTVVTPKLLENLVVEYRTISFSGCIMQFCFACIFGVTETFMLAAMAYDRFVAVCK
PLLYTTIMSQKLCALLVAGSYTWGIVCSLILTYFLLDLSFCESTFINNFICDHSVIVSASYSDPYIS
QRLCFIIAIFNEVSSLIIILTSYMLIFTTIMKMRSASGRQKTFSTCASHLTAITIFHGTILFLYCVPNP
KTSSLIVTVASVFYTVAIPMLNPLIYSLRNKDINNMFEKLVVTKLIYH (SEQ ID NO: 11)

20   ATGATGGCATCTGAAAGAAATCAAAGCAGCACACCCACTTTTATTCTCTTGGGTTTTTCAG
AATACCCAGAAATCCAGGTTCCACTCTTTCTGGTTTTCTTGTTCGTCTACACAGTCACTGTA
GTGGGGAACTTGGGCATGATAATAATCATCAGACTCAATTCAAAACTCCATACAATCATGT
ACTTTTTCCTTAGTCACTTGTCCTTGACAGACTTCTGTTTTTCCACTGTAGTTACACCTAAA
CTGTTGGAGAACTTGGTTGTGGAATACAGAACCATCTCTTTCTCTGGTTGCATCATGCAAT
25   TTTGTTTTGCTTGCATTTTTGGAGTGACAGAAACTTTCATGTTAGCAGCGATGGCTTATGAC
CGTTTTGTGGCAGTTTGTAAACCCTTGCTGTATACCACTATTATGTCTCAGAAGCTCTGTGC
TCTTCTGGTGGCTGGGTCCTATACATGGGGGATAGTGTGCTCCCTGATACTCACATATTTT
CTTCTTGACTTATCGTTTTGTGAATCTACCTTCATAAATAATTTTATCGTGACCACTCTGT
AATTGTTTCTGCCTCCTACTCAGACCCCTATATCAGCCAGAGGCTATGCTTTATTATTGCCA
30   TATTCAATGAGGTGAGCAGCCTAATTATCATTCTGACATCATATATGCTTATTTTCACTACC
ATTATGAAGATGCGATCTGCAAGTGGGCGCCAGAAAACTTTCTCCACCTGTGCCTCCCACC
TGACAGCCATCACTATCTTCCATGGAACTATCCTTTTCCTTTACTGTGTTCCTAATCCTAAA
ACTTCTAGCCTCATAGTTACAGTGGCTTCTGTGTTTTACACAGTGGCGATTCCAATGCTGA
ACCCATTGATCTACAGCCTTAGGAACAAAGATATCAATAACATGTTTGAAAAATTAGTTGT
35   CACCAAATTGATTTACCACTGA (SEQ ID NO: 12)

AOLFR7 sequences:

MSYFYRLKLMKEAVLVKLPFTSLPLLLQTLSRKSRDMEIKNYSSSTSGFILLGLSSNPQLQKPLF
AIFLIMYLLAAVGNVLIIPAIYSDPRLHTPMYFFLSNLSFMDICFTTVIVPKMLVNFLSETKVISY
40   VGCLAQMYFFMAFGNTDSYLLASMAIDRLVAICNPLHYDVVMKPRHCLLMLLGSCSISHLHSL
FRVLLMSRLSFCASHIIKHFFCDTQPVLKLSCSDTSSSQMVVMTETLAVIVTPFLCIIFSYLRIMV
TVLRIPSAAGKWKAFSTCGSHLTAVALFYGSIIYVYFRPLSMYSVVRDRVATVMYTVVTPMLN
PFIYSLRNKDMKRGLKKLQDRIYR (SEQ ID NO: 13)

45   ATGAGCTATTTTTACAGGCTTAAGCTTATGAAAGAAGCTGTCTTGGTCAAACTGCCCTTTA
CATCTCTCCCACTGCTTCTCCAAACCCTATCCAGGAAGTCCAGAGACATGGAGATAAAGAA
CTACAGCAGCAGCACCTCAGGCTTCATCCTCCTGGGCCTCTCTTCCAACCCTCAGCTGCAG
AAACCTCTCTTTGCCATCTTCCTCATCATGTACCTGCTCGCTGCGGTGGGGAATGTGCTCAT
CATCCCGGCCATCTACTCTGACCCCAGGCTCCACACCCCTATGTACTTTTTTCTCAGCAACT
50   TGTCTTTCATGGATATCTGCTTCACAACAGTCATAGTGCCTAAGATGCTGGTGAATTTTCTA
TCAGAGACAAAGGTTATCTCCTATGTGGGCTGCCTGGCCCAGATGTACTTCTTTATGGCAT
TTGGGAACACTGACAGCTACCTGCTGGCCTCTATGGCCATCGACCGGCTGGTGGCCATCTG
CAACCCCTTACACTATGATGTGGTTATGAAACCACGGCATTGCCTGCTCATGCTATTGGGT
TCTTGCAGCATCTCCCACCTACATTCCCTGTTCCGCGTGCTACTTATGTCTCGCTTGTCTTT
55   CTGTGCCTCTCACATCATTAAGCACTTTTTCTGTGACACCCAGCCTGTGCTAAAGCTCTCCT
GCTCTGACACATCCTCCAGCCAGATGGTGGTGATGACTGAGACCTTAGCTGTCATTGTGAC

CCCCTTCCTGTGTATCATCTTCTCCTACCTGCGAATCATGGTCACTGTGCTCAGAATCCCCT
CTGCAGCCGGGAAGTGGAAGGCCTTCTCTACCTGTGGCTCCCACCTCACTGCAGTAGCCCT
TTTCTATGGGAGTATTATTTATGTCTATTTTAGGCCCCTGTCCATGTACTCAGTGGTTAGGG
ACCGGGTAGCCACAGTTATGTACACAGTAGTGACACCCATGCTGAACCCTTTCATCTACAG
5   CCTGAGGAACAAAGATATGAAGAGGGGTTTGAAGAAATTACAGGACAGAATTTACCGGTA
A (SEQ ID NO: 14)

AOLFR8 sequences:

MATSNHSSGAEFILAGLTQRPELQLPLFLLFLGIYVVTVVGNLGMIFLIALSSQLYPPVYYFLSH
LSFIDLCYSSVITPKMLVNFVPEENIISFLECITQLYFFLIFVIAEGYLLTAMEYDRYVAICRPLLY
10 NIVMSHRVCSIMMAVVYSLGFLWATVHTTRMSVLSFCRSHTVSHYFCDILPLLTLSCSSTHINEI
LLFIIGGVNTLATTLAVLISYAFIFSSILGIHSTEGQSKAFGTCSSHLLAVGIFFGSITFMYFKPPSS
TTMEKEKVSSVFYITIIPMLNPLIYSLRNKDVKNALKKMTRGRQSS (SEQ ID NO: 15)

ATGGCTACTTCAAACCATTCTTCAGGGGCTGAGTTTATCCTGGCAGGCTTGACACAACGCC
15 CAGAACTTCAACTGCCACTCTTCCTCCTGTTCCTTGGAATATATGTGGTCACAGTGGTGGG
GAACCTGGGCATGATCTTCTTAATTGCTCTCAGTTCTCAACTTTACCCTCCAGTGTATTATT
TTCTCAGTCATTTGTCTTTCATTGATCTCTGCTACTCCTCTGTCATTACCCCTAAGATGCTG
GTGAACTTTGTTCCAGAGGAGAACATTATCTCCTTTCTGGAATGCATTACTCAACTTTATTT
CTTCCTTATTTTTGTAATTGCAGAAGGCTACCTTCTGACAGCCATGGAATATGACCGTTAT
20 GTTGCTATCTGTCGCCCACTGCTTTACAATATTGTCATGTCCCACAGGGTCTGTTCCATAAT
GATGGCTGTGGTATACTCACTGGGTTTTCTGTGGGCCACAGTCCATACTACCCGCATGTCA
GTGTTGTCATTCTGTAGGTCTCATACGGTCAGTCATTATTTTTGTGATATTCTCCCCTTATT
GACTCTGTCTTGCTCCAGCACCCACATCAATGAGATTCTGCTGTTCATTATTGGAGGAGTT
AATACCTTAGCAACTACACTGGCGGTCCTTATCTCTTATGCTTTCATTTTCTCTAGTATCCT
25 TGGTATTCATTCCACTGAGGGGCAATCCAAAGCCTTTGGCACTTGTAGCTCCCATCTCTTG
GCTGTGGGCATCTTTTTTGGGTCTATAACATTCATGTATTTCAAGCCCCCTTCCAGCACTAC
TATGGAAAAAGAGAAGGTGTCTTCTGTGTTCTACATCACAATAATCCCCATGCTGAATCCT
CTAATCTATAGCCTGAGGAACAAGGATGTGAAAAATGCACTGAAGAAGATGACTAGGGGA
30 AGGCAGTCATCCTGA (SEQ ID NO: 16)

AOLFR9 sequences:

MLARNNSLVTEFILAGLTDRPEFWQPFFFLFLVIYIVTMVGNLGLITLFGLNSHLHTPMYYFLFN
LSFIDLCYSSVFTPKMLMNFVSKKNIISNVGCMTRLFFFLFFVISECYMLTSMAYDRYVAICNPL
35 LYKVTMSHQVCSMLTFAAYIMGLAGATAHTGCMFRLTFCSANIINHYLCDILPLLQLSCTSTYV
NEVVVLIVVGTNITVPSCTILISYVFIVTSILHIKSTQGRSKAFSTCSSHVIALSLFFGSAAFMYIKY
SSGSMEQGKVFSVFYTNVVPMLNPLIYSLRNKDVKVALRKALIKIQRRNIF (SEQ ID NO: 17)

ATGCTGGCTAGAAACAACTCCTTAGTGACTGAATTTATTCTTGCTGGATTAACAGATCGTC
40 CAGAGTTCTGGCAACCCTTCTTTTTCCTGTTCCTAGTGATCTACATTGTCACCATGGTAGGC
AACCTTGGCTTGATCACTCTTTTCGGTCTAAATTCTCACCTCCACACACCAATGTACTATTT
CCTCTTCAATCTCTCCTTCATTGATCTCTGTTACTCCTCTGTTTTCACTCCCAAAATGCTAAT
GAACTTTGTGTCAAAAAAGAATATTATCTCCAATGTTGGGTGCATGACTCGGCTGTTTTTC
TTTCTCTTTTTCGTCATCTCTGAATGTTACATGTTGACCTCAATGGCATATGATCGCTATGT
45 GGCCATCTGTAATCCATTGCTGTATAAGGTCACCATGTCCCATCAGGTCTGTTCTATGCTCA
CTTTTGCTGCTTACATAATGGGATTGGCTGGAGCCACGGCCCACACCGGGTGCATGTTTAG
ACTCACCTTCTGCAGTGCTAATATCATTAACCATTACTTGTGTGACATACTCCCCCTCCTCC
AGCTTTCCTGCACCAGCACCTATGTCAACGAGGTGGTTGTTCTCATTGTTGTGGGTACTAA
TATCACGGTACCCAGTTGTACCATCCTCATTTCTTATGTTTTCATTGTCACTAGCATTCTTC
50 ATATCAAATCCACTCAAGGAAGATCAAAAGCCTTCAGTACTTGTAGCTCTCATGTCATTGC
TCTGTCTCTGTTTTTTGGGTCAGCGGCATTCATGTATATTAAATATTCTTCTGGATCTATGG
AGCAGGGAAAAGTTTTTTCTGTTTTCTACACTAATGTGGTGCCCATGCTCAATCCCCTCATC
TACAGTTTGAGGAACAAGGATGTCAAAGTTGCACTGAGGAAAGCTCTGATTAAAATTCAG
AGGAGAAATATATTCTAA (SEQ ID NO: 18)

55

AOLFR10 sequences:

MLARNNSLVTEFILAGLTDRPEFRQPLFFLFLVIYIVTMVGNLGLIILFGLNSHLHTPMYYFLFNL
SFIDLCYSSVFTPKMLMNFVSKKNIISYVGCMTQLFFFLFFVISECYILTSMAYDRYVAICNPLLY
KVTMSHQVCSMLTFAAYIMGLAGATAHTGCMLRLTFCSANIINHYLCDILPLLQLSCTSTYVN
5   EVVVLIVVGINIMVPSCTILISYVFIVTSILHIKSTQGRSKAFSTCSSHVIALSLFFGSAAFMYIKYS
SGSMEQGKVSSVFYTNVVPMLNPLIYSLRNKDVKVALRKALIKIQRRNIF (SEQ ID NO: 19)

ATGCTGGCTAGAAACAACTCCTTAGTGACTGAATTTATTCTTGCTGGATTAACAGATCGTC
CAGAGTTCCGGCAACCCCTCTTTTTCCTGTTTCTAGTGATCTACATTGTCACCATGGTAGGC
10 AACCTTGGCTTGATCATTCTTTTCGGTCTAAATTCTCACCTCCACACACCAATGTACTATTT
CCTCTTCAATCTCTCCTTCATTGATCTCTGTTACTCCTCTGTTTTCACTCCCAAAATGCTAAT
GAACTTTGTATCAAAAAAGAATATTATCTCCTATGTTGGGTGCATGACTCAGCTGTTTTTCT
TTCTCTTTTTTGTCATCTCTGAATGCTACATATTGACCTCAATGGCATATGATCGCTATGTG
GCCATCTGTAATCCATTGCTGTATAAGGTCACCATGTCCCATCAGGTCTGTTCTATGCTCAC
15 TTTTGCTGCTTACATAATGGGATTGGCTGGAGCCACGGCCCACACCGGGTGCATGCTTAGA
CTCACCTTCTGCAGTGCTAATATCATCAACCATTACTTGTGTGACATACTCCCCCTCCTCCA
GCTTTCCTGCACCAGCACCTATGTCAACGAGGTGGTTGTTCTCATTGTTGTGGGTATTAAT
ATCATGGTACCCAGTTGTACCATCCTCATTTCTTATGTTTTCATTGTCACTAGCATTCTTCA
TATCAAATCCACTCAAGGAAGATCAAAAGCCTTCAGTACTTGTAGCTCTCATGTCATTGCT
20 CTGTCTCTGTTTTTTGGGTCAGCGGCATTCATGTATATTAAATATTCTTCTGGATCTATGGA
GCAGGGAAAAGTTTCTTCTGTTTTCTACACTAATGTGGTGCCCATGCTCAATCCTCTCATCT
ACAGTTTGAGGAACAAGGATGTCAAAGTTGCACTGAGGAAAGCTCTGATTAAAATTCAGA
GAAGAAATATATTCTAA (SEQ ID NO: 20)

25 **AOLFR11 sequences:**

MTLRNSSSVTEFILVGLSEQPELQLPLFLLFLGIYVFTVVGNLGLITLIGINPSLHTPMYFFLFNLS
FIDLCYSCVFTPKMLNDFVSESIISYVGCMTQLFFFCFFVNSECYVLVSMAYDRYVAICNPLLY
MVTMSPRVCFLLMFGSYVVGFAGAMAHTGSMLRLTFCDSNVIDHYLCDVLPLLQLSCTSTHV
SELVFFIVVGVITMLSSISIVISYALILSNILCIPSAEGRSKAFSTWGSHIIAVALFFGSGTFTYLTTS
30 FPGSMNHGRFASVFYTNVVPMLNPSIYSLRNKDDKLALGKTLKRVLF (SEQ ID NO: 21)

ATGACTCTGAGAAACAGCTCCTCAGTGACTGAGTTTATCCTTGTGGGATTATCAGAACAGC
CAGAGCTCCAGCTCCCTCTTTTCCTTCTATTCTTAGGGATCTATGTGTTCACTGTGGTGGGC
AACTTGGGCTTGATCACCTTAATTGGGATAAATCCTAGCCTTCACACCCCCATGTACTTTTT
CCTCTTCAACTTGTCCTTTATAGATCTCTGTTATTCCTGTGTGTTTACCCCCAAAATGCTGA
35 ATGACTTTGTTTCAGAAAGTATCATCTCTTATGTGGGATGTATGACTCAGCTATTTTTCTTC
TGTTTCTTTGTCAATTCTGAGTGCTATGTGTTGGTATCAATGGCCTATGATCGCTATGTGGC
CATCTGCAACCCCCTGCTCTACATGGTCACCATGTCCCCAAGGGTCTGCTTTCTGCTGATGT
TTGGTTCCTATGTGGTAGGGTTTGCTGGGGCCATGGCCCACACTGGAAGCATGCTGCGACT
GACCTTCTGTGATTCCAACGTCATTGACCATTATCTGTGTGACGTTCTCCCCCTCTTGCAGC
40 TCTCCTGCACCAGCACCCATGTCAGTGAGCTGGTATTTTTCATTGTTGTTGGAGTAATCACC
ATGCTATCCAGCATAAGCATCGTCATCTCTTACGCTTTGATACTCTCCAACATCCTCTGTAT
TCCTTCTGCAGAGGGCAGATCCAAAGCCTTTAGCACATGGGGCTCCCACATAATTGCTGTT
GCTCTGTTTTTTGGGTCAGGGACATTCACCTACTTAACAACATCTTTTCCTGGCTCTATGAA
CCATGGCAGATTTGCCTCAGTCTTTTACACCAATGTGGTTCCCATGCTTAACCCTTCGATCT
45 ACAGTTTGAGGAATAAGGATGATAAACTTGCCCTGGGCAAAACCCTGAAGAGAGTGCTCT
TCTAA (SEQ ID NO: 22)

AOLFR12 sequences:

50 MERNHNPDNCNVLNFFFADKKNKRRNFGQIVSDVGRICYSVSLSLGEPTTMGRNNLTRPSEFIL
LGLSSRPEDQKPLFAVFLPIYLITVIGNLLIILAIRSDTRLQTPMYFFLSILSFVDICYVTVIIPKMLV
NFLSETKTISYGECLTQMYFFLAFGNTDSYLLAAMAIDRYVAICNPFHYITIMSHRCCVLLLVLS
FCIPHFHSLLHILLTNQLIFCASNVIHHFFCDDQPVLKLSCSSHFVKEITVMTEGLAVIMTPFSCIII
SYLRILITVLKIPSAAGKRKAFSTCGSHLTVVTLFYGSISYVYFQPLSNYTVKDQIATIIYTVLTP
55 MLNPFIYSLRNKDMKQGLAKLMHRMKCQ (SEQ ID NO: 23)

63

ATGGAAAGAAACCACAATCCAGATAATTGTAATGTTTTAAATTTTTTCTTTGCTGATAAGA
AGAATAAAAGGAGAAATTTTGGACAGATTGTATCAGATGTTGGAAGAATCTGTTACAGTG
TTAGTTTATCTTTAGGTGAACCCACAACTATGGGAAGAAATAACCTAACAAGACCCTCTGA
ATTCATCCTCCTTGGACTCTCCTCTCGACCTGAGGATCAGAAGCCGCTCTTTGCTGTGTTCC

5   TCCCCATCTACCTTATCACAGTGATAGGAAACCTGCTTATCATCCTGGCCATCCGCTCAGA
CACTCGTCTCCAGACGCCCATGTACTTCTTTCTAAGCATCCTGTCTTTTGTTGACATTTGCT
ATGTGACAGTCATTATCCCTAAGATGCTGGTGAACTTCTTATCAGAGACAAAGACCATCTC
TTACGGTGAGTGTCTGACCCAGATGTACTTTTTCTTAGCCTTTGGAAACACAGACAGTTAC
CTGCTAGCAGCCATGGCCATTGACCGCTATGTGGCCATATGTAATCCCTTCCACTACATCA

10 CCATTATGAGTCACAGATGCTGTGTCCTGCTTCTGGTTCTCTCCTTCTGCATTCCACATTTT
CACTCCCTCCTGCACATTCTTCTGACTAATCAGCTCATCTTCTGTGCCTCCAATGTCATCCA
TCACTTTTTCTGCGATGATCAACCAGTGCTAAAATTGTCCTGTTCCTCCCATTTTGTCAAAG
AAATCACAGTAATGACAGAAGGCTTGGCTGTCATAATGACCCCGTTTTCATGCATCATCAT
CTCTTATTTAAGAATCCTCATCACTGTTCTGAAGATTCCTTCAGCTGCTGGAAAGCGTAAA

15 GCATTTTCTACCTGTGGCTCTCATCTCACAGTGGTGACCCTGTTTTATGGAAGCATTAGCTA
TGTCTATTTTCAGCCCCTGTCCAACTATACTGTCAAGGATCAAATAGCAACAATTATCTAC
ACCGTACTGACTCCTATGCTAAATCCATTTATCTATAGTCTGAGGAACAAAGACATGAAGC
AGGGTTTGGCAAAGTTGATGCACAGGATGAAATGTCAGTAA (SEQ ID NO: 24)

20 **AOLFR13 sequences:**

MDQKNGSSFTGFILLGFSDRPQLELVLFVVLLIFYIFTLLGNKTIIVLSHLDPHLHNPMYFFFSNL
SFLDLCYTTGIVPQLLVNLRGADKSISYGGCVVQLYISLGLGSTECVLLGVMAFDRYAAVCRPL
HYTVVMHPCLYVLMASTSWVVIGFANSLLQTVLILLLTLCGRNKLEHFLCEVPPLLKLACVDTT
MNESELFFVSVIILLVPVALIIFSYSQIVRAVVRIKSATGQRKVFGTCGSHLTVVSLFYGTAIYAY

25 LQPGNNYSQDQGKXISLFYTIITPMINPLIYTLRNKDVKGALKKVLWKNYDSR (SEQ ID NO:
25)

ATGGATCAGAAAAATGGAAGTTCTTTCACTGGATTTATCCTACTGGGTTTCTCTGACAGGC
CTCAGCTGGAGCTAGTCCTCTTTGTGGTTcTTTTGATCTTCTATATCTTCACTTTGCTGGGG

30 AACAAAACCATCATTGTATTATCTCACTTGGACCCACATCTTCACAATCCTATGTATTTTTT
CTTCTCCAACCTAAGCTTTTTGGATCTGTGTTACACAACCGGCATTGTTCCACAGCTCCTGG
TTAATCTCAGGGGAGCAGACAAATCAATCTCCTATGGTGGTTGTGTAGTTCAGCTGTACAT
CTCTCTAGGCTTGGGATCTACAGAATGCGTTCTCTTAGGAGTGATGGCATTTGACCGCTAT
GCAGCTGTTTGCAGGCCCCTCCACTACACAGTAGTCATGCACCCTTGTCTGTATGTGCTGA

35 TGGCTTCTACTTCATGGGTCATTGGTTTTGCCAACTCCCTATTGCAGACGGTGCTCATCTTG
CTTTTAACACTTTGTGGAAGAAATAAATTAGAACACTTTCTTTGTGAGGTTCCTCCATTGCT
CAAGCTTGCCTGTGTTGACACTACTATGAATGAATCTGAACTCTTCTTTGTCAGTGTCATTA
TTCTTCTTGTACCTGTTGCATTAATCATATTCTCCTATAGTCAGATTGTCAGGGCAGTCGTG
AGGATAAAGTCAGCAACAGGGCAGAGAAAAGTGTTTGGGACATGTGGCTCCCACCTCACA

40 GTGGTTTCCCTGTTCTACGGCACAGCTATCTATGCTtACCTCCAGCCCGGCAACAACTACTC
TCAGGATCAGGGCAAGKTCATCTCTCTCTTCTACACCATCATTACACCCATGATCAACCCC
CTCATATATACACTGAGGAACAAGGATGTGAAAGGAGCACTTAAGAAGGTGCTCTGGAAG
AACTACGACTCCAGATGA(SEQ ID NO: 26)

45 **AOLFR14 sequences:**

MALPLLLSPSCFASSQSLSSRMNSENLTRAAVAPAEFVLLGITNRWDLRVALFLTCLPVYLVSL
LGNMGMALLIRMDARLHTPMYFFLANLSLLDACYSSAIGPKMLVDLLLPRATIPYTACALQMF
VFAGLADTECCLLAAMAYDRYVAIRNPLLYTTAMSQRLCLALLGASGLGGAVSAFVHTTLTF
RLSFCRSRKINSFFCDIPPLLAISCSDTSLNELLLFAICGFIQTATVLAITVSYGFIAGAVIHMRSVE

50 GSRRAASTGGSHLTAVAMMYGTLIFMYLRPSSSYALDTDKMASVFYTLVIPSLNPLIYSLRNKE
VKEALRQTWSRFHCPGQGSQ (SEQ ID NO: 27)

ATGGCCTTGCCATTGCTCTTATCTCCCTCCTGCTTTGCCTCTTCTCAGTCTCTGTCCAGTAG
GATGAACTCAGAGAACCTCACCCGGGCCGCGGTTGCCCCTGCTGAATTCGTCCTCCTGGGC

55 ATCACAAATCGCTGGGACCTGCGTGTGGCCCTCTTCCTGACCTGCCTGCCTGTCTACCTGG
TGAGCCTGCTGGGAAACATGGGCATGGCGCTGCTGATCCGCATGGATGCCCGGCTCCACA

CACCTATGTACTTCTTCCTGGCCAACCTCTCCCTGCTGGATGCCTGCTATTCCTCCGCCATC
GGCCCCAAGATGCTAGTGGACCTGCTGCTGCCCCGAGCCACCATCCCTTACACAGCCTGTG
CCCTCCAGATGTTTGTCTTTGCAGGTCTGGCTGATACTGAGTGTTGCTTGCTGGCAGCCAT
GGCCTATGACCGCTACGTGGCCATCAGAAACCCACTTCTCTATACAACAGCTATGTCGCAG
5   CGTCTATGCCTGGCCTTGCTGGGAGCATCAGGCCTGGGTGGGGCAGTGAGTGCCTTTGTTC
ACACAACCCTCACCTTCCGCCTGAGCTTCTGCCGCTCCCGGAAGATCAATAGCTTCTTCTG
CGATATCCCTCCACTGCTGGCCATCTCGTGCAGTGACACCAGTCTCAATGAACTCCTTCTCT
TCGCCATCTGTGGCTTCATCCAGACAGCCACGGTGTTAGCTATCACGGTGTCTTATGGCTT
CATCGCTGGGGCTGTGATCCACATGCGCTCGGTCGAGGGCAGTCGGCGAGCAGCCTCCAC
10   CGGTGGTTCCCACCTCACAGCCGTGGCCATGATGTACGGGACACTCATTTTCATGTACCTG
CGCCCCAGCTCCAGCTATGCCCTGGACACTGACAAGATGGCCTCTGTGTTCTATACCCTGG
TCATCCCGTCTCTCAACCCACTCATCTACAGCCTCCGCAATAAGGAGGTCAAGGAGGCCCT
CAGGCAGACCTGGAGCCGATTCCACTGTCCAGGGCAGGGGTCCCAGTGA (SEQ ID NO: 28)

15   **AOLFR15 sequences:**

MRENNQSSTLEFILLGVTGQQEQEDFFYILFLFIYPITLIGNLLIVLAICSDVRLHNPMYFLLANLS
LVDIFFSSVTIPKMLANHLLGSKSISFGGCLTQMYFMIALGNTDSYILAAMAYDRAVAISHPLH
YTTIMSPRSCIWLIAGSWVIGNANALPHTLLTASLSFCGNQEVANFYCDITPLLKLSCSDIHFHV
KMMYLGVGIFSVPLLCIIVSYIRVFSTVFQVPSTKGVLKAFSTCGSHLTVVSLYYGTVMGTYFR
20   PLTNYSLKDAVITVMYTAVTPMLNPFIYSLRNRDMKAALRKLFNKRISS (SEQ ID NO: 29)

ATGAGGGAAAATAACCAGTCCTCTACACTGGAATTCATCCTCCTGGGAGTTACTGGTCAGC
AGGAACAGGAAGATTTCTTCTACATCCTCTTCCTGTTCATTTACCCCATCACATTGATTGGA
AACCTGCTCATTGTCCTAGCCATTTGCTCTGATGTTCGCCTTCACAACCCCATGTATTTTCT
CCTTGCCAACCTCTCCTTGGTTGACATCTTCTTCTCATCGGTAACCATCCCTAAGATGCTGG
25   CCAACCATCTCTTGGGCAGCAAATCCATCTCTTTTGGGGGATGCCTAACGCAGATGTATTT
CATGATAGCCTTGGGTAACACAGACAGCTATATTTTGGCTGCAATGGCATATGATCGAGCT
GTGGCCATCAGCCACCCACTTCACTACACAACAATTATGAGTCCACGGTCTTGTATCTGGC
TTATTGCTGGGTCTTGGGTGATTGGAAATGCCAATGCCCTCCCCCACACTCTGCTCACAGC
TAGTCTGTCCTTCTGTGGCAACCAGGAAGTGGCCAACTTCTACTGTGACATTACCCCCTTG
30   CTGAAGTTATCCTGTTCTGACATCCACTTTCATGTGAAGATGATGTACCTAGGGGTTGGCA
TTTTCTCTGTGCCATTACTATGCATCATTGTCTCCTATATTCGAGTCTTCTCCACAGTCTTCC
AGGTTCCTTCCACCAAGGGCGTGCTCAAGGCCTTCTCCACCTGTGGTTCCCACCTCACGGT
TGTCTCTTTGTATTATGGTACAGTCATGGGCACGTATTTCCGCCCTTTGACCAATTATAGCC
TAAAAGACGCAGTGATCACTGTAATGTACACGGCAGTGACCCCAATGTTAAATCCTTTCAT
35   CTACAGTCTGAGAAATCGGGACATGAAGGCTGCCCTGCGGAAACTCTTCAACAAGAGAAT
CTCCTCGTAA (SEQ ID NO: 30)

AOLFR16 sequences:
40   MRRNCTLVTEFILLGLTSRRELQILLFTLFLAIYMVTVAGNLGMIVLIQANAWLHMPMYFFLSH
LSFVDLCFSSNVTPKMLEIFLSEKKSISYPACLVQCYLFIALVHVEIYILAVMAFDRYMAICNPLL
YGSRMSKSVCSFLITVPYVYGALTGLMETMWTYNLAFCGPNEINHFYCADPPLIKLACSDTYN
KELSMFIVAGWNLSFSLFIICISYLYIFPAILKIRSTEGRQKAFSTCGSHLTAVTIFYATLFFMYLR
PPSKESVEQGKMVAVFYTTVIPMLNLIIYSLRNKNVKEALIKELSMKIYFS (SEQ ID NO: 31)

45
ATGAGAAGAAACTGCACGTTGGTGACTGAGTTCATTCTCCTGGGACTGACCAGTCGCCGG
GAATTACAAATTCTCCTCTTCACGCTGTTTCTGGCCATTTACATGGTCACGGTGGCAGGGA
ACCTTGGCATGATTGTCCTCATCCAGGCCAACGCCTGGCTCCACATGCCCATGTACTTTTTC
CTGAGCCACTTATCCTTCGTGGATCTGTGCTTCTCTTCCAATGTGACTCCAAAGATGCTGG
50   AGATTTTCCTTTCAGAGAAGAAAAGCATTTCCTATCCTGCCTGTCTTGTGCAGTGTTACCTT
TTTATCGCCTTGGTCCATGTTGAGATCTACATCCTGGCTGTGATGGCCTTTGACCGGTACAT
GGCCATCTGCAACCCTCTGCTTTATGGCAGCAGAATGTCCAAGAGTGTGTGCTCCTTCCTC
ATCACGGTGCCTTATGTGTATGGAGCGCTCACTGGCCTGATGGAGACCATGTGGACCTACA
ACCTAGCCTTCTGTGGCCCCAATGAAATTAATCACTTCTACTGTGCGGACCCACCACTGAT
55   TAAGCTGGCTTGTTCTGACACCTACAACAAGGAGTTGTCAATGTTTATTGTGGCTGGCTGG
AACCTTTCTTTTTCTCTCTTCATCATATGTATTTCCTACCTTTACATTTTCCCTGCTATTTTA

AAGATTCGCTCTACAGAGGGCAGGCAAAAAGCTTTTTCTACCTGTGGCTCCCATCTGACAG
CTGTCACTATATTCTATGCAACCCTTTTCTTCATGTATCTCAGACCCCCCTCAAAGGAATCT
GTTGAACAGGGTAAAATGGTAGCTGTATTTTATACCACAGTAATCCCTATGCTGAACCTTA
TAATTTATAGCCTTAGAAATAAAAATGTAAAAGAAGCATTAATCAAAGAGCTGTCAATGA

5   AGATATACTTTCTTAA (SEQ ID NO: 32)

AOLFR17 sequences:
MLNFTDVTEFILLGLTSRREWQVLFFIIFLVVYIITMVGNIGMMVLIKVSPQLNNPMYFFLSHLS
FVDVWFSSNVTPKMLENLFSDKKTITYAGCLVQCFFFIALVHVEIFILAAMAFDRYMAIGNPLL

10 YGSKMSRVVCIRLITFPYIYGFLTSLAATLWTYGLYFCGKIEINHFYCADPPLIKMACAGTFVKE
YTMIILAGINFTYSLTVIISYLFILIAILRMRSAEGRQKAFSTCGSHLTAVIIFYGTLIFMYLRRPTE
ESVEQGKMVAVFYTTVIPMLNPMIYSLRNKDVKKAMMKVISRSC (SEQ ID NO: 33)

ATGCTCAATTTCACCGATGTGACAGAGTTCATTCTTTTGGGGCTAACGAGCCGTCGAGAAT

15 GGCAAGTTCTCTTCTTCATCATCTTTCTTGTGGTCTACATCATCACCATGGTGGGCAATATC
GGCATGATGGTGTTAATCAAGGTCAGTCCTCAGCTTAACAACCCCATGTACTTTTTCCTCA
GTCACTTGTCATTTGTTGATGTGTGGTTTTCTTCCAATGTCACCCCTAAAATGTTGGAAAAC
CTGTTTTCAGATAAAAAAACAATTACTTATGCTGGTTGTTTAGTACAGTGTTTCTTCTTCAT
TGCTCTTGTCCATGTGGAAATTTTTATTCTTGCTGCGATGGCCTTTGATAGATACATGGCAA

20 TTGGGAATCCTCTGCTTTATGGCAGTAAAATGTCAAGGGTTGTCTGTATTCGACTGATTAC
TTTCCCTTACATTTATGGTTTTCTGACGAGTCTGGCAGCAACATTATGGACTTACGGCTTGT
ACTTCTGTGGAAAAATTGAGATCAACCATTTCTACTGTGCAGATCCACCTCTCATCAAAAT
GGCCTGTGCCGGGACCTTTGTAAAAGAATATACAATGATCATACTTGCCGGCATTAACTTC
ACATATTCCCTGACTGTAATTATCATCTCTTACTTATTCATCCTCATTGCCATTCTGCGAAT

25 GCGCTCAGCAGAAGGAAGGCAGAAGGCCTTTTCCACATGTGGGTCCCATCTGACAGCTGT
CATTATATTCTATGGTACTCTGATCTTCATGTATCTCAGACGTCCCACAGAGGAGTCTGTG
GAGCAGGGGAAGATGGTGGCTGTGTTCTATACCACAGTGATCCCCATGTTGAATCCCATGA
TCTACAGTCTGAGGAACAAGGATGTGAAAAAGGCCATGATGAAAGTGATCAGCAGATCAT
GTTAA (SEQ ID NO: 34)

30

AOLFR18 sequences:
MSNTNGSAITEFILLGLTDCPELQSLLFVLFLVVYLVTLLGNLGMIMLMRLDSRLHTPMYFFLT
NLAFVDLCYTSNATPQMSTNIVSEKTISFAGCFTQCYIFIALLLTEFYMLAAMAYDRYVAIYDP
LRYSVKTSRRVCICLATFPYVYGFSDGLFQAILTFRLTFCRSNVINHFYCADPPLIKLSCSDTYVK

35 EHAMFISAGFNLSSSLTIVLVSYAFILAAILRIKSAEGRHKAFSTCGSHMMAVTLFYGTLFCMYI
RPPTDKTVEESKIIAVFYTFVSPVLNPLIYSLRNKDVKQALKNVLR (SEQ ID NO: 35)

ATGTCCAACACAAATGGCAGTGCAATCACAGAATTCATTTTACTTGGGCTCACAGATTGCC

40 CGGAACTCCAGTCTCTGCTTTTTGTGCTGTTTCTGGTTGTTTACCTCGTCACCCTGCTAGGC
AACCTGGGCATGATAATGTTAATGAGACTGGACTCTCGCCTTCACACGCCCATGTACTTCT
TCCTCACTAACTTAGCCTTTGTGGATTTGTGCTATACATCAAATGCAACCCCGCAGATGTC
GACTAATATCGTATCTGAGAAGACCATTTCCTTTGCTGGTTGCTTTACACAGTGCTACATTT
TCATTGCCCTTCTACTCACTGAGTTTTACATGCTGGCAGCAATGGCCTATGACCGCTATGT

45 GGCCATATATGACCTCTGCGCTACAGTGTGAAAACGTCCAGGAGAGTTTGCATCTGCTTG
GCCACATTTCCCTATGTCTATGGCTTCTCAGATGGACTCTTCCAGGCCATCCTGACCTTCCG
CCTGACCTTCTGTAGATCCAATGTCATCAACCACTTCTACTGTGCTGACCCGCCGCTCATTA
AGCTTTCTTGTTCTGATACTTATGTCAAAGAGCATGCCATGTTCATATCTGCTGGCTTCAAC
CTCTCCAGCTCCCTCACCATCGTCTTGGTGTCCTATGCCTTCATTCTTGCTGCCATCCTCCG

50 GATCAAATCAGCAGAGGGAAGGCACAAGGCATTCTCCACCTGTGGTTCCCATATGATGGC
TGTCACCCTGTTTTATGGGACTCTCTTTTGCATGTATATAAGACCACCAACAGATAAGACT
GTTGAGGAATCTAAAATAATAGCTGTCTTTTACACCTTTGTGAGTCCGGTACTTAATCCAT
TGATCTACAGTCTGAGGAATAAAGATGTGAAGCAGGCCTTGAAGAATGTCCTGAGATGA
(SEQ ID NO: 36)

55

AOLFR19 sequences:

METKNYSSSTSGFILLGLSSNPKLQKPLFAIFLIMYLLTAVGNVLIILAIYSDPRLHTPMYFFLSNL
SFMDICFTTVIVPKMLVNFLSETKIISYVGCLIQMYFFMAFGNTDSYLLASMAIDRLVAICNPLH
YDVVMKPWHCLLMLLGSCSISHLHSLFRVLLMSRLSFCASHIIKHFFCDTQPVLKLSCSDTSSSQ

5   MVVMTETLAVIVTPFLCTIFSYLQIIVTVLRIPSAAGKWKAFSTCGSHLTVVVLFYGSVIYVYFR
PLSMYSVMKGRVATVMYTVVTPMLNPFIYSLRNKDMKRGLKKLRHRIYS (SEQ ID NO: 37)

ATGGAGACAAAGAATTATAGCAGCAGCACCTCAGGCTTCATCCTCCTGGGCCTCTCTTCCA
ACCCTAAGCTGCAGAAACCTCTCTTTGCCATCTTCCTCATCATGTACCTACTCACTGCGGTG

10   GGGAATGTGCTCATCATCCTGGCCATCTACTCTGACCCCAGGCTCCACACCCCTATGTACT
TTTTTCTCAGCAACTTGTCTTTCATGGATATCTGCTTCACAACAGTCATAGTGCCTAAGATG
CTGGTGAATTTTCTATCAGAGACAAAGATTATCTCTTATGTGGGCTGCCTGATCCAGATGT
ACTTCTTCATGGCATTTGGGAACACTGACAGCTACCTGCTGGCCTCTATGGCCATCGACCG
GCTGGTGGCCATCTGCAACCCCTTACACTATGATGTGGTTATGAAACCATGGCATTGCCTA

15   CTCATGCTATTGGGTTCTTGCAGCATCTCCCACCTACATTCCCTGTTCCGCGTGCTACTTAT
GTCTCGCTTGTCTTTCTGTGCCTCTCACATCATTAAGCACTTTTTCTGTGACACCCAGCCTG
TGCTAAAGCTCTCCTGCTCTGACACATCCTCCAGCCAGATGGTGGTGATGACTGAGACCTT
AGCTGTCATTGTGACCCCCTTCCTGTGTACCATCTTCTCCTACCTGCAAATCATCGTCACTG
TGCTCAGAATCCCCTCTGCAGCCGGGAAGTGGAAGGCCTTCTCTACCTGTGGCTCCCACCT

20   CACTGTAGTGGTCCTGTTCTATGGGAGTGTCATCTATGTCTATTTTAGGCCTCTGTCCATGT
ACTCAGTGATGAAGGGCCGGGTAGCCACAGTTATGTACACAGTAGTGACACCCATGCTGA
ACCCTTTCATCTACAGCCTGAGGAACAAAGATATGAAAAGGGGTTTGAAGAAATTAAGAC
ACAGAATTTACTCATAG (SEQ ID NO: 38)

25   **AOLFR20 sequences:**

MVEENHTMKNEFILTGFTDHPELKTLLFVVFFAIYLITVVGNISLVALIFTHCRLHTPMYIFLGN
LALVDSCCACAITPKMLENFFSEGKRISLYECAVQFYFLCTVETADCFLLAAVAYDRYVAICNP
LQYHIMMSKKLCIQMTTGAFIAGNLHSMIHVGLVFRLVFCGLNHINHFYCDTLPLYRLSCVDPF
INELVLFIFSGSVQVFTIGSVLISYLYILLTIFRMKSKEGRAKAFSTCASHFSSVSLFYGSIFFLYIRP

30   NLLEEGGNDIPAAILFTIVVPLLNPFIYSLRNKEVISVLRKILLKIKSQGSVNK (SEQ ID NO: 39)

ATGGTTGAAGAAAATCATACCATGAAAAATGAGTTTATCCTCACAGGATTTACAGATCACC
CTGAGCTGAAGACTCTGCTGTTTGTGGTGTTCTTTGCCATCTATCTGATCACCGTGGTGGGG
GAATATTAGTTTGGTGGCACTGATATTTACACACTGTCGGCTTCACACACCAATGTACATC

35   TTTCTGGGAAATCTGGCTCTTGTGGATTCTTGCTGTGCCTGTGCTATTACCCCCAAAATGTT
AGAGAACTTCTTTTCTGAGGGCAAAAGGATTTCCCTCTATGAATGTGCAGTACAGTTTTAT
TTTCTTTGCACTGTGGAAACTGCAGACTGCTTTCTTCTGGCAGCAGTGGCCTATGACCGCT
ATGTGGCCATCTGCAACCCACTGCAGTACCACATCATGATGTCCAAGAAACTCTGCATTCA
GATGACCACAGGCGCCTTCATAGCTGGAAATCTGCATTCCATGATTCATGTAGGGCTTGTA

40   TTTAGGTTAGTTTTCTGTGGATTGAATCACATCAACCACTTTTACTGTGATACTCTTCCCTT
GTATAGACTCTCCTGTGTTGACCCTTTCATCAATGAACTGGTTCTATTCATCTTCTCAGGTT
CAGTTCAAGTCTTTACCATAGGTAGTGTCTTAATATCTTATCTCTATATTCTTCTTACTATT
TTCAGAATGAAATCCAAGGAGGGAAGGGCCAAAGCCTTTTCTACTTGTGCATCCCACTTTT
CATCAGTTTCATTATTCTATGGATCTATTTTTTTCCTATACATTAGACCAAATTTGCTTGAA

45   GAAGGAGGTAATGATATACCAGCTGCTATTTTATTTACAATAGTAGTTCCCTTACTAAATC
CTTTCATTTATAGTCTGAGAAACAAGGAAGTAATAAGTGTCTTAAGAAAAATTCTGCTGAA
AATAAAATCTCAAGGAAGTGTGAACAAATGA (SEQ ID NO: 40)

AOLFR21 sequences:

50   MEPRKNVTDFVLLGFTQNPKEQKVLFVMFLLFYILTMVGNLLIVVTVTVSETLGSPMSFFLAGL
TFIDIIYSSSISPRLISDLFFGNNSISFQSFMAQLFIEHLFGGSEVFLLLVMAYDRYVAICKPLHYLV
IMRQWVCVLLLVVSWVGGFLQSVFQLSIIYGLPFCGPNVIDHFFCDMYPLLKLACTDTHVIGLL
VVANGGLSCTIAFLLLLISYGVILHSLKKLSQKGRQKAHSTCSSHITVVVFFFVPCIFMCARPAR
TFSIDKSVSVFYTVITPMLNPLIYTLRNSEMTSAMKKL (SEQ ID NO: 41)

55

TCACCCTCTCCTTCTGTAAGGACAATCAAATAAACTTCTTCTTCTGTGACCTCCCACCCCTG
CTGAAGCTTGCCTGCAGTGACACAGCAAACATCGAGATTGTCATCATCTTCTTTGGCAATT
TTGTGATTTTGGCCAATGCCTCCGTCATCCTGATTTCCTATCTGCTCATCATCAAGACCATT
TTGAAAGTGAAGTCTTCAGGTGGCAGGGCCAAGACTTTCTCCACATGTGCCTCTCACATCA
CTGCTGTGGCCCTTTTCTTTGGAGCCCTTATCTTCATGTATCTGCAAAGTGGCTCAGGCAAA
TCTCTGGAGGAAGACAAAGTCGTGTCTGTCTTCTATACAGTGGTCATCCCCATGCTGAACC
CTCTGATCTACAGCTTAAGAAACAAAGATGTAAAAGACGCCTTCAGAAAGGTCGCTAGGA
GACTCCAGGTGTCCCTGAGCATGTAG (SEQ ID NO: 46)

AOLFR25 sequences:

METGNLTWVSDFVFLGLSQTRELQRFLFLMFLFVYITTVMGNILIIITVTSDSQLHTPMYFLLRN
LAVLDLCFSSVTAPKMLVDLLSEKKTISYQGCMGQIFFFHFLGGAMVFFLSVMAFDRLIAISRPL
RYVTVMNTQLWVGLVVATWVGGFVHSIVQLALMLPLPFCGPNILDNFYCDVPQVLRLACTDT
SLLEFLKISNSGLLDVVWFFLLLMSYLFILVMLRSHPGEARRKAASTCTTHIIVVSMIFVPSIYLY
ARPFTPFPMDKLVSIGHTVMTPMLNPMIYTLRNQDMQAAVRRLGRHRLV (SEQ ID NO: 47)

ATGGAAACAGGGAACCTCACGTGGGTATCAGACTTTGTCTTCCTGGGGCTCTCGCAGACTC
GGGAGCTCCAGCGTTTCCTGTTTCTAATGTTCCTGTTTGTCTACATCACCACTGTTATGGGA
AACATCCTTATCATCATCACAGTGACCTCTGATTCCCAGCTCCACACACCCATGTACTTTCT
GCTCCGAAACCTGGCTGTCCTAGACCTCTGTTTCTCTTCAGTCACTGCTCCCAAAATGCTAG
TGGACCTCCTCTCTGAGAAGAAAACCATCTCTTACCAGGGCTGCATGGGTCAGATCTTCTT
CTTCCACTTTTTGGGAGGTGCCATGGTCTTCTTCCTCTCAGTGATGGCCTTTGACCGCCTCA
TTGCCATCTCCCGGCCCCTCCGCTATGTCACCGTCATGAACACTCAGCTCTGGGTGGGGCT
GGTGGTAGCCACCTGGGTGGGAGGCTTTGTCCACTCTATTGTCCAGCTGGCTCTGATGCTC
CCACTGCCCTTCTGTGGCCCCAACATTTTGGATAACTTCTACTGTGATGTTCCCCAAGTACT
GAGACTTGCCTGCACTGACACCTCACTGCTGGAGTTCCTCAAGATCTCCAACAGTGGGCTG
CTGGATGTCGTCTGGTTCTTCCTCCTCCTGATGTCCTACTTATTCATCCTGGTGATGCTGAG
GTCACATCCAGGGGAGGCAAGAAGGAAGGCAGCTTCCACCTGCACCACCCACATCATCGT
GGTTTCCATGATCTTCGTTCCAAGCATTTACCTCTATGCCCGGCCCTTCACTCCATTCCCTA
TGGACAAGCTTGTGTCCATCGGCCACACAGTCATGACCCCCATGCTCAACCCCATGATCTA
TACCCTGAGGAACCAGGACATGCAGGCAGCAGTGAGAAGATTAGGGAGACACCGGCTGGT
TTGA (SEQ ID NO: 48)

AOLFR26 sequences:

MAAKNSSVTEFILEGLTHQPGLRIPLFFLFLGFYTVTVVGNLGLITLIGLNSHLHTPMYFFLFNLS
LIDFCFSTTITPKMLMSFVSRKNIISFTGCMTQLFFFCFFVVSESFILSAMAYDRYVAICNPLLYT
VTMSCQVCLLLLLLGAYGMGFAGAMAHTGSIMNLTFCADNLVNHFMCDILPLLELSCNSSYMN
ELVVFIVVAVDVGMPIVTVFISYALILSSILHNSSTEGRSKAFSTCSSHIIVVSLFFGSGAFMYLKP
LSILPLEQGKVSSLFYTIIVPVLNPLIYSLRNKDVKVALRRTLGRKIFS (SEQ ID NO: 49)

ATGGCAGCCAAAAACTCTTCTGTGACAGAGTTTATCCTCGAAGGCTTAACCCACCAGCCGG
GACTGCGGATCCCCCTCTTCTTCCTGTTTCTGGGTTTCTACACGGTCACCGTGGTGGGGGAA
CCTGGGCTTGATAACCCTGATTGGGCTGAACTCTCACCTGCACACTCCCATGTACTTCTTCC
TTTTTAACCTCTCTTTAATAGATTTCTGTTTCTCCACTACCATCACTCCCAAAATGCTGATG
AGTTTTGTCTCAAGGAAGAACATCATTTCCTTCACAGGGTGTATGACTCAGCTCTTCTTCTT
CTGCTTCTTTGTCGTCTCTGAGTCCTTCATCCTGTCAGCGATGGCGTATGACCGCTACGTGG
CCATCTGTAACCCACTGTTGTACACAGTCACCATGTCTTGCCAGGTGTGTTTGCTCCTTTTG
TTGGGTGCCTATGGGATGGGGTTTGCTGGGGCCATGGCCCACACAGGAAGCATAATGAAC
CTGACCTTCTGTGCTGACAACCTTGTCAATCATTTCATGTGTGACATCCTTCCTCTCCTTGA
GCTCTCCTGCAACAGCTCTTACATGAATGAGCTGGTGGTCTTTATTGTGGTGGCTGTTGAC
GTTGGAATGCCCATTGTCACTGTCTTTATTTCTTATGCCCTCATCCTCTCCAGCATTCTACA
CAACAGTTCTACAGAAGGCAGGTCCAAAGCCTTTAGTACTTGCAGTTCCCACATAATTGTA
GTTTCTCTTTTCTTTGGTTCTGGTGCTTTCATGTATCTCAAACCCCTTTCCATCCTGCCCCTC
GAGCAAGGGAAAGTGTCCTCCCTGTTCTATACCATAATAGTCCCCGTGTTAAACCCATTAA
TCTATAGCTTGAGGAACAAGGATGTCAAAGTTGCCCTGAGGAGAACTTTGGGCAGAAAAA
TCTTTTCTTAA (SEQ ID NO: 50)

AOLFR27 sequences:

MPSQNYSIISEFNLFGFSAFPQHLLPILFLLYLLMFLFTLLGNLLIMATIWIEHRLHTPMYLFLCTL
SVSEILFTVAITPRMLADLLSTHHSITFVACANQMFFSFMFGFTHSFLLLVMGYDRYVAICHPLR
5   YNVLMSPRDCAHLVACTWAGGSVMGMMVTTIVFHLTFCGSNVIHHFFCHVLSLLKLACENKT
SSVIMGVMLVCVTALIGCLFLIILSYVFIVAAILRIPSAEGRHKTFSTCVSHLTVVVTHYSFASFIY
LKPKGLHSMYSDALMATTYTVFTPFLSPIIFSLRNKELKNAINKNFYRKFCPPSS (SEQ ID NO:
51)

10   ATGCCTAGTCAGAACTATAGCATCATATCTGAATTTAACCTCTTTGGCTTCTCAGCCTTCCC
CCAGCACCTCCTGCCCATCTTGTTCCTGCTGTACCTCCTGATGTTCCTGTTCACATTGCTGG
GCAACCTTCTCATCATGGCCACAATCTGGATTGAACACAGACTCCACACACCCATGTACCT
CTTCTTGTGCACCCTCTCCGTCTCTGAGATTCTGTTCACTGTTGCCATCACCCCTCGCATGC
TGGCTGATCTGCTTTCCACCCATCATTCCATCACCTTTGTGGCTTGTGCCAACCAGATGTTC
15   TTCTCCTTCATGTTTGGCTTCACTCACTCCTTCCTTCTCCTGGTCATGGGCTATGATCGCTA
TGTGGCCATCTGCCACCCACTGCGTTACAATGTGCTCATGAGCCCCCGTGACTGTGCCCAT
CTTGTGGCCTGTACCTGGGCTGGTGGCTCAGTCATGGGGATGATGGTGACAACGATAGTTT
TCCACCTCACTTTCTGTGGGTCTAATGTGATCCACCATTTTTTCTGTCATGTGCTTTCCCTCT
TGAAGTTGGCCTGTGAAAACAAGACATCATCTGTCATCATGGGTGTGATGCTGGTGTGTGT
20   CACAGCCCTGATAGGCTGTTTATTCCTCATCATCCTCTCCTATGTCTTCATTGTGGCTGCCA
TCTTGAGGATTCCCTCTGCCGAAGGCCGGCACAAGACATTTTCTACGTGTGTATCCCACCT
CACTGTGGTGGTCACGCACTATAGTTTTGCCTCCTTTATCTACCTCAAGCCCAAGGGCCTCC
ATTCTATGTACAGTGACGCCTTGATGGCCACCACCTATACTGTCTTCACCCCCTTCCTTAGC
CCAATCATTTTCAGCCTAAGGAACAAGGAGCTGAAGAATGCCATAAATAAAAACTTTTACA
25   GAAAATTCTGTCCTCCAAGTTCCTGA (SEQ ID NO: 52)

AOLFR28 sequences:

MPNFTDVTEFTLLGLTCRQELQVLFFVVFLAVYMITLLGNIGMIILISISPQLQSPMYFFLSHLSF
ADVCFSSNVTPKMLENLLSETKTISYVGCLVQCYFFIAVVHVEVYILAVMAFDRYMAGCXPLL
30   YGSKMSRTVCVRLISVXYXYGFSVSLICTLWTYGLYFCGNFEINHFYCADPPLIQIACGRVHIKE
ITMIVIAGINFTYSLSVVLISYTLIVVAVLRMRSADGRRKAFSTCGSHLTAVSMFYGTPIFMYLR
RPTEESVEQGKMVAVFYTTVIPMLNPMIYSLRNKDVKEAVNKAITKTYVRQ (SEQ ID NO: 53)

ATGCCTAATTTCACGGATGTGACAGAATTTACTCTCCTGGGGCTGACCTGTCGTCAGGAGC
35   TACAGGTTCTCTTTTTTGTGGTGTTCCTAGCGGTTTACATGATCACTCTGTTGGGAAATATT
GGTATGATCATTTTGATTAGCATCAGTCCTCAGCTTCAGAGTCCCATGTACTTTTTCCTGAG
TCATCTGTCTTTTGCGGACGTGTGCTTCTCCTCCAACGTTACCCCCAAAATGCTGGAAAACT
TATTATCAGAGACAAAAACCATTTCCTATGTGGGATGCTTGGTGCAGTGCTACTTTTTCAT
TGCCGTTGTCCACGTGGAGGTCTATATCCTGGCTGTGATGGCCTTTGACAGGTACATGGCC
40   GGCTGCAANCCTCTGCTTTATGGCAGTAAAATGTCTAGGACTGTGTGTGTTCGGCTCATCT
CTGTGNNNTATGNNTATGGATTCTCTGTCAGCCTAATATGCACACTATGGACTTATGGCTT
ATACTTCTGTGGAAACTTTGAAATCAATCACTTCTATTGTGCAGATCCCCCTCTCATCCAGA
TTGCCTGTGGGAGAGTGCACATCAAAGAAATCACAATGATTGTTATTGCTGGAATTAACTT
CACATATTCCCTCTCGGTGGTCCTCATCTCCTACACTCTCATTGTAGTAGCTGTGCTACGCA
45   TGCGCTCTGCCGATGGCAGGAGGAAGGCGTTCTCCACCTGTGGGTCCCACTTGACGGCTGT
TTCTATGTTTTATGGGACCCCCATCTTCATGTATCTCAGGAGACCCACTGAGGAATCCGTA
GAGCAGGGCAAAATGGTGGCTGTGTTTTACACCACAGTAATTCCTATGTTGAATCCCATGA
TCTACAGTCTGAGAAATAAGGATGTAAAAGAAGCAGTCAACAAAGCAATCACCAAGACAT
ATGTGAGGCAGTAA (SEQ ID NO: 54)
50

AOLFR29 sequences:

MMSFAPNASHSPVFLLLGFSRANISYTLLFFLFLAIYLTTILGNVTLVLLISWDSRLHSPMYYLLR
GLSVIDMGLSTVTLPQLLAHLVSHYPTIPAARCLAQFFFFYAFGVTDTLVIAVMALDRYVAICD
PLHYALVMNHQRCACLLALSWVVSILHTMLRVGLVLPLCWTGDAGGNVNLPHFFCDHRPLLR
55   ASCSDIHSNELAIFFEGGFLMLGPCALIVLSYVRIGAAILRLPSAAGRRRAVSTCGSHLTMVGFL

69

TCCTCTGCCATTTGGCCTTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTC
ATGAGCTTCCTAAGGAAAGAAACCTCTCTCCCTGTTGCTGGTTGTGTGGCCCAGCTCTGTT
CTGTAGTGACGTTTGGTACGGCCGAGTGCTTCCTGCTGGCTGCCATGGCCTATGATCGCTA
TGTGGCCATCTGCTCACCCCTGCTCTACTCTACCTGCATGTCCCCTGGAGTCTGCATCATCT
5   TAGTGGGCATGTCCTACCTGGGTGGATGTGTGAATGCTTGGACATTCATTGGCTGCTTATT
AAGACTGTCCTTCTGTGGGCCAAATAAAGTCAATCACTTTTTCTGTGACTATTCACCACTTT
TGAAGCTTGCTTGTTCCCATGATTTTACTTTTGAAATAATTCCAGCTATCTCTTCTGGATCT
ATCATTGTGGCCACTGTGTGTGTCATAGCCATATCCTACATCTATATCCTCATCACCATCCT
GAAGATGCACTCCACCAAGGGCCGCCACAAGGCCTTCTCCACCTGCACCTCCCACCTCACT
10   GCAGTCACTCTGTTCTATGGGACCATTACCTTCATTTATGTGATGCCCAAGTCCAGCTACTC
AACTGACCAGAACAAGGTGGTGTCTGTGTTCTACACCGTGGTGATTCCCATGTTGAACCCC
CTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTAGAATA
AAAATATTTTCTTGA (SEQ ID NO: 60)

15   **AOLFR32 sequences:**

MNSLKDGNHTALTGFILLGLTDDPILRVILFMIILSGNLSIIILIRISSQLHHPMYFFLSHLAFADM
AYSSSVTPNMLVNFLVERNTVSYLGCAIQLGSAAFFATVECVLLAAMAYDRFVAICSPLLYSTK
MSTQVSVQLLLVVYIAGFLIAVSYTTSFYFLLFCGPNQVNHFFCDFAPLLELSCSDISVSTVVLSF
SSGSIIVVTVCVIAVCYIYILITILKMRSTEGHHKAFSTCTSHLTVVTLFYGTITFIYVMPNFSYST
20   DQNKVVSVLYTVVIPMLNPLIYSLRNKEIKGALKRELVRKILSHDACYFSRTSNNDIT (SEQ ID
NO: 61)

ATGAATTCCCTGAAGGACGGGAATCACACCGCTCTGACGGGGGTTCATCCTATTGGGCTTAA
CAGATGATCCAATCCTTCGAGTCATCCTCTTCATGATCATCCTATCTGGTAATCTCAGCATA
25   ATTATTCTTATCAGAATTTCTTCTCAGCTCCATCATCCTATGTATTTCTTTCTGAGCCACTT
GGCTTTTGCTGACATGGCCTATTCATCTTCTGTCACACCCAACATGCTTGTAAACTTCCTGG
TGGAGAGAAATACAGTCTCCTACCTTGGATGTGCCATCCAGCTTGGTTCAGCGGCTTTCTT
TGCAACAGTCGAATGCGTCCTTCTGGCTGCCATGGCCTATGACCGCTTTGTGGCAATTTGC
AGTCCACTGCTTTATTCAACCAAAATGTCCACACAAGTCAGTGTCCAGCTACTCTTAGTAG
30   TTTACATAGCTGGTTTTCTCATTGCTGTCTCCTATACTACTTCCTTCTATTTTTTACTCTTCT
GTGGACCAAATCAAGTCAATCATTTTTTCTGTGATTTCGCTCCCTTACTTGAACTCTCCTGT
TCTGATATCAGTGTCTCCACAGTTGTTCTCTCATTTTCTTCTGGATCCATCATTGTGGTCAC
TGTGTGTGTCATAGCCGTCTGCTACATCTATATCCTCATCACCATCCTGAAGATGCGCTCCA
CTGAGGGGCACCACAAGGCCTTCTCCACCTGCACTTCCCACCTCACTGTGGTTACCCTGTT
35   CTATGGGACCATTACCTTCATTTATGTGATGCCCAATTTTAGCTACTCAACTGACCAGAAC
AAGGTGGTGTCTGTGTTGTACACAGTGGTGATTCCCATGTTGAACCCCCTGATCTACAGCC
TCAGGAACAAGGAGATTAAGGGGGCTCTGAAGAGAGAGCTTGTTAGAAAAATACTTTCTC
ATGATGCTTGTTATTTTAGTAGAACTTCAAATAATGATATTACATAG (SEQ ID NO: 62)

40   **AOLFR34 sequences:**

MLEGVEHLLLLLLLLTDVNSKELQSGNQTSVSHFILVGLHHPPQLGAPLFLAFLVTYLLTVSGNG
LIILTVLVDIRLHRPMCLFLCHLSFLDMTISCAIVPKMLAGFLLGSRIISFGGCVIQLFSFHFLGCT
ECFLYTLMAYDRFLAICKPLHYATIMTHRVCNSLALGTWLGGTIHSLFQTSFVFRLPFCGPNRV
DYIFCDIPAMLRLACADTAINELVTFADIGFLALTCFMLILTSYGYIVAAILRIPSADGRRNAFST
45   CAAHLTVVIVYVPCTFIYLRPCSQEPLDGVVAVFYTVITPLLNSIIYTLCNKEMKAALQRLGG
HKEVQPH (SEQ ID NO: 63)

ATGTTAGAGGGTGTTGAGCATCTCCTTCTGCTACTTCTTTTGACAGATGTGAACAGCAAGG
AACTGCAAAGTGGAAACCAGACTTCTGTGTCTCACTTCATTTTGGTGGGCCTGCACCACCC
50   ACCACAGCTGGGAGCGCCACTCTTCTTAGCTTTCCTTGTCATCTATCTCCTCACTGTTTCTG
GAAATGGGCTCATCATCCTCACTGTCTTAGTGGACATCCGGCTCCATCGTCCCATGTGCTT
GTTCCTGTGTCACCTCTCCTTCTTGGACATGACCATTTCTTGTGCTATTGTCCCCAAGATGC
TGGCTGGCTTTCTCTTGGGTAGTAGGATTATCTCCTTTGGGGGCTGTGTAATCCAACTATTT
TCTTTCCATTTCCTGGGCTGTACTGAGTGCTTCCTTTACACACTCATGGCTTATGACCGTTT
55   CCTTGCCATTTGTAAGCCCTTACACTATGCTACCATCATGACCCACAGAGTCTGTAACTCCC
TGGCTTTAGGCACCTGGCTGGGAGGGACTATCCATTCACTTTTCCAAACAAGTTTTGTATT

CCGGCTGCCCTTCTGTGGCCCCAATCGGGTCGACTACATCTTCTGTGACATTCCTGCCATGC
TGCGTCTAGCCTGCGCCGATACGGCCATCAACGAGCTGGTCACCTTTGCAGACATTGGCTT
CCTGGCCCTCACCTGCTTCATGCTCATCCTCACTTCCTATGGCTATATTGTAGCTGCCATCC
TGCGAATTCCGTCAGCAGATGGGCGCCGCAATGCCTTCTCCACTTGTGCTGCCCACCTCAC
5   TGTTGTCATTGTTTACTATGTGCCCTGCACCTTCATTTACCTGCGGCCTTGTTCACAGGAGC
CCCTGGATGGGGTGGTAGCTGTCTTTTACACTGTCATCACTCCCTTGCTTAACTCCATCATC
TACACACTGTGCAACAAAGAAATGAAGGCAGCATTACAGAGGCTAGGGGGGCCACAAGGAA
GTGCAGCCTCACTGA (SEQ ID NO: 64)

10   **AOLFR35 sequences:**

MEPLNRTEVSEFFLKGFSGYPALEHLLFPLCSAMYLVTLLGNTAIMAVSVLDIHLHTPVYFFLG
NLSTLDICYTPTFVPLMLVHLLSSRKTISFAVCAIQMCLSLSTGSTECLLLAITAYDRYLAICQPL
RYHVLMSHRLCVLLMGAAWVLCLLKSVTEMVISMRLPFCGHHVVSHFTCKILAVLKLACGNT
SVSEDFLLAGSILLLPVPLAFICLSYLLILATILRVPSAARCCKAFSTCLAHLAVVLLFYGTIIFMY
15   LKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASR (SEQ ID NO:
65)

ATGGAGCCGCTCAACAGAACAGAGGTGTCCGAGTTCTTTCTGAAAGGATTTTCTGGCTACC
CAGCCCTGGAGCATCTGCTCTTCCCTCTGTGCTCAGCCATGTACCTGGTGACCCTCCTGGG
20   GAACACAGCCATCATGGCGGTGAGCGTGCTAGATATCCACCTGCACACGCCCGTGTACTTC
TTCCTGGGCAACCTCTCTACCCTGGACATCTGCTACACGCCCACCTTTGTGCCTCTGATGCT
GGTCCACCTCCTGTCATCCCGGAAGACCATCTCCTTTGCTGTCTGTGCCATCCAGATGTGTC
TGAGCCTGTCCACGGGCTCCACGGAGTGCCTGCTACTGGCCATCACGGCCTATGACCGCTA
CCTGGCCATCTGCCAGCCACTCAGGTACCACGTGCTCATGAGCCACCGGCTCTGCGTGCTG
25   CTGATGGGAGCTGCCTGGGTCCTCTGCCTCCTCAAGTCGGTGACTGAGATGGTCATCTCCA
TGAGGCTGCCCTTCTGTGGCCACCACGTGGTCAGTCACTTCACCTGCAAGATCCTGGCAGT
GCTGAAGCTGGCATGCGGCAACACGTCGGTCAGCGAAGACTTCCTGCTGGCGGGCTCCAT
CCTGCTGCTGCCTGTACCCCTGGCATTCATCTGCCTGTCCTACTTGCTCATCCTGGCCACCA
TCCTGAGGGTGCCCTCGGCCGCCAGGTGCTGCAAAGCCTTCTCCACCTGCTTGGCACACCT
30   GGCTGTAGTGCTGCTTTTCTACGGCACCATCATCTTCATGTACTTGAAGCCCAAGAGTAAG
GAAGCCCACATCTCTGATGAGGTCTTCACAGTCCTCTATGCCATGGTCACGACCATGCTGA
ACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCGCCAGGAAGGTGTGGG
GCAGGAGTCGGGCCTCCAGGTGA (SEQ ID NO: 66)

35   **AOLFR36 sequences:**

MYLVTVLRNLLSILAVSSDSHPHTPMYFFLSNLCWADIGFTLATVPKMIVDMGSHSKVISYGG
CLTQMSFLVLFACIVDMFLTVMAYDCFVAICRPLHYPVIVNPHLCVFFVLVSFFLSLLDSQLHS
WIVLQFTFFKNVEISNFVCEPSQLLKLASYDSVINSIFIYFDNTMFGFLPISGILLSYYKIVPSILRIS
SSDGKYKAFSACGCHLAVVCLFYGTGIGVYLTSAVAPPLRNGMVASVMYAVVTPMLNPFIYS
40   LRNRDIQSALWRVCNKTVESHDLFHPFSCVVEKGQPHSIPTSANPAP (SEQ ID NO: 67)

ATGTATCTGGTCACGGTGCTGAGGAACCTGCTCAGCATCCTGGCTGTCAGCTCTGACTCCC
ACCCCCACACACCCATGTACTTCTTCCTCTCCAACCTGTGCTGGGCTGACATCGGTTTCACC
TTGGCCACGGTTCCCAAAATGATTGTGGACATGGGGTCGCATAGCAAAGTCATCTCTTATG
GGGGCTGCCTGACACAGATGTCTTTCTTGGTACTTTTTGCATGTATAGTAGACATGTTCCT
45   GACTGTGATGGCTTATGACTGCTTTGTAGCCATCTGTCGCCCTCTGCACTACCCAGTCATC
GTGAATCCTCACCTCTGTGTCTTCTTCGTTTTGGTGTCCTTTTTCCTTAGCCTGTTGGATTCC
CAGCTGCACAGTTGGATTGTGTTACAATTCACCTTCTTCAAGAATGTGGAAATCTCTAATT
TTGTCTGTGAGCCATCTCAACTTCTCAAGCTTGCCTCTTATGACAGCGTCATCAATAGCATA
TTCATATATTTTGATAATACTATGTTTGGTTTTCTTCCCATTTCAGGGATCCTTTTGTCTTAC
50   TATAAAATTGTCCCCTCCATTCTAAGGATTTCATCATCAGATGGGAAGTACAAAGCCTTCT
CAGCCTGTGGCTGTCACCTGGCAGTTGTTTGCTTATTTTATGGAACAGGCATTGGCGTGTA
CCTGACTTCAGCTGTGGCACCACCCCTCAGGAATGGTATGGTGGCGTCAGTGATGTACGCT
GTGGTCACCCCCATGCTGAACCCTTTCATCTACAGCCTGAGAAACAGGGACATTCAAAGTG
55   CCCTGTGGAGGGTGTGCAACAAAACAGTCGAATCTCATGATCTGTTCCATCCTTTTTCTTG

TGTGGTTGAGAAAGGGCAACCACATTCAATCCCTACATCTGCAAATCCTGCCCCTTAG
(SEQ ID NO: 68)

AOLFR37 sequences:

5   MEKANETSPVMGFVLLRLSAHPELEKTFFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLG
NLSFLDICFTTSSVPLVLDSFLTPQETISFSACAVQMALSFAMAGTECLLLSMMAFDRYVAICNP
LRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVINHFTCEILAVLKLACADIS
INVISMEVTNVIFLGVPVLFISFSYVFIITTILRIPSAEGRKKVFSTCSAHLTVVIVFYGTLFFMYG
KPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPIIYSLRNKDVKAAVRRLLRPKGFTQ (SEQ ID

10   NO: 69)

ATGGAAAAAGCCAATGAGACCTCCCCTGTGATGGGGTTCGTTCTCCTGAGGCTCTCTGCCC
ACCCAGAGCTGGAAAAGACATTCTTCGTGCTCATCCTGCTGATGTACCTCGTGATCCTGCT
GGGCAATGGGGTCCTCATCCTGGTGACCATCCTTGACTCCCGCCTGCACACGCCCATGTAC
15   TTCTTCCTAGGGAACCTCTCCTTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCACTGGT
CCTGGACAGCTTTTTGACTCCCCAGGAAACCATCTCCTTCTCAGCCTGTGCTGTGCAGATG
GCACTCTCCTTTGCCATGGCAGGAACAGAGTGCTTGCTCCTGAGCATGATGGCATTTGATC
GCTATGTGGCCATCTGCAACCCCCTTAGGTACTCCGTGATCATGAGCAAGGCTGCCTACAT
GCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTGCTGCTTCCGTGGTACACACATCCTTG
20   GCAATTCAGCTGCCCTTCTGTGGAGACAATGTCATCAACCACTTCACCTGTGAGATTCTGG
CTGTTCTAAAGTTGGCCTGTGCTGACATTTCCATCAATGTGATCAGCATGGAGGTGACGAA
TGTGATCTTCCTAGGAGTCCCGGTTCTGTTCATCTCTTTCTCCTATGTCTTCATCATCACCA
CCATCCTGAGGATCCCCTCAGCTGAGGGGAGGAAAAAGGTCTTCTCCACCTGCTCTGCCCA
CCTCACCGTGGTGATCGTCTTCTACGGGACCTTATTCTTCATGTATGGGAAGCCTAAGTCT
25   AAGGACTCCATGGGAGCAGACAAAGAGGATCTTTCAGACAAACTCATCCCCCTTTTCTATG
GGGTGGTGACCCCGATGCTCAACCCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGG
CTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGA (SEQ ID NO: 70)

AOLFR38 sequences:

30   MYLVTVLRNLLIILAVSSDSHLHTPMCFFLSNLCWADIGFTSAMVPKMIVDMQSHSRVISYAGC
LTQMSFFVLFACIEDMLLTVMAYDRFVAICHPLHYPVIMNPHLGVFLVLVSFFLSLLDSQLHSW
IVLQFTFFKNVEISNFVCDPSQLLNLACSDSVINSIFIYLDSIMFGFLPISGILLSYANNVPSILRISS
SDRKSKAFSTCGSHLAVVCLFYGTGIGVYLTSAVSPPPRNGVVASVMYAVVTPMLNPFIYSLR
NRDIQSALWRLRSRTVESHDLLSQDLLHPFSCVGEKGQPH (SEQ ID NO: 71)

35

ATGTACCTGGTCACGGTGCTGAGGAACCTGCTCATCATCCTGGCTGTCAGCTCTGACTCCC
ACCTCCACACCCCCATGTGCTTCTTCCTCTCCAACCTGTGCTGGGCTGACATCGGTTTCACC
TCGGCCATGGTTCCCAAGATGATTGTGGACATGCAGTCGCATAGCAGAGTCATCTCTTATG
CGGGCTGCCTGACACAGATGTCTTTCTTTGTCCTTTTTGCATGTATAGAAGACATGCTCCTG
40   ACAGTGATGGCCTATGACCGATTTGTGGCCATCTGTCACCCCCTGCACTACCCAGTCATCA
TGAATCCTCACCTTGGTGTCTTCTTAGTTTTGGTGTCCTTTTTCCTCAGCCTGTTGGATTCC
CAGCTGCACAGTTGGATTGTGTTACAATTCACCTTCTTCAAGAATGTGGAAATCTCCAATT
TTGTCTGTGACCCATCTCAACTTCTCAACCTTGCCTGTTCTGACAGTGTCATCAATAGCATA
TTCATATATTTAGATAGTATTATGTTTGGTTTTCTTCCCATTTCAGGGATCCTTTTGTCTTAC
45   GCTAACAATGTCCCCTCCATTCTAAGAATTTCATCATCAGATAGGAAGTCTAAAGCCTTCT
CCACCTGTGGCTCTCACCTGGCAGTTGTTTGCTTATTTTATGGAACAGGCATTGGCGTGTA
CCTGACTTCAGCTGTGTCACCACCCCCCAGGAATGGTGTGGTGGCATCAGTGATGTACGCT
GTGGTCACCCCCATGCTGAACCCTTTCATCTACAGCCTGAGAAATAGGGACATTCAAAGTG
CCCTGTGGAGGCTGCGCAGCAGAACAGTCGAATCTCATGATCTGTTATCTCAAGATCTGCT
50   CCATCCTTTTTCTTGTGTGGGTGAGAAAGGTCAACCACATTAA (SEQ ID NO: 72)

AOLFR39 sequences:

MGVKNHSTVTEFLLSGLTEQAELQLPLFCLFLGIYTVTVVGNLSMISIIRLNRQLHTPMYYFLSS
LSFLDFCYSSVITPKMLSGFLCRDRSISYSGCMIQLFFFCVCVISECYMLAAMACDRYVAICSPL
55   LYRVIMSPRVCSLLVAAVFSVGFTDAVIHGGCILRLSFCGSNIIKHYFCDIVPLIKLSCSSTYIDEL

LIFVIGGFNMVATSLTIIISYAFILTSILRIHSKKGRCKAFSTCSSHLTAVLMFYGSLMSMYLKPAS
SSSLTQEKVSSVFYTTVILMLNPLIYSLRNNEVRNALMKLLRRKISLSPG (SEQ ID NO: 73)

ATGGGTGTAAAAAACCATTCCACAGTGACTGAGTTTCTTCTTTCAGGATTAACTGAACAAG
CAGAGCTTCAGCTGCCCCTCTTCTGCCTCTTCTTAGGAATTTACACAGTTACTGTGGTGGG
AAACCTCAGCATGATCTCAATTATTAGGCTGAATCGTCAACTTCATACCCCCATGTACTAT
TTCCTGAGTAGTTTGTCTTTTTTAGATTTCTGCTATTCTTCTGTCATTACCCCTAAAATGCT
ATCAGGGTTTTTATGCAGAGATAGATCCATCTCCTATTCTGGATGCATGATTCAGCTGTTTT
TTTTCTGTGTTTGTGTTATTTCTGAATGCTACATGCTGGCAGCCATGGCCTGCGATCGCTAC
GTGGCCATCTGCAGCCCACTGCTCTACAGGGTCATCATGTCCCCTAGGGTCTGTTCTCTGC
TGGTGGCTGCTGTCTTCTCAGTAGGTTTCACTGATGCTGTGATCCATGGAGGTTGTATACT
CAGGTTGTCTTTCTGTGGATCAAACATCATTAAACATTATTTCTGTGACATTGTCCCTCTTA
TTAAACTCTCCTGCTCCAGCACTTATATTGATGAGCTTTTGATTTTTGTCATTGGTGGATTT
AACATGGTGGCCACAAGCCTAACAATCATTATTTCATATGCTTTTATCCTCACCAGCATCCT
GCGCATCCACTCTAAAAAGGGCAGGTGCAAAGCGTTTAGCACCTGTAGCTCCCACCTGACA
GCTGTTCTTATGTTTTATGGGTCTCTGATGTCCATGTATCTCAAACCTGCTTCTAGCAGTTC
ACTCACCCAGGAGAAAGTATCCTCAGTATTTTATACCACTGTGATTCTCATGTTGAATCCC
TTGATATATAGTCTGAGGAACAATGAAGTAAGAAATGCTCTGATGAAACTTTTAAGAAGA
AAAATATCTTTATCTCCAGGATAA (SEQ ID NO: 74)

AOLFR40 sequences:

MSNATLLTAFILTGLPHAPGLDAPLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYYFLTNLS
FIDMWFSTVTVPKMLMTLVSPSGRTISFHSCVAQLYFFHFLGSTECFLYTVMSYDRYLAISYPL
RYTNMMTGRSCALLATGTWLSGSLHSAVQTILTFHLPYCGPNQIQHYFCDAPPILKLACADTS
ANEMVIFVNIGLVASGCFVLIVLSYVSIVCSILRIRTSEGRHRAFQTCASHCIVVLCFFGPGLFIYL
RPGSRDALHGVVAVFYTTLTPLFNPVVYTLRNKEVKKALLKLKNGSVFAQGE (SEQ ID NO:
75)

ATGTCCAACGCCACCCTACTGACAGCGTTCATCCTCACGGGCCTTCCCCATGCCCCAGGGC
TGGACGCCCCCCTCTTTGGAATCTTCCTGGTGGTTTACGTGCTCACTGTGCTGGGGAACCT
CCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCCCCATGTACTACTTCCTCA
CCAACCTGTCCTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCCAAAATGCTGATGAC
CTTGGTGTCCCCAAGCGGCAGGACTATCTCCTTCCACAGCTGCGTGGCTCAGCTCTATTTTT
TCCACTTCCTGGGGAGCACCGAGTGTTTCCTCTACACAGTCATGTCCTATGATCGCTACCT
GGCCATCAGTTACCCGCTCAGGTACACCAACATGATGACTGGGCGCTCGTGTGCCCTCCTG
GCCACCGGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGACCATATTGACTTTCC
ATTTGCCCTACTGTGGACCCAACCAGATCCAGCACTACTTCTGTGACGCACCGCCCATCCT
GAAACTGGCCTGTGCAGACACCTCAGCCAACGAGATGGTCATCTTTGTGAATATTGGGCTA
GTGGCCTCGGGCTGCTTTGTCCTGATAGTGCTGTCCTATGTGTCCATCGTCTGTTCCATCCT
GCGGATCCGCACCTCAGAGGGGAGGCACAGAGCCTTTCAGACCTGTGCCTCCCACTGTATC
GTGGTCCTTTGCTTCTTTGGCCCTGGTCTTTTCATTTACCTGAGGCCAGGCTCCAGGGACGC
CTTGCATGGGGTTGTGGCCGTTTTCTACACCACGCTGACTCCTCTTTTCAACCCTGTTGTGT
ACACCCTGAGAAACAAGGAGGTAAAGAAAGCTCTGTTGAAGCTGAAAAATGGGTCAGTAT
TTGCTCAGGGTGAATAG(SEQ ID NO: 76)

AOLFR41 sequences:

MNPENWTQVTSFVLLGFPSSHLIQFLVFLGLMVTYIVTATGKLLIIVLSWIDQRLHIQMYFFLRN
FSFLELLLVTVVVPKMLVVILTGDHTISFVSCIIQSYLYFFLGTTDFFLLAVMSLDRYLAICRPLR
YETLMNGHVCSQLVLASWLAGFLWVLCPTVLMASLPFCGPNGIDHFFRDSWPLLRLSCGDTH
LLKLVAFMLSTLVLLGSLALTSVSYACILATVLRAPTAAERRKAFSTCASHLTVVVIIYGSSIFLY
IRMSEAQSKLLNKGASVLSCIITPLLNPFIFTLRNDKVQQALREALGWPRLTAVMKLRVTSQRK
(SEQ ID NO: 77)

ATGAACCCTGAAAACTGGACTCAGGTAACAAGCTTTGTCCTTCTGGGTTTCCCCAGTAGCC
ACCTCATACAGTTCCTGGTGTTCCTGGGGTTAATGGTGACCTACATTGTAACAGCCACAGG
CAAGCTGCTAATTATTGTGCTCAGCTGGATAGACCAACGCCTGCACATACAGATGTACTTC

TTCCTGCGGAATTTCTCCTTCCTGGAGCTGTTGCTGGTAACTGTTGTGGTTCCCAAGATGCT
TGTCGTCATCCTCACGGGGGATCACACCATCTCATTTGTCAGCTGCATCATCCAGTCCTACC
TCTACTTCTTTCTAGGCACCACTGACTTCTTCCTCTTGGCCGTCATGTCTCTGGATCGTTAC
CTGGCAATCTGCCGACCACTCCGCTATGAGACCCTGATGAATGGCCATGTCTGTTCCCAAC
TAGTGCTGGCCTCCTGGCTAGCTGGATTCCTCTGGGTCCTTTGCCCCACTGTCCTCATGGCC
AGCCTGCCTTTCTGTGGCCCCAATGGTATTGACCACTTCTTTCGTGACAGTTGGCCCTTGCT
CAGGCTTTCTTGTGGGGACACCCACCTGCTGAAACTGGTGGCTTTCATGCTCTCTACGTTG
GTGTTACTGGGCTCACTGGCTCTGACCTCAGTTTCCTATGCCTGCATTCTTGCCACTGTTCT
CAGGGCCCCTACAGCTGCTGAGCGAAGGAAAGCGTTTTCCACTTGCGCCTCGCATCTTACA
GTGGTGGTCATCATCTATGGCAGTTCCATCTTTCTCTACATTCGTATGTCAGAGGCTCAGTC
CAAACTGCTCAACAAAGGTGCCTCCGTCCTGAGCTGCATCATCACACCCCTCTTGAACCCA
TTCATCTTCACTCTCCGCAATGACAAGGTGCAGCAAGCACTGAGAGAAGCCTTGGGGTGGC
CCAGGCTCACTGCTGTGATGAAACTGAGGGTCACAAGTCAAAGGAAATGA (SEQ ID NO: 78)

AOLFR42 sequences:
MNPANHSQVAGFVLLGLSQVWELRFVFFTVFSAVYFMTVVGNLLIVVIVTSDPHLHTTMYFLL
GNLSFLDFCYSSITAPRMLVDLLSGNPTISFGGCLTQLFFFHFIGGIKIFLLTVMAYDRYIAISQPL
HYTLIMNQTVCALLMAASWVGGFIHSIVQIALTIQLPFCGPDKLDNFYCDVPQLIKLACTDTFV
LELLMVSNNGLVTLMCFLVLLGSYTALLVMLRSHSREGRSKALSTCASHIAVVTLIFVPCIYVY
TRPFRTFPMDKAVSVLYTIVTPMLNPAIYTLRNKEVIMAMKKLWRRKKDPIGPLEHRPLH
(SEQ ID NO: 79)

ATGAATCCAGCAAATCATTCCCAGGTGGCAGGATTTGTTCTACTGGGGCTCTCTCAGGTTT
GGGAGCTTCGGTTTGTTTTCTTCACTGTTTTCTCTGCTGTGTATTTTATGACTGTAGTGGGA
AACCTTCTTATTGTGGTCATAGTGACCTCCGACCCACACCTGCACACAACCATGTATTTTCT
CTTGGGCAATCTTTCTTTCCTGGACTTTTGCTACTCTTCCATCACAGCACCTAGGATGCTGG
TTGACTTGCTCTCAGGCAACCCTACCATTTCCTTTGGTGGATGCCTGACTCAACTCTTCTTC
TTCCACTTCATTGGAGGCATCAAGATCTTCCTGCTGACTGTCATGGCGTATGACCGCTACA
TTGCCATTTCCCAGCCCCTGCACTACACGCTCATTATGAATCAGACTGTCTGTGCACTCCTT
ATGGCAGCCTCCTGGGTGGGGGGCTTCATCCACTCCATAGTACAGATTGCATTGACTATCC
AGCTGCCATTCTGTGGGCCTGACAAGCTGGACAACTTTTATTGTGATGTGCCTCAGCTGAT
CAAATTGGCCTGCACAGATACCTTTGTCTTAGAGCTTTTAATGGTGTCTAACAATGGCCTG
GTGACCCTGATGTGTTTTCTGGTGCTTCTGGGATCGTACACAGCACTGCTAGTCATGCTCC
GAAGCCACTCACGGGAGGGCCGCAGCAAGGCCCTGTCTACCTGTGCCTCTCACATTGCTGT
GGTGACCTTAATCTTTGTGCCTTGCATCTACGTCTATACAAGGCCTTTTCGGACATTCCCCA
TGGACAAGGCCGTCTCTGTGCTATACACAATTGTCACCCCCATGCTGAATCCTGCCATCTA
TACCCTGAGAAACAAGGAAGTGATCATGGCCATGAAGAAGCTGTGGAGGAGGAAAAAGG
ACCCTATTGGTCCCCTGGAGCACAGACCCTTACATTAG (SEQ ID NO: 80)

AOLFR43 sequences:
MQKPQLLVPIIATSNGNLVHAAYFLLVGIPGLGPTIHFWLAFPLCFMYALATLGNLTIVLIIRVE
RRLHEPMYLFLAMLSTIDLVLSSITMPKMASLFLMGIQEIEFNICLAQMFLIHALSAVESAVLLA
MAFDRFVAICHPLRHASVLTGCTVAKIGLSALTRGFVFFFPLPFILKWLSYCQTHTVTHSFCLHQ
DIMKLSCTDTRVNVVYGLFIILSVMGVDSLFIGFSYILILWAVLELSSRRAALKAFNTCISHLCAV
LVFYVPLIGLSVVHRLGGPTSLLHVVMANTYLLLPPVVNPLVYGAKTKEICSRVLCMFSQGGK
(SEQ ID NO: 81)

ATGCAGAAGCCCCAGCTCTTGGTCCCTATCATAGCCACTTCAAATGGAAATCTGGTCCACG
CAGCATACTTCCTTTTGGTGGGTATCCCTGGCCTGGGGCCTACCATACACTTTTGGCTGGCT
TTCCCACTGTGTTTTATGTATGCCTTGGCCACCCTGGGTAACCTGACCATTGTCCTCATCAT
TCGTGTGGAGAGGCGACTGCATGAGCCCATGTACCTCTTCCTGGCCATGCTTTCCACTATT
GACCTAGTCCTCTCCTCTATCACCATGCCCAAGATGGCCAGTCTTTTCCTGATGGGCATCCA
GGAGATCGAGTTCAACATTTGCCTGGCCCAGATGTTCCTTATCCATGCTCTGTCAGCCGTG
GAGTCAGCTGTCCTGCTGGCCATGGCTTTTGACCGCTTTGTGGCCATTTGCCACCCATTGC
GCCATGCTTCTGTGCTGACAGGGTGTACTGTGGCCAAGATTGGACTATCTGCCCTGACCAG

GGGGTTTGTATTCTTCTTCCCACTGCCCTTCATCCTCAAGTGGTTGTCCTACTGCCAAACAC
ATACTGTCACACACTCCTTCTGTCTGCACCAAGATATTATGAAGCTGTCCTGTACTGACAC
CAGGGTCAATGTGGTTTATGGACTCTTCATCATCCTCTCAGTCATGGGTGTGGACTCTCTCT
TCATTGGCTTCTCATATATCCTCATCCTGTGGGCTGTTTTGGAGCTGTCCTCTCGGAGGGCA

5   GCACTCAAGGCTTTCAACACCTGCATCTCCCACCTCTGTGCTGTTCTGGTCTTCTATGTACC
CCTCATTGGGCTCTCGGTGGTGCATAGGCTGGGTGGTCCCACCTCCCTCCTCCATGTGGTT
ATGGCTAATACCTACTTGCTGCTACCACCTGTAGTCAACCCCCTTGTCTATGGAGCCAAGA
CCAAAGAGATCTGTTCAAGGGTCCTCTGTATGTTCTCACAAGGTGGCAAGTGA (SEQ ID
NO: 82)

10

AOLFR44 sequences:

MSSCNFTHATFVLIGIPGLEKAHFWVGFPLLSMYVVAMFGNCIVVFIVRTERSLHAPMYLFLC
MLAAIDLALSTSTMPKILALFWFDSREISFEACLTQMFFIHALSAIESTILLAMAFDRYVAICHPL
RHAAVLNNTVTAQIGIVAVVRGSLFFFPLPLLIKRLAFCHSNVLSHSYCVHQDVMKLAYADTLP
15   NVVYGLTAILLVMGVDVMFISLSYFLIIRTVLQLPSKSERAKAFGTCVSHIGVVLAFYVPLIGLS
VVHRFGNSLHPIVRVVMGDIYLLLPPVINPIIYGAKTKQIRTRVLAMFKISCDKDLQAVGGK
(SEQ ID NO: 83)

ATGAGTTCCTGCAACTTCACACATGCCACCTTTGTGCTTATTGGTATCCCAGGATTAGAGA
20   AAGCCCATTTCTGGGTTGGCTTCCCCCTCCTTTCCATGTATGTAGTGGCAATGTTTGGAAAC
TGCATCGTGGTCTTCATCGTAAGGACGGAACGCAGCCTGCACGCTCCGATGTACCTCTTTC
TCTGCATGCTTGCAGCCATTGACCTGGCCTTATCCACATCCACCATGCCTAAGATCCTTGCC
CTTTTCTGGTTTGATTCCCGAGAGATTAGCTTTGAGGCCTGTCTTACCCAGATGTTCTTTAT
TCATGCCCTCTCAGCCATTGAATCCACCATCCTGCTGGCCATGGCCTTTGACCGTTATGTGG
25   CCATCTGCCACCCACTGCGCCATGCTGCAGTGCTCAACAATACAGTAACAGCCCAGATTGG
CATCGTGGCTGTGGTCCGCGGATCCCTCTTTTTTTTCCCACTGCCTCTGCTGATCAAGCGGC
TGGCCTTCTGCCACTCCAATGTCCTCTCGCACTCCTATTGTGTCCACCAGGATGTAATGAA
GTTGGCCTATGCAGACACTTTGCCCAATGTGGTATATGGTCTTACTGCCATTCTGCTGGTC
ATGGGCGTGGACGTAATGTTCATCTCCTTGTCCTATTTTCTGATAATACGAACGGTTCTGC
30   AACTGCCTTCCAAGTCAGAGCGGGCCAAGGCCTTTGGAACCTGTGTGTCACACATTGGTGT
GGTACTCGCCTTCTATGTGCCACTTATTGGCCTCTCAGTGGTACACCGCTTTGGAAACAGC
CTTCATCCCATTGTGCGTGTTGTCATGGGTGACATCTACCTGCTGCTGCCTCCTGTCATCAA
TCCCATCATCTATGGTGCCAAAACCAAACAGATCAGAACACGGGTGCTGGCTATGTTCAAG
ATCAGCTGTGACAAGGACTTGCAGGCTGTGGGAGGCAAGTGA (SEQ ID NO: 84)

35

AOLFR45 sequences:

MLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFIIQADAALHEPMYLFLA
MLATIDLVLSSTTLPKMLAIFWFRDQEINFFACLVQMFFLHSFSIMESAVLLAMAFDRYVAICKP
LHYTTVLTGSLITKIGMAAVARAVTLMTPLPFLLRRFHYCRGPVIAHCYCEHMAVVRLACGDT
40   SFNNIYGIAVAMFSVVLDLLFVILSYVFILQAVLQLASQEARYKAFGTCVSHIGAILSTYTPVVIS
SVMHRVARHAAPRVHILLAIFYLLFPPMVNPIIYGVKTKQIREYVLSLFQRKNM (SEQ ID NO:
85)

TGGAAACAAGAGGTAATCTTTGCAGGTGGGATAGCACAGGTTGAACTCTAATCATATATA
45   CTGTAGAAGGTATATATAGAAGGTGAAGAAGCCCTGTAAAAATTGACAAGGAGATTTCCA
GGAGCCATGCTTCCCTCTAATATCACCTCAACACATCCAGCTGTCTTTTTGTTGGTAGGAAT
TCCTGGTTTGGAACACCTGCATGCCTGGATCTCCATCCCCTTCTGCTTTGCTTATACTCTGG
CCCTGCTAGGCAACTGTACCCTTCTCTTCATTATCCAGGCTGATGCAGCCCTCCATGAACCC
ATGTACCTCTTTCTGGCCATGTTGGCAACCATTGACTTGGTTCTTTCTTCTACAACGCTGCC
50   CAAAATGCTTGCCATATTCTGGTTCAGGGATCAGGAGATCAACTTCTTTGCCTGTCTGGTC
CAGATGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTT
TGACCGCTATGTGGCCATCTGCAAGCCATTGCACTACACGACGGTCCTGACTGGGTCCCTC
ATCACCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCT
TCCTGCTCAGACGCTTCCACTACTGCCGAGGCCCAGTGATTGCCCATTGCTACTGTGAACA
55   CATGGCTGTGGTAAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATTGCT
GTGGCCATGTTTAGTGTGGTGTTGGACCTGCTCTTTGTTATCCTGTCTTATGTCTTCATCCT

TCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCCGCTACAAAGCATTTGGGACATGTGTG
TCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCG
TGTAGCCCGCCATGCTGCCCCTCGTGTCCACATACTCCTTGCTATTTTCTATCTCCTTTTCC
CACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTCGTGAGTATGTGCT

5   CAGTCTATTCCAGAGAAAGAACATGTAGATGGATAGTTCTCTTTTTTTATCCCACTTGCCA
AGTAATGAGAATGCTGGATTGGGGGTTGAGGGGAAAAATCTAAATAGGAAAATTGCAGAGT
ATCTTTGACAATTCTCTAGTATGATAAGGAAAATGAGGTTTCATTCCTCACAGATCTACGA
GTCAGGTCAAACCAGGAGTGCACCTATAGTCTGGTCTGATAGTAGAGGTTTGACCTTCCCA
TTGTCATAGACTCATCACATGGCTAAGGAAGACAAACCTCTCAAAGTGGTATTGTAATCTG

10   GGTGAAAGACAGTAGGACCTTTATTGGCTGAGATTGGCCCAAACAGCTGAGTC (SEQ ID
NO: 86)

AOLFR46 sequences:
MNIKHCGWHMIHTWLNIREDDDSDFKNFIGQIQGLSGNPHSTTSRMYFLCFCTSLLGFKVHWV

15   SRLIXKLYMASPNNDSTAPVSEFLLICFPNFQSWQHWLSLPLSLLFLLAMGANTTLLITIQLEAS
LHQPLYYLLSLLSLLDIVLCLTVIPKVLAIFWFDLRSISFPACFLQMFIMNSFLTMESCTFMVMA
YDRYVAICHPLRYPSIITDQFVARAVVFVIARNAFVSLPVPMLSARLRYCAGNIIKNCICSNLSVS
KLSCDDITFNQLYQFVAGWTLLGSDLILIVISYSFILKVVLRIKAEGAVAKALSTCGSHFILILFFS
TVLLVLVITNLARKRIPPDVPILLNILHHLIPPALNPIVYGVRTKEIKQGIQNLLKRL (SEQ ID NO:

20   87)

ATGAATATAAAACATTGTGGCTGGCATATGATACATACTTGGTTAAATATAAGGGAGGAT
GATGACAGTGATTTTAAAAACTTTATTGGACAGATACAGGGCCTCAGTGGAAACCCACACT
CTACTACGTCTAGAATGTACTTTTTATGTTTCTGTACTTCTCTACTAGGTTTTAAGGTACAC

25   TGGGTCTCCAGATTGATCANGAAACTTTACATGGCATCTCCCAACAATGACTCCACTGCCC
CAGTCTCTGAATTCCTCCTCATCTGCTTCCCCAACTTCCAGAGCTGGCAGCACTGGTTGTCT
CTGCCCCTCAGCCTTCTCTTCCTCCTGGCCATGGGAGCTAACACCACCCTCCTGATCACCAT
CCAGCTGGAGGCCTCTCTGCACCAGCCCCTGTACTACCTGCTCAGCCTCCTCTCCCTGCTGG
ACATCGTGCTCTGCCTCACCGTCATCCCCAAGGTCCTGGCCATCTTCTGGTTTGACCTCAGG

30   TCGATCAGCTTCCCAGCCTGCTTCCTCCAGATGTTCATCATGAACAGTTTTTTGACCATGGA
GTCCTGCACGTTCATGGTCATGGCCTATGACCGTTATGTGGCCATCTGCCATCCATTGAGA
TACCCGTCTATCATCACTGACCAGTTTGTGGCTAGGGCCGTGGTCTTTGTTATAGCCCGGA
ATGCCTTTGTTTCTCTTCCTGTTCCCATGCTTTCTGCCAGGCTCAGATACTGTGCAGGAAAC
ATAATCAAGAACTGCATCTGCAGTAACCTGTCTGTGTCCAAACTCTCTTGTGATGACATCA

35   CTTTCAATCAGCTCTACCAGTTTGTGGCAGGCTGGACTCTGTTGGGCTCTGATCTTATCCTT
ATTGTTATCTCCTATTCTTTTATATTGAAAGTTGTGCTTAGGATCAAGGCCGAGGGTGCTGT
GGCCAAGGCCTTGAGCACGTGTGGTTCCCACTTCATCCTCATCCTCTTCTTCAGCACAGTCC
TGCTGGTTCTGGTCATCACTAACCTGGCCAGGAAGAGAATTCCTCCAGATGTCCCCATCCT
GCTCAACATCCTGCACCACCTCATTCCCCCAGCTCTGAACCCCATTGTTTATGGTGTGAGA

40   ACCAAGGAGATCAAGCAGGGAATCCAAAACCTGCTGAAGAGGTTGTAA (SEQ ID NO: 88)

AOLFR47 sequences:
MSASNITLTHPTAFLLVGIPGLEHLHIWISIPFCLAYTLALLGNCTLLLIIQADAALHEPMYLFLA
MLAAIDLVLSSSALPKMLAIFWFRDREINFFACLAQMFFLHSFSIMESAVLLAMAFDRYVAICK

45   PLHYTKVLTGSLITKIGMAAVARAVTLMTPLPFLLRCFHYCRGPVIAHCYCEHMAVVRLACGD
TSFNNIYGIAVAMFIVVLDLLLVILSYIFILQAVLLLASQEARYKAFGTCVSHIGAILAFYTTVVIS
SVMHRVARHAAPHVHILLANFYLLFPPMVNPIIYGVKTKQIRESILGVFPRKDM (SEQ ID NO:
89)

50   ATGTCAGCCTCCAATATCACCTTAACACATCCAACTGCCTTCTTGTTGGTGGGGATTCCAG
GCCTGGAACACCTGCACATCTGGATCTCCATCCCTTTCTGCTTAGCATATACACTGGCCCTG
CTTGGAAACTGCACTCTCCTTCTCATCATCCAGGCTGATGCAGCCCTCCATGAACCCATGT
ACCTCTTTCTGGCCATGTTGGCAGCCATCGACCTGGTCCTTTCCTCCTCAGCACTGCCCAAA
ATGCTTGCCATATTCTGGTTCAGGGATCGGGAGATAAACTTCTTTGCCTGTCTGGCCCAGA

55   TGTTCTTCCTTCACTCCTTCTCCATCATGGAGTCAGCAGTGCTGCTGGCCATGGCCTTTGAC
CGCTATGTGGCTATCTGCAAGCCACTGCACTACACCAAGGTCCTGACTGGGTCCCTCATCA

CCAAGATTGGCATGGCTGCTGTGGCCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCT
GCTGAGATGTTTCCACTACTGCCGAGGCCCAGTGATCGCTCACTGCTACTGTGAACACATG
GCTGTGGTGAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATCGCTGTGG
CCATGTTTATTGTGGTGTTGGACCTGCTCCTTGTTATCCTGTCTTATATCTTTATTCTTCAG
GCAGTTCTACTGCTTGCCTCTCAGGAGGCCCGCTACAAGGCATTTGGGACATGTGTCTCTC
5 ATATAGGTGCCATCTTAGCCTTCTACACAACTGTGGTCATCTCTTCAGTCATGCACCGTGTA
GCCCGCCATGCTGCCCCTCATGTCCACATCCTCCTTGCCAATTTCTATCTGCTCTTCCCACC
CATGGTCAATCCCATAATCTATGGTGTCAAGACCAAGCAAATCCGTGAGAGCATCTTGGGA
GTATTCCCAAGAAAGGATATGTAG (SEQ ID NO: 90)

10

AOLFR48 sequences:
MMVDPNGNESSATYFILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFL
CMLSGIDILISTSSMPKMLAIFWFNSTTIQFDACLLQMFAIHSLSGMESTVLLAMAFDRYVAICH
PLRHATVLTLPRVTKIGVAAVVRGAALMAPLPVFIKQLPFCRSNILSHSYCLHQDVMKLACDDI
RVNVVYGLIVIISAIGLDSLLISFSYLLILKTVLGLTREAQAKAFGTCVSHVCAVFIFYVPFIGLSM
15 VHRFSKRRDSPLPVILANIYLLVPPVLNPIVYGVKTKEIRQRILRLFHVATHASEP (SEQ ID NO:
91)

ATGATGGTGGATCCCAATGGCAATGAATCCAGTGCTACATACTTCATCCTAATAGGCCTCC
CTGGTTTAGAAGAGGCTCAGTTCTGGTTGGCCTTCCCATTGTGCTCCCTCTACCTTATTGCT
20 GTGCTAGGTAACTTGACAATCATCTACATTGTGCGGACTGAGCACAGCCTGCATGAGCCCA
TGTATATATTTCTTTGCATGCTTTCAGGCATTGACATCCTCATCTCCACCTCATCCATGCCC
AAAATGCTGGCCATCTTCTGGTTCAATTCCACTACCATCCAGTTTGATGCTTGTCTGCTACA
GATGTTTGCCATCCACTCCTTATCTGGCATGGAATCCACAGTGCTGCTGGCCATGGCTTTT
GACCGCTATGTGGCCATCTGTCACCCACTGCGCCATGCCACAGTACTTACGTTGCCTCGTG
25 TCACCAAAATTGGTGTGGCTGCTGTGGTGCGGGGGGCTGCACTGATGGCACCCCTTCCTGT
CTTCATCAAGCAGCTGCCCTTCTGCCGCTCCAATATCCTTTCCCATTCCTACTGCCTACACC
AAGATGTCATGAAGCTGGCCTGTGATGATATCCGGGTCAATGTCGTCTATGGCCTTATCGT
CATCATCTCCGCCATTGGCCTGGACTCACTTCTCATCTCCTTCTCATATCTGCTTATTCTTA
AGACTGTGTTGGGCTTGACACGTGAAGCCCAGGCCAAGGCATTTGGCACTTGCGTCTCTCA
30 TGTGTGTGCTGTGTTCATATTCTATGTACCTTTCATTGGATTGTCCATGGTGCATCGCTTTA
GCAAGCGGCGTGACTCTCCGCTGCCCGTCATCTTGGCCAATATCTATCTGCTGGTTCCTCCT
GTGCTCAACCCAATTGTCTATGGAGTGAAGACAAAGGAGATTCGACAGCGCATCCTTCGA
CTTTTTCCATGTGGCCACACACGCTTCAGAGCCCTAG (SEQ ID NO: 92)

35

AOLFR49 sequences:
MLTFHNVCSVPSSFWLTGIPGLESLHVWLSIPFGSMYLVAVVGNVTILAVVKIERSLHQPMYFF
LCMLAAIDLVLSTSTIPKLLGIFWFGACDIGLDACLGQMFLIHCFATVESGIFLAMAFDRYVAIC
NPLRHSMVLTYTVVGRLGLVSLLRGVLYIGPLPLMIRLRLPLYKTHVISHSYCEHMAVVALTC
GDSRVNNVYGLSIGFLVLILDSVAIAASYVMIFRAVMGLATPEARLKTLGTCASHLCAILIFYVP
40 IAVSSLIHRFGQCVPPPVHTLLANFYLLIPPILNPIVYAVRTKQIRESLLQIPRIEMKIR (SEQ ID
NO: 93)

ATGCTCACTTTTCATAATGTCTGCTCAGTACCCAGCTCCTTCTGGCTCACTGGCATCCCAGG
GCTGGAGTCCCTACACGTCTGGCTCTCCATCCCCTTTGGCTCCATGTACCTGGTGGCTGTG
45 GTGGGGAATGTGACCATCCTGGCTGTGGTAAAGATAGAACGCAGCCTGCACCAGCCCATG
TACTTTTTCTTGTGCATGTTGGCTGCCATTGACCTGGTTCTGTCTACTTCCACTATACCCAA
ACTTCTGGGAATCTTCTGGTTCGGTGCTTGTGACATTGGCCTGGACGCCTGCTTGGGCCAA
ATGTTCCTTATCCACTGCTTTGCCACTGTTGAGTCAGGCATCTTCCTTGCCATGGCTTTTGA
TCGCTACGTGGCCATCTGCAACCCACTACGTCATAGCATGGTGCTCACTTATACAGTGGTG
50 GGTCGTTTGGGGCTTGTTTCTCTCCTCCGGGGTGTTCTCTACATTGGACCTCTGCCTCTGAT
GATCCGCCTGCGGCTGCCCCTTTATAAAACCCATGTTATCTCCCACTCCTACTGTGAGCAC
ATGGCTGTAGTTGCCTTGACATGTGGCGACAGCAGGGTCAATAATGTCTATGGGCTGAGC
ATCGGCTTTCTGGTGTTGATCCTGGACTCAGTGGCTATTGCTGCATCCTATGTGATGATTTT
CAGGGCCGTGATGGGGTTAGCCACTCCTGAGGCTAGGCTTAAAACCCTGGGGACATGCGC
55 TTCTCACCTCTGTGCCATCCTGATCTTTTATGTTCCCATTGCTGTTTCTTCCCTGATTCACCG

ATTTGGTCAGTGTGTGCCTCCTCCAGTCCACACTCTGCTGGCCAACTTCTATCTCCTCATTC
CTCCAATCCTCAATCCCATTGTCTATGCTGTTCGCACCAAGCAGATCCGAGAGAGCCTTCT
CCAAATACCAAGGATAGAAATGAAGATTAGATGA (SEQ ID NO: 94)

5　**AOLFR50 sequences:**

MNLDSFFSFLLKSLIMALSNSSWRLPQPSFFLVGIPGLEESQHWIALPLGILYLLALVGNVTILFII
WMDPSLHQSMYLFLSMLAAIDLVVASSTAPKALAVLLVRAQEIGYTVCLIQMFFTHAFSSMES
GVLVAMALDRYVAICHPLHHSTILHPGVIGHIGMVVLVRGLLLLIPFLILLRKLIFCQATIIGHAY
CEHMAVVKLACSETTVNRAYGLTVALLVVGLDVLAIGVSYAHILQAVLKVPGNEARLKAFST
10　CGSHVCVILVFYIPGMFSFLTHRFGHHVPHHVHVLLAILYRLVPPALNPLVYRVKTQKIHQ
(SEQ ID NO: 95)

ATGAATTTGGATTCTTTTTTCTCTTTCCTCCTCAAGTCATTGATAATGGCACTTAGCAATTC
CAGCTGGAGGCTACCCCAGCCTTCTTTTTTCCTGGTAGGAATTCCGGGTTTAGAGGAAAGC
15　CAGCACTGGATCGCACTGCCCCTGGGCATCCTTTACCTCCTTGCTCTAGTGGGCAATGTTA
CCATTCTCTTCATCATCTGGATGGACCCATCCTTGCACCAATCTATGTACCTCTTCCTGTCC
ATGCTAGCTGCCATCGACCTGGTTGTGGCCTCCTCCACTGCACCCAAAGCCCTTGCAGTGC
TCCTGGTTCGTGCCCAAGAGATTGGTTACACTGTCTGCCTGATCCAGATGTTCTTCACCCAT
GCATTCTCCTCCATGGAGTCAGGGGTACTTGTGGCCATGGCTCTGGATCGCTATGTAGCCA
20　TTTGTCACCCCTTGCACCATTCCACAATCCTGCATCCAGGGGTCATAGGGCACATCGGAAT
GGTGGTGCTGGTGCGGGGATTACTACTCCTCATCCCCTTCCTCATTCTGTTGCGAAAACTT
ATCTTCTGCCAAGCCACCATCATAGGCCATGCCTATTGTGAACATATGGCTGTTGTGAAAC
TTGCCTGCTCAGAAACCACAGTCAATCGAGCTTATGGGCTGACTGTGGCCTTGCTTGTGGT
TGGGCTGGATGTCCTGGCCATTGGTGTTTCCTATGCCCACATTCTCCAGGCAGTGCTGAAG
25　GTACCAGGAAATGAGGCCCGACTTAAGGCCTTTAGCACATGTGGCTCTCATGTTTGTGTCA
TCCTGGTCTTCTATATCCCGGGAATGTTCTCCTTCCTCACTCACCGCTTTGGTCATCATGTA
CCCCATCACGTCCATGTTCTTCTGGCCATACTGTATCGCCTTGTGCCACCTGCACTCAATCC
TCTTGTCTATAGGGTGAAGACCCAGAAGATCCACCAGTGA (SEQ ID NO: 96)

30　**AOLFR51 sequences:**

MCQQILRDCILLIHHLCINRKKVSLVMLGPAYNHTMETPASFLLVGIPGLQSSHLWLAISLSAM
YIIALLGNTIIVTAIWMDSTRHEPMYCFLCVLAAVDIVMASSVVPKMVSIFCSGDSSISFSACFTQ
MFFVHLATAVETGLLLTMAFDRYVAICKPLHYKRILTPQVMLGMSMAITIRAIIAITPLSWMVS
HLPFCGSNVVVHSYCEHIALARLACADPVPSSLYSLIGSSLMVGSDVAFIAASYILILKAVFGLSS
35　KTAQLKALSTCGSHVGVMALYYLPGMASIYAAWLGQDVVPLHTQVLLADLYVIIPATLNPIIY
GMRTKQLRERIWSYLMHVLFDHSNLGS (SEQ ID NO: 97)

ATGTGTCAACAAATCTTACGGGATTGCATTCTTCTCATACATCATTTGTGCATTAACAGGA
AAAAAGTCTCACTTGTGATGCTGGGTCCAGCTTATAACCACACAATGGAAACCCCTGCCTC
40　CTTCCTCCTTGTGGGTATCCCAGGACTGCAATCTTCACATCTTTGGCTGGCTATCTCACTGA
GTGCCATGTACATCATAGCCCTGTTAGGAAACACCATCATCGTGACTGCAATCTGGATGGA
TTCCACTCGGCATGAGCCCATGTATTGCTTTCTGTGTGTTCTGGCTGCTGTGGACATTGTTA
TGGCCTCCTCGGTGGTACCCAAGATGGTGAGCATCTTCTGCTCAGGAGACAGCTCAATCAG
CTTTAGTGCTTGTTTCACTCAGATGTTTTTTGTCCACTTAGCCACAGCTGTGGAGACGGGG
45　CTGCTGCTGACCATGGCTTTTGACCGCTATGTAGCCATCTGCAAGCCTCTACACTACAAGA
GAATTCTCACGCCTCAAGTGATGCTGGGAATGAGTATGGCCATCACCATCAGAGCTATCAT
AGCCATAACTCCACTGAGTTGGATGGTGAGTCATCTACCTTTCTGTGGCTCCAATGTGGTT
GTCCACTCCTACTGTGAGCACATAGCTTTGGCCAGGTTAGCATGTGCTGACCCCGTGCCCA
GCAGTCTCTACAGTCTGATTGGTTCCTCTCTTATGGTGGGCTCTGATGTGGCCTTCATTGCT
50　GCCTCCTATATCTTAATTCTCAAGGCAGTATTTGGTCTCTCCTCAAAGACTGCTCAGTTGAA
AGCATTAAGCACATGTGGCTCCCATGTGGGGGGTTATGGCTTTGTACTATCTACCTGGGATG
GCATCCATCTATGCGGCCTGGTTGGGGCAGGATGTAGTGCCCTTGCACACCCAAGTCCTGC
TAGCTGACCTGTACGTGATCATCCCAGCCACCTTAAATCCCATCATCTATGGCATGAGGAC
CAAACAACTGCGGGAGAGAATATGGAGTTATCTGATGCATGTCCTCTTTGACCATTCCAAC
55　CTGGGGTTCATGA (SEQ ID NO: 98)

AOLFR52 sequences:

MLGPAYNHTMETPASFLLVGIPGLQSSHLWLAISLSAMYITALLGNTLIVTAIWMDSTRHEPMY
CFLCVLAAVDIVMASSVVPKMVSIFCSGDSSISFSACFTQMFFVHLATAVETGLLLTMAFDRYV
AICKPLHYKRILTPQVMLGMSMAVTIRAVTFMTPLSWMMNHLPFCGSNVVVHSYCKHIALAR

5   LACADPVPSSLYSLIGSSLMVGSDVAFIAASYILILRAVFDLSSKTAQLKALSTCGSHVGVMALY
YLPGMASIYAAWLGQDIVPLHTQVLLADLYVIIPATLNPIIYGMRTKQLLEGIWSYLMHFLFDH
SNLGS (SEQ ID NO: 99)

ATGCTGGGTCCAGCTTACAACCACACAATGGAAACCCCTGCCTCCTTCCTCCTTGTGGGTA

10   TCCCAGGACTGCAATCTTCACATCTTTGGCTGGCTATCTCACTGAGTGCCATGTACATCAC
AGCCCTGTTAGGAAACACCCTCATCGTGACTGCAATCTGGATGGATTCCACTCGGCATGAG
CCCATGTATTGCTTTCTGTGTGTTCTGGCTGCTGTGGACATTGTTATGGCCTCCTCCGTGGT
ACCCAAGATGGTGAGCATCTTCTGCTCGGGAGACAGCTCCATCAGCTTTAGTGCTTGTTTC
ACTCAGATGTTTTTTGTCCACTTAGCCACAGCTGTGGAGACGGGGCTGCTGCTGACCATGG

15   CTTTTGACCGCTATGTAGCCATCTGCAAGCCTCTACACTACAAGAGAATTCTCACGCCTCA
AGTGATGCTGGGAATGAGTATGGCCGTCACCATCAGAGCTGTCACATTCATGACTCCACTG
AGTTGGATGATGAATCATCTACCTTTCTGTGGCTCCAATGTGGTTGTCCACTCCTACTGTAA
GCACATAGCTTTGGCCAGGTTAGCATGTGCTGACCCCGTGCCCAGCAGTCTCTACAGTCTG
ATTGGTTCCTCTCTTATGGTGGGCTCTGATGTGGCCTTCATTGCTGCCTCCTATATCTTAAT

20   TCTCAGGGCAGTATTTGATCTCTCCTCAAAGACTGCTCAGTTGAAAGCATTAAGCACATGT
GGCTCCCATGTGGGGGTTATGGCTTTGTACTATCTACCTGGGATGGCATCCATCTATGCGG
CCTGGTTGGGGCAGGATATAGTGCCCTTGCACACCCAAGTGCTGCTAGCTGACCTGTACGT
GATCATCCCAGCCACTTTAAATCCCATCATCTATGGCATGAGGACCAAACAATTGCTGGAG
GGAATATGGAGTTATCTGATGCACTTCCTCTTTGACCACTCCAACCTGGGTTCATGA (SEQ

25   ID NO: 100)

AOLFR54 sequences:

MSDSNLSDNHLPDTFFLTGIPGLEAAHFWIAIPFCAMYLVALVGNAALILVIAMDNALHAPMY
LFLCLLSLTDLALSSTTVPKMLAILWLHAGEISFGGCLAQMFCVHSIYALESSILLAMAFDRYVA

30   ICNPLRYTTILNHAVIGRIGFVGLFRSVAIVSPFIFLLRRLPYCGHRVMTHTYCEHMGIARLACA
NITVNIVYGLTVALLAMGLDSILIAISYGFILHAVFHLPSHDAQHKALSTCGSHIGIILVFYIPAFF
SFLTHRFGHHEVPKHVHIFLANLYVLVPPVLNPILYGARTKEIRSRLLKLLHLGKTSI (SEQ ID
NO: 101)

35   ATGTCAGATTCCAACCTCAGTGATAACCATCTTCCAGACACCTTCTTCTTAACAGGGATCC
CAGGGCTGGAGGCTGCCCACTTCTGGATTGCCATCCCTTTCTGTGCCATGTATCTTGTAGC
ACTGGTTGGAAATGCTGCCCTCATCCTGGTCATTGCCATGGACAATGCTCTTCATGCACCT
ATGTACCTCTTCCTCTGCCTTCTCTCACTCACAGACCTGGCTCTCAGTTCTACCACTGTGCC
CAAGATGCTGGCCATTTTGTGGCTCCATGCTGGTGAGATTTCCTTTGGTGGATGCCTGGCC

40   CAGATGTTTTGTGTCCATTCTATCTATGCTCTGGAGTCCTCGATTCTACTTGCCATGGCCTT
TGATAGGTATGTGGCTATCTGTAACCCATTAAGGTATACAACCATTCTCAACCATGCTGTC
ATAGGCAGAATTGGCTTTGTTGGGCTATTCCGTAGTGTGGCTATTGTCTCCCCCTTCATCTT
CTTGCTGAGGCGACTCCCCTACTGTGGTCACCGTGTCATGACACACACATACTGTGAGCAT
ATGGGCATCGCCCGACTGGCCTGTGCCAACATCACTGTCAATATTGTCTATGGGCTAACTG

45   TGGCTCTGCTGGCCATGGGACTGGATTCCATTCTCATTGCCATTTCCTATGGCTTTATCCTC
CATGCAGTCTTTCACCTTCCATCTCATGATGCCCAGCACAAAGCTCTGAGTACCTGTGGCT
CCCACATTGGCATCATCCTGGTTTTCTACATCCCTGCCTTCTTCTCCTTCCTCACCCACCGC
TTTGGTCACCACGAAGTCCCCAAGCATGTGCACATCTTTCTGGCTAATCTCTATGTGCTGG
TGCCTCCTGTACTCAATCCTATTCTCTATGGAGCTAGAACCAAGGAGATTCGGAGTCGACT

50   TCTAAAACTGCTTCACCTGGGGAAGACTTCAATATGA (SEQ ID NO: 102)

AOLFR57 sequences:

MSFQVTYMFYLHWTMEKSNNSTLFILLGFSQNKNIEVLCFVLFLFCYIAIWMGNLLIMISITCTQ
LIHQPMYFFLNYLSLSDLCYTSTVTPKLMVDLLAERKTISYNNCMIQLFTTHFFGGIEIFILTGM

55   AYDRYVAICKPLHYTIIMSRQKCNTIIVCCTGGFIHSASQFLLTIFVPFCGPNEIDHYFCDVYPLL
KLACSNIHMIGLLVIANSGLIALVTFVVLLLSYVFILYTIRAYSAERRSKALATCSSHVIVVVLFF

APALFIYIRPVTTFSEDKVFALFYTIIAPMFNPLIYTLRNTEMKNAMRKVWCCQILLKRNQLF
(SEQ ID NO: 103)

ATGTCATTTCAGGTGACTTATATGTTCTATCTACACTGGACCATGGAAAAAAGCAATAATA
5   GCACTTTGTTTATTCTCTTGGGGGTTTTCCCAAAATAAGAACATTGAAGTCCTCTGCTTTGTA
TTATTTTTGTTTTGCTACATTGCTATTTGGATGGGAAACTTACTCATAATGATTTCTATCAC
GTGCACCCAGCTCATTCACCAACCCATGTATTTCTTCCTCAATTACCTCTCACTCTCCGACC
TTTGCTACACATCCACAGTGACCCCCAAATTAATGGTTGACTTACTGGCAGAAAGAAAGAC
CATTTCCTATAATAACTGTATGATACAACTCTTTACCACCCATTTTTTTGGAGGCATAGAGA
10   TCTTCATTCTCACAGGGATGGCCTATGACCGCTATGTGGCCATTTGCAAGCCCCTGCACTA
CACCATTATTATGAGCAGGCAAAAGTGTAACACAATCATCATAGTTTGTTGTACTGGGGGA
TTTATACATTCTGCCAGTCAGTTTCTTCTCACCATCTTTGTACCATTTGTGGCCCAAATGA
GATAGATCACTACTTCTGTGATGTGTATCCTTTGCTGAAATTGGCCTGTTCTAATATACACA
TGATAGGTCTCTTAGTCATTGCTAATTCAGGCTTAATTGCTTTGGTGACATTTGTTGTCTTG
15   TTGTTGTCTTATGTTTTTATATTGTATACCATCAGAGCATACTCTGCAGAGAGACGCAGCA
AAGCTCTTGCCACTTGTAGTTCTCATGTAATTGTTGTGGTCCTGTTTTTTGCTCCTGCATTG
TTCATTTACATTAGACCGGTCACAACATTCTCAGAAGATAAAGTGTTTGCCCTTTTTATAC
CATCATTGCTCCCATGTTCAACCCTCTCATATACACGCTGAGAAACACAGAGATGAAGAAC
GCCATGAGGAAAGTGTGGTGTTGTCAAATACTCCTGAAAAGAAATCAACTTTTCTGA (SEQ
20   ID NO: 104)

AOLFR58 sequences:

MFSMTTEALNNFALGCTNLLMTMIPQIDLKQIFLCPNCRLYMIPVGAFIFSLGNMQNQSFVTEF
VLLGLSQNPNVQEIVFVVFLFVYIATVGGNMLIVVTILSSPALLVSPMYFFLGFLSFLDACFSSVI
25   TPKMIVDSLYVTKTISFEGCMMQLFAEHFFAGVEVIVLTAMAYDRYVAICKPLHYSSIMNRRL
CGILMGVAWTGGLLHSMIQILFTFQLPFCGPNVINHFMCDLYPLLELACTDTHIFGLMVVINSG
FICIINFSLLLVSYAVILLSLRTHSSEGRWKALSTCGSHIAVVILFFVPCIFVYTRPPSAFSLDKMA
AIFYIILNPLLNPLIYTFRNKEVKQAMRRIWNRLMVVSDEKENIKL (SEQ ID NO: 105)

ATGTTCTCAATGACAACAGAAGCACTCAATAATTTTGCACTTGGATGTACCAACTTGTTAA
30   TGACTATGATACCACAAATTGATCTGAAGCAAATTTTCCTTTGTCCTAATTGCAGACTATA
CATGATCCCTGTTGGAGCTTTCATCTTTTCCTTGGGAAACATGCAAAACCAAAGCTTTGTA
ACTGAGTTTGTCCTCCTGGGACTTTCACAGAATCCAAATGTTCAGGAAATAGTATTTGTTG
TATTTTTGTTTGTCTACATTGCAACTGTTGGGGGCAACATGCTAATTGTAGTAACCATTCTC
AGCAGCCCTGCTCTTCTGGTGTCTCCTATGTACTTCTTCTTGGGCTTCCTGTCCTTCCTGGA
35   TGCGTGCTTCTCATCTGTCATCACCCCAAAGATGATTGTAGACTCCCTCTATGTGACAAAA
ACCATCTCTTTTGAAGGCTGCATGATGCAGCTCTTTGCTGAACACTTCTTTGCTGGGGTGG
AGGTGATTGTCCTCACAGCCATGGCCTATGATCGTTATGTGGCCATTTGCAAGCCCTTGCA
TTACTCTTCTATCATGAACAGGAGGCTCTGTGGCATTCTGATGGGGGTAGCCTGGACAGGG
GGCCTCTTGCATTCCATGATACAAATTCTTTTTACTTTCCAGCTTCCCTTTTGTGGCCCCAA
40   TGTCATCAATCACTTTATGTGTGACTTGTACCCGTTACTGGAGCTTGCCTGCACTGATACTC
ACATCTTTGGCCTCATGGTGGTCATCAACAGTGGGTTTATCTGCATCATAAACTTCTCCTTG
TTGCTTGTCTCCTATGCTGTCATCTTGCTCTCTCTGAGAACACACAGTTCTGAAGGGCGCTG
GAAAGCTCTCTCCACCTGTGGATCTCACATTGCTGTTGTGATTTTGTTCTTTGTCCCATGCA
TATTTGTATATACACGACCTCCATCTGCTTTTTCCCTTGACAAAATGGCGGCAATATTTTAT
45   ATCATCTTAAATCCCTTGCTCAATCCTTTGATTTACACTTTCAGGAATAAGGAAGTAAAAC
AGGCCATGAGGAGAATATGGAACAGACTGATGGTGGTTTCTGATGAGAAGAAAATATTA
AACTTTAA (SEQ ID NO: 106)

50   **AOLFR59 sequences:**

MGDWNNSDAVEPIFILRGFPGLEYVHSWLSILFCLAYLVAFMGNVTILSVIWIESSLHQPMYYFI
SILAVNDLGMSLSTLPTMLAVLWLDAPEIQASACYAQLFFIHTFTFLESSVLLAMAFDRFVAICH
PLHYPTILTNSVIGKIGLACLLRSLGVVLPTPLLLRHYHYCHGNALSHAFCLHQDVLRLSCTDA
RTNSIYGLCVVIATLGVDSIFILLSYVLILNTVLDIASREEQLKALNTCVSHICVVLIFFVPVIGVS
55   MVHRFGKHLSPIVHILMADIYLLLPPVLNPIVYSVRTKQIRLGILHKFVLRRRF (SEQ ID NO:
107)

ATGGGAGACTGGAATAACAGTGATGCTGTGGAGCCCATATTTATCCTGAGGGGTTTTCCTG
GACTGGAGTATGTTCATTCTTGGCTCTCCATCCTCTTCTGTCTTGCATATTGGTAGCATTT
ATGGGTAATGTTACCATCCTGTCTGTCATTTGGATAGAATCCTCTCTCCATCAGCCCATGTA
5 TTACTTTATTTCCATCTTAGCAGTGAATGACCTGGGGATGTCCCTGTCTACACTTCCCACCA
TGCTTGCTGTGTTATGGTTGGATGCTCCAGAGATCCAGGCAAGTGCTTGCTATGCTCAGCT
GTTCTTCATCCACACATTCACATTCCTGGAGTCCTCAGTGTTGCTGGCCATGGCCTTTGACC
GTTTTGTTGCTATCTGCCATCCACTGCACTACCCCACCATCCTCACCAACAGTGTAATTGGC
AAAATTGGTTTGGCCTGTTTGCTACGAAGCTTGGGAGTTGTACTTCCCACACCTTTGCTACT
10 GAGACACTATCACTACTGCCATGGCAATGCCCTCTCTCACGCCTTCTGTTTGCACCAGGAT
GTTCTAAGATTATCCTGTACAGATGCCAGGACCAACAGTATTTATGGGCTTTGTGTAGTCA
TTGCCACACTAGGTGTGGATTCAATCTTCATACTTCTTTCTTATGTTCTGATTCTTAATACT
GTGCTGGATATTGCATCTCGTGAAGAGCAGCTAAAGGCACTCAACACATGTGTATCCCATA
TCTGTGTGGTGCTTATCTTCTTTGTGCCAGTTATTGGGGTGTCAATGGTCCATCGCTTTGGG
15 AAGCATCTGTCTCCCATAGTCCACATCCTCATGGCAGACATCTACCTTCTTCTTCCCCCAGT
CCTTAACCCTATTGTCTATAGTGTCAGAACAAAGCAGATTCGTCTAGGAATTCTCCACAAG
TTTGTCCTAAGGAGGAGGTTTTAA (SEQ ID NO: 108)

AOLFR60 sequences:

20 MFLPNDTQFHPSSFLLLGIPGLETLHIWIGFPFCAVYMIALIGNFTILLVIKTDSSLHQPMFYFLA
MLATTDVGLSTATIPKMLGIFWINLRGIIFEACLTQMFFIHNFTLMESAVLVAMAYDSYVAICN
PLQYSAILTNKVVSVIGLGVFVRALIFVIPSILLILRLPFCGNHVIPHTYCEHMGLAHLSCASIKINI
IYGLCAICNLVFDITVIALSYVHILCAVFRLPTHEPRLKSLSTCGSHVCVILAFYTPALFSFMTHC
FGRNVPRYIHILLANLYVVVPPMLNPVIYGVRTKQIYKCVKKILLQEQGMEKEEYLIHTRF
25 (SEQ ID NO: 109)

ATGTTCCTTCCCAATGACACCCAGTTTCACCCCTCCTCCTTCCTGTTGCTGGGGATCCCAGG
ACTAGAAACACTTCACATCTGGATCGGCTTTCCCTTCTGTGCTGTGTACATGATCGCACTC
ATAGGGAACTTCACTATTCTACTTGTGATCAAGACTGACAGCAGCCTACACCAGCCCATGT
30 TCTACTTCCTGGCCATGTTGGCCACCACTGATGTGGGTCTCTCAACAGCTACCATCCCTAA
GATGCTTGGAATCTTCTGGATCAACCTCAGAGGGATCATCTTTGAAGCCTGCCTCACCCAG
ATGTTTTTTATCCACAACTTCACACTTATGGAGTCAGCAGTCCTTGTGGCAATGGCTTATG
ACAGCTATGTGGCCATCTGCAATCCACTCCAATATAGCGCCATCCTCACCAACAAGGTTGT
TTCTGTGATTGGTCTTGGTGTGTTTGTGAGGGCTTTAATTTTCGTCATTCCCTCTATACTTC
35 TTATATTGCGGTTGCCCTTCTGTGGGAATCATGTAATTCCCCACACCTACTGTGAGCACAT
GGGTCTTGCTCATCTATCTTGTGCCAGCATCAAAATCAATATTATTTATGGTTTATGTGCCA
TTTGTAATCTGGTGTTTGACATCACAGTCATTGCCCTCTCTTATGTGCATATTCTTTGTGCT
GTTTTCCGTCTTCCTACTCATGAGCCCCGACTCAAGTCCCTCAGCACATGTGGTTCACATGT
GTGTGTAATCCTTGCCTTCTATACACCAGCCCTCTTTTCCTTTATGACTCATTGCTTTGGCC
40 GAAATGTGCCCCGCTATATCCATATACTCCTAGCCAATCTCTATGTTGTGGTGCCACCAAT
GCTCAATCCTGTCATATATGGAGTCAGAACCAAGCAGATCTATAAATGTGTAAAGAAAAT
ATTATTGCAGGAACAAGGAATGGAAAAGGAAGAGTACCTAATACATACGAGGTTCTGA
(SEQ ID NO: 110)

45 **AOLFR61 sequences:**

MSIINTSYVEITTFFFLVGMPGLEYAHIWISIPICSMYLIAILGNGTILFIIKTEPSLHGPMYYFLSML
AMSDLGLSLSSLPTVLSIFLFNAPETSSSACFAQEFFIHGFSVLESSVLLIMSFDRFLAIHNPLRYT
SILTTVRVAQIGIVFSFKSMLLVLPFPFTLRSLRYCKKNQLSHSYCLHQDVMKLACSDNRIDVIY
GFFGALCLMVDFILIAVSYTLILKTVPGIASKKEELKALNTCVSHICAVIIFYLPIINLAVVHRFAG
50 HVSPLINVLMANVLLLVPPLMKPIVYCVKTKQIRVRVVAKLCQWKI (SEQ ID NO: 111)

ATGTCCATTATCAACACATCATATGTTGAAATCACCACCTTCTTCTTGGTTGGGATGCCAG
GGCTAGAATATGCACACATCTGGATCTCTATCCCCATCTGCAGCATGTATCTTATTGCTATT
CTAGGAAATGGCACCATTCTTTTTATCATCAAGACAGAGCCCTCCTTGCATGGGCCCATGT
55 ACTATTTTCTTTCCATGTTGGCTATGTCAGACTTGGGTTTGTCTTTATCATCTCTGCCCACT
GTGTTAAGCATCTTCCTGTTCAATGCCCCTGAAACTTCTTCTAGTGCCTGCTTTGCCCAGGA

ATTCTTCATTCATGGATTCTCAGTACTGGAGTCCTCAGTCCTCCTGATCATGTCATTTGATA
GATTCCTAGCCATCCACAATCCTCTGAGATACACCTCAATCCTGACAACTGTCAGAGTTGC
CCAAATAGGGATAGTATTCTCCTTTAAGAGCATGCTCCTGGTTCTTCCCTTCCCTTTCACTT
TAAGAAGCTTGAGATATTGCAAGAAAAACCAATTATCCCATTCCTACTGTCTCCACCAGGA
5   TGTCATGAAGTTGGCCTGTTCTGACAACAGAATTGATGTTATCTATGGCTTTTTTGGAGCA
CTCTGCCTTATGGTAGACTTTATTCTCATTGCTGTGTCTTACACCCTGATCCTCAAGACTGT
ACCGGGAATTGCATCCAAAAAGGAGGAGCTTAAGGCTCTCAATACTTGTGTTTCACACATC
TGTGCAGTGATCATCTTCTACCTGCCCATCATCAACCTGGCCGTTGTCCACCGCTTTGCCGG
GCATGTCTCTCCCCTCATTAATGTTCTCATGGCAAATGTTCTCCTACTTGTACCTCCGCTGA
10   TGAAACCAATTGTTTATTGTGTAAAAACTAAACAGATTAGAGTGAGAGTTGTAGCAAAATT
GTGTCAATGGAAGATTTAA (SEQ ID NO: 112)

AOLFR62 sequences:
MFYHNKSIFHPVTFFLIGIPGLEDFHMWISGPFCSVYLVALLGNATILLVIKVEQTLREPMFYFL
15   AILSTIDLALSATSVPRMLGIFWFDAHEINYGACVAQMFLIHAFTGMEAEVLLAMAFDRYVAIC
APLHYATILTSLVLVGISMCIVIRPVLLTLPMVYLIYRLPFCQAHIIAHSYCEHMGIAKLSCGNIRI
NGIYGLFVVSFFVLNLVLIGISYVYILRAVFRLPSHDAQLKALSTCGAHVGVICVFYIPSVFSFLT
HRFGHQIPGYIHILVANLYLIIPPSLNPIIYGVRTKQIRERVLYVFTKK (SEQ ID NO: 113) .

ATGTTTTATCACAACAAGAGCATATTTCACCCAGTCACATTTTTCCTCATTGGAATCCCAGG
20   TCTGGAAGACTTCCACATGTGGATCTCCGGGCCTTTCTGCTCTGTTTACCTTGTGGCTTTGC
TGGGCAATGCCACCATTCTGCTAGTCATCAAGGTAGAACAGACTCTCCGGGAGCCCATGTT
CTACTTCCTGGCCATTCTTTCCACTATTGATTTGGCCCTTTCTGCAACCTCTGTGCCTCGCA
TGCTGGGTATCTTCTGGTTTGATGCTCACGAGATTAACTATGGAGCTTGTGTGGCCCAGAT
25   GTTTCTGATCCATGCCTTCACTGGCATGGAGGCTGAGGTCTTACTGGCTATGGCTTTTGAC
CGTTATGTGGCCATCTGTGCTCCACTACATTACGCAACCATCTTGACATCCCTAGTGTTGGT
GGGCATTAGCATGTGCATTGTAATTCGTCCCGTTTTACTTACACTTCCCATGGTCTATCTTA
TCTACCGCCTACCCTTTTGTCAGGCTCACATAATAGCCCATTCCTACTGTGAGCACATGGG
CATTGCAAAATTGTCCTGTGGAAACATTCGTATCAATGGTATCTATGGGCTTTTTGTAGTTT
30   CTTTCTTTGTTCTGAACCTGGTGCTCATTGGCATCTCGTATGTTTACATTCTCCGTGCTGTC
TTCCGCCTCCCATCACATGATGCTCAGCTAAAAGCCCTAAGCACGTGTGGCGCTCATGTTG
GAGTCATCTGTGTTTTCTATATCCCTTCAGTCTTCTCTTTCCTTACTCATCGATTTGGACAC
CAAATACCAGGTTACATTCACATTCTTGTTGCCAATCTCTATTTGATTATCCCACCCTCTCT
CAACCCCATCATTTATGGGGTGAGGACCAAACAGATTCGAGAGCGAGTGCTCTATGTTTTT
35   ACTAAAAAATAA (SEQ ID NO: 114)

AOLFR63 sequences:
MSIINTSYVEITTFFLVGMPGLEYAHIWISIPICSMYLIAILGNGTILFIIKTEPSLHEPMYYFLSML
AMSDLGLSLSSLPTVLSIFLFNAPEISSNACFAQEFFIHGFSVLESSVLLIMSFDRFLAIHNPLRYTS
40   ILTTVRVAQIGIVFSFKSMLLVLPFPFTLRNLRYCKKNQLSHSYCLHQDVMKLACSDNRIDVIY
GFFGALCLMVDFILIAVSYTLILKTVLGIASKKEQLKALNTCVSHICAVIIFYLPIINLAVVHRFAR
HVSPLINVLMANVLLLVPPLTNPIVYCVKTKQIRVRVVAKLCQRKI (SEQ ID NO: 115)

ATGTCCATTATCAACACATCATATGTTGAAATCACCACCTTCTTCTTGGTTGGGATGCCAG
45   GGCTAGAATATGCACACATCTGGATCTCTATCCCCATCTGCAGCATGTATCTTATTGCTATT
CTAGGAAATGGCACCATTCTTTTTATCATCAAGACAGAGCCCTCCTTGCATGAGCCCATGT
ACTATTTTCTTTCCATGTTGGCTATGTCAGACTTGGGTTTGTCTTTATCATCTCTGCCCACT
GTGTTAAGCATCTTCCTGTTCAATGCTCCTGAAATTTCATCCAATGCCTGCTTTGCCCAGGA
ATTCTTCATTCATGGATTCTCAGTACTGGAGTCCTCAGTCCTCCTGATCATGTCATTTGATA
50   GATTCCTAGCCATCCACAACCCTCTGAGATACACCTCAATCCTGACAACTGTCAGAGTTGC
CCAAATAGGGATAGTATTCTCCTTTAAGAGCATGCTCCTGGTTCTTCCCTTCCCTTTCACTT
TAAGAAACTTGAGATATTGCAAGAAAAACCAATTATCCCATTCCTACTGTCTCCACCAGGA
TGTCATGAAGTTGGCCTGTTCTGACAACAGAATTGATGTTATCTATGGCTTTTTTGGAGCA
CTCTGCCTTATGGTAGACTTTATTCTCATTGCTGTGTCTTACACCCTGATCCTCAAGACTGT
55   ACTGGGAATTGCATCCAAAAAGGAGCAGCTTAAGGCTCTCAATACTTGTGTTTCACACATC
TGTGCAGTGATCATCTTCTACCTGCCCATCATCAACCTGGCCGTTGTCCACCGCTTTGCCCG

82

GCATGTCTCTCCCCTCATTAATGTTCTCATGGCAAATGTTCTCCTACTTGTACCTCCACTGA
CGAACCCAATTGTTTATTGTGTAAAAACTAAACAGATTAGAGTGAGAGTTGTAGCAAAATT
GTGTCAACGGAAGATTTAA (SEQ ID NO: 116)

5   **AOLFR64 sequences:**

MTILLNSSLQRATFFLTGFQGLEGLHGWISIPFCFIYLTVILGNLTILHVICTDATLHGPMYYFLG
MLAVTDLGLCLSTLPTVLGIFWFDTREIGIPACFTQLFFIHTLSSMESSVLLSMSIDRSVAVCNPL
HDSTVLTPACIVKMGLSSVLRSALLILPLPFLLKRFQYCHSHVLAHAYCLHLEIMKLACSSIIVN
HIYGLFVVACTVGVDSLLIFLSYALILRTVLSIASHQERLRALNTCVSHICAVLLFYIPMIGLSLV
10   HRFGEHLPRVVHLFMSYVYLLVPPLMNPIIYSIKTKQIRQRIIKKFQFIKSLRCFWKD (SEQ ID
NO: 117)

ATGACAATTCTTCTTAATAGCAGCCTCCAAAGAGCCACTTTCTTCCTGACGGGCTTCCAAG
GTCTAGAAGGTCTCCATGGCTGGATCTCTATTCCCTTCTGCTTCATCTACCTGACAGTTATC
15   TTGGGGAACCTCACCATTCTCCACGTCATTTGTACTGATGCCACTCTCCATGGACCCATGT
ACTATTTCTTGGGCATGCTAGCTGTCACAGACTTAGGCCTTTGCCTTTCCACACTGCCCACT
GTGCTGGGCATTTTCTGGTTTGATACCAGAGAGATTGGCATCCCTGCCTGTTTCACTCAGC
TCTTCTTCATCCACACCTTGTCTTCAATGGAGTCATCAGTTCTGTTATCCATGTCCATTGAC
CGCTCCGTGGCCGTCTGCAACCCACTGCATGACTCCACCGTCCTGACACCTGCATGTATTG
20   TCAAGATGGGGCTAAGCTCAGTGCTTAGAAGTGCTCTCCTCATCCTCCCCTTGCCATTCCTC
CTGAAGCGCTTCCAATACTGCCACTCCCATGTGCTGGCTCATGCTTATTGTCTTCACCTGGA
GATCATGAAGCTGGCCTGCTCTAGCATCATTGTCAATCACATCTATGGGCTCTTTGTTGTG
GCCTGCACCGTGGGTGTGGACTCCCTGCTCATCTTTCTCTCATACGCCCTCATCCTTCGCAC
CGTGCTCAGCATTGCCTCCCACCAGGAGCGACTCCGAGCCCTCAACACCTGTGTCTCTCAT
25   ATCTGTGCTGTACTGCTCTTCTACATCCCCATGATTGGCTTGTCTCTTGTGCATCGCTTTGG
TGAACATCTGCCCCGCGTTGTACACCTCTTCATGTCCTATGTGTATCTGCTGGTACCACCCC
TTATGAACCCCATCATCTACAGCATCAAGACCAAGCAAATTCGCCAGCGCATCATTAAGAA
GTTTCAGTTTATAAAGTCACTTAGGTGTTTTTGGAAGGATTAA (SEQ ID NO: 118)

30   **AOLFR65 sequences:**

MAGRMSTSNHTQFHPSSFLLLGIPGLEDVHIWIGVPFFFVYLVALLGNTALLFVIQTEQSLHEPM
YYFLAMLDSIDLGLSTATIPKMLGIFWFNTKEISFGGCLSHMFFIHFFTAMESIVLVAMAFDRYI
AICKPLRYTMILTSKIISLIAGIAVLRSLYMVVPLVFLLLRLPFCGHRIIPHTYCEHMGIARLACAS
IKVNIRFGLGNISLLLLDVILIILSYVRILYAVFCLPSWEARLKALNTCGSHIGVILAFFTPAFFSFL
35   THRFGHNIPQYIHIILANLYVVVPPALNPVIYGVRTKQIRERVLRIFLKTNH (SEQ ID NO: 119)

ATGGCAGGAAGAATGTCTACGTCTAATCACACCCAGTTCCATCCTTCTTCATTCCTACTGCT
GGGTATCCCAGGGCTAGAAGATGTGCACATTTGGATTGGAGTCCCTTTTTTTCTTTGTGTAT
CTTGTTGCACTCCTGGGAAACACTGCTCTCTTGTTTGTGATCCAGACTGAGCAGAGTCTCC
40   ATGAGCCTATGTACTACTTCCTGGCCATGTTGGATTCCATTGACCTGGGCTTGTCTACAGC
CACCATCCCCAAAATGTTGGGCATCTTCTGGTTCAATACCAAAGAAATATCTTTTGGAGGC
TGCCTTTCTCACATGTTCTTCATCCATTTCTTCACTGCTATGGAGAGCATTGTGTTGGTGGC
CATGGCCTTTGACCGCTACATTGCCATTTGCAAACCTCTTCGGTACACCATGATCCTCACCA
GCAAAATCATCAGCCTCATTGCAGGCATTGCTGTCCTGAGGAGCCTGTACATGGTTGTTCC
45   ACTGGTGTTTCTCCTTCTGAGGCTGCCCTTCTGTGGGCATCGTATCATCCCTCATACTTATT
GTGAGCACATGGGCATTGCCCGTCTGGCCTGTGCCAGCATCAAAGTCAACATTAGGTTTGG
CCTTGGCAACATATCTCTCTTGTTACTGGATGTTATCCTTATTATTCTCTCCTATGTCAGGA
TCCTGTATGCTGTCTTCTGCCTGCCCTCCTGGGAAGCTCGACTCAAAGCTCTCAACACCTGT
GGTTCTCATATTGGTGTTATCTTAGCCTTTTTTACACCAGCATTTTTTTCATTCTTGACACA
50   TCGTTTTGGCCATAATATCCCACAGTATATACATATTATATTAGCCAACCTGTATGTGGTTG
TCCCACCAGCCCTCAATCCTGTAATCTATGGAGTCAGGACAAAGCAGATTCGAGAGAGAG
TGCTGAGGATTTTTCTCAAGACCAATCACTAA (SEQ ID NO: 120)

  AOLFR66 sequences:
55   MSFLNGTSLTPASFILNGIPGLEDVHLWISFPLCTMYSIAITGNFGLMYLIYCDEALHRPMYVFL
ALLSFTDVLMCTSTLPNTLFILWFNLKEIDFKACLAQMFFVHTFTGMESGVLMLMALDHCVAI

CFPLRYATILTNSVIAKAGFLTFLRGVMLVIPSTFLTKRLPYCKGNVIPHTYCDHMSVAKISCGN
VRVNAIYGLIVALLIGGFDILCITISYTMILQAVVSLSSADARQKAFSTCTAHFCAIVLTYVPAFF
TFFTHHFGGHTIPLHIHIIMANLYLLMPPTMNPIVYGVKTRQVRESVIRFFLKGKDNSHNF (SEQ
ID NO: 121)

5

ATGTCATTTCTAAATGGCACCAGCCTAACTCCAGCTTCATTCATCCTAAATGGCATCCCTG
GTTTGGAAGATGTGCATTTGTGGATCTCCTTCCCACTGTGTACCATGTACAGCATTGCTATT
ACAGGGAACTTCGGCCTTATGTACCTCATCTACTGTGATGAGGCCTTACACAGACCTATGT
ATGTCTTCCTTGCCCTTCTTTCCTTCACAGATGTGCTCATGTGCACCAGCACCCTTCCCAAC
ACTCTCTTCATATTGTGGTTTAATCTCAAGGAGATTGATTTTAAAGCCTGCCTCGCCCAGAT
GTTCTTTGTGCACACCTTCACAGGGATGGAGTCTGGGGTGCTCATGCTCATGGCCCTGGAC
CACTGTGTGGCCATCTGCTTCCCTCTGCGTTATGCCACCATCCTCACTAATTCAGTCATTGC
TAAAGCTGGGTTCCTCACTTTTCTTAGGGGTGTGATGCTTGTTATCCCTTCCACTTTCCTCA
CCAAGCGCCTTCCATACTGCAAGGGCAACGTCATACCCCACACCTACTGTGACCACATGTC
TGTGGCCAAGATATCTTGTGGTAATGTCAGGGTTAACGCCATCTATGGTTTGATAGTTGCC
CTGCTGATTGGGGGCTTTGATATCCTGTGCATTACAATCTCCTACACTATGATTCTTCAAGC
AGTTGTGAGTCTATCATCAGCAGATGCTCGACAGAAGGCCTTCAGCACCTGCACTGCCCAC
TTCTGTGCCATAGTCCTCACCTATGTTCCAGCCTTCTTTACCTTCTTTACACACCATTTTGG
GGGACACACCATTCCTCTACACATACATATTATTATGGCTAATCTCTACCTACTAATGCCTC
CCACAATGAACCCTATTGTGTATGGGGTGAAAACCAGGCAGGTACGAGAAAGTGTCATTA
GGTTCTTTCTTAAGGGAAAGGACAATTCTCATAACTTTTAA (SEQ ID NO: 122)

AOLFR67 sequences:

MSGDNSSSLTPGFFILNGVPGLEATHIWISLPFCFMYIIAVVGNCGLICLISHEEALHRPMYYFLA
LLSFTDVTLCTTMVPNMLCIFWFNLKEIDFNACLAQMFFVHMLTGMESGVLMLMALDRYVAI
CYPLRYATILTNPVIAKAGLATFLRNVMLIIPFTLLTKRLPYCRGNFIPHTYCDHMSVAKVSCGN
FKVNAIYGLMVALLIGVFDICCISVSYTMILQAVMSLSSADARHKAFSTCTSHMCSIVITYVAAF
FTFFTHRFVGHNIPNHIHIIVANLYLLLPPTMNPIVYGVKTKQIQEGVIKFLLGDKVSFTYDK
(SEQ ID NO: 123)

ATGTCTGGGGACAACAGCTCCAGCCTGACCCCAGGATTCTTTATCTTGAATGGCGTTCCTG
GGCTGGAAGCCACACACATCTGGATCTCCCTGCCATTCTGCTTTATGTACATCATTGCTGTC
GTGGGGAACTGTGGGCTCATCTGCCTCATCAGCCATGAGGAGGCCCTGCACCGGCCCATGT
ACTACTTCCTGGCCCTGCTCTCCTTCACTGATGTCACCTTGTGCACCACCATGGTACCTAAT
ATGCTGTGCATATTCTGGTTCAACCTCAAGGAGATTGACTTTAACGCCTGCCTGGCCCAGA
TGTTTTTTGTCCATATGCTGACAGGGATGGAGTCTGGGGTGCTCATGCTCATGGCCCTGGA
CCGCTATGTGGCCATCTGCTACCCCTTACGCTATGCCACCATCCTTACCAACCCTGTCATCG
CCAAGGCTGGTCTTGCCACCTTCTTGAGGAATGTGATGCTCATCATCCCATTCACTCTCCTC
ACCAAGCGCCTGCCCTATTGCCGGGGGAACTTCATCCCCCACACCTACTGTGACCATATGT
CTGTGGCCAAGGTATCCTGTGGCAATTTCAAGGTCAATGCTATTTATGGTCTGATGGTTGC
TCTCCTGATTGGTGTGTTTGATATCTGCTGTATCTCTGTATCTTACACTATGATTTTGCAGG
CTGTTATGAGCCTGTCATCAGCAGATGCTCGTCACAAAGCCTTCAGCACCTGCACATCTCA
CATGTGTTCCATTGTGATCACCTATGTTGCTGCTTTTTTCACTTTTTTCACTCATCGTTTTGT
AGGACACAATATCCCAAACCACATACACATCATCGTGGCCAACCTTTATCTGCTACTGCCT
CCTACCATGAACCCAATTGTTTATGGAGTCAAGACCAAGCAGATTCAGGAAGGTGTAATTA
AATTTTTACTTGGAGACAAGGTTAGTTTTACCTATGACAAATGA (SEQ ID NO: 124)

AOLFR68 sequences:

MTTHRNDTLSTEASDFLLNCFVRSPSWQHWLSLPLSLLFLLAVGANTTLLMTIWLEASLHQPL
YYLLSLLSLLDIVLCLTVIPKVLTIFWFDLRPISFPACFLQMYIMNCFLAMESCTFMVMAYDRY
VAICHPLRYPSIITDHFVVKAAMFILTRNVLMTLPIPILSAQLRYCGRNVIENCICANMSVSRLSC
DDVTINHLYQFAGGWTLLGSDLILIFLSYTFILRAVLRLKAEGAVAKALSTCGSHFMLILFFSTIL
LVFVLTHVAKKKVSPDVPVLLNVLHHVIPAALNPIIYGVRTQEIKQGMQRLLKKGC (SEQ ID
NO: 125)

```
ATGACAACACACCGAAATGACACCCTCTCCACTGAAGCTTCAGACTTCCTCTTGAATTGTT
TTGTCAGATCCCCCAGCTGGCAGCACTGGCTGTCCCTGCCCCTCAGCCTCCTTTTCCTCTTG
GCCGTAGGGGCCAACACCACCCTCCTGATGACCATCTGGCTGGAGGCCTCTCTGCACCAGC
CCCTGTACTACCTGCTCAGCCTCCTCTCCCTGCTGGACATCGTGCTCTGCCTCACTGTCATC
CCCAAGGTCCTGACCATCTTCTGGTTTGACCTCAGGCCCATCAGCTTCCCTGCCTGCTTCCT
CCAGATGTACATCATGAATTGTTTCCTAGCCATGGAGTCTTGCACATTCATGGTCATGGCC
TATGATCGTTATGTAGCCATCTGCCACCCACTGAGATATCCATCAATCATCACTGATCACTT
TGTAGTCAAGGCTGCCATGTTATTTTGACCAGAAATGTGCTTATGACTCTGCCCATCCCC
ATCCTTTCAGCACAACTCCGTTATTGTGGAAGAAATGTCATTGAGAACTGCATCTGTGCCA
ATATGTCTGTTTCCAGACTCTCCTGCGATGATGTCACCATCAATCACCTTTACCAATTTGCT
GGAGGCTGGACTCTGCTAGGATCTGACCTCATCCTTATCTTCCTCTCCTACACCTTCATTCT
GCGAGCTGTGCTGAGACTCAAGGCAGAGGGTGCCGTGGCAAAGGCCCTAAGCACATGTGG
CTCCCACTTCATGCTCATCCTCTTCTTCAGCACCATCCTTCTGGTTTTTGTCCTCACACATGT
GGCTAAGAAGAAAGTCTCCCCTGATGTGCCAGTCTTGCTCAATGTTCTCCACCATGTCATT
CCTGCAGCCCTTAACCCCATCATTTACGGGGTGAGAACCCAAGAAATTAAGCAGGGAATG
CAGAGGTTGTTGAAGAAAGGGTGCTAA (SEQ ID NO: 126)
```

AOLFR69 sequences:

```
MSYSIYKSTVNIPLSHGVVHSFCHNMNCNFMHIFKFVLDFNMKNVTEVTLFVLKGFTDNLELQ
TIFFFLFLAIYLFTLMGNLGLILVVIRDSQLHKPMYYFLSMLSSVDACYSSVITPNMLVDFTTKN
KVISFLGCVAQVFLACSFGTTECFLLAAMAYDRYVAIYNPLLYSVSMSPRVYMPLINASYVAGI
LHATIHTVATFSLSFCGANEIRRVFCDIPPLLAISYSDTHTNQLLLFYFVGSIELVTILIVLISYGLIL
LAILKMYSAEGRRKVFSTCGAHLTGVSIYYGTILFMYVRPSSSYASDHDMIVSIFYTIVIPLLNPV
IYSLRNKDVKDSMKKMFGKNQVINKVYFHTKK (SEQ ID NO: 127)
```

```
ATGTCGTACAGTATATACAAGAGCACAGTTAACATCCCCTTGAGTCATGGTGTTGTTCATT
CTTTTTGTCATAATATGAACTGTAACTTATGCATATCTTCAAGTTTGTTCTAGATTTCAAC
ATGAAGAATGTCACTGAAGTTACCTTATTTGTACTGAAGGGCTTCACAGACAATCTTGAAC
TGCAGACTATCTTCTTCTTCCTGTTTCTAGCAATCTACCTCTTCACTCTCATGGGAAATTTA
GGACTGATTTTAGTGGTCATTAGGGATTCCCAGCTCCACAAACCCATGTACTATTTTCTGA
GTATGTTGTCTTCTGTGGATGCCTGCTATTCCTCAGTTATTACCCCAAATATGTTAGTAGAT
TTTACGACAAAGAATAAAGTCATTTCATTCCTTGGATGTGTAGCACAGGTGTTTCTTGCTT
GTAGTTTTGGAACCACAGAATGCTTTCTCTTGGCTGCAATGGCTTATGATCGCTATGTAGC
CATCTACAACCCTCTCCTGTATTCAGTGAGCATGTCACCCAGAGTCTACATGCCACTCATC
AATGCTTCCTATGTTGCTGGCATTTTACATGCTACTATACATACAGTGGCTACATTTAGCCT
ATCCTTCTGTGGAGCCAATGAAATTAGGCGTGTCTTTTGTGATATCCCTCCTCTCCTTGCTA
TTTCTTATTCTGACACTCACACAAACCAGCTTCTACTCTTCTACTTTGTGGGCTCTATCGAG
CTGGTCACTATCCTGATTGTTCTGATCTCCTATGGTTTGATTCTGTTGGCCATTCTGAAGAT
GTATTCTGCTGAAGGGAGGAGAAAAGTCTTCTCCACATGTGGAGCTCACCTAACTGGAGT
GTCAATTTATTATGGGACAATCCTCTTCATGTATGTGAGACCAAGTTCCAGCTATGCTTCG
GACCATGACATGATAGTGTCAATATTTTACACCATTGTGATTCCCTTGCTGAATCCCGTCAT
CTACAGTTTGAGGAACAAAGATGTAAAAGACTCAATGAAAAAAATGTTTGGGAAAAATCA
GGTTATCAATAAAGTATATTTTCATACTAAAAAATAA (SEQ ID NO: 128)
```

AOLFR70 sequences:

```
MDSTFTGYNLYNLQVKTEMDKLSSGLDIYRNPLKNKTEVTMFILTGFTDDFELQVFLFLLFFAI
YLFTLIGNLGLVVLVIEDSWLHNPMYYFLSVLSFLDACYSTVVTPKMLVNFLAKNKSISFIGCA
TQMLLFVTFGTTECFLLAAMAYDHYVAIYNPLLYSVSMSPRVYVPLITASYVAGILHATIHIVA
TFSLSFCGSNEIRHVFCDMPPLLAISCSDTHTNQLLLFYFVGSIEIVTILIVLISCDFILLSILKMHSA
KGRQKAFSTCGSHLTGVTIYHGTILVSYMRPSSSYASDHDIIVSIFYTIVIPKLNPIIYSLRNKEVK
KAVKKMLKLVYK (SEQ ID NO: 129)
```

```
ATGGACTCCACTTTCACAGGCTATAACCTTTATAACCTGCAAGTAAAAACTGAAATGGACA
AGTTGTCATCAGGTTTGGATATATACAGGAATCCACTGAAGAACAAGACTGAAGTCACCA
TGTTTATATTGACAGGCTTCACAGATGATTTTGAGCTGCAAGTCTTCCTATTTTTACTATTT
TTTGCAATCTATCTCTTTACCTTGATAGGCAATTTAGGGCTGGTTGTGTTGGTCATTGAGG
```

ATTCCTGGCTCCACAACCCCATGTATTATTTTCTTAGTGTTTTATCATTCTTGGATGCTTGC
TATTCTACAGTTGTCACTCCAAAAATGTTGGTCAATTTCCTGGCAAAAAATAAATCCATTT
CATTTATCGGATGTGCAACACAGATGCTTCTTTTTGTTACTTTTGGAACTACAGAATGTTTT
CTCTTGGCTGCAATGGCTTATGATCACTATGTAGCCATCTACAACCCTCTCCTGTATTCAGT
5   GAGCATGTCACCCAGAGTCTATGTGCCACTCATCACTGCTTCCTACGTTGCTGGCATTTTAC
ATGCTACTATACATATAGTGGCTACATTTAGCCTGTCCTTCTGTGGATCCAATGAAATTAG
GCATGTCTTTTGTGATATGCCTCCTCTCCTTGCTATTCTTGTTCTGACACTCACACAAACC
AGCTTCTACTCTTCTACTTTGTGGGTTCTATTGAGATAGTCACTATCCTGATTGTCCTCATT
TCCTGTGATTTCATTCTGTTGTCCATTCTGAAGATGCATTCTGCTAAGGGAAGGCAAAAGG
10   CCTTCTCTACATGTGGCTCTCACCTAACTGGAGTGACAATTTATCATGGAACAATTCTCGTC
AGTTATATGAGACCAAGTTCCAGCTATGCTTCAGACCATGACATCATAGTGTCAATATTTT
ACACAATTGTGATTCCCAAGTTGAATCCCATCATCTATAGTTTGAGGAACAAAGAAGTAAA
AAAGGCAGTGAAGAAAATGTTGAAATTGGTTTACAAATGA (SEQ ID NO: 130)

15   **AOLFR71 sequences:**

MGRRNNTNVPDFILTGLSDSEEVQMALFILFLLIYLITMLGNVGMILIIRLDLQLHTPMYFFLTH
LSFIDLSYSTVITPKTLANLLTSNYISFMGCFAQMFFFVFLGAAECFLLSSMAYDRYVAICSPLRY
PVIMSKRLCCALVTGPYVISFINSFVNVVWMSRLHFCDSNVVRHFFCDTSPILALSCMDTYDIEI
MIHILAGSTLMVSLITISASYVSILSTILKINSTSGKQKALSTCASHLLGVTIFYGTMIFTYLKPRK
20   SYSLGRDQVASVFYTIVIPMLNPLIYSLRNKEVKNALIRVMQRRQDSR (SEQ ID NO: 131)

ATGGGTAGAAGAAATAACACAAATGTGCCTGACTTCATCCTTACGGGACTGTCAGATTCTG
AAGAGGTCCAGATGGCCCTCTTTATACTATTTCTCCTGATATACCTAATTACTATGCTGGGC
AATGTGGGGATGATATTGATAATCCGCCTGGACCTCCAGCTTCACACTCCCATGTATTTTT
25   TCCTTACTCACTTGTCATTTATTGACCTCAGTTACTCAACTGTCATCACACCTAAAACCTTA
GCGAACTTACTGACTTCCAACTATATTTCCTTCATGGGCTGCTTTGCCCAGATGTTCTTTTT
TGTCTTCTTGGGAGCTGCTGAATGTTTTCTTCTCTCATCAATGGCCTATGATCGCTACGTAG
CTATCTGCAGTCCTCTACGTTACCCAGTTATTATGTCCAAAAGGCTGTGTTGCGCTCTTGTC
ACTGGGCCCTATGTGATTAGCTTTATCAACTCCTTTGTCAATGTGGTTTGGATGAGCAGAC
30   TGCATTTCTGCGACTCAAATGTAGTTCGTCACTTTTTCTGCGACACGTCTCCAATTTTAGCT
CTGTCCTGCATGGACACATACGACATTGAAATCATGATACACATTTTAGCTGGTTCCACCC
TGATGGTGTCCCTTATCACAATATCTGCATCCTATGTGTCCATTCTCTCTACCATCCTGAAA
ATTAATTCCACTTCAGGAAAGCAGAAAGCTTTGTCTACTTGTGCCTCTCATCTCTTGGGAG
TCACCATCTTTTATGGAACTATGATTTTTACTTATTTAAAACCAAGAAAGTCTTATTCTTTG
35   GGAAGGGATCAAGTGGCTTCTGTTTTTTATACTATTGTGATTCCCATGCTGAATCCACTCAT
TTATAGTCTTAGAAACAAAGAAGTTAAAAATGCTCTCATTAGAGTCATGCAGAGAAGACA
GGACTCCAGGTAA (SEQ ID NO: 132)

AOLFR72 sequences:

40   MAPENFTRVTEFILTGVSSCPELQIPLFLVFLVLYGLTMAGNLGIITLTSVDSRLQTPMYFFLQHL
ALINLGNSTVIAPKMLINFLVKKKTTSFYECATQLGGFLFFIVSEVIMLALMACDRYVAICNPLL
YMVVVSRRLCLLLVSLTYLYGFSTAIVVSSYVFSVSYCSSNIINHFYCDNVPLLALSCSDTYLPE
TVVFISAATNVVGSLIIVLVSYFNIVLSILKICSSEGRKKAFSTCASHMMAVTIFYGTLLFMYVQP
RSNHSLDTDDKMASVFYTLVIPMLNPLIYSLRNKDVKTALQRFMTNLCYSFKTM (SEQ ID NO:
45   133)

ATGGCTCCTGAAAATTTCACCAGGGTCACTGAGTTTATTCTTACAGGTGTCTCTAGCTGTC
CAGAGCTCCAGATTCCCCTCTTCCTGGTCTTTCTGGTGCTCTATGGGCTGACCATGGCAGG
GAACCTGGGCATCATCACCCTCACCAGTGTTGACTCTCGACTTCAAACCCCCATGTACTTTT
50   TCCTGCAACATCTGGCTCTCATTAATCTTGGTAACTCTACTGTCATTGCCCCTAAAATGCTG
ATTAACTTTTTAGTAAAGAAGAAAACTACCTCATTCTATGAATGTGCCACCCAACTGGGAG
GGTTCTTGTTCTTTATTGTATCGGAGGTAATCATGCTGGCTTTGATGGCCTGTGACCGCTAT
GTGGCTATTTGTAACCCTCTGCTGTACATGGTGGTGGTGTCTCGGCGGCTCTGCCTCCTGCT
GGTCTCCCTCACATACCTCTATGGCTTTTCTACAGCTATTGTGGTTTCATCTTATGTATTCT
55   CTGTGTCTTATTGCTCTTCTAATATAATCAATCATTTTTACTGTGATAATGTTCCTCTGTTA
GCATTATCTTGCTCTGATACTTACTTACCAGAAACAGTTGTCTTTATATCTGCAGCAACAA

86

ATGTGGTTGGTTCCTTGATTATAGTTCTAGTATCTTATTTCAATATTGTTTTGTCTATTTTA
AAAATATGTTCATCAGAAGGAAGGAAAAAAGCCTTTTCTACCTGTGCTTCACATATGATGG
CAGTCACAATTTTTTATGGGACATTGCTATTCATGTATGTGCAGCCCCGAAGTAACCATTC
ATTGGATACTGATGATAAGATGGCTTCTGTGTTTTACACGTTGGTAATTCCTATGCTGAAT
5   CCCTTGATCTACAGCCTGAGGAATAAGGATGTGAAGACTGCTCTACAGAGATTCATGACA
AATCTGTGCTATTCCTTTAAAACAATGTAA (SEQ ID NO: 134)

AOLFR73 sequences:

MNHVVKHNHTAVTKVTEFILMGITDNPGLQAPLFGLFLIIYLVTVIGNLGMVILTYLDSKLHTP
10 MYFFLRHLSITDLGYSTVIAPKMLVNFIVHKNTISYNWYATQLAFFEIFIISELFILSAMAYDRYV
AICKPLLYVIIMAEKVLWVLVIVPYLYSTFVSLFLTIKLFKLSFCGSNIISYFYCDCIPLMSILCSDT
NELELIILIFSGCNLLFSLSIVLISYMFILVAILRMNSRKGRYKAFSTCSSHLTVVIMFYGTLLFIYL
QPKSSHTLAIDKMASVFYTLLIPMLNPLIYSLRNKEVKDALKRTLTNRFKIPI (SEQ ID NO: 135)

15 ATGAATCATGTGGTAAAACACAATCACACGGCAGTGACCAAGGTGACTGAATTTATTCTCA
TGGGGATTACAGACAACCCTGGGCTGCAGGCTCCACTGTTTGGACTCTTCCTCATCATATA
TCTGGTCACAGTGATAGGCAATCTGGGCATGGTTATCTTGACCTACTTGGACTCCAAGCTA
CACACCCCCATGTACTTTTTCCTTAGACATTTGTCAATCACTGATCTTGGTTACTCCACTGT
CATTGCCCCGAAGATGTTAGTAAACTTCATAGTGCACAAAAACACAATTTCTTACAATTGG
20 TATGCCACTCAGCTAGCATTCTTTGAGATTTTCATCATCTCTGAGCTCTTTATTCTATCAGC
AATGGCCTATGATCGCTACGTAGCCATCTGTAAACCTCTTCTGTACGTGATCATCATGGCA
GAGAAAGTACTTTGGGTGCTGGTAATTGTTCCCTATCTCTATAGCACGTTTGTGTCACTATT
TCTCACAATTAAGTTATTTAAACTGTCCTTCTGTGGCTCAAACATAATCAGCTATTTTTACT
GTGACTGTATCCCTCTGATGTCCATACTCTGTTCTGACACAAATGAATTAGAATTAATAAT
25 TTTGATCTTCTCAGGCTGTAATTTGCTCTTCTCCCTCTCAATTGTTCTCATATCCTACATGTT
TATTCTAGTGGCCATTCTCAGAATGAACTCAAGGAAAGGGAGGTACAAAGCCTTCTCCACC
TGTAGCTCTCATCTGACAGTGGTGATCATGTTCTATGGGACATTGTTATTTATTTACTTGCA
ACCCAAGTCCAGTCATACTTTGGCTATTGATAAAATGGCCTCAGTGTTTTATACCCTGTTG
ATTCCTATGCTGAATCCGTTGATCTACAGCCTAAGGAACAAAGAAGTAAAAGATGCTCTAA
30 AGAGAACTTTAACCAATCGATTCAAAATTCCCATTTAA (SEQ ID NO: 136)

AOLFR74 sequences:

MEQHNLTTVNEFILTGITDIAELQAPLFALFLMIYVISVMGNLGMIVLTKLDSRLQTPMYFFLRH
LAFMDLGYSTTVGPKMLVNFVVDKNIISYYFCATQLAFFLVFIGSELFILSAMSYDLYVAICNPL
35 LYTVIMSRRVCQVLVAIPYLYCTFISLLVTIKIFTLSFCGYNVISHFYCDSLPLLPLLCSNTHEIELI
ILIFAAIDLISSLLIVLLSYLLILVAILRMNSAGRQKAFSTCGAHLTVVIVFYGTLLFMYVQPKSSH
SFDTDKVASIFYTLVIPMLNPLIYSLRNKDVKYALRRTWNNLCNIFV (SEQ ID NO: 137)

ATGGAACAACACAATCTAACAACGGTGAATGAATTCATTCTTACGGGAATCACAGATATC
40 GCTGAGCTGCAGGCACCATTATTTGCATTGTTCCTCATGATCTATGTGATCTCAGTGATGG
GCAATTTGGGCATGATTGTCCTCACCAAGTTGGACTCCAGGTTGCAAACCCCTATGTACTT
TTTTCTCAGACATCTGGCTTTCATGGATCTTGGTTATTCAACAACTGTGGGACCCAAAATG
TTAGTAAATTTTGTTGTGGATAAGAATATAATTTCTTATTATTTTTGTGCAACACAGCTAGC
TTTCTTTCTTGTGTTCATTGGTAGTGAACTTTTTATTCTCTCAGCCATGTCCTACGACCTCT
45 ATGTGGCCATCTGTAACCCTCTGCTATACACAGTAATCATGTCACGAAGGGTATGTCAGGT
GCTGGTAGCAATCCCTTACCTCTATTGCACATTCATTTCTCTTCTAGTCACCATAAAGATTT
TTACTTTATCCTTCTGTGGCTACAACGTCATTAGTCATTTCTACTGTGACAGTCTCCCTTTG
TTACCTTTGCTTTGTTCAAATACACATGAAATTGAATTGATAATTCTGATCTTTGCAGCTAT
TGATTTGATTTCATCTCTTCTGATAGTTCTTTTATCTTACCTGCTCATCCTTGTAGCCATTCT
50 CAGGATGAATTCTGCTGGCAGACAAAAGGCTTTTTCTACCTGTGGAGCCCACCTGACAGTG
GTCATAGTGTTCTATGGGACTTTGCTTTTCATGTACGTGCAGCCCAAGTCCAGTCATTCCTT
TGACACTGATAAAGTGGCTTCCATATTTTACACCCTGGTTATCCCCATGTTGAATCCCTTGA
TCTATAGTTTACGAAACAAAGATGTAAAATATGCCCTACGAAGGACATGGAATAACTTATG
TAATATTTTTGTTTAA (SEQ ID NO: 138)

55

AOLFR75 sequences:

MEGKNQTNISEFLLLGFSSWQQQQVLLFALFLCLYLTGLFGNLLILLAIGSDHCLHTPMYFFLA
NLSLVDLCLPSATVPKMLLNIQTQTQTISYPGCLAQMYFCMMFANMDNFLLTVMAYDRYVAI
CHPLHYSTIMALRLCASLVAAPWVIAILNPLLHTLMMAHLHFCSDNVIHHFFCDINSLLPLSCSD
TSLNQLSVLATVGLIFVVPSVCILVSYILIVSAVMKVPSAQGKLKAFSTCGSHLALVILFYGANT
GVYMSPLSNHSTEKDSAASVIFMVVAPVLNPFIYSLRNNELKGTLKKTLSRPGAVAHACNPSTL
GGRGGWIMRSGDRDHPG (SEQ ID NO: 139)

ATGGAAGGGAAAAATCAAACCAATATCTCTGAATTTCTCCTCCTGGGCTTCTCAAGTTGGC
AACAACAGCAGGTGCTACTCTTTGCACTTTTCCTGTGTCTCTATTTAACAGGGCTGTTTGGA
AACTTACTCATCTTGCTGGCCATTGGCTCGGATCACTGCCTTCACACACCCATGTATTTCTT
CCTTGCCAATCTGTCCTTGGTAGACCTCTGCCTTCCCTCAGCCACAGTCCCCAAGATGCTAC
TGAACATCCAAACCCAAACCCAAACCATCTCCTATCCCGGCTGCCTGGCTCAGATGTATTT
CTGTATGATGTTTGCCAATATGGACAATTTTCTTCTCACAGTGATGGCATATGACCGTTAC
GTGGCCATCTGTCACCCTTTACATTACTCCACCATTATGGCCCTGCGCCTCTGTGCCTCTCT
GGTAGCTGCACCTTGGGTCATTGCCATTTTGAACCCTCTCTTGCACACTCTTATGATGGCCC
ATCTGCACTTCTGCTCTGATAATGTTATCCACCATTTCTTCTGTGATATCAACTCTCTCCTC
CCTCTGTCCTGTTCCGACACCAGTCTTAATCAGTTGAGTGTTCTGGCTACGGTGGGGCTGA
TCTTTGTGGTACCTTCAGTGTGTATCCTGGTATCCTATATCCTCATTGTTTCTGCTGTGATG
AAAGTCCCTTCTGCCCAAGGAAAACTCAAGGCTTTCTCTACCTGTGGATCTCACCTTGCCTT
GGTCATTCTTTTCTATGGAGCAAACACAGGGGTCTATATGAGCCCCTTATCCAATCACTCT
ACTGAAAAAGACTCAGCCGCATCAGTCATTTTTATGGTTGTAGCACCTGTGTTGAATCCAT
TCATTTACAGTTTAAGAAACAATGAACTGAAGGGGACTTTAAAAAAGACCCTAAGCCGGC
CGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGTGGATCA
TGAGGTCAGGAGATCGAGACCATCCTGGCTAA (SEQ ID NO: 140)

AOLFR76 sequences:

MENNTEVSEFILLGLTNAPELQVPLFIMFTLIYLITLTGNLGMIILILLDSHLHTPMYFFLSNLSLA
GIGYSSAVTPKVLTGLLIEDKAISYSACAAQMFFCAVFATVENYLLSSMAYDRYAAVCNPLHY
TTTMTTRVCACLAIGCYVIGFLNASIQIGDTFRLSFCMSNVIHHFFCDKPAVITLTCSEKHISELIL
VLISSFNVFFALLVTLISYLFILITILKRHTGKGYQKPLSTCGSHLIAIFLFYITVIIMYIRPSSSHSM
DTDKIASVFYTMIIPMLSPIVYTLRNKDVKNAFMKVVEKAKYSLDSVF (SEQ ID NO: 141)

ATGGAGAATAATACAGAGGTGAGTGAATTCATCCTGCTTGGTCTAACCAATGCCCCAGAA
CTACAGGTTCCCCTCTTTATCATGTTTACCCTCATCTACCTCATCACTCTGACTGGGAACCT
GGGGATGATCATATTAATCCTGCTGGACTCTCATCTCCACACTCCCATGTACTTTTTTCTCA
GTAACCTGTCTCTTGCAGGCATTGGTTACTCCTCAGCTGTCACTCCAAAGGTTTTAACTGG
GTTGCTTATAGAAGACAAAGCCATCTCCTACAGTGCCTGTGCTGCTCAGATGTTCTTTTGT
GCAGTCTTGCCACTGTGGAAAATTACCTCTTGTCCTCAATGGCCTATGACCGCTACGCAG
CAGTGTGTAACCCCCTACATTATACCACCACCATGACAACACGTGTGTGTGCTTGTCTGGC
TATAGGCTGTTATGTCATTGGTTTTCTGAATGCTTCTATCCAAATTGGAGATACATTTCGCC
TCTCTTTCTGCATGTCCAATGTGATTCATCACTTTTTCTGTGACAAACCAGCAGTCATTACT
CTGACCTGCTCTGAGAAACACATTAGTGAGTTGATTCTTGTTCTTATATCAAGTTTTAATGT
CTTTTTTGCACTTCTTGTTACCTTGATTTCCTATCTGTTCATATTGATCACCATTCTTAAGAG
GCACACAGGTAAGGGATACCAGAAGCCTTTATCTACCTGTGGTTCTCACCTCATTGCCATT
TTCTTATTTTATATAACTGTCATCATCATGTACATACGACCAAGTTCCAGTCATTCCATGGA
CACAGACAAAATTGCATCTGTGTTCTACACTATGATCATCCCCATGCTCAGTCCTATAGTCT
ATACCCTGAGGAACAAAGACGTGAAGAATGCATTCATGAAGGTTGTTGAGAAGGCAAAAT
ATTCTCTAGATTCAGTCTTTTAA (SEQ ID NO: 142)

AOLFR77 sequences:

MGDVNQSVASDFILVGLFSHSGSRQLLFSLVAVMFVIGLLGNTVLLFLIRVDSRLHTPMYFLLS
QLSLFDIGCPMVTIPKMASDFLRGEGATSYGGGAAQIFFLTLMGVAEGVLLVLMSYDRYVAVC
QPLQYPVLMRRQVCLLMMGSSWVVGVLNASIQTSITLHFPYCASRIVDHFFCEVPALLKLSCA
DTCAYEMALSTSGVLILMLPLSLIATSYGHVLQAVLSMRSEEARHKAVTTCSSHITVVGLFYGA

AVFMYMVPCAYHSPQQDNVVSLFYSLVTPTLNPLIYSLRNPEVWMALVKVLSRAGLRQMC
(SEQ ID NO: 143)

5   ATGGGGGATGTGAATCAGTCGGTGGCCTCAGACTTCATTCTGGTGGGCCTCTTCAGTCACT
CAGGATCACGCCAGCTCCTCTTCTCCCTGGTGGCTGTCATGTTTGTCATAGGCCTTCTGGGC
AACACCGTTCTTCTCTTCTTGATCCGTGTGGACTCCCGGCTCCACACACCCATGTACTTCCT
GCTCAGCCAGCTCTCCCTGTTTGACATTGGCTGTCCCATGGTCACCATCCCCAAGATGGCA
TCAGACTTTCTGCGGGGAGAAGGTGCCACCTCCTATGGAGGTGGTGCAGCTCAAATATTCT
TCCTCACACTGATGGGTGTGGCTGAGGGCGTCCTGTTGGTCCTCATGTCTTATGACCGTTA
10   TGTTGCTGTGTGCCAGCCCCTGCAGTATCCTGTACTTATGAGACGCCAGGTATGTCTGCTG
ATGATGGGCTCCTCCTGGGTGGTAGGTGTGCTCAACGCCTCCATCCAGACCTCCATCACCC
TGCATTTTCCCTACTGTGCCTCCCGTATTGTGGATCACTTCTTCTGTGAGGTGCCAGCCCTA
CTGAAGCTCTCCTGTGCAGATACCTGTGCCTACGAGATGGCGCTGTCCACCTCAGGGGTGC
TGATCCTAATGCTCCCTCTTTCCCTCATCGCCACCTCCTACGGCCACGTGTTGCAGGCTGTT
15   CTAAGCATGCGCTCAGAGGAGGCCAGACACAAGGCTGTCACCACCTGCTCCTCGCACATCA
CGGTAGTGGGGCTCTTTTATGGTGCCGCCGTGTTCATGTACATGGTGCCTTGCGCCTACCA
CAGTCCACAGCAGGATAACGTGGTTTCCCTCTTCTATAGCCTTGTCACCCCTACACTCAAC
CCCCTTATCTACAGTCTGAGGAATCCGGAGGTGTGGATGGCTTTGGTCAAAGTGCTTAGCA
GAGCTGGACTCAGGCAAATGTGCTGA (SEQ ID NO: 144)

20

AOLFR78 sequences:
MSPDGNHSSDPTEFVLAGLPNLNSARVELFSVFLLVYLLNLTGNVLIVGVVRADTRLQTPMYF
FLGNLSCLEILLTSVIIPKMLSNFLSRQHTISFAACITQFYFYFFLGASEFLLLAVMSADRYLAICH
PLRYPLLMSGAVCFRVALACWVGGLVPVLGPTVAVALLPFCKQGAVVQHFFCDSGPLLRLAC
25   TNTKKLEETDFVLASLVIVSSLLITAVSYGLIVLAVLSIPSASGRQKAFSTCTSHLIVVTLFYGSAI
FLYVRPSQSGSVDTNWAVTVITTFVTPLLNPFIYALRNEQVKEALKDMFRKVVAGVLGNLLLD
KCLSEKAVK (SEQ ID NO: 145)

ATGAGTCCTGATGGGAACCACAGTAGTGATCCAACAGAGTTCGTCCTGGCAGGGCTCCCA
30   AATCTCAACAGCGCAAGAGTGGAATTATTTTCTGTGTTTCTTCTTGTCTATCTCCTGAATCT
GACAGGCAATGTGTTGATTGTGGGGGGTGGTAAGGGCTGATACTCGACTACAGACCCCTAT
GTACTTCTTTCTGGGTAACCTGTCCTGCCTAGAGATACTGCTCACTTCTGTCATCATTCCAA
AGATGCTGAGCAATTTCCTCTCAAGGCAACACACTATTTCCTTTGCTGCATGTATCACCCA
ATTCTATTTCTACTTCTTTCTCGGGGCCTCCGAGTTCTTACTGTTGGCTGTCATGTCTGCGG
35   ATCGCTACCTGGCCATCTGTCATCCTCTGCGCTACCCCTTGCTCATGAGTGGGGCTGTGTG
CTTTCGTGTGGCCTTGGCCTGCTGGGTGGGGGGACTCGTCCCTGTGCTTGGTCCCACAGTG
GCTGTGGCCTTGCTTCCTTTCTGTAAGCAGGGTGCTGTGGTACAGCACTTCTTCTGCGACA
GTGGCCCACTGCTCCGCCTGGCTTGCACCAACACCAAGAAGCTGGAGGAGACTGACTTTGT
CCTGGCCTCCCTCGTCATTGTATCTTCCTTGCTGATCACTGCTGTGTCCTACGGCCTCATTG
40   TGCTGGCAGTCCTGAGCATCCCCTCTGCTTCAGGCCGTCAGAAGGCCTTCTCTACCTGTAC
CTCCCACTTGATAGTGGTGACCCTCTTCTATGGAAGTGCCATTTTTCTCTATGTGCGGCCAT
CGCAGAGTGGTTCTGTGGACACTAACTGGGCAGTGACAGTAATAACGACATTTGTGACAC
CACTGTTGAATCCATTCATCTATGCCTTACGTAATGAGCAAGTCAAGGAAGCTTTGAAGGA
CATGTTTAGGAAGGTAGTGGCAGGCGTTTTAGGGAATCTTTTACTTGATAAATGTCTCAGT
45   GAGAAAGCAGTAAAGTAA (SEQ ID NO: 146)

AOLFR79 sequences:
MTPGELALASGNHTPVTKFILQGFSNYPDLQELLFGAILLIYAITVVGNLGMMALIFTDSHLQSP
MYFFLNVLSFLDICYSSVVTPKLLVNFLVSDKSISFEGCVVQLAFFVVHVTAESFLLASMAYDR
50   FLAICQPLHYGSIMTRGTCLQLVAVSYAFGGANSAIQTGNVFALPFCGPNQLTHYYCDIPPLLH
LACANTATARVVLYVFSALVTLLPAAVILTSYCLVLVAIGRMRSVAGREKDLSTCASHFLAIAI
FYGTVVFTYVQPHGSTNNTNGQVVSVFYTIIIPMLNPFIYSLRNKEVKGALQRKLQVNIFPG
(SEQ ID NO: 147)

55   ATGACACCTGGAGAACTAGCCCTTGCCAGTGGCAACCACACCCCAGTCACCAAGTTCATCT
TGCAGGGATTCTCCAATTATCCAGACCTCCAGGAGCTTCTCTTCGGAGCCATCCTGCTCAT

CTATGCCATAACAGTGGTGGGCAACTTGGGAATGATGGCACTCATCTTCACAGACTCCCAT
CTCCAAAGCCCAATGTATTTCTTCCTCAATGTCCTCTCGTTTCTTGATATTTGTTACTCTTCT
GTGGTCACACCTAAGCTCTTGGTCAACTTCCTGGTCTCTGACAAGTCCATCTCTTTTGAGG
GCTGTGTGGTCCAGCTCGCCTTCTTTGTAGTGCATGTGACAGCTGAGAGCTTCCTGCTGGC
5   CTCCATGGCCTATGACCGCTTCCTAGCCATCTGTCAACCCCTCCATTATGGTTCTATCATGA
CCAGGGGGACCTGTCTCCAGCTGGTAGCTGTGTCCTATGCATTTGGTGGAGCCAACTCCGC
TATCCAGACTGGAAATGTCTTTGCCCTGCCTTTCTGTGGGCCCAACCAGCTAACACACTAC
TACTGTGACATACCACCCCTTCTCCACCTGGCTTGTGCCAACACAGCCACAGCAAGAGTGG
TCCTCTATGTCTTTTCTGCTCTGGTCACCCTTCTGCCTGCTGCAGTCATTCTCACCTCCTACT
10   GCTTGGTCTTGGTGGCCATTGGGAGGATGCGCTCAGTAGCAGGGAGGGAGAAGGACCTCT
CCACTTGTGCCTCCCACTTTCTGGCCATTGCCATTTTCTATGGCACTGTGGTTTTCACCTAT
GTTCAGCCCCATGGATCTACTAACAATACCAATGGCCAAGTAGTGTCCGTCTTCTACACCA
TCATAATTCCCATGCTCAATCCCTTCATCTATAGCCTCCGCAACAAGGAGGTGAAGGGCGC
TCTGCAGAGGAAGCTTCAGGTCAACATCTTTCCCGGCTGA (SEQ ID NO: 148)

15

AOLFR80 sequences:

MEGINKTAKMQFFFRPFSPDPEVQMLIFVVFLMMYLTSLGGNATIAVIVQINHSLHTPMYFFLA
NLAVLEIFYTSSITPLALANLLSMGKTPVSITGCGTQMFFFVFLGGADCVLLVVMAYDRFIAICH
PLRYRLIMSWSLCVELLVGSLVLGFLLSLPLTILIFHLPFCHNDEIYHFYCDMPAVMRLACADTR
20   VHKTALYIISFIVLSIPLSLISISYVFIVVAILRIRSAEGRQQAYSTCSSHILVVLLQYGCTSFIYLSPS
SSYSPEMGRVVSVAYTFITPILNPLIYSLRNKELKDALRKALRKF (SEQ ID NO: 149)

ATGGAAGGAATAAATAAAACTGCAAAGATGCAGTTTTTCTTTCGTCCATTCTCACCTGACC
CTGAGGTCCAGATGCTGATTTTTGTGGTCTTCCTGATGATGTATCTGACCAGCCTCGGTGG
25   AAATGCTACAATTGCAGTCATTGTTCAGATCAATCATTCCCTCCACACCCCCATGTACTTTT
TCCTGGCTAATCTGGCAGTTCTAGAAATCTTCTATACATCTTCCATCACCCCATTGGCCTTG
GCAAACCTCCTTTCAATGGGCAAAACTCCTGTTTCCATCACGGGATGTGGCACCCAGATGT
TTTTCTTTGTCTTCTTGGGTGGGGCTGATTGTGTCCTGCTGGTAGTCATGGCTTATGACCGG
TTTATAGCGATCTGTCACCCTCTGCGATACAGGCTCATCATGAGCTGGTCCTTGTGTGTGG
30   AGCTGCTGGTAGGCTCCTTGGTGCTGGGGTTCCTGTTGTCACTGCCACTCACCATTTTAATC
TTCCATCTCCCATTCTGCCACAATGATGAGATCTACCACTTCTACTGTGACATGCCTGCAGT
CATGCGCCTGGCTTGTGCAGACACACGCGTTCACAAGACTGCTCTGTATATCATCAGCTTC
ATCGTCCTTAGCATCCCCCTCTCATTGATCTCCATCTCCTATGTCTTCATCGTGGTAGCCAT
TTTACGGATCCGGTCAGCAGAAGGGCGCCAGCAAGCCTACTCTACCTGCTCTTCTCACATC
35   TTAGTGGTCCTCCTGCAGTATGGCTGCACCAGCTTTATATACTTGTCCCCCAGTTCCAGCTA
CTCTCCTGAGATGGGCCGGGGTGGTATCTGTGGCCTACACATTTATCACTCCCATTTTAAAC
CCCTTGATCTATAGTTTGAGGAACAAGGAACTGAAAGATGCCCTAAGGAAAGCATTGAGA
AAATTCTAG (SEQ ID NO: 150)

40   **AOLFR81 sequences:**

MGVKNHSTVTEFLLSGLTEQAELQLPLFCLFLGIYTVTVVGNLSMISIIRLNRQLHTPMYYFLSS
LSFLDFCYSSVITPKMMKLWMESHLIVPETRPSPRMMSNQTLVTEFILQGFSEHPEYRVFLFSCF
LFLYSGALTGNVLITLAITFNPGLHAPMYFFLLNLATMDIICTSSIMPKALASLVSEESSISYGGC
MAQLYFLTWAASSELLLLTVMAYDRYAAICHPLHYSSMMSKVFCSGLATAVWLLCAVNTAIH
45   TGLMLRLDFCGPNVIIHFFCEVPPLLLLSCSSTYVNGVMIVLADAFYGIVNFLMTIASYGFIVSSI
LKVKTAWGRQKAFSTCSSHLTVVCMYYTAVFYAYISPVSGYSAGKSKLAGLLYTVLSPTLNPL
IYTLRNKEVKAALRKLFPFFRN (SEQ ID NO: 151)

ATGAAGCTGTGGATGGAGAGTCACCTGATAGTCCCAGAAACCCGTCCCAGCCCAAGGATG
50   ATGAGTAACCAGACGTTGGTAACCGAGTTCATCCTGCAGGGCTTTTCGGAGCACCCAGAAT
ACCGGGTGTTCTTATTCAGCTGTTTCCTCTTCCTCTACTCTGGGGCCCTCACAGGTAATGTC
CTCATCACCTTGGCCATCACGTTCAACCCTGGGCTCCACGCTCCTATGTACTTTTTTCTTACT
CAACTTGGCTACTATGGACATTATCTGCACCTCTTCCATCATGCCCAAGGCGCTGGCCAGT
CTGGTGTCGGAAGAGAGCTCCATCTCCTACGGGGGCTGCATGGCCCAGCTCTATTTCCTCA
55   CGTGGGCTGCATCCTCAGAGCTGCTGCTCCTCACGGTCATGGCCTATGACCGGTACGCAGC
CATCTGCCACCCGCTGCATTACAGCAGCATGATGAGCAAGGTGTTCTGCAGCGGGCTGGCC

ACAGCCGTGTGGCTGCTCTGCGCCGTCAACACGGCCATCCACACGGGGCTGATGCTGCGCT
TGGATTTCTGTGGCCCCAATGTCATTATCCATTTCTTCTGCGAGGTCCCTCCCCTGCTGCTT
CTCTCCTGCAGCTCCACCTACGTCAACGGTGTCATGATTGTCCTGGCGGATGCTTTCTACG
GCATAGTGAACTTCCTGATGACCATCGCGTCCTATGGCTTCATCGTCTCCAGCATCCTGAA
5 GGTGAAGACTGCCTGGGGGAGGCAGAAAGCCTTCTCCACCTGCTCTTCCCACCTCACCGTG
GTGTGCATGTATTACACCGCTGTCTTCTACGCCTACATAAGCCCGGTCTCTGGCTACAGCG
CAGGGAAGAGCAAGTTGGCTGGCCTGCTGTACACTGTGCTGAGTCCTACCCTCAACCCCCT
CATCTATACTTTGAGAAACAAGGAGGTCAAAGCAGCCCTCAGGAAGCTTTTCCCTTTCTTC
AGAAATTAA (SEQ ID NO: 152)

10

AOLFR82 sequences:

MQLNNNVTEFILLGLTQDPFWKKIVFVIFLRLYLGTLLGNLLIIISVKASQALKNPMFFFLFYLSL
SDTCLSTSIAPRMIVDALLKKTTISFSECMIQVFSSHVFGCLEIFILILTAVDRYVDICKPLHYMTII
SQWVCGVLMAVAWVGSCVHSLVQIFLALSLPFCGPNVINHCFCDLQPLLKQACSETYVVNLLL
15 VSNSGAICAVSYVMLIFSYVIFLHSLRNHSAEVIKKALSTCVSHIIVVILFFGPCIFMYTCPATVFP
MDKMIAVFYTVGTSFLNPVIYTLKNTEVKSAMRKLWSKKLITDDKR (SEQ ID NO: 153)

ATGCAACTGAATAATAATGTGACTGAGTTCATTCTGCTTGGATTGACACAGGATCCTTTTT
GGAAGAAAATAGTGTTTGTTATTTTTTTGCGTCTCTACTTGGGAACACTGTTGGGTAATTT
20 GCTAATCATTATTAGTGTCAAGGCCAGCCAGGCACTTAAGAACCCAATGTTCTTCTTCCTT
TTCTACTTATCTTTATCTGATACTTGCCTCTCTACTTCCATAGCCCCTAGAATGATTGTGGA
TGCCCTTTTGAAGAAGACAACTATCTCCTTCAGCGAGTGCATGATCCAAGTCTTTTCATCC
CATGTCTTTGGCTGCCTGGAGATCTTCATCCTCATCCTCACGGCTGTTGACCGCTATGTGGA
CATCTGTAAGCCCCTGCACTACATGACCATCATAAGCCAGTGGGTCTGTGGTGTTTTGATG
25 GCTGTGGCCTGGGTGGGATCCTGTGTGCATTCTTTAGTTCAGATTTTTCTTGCCCTGAGTTT
GCCATTCTGTGGCCCCAATGTGATCAATCACTGTTTCTGTGACTTGCAGCCCTTGTTGAAA
CAAGCCTGTTCAGAAACCTATGTGGTTAACCTACTCCTGGTTTCCAATAGTGGGGCCATTT
GTGCAGTGAGTTATGTCATGCTAATATTCTCCTATGTCATCTTCTTGCATTCTCTGAGAAAC
CACAGTGCTGAAGTGATAAAGAAAGCACTTTCCACATGTGTCTCCCACATCATTGTGGTCA
30 TCTTGTTCTTTGGACCTTGCATATTTATGTACACATGCCCTGCAACCGTATTCCCCATGGAT
AAGATGATAGCTGTATTTTATACAGTTGGAACATCTTTTCTCAACCCTGTGATTTACACGCT
GAAGAATACAGAAGTGAAAAGTGCCATGAGGAAGCTTTGGAGCAAGAAATTGATCACAGA
TGACAAAGATAA (SEQ ID NO: 154)

35 **AOLFR83 sequences:**

MGNWTAAVTEFVLLGFSLSREVELLLLVLLLPTFLLTLLGNLLIISTVLSCSRLHTPMYFFLCNL
SILDILFTSVISPKVLANLGSRDKTISFAGCITQCYFYFFLGTVEFLLLTVMSYDRYATICCPLRYT
TIMRPSVCIGTVVFSWVGGFLSVLFPTILISQLPFCGSNIINHFFCDSGPLLALACADTTAIELMDF
MLSSMVILCCIVLVAYSYTYIILTIVRIPSASGRKKAFNTCASHLTIVIIPSGITVFIYVTPSQKEYL
40 EINKIPLVLSSVVTPFLNPFIYTLRNDTVQGVLRDVWVRVRGVFEKRMRAVLRSRLSSNKDHQ
GRACSSPPCVYSVKLQC (SEQ ID NO: 155)

ATGGGTAACTGGACTGCAGCGGTGACTGAGTTTGTTCTGCTGGGGTTTTCCCTGAGCAGGG
AGGTGGAGCTGCTGCTCCTGGTGCTCCTGCTGCCCACGTTCCTGCTGACTCTTCTGGGGGAA
45 CCTGCTCATCATCTCCACTGTGCTGTCCTGCTCCCGCCTCCACACCCCCATGTACTTCTTCT
TGTGCAACCTCTCTATCCTGGACATCCTCTTCACCTCAGTCATCTCTCCAAAAGTGTTGGCC
AACTTAGGATCTAGGGATAAAACCATCTCCTTTGCCGGATGTATCACCCAGTGCTATTTCT
ACTTTTTCTTGGGCACAGTTGAGTTCCTCCTGCTGACGGTCATGTCCTATGACCGTTATGCC
ACCATCTGCTGCCCCCTGCGGTACACCACCATCATGAGACCTTCTGTCTGCATTGGGACCG
50 TTGTATTCTCTTGGGTGGGAGGCTTCCTGTCTGTGCTCTTTCCAACCATCCTCATCTCCCAG
CTGCCCTTCTGTGGCTCCAATATCATTAACCACTTCTTCTGTGACAGTGGACCCTTGCTGGC
CCTGGCCTGTGCAGACACCACTGCCATCGAGCTGATGGATTTTATGCTTTCTTCCATGGTC
ATCCTCTGCTGCATAGTCCTCGTGGCCTATTCCTATACGTACATCATCTTGACCATAGTGCG
CATTCCTTCTGCAAGTGGAAGGAAGAAGGCCTTTAATACCTGTGCTTCCCACCTGACCATA
55 GTCATCATTCCTAGTGGCATCACTGTGTTTATCTATGTGACTCCCTCCCAGAAAGAATATCT
GGAGATCAACAAGATCCCTTTGGTTCTGAGCAGTGTGGTGACTCCATTCCTCAACCCCTTT

ATATATACTCTGAGGAATGACACAGTGCAGGGAGTCCTCAGGGATGTGTGGGTCAGGGTT
CGAGGAGTTTTTGAAAAGAGGATGAGGGCAGTGCTGAGAAGCAGATTATCCTCCAACAAA
GACCACCAAGGAAGGGCTTGCTCTTCTCCACCATGTGTCTATTCTGTAAAGCTCCAGTGTT
AG (SEQ ID NO: 156)

5

AOLFR85 sequences:

MGAKNNVTEFVLFGLFESREMQHTCFVVFFLFHVLTVLGNLLVIITINARKTLKSPMYFFLSQL
SFADICYPSTTIPKMIADTFVEHKIISFNGCMTQLFSAHFFGGTEIFLLTAMAYDRYVAICRPLHY
TAIMDCRKCGLLAGASWLAGFLHSILQTLLTVQLPFCGPNEIDNFFCDVHPLLKLACADTYMV
GLIVVANSGMISLASFFILIISYVIILLNLRSQSSEDRRKAVSTCGSHVITVLLVLMPPMFMYIRPS
TTLAADKLIILFNIVMPPLLNPLIYTLRNNDVKNAMRKLFRVKRSLGEK (SEQ ID NO: 157)

10

ATGGGTGCCAAGAACAATGTGACTGAGTTTGTTTTATTTGGCCTTTTTGAGAGCAGAGAGA
TGCAGCATACATGCTTTGTGGTATTCTTCCTCTTTCATGTGCTCACTGTCCTGGGGAACCTT
CTGGTCATCATCACCATCAATGCTAGAAAGACCCTGAAGTCTCCCATGTATTTCTTCCTGA
GCCAGTTGTCTTTTGCTGACATATGTTATCCATCCACTACCATACCCAAGATGATTGCTGAC
ACTTTTGTGGAGCATAAGATCATCTCCTTCAATGGCTGCATGACCCAGCTCTTTTCTGCCCA
CTTCTTTGGTGGCACTGAGATCTTCCTCCTTACAGCCATGGCCTATGACCGCTATGTGGCC
ATCTGTAGGCCCCTGCACTACACAGCCATCATGGATTGCCGGAAGTGTGGCCTGCTAGCGG
GGGCCTCCTGGTTAGCTGGCTTCCTGCATTCCATCCTGCAGACCCTCCTCACGGTTCAGCTG
CCTTTTTGTGGGCCCAATGAGATAGACAACTTCTTCTGTGATGTTCATCCCCTGCTCAAGTT
GGCCTGTGCAGACACCTACATGGTAGGTCTCATCGTGGTGGCCAACAGCGGTATGATTTCT
TTAGCATCCTTTTTTATCCTTATCATTTCCTATGTTATCATCTTACTGAACCTAAGAAGCCA
GTCATCTGAGGACCGGCGTAAGGCTGTCTCCACATGTGGCTCACACGTAATCACTGTCCTT
TTGGTTCTCATGCCCCCCATGTTCATGTACATTCGTCCCTCCACCACCCTGGCTGCTGACAA
ACTTATCATCCTCTTTAACATTGTGATGCCACCTTTGCTGAACCCTTTGATCTATACACTAA
GGAACAACGATGTGAAAAATGCCATGAGGAAGCTGTTTAGGGTCAAGAGGAGCTTAGGGG
AGAAGTGA (SEQ ID NO: 158)

15

20

25

AOLFR86 sequences:

MQLVLLLMFLLVFIGNTAPAFSVTLESMDIPQNITEFFMLGLSQNSEVQRVLFVVFLLIYVVTVC
GNMLIVVTITSSPTLASPVYFFLANLSFIDTFYSSSMAPKLIADSLYEGRTISYECCMAQLFGAHF
LGGVEIILLTVMAYDRYVAICKPLHNTTIMTRHLCAMLVGVAWLGGFLHSLVQLLLVLWLPFC
GPNVINHFACDLYPLLEVACTNTYVIGLLVVANSGLICLLNFLMLAASYIVILYSLRSHSADGRC
KALSTCGAHFIVVALFFVPCIFTYVHPFSTLPIDKNMALFYGILTPMLNPLIYTLRNEEVKNAMR
KLFTW (SEQ ID NO: 159)

30

35

ATGCAATTAGTTCTATTACTTATGTTTCTCCTTGTCTTTATAGGCAATACTGCACCTGCATT
CTCAGTGACCTTGGAATCTATGGACATACCACAAAATATCACAGAATTTTTCATGCTGGGG
CTCTCACAGAACTCAGAGGTACAGAGAGTTCTCTTTGTGGTCTTTTTGCTGATCTATGTGG
TCACGGTTTGTGGCAACATGCTCATTGTGGTCACTATCACCTCCAGCCCCACGCTGGCTTC
CCCTGTGTATTTTTTCCTGGCCAACCTATCCTTTATTGACACCTTTTATTCTTCTTCTATGGC
TCCTAAACTCATTGCTGACTCATTGTATGAGGGGAGAACCATCTCTTATGAGTGCTGCATG
GCTCAGCTCTTTGGAGCTCATTTTTTGGGAGGTGTTGAGATCATTCTGCTCACAGTGATGG
CTTATGACCGCTATGTGGCCATCTGTAAGCCCCTGCACAATACTACCATCATGACCAGGCA
TCTCTGTGCCATGCTTGTAGGGGTGGCTTGGCTTGGGGGCTTCCTGCATTCATTGGTTCAG
CTCCTCCTGGTCCTTTGGTTGCCCTTCTGTGGGCCCAATGTGATCAATCACTTTGCCTGTGA
CTTGTACCCTTTGCTGGAAGTTGCCTGCACCAATACGTATGTCATTGGTCTGCTGGTGGTT
GCCAACAGTGGTTTAATCTGCCTGTTGAACTTCCTCATGCTGGCTGCCTCCTACATTGTCAT
CCTGTACTCCTTGAGGTCCCACAGTGCAGATGGGAGATGCAAAGCCCTCTCCACCTGTGGA
GCCCACTTCATTGTTGTTGCCTTGTTCTTTGTGCCCTGTATATTTACTTATGTGCATCCATTT
TCTACTTTACCTATAGACAAAAATATGGCATTATTTTATGGTATTCTGACACCTATGTTGAA
TCCACTCATTTATACCCTGAGAAATGAAGAGGTAAAAAATGCCATGAGAAAGCTCTTTACA
TGGTAA (SEQ ID NO: 160)

40

45

50

55

AOLFR87 sequences:

MNNIAQLSLGFIDLGIPSVLQKIILTKIILLFKMYVSNCNPCAIHRKINYPNTKLDFEQVNNITEFI
LLGLTQNAEAQKLLFAVFTLIYFLTMVDNLIIVVTITTSPALDSPVYFFLSFFSFIDGCSSSTMAP
KMIFDLLTEKKTISFSGCMTQLFVEHFFGGVEIILLVVMAYDCYVAICKPLYYLITMNRQVCGL
LVAMAWVGGFLHALIQMLLIVWLPFCGPNVIDHFICDLFPLLKLSCTDTHVFGLFVAANSGLM
CMLIFSILITSYVLILCSQRKALSTCAFHITVVVLFFVPCILVYLRPMITFPIDKAVSVFYTVVTPM
LNPLIYTLRNTEVKNAMKQLWSQIIWGNNLCD (SEQ ID NO: 161)

ATGAATAACATAGCTCAACTTAGTCTTGGGTTTATAGATTTAGGGATTCCATCAGTGTTAC
AGAAAATAATCCTGACCAAAATTATTTTATTGTTCAAAATGTATGTGTCAAATTGCAATCC
TTGTGCTATTCACAGAAAAATCAATTATCCAAATACCAAACTGGATTTCGAGCAAGTGAAC
AACATAACGGAATTCATCTTGCTTGGCCTGACACAGAACGCAGAGGCACAGAAACTCTTGT
TTGCTGTGTTTACACTCATCTACTTTCTCACCATGGTAGACAACCTAATCATTGTGGTGACA
ATCACCACCAGCCCAGCCCTGGACTCCCCCGTGTATTTTTTTCTGTCTTTCTTTTCCTTCAT
AGATGGCTGCTCCTCTTCTACCATGGCCCCCAAAATGATATTTGACTTACTCACTGAAAAG
AAAACTATTTCCTTCAGTGGGTGCATGACCCAGCTCTTTGTAGAACATTTCTTTGGGGGAG
TTGAGATCATTCTGCTCGTGGTGATGGCCTATGACTGCTATGTGGCCATCTGCAAGCCCCT
GTACTACCTGATCACAATGAACAGGCAGGTATGTGGCCTCCTGGTGGCCATGGCATGGGTC
GGGGGATTTCTTCACGCTCTGATTCAAATGCTTTTAATAGTCTGGCTGCCCTTCTGTGGCCC
CAATGTCATTGACCATTTCATCTGTGACCTTTTCCCTCTGCTAAAACTCTCCTGCACTGACA
CTCACGTCTTTGGACTCTTTGTTGCCGCCAACAGTGGGCTGATGTGTATGCTCATTTTTTCT
ATTCTTATTACCTCTTACGTCCTAATCCTCTGCTCACAGCGGAAGGCTCTCTCTACCTGCGC
CTTCCATATCACTGTAGTCGTCCTATTCTTTGTTCCCTGTATATTGGTGTACCTTCGACCCA
TGATCACCTTCCCTATTGATAAAGCTGTGTCTGTGTTTTATACTGTGGTAACACCCATGTTA
AACCCTTTAATCTACACCCTCAGAAACACAGAGGTGAAAAATGCCATGAAGCAGCTCTGG
AGCCAAATAATCTGGGGTAACAATTTGTGTGATTAG (SEQ ID NO: 162)

AOLFR88 sequences:

MWQKNQTSLADFILEGLFDDSLTHLFLFSLTMVVFLIAVSGNTLTILLICIDPQLHTPMYFLLSQ
LSLMDLMHVSTIILKMATNYLSGKKSISFVGCATQHFLYLCLGGAECFLLAVMSYDRYVAICH
PLRYAVLMNKKVGLMMAVMSWLGASVNSLIHMAILMHFPFCGPRKVYHFYCEFPAVVKLVC
GDITVYETTVYISSILLLLPIFLISTSYVFILQSVIQMRSSGSKRNAFATCGSHLTVVSLWFGACIFS
YMRPRSQCTLLQNKVGSVFYSIITPTLNSLIYTLRNKDVAKALRRVLRRDVITQCIQRLQLWLP
RV (SEQ ID NO: 163)

ATGTGGCAGAAGAATCAGACCTCTCTGGCAGACTTCATCCTTGAGGGGCTCTTCGATGACT
CCCTTACCCACCTTTTCCTTTTCTCCTTGACCATGGTGGTCTTCCTTATTGCGGTGAGTGGC
AACACCCTCACCATTCTCCTCATCTGCATTGATCCCCAGCTTCATACACCAATGTATTTCCT
GCTCAGCCAGCTCTCCCTCATGGATCTGATGCATGTCTCCACAATCATCCTGAAGATGGCT
ACCAACTACCTATCTGGCAAGAAATCTATCTCCTTTGTGGGCTGTGCAACCCAGCACTTCC
TCTATTTGTGTCTAGGTGGTGCTGAATGTTTTCTCTTAGCTGTCATGTCCTATGACCGCTAT
GTTGCCATCTGTCATCCACTGCGCTATGCTGTGCTCATGAACAAGAAGGTGGGACTGATGA
TGGCTGTCATGTCATGGTTGGGGGCATCCGTGAACTCCCTAATTCACATGGCGATCTTGAT
GCACTTCCCTTTCTGTGGGCCTCGGAAAGTCTACCACTTCTACTGTGAGTTCCCAGCTGTTG
TGAAGTTGGTATGTGGCGACATCACTGTGTATGAGACCACAGTGTACATCAGCAGCATTCT
CCTCCTCCTCCCCATCTTCCTGATTTCTACATCCTATGTCTTCATCCTTCAAAGTGTCATTCA
GATGCGCTCATCTGGGAGCAAGAGAAATGCCTTTGCCACTTGTGGCTCCCACCTCACGGTG
GTTTCTCTTTGGTTTGGTGCCTGCATCTTCTCCTACATGAGACCCAGGTCCCAGTGCACTCT
ATTGCAGAACAAAGTTGGTTCTGTGTTCTACAGCATCATTACGCCCACATTGAATTCTCTG
ATTTATACTCTCCGGAATAAAGATGTAGCTAAGGCTCTGAGAAGAGTGCTGAGGAGAGAT
GTTATCACCCAGTGCATTCAACGACTGCAATTGTGGTTGCCCCGAGTGTAG (SEQ ID NO:
164)

AOLFR89 sequences:

MLDPSISSHTLYLHSLFPQGLRKGTMWQKNQTSLADFILEGLFDDSLTHLFLFSLTMVVFLIAVS
GNTLTILLICIDPQLHTPMYFLLSQLSLMDLMHVSTTILKMATNYLSGKKSISFVGCATQHFLYL

CLGGAECFLLAVMSYDRYVAICHPLRYAVLMNKKVGLMMAVMSWLGASVNSLIHMAILMHF
PFCGPRKVYHFYCEFPAVVKLVCGDITVYETTVYISSILLLLPIFLISTSYVFILQSVIQMRSSGSK
RNAFATCGSHLTVVSLWFGACIFSYMRPRSQCTLLQNKVGSVFYSIITPTLNSLIYTLRNKDVA
KALRRVLRRDVITQCIQRLQLWLPRV (SEQ ID NO: 165)

5

ATGCTGGACCCCAGTATTTCCAGTCACACTCTTTATCTCCACTCTCTGTTTCCTCAGGGATT
GAGAAAGGGGACAATGTGGCAGAAGAATCAGACCTCTCTGGCAGACTTCATCCTTGAGGG
GCTCTTCGATGACTCCCTTACCCACCTTTTCCTTTTCTCCTTGACCATGGTGGTCTTCCTTAT
TGCGGTGAGTGGCAACACCCTCACCATTCTCCTCATCTGCATTGATCCCCAGCTTCATACA
CCAATGTATTTCCTGCTCAGCCAGCTCTCCCTCATGGATCTGATGCATGTCTCCACAACCAT
CCTGAAGATGGCTACCAACTACCTATCTGGCAAGAAATCTATCTCCTTTGTGGGCTGTGCA
ACCCAGCACTTCCTCTATTTGTGTCTAGGTGGTGCTGAATGTTTTCTCTTAGCTGTCATGTC
CTATGACCGCTATGTTGCCATCTGTCATCCACTGCGCTATGCTGTGCTCATGAACAAGAAG
GTGGGACTGATGATGGCTGTCATGTCATGGTTGGGGGCATCCGTGAACTCCCTAATTCACA
TGGCGATCTTGATGCACTTCCCTTTCTGTGGGCCTCGGAAAGTCTACCACTTCTACTGTGA
GTTCCCAGCTGTTGTGAAGTTGGTATGTGGCGACATCACTGTGTATGAGACCACAGTGTAC
ATCAGCAGCATTCTCCTCCTCCTCCCCATCTTCCTGATTTCTACATCCTATGTCTTCATCCTT
CAAAGTGTCATTCAGATGCGCTCATCTGGGAGCAAGAGAAATGCCTTTGCCACTTGTGGCT
CCCACCTCACGGTGGTTTCTCTTTGGTTTGGTGCCTGCATCTTCTCCTACATGAGACCCAGG
TCCCAGTGCACTCTATTGCAGAACAAAGTTGGTTCTGTGTTCTACAGCATCATTACGCCCA
CATTGAATTCTCTGATTTATACTCTCCGGAATAAAGATGTAGCTAAGGCTCTGAGAAGAGT
GCTGAGGAGAGATGTTATCACCCAGTGCATTCAACGACTGCAATTGTGGTTGCCCCGAGTG
TAG (SEQ ID NO: 166)

25   **AOLFR90 sequences:**

MFSMTTEALNNFALGCTNLLMTMIPQIDLKQIFLCPNCRLYMIPVGAFIFSLGNMQNQSFVTEF
VLLGLSQNPNVQEIVFVVFLFVYIATVGGNMLIVVTILSSPALLVSPMYFFLGFLSFLDACFSSVI
TPKMIVDSLYVTKTISFEGCMMQLFAEHFFAGVEVIVLTAMAYDRYVAICKPLHYSSIMNRRL
CGILMGVAWTGGLLHSMIQILFTFQLPFCGPNVINHFMCDLYPLLELACTDTHIFGLMVVINSG
30   FICIINFSLLLVSYAVILLSLRTHSSEGRWKALSTCGSHIAVVILFFVPCIFVYTRPPSAFSLDKMA
AIFYIILNPLLNPLIYTFRNKEVKQAMRRIWNRLMVVSDEKENIKL (SEQ ID NO: 167)

ATGTTCTCAATGACAACAGAAGCACTCAATAATTTTGCACTTGGATGTACCAACTTGTTAA
TGACTATGATACCACAAATTGATCTGAAGCAAATTTTCCTTTGTCCTAATTGCAGACTATA
35   CATGATCCCTGTTGGAGCTTTCATCTTTTCCTTGGGAAACATGCAAAACCAAAGCTTTGTA
ACTGAGTTTGTCCTCCTGGGACTTTCACAGAATCCAAATGTTCAGGAAATAGTATTTGTTG
TATTTTTGTTTGTCTACATTGCAACTGTTGGGGGCAACATGCTAATTGTAGTAACCATTCTC
AGCAGCCCTGCTCTTCTGGTGTCTCCTATGTACTTCTTCTTGGGCTTCCTGTCCTTCCTGGA
TGCGTGCTTCTCATCTGTCATCACCCCAAAGATGATTGTAGACTCCCTCTATGTGACAAAA
40   ACCATCTCTTTTGAAGGCTGCATGATGCAGCTCTTTGCTGAACACTTCTTTGCTGGGGTGG
AGGTGATTGTCCTCACAGCCATGGCCTATGATCGTTATGTGGCCATTTGCAAGCCCTTGCA
TTACTCTTCTATCATGAACAGGAGGCTCTGTGGCATTCTGATGGGGGTAGCCTGGACAGGG
GGCCTCTTGCATTCCATGATACAAATTCTTTTTACTTTCCAGCTTCCCTTTTGTGGCCCCAA
TGTCATCAATCACTTTATGTGTGACTTGTACCCGTTACTGGAGCTTGCCTGCACTGATACTC
45   ACATCTTTGGCCTCATGGTGGTCATCAACAGTGGGTTTATCTGCATCATAAACTTCTCCTTG
TTGCTTGTCTCCTATGCTGTCATCTTGCTCTCTCTGAGAACACACAGTTCTGAAGGGCGCTG
GAAAGCTCTCTCCACCTGTGGATCTCACATTGCTGTTGTGATTTTGTTCTTTGTCCCATGCA
TATTTGTATATACGACCTCCATCTGCTTTTTCCCTTGACAAAATGGCGGCAATATTTTAT
ATCATCTTAAATCCCTTGCTCAATCCTTTGATTTACACTTTCAGGAATAAGGAAGTAAAAC
50   AGGCCATGAGGAGAATATGGAACAGACTGATGGTGGTTTCTGATGAGAAGAAAATATTA
AACTTTAA (SEQ ID NO: 168)

AOLFR91 sequences:

MGNWSTVTEITLIAFPALLEIRISLFVVLVVTYTLTATGNITIISLIWIDHRLQTPMYFFLSNLSFL
55   DILYTTVITPKLLACLLGEEKTISFAGCMIQTYFYFFLGTVEFILLAVMSFDRYMAICDPLHYTVI
MNSRACLLLVLGCWVGAFLSVLFPTIVVTRLPYCRKEINHFFCDIAPLLQVACINTHLIEKINFLL

SALVILSSLAFTTGSYVYIISTILRIPSTQGRQKAFSTCASHITVVSIAHGSNIFVYVRPNQNSSLD
YDKVAAVLITVVTPLLNPFIYSLRNEKVQEVLRETVNRIMTLIQRKT (SEQ ID NO: 169)

ATGGGAAACTGGAGCACTGTGACTGAAATCACCCTAATTGCCTTCCCAGCTCTCCTGGAGA
5   TTCGAATATCTCTCTTCGTGGTTCTTGTGGTAACTTACACATTAACAGCAACAGGAAACAT
CACCATCATCTCCCTGATATGGATTGATCATCGCCTGCAAACTCCAATGTACTTCTTCCTCA
GTAATTTGTCCTTTCTGGATATCTTATACACCACTGTCATTACCCCAAAGTTGTTGGCCTGC
CTCCTAGGAGAAGAGAAAACCATATCTTTTGCTGGTTGCATGATCCAAACATATTTCTACT
TCTTTCTGGGGACGGTGGAGTTTATCCTCTTGGCGGTGATGTCCTTTGACCGCTACATGGC
10   TATCTGCGACCCACTGCACTACACGGTCATCATGAACAGCAGGGCCTGCCTTCTGCTGGTT
CTGGGATGCTGGGTGGGAGCCTTCCTGTCTGTGTTGTTTCCAACCATTGTAGTGACAAGGC
TACCTTACTGTAGGAAAGAAATTAATCATTTCTTCTGTGACATTGCCCCTCTTCTTCAGGTG
GCCTGTATAAATACTCACCTCATTGAGAAGATAAACTTTCTCCTCTCTGCCCTTGTCATCCT
GAGCTCCCTGGCATTCACTACTGGGTCCTACGTGTACATAATTTCTACCATCCTGCGTATCC
15   CCTCCACCCAGGGCCGTCAGAAAGCTTTTTCTACCTGTGCTTCTCACATCACTGTTGTCTCC
ATTGCCCACGGGAGCAACATCTTTGTGTATGTGAGACCCAATCAGAACTCCTCACTGGATT
ATGACAAGGTGGCCGCTGTCCTCATCACAGTGGTGACCCCTCTCCTGAACCCTTTTATCTA
CAGCTTGAGGAATGAGAAGGTACAGGAAGTGTTGAGAGAGACAGTGAACAGAATCATGAC
CTTGATACAAAGGAAAACTTGA (SEQ ID NO: 170)
20

AOLFR92 sequences:

MRNGTVITEFILLGFPVIQGLQTPLFIAIFLTYILTLAGNGLIIATVWAEPRLQIPMYFFLCNLSFLE
IWYTTTVIPKLLGTFVVARTVICMSCCLLQAFFHFFVGTTEFLILTIMSFDRYLTICNPLHHPTIM
TSKLCLQLALSSWVVGFTIVFCQTMLLIQLPFCGNNVISHFYCDVGPSLKAACIDTSILELLGVIA
25   TILVIPGSLLFNMISYIYILSAILRIPSATGHQKTFSTCASHLTVVSLLYGAVLFMYLRPTAHSSFK
INKVVSVLNTILTPLLNPFIYTIRNKEVKGALRKAMTCPKTGHAK (SEQ ID NO: 171)

ATGAGAAATGGCACAGTAATCACAGAATTCATCCTGCTAGGCTTTCCTGTTATCCAAGGCC
TACAAACACCTCTCTTTATTGCAATCTTTCTCACCTACATATTAACCCTTGCAGGCAATGGG
30   CTTATTATTGCCACTGTGTGGGCTGAGCCCAGGCTACAAATTCCAATGTACTTCTTCCTTTG
TAACTTGTCTTTCTTAGAAATCTGGTACACCACCACAGTCATCCCCAAACTGCTAGGAACC
TTTGTAGTGGCAAGAACAGTAATCTGCATGTCCTGCTGCCTGCTGCAGGCCTTCTTCCACT
TCTTCGTGGGCACCACCGAGTTCTTGATCCTCACTATCATGTCTTTTGACCGCTACCTCACC
ATCTGCAATCCCCTTCACCACCCCACCATCATGACCAGCAAACTCTGCCTGCAGCTGGCCC
35   TGAGCTCCTGGGTGGTGGGCTTCACCATTGTCTTTTGTCAGACGATGCTGCTCATCCAGTT
GCCATTCTGTGGCAATAATGTTATCAGTCATTTCTACTGTGATGTTGGGCCCAGTTTGAAA
GCCGCCTGCATAGACACCAGCATTTTGGAACTCCTGGGCGTCATAGCAACCATCCTTGTGA
TCCCAGGGTCACTTCTCTTTAATATGATTTCTTATATCTACATTCTGTCCGCAATCCTACGA
ATTCCTTCAGCCACTGGCCACCAAAAGACTTTCTCTACCTGTGCCTCGCACCTGACAGTTGT
40   CTCCCTGCTCTACGGGGCTGTTCTGTTCATGTACCTAAGACCCACAGCACACTCCTCCTTTA
AGATTAATAAGGTGGTGTCTGTGCTAAATACTATCCTCACCCCCCTTCTGAATCCCTTTATT
TATACTATTAGAAACAAGGAGGTGAAGGGAGCCTTAAGAAAGGCAATGACTTGCCCAAAG
ACTGGTCATGCAAAGTAA (SEQ ID NO: 172)

45   **AOLFR93 sequences:**

MLMNYSSATEFYLLGFPGSEELHHILFAIFFFFYLVTLMGNTVIIMIVCVDKRLQSPMYFFLGHL
SALEILVTTIVPVMLWGLLLPGMQTIYLSACVVQLFLYLAVGTTEFALLGAMAVDRYVAVCN
PLRYNIIMNRHTCNFVVLVSWVFGFLFQIWPVYVMFQLTYCKSNVVNNFFCDRGQLLKLSCN
NTLFTEFILFLMAVFVLFGSLIPTIVSNAYIISTILKIPSSSGRRKSFSTCASHFTCVVIGYGSCLFLY
50   VKPKQTQAADYNWVVSLMVSVVTPFLNPFIFTLRNDKVIEALRDGVKRCCQLFRN (SEQ ID
NO: 173)

ATGTTGATGAATTACTCTAGTGCCACTGAATTTTATCTCCTTGGCTTCCCTGGCTCTGAAGA
ACTACATCATATCCTTTTTGCTATATTCTTCTTTTTCTACTTGGTGACATTAATGGGAAACA
55   CAGTCATCATCATGATTGTCTGTGTGGATAAACGTCTGCAGTCCCCCATGTATTTCTTCCTC
GGCCACCTCTCTGCCCTGGAGATCCTGGTCACAACCATAATCGTCCCCGTGATGCTTTGGG

GATTGCTGCTCCCTGGGATGCAGACAATATATTTGTCTGCCTGTGTTGTCCAGCTCTTCTTG
TACCTTGCTGTGGGGACAACAGAGTTCGCATTACTTGGAGCAATGGCTGTGGACCGTTATG
TGGCTGTCTGTAACCCTCTGAGGTACAACATCATTATGAACAGACACACCTGCAACTTTGT
GGTTCTTGTGTCATGGGTGTTTGGGTTTCTTTTTCAAATCTGGCCGGTCTATGTCATGTTTC
5   AGCTTACTTACTGCAAATCAAATGTGGTGAACAATTTTTTTTGTGACCGAGGGCAATTGCT
CAAACTATCCTGCAATAATACTCTTTTCACGGAGTTTATCCTCTTCTTAATGGCTGTTTTTG
TTCTCTTTGGTTCTTTGATCCCTACAATTGTCTCCAACGCCTACATCATCTCCACCATTCTC
AAGATCCCGTCATCCTCTGGCCGGAGGAAATCCTTCTCCACTTGTGCCTCCCACTTCACCTG
TGTTGTGATTGGCTACGGCAGCTGCTTGTTTCTCTACGTGAAACCCAAGCAAACGCAGGCA
10   GCTGATTACAATTGGGTAGTTTCCCTGATGGTTTCAGTAGTAACTCCTTTCCTCAATCCTTT
CATCTTCACCCTCCGGAATGATAAAGTCATAGAGGCCCTTCGGGATGGGGTGAAACGCTGC
TGTCAACTATTCAGGAATTAG (SEQ ID NO: 174)

AOLFR94 sequences:

15   METWVNQSYTDGFFLLGIFSHSTADLVLFSVVMAVFTVALCGNVLLIFLIYMDPHLHTPMYFF
LSQLSLMDLMLVCTNVPKMAANFLSGRKSISFVGCGIQIGLFVCLVGSEGLLLGLMAYDRYVA
ISHPLHYPILMNQRVCLQITGSSWAFGIIDGLIQMVVVMNFPYCGLRKVNHFFCEMLSLLKLAC
VDTSLFEKVIFACCVFMLLFPFSIIVASYAHILGTVLQMHSAQAWKKALATCSSHLTAVTLFYG
AAMFIYLRPRHYRAPSHDKVASIFYTVLTPMLNPLIYSLRNREVMGALRKGLDRCRIGSQH
20   (SEQ ID NO: 175)

ATGGAGACGTGGGTGAACCAGTCCTACACAGATGGCTTCTTCCTCTTAGGCATCTTCTCCC
ACAGTACTGCTGACCTTGTCCTCTTCTCCGTGGTTATGGCGGTCTTCACAGTGGCCCTCTGT
GGGAATGTCCTCCTCATCTTCCTCATCTACATGGACCCTCACCTTCACACCCCCATGTACTT
25   CTTCCTCAGCCAGCTCTCCCTCATGGACCTCATGTTGGTCTGTACCAATGTGCCAAAGATG
GCAGCCAACTTCCTGTCTGGCAGGAAGTCCATCTCCTTTGTGGGCTGTGGCATACAAATTG
GCCTCTTTGTCTGTCTTGTGGGATCTGAGGGGCTCTTGCTGGGACTCATGGCTTATGACCG
CTATGTGGCCATTAGCCACCCACTTCACTATCCCATCCTCATGAATCAGAGGGTCTGTCTCC
AGATTACTGGGAGCTCCTGGGCCTTTGGGATAATCGATGGCTTGATCCAGATGGTGGTAGT
30   AATGAATTTCCCCTACTGTGGCTTGAGGAAGGTGAACCATTTCTTCTGTGAGATGCTATCC
TTGTTGAAGCTGGCCTGTGTAGACACATCCCTGTTTGAGAAGGTGATATTTGCTTGCTGTG
TCTTCATGCTTCTCTTCCCATTCTCCATCATCGTGGCCTCCTATGCTCACATTCTAGGGACT
GTGCTGCAAATGCACTCTGCTCAGGCCTGGAAAAAGGCCCTGGCCACCTGCTCCTCCCACC
TGACAGCTGTCACCCTCTTCTATGGGGCAGCCATGTTCATCTACCTGAGGCCTAGGCACTA
35   CCGGGCCCCCAGCCATGACAAGGTGGCCTCTATCTTCTACACGGTCCTTACTCCCATGCTC
AACCCCCTCATTTACAGCTTGAGGAACAGGGAGGTGATGGGGGCACTGAGGAAGGGGCTG
GACCGCTGCAGGATCGGCAGCCAGCACTGA (SEQ ID NO: 176)

AOLFR95 sequences:

40   MLGSKPRVHLYILPCASQQVSTMGDRGTSNHSEMTDFILAGFRVRPELHILLFLLFLFVYAMILL
GNVGMMTIIMTDPRLNTPMYFFLGNLSFIDLFYSSVIEPKAMINFWSENKSISFAGCVAQLFLFA
LLIVTEGFLLAAMAYDRFIAICNPLLYSVQMSTRLCTQLVAGSYFCGCISSVIQTSMTFTLSFCAS
RAVDHFYCDSRPLQRLSCSDLFIHRMISFSLSCIIILPTIIVIIVSYMYIVSTVLKIHSTEGHKKAFST
CSSHLGVVSVLYGAVFFMYLTPDRFPELSKVASLCYSLVTPMLNPLIYSLRNKDVQEALKKFLE
45   KKNIIL (SEQ ID NO: 177)

ATGCTAGGATCCAAACCAAGAGTTCATTTGTATATTTTGCCCTGTGCCTCTCAACAGGTTTC
TACCATGGGTGACAGGGGAACAAGCAATCACTCAGAAATGACTGACTTCATTCTTGCAGG
CTTCAGGGTACGCCCAGAGCTCCACATTCTCCTCTTCCTGCTATTTTTGTTTGTTTATGCCA
50   TGATCCTTCTAGGGAATGTTGGGATGATGACCATTATTATGACTGATCCTCGGCTGAACAC
ACCAATGTATTTTTTCCTAGGCAATCTCTCCTTCATTGATCTTTTCTATTCATCTGTTATTGA
ACCCAAGGCTATGATCAACTTCTGGTCTGAAAACAAGTCTATCTCCTTTGCAGGCTGTGTG
GCCCAGCTCTTTCTCTTTGCCCTCCTCATTGTGACTGAGGGATTTCTCCTGGCGGCCATGGC
TTATGACCGCTTTATTGCCATCTGCAACCCTCTGCTCTACTCTGTTCAAATGTCCACACGTC
55   TGTGTACTCAGTTGGTGGCTGGTTCCTATTTTGTGGCTGCATTAGCTCAGTTATTCAGACT
AGCATGACATTTACTTTATCTTTTTGCGCTTCTCGGGCTGTTGACCACTTTTACTGTGATTC

TCGCCCACTTCAGAGACTGTCTTGTTCTGATCTCTTTATCCATAGAATGATATCTTTTTCCT
TATCATGTATTATTATCTTGCCTACTATCATAGTCATTATAGTATCTTACATGTATATTGTG
TCCACAGTTCTAAAGATACATTCTACTGAGGGACATAAGAAGGCCTTCTCCACCTGCAGCT
CTCACCTGGGAGTTGTGAGTGTGCTGTATGGTGCTGTCTTTTTTATGTATCTCACTCCTGAC

5   AGATTTCCTGAGCTGAGTAAAGTGGCATCCTTATGTTACTCCCTAGTCACTCCCATGTTGA
ATCCTTTGATTTACTCTCTGAGGAACAAAGATGTCCAAGAGGCTCTAAAAAAATTTCTAGA
GAAGAAAAATATTATTCTTTGA (SEQ ID NO: 178)

AOLFR96 sequences:

10   MICENHTRVTEFILLGFTNNPEMQVSLFIFFLAIYTVTLLGNFLIVTVTSVDLALQTPMYFFLQN
LSLLEVCFTLVMVPKMLVDLVSPRKIISFVGCGTQMYFFFFFGSSECFLLSMMAYDRFVAICNP
LHYSVIMNRSLCLWMAIGSWMSGVPVSMLQTAWMMALPFCGPNAVDHFFCDGPPVLKLVTV
DTTMYEMQALASTLLFIMFPFCLILVSYTRIIITILRMSSATGRQKAFSTCSSHLIVVSLFYGTASL
TYLRPKSNQSPESKKLVSLSYTVITPMLNPIIYGLRNNEVKGAVKRTITQKVLQKLDVF (SEQ

15   ID NO: 179)

ATGATCTGTGAAAATCACACCAGAGTCACTGAATTTATTCTTCTTGGTTTTACAAACAACC
CCGAGATGCAAGTTTCCCTCTTTATTTTTTTCCTGGCCATTTATACAGTCACTTTGTTGGGC
AACTTTCTTATTGTCACAGTTACCAGTGTGGATCTCGCACTTCAAACACCCATGTACTTCTT

20   TCTTCAAAATCTGTCACTTCTTGAAGTATGTTTCACCTTGGTTATGGTGCCAAAAATGCTTG
TAGATCTAGTGTCCCCAAGGAAAATTATCTCTTTTGTGGGCTGTGGTACCCAGATGTACTT
CTTCTTCTTCTTTGGCAGTTCTGAATGTTTCCTTCTCTCCATGATGGCTTATGATCGCTTTGT
GGCCATCTGTAACCCTCTCCATTATTCAGTCATAATGAACAGGTCCCTATGCTTGTGGATG
GCCATAGGCTCTTGGATGTCCGGTGTTCCTGTGTCTATGCTACAGACAGCTTGGATGATGG

25   CCCTTCCTTTCTGTGGACCAAATGCCGTGGACCACTTTTTCTGTGATGGTCCCCAGTGTTA
AAACTAGTCACAGTGGATACAACCATGTATGAAATGCAAGCACTTGCCTCCACACTCCTGT
TTATCATGTTTCCCTTTTGTCTCATTTTGGTTTCCTACACCCGCATTATCATAACAATTCTG
AGGATGTCCTCTGCCACTGGCCGCCAGAAGGCATTTTCTACTTGTTCCTCACACCTCATTGT
GGTGTCCCTCTTCTACGGAACAGCCAGTCTGACCTACCTGCGGCCCAAATCAAACCAGTCC

30   CCTGAGAGCAAGAAGCTAGTGTCATTGTCCTACACTGTCATCACACCTATGCTAAACCCCA
TCATCTACGGCCTGAGGAACAATGAAGTGAAAGGGGCTGTCAAGAGGACAATCACTCAAA
AAGTCTTACAGAAGTTAGATGTGTTTTGA (SEQ ID NO: 180)

AOLFR97 sequences:

35   MTEFHLQSQMPSIRLIFRRLSLGRIKPSQSPRCSTSFMVVPSFSIAEHWRRMKGANLSQGMEFEL
LGLTTDPQLQRLLFVVFLGMYTATLLGNLVMFLLIHVSATLHTPMYSLLKSLSFLDFCYSSTVV
PQTLVNFLAKRKVISYFGCMTQMFFYAGFATSECYLIAAMAYDRYAAICNPLLYSTIMSPEVC
ASLIVGSYSAGFLNSLIHTGCIFSLKFCGAHVVTHFFCDGPPILSLSCVDTSLCEILLFIFAGFNLLS
CTLTILISYFLILNTILKMSSAQGRFKAFSTCASHLTAICLFFGTTLFMYLRPRSSYSLTQDRTVA

40   VIYTVVIPVLNPLMYSLRNKDVKKALIKVWGRKTME (SEQ ID NO: 181)

ATGACAGAGTTTCATCTGCAAAGCCAAATGCCCTCAATAAGACTCATCTTCAGAAGGCTGT
CCTTAGGCAGAATTAAACCCAGTCAGAGCCCCAGGTGTTCAACCTCATTTATGGTGGTGCC
TTCTTTCTCCATCGCAGAGCACTGGAGAAGGATGAAAGGGGCAAACCTGAGCCAAGGGAT

45   GGAGTTTGAGCTCTTGGGCCTCACCACTGACCCCCAGCTCCAGAGGCTGCTCTTCGTGGTG
TTCCTGGGCATGTACACAGCCACTCTGCTGGGGAACCTGGTCATGTTCCTCCTGATCCATG
TGAGTGCCACCCTGCACACACCCATGTACTCCCTCCTGAAGAGCCTCTCCTTCTTGGATTTC
TGCTACTCCTCCACGGTTGTGCCCCAGACCCTGGTGAACTTCTTGGCCAAGAGGAAAGTGA
TCTCTTATTTTGGCTGCATGACTCAGATGTTCTTCTATGCGGGTTTTGCCACCAGTGAGTGC

50   TATCTCATCGCTGCCATGGCCTATGACCGCTATGCCGCTATTTGTAACCCCCTGCTCTACTC
AACCATCATGTCTCCTGAGGTCTGTGCCTCGCTGATTGTGGGCTCCTACAGTGCAGGATTC
CTCAATTCTCTTATCCACACTGGCTGTATCTTTAGTCTGAAATTCTGCGGTGCTCATGTCGT
CACTCACTTCTTCTGTGATGGGCCACCCATCCTGTCCTTGTCTTGTGTAGACACCTCACTGT
GTGAGATCCTGCTCTTCATTTTTGCTGGTTTCAACCTTTTGAGCTGCACCCTCACCATCTTG

55   ATCTCCTACTTCTTAATTCTCAACACCATCCTGAAAATGAGCTCGGCCCAGGGCAGGTTTA
AGGCATTTTCCACCTGTGCATCCCACCTCACTGCCATCTGCCTCTTCTTTGGCACAACACTT

TTTATGTACCTGCGCCCCAGGTCCAGCTACTCCTTGACCCAGGACCGCACAGTTGCTGTCA
TCTACACAGTGGTGATCCCAGTGCTGAACCCCCTCATGTACTCTTTGAGAAACAAGGATGT
GAAGAAAGCTTTAATAAAGGTTTGGGGTAGGAAAACAATGGAATGA (SEQ ID NO: 182)

5   **AOLFR98 sequences:**
MRGFNKTTVVTQFILVGFSSLGELQLLLFVIFLLLYLTILVANVTIMAVIRFSWTLHTPMYGFLFI
LSFSESCYTFVIIPQLLVHLLSDTKTISFMACATQLFFFLGFACTNCLLIAVMGYDRYVAICHPLR
YTLIINKRLGLELISLSGATGFFIALVATNLICDMRFCGPNRVNHYFCDMAPVIKLACTDTHVKE
LALFSLSILVIMVPFLLILISYGFIVNTILKIPSAEGKKAFVTCASHLTVVFVHYGCASIIYLRPKSK
10   SASDKDQLVAVTYTVVTPLLNPLVYSLRNKEVKTALKRVLGMPVATKMS (SEQ ID NO: 183)

ATGCGAGGTTTCAACAAAACCACTGTGGTTACACAGTTCATCCTGGTGGGGTTTCTCCAGCC
TGGGGGAGCTCCAGCTGCTGCTTTTTGTCATCTTTCTTCTCCTATACTTGACAATCCTGGTG
GCCAATGTGACCATCATGGCCGTTATTCGCTTCAGCTGGACTCTCCACACTCCCATGTATG
15   GCTTTCTATTCATCCTTTCATTTTCTGAGTCCTGCTACACTTTTGTCATCATCCCTCAGCTGC
TGGTCCACCTGCTCTCAGACACCAAGACCATCTCCTTCATGGCCTGTGCCACCCAGCTGTT
CTTTTTCCTTGGCTTTGCTTGCACCAACTGCCTCCTCATTGCTGTGATGGGATATGATCGCT
ATGTAGCAATTTGTCACCCTCTGAGGTACACACTCATCATAAACAAAAGGCTGGGGTTGGA
GTTGATTTCTCTCTCAGGAGCCACAGGTTTCTTTATTGCTTTGGTGGCCACCAACCTCATTT
20   GTGACATGCGTTTTTGTGGCCCCAACAGGGTTAACCACTATTTCTGTGACATGGCACCTGT
TATCAAGTTAGCCTGCACTGACACCCATGTGAAAGAGCTGGCTTTATTTAGCCTCAGCATC
CTGGTAATTATGGTGCCTTTTCTGTTAATTCTCATATCCTATGGCTTCATAGTTAACACCAT
CCTGAAGATCCCCTCAGCTGAGGGCAAGAAGGCCTTTGTCACCTGTGCCTCACATCTCACT
GTGGTCTTTGTCCACTATGGCTGTGCCTCTATCATCTATCTGCGGCCCAAGTCCAAGTCTGC
25   CTCAGACAAGGATCAGTTGGTGGCAGTGACCTACACAGTGGTTACTCCCTTACTTAATCCT
CTTGTCTACAGTCTGAGGAACAAAGAGGTAAAAACTGCATTGAAAAGAGTTCTTGGAATG
CCTGTGGCAACCAAGATGAGCTAA (SEQ ID NO: 184)

AOLFR99 sequences:
30   MERVNETVVREVIFLGFSSLARLQQLLFVIFLLLYLFTLGTNAIIISTIVLDRALHIPMYFFLAILSC
SEICYTFIIVPKMLVDLLSQKKTISFLGCAIQMFSFLFLGCSHSFLLAVMGYDRYIAICNPLRYSV
LMGHGVCMGLVAAACACGFTVAQIITSLVFHLPFYSSNQLHHFFCDIAPVLKLASHHNHFSQIV
IFMLCTLVLAIPLLLILVSYVHILSAILQFPSTLGRCKAFSTCVSHLIIVTVHYGCASFIYLRPQSNY
SSSQDALISVSYTIITPLFNPMIYSLRNKEFKSALCKIVRRTISLL (SEQ ID NO: 185)
35

ATGGAGCGGGTCAATGAGACTGTGGTGAGAGAGGTCATCTTCCTCGGCTTCTCATCCCTGG
CCAGGCTGCAGCAGCTGCTCTTTGTTATCTTCCTGCTCCTCTACCTGTTCACTCTGGGCACC
AATGCAATCATCATTTCCACCATTGTCCTGGACAGGGCCCTTCATATCCCCATGTACTTCTT
CCTTGCCATCCTCTCTTGCTCTGAGATTTGCTACACCTTCATCATTGTACCCAAGATGCTGG
40   TTGACCTGCTGTCCCAGAAGAAGACCATTTCTTTCCTGGGCTGTGCCATCCAAATGTTTTCC
TTCCTCTTCCTTGGCTGCTCTCACTCCTTTCTGCTGGCAGTCATGGGTTATGATCGTTACAT
AGCCATCTGTAACCCACTGCGCTACTCAGTGCTAATGGGACATGGGGTGTGTATGGGACTA
GTGGCTGCTGCCTGTGCCTGTGGCTTCACTGTTGCACAGATCATCACATCCTTGGTATTTCA
CCTGCCTTTTTATTCCTCCAATCAACTACATCACTTCTTCTGTGACATTGCTCCTGTCCTCA
45   AGCTGGCATCTCACCATAACCACTTTAGTCAGATTGTCATCTTCATGCTCTGTACATTGGTC
CTGGCTATCCCCTTATTGTTGATCTTGGTGTCCTATGTTCACATCCTCTCTGCCATACTTCA
GTTTCCTTCCACACTGGGTAGGTGCAAAGCTTTTTCTACCTGTGTATCTCACCTCATTATTG
TCACTGTCCACTATGGCTGTGCCTCCTTTATCTACTTAAGGCCTCAGTCCAACTACTCCTCA
AGCCAGGATGCTCTAATATCAGTATCCTACACTATTATAACTCCATTGTTCAACCCAATGA
50   TTTATAGCTTGAGAAATAAAGAGTTCAAATCAGCTCTTTGTAAAATTGTGAGAAGAACAAT
TTCCCTGTTGTAA (SEQ ID NO: 186)

AOLFR101 sequences:
MDTGNWSQVAEFIILGFPHLQGVQIYLFLLLLLLIYLMTVLGNLLIFLVVCLDSRLHTPMYHFVSI
55   LSFSELGYTAATIPKMLANLLSEKKTISFSGCLLQIYFFHSLGATECYLLTAMAYDRYLAICRPL
HYPTLMTPTLCAEIAIGCWLGGLAGPVVEISLISRLPFCGPNRIQHVFCDFPPVLSLACTDTSINV

LVDFVINSCKILATFLLILCSYVQIICTVLRIPSAAGKRKAISTCASHFTVVLIFYGSILSMYVQLK
KSYSLDYDQALAVVYSVLTPFLNPFIYSLRNKEIKEAVRRQLKRIGILA (SEQ ID NO: 187)

5
ATGGACACAGGGAACTGGAGCCAGGTAGCAGAATTCATCATCTTGGGCTTCCCCCATCTCC
AGGGTGTCCAGATTTATCTCTTCCTCTTGTTGCTTCTCATTTACCTCATGACTGTGTTGGGA
AACCTGCTGATATTCCTGGTGGTCTGCCTGGACTCCCGGCTTCACACACCCATGTACCACT
TTGTCAGCATTCTCTCCTTCTCAGAGCTTGGCTATACAGCTGCCACCATCCCTAAGATGCTG
GCAAACTTGCTCAGTGAGAAAAAGACCATTTCATTCTCTGGGTGTCTCCTGCAGATCTATT
10
TCTTTCACTCCCTTGGAGCGACTGAGTGCTATCTCCTGACAGCTATGGCCTACGATAGGTA
TTTAGCCATCTGCCGGCCCCTCCACTACCCAACCCTCATGACCCCAACACTTTGTGCAGAG
ATTGCCATTGGCTGTTGGTTGGGAGGCTTGGCTGGGCCAGTAGTTGAAATTTCCTTGATTT
CACGCCTCCCATTCTGTGGCCCCAATCGCATTCAGCACGTCTTTTGTGACTTCCCTCCTGTG
CTGAGTTTGGCTTGCACTGATACGTCTATAAATGTCCTAGTAGATTTTGTTATAAATTCCTG
15
CAAGATCCTAGCCACCTTCCTGCTGATCCTCTGCTCCTATGTGCAGATCATCTGCACAGTGC
TCAGAATTCCCTCAGCTGCCGGCAAGAGGAAGGCCATCTCCACGTGTGCCTCCCACTTCAC
TGTGGTTCTCATCTTCTATGGGAGCATCCTTTCCATGTATGTGCAGCTGAAGAAGAGCTAC
TCACTGGACTATGACCAGGCCCTGGCAGTGGTCTACTCAGTGCTCACACCCTTCCTCAACC
CCTTCATCTACAGCTTGCGCAACAAGGAGATCAAGGAGGCTGTGAGGAGGCAGCTAAAGA
GAATTGGGATATTGGCATGA (SEQ ID NO: 188)
20

AOLFR102 sequences:
MPVGKLVFNQSEPTEFVFRAFTTATEFQVLLFLLFLLLYLMILCGNTAIIWVVCTHSTLRTPMYF
FLSNLSFLELCYTTVVVPLMLSNILGAQKPISLAGCGAQMFFFVTLGSTDCFLLAIMAYDRYVAI
CHPLHYTLIMTRELCTQMLGGALGLALFPSLQLTALIFTLPFCGHHQEINHFLCDVPPVLRLACA
25 ˙ DIRVHQAVLYVVSILVLTIPFLLICVSYVFITCAILSIRSAEGRRRAFSTCSFHLTVVLLQYGCCSL
VYLRPRSSTSEDEDSQIALVYTFVTPLLNPLLYSLRNKDVKGALRSAIIRKAASDAN (SEQ ID
NO: 189)

30
ATGCCTGTGGGGGAAACTTGTCTTCAACCAGTCTGAGCCCACTGAGTTTGTGTTCCGTGCGT
TCACCACAGCCACTGAATTCCAGGTTCTTCTCTTCCTTCTCTTCCTCCTCCTCTACTTGATG
ATCCTCTGTGGCAACACAGCCATCATCTGGGTGGTGTGCACACACAGCACCCTCCGCACCC
CGATGTATTTCTTCCTGTCCAACCTGTCTTTCCTGGAACTCTGCTACACCACCGTGGTAGTA
CCCTTGATGCTTTCCAACATTTTGGGGGCCCAGAAGCCCATTTCGTTGGCTGGATGTGGGG
CCCAAATGTTCTTCTTTGTCACCCTCGGCAGCACGGACTGTTTCCTCTTGGCGATCATGGCC
35
TATGACCGCTATGTGGCTATCTGCCACCCGCTGCACTACACCCTCATCATGACCCGCGAGC
TGTGCACGCAGATGCTGGGTGGGGCCCTGGGCCTGGCCCTCTTCCCCTCCCTGCAGCTCAC
CGCCTTAATCTTCACCCTGCCCTTTTGCGGCCACCACCAGGAAATCAACCACTTCCTCTGCG
ATGTGCCTCCCGTCCTGCGCCTGGCCTGCGCTGACATCCGCGTGCACCAGGCTGTCCTCTA
TGTCGTGAGCATCCTCGTGCTGACCATCCCCTTCCTGCTCATCTGCGTCTCCTACGTGTTCA
40
TCACCTGTGCCATCCTGAGCATCCGTTCTGCCGAGGGCCGCCGCCGGGCCTTCTCCACCTG
CTCCTTCCACCTCACCGTGGTCCTGCTGCAGTATGGCTGCTGCAGCCTCGTGTACCTGCGTC
CTCGGTCCAGCACCTCAGAGGATGAGGACAGCCAAATCGCGTTGGTCTACACCTTTGTCAC
CCCCTTACTCAACCCTTTGCTTTACAGCCTTAGGAACAAGGATGTCAAAGGTGCTCTGAGG
AGTGCCATTATCCGTAAAGCAGCCTCTGACGCCAACTGA (SEQ ID NO: 190)
45

AOLFR103 sequences:
MAEMNLTLVTEFLLIAFTEYPEWALPLFLLLLFMYLITVLGNLEMIILILMDHQLHAPMYFLLSH
LAFMDVCYSSITVPQMLAVLLEHGAALSYTRCAAQFFLFTFFGSIDCYLLALMAYDRYLAVCQ
PLLYVTILTQQARLSLVAGAYVAGLISALVRTVSAFTLSFCGTSEIDFIFCDLPPLLKLTCGESYT
50 QEVLIIMFAIFVIPASMVVILVSYLFIIVAIMGIPAGSQAKTFSTCTSHLTAVSLFFGTLIFMYLRG
NSDQSSEKNRVVSVLYTEVIPMLNPLIYSLRNKEVKEALRKILNRAKLS (SEQ ID NO: 191)

ATGGCAGAGATGAACCTCACCTTGGTGACCGAGTTCCTCCTTATTGCATTCACTGAATATC
CTGAATGGGCACTCCCTCTCTTCCTCTTGTTATTATTTATGTATCTCATCACCGTATTGGGG
55 AACTTAGAGATGATTATTCTGATCCTCATGGATCACCAGCTCCACGCTCCAATGTATTTCCT
TCTGAGTCACCTCGCTTTCATGGACGTCTGCTACTCATCTATCACTGTCCCCCAGATGCTGG

99

CAGTGCTGCTGGAGCATGGGGCAGCTTTATCTTACACACGCTGTGCTGCTCAGTTCTTTCT
GTTCACCTTCTTTGGTTCCATCGACTGCTACCTCTTGGCCCTCATGGCCTATGACCGCTACT
TGGCTGTGTGCCAGCCCCTGCTTTATGTCACCATCCTGACACAGCAGGCCCGCTTGAGTCT
TGTGGCTGGGGGCTTACGTTGCTGGTCTCATCAGTGCCTTGGTGCGGACAGTCTCAGCCTTC
ACTCTCTCCTTCTGTGGAACCAGTGAGATTGACTTTATTTTCTGTGACCTCCCTCCTCTGTT
AAAGTTGACCTGTGGGGAGAGCTACACTCAAGAAGTGCTGATTATTATGTTTGCCATTTTT
GTCATCCCTGCTTCCATGGTGGTGATCTTGGTGTCCTACCTGTTTATCATCGTGGCCATCAT
GGGGATCCCTGCTGGAAGCCAGGCCAAGACCTTCTCCACCTGCACCTCCCACCTCACTGCT
GTGTCACTCTTCTTTGGTACCCTCATCTTCATGTACTTGAGAGGTAACTCAGATCAGTCTTC
GGAGAAGAATCGGGTAGTGTCTGTGCTTTACACAGAGGTCATCCCCATGTTGAATCCCCTC
ATCTACAGCCTGAGGAACAAGGAAGTGAAGGAGGCCCTGAGAAAAATTCTCAATAGAGCC
AAGTTGTCCTAA (SEQ ID NO: 192)

AOLFR105 sequences:

MQGLNHTSVSEFILVGFSAFPHLQLMLFLLFLLMYLFTLLGNLLIMATVWSERSLHMPMYLFLC
ALSITEILYTVAIIPRMLADLLSTQRSIAFLACASQMFFSFSFGFTHSFLLTVMGYDRYVAICHPL
RYNVLMSLRGCTCRVGCSWAGGLVMGMVVTSAIFHLAFCGHKEIHHFFCHVPPLLKLACGDD
VLVVAKGVGLVCITALLGCFLLILLSYAFIVAAILKIPSAEGRNKAFSTCASHLTVVVVHYGFAS
VIYLKPKGPQSPEGDTLMGITYTVLTPFLSPIIFSLRNKELKVAMKKTCFTKLFPQNC (SEQ ID
NO: 193)

ATGCAGGGGCTAAACCACACCTCCGTGTCTGAATTCATCCTCGTTGGCTTCTCTGCCTTCCC
CCACCTCCAGCTGATGCTCTTCCTGCTGTTCCTGCTGATGTACCTGTTCACGCTGCTGGGCA
ACCTGCTCATCATGGCCACTGTCTGGAGCGAGCGCAGCCTCCACATGCCCATGTACCTCTT
CCTGTGTGCCCTCTCCATCACCGAGATCCTCTACACCGTGGCCATCATCCCGCGCATGCTG
GCCGACCTGCTGTCCACCCAGCGCTCCATCGCCTTCCTGGCCTGTGCCAGTCAGATGTTCTT
CTCCTTCAGCTTCGGCTTCACCCACTCCTTCCTGCTCACTGTCATGGGCTACGACCGCTACG
TGGCCATCTGCCACCCCCTGCGTTACAACGTGCTCATGAGCCTGCGGGGCTGCACCTGCCG
GGTGGGCTGCTCCTGGGCTGGTGGCTTGGTCATGGGGATGGTGGTGACCTCGGCCATTTTC
CACCTCGCCTTCTGTGGACACAAGGAGATCCACCATTTCTTCTGCCACGTGCCACCTCTGTT
GAAGTTGGCCTGTGGAGATGATGTGCTGGTGGTGGCCAAAGGCGTGGGCTTGGTGTGTAT
CACGGCCCTGCTGGGCTGTTTTCTCCTCATCCTCCTCTCCTATGCCTTCATCGTGGCCGCCA
TCTTGAAGATCCCTTCTGCTGAAGGTCGGAACAAGGCCTTCTCCACCTGTGCCTCTCACCT
CACTGTGGTGGTCGTGCACTATGGCTTTGCCTCCGTCATTTACCTGAAGCCCAAAGGTCCC
CAGTCTCCGGAAGGAGACACCTTGATGGGCATCACCTACACGGTCCTCACACCCTTCCTCA
GCCCCATCATCTTCAGCCTCAGGAACAAGGAGCTGAAGGTCGCCATGAAGAAGACTTGCTT
CACCAAACTCTTTCCACAGAACTGCTGA (SEQ ID NO: 194)

AOLFR106 sequences:

METANYTKVTEFVLTGLSQTPEVQLVLFVIFLSFYLFILPGNILIICTISLDPHLTSPMYFLLANLA
FLDIWYSSITAPEMLIDFFVERKIISFDGCIAQLFFLHFAGASEMFLLTVMAFDLYTAICRPLHYA
TIMNQRLCCILVALSWRGGFIHSIIQVALIVRLPFCGPNELDSYFCDITQVVRIACANTFPEELVM
ICSSGLISVVCLIALLMSYAFLLALFKKLSGSGENTNRAMSTCYSHITIVVLMFGPSIYTYARPFD
SFSLDKVVSVFNTLIFPLRNPIIYTLRNKEVKAAMRKLVTKYILCKEK (SEQ ID NO: 195)

ATGGAAACTGCAAATTACACCAAGGTGACAGAATTTGTTCTCACTGGCCTATCCCAGACTC
CAGAGGTCCAACTAGTCCTATTTGTTATATTTCTATCCTTCTATTTGTTCATCCTACCAGGA
AATATCCTTATCATTTGCACCATCAGTCTAGACCCTCATCTGACCTCTCCTATGTATTTCCT
GTTGGCTAATCTGGCCTTCCTTGATATTTGGTACTCTTCCATTACAGCCCCTGAAATGCTCA
TAGACTTCTTTGTGGAGAGGAAGATAATTTCTTTTGATGGATGCATTGCACAGCTCTTCTT
CTTACACTTTGCTGGGGCTTCGGAGATGTTCTTGCTCACAGTGATGGCCTTTGACCTCTACA
CTGCTATCTGCCGACCCCTCCACTATGCTACCATCATGAATCAACGTCTCTGCTGTATCCTG
GTGGCTCTCTCCTGGAGGGGGGGCTTCATTCATTCTATCATACAGGTGGCTCTCATTGTTC
GACTTCCTTTCTGTGGGCCCAATGAGTTAGACAGTTACTTCTGTGACATCACACAGGTTGT
CCGGATTGCCTGTGCCAACACCTTCCCAGAGGAGTTAGTGATGATCTGTAGTAGTGGTCTG
ATCTCTGTGGTGTGTTTGATTGCTCTGTTAATGTCCTATGCCTTCCTTCTGGCCTTGTTCAA

GAAACTTTCAGGCTCAGGTGAGAATACCAACAGGGCCATGTCCACCTGCTATTCCCACATT
ACCATTGTGGTGCTAATGTTTGGGCCATCCATCTACATTTATGCTCGCCCATTTGACTCGTT
TTCCCTAGATAAAGTGGTGTCTGTGTTCAATACTTTAATATTCCCTTTACGTAATCCCATTA
TTTACACATTGAGAAACAAGGAAGTAAAGGCAGCCATGAGGAAGTTGGTCACCAAATATA

5   TTTTGTGTAAAGAGAAGTGA (SEQ ID NO: 196)

AOLFR107 sequences:

MELWNFTLGSGFILVGILNDSGSPELLCATITILYLLALISNGLLLLAITMEARLHMPMYLLLGQ
LSLMDLLFTSVVTPKALADFLRRENTISFGGCALQMFLALTMGGAEDLLLAFMAYDRYVAICH
10   PLTYMTLMSSRACWLMVATSWILASLSALIYTVYTMHYPFCRAQEIRHLLCEIPHLLKVACAD
TSRYELMVYVMGVTFLIPSLAAILASYTQILLTVLHMPSNEGRKKALVTCSSHLTVVGMFYGA
ATFMYVLPSSFHSTRQDNIISVFYTIVTPALNPLIYSLRNKEVMRALRRVLGKYMLPAHSTL
(SEQ ID NO: 197)

15   ATGGAGCTCTGGAACTTCACCTTGGGAAGTGGCTTCATTTTGGTGGGGATTCTGAATGACA
GTGGGTCTCCTGAACTGCTCTGTGCTACAATTACAATCCTATACTTGTTGGCCCTGATCAG
CAATGGCCTACTGCTCCTGGCTATCACCATGGAAGCCCGGCTCCACATGCCCATGTACCTC
CTGCTTGGGCAGCTCTCTCTCATGGACCTCCTGTTCACATCTGTTGTCACTCCCAAGGCCCT
TGCGGACTTTCTGCGCAGAGAAAACACCATCTCCTTTGGAGGCTGTGCCCTTCAGATGTTC
20   CTGGCACTGACAATGGGTGGTGCTGAGGACCTCCTACTGGCCTTCATGGCCTATGACAGGT
ATGTGGCCATTTGTCATCCTCTGACATACATGACCCTCATGAGCTCAAGAGCCTGCTGGCT
CATGGTGGCCACGTCCTGGATCCTGGCATCCCTAAGTGCCCTAATATATACCGTGTATACC
ATGCACTATCCCTTCTGCAGGGCCCAGGAGATCAGGCATCTTCTCTGTGAGATCCCACACT
TGCTGAAGGTGGCCTGTGCTGATACCTCCAGATATGAGCTCATGGTATATGTGATGGGTGT
25   GACCTTCCTGATTCCCTCTCTTGCTGCTATACTGGCCTCCTATACACAATTCTACTCACTG
TGCTCCATATGCCATCAAATGAGGGGAGGAAGAAAGCCCTTGTCACCTGCTCTTCCCACCT
GACTGTGGTTGGGATGTTCTATGGAGCTGCCACATTCATGTATGTCTTGCCCAGTTCCTTCC
ACAGCACCAGACAAGACAACATCATCTCTGTTTTCTACACAATTGTCACTCCAGCCCTGAA
TCCACTCATCTACAGCCTGAGGAATAAGGAGGTCATGCGGGCCTTGAGGAGGGTCCTGGG
30   AAAATACATGCTGCCAGCACACTCCACGCTCTAG (SEQ ID NO: 198)

AOLFR108 sequences:

MCSFFLCQTGKQAKISMGEENQTFVSKFIFLGLSQDLQTQILLFILFLIIYLLTVLGNQLIIILIFLD
SRLHTPMYFFLRNLSFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIIVFLLVGCTECALLAV
35   MSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPYWGQNIINHYFCE
PPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNIISTVIQMQSGEGRLKAFSTCGSHLI
VVVLFYGSGIFTYMRPNSKTTKELDKMISVFYTAVTPMLNPIIYSLRNKDVKGALRKLVGRKC
FSHRQ (SEQ ID NO: 199)

40   ATGTGTTCTTTTTTCTTGTGCCAAACAGGTAAACAGGCAAAAATATCAATGGGAGAAGAAA
ACCAAACCTTTGTGTCCAAGTTTATCTTCCTGGGTCTTTCACAGGACTTGCAGACCCAGAT
CCTGCTATTTATCCTTTTCCTCATCATTTATCTGCTGACCGTGCTTGGAAACCAGCTCATCA
TCATTCTCATCTTCCTGGATTCTCGCCTTCACACTCCCATGTATTTTTTTCTTAGAAATCTCT
CCTTTGCAGATCTCTGTTTCTCTACTAGCATTGTCCCTCAAGTGTTGGTTCACTTCTTGGTA
45   AAGAGGAAAACCATTTCTTTTTATGGGTGTATGACACAGATAATTGTCTTTCTTCTGGTTG
GGTGTACAGAGTGTGCGCTGCTGGCAGTGATGTCCTATGACCGGTATGTGGCTGTCTGCAA
GCCCCTGTACTACTCTACCATCATGACACAACGGGTGTGTCTCTGGCTGTCCTTCAGGTCCT
GGGCCAGTGGGGCACTAGTGTCTTTAGTAGATACCAGCTTTACTTTCCATCTTCCCTACTG
GGGACAGAATATAATCAATCACTACTTTGTGAACCTCCTGCCCTCCTGAAGCTGGCTTCC
50   ATAGACACTTACAGCACAGAAATGGCCATCTTTTCAATGGGCGTGGTAATCCTCCTGGCCC
CTGTCTCCCTGATTCTTGGTTCTTATTGGAATATTATCTCCACTGTTATCCAGATGCAGTCT
GGGGAAGGGAGACTCAAGGCTTTTTCCACCTGTGGCTCCCATCTTATTGTTGTTGTCCTCTT
CTATGGGTCAGGAATATTCACCTACATGCGACCAAACTCCAAGACTACAAAAGAACTGGA
TAAAATGATATCTGTGTTCTATACAGCGGTGACTCCAATGTTGAACCCCATAATTTATAGC
55   TTGAGGAACAAAGATGTCAAAGGGGCTCTCAGGAAACTAGTTGGGAGAAAGTGCTTCTCT
CATAGGCAGTGA (SEQ ID NO: 200)

AOLFR109 sequences:

MLRNGSIVTEFILVGFQQSSTSTRALLFALFLALYSLTMAMNGLIIFITSWTDPKLNSPMYFFLG
HLSLLDVCFITTTIPQMLIHLVVRDHIVSFVCCMTQMYFVFCVGVAECILLAFMAYDRYVAICY
PLNYVPIISQKVCVRLVGTAWFFGLINGIFLEYISFREPFRRDNHIESFFCEAPIVIGLSCGDPQFSL
WAIFADAIVVILSPMVLTVTSYVHILATILSKASSSGRGKTFSTCASHLTVVIFLYTSAMFSYMN
PHSTHGPDKDKPFSLLYTIITPMCNPIIYSFRNKEIKEAMVRALGRTRLAQPQSV (SEQ ID NO:
201)

ATGCTAAGGAATGGCAGCATAGTGACGGAATTTATCCTCGTGGGCTTTCAGCAGAGCTCCA
CTTCCACACGAGCATTGCTCTTTGCCCTCTTCTTGGCCCTCTACAGCCTCACCATGGCCATG
AATGGCCTCATCATCTTTATCACCTCCTGGACAGACCCCAAGCTCAACAGCCCCATGTACT
TCTTCCTCGGCCATCTGTCTCTCCTGGATGTCTGCTTCATCACCACTACCATCCCACAGATG
TTGATCCACCTCGTGGTCAGGGACCACATTGTCTCCTTTGTATGTTGCATGACCCAGATGT
ACTTTGTCTTCTGTGTTGGTGTGGCCGAGTGCATCCTCTTGGCTTTCATGGCCTATGACCGT
TATGTTGCTATCTGCTACCCACTTAACTATGTCCCGATCATAAGCCAGAAGGTCTGTGTCA
GGCTTGTGGGAACTGCCTGGTTCTTTGGGCTGATCAATGGCATCTTTCTCGAGTATATTTC
ATTCCGAGAGCCCTTCCGCAGAGACAACCACATAGAAAGCTTCTTCTGTGAGGCCCCCATA
GTGATTGGCCTCTCTTGTGGGGACCCTCAGTTTAGTCTGTGGGCAATCTTTGCCGATGCCA
TCGTGGTAATTCTCAGCCCCATGGTGCTCACTGTCACTTCCTATGTGCACATCCTGGCCACC
ATCCTCAGCAAAGCCTCCTCCTCAGGTCGGGGGAAGACTTTCTCTACTTGTGCCTCTCACC
TGACTGTGGTCATCTTTCTCTACACTTCAGCTATGTTCTCTTACATGAACCCCCACAGCACA
CATGGGCCTGACAAAGACAAACCTTTCTCCCTCCTGTACACCATCATTACCCCCATGTGCA
ACCCCATCATTTATAGTTTCCGCAACAAGGAAATTAAGGAGGCCATGGTGAGGGCACTTG
GAAGAACCAGGCTGGCCCAGCCACAGTCTGTCTAG (SEQ ID NO: 202)

AOLFR110 sequences:

MKIANNTVVTEFILLGLTQSQDIQLLVFVLILIFYLIILPGNFLIIFTIRSDPGLTAPLYLFLGNLAFL
DASYSFIVAPRMLVDFLSEKKVISYRGCITQLFFLHFLGGGEGLLLVVMAFDRYIAICRPLHCST
VMNPRACYAMMLALWLGGFVHSIIQVVLILRLPFCGPNQLDNFFCDVRQVIKLACTDMFVVEL
LMVFNSGLMTLLCFLGLLASYAVILCHVRRAASEGKNKAMSTCTTRVIIILLMFGPAIFIYMCPF
RALPADKMVSLFHTVIFPLMNPMIYTLRNQEVKTSMKRLLSRHVVCQVDFIIRN (SEQ ID NO:
203)

ATGAAGATAGCAAACAACACAGTAGTGACAGAATTTATCCTCCTTGGTCTGACTCAGTCTC
AAGATATTCAGCTCTTGGTCTTTGTGCTGATCTTAATTTTCTACCTTATCATCCTCCCTGGA
AATTTTCTCATTATTTTCACCATAAGGTCAGACCCTGGGCTCACAGCCCCCCTCTATTTATT
TCTGGGCAACTTGGCCTTCCTGGATGCATCCTACTCCTTCATTGTGGCTCCCAGGATGTTGG
TGGACTTCCTCTCTGAGAAAAAGGTAATCTCCTACAGAGGCTGCATCACTCAGCTCTTTTT
CTTGCACTTCCTTGGAGGAGGGGAGGGATTACTCCTTGTTGTGATGGCCTTTGACCGCTAC
ATCGCCATCTGCCGGCCTCTGCACTGTTCAACTGTCATGAACCCTAGAGCCTGCTATGCAA
TGATGTTGGCTCTGTGGCTTGGGGGTTTTGTCCACTCCATTATCCAGGTGGTCCTCATCCTC
CGCTTGCCTTTTGTGGCCCAAACCAGCTGGACAACTTCTTCTGTGATGTCCGACAGGTCA
TCAAGCTGGCTTGCACCGACATGTTTGTGGTGGAGCTTCTAATGGTCTTCAACAGTGGCCT
GATGACACTCCTGTGCTTTCTGGGGCTTCTGGCTTCCTATGCAGTCATCCTCTGCCATGTTC
GTAGGGCAGCTTCTGAAGGGAAGAACAAGGCCATGTCCACGTGCACCACTCGTGTCATTA
TTATACTTCTTATGTTTGGACCTGCTATCTTCATCTACATGTGCCCTTTCAGGGCCTTACCA
GCTGACAAGATGGTTTCTCTCTTTCACACAGTGATCTTTCCATTGATGAATCCTATGATTTA
TACCCTTCGCAACCAGGAAGTGAAAACTTCCATGAAGAGGTTATTGAGTCGACATGTAGTC
TGTCAAGTGGATTTTATAATAAGAAACTGA (SEQ ID NO: 204)

AOLFR111 sequences:

MCYIYLIFKEWTLIFYFSLLLFLQITPAIMANLTIVTEFILMGFSTNKNMCILHSILFLLIYLCALM
GNVLIIMITTLDHHLHTPVYFFLKNLSFLDLCLISVTAPKSIANSLIHNNSISFLGCVSQVFLLLSS
ASAELLLLTVMSFDRYTAICHPLHYDVIMDRSTCVQRATVSWLYGGLIAVMHTAGTFSLSYCG
SNMVHQFFCDIPQLLAISCSENLIREIALILINVVLDFCCFIVIIITYVHVFSTVKKIPSTEGQSKAY

SICLPHLLVVLFLSTGFIAYLKPASESPSILDAVISVFYTMLPPTFNPIIYSLRNKAIKVALGMLIKG
KLTKK (SEQ ID NO: 205)

ATGTGTTATATATATTTAATATTTAAAGAGTGGACATTGATATTTTACTTCAGTCTTCTCCT
TTTCCTGCAGATTACTCCTGCAATAATGGCAAATCTCACAATCGTGACTGAATTTATCCTTA
TGGGGTTTTCTACCAATAAAAATATGTGCATTTTGCATTCGATTCTCTTCTTGTTGATTTAT
TTGTGTGCCCTGATGGGGAATGTCCTCATTATCATGATCACAACTTTGGACCATCATCTCC
ACACCCCCGTGTATTTCTTCTTGAAGAATCTATCTTTCTTGGATCTCTGCCTTATTTCAGTC
ACGGCTCCCAAATCTATCGCCAATTCTTTGATACACAACAACTCCATTTCATTCCTTGGCTG
TGTTTCCCAGGTCTTTTTGTTGCTTTCTTCAGCATCTGCAGAGCTGCTCCTCCTCACGGTGA
TGTCCTTTGACCGCTATACTGCTATATGTCACCCTCTGCACTATGATGTCATCATGGACAGG
AGCACCTGTGTCCAAAGAGCCACTGTGTCTTGGCTGTATGGGGGTCTGATTGCTGTGATGC
ACACAGCTGGCACCTTCTCCTTATCCTACTGTGGGTCCAACATGGTCCATCAGTTCTTCTGT
GACATTCCCCAGTTATTAGCTATTTCTTGCTCAGAAAATTTAATAAGAGAAATTGCACTCA
TCCTTATTAATGTAGTTTTGGATTTCTGCTGTTTTATTGTCATCATCATTACCTATGTCCAC
GTCTTCTCTACAGTCAAGAAGATCCCTTCCACAGAAGGCCAGTCAAAAGCCTACTCTATTT
GCCTTCCACACTTGCTGGTTGTGTTATTTCTTTCCACTGGATTCATTGCTTATCTGAAGCCA
GCTTCAGAGTCTCCTTCTATTTTGGATGCTGTAATTTCTGTGTTCTACACTATGCTGCCCCC
AACCTTTAATCCCATTATATACAGTTTGAGAAACAAGGCCATAAAGGTGGCTCTGGGGATG
TTGATAAAGGGAAAGCTCACCAAAAAGTAA (SEQ ID NO: 206)

AOLFR113 sequences:
MKFWHGFSSHLNPMFSSFLLYLSLPWINTTIQAWLNLCSLALPVWAMSGAGFLSCCYWHTCSP
SVVTCSSSQSSDWMQLCTHLCTTLSVFFPSWSCGIQLPLSLRCCLIFSVRRKPFLLQDASFRPTSS
TPWGACECYLLTAMAYDRYLAICRPLHYPIIMTTTLCAKMAAACWTCGFLCPISEVILASQLPF
CAYNEIQHIFCDFPPLLSLACKDTSANILVDFAINAFIILITFFFIMISYARIIGAVLKIKTASGRKK
AFSTCASHLAVVLIFFGSIIFMYVRLKKSYSLTLDRTLAIVYSVLTPMVNPIIYSLRNKEIIKAIKR
TIFQKGDKASLAHL (SEQ ID NO: 207)

ATGTGTCAACAAATCTTACGGGATTGCATTCTTCTCATACATCATTTGTGCATTAACAGGA
AAAAAGTCTCACTTGTGATGCTGGGTCCAGCTTATAACCACACAATGGAAACCCCTGCCTC
CTTCCTCCTTGTGGGTATCCCAGGACTGCAATCTTCACATCTTTGGCTGGCTATCTCACTGA
GTGCCATGTACATCATAGCCCTGTTAGGAAACACCATCATCGTGACTGCAATCTGGATGGA
TTCCACTCGGCATGAGCCCATGTATTGCTTTCTGTGTGTTCTGGCTGCTGTGGACATTGTTA
TGGCCTCCTCGGTGGTACCCAAGATGGTGAGCATCTTCTGCTCAGGAGACAGCTCAATCAG
CTTTAGTGCTTGTTTCACTCAGATGTTTTTGTCCACTTAGCCACAGCTGTGGAGACGGGG
CTGCTGCTGACCATGGCTTTTGACCGCTATGTAGCCATCTGCAAGCCTCTACACTACAAGA
GAATTCTCACGCCTCAAGTGATGCTGGGAATGAGTATGGCCATCACCATCAGAGCTATCAT
AGCCATAACTCCACTGAGTTGGATGGTGAGTCATCTACCTTTCTGTGGCTCCAATGTGGTT
GTCCACTCCTACTGTGAGCACATAGCTTTGGCCAGGTTAGCATGTGCTGACCCCGTGCCCA
GCAGTCTCTACAGTCTGATTGGTTCCTCTCTTATGGTGGGCTCTGATGTGGCCTTCATTGCT
GCCTCCTATATCTTAATTCTCAAGGCAGTATTTGGTCTCTCCTCAAAGACTGCTCAGTTGAA
AGCATTAAGCACATGTGGCTCCCATGTGGGGGTTATGGCTTTGTACTATCTACCTGGGATG
GCATCCATCTATGCGGCCTGGTTGGGGCAGGATGTAGTGCCCTTGCACACCCAAGTCCTGC
TAGCTGACCTGTACGTGATCATCCCAGCCACCTTAAATCCCATCATCTATGGCATGAGGAC
CAAACAACTGCGGGAGAGAATATGGAGTTATCTGATGCATGTCCTCTTTGACCATTCCAAC
CTGGGTTCATGA (SEQ ID NO: 208)

AOLFR114 sequences:
MERINHTSSVSEFILLGLSSRPEDQKTLFVLFLIVYLVTITGNLLIILAIRFNPHLQTPMYFFLSFLS
LTDICFTTSVVPKMLMNFLSEKKTISYAGCLTQMYFLYALGNSDSCLLAVMAFDRYVAVCDPF
HYVTTMSHHHCVLLVAFSCSFPHLHSLLHTLLLNRLTFCDSNVIIHHFLCDLSPVLKLSCSSIFVN
EIVQMTEAPIVLVTRFLCIAFSYIRILTTVLKIPSTSGKRKAFSTCGFYLTVVTLFYGSIFCVYLQP
PSTYAVKDHVATIVYTVLSSMLNPFIYSLRNKDLKQGLRKLMSKRS (SEQ ID NO: 209)

ATGGAAAGAATCAACCACACCAGCAGTGTCTCCGAGTTTATCCTCCTGGGACTCTCCTCCC
GGCCTGAGGACCAAAAGACACTCTTTGTTCTCTTCCTCATCGTGTACCTGGTCACCATAAC
AGGGAACCTGCTCATCATCCTGGCCATTCGCTTCAACCCCCATCTTCAGACCCCTATGTATT
TCTTCTTGAGTTTTCTGTCTCTCACTGATATTTGCTTTACAACAAGCGTTGTCCCCAAGATG
5   CTGATGAACTTCCTGTCAGAAAAGAAGACCATCTCCTATGCTGGGTGTCTGACACAGATGT
ATTTTCTCTATGCCTTGGGCAACAGTGACAGCTGCCTTCTGGCAGTCATGGCCTTTGACCG
CTATGTGGCCGTCTGTGACCCTTTCCACTATGTCACCACCATGAGCCACCACCACTGTGTCC
TGCTGGTGGCCTTCTCCTGCTCATTCCTCACCTCCACTCACTCCTGCACACACTTCTGCTG
AATCGTCTCACCTTCTGTGACTCCAATGTTATCCACCACTTTCTCTGTGACCTCAGCCCTGT
10 GCTGAAATTGTCCTGCTCTTCCATATTTGTCAATGAAATTGTGCAGATGACAGAAGCACCT
ATTGTTTTGGTGACTCGTTTTCTCTGCATTGCTTTCTCTTATATACGAATCCTCACTACAGT
TCTCAAGATTCCCTCTACTTCTGGGAAACGCAAAGCCTTCTCCACCTGTGGTTTTTACCTCA
CCGTGGTGACGCTCTTTTATGGAAGCATCTTCTGTGTCTATTTACAGCCCCCATCCACCTAC
GCTGTCAAGGACCACGTGGCAACAATTGTTTACACAGTTTTGTCATCCATGCTCAATCCTT
15 TTATCTACAGCCTGAGAAACAAAGACCTGAAACAGGGCCTGAGGAAGCTTATGAGCAAGA
GATCCTAG (SEQ ID NO: 210)

AOLFR115 sequences:

20 MEGFYLRRSHELQGMGKPGRVNQTTVSDFLLLGLSEWPEEQPLLFGIFLGMYLVTMVGNLLII
LAISSDPHLHTPMYFFLANLSLTDACFTSASIPKMLANIHTQSQIISYSGCLAQLYFLLMFGGLD
NCLLAVMAYDRYVAICQPLHYSTSMSPQLCALMLGVCWVLTNCPALMHTLLLTRVAFCAQK
AIPHFYCDPSALLKLACSDTHVNELMIITMGLLFLTVPLLLIVFSYVRIFWAVFVISSPGGRWKA
FSTCGSHLTVVLLFYGSLMGVYLLPPSTYSTERESRAAVLYMVIIPTLNPFIYSLRNRDMKEALG
KLFVSGKTFFL (SEQ ID NO: 211)

25

ATGGAAGGTTTTTATCTGCGCAGATCACACGAACTACAAGGGATGGGAAAACCAGGCAGA
GTGAACCAAACCACTGTTTCAGACTTCCTCCTTCTAGGACTCTCTGAGTGGCCAGAGGAGC
AGCCTCTTCTGTTTGGCATCTTCCTTGGCATGTACCTGGTCACCATGGTGGGGAACCTGCTC
ATTATCCTGGCCATCAGCTCTGACCCACACCTCCATACTCCCATGTACTTCTTTCTGGCCAA
30 CCTGTCATTAACTGATGCCTGTTTCACTTCTGCCTCCATCCCCAAAATGCTGGCCAACATTC
ATACCCAGAGTCAGATCATCTCGTATTCTGGGTGTCTTGCACAGCTATATTTCCTCCTTATG
TTTGGTGGCCTTGACAACTGCCTGCTGGCTGTGATGGCATATGACCGCTATGTGGCCATCT
GCCAACCACTCCATTACAGCACATCTATGAGTCCCCAGCTCTGTGCACTAATGCTGGGTGT
GTGCTGGGTGCTAACCAACTGTCCTGCCCTGATGCACACACTGTTGCTGACCCGCGTGGCT
35 TTCTGTGCCCAGAAAGCCATCCCTCATTTCTATTGTGATCCTAGTGCTCTCCTGAAGCTTGC
CTGCTCAGATACCCATGTAAACGAGCTGATGATCATCACCATGGGCTTGCTGTTCCTCACT
GTTCCCCTCCTGCTGATCGTCTTCTCCTATGTCCGCATTTTCTGGGCTGTGTTTGTCATCTC
ATCTCCTGGAGGGAGATGGAAGGCCTTCTCTACCTGTGGTTCTCATCTCACGGTGGTTCTG
CTCTTCTATGGGTCTCTTATGGGTGTGTATTTACTTCCTCCATCAACTTACTCTACAGAGAG
40 GGAAAGTAGGGCTGCTGTTCTCTATATGGTGATTATTCCCACGCTAAACCCATTCATTTAT
AGCTTGAGGAACAGAGACATGAAGGAGGCTTTGGGTAAACTTTTTGTCAGTGGAAAAACA
TTCTTTTTATGA (SEQ ID NO: 212)

AOLFR116 sequences:

45 MDEANHSVVSEFVFLGLSDSRKIQLLLFLFFSVFYVSSLMGNLLIVLTVTSDPRLQSPMYFLLAN
LSIINLVFCSSTAPKMIYDLFRKHKTISFGGCVVQIFFIHAVGGTEMVLLIAMAFDRYVAICKPLH
YLTIMNPQRCILFLVISWIIGIIHSVIQLAFVVDLLFCGPNELDSFFCDLPRFIKLACIETYTLGFMV
TANSGFISLASFLILIISYIFILVTVQKKSSGGIFKAFSMLSAHVIVVVLVFGPLIFFYIFPFPTSHLD
KFLAIFDAVITPVLNPVIYTFRNKEMMVAMRRRCSQFVNYSKIF (SEQ ID NO: 213)

50

ATGGATGAAGCCAATCACTCTGTGGTCTCTGAGTTTGTGTTCCTGGGACTCTCTGACTCGC
GGAAGATCCAGCTCCTCCTCTTCCTCTTTTTCTCAGTGTTCTATGTATCAAGCCTGATGGGA
AATCTCCTCATTGTGCTAACTGTGACCTCTGACCCTCGTTTACAGTCCCCCATGTACTTCCT
GCTGGCCAACCTTTCCATCATCAATTTGGTATTTTGTTCCTCCACAGCTCCCAAGATGATTT
55 ATGACCTTTTTCAGGAAGCACAAGACCATCTCTTTTGGGGGCTGTGTAGTTCAGATCTTCTT
TATCCATGCAGTTGGGGGAACTGAGATGGTGCTGCTCATAGCCATGGCTTTTGACCGATAT

```
GTGGCCATATGTAAGCCTCTCCACTACCTGACCATCATGAACCCACAAAGGTGCATTTTGT
TTTTAGTCATTTCCTGGATTATAGGTATTATTCACTCAGTGATTCAGTTGGCTTTTGTTGTA
GACCTGCTGTTCTGTGGCCCTAATGAATTAGATAGTTTCTTTTGTGATCTTCCTCGATTTAT
CAAACTGGCTTGCATAGAGACCTACACATTGGGATTCATGGTTACTGCCAATAGTGGATTT
```
5
```
ATTTCTCTGGCTTCTTTTTTAATTCTCATAATCTCTTACATCTTTATTTTGGTGACTGTTCAG
AAAAAATCTTCAGGTGGTATATTCAAGGCTTTCTCTATGCTGTCAGCTCATGTCATTGTGG
TGGTTTTGGTCTTTGGGCCATTAATCTTTTTCTATATTTTTCCATTTCCCACATCACATCTTG
ATAAATTCCTTGCCATCTTTGATGCAGTTATCACTCCCGTTTTGAATCCAGTCATCTATACT
TTTAGAAATAAAGAGATGATGGTGGCAATGAGAAGACGATGCTCTCAGTTTGTGAATTAC
```
10
```
AGTAAAATCTTTTAA (SEQ ID NO: 214)
```

AOLFR117 sequences:

```
MNNTIVFVIKIQIEKSDLKYRAISLQEISKISLLFWVLLLVISRLLLAMTLGNSTEVTEFYLLGFGA
QHEFWCILFIVFLLIYVTSIMGNSGIILLINTDSRFQTLTYFFLQHLAFVDICYTSAITPKMLQSFT
```
15
```
EEKNLILFQGCVIQFLVYATFATSDCYLLAMMAVDPYVAICKPLHYTVIMSRTVCIRLVAGSYI
MGSINASVQTGFTCSLSFCKSNSINHFFCDVPPILALSCSNVDINIMLLVVFVGSNLIFTGLVVIFS
YIYIMATILKMSSSAGRKKSFSTCASHLTAVTIFYGTLSYMYLQSHSNNSQENMKVAFIFYGTVI
PMLNPLIYSLRNKEVKEALKVIGKKLF (SEQ ID NO: 215)
```

20
```
ATGAATAACACTATTGTATTTGTCATAAAAATACAAATAGAAAAAAGTGACTTGAAATATA
GAGCCATTTCATTGCAAGAAATCTCAAAGATTTCCCTTCTTTTCTGGGTCCTTCTCTTGGTC
ATTTCTAGACTTTTACTAGCCATGACACTAGGAAACAGCACTGAAGTCACTGAATTCTATC
TTCTGGGATTTGGTGCCCAGCATGAGTTTTGGTGTATCCTCTTCATTGTATTCCTTCTCATC
TATGTGACCTCCATAATGGGTAATAGTGGAATAATCTTACTCATCAACACAGATTCCAGAT
```
25
```
TTCAAACACTCACGTACTTTTTTCTACAACATTTGGCTTTTGTTGATATCTGTTACACTTCT
GCTATCACTCCCAAGATGCTCCAAAGCTTCACAGAAGAAAAGAATTTGATATTATTTCAGG
GCTGTGTGATACAATTCTTAGTTTATGCAACATTTGCAACCAGTGACTGTTATCTCCTGGCT
ATGATGGCAGTGGATCCTTATGTTGCCATCTGTAAGCCCCTTCACTATACTGTAATCATGT
CCCGAACAGTCTGCATCCGTTTGGTAGCTGGTTCATACATCATGGGCTCAATAAATGCCTC
```
30
```
TGTACAAACAGGTTTTACATGTTCACTGTCCTTCTGCAAGTCCAATAGCATCAATCACTTTT
TCTGTGATGTTCCCCCTATTCTTGCTCTTTCATGCTCCAATGTTGACATCAACATCATGCTA
CTTGTTGTCTTTGTGGGATCTAACTTGATATTCACTGGGTTGGTCGTCATCTTTTCCTACAT
CTACATCATGGCCACCATCCTGAAAATGTCTTCTAGTGCAGGAAGGAAAAAATCCTTCTCA
ACATGTGCTTCCCACCTGACCGCAGTCACCATTTTCTATGGGACACTCTCTTACATGTATTT
```
35
```
GCAGTCTCATTCTAATAATTCCCAGGAAAAATATGAAAGTGGCCTTTATATTTTATGGCACA
GTTATTCCCATGTTAAATCCTTTAATCTATAGCTTGAGAAATAAGGAAGTAAAAGAAGCTT
TAAAAGTGATAGGGAAAAAGTTATTTTAA (SEQ ID NO: 216)
```

AOLFR118 sequences:

40
```
MNHMSASLKISNSSKFQVSEFILLGFPGIHSWQHWLSLPLALLYLSALAANTLILIIIWQNPSLQQ
PMYIFLGILCMVDMGLATTIIPKILAIFWFDAKVISLPECFAQIYAIHFFVGMESGILLCMAFDRY
VAICHPLRYPSIVTSSLILKATLFMVLRNGLFVTPVPVLAAQRDYCSKNEIEHCLCSNLGVTSLA
CDDRRPNSICQLVLAWLGMGSDLSLIILSYILILYSVLRLNSAEAAAKALSTCSSHLTLILFFYTIV
VVISVTHLTEMKATLIPVLLNVLHNIIPPSLNPTVYALQTKELRAAFQKVLFALTKEIRS (SEQ ID
```
45
```
NO: 217)
```

```
ATGAATCATATGTCTGCATCTCTCAAAATCTCCAATAGCTCCAAATTCCAGGTCTCTGAGTT
CATCCTGCTGGGATTCCCGGGCATTCACAGCTGGCAACACTGGCTATCTCTGCCCCTGGCA
CTACTGTATCTCTCAGCACTTGCTGCAAACACCCTCATCCTCATCATCATCTGGCAGAACCC
```
50
```
TTCTTTACAGCAGCCCATGTATATTTTCCTTGGCATCCTCTGTATGGTAGACATGGGTCTGG
CCACTACTATCATCCCTAAGATCCTGGCCATCTTCTGGTTTGATGCCAAGGTTATTAGCCTC
CCTGAGTGCTTTGCTCAGATTTATGCCATTCACTTCTTTGTGGGCATGGAGTCTGGTATCCT
ACTCTGCATGGCTTTTGATAGATATGTGGCTATTTGTCACCCTCTTCGCTATCCATCAATTG
TCACCAGTTCCTTAATCTTAAAAGCTACCCTGTTCATGGTGCTGAGAAATGGCTTATTTGTC
```
55
```
ACTCCAGTGCCTGTGCTTGCAGCACAGCGTGATTATTGCTCCAAGAATGAAATTGAACACT
GCCTGTGCTCTAACCTTGGGGTCACAAGCCTGGCTTGTGATGACAGGAGGCCAAACAGCAT
```

TTGCCAGTTGGTTCTGGCATGGCTTGGAATGGGGAGTGATCTAAGTCTTATTATACTGTCA
TATATTTTGATTCTGTACTCTGTACTTAGACTGAACTCAGCTGAAGCTGCAGCCAAGGCCC
TGAGCACTTGTAGTTCACATCTCACCCTCATCCTTTTCTTTTACACTATTGTTGTAGTGATT
TCAGTGACTCATCTGACAGAGATGAAGGCTACTTTGATTCCAGTTCTACTTAATGTGTTGC

5   ACAACATCATCCCCCCTTCCCTCAACCCTACAGTTTATGCACTTCAGACCAAAGAACTTAG
GGCAGCCTTCCAAAAGGTGCTGTTTGCCCTTACAAAGAAATAAGATCTTAG (SEQ ID NO:
218)

AOLFR119 sequences:

10   MPLFNSLCWFPTIHVTPPSFILNGIPGLERVHVWISLPLCTMYIIFLVGNLGLVYLIYYEESLHHP
MYFFFGHALSLIDLLTCTTTLPNALCIFWFSLKEINFNACLAQMFFVHGFTGVESGVLMLMALD
RYIAICYPLRYATTLTNPIIAKAELATFLRGVLLMIPFPFLVKRLPFCQSNIISHTYCDHMSVVKL
SCASIKVNVIYGLMVALLIGVFDICCISLSYTLILKAAISLSSSDARQKAFSTCTAHISAIIITYVPA
FFTFFAHRFGGHTIPPSLHIIVANLYLLLPPTLNPIVYGVKTKQIRKSVIKFFQGDKGAG (SEQ ID

15   NO: 219)

ATGCCTCTATTTAATTCATTATGCTGGTTTCCAACAATTCATGTGACTCCTCCATCTTTTAT
TCTTAATGGAATACCTGGTCTGGAAAGAGTACATGTATGGATCTCCCTCCCACTCTGCACA
ATGTACATCATCTTCCTTGTGGGGAATCTTGGTCTTGTGTACCTCATTTATTATGAGGAGTC

20   CTTACATCATCCGATGTATTTTTTTTTTGGCCATGCTCTCTCCCTCATTGACCTCCTTACCTG
CACCACCACTCTACCCAATGCACTCTGCATCTTCTGGTTCAGTCTCAAAGAAATTAACTTCA
ATGCTTGCTTGGCCCAGATGTTCTTTGTTCATGGGTTCACAGGTGTGGAGTCTGGGGTGCT
CATGCTCATGGCTCTAGACCGCTATATAGCCATTTGCTACCCTTTGCGTTATGCTACCACAC
TCACCAACCCTATCATTGCCAAGGCTGAGCTTGCCACCTTCCTGAGGGGTGTATTGCTGAT

25   GATTCCTTTCCCATTCTTGGTTAAGCGTTTGCCTTTCTGCCAAAGCAATATTATCTCCCATA
CGTACTGCGACCACATGTCTGTAGTAAAGCTATCTTGTGCCAGCATCAAGGTCAATGTAAT
CTATGGTCTAATGGTTGCTCTCCTGATTGGAGTGTTTGACATTTGTTGTATATCTTTGTCTT
ACACTTTGATCCTCAAGGCAGCGATCAGCCTCTCTTCATCAGATGCTCGGCAGAAGGCTTT
CAGCACCTGCACTGCCCATATATCTGCCATCATCATCACCTATGTTCCAGCATTCTTCACTT

30   TCTTTGCCCACCGTTTTGGGGGACACACAATTCCCCCTTCTCTTCACATCATTGTGGCTAAT
CTTTATCTTCTTCTTCCCCCAACTCTAAACCCTATTGTTTATGGAGTAAAGACAAAACAGAT
ACGCAAGAGTGTCATAAAGTTCTTCCAGGGTGATAAGGGTGCAGGTTGA (SEQ ID NO: 220)

AOLFR120 sequences:

35   MQPYTKNWTQVTEFVMMGFAGIHEAHLLFFILFLTMYLFTLVENLAIILVVGLDHRLRRPMYF
FLTHLSCLEIWYTSVTVPKMLAGFIGVDGGKNISYAGCLSQLFIFTFLGATECFLLAAMAYDRY
VAICMPLHYGAFVSWGTCIRLAAACWLVGFLTPILPIYLLSQLTFCGPNVIDHFSCDASPLLALS
CSDVTWKETVDFLVSLAVLLASSMVIAVSYGNIVWTLLHIRSAAERWKAFSTCAAHLTVVSLF
YGTLFFMYVQTKVTSSINFNKVVSVFYSVVTPMLNPLIYSLRNKEVKGALGRVFSLNFWKGQ

40   (SEQ ID NO: 221)

ATGCAACCATATACCAAAAACTGGACCCAGGTAACTGAATTTGTCATGATGGGCTTTGCTG
GCATCCATGAAGCACACCTCCTCTTCTTCATACTCTTCCTCACCATGTACCTGTTCACCTTG
GTGGAGAATTTGGCCATCATTTTAGTGGTGGGTTTGGACCACCGACTACGGAGACCCATGT

45   ATTTCTTCCTGACACACTTGTCCTGCCTTGAAATCTGGTACACTTCTGTTACAGTGCCCAAG
ATGCTGGCTGGTTTTATTGGGGTGGATGGTGGCAAGAATATCTCTTATGCTGGTTGCCTAT
CCCAGCTCTTCATCTTCACCTTTCTTGGGGCAACTGAGTGTTTCCTACTGGCTGCCATGGCC
TATGATCGTTATGTGGCCATTTGTATGCCTCTCCACTATGGGGCTTTTGTGTCCTGGGGCAC
CTGCATCCGTCTGGCAGCTGCCTGTTGGCTGGTAGGTTTCCTCACACCCATCTTGCCAATCT

50   ACCTCTTGTCTCAGCTAACATTTTGTGGCCCAAATGTCATTGACCATTTCTCCTGTGATGCC
TCACCCTTGCTAGCCTTGTCGTGCTCAGATGTCACTTGGAAGGAGACTGTGGATTTCCTGG
TGTCTCTGGCTGTGCTACTGGCCTCCTCTATGGTCATTGCTGTGTCCTATGGCAACATCGTC
TGGACACTGCTGCACATCCGCTCAGCTGCTGAGCGCTGGAAGGCCTTCTCTACCTGTGCAG
CTCACCTGACTGTGGTGAGCCTCTTCTATGGCACTCTTTTCTTTATGTATGTCCAGACCAAG

55   GTGACCTCCTCCATCAACTTCAACAAGGTGGTATCTGTCTTCTACTCTGTTGTCACGCCCAT

GCTCAATCCTCTCATCTACAGTCTTAGGAACAAGGAAGTGAAGGGAGCTCTGGGTCGAGTC
TTTTCTCTCAACTTTTGGAAGGGACAGTGA (SEQ ID NO: 222)

AOLFR121 sequences:

MKRKNFTEVSEFIFLGFSSFGKHQITLFVVFLTVYILTLVANIIIVTIICIDHHLHTPMYFFLSMLA
SSETVYTLVIVPRMLLSLIFHNQPISLAGCATQMFFFVILATNNCFLLTAMGYDRYVAICRPLRY
TVIMSKGLCAQLVCGSFGIGLTMAVLHVTAMFNLPFCGTVVDHFFCDIYPVMKLSCIDTTINEII
NYGVSSFVIFVPIGLIFISYVLVISSILQIASAEGRKKTFATCVSHLTVVIVHCGCASIAYLKPKSES
SIEKDLVLSVTYTIITPLLNPVVYSLRNKEVKDALCRVVGRNIS (SEQ ID NO: 223)

ATGAAGAGAAAGAACTTCACAGAAGTGTCAGAATTCATTTTCTTGGGATTTTCTAGCTTTG
GAAAGCATCAGATAACCCTCTTTGTGGTTTTCCTAACTGTCTACATTTTAACTCTGGTTGCT
AACATCATCATTGTGACTATCATCTGCATTGACCATCATCTCCACACTCCCATGTATTTCTT
CCTAAGCATGCTGGCTAGTTCAGAGACGGTGTACACACTGGTCATTGTGCCACGAATGCTT
TTGAGCCTCATTTTTCATAACCAACCTATCTCCTTGGCAGGCTGTGCTACACAAATGTTCTT
TTTTGTTATCTTGGCCACTAATAATTGCTTCCTGCTTACTGCAATGGGGTATGACCGCTATG
TGGCCATCTGCAGACCCCTGAGATACACTGTCATCATGAGCAAGGGACTATGTGCCCAGCT
GGTGTGTGGGTCCTTTGGCATTGGTCTGACTATGGCAGTTCTCCATGTGACAGCCATGTTC
AATTTGCCGTTCTGTGGCACAGTGGTAGACCACTTCTTTTGTGACATTTACCCAGTCATGA
AACTTTCTTGCATTGATACCACTATCAATGAGATAATAAATTATGGTGTAAGTTCATTTGT
GATTTTTGTGCCCATAGGCCTGATATTTATCTCCTATGTCCTTGTCATCTCTTCCATCCTTC
AAATTGCCTCAGCTGAGGGCCGGAAGAAGACCTTTGCCACCTGTGTCTCCCACCTCACTGT
GGTTATTGTCCACTGTGGCTGTGCCTCCATTGCCTACCTCAAGCCGAAGTCAGAAAGTTCA
ATAGAAAAAGACCTTGTTCTCTCAGTGACGTACACCATCATCACTCCCTTGCTGAACCCTG
TTGTTTACAGTCTGAGAAACAAGGAGGTAAAGGATGCCCTATGCAGAGTTGTGGGCAGAA
ATATTTCTTAA (SEQ ID NO: 224)

AOLFR122 sequences:

MEWENQTILVEFFLKGHSVHPRLELLFFVLIFIMYVVILLGNGTLILISILDPHLHTPMYFFLGNL
SFLDICYTTTSIPSTLVSFLSERKTISFSGCAVQMFLGLAMGTTECVLLGMMAFDRYVAICNPLR
YPIIMSKNAYVPMAVGSWFAGIVNSAVQTTFVVQLPFCRKNVINHFSCEILAVMKLACADISGN
EFLMLVATILFTLMPLLLIVISYSLIISSILKIHSSEGRSKAFSTCSAHLTVVIIFYGTILFMYMKPKS
KETLNSDDLDATDKIISMFYGVMTPMMNPLIYSLRNKDVKEAVKHLPNRRFFSK (SEQ ID NO:
225)

ATGGAATGGGAAAACCAAACCATTCTGGTGGAATTTTTTCTGAAGGGACATTCTGTTCACC
CAAGGCTTGAGTTACTCTTTTTTGTGCTAATCTTCATAATGTATGTGGTCATCCTTCTGGGG
AATGGTACTCTCATTTTAATCAGCATCTTGGACCCTCACCTTCACACCCCTATGTACTTCTT
TCTGGGGAACCTCTCCTTCTTGGACATCTGCTACACCACCACCTCTATTCCCTCCACACTAG
TGAGCTTCCTTTCAGAAAGAAAGACCATTTCCTTTTCTGGCTGTGCAGTGCAGATGTTCCTT
GGCTTGGCCATGGGGACAACAGAGTGTGTGCTTCTGGGCATGATGGCCTTTGACCGCTATG
TGGCTATCTGCAACCCTCTGAGATATCCCATCATCATGAGCAAGAATGCCTATGTACCCAT
GGCTGTTGGGTCCTGGTTTGCAGGGATTGTCAACTCTGCAGTACAAACTACATTTGTAGTA
CAATTGCCTTTCTGCAGGAAGAATGTCATCAATCATTTCTCATGTGAAATTCTAGCTGTCAT
GAAGTTGGCCTGTGCTGACATCTCAGGCAATGAGTTCCTCATGCTTGTGGCCACAATATTG
TTCACATTGATGCCACTGCTCTTGATAGTTATCTCTTACTCATTAATCATTTCCAGCATCCT
CAAGATTCACTCCTCTGAGGGGGAGAAGCAAAGCTTTCTCTACCTGCTCAGCCCATCTGACT
GTGGTCATAATATTCTATGGGACCATCCTCTTCATGTATATGAAGCCCAAGTCTAAAGAGA
CACTTAATTCAGATGACTTGGATGCTACCGACAAAATTATATCCATGTTCTATGGGGTGAT
GACTCCCATGATGAATCCTTTAATCTACAGTCTTAGAAACAAGGATGTGAAAGAGGCAGT
AAAACACCTACCGAACAGAAGGTTCTTTAGCAAGTGA (SEQ ID NO: 226)

AOLFR123 sequences:

MYRFTDFDVSNISIYLNHVLFYTTQQAGDLEHMETRNYSAMTEFFLVGLSQYPELQLFLFLLCL
IMYMIILLGNSLLIIITILDSRLHTPMYFFLGNLSFLDICYTSSSIPPMLIIFMSERKSISFIGCALQM
VVSLGLGSTECVLLAVMAYDHYVAICNPLRYSIIMNGVLYVQMAAWSWIIGCLTSLLQTVLT

MMLPFCGNNVIDHITCEILALLKLVCSDITINVLIMTVTNIVSLVILLLLIFISYVFILSSILRINCAE
GRKKAFSTCSAHSIVVILFYGSALFMYMKPKSKNTNTSDEIIGLSYGVVSPMLNPIIYSLRNKEV
KEAVKKVLSRHLHLLKM (SEQ ID NO: 227)

5   ATGTACAGATTTACAGATTTTGATGTATCAAACATTTCAATTTACCTGAATCATGTCCTTTT
    CTATACTACCCAGCAGGCAGGTGACCTAGAACACATGGAGACAAGAAATTACTCTGCCAT
    GACTGAATTCTTTCTGGTGGGGCTTTCCCAATATCCAGAGCTCCAGCTTTTTCTGTTCCTGC
    TCTGCCTCATCATGTACATGATAATCCTCCTGGGAAATAGCCTCCTCATTATCATCACCATC
    TTGGATTCTCGCCTCCATACTCCCATGTATTTCTTTCTTGGAAACCTCTCATTCTTGGACAT
10 CTGTTACACATCCTCATCCATTCCTCCAATGCTTATTATATTTATGTCTGAGAGAAAATCCA
    TCTCCTTCATTGGCTGTGCTCTGCAGATGGTTGTGTCCCTTGGCTTGGGCTCCACTGAGTGT
    GTCCTCCTGGCTGTGATGGCCTATGACCACTATGTGGCCATCTGCAACCCACTGAGGTACT
    CCATCATCATGAACGGAGTGCTGTATGTGCAAATGGCTGCATGGTCCTGGATCATAGGCTG
    TCTGACCTCCCTATTGCAAACAGTTCTGACAATGATGTTGCCTTTCTGTGGGAATAATGTC
15 ATTGATCATATTACCTGTGAAATTTTGGCCCTTCTAAAACTTGTTTGTTCAGATATCACCAT
    CAATGTGCTTATCATGACAGTGACAAATATTGTTTCACTGGTGATTCTTCTACTGTTAATTT
    TCATCTCCTATGTGTTTATTCTCTCTTCCATCCTGAGAATTAATTGTGCTGAGGGAAGAAAG
    AAAGCCTTCTCTACCTGTTCAGCGCACTCGATTGTGGTCATCTTATTCTACGGTTCAGCCCT
    TTTTATGTACATGAAACCCAAGTCAAAGAACACTAATACATCTGATGAGATTATTGGGCTG
20 TCTTATGGAGTGGTAAGCCCAATGTTAAATCCCATCATCTATAGCCTCAGGAATAAAGAGG
    TCAAAGAGGCTGTAAAGAAAGTCCTGAGCAGACATCTGCATTTATTGAAAATGTGA (SEQ
    ID NO: 228)

    AOLFR124 sequences:
25 MNHSVVTEFIILGLTKKPELQGIIFLFFLIVYLVAFLGNMLIIIAKIYNNTLHTPMYVFLLTLAVV
    DIICTTSIIPKMLGTMLTSENTISYAGCMSQLFLFTWSLGAEMVLFTTMAYDRYVAICFPLHYST
    VMNHHMCVALLSMVMAIAVTNSWVHTALIMRLTFCGPNTIDHFFCEIPPLLALSCSPVRINEV
    MVYVADITLAIGDFILTCISYGFIIVAILRIRTVEGKRKAFSTCSSHLTVVTLYYSPVIYTYIRPASS
    YTFERDKVVAALYTLVTPTLNPMVYSFQNREMQAGIRKVFAFLKH (SEQ ID NO: 229)

30
    ATGAATCACAGCGTTGTAACTGAGTTCATTATTCTGGGCCTCACCAAAAAGCCTGAACTCC
    AGGGAATTATCTTCCTCTTTTTTCTCATTGTCTATCTTGTGGCTTTTCTCGGCAACATGCTC
    ATCATCATTGCCAAAATCTATAACAACACCTTGCATACGCCCATGTATGTTTTCCTTCTGAC
    ACTGGCTGTTGTGGACATCATCTGCACAACAAGCATCATACCGAAGATGCTGGGGACCAT
35 GCTAACATCAGAAAATACCATTTCATATGCAGGCTGCATGTCCCAGCTCTTCTTGTTCACA
    TGGTCTCTGGGAGCTGAGATGGTTCTCTTCACCACCATGGCCTATGACCGCTATGTGGCCA
    TTTGTTTCCCTCTTCATTACAGTACTGTTATGAACCACCATATGTGTGTAGCCTTGCTCAGC
    ATGGTCATGGCTATTGCAGTCACCAATTCCTGGGTGCACACAGCTCTTATCATGAGGTTGA
    CTTTCTGTGGGCCAAACACCATTGACCACTTCTTCTGTGAGATACCCCCATTGCTGGCTTTG
40 TCCTGTAGCCCTGTAAGAATCAATGAGGTGATGGTGTATGTTGCTGATATTACCCTGGCCA
    TAGGGGACTTTATTCTTACCTGCATCTCCTATGGTTTTATCATTGTTGCTATTCTCCGTATC
    CGCACAGTAGAAGGCAAGAGGAAGGCCTTCTCAACATGCTCATCTCATCTCACAGTGGTG
    ACCCTTTACTATTCTCCTGTAATCTACACCTATATCCGCCCTGCTTCCAGCTATACATTTGA
    AAGAGACAAGGTGGTAGCTGCACTCTATACTCTTGTGACTCCCACATTAAACCCGATGGTG
45 TACAGCTTCCAGAATAGGGAGATGCAGGCAGGAATTAGGAAGGTGTTTGCATTTCTGAAA
    CACTAG (SEQ ID NO: 230)

    AOLFR125 sequences:
    MTNQTQMMEFLLVRFTENWVLLRLHALLFSLIYLTAVLMNLVIILLMILDHRLHMAMYFFLRH
50 LSFLDLCLISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHC
    EAVMSRGLCVQLMALSWLNRGALGLLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAI
    ISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTVFLVTGAVAYL
    KPGSDAPSILDLLVSVFYSVAPPTLNPVIYCLKNKDIKSALSKVLWNVRSSGVMKDD (SEQ ID
    NO: 231)
55

ATGACCAATCAGACACAGATGATGGAATTCTTGCTTGTGAGATTTACTGAGAATTGGGTGC
TCCTGAGGCTGCATGCTTTGCTCTTCTCACTGATCTACCTCACGGCTGTGCTGATGAATTTA
GTCATCATTCTCCTCATGATTCTGGACCATCGTCTCCACATGGCAATGTACTTTTTCCTCCG
ACATTTGTCCTTCTTAGACCTGTGTCTCATTTCTGCCACAGTCCCCAAATCCATCCTCAACT
5   CTGTCGCCTCCACTGACTCCATCTCCTTCCTGGGGTGTGTGTTGCAGCTCTTCTTGGTGGTA
CTGCTGGCTGGATCAGAGATTGGCATCCTTACTGCCATGTCCTATGACCGCTATGCTGCCA
TCTGCTGCCCCCTACACTGTGAGGCTGTCATGAGCAGAGGGCTCTGTGTCCAGTTGATGGC
TCTGTCCTGGCTCAACAGAGGGGCCTTGGGACTCTTGTACACAGCTGGAACATTCTCTCTG
AATTTTTATGGCTCTGATGAGCTACATCAGTTCTTCTGCGATGTCCCTGCCCTACTAAAGCT
10   CACTTGTTCTAAAGAACATGCCATCATTAGTGTCAGTGTGGCCATTGGGGTCTGTTATGCA
TTTTCATGTTTAGTTTGCATTGTAGTTTCCTATGTGTACATTTTCTCTGCTGTGTTAAGGAT
ATCACAGAGACAGAGACAATCCAAAGCCTTTTCCAACTGTGTGCCTCACCTCATTGTTGTC
ACTGTGTTTCTTGTAACAGGTGCTGTTGCTTATTTAAAGCCAGGGTCTGATGCACCTTCTAT
TCTAGACTTGCTGGTGTCTGTGTTCTATTCTGTCGCACCTCCAACCTTGAACCCTGTTATCT
15   ACTGTCTGAAGAACAAGGACATTAAATCCGCTCTGAGTAAAGTCCTGTGGAATGTTAGAA
GCAGTGGGGTAATGAAAGATGACTAA (SEQ ID NO: 232)

AOLFR126 sequences:

MFLYLCFIFQRTCSEEMEEENATLLTEFVLTGFLHQPDCKIPLFLAFLVIYLITIMGNLGLIVLIW
20   KDPHLHIPMYLFLGSLAFVDASLSSTVTPKMLINFLAKSKMISLSECMVQFFSLVTTVTTECFLL
ATMAYDRYVAICKALLYPVIMTNELCIQLLVLSFIGGLLHALIHEAFSFRLTFCNSNIIQHFYCDII
PLLKISCTDSSINFLMVFIFAGSVQVFTIGTILISYTIILFTILEKKSIKGIRKAVSTCGAHLLSVSLY
YGPLTFKYLGSASPQADDQDMMESLFYTVIVPLLNPMIYSLRNKQVIASFTKMFKSNV (SEQ ID
NO: 233)

25

ATGTTCCTTTACCTTTGCTTCATTTTTCAGAGGACATGCAGTGAGGAGATGGAAGAGGAAA
ATGCAACATTGCTGACAGAGTTTGTTCTCACAGGATTTTTACATCAACCTGACTGTAAAAT
ACCGCTCTTCCTGGCATTCTTGGTAATATATCTCATCACCATCATGGGGAATCTTGGTCTAA
TTGTTCTCATCTGGAAAGACCCTCACCTTCATATCCCAATGTACTTATTCCTTGGGAGTTTA
30   GCCTTTGTGGATGCTTCGTTATCATCCACAGTGACTCCGAAGATGCTGATCAACTTCTTAG
CTAAGAGTAAGATGATATCTCTCTCTGAATGCATGGTACAATTTTTTTCCCTTGTAACCACT
GTAACCACAGAATGTTTTCTCTTGGCAACAATGGCATATGATCGCTATGTAGCCATTTGCA
AAGCTTTACTTTATCCAGTCATTATGACCAATGAACTATGCATTCAGCTATTAGTCTTGTCA
TTTATAGGTGGCCTTCTTCATGCTTTAATCCATGAAGCTTTTTCATTCAGATTAACCTTCTG
35   TAATTCCAACATAATACAACACTTTTACTGTGACATTATCCCATTGTTAAAGATTTCCTGTA
CTGATTCCTCTATTAACTTTCTAATGGTTTTTATTTTCGCAGGTTCTGTTCAAGTTTTTACCA
TTGGAACTATTCTTATATCTTATACAATTATCCTCTTTACAATCTTAGAAAAGAAGTCTATC
AAAGGGATACGAAAGCTGTCTCCACCTGTGGGGCTCATCTCTTATCTGTATCTTTATACT
ATGGCCCCCTCACCTTCAAATATCTGGGCTCTGCATCTCCGCAAGCAGATGACCAAGATAT
40   GATGGAGTCTCTATTTTACACTGTCATAGTTCCTTTATTAAATCCCATGATCTACAGCCTGA
GAAACAAGCAAGTAATAGCTTCATTCACAAAAATGTTCAAAGCAATGTTTAG (SEQ ID
NO: 234)

AOLFR127 sequences:

45   MSNEDMEQDNTTLLTEFVLTGLTYQPEWKMPLFLVFLVIYLITIVWNLGLIALIWNDPQLHIPM
YFFLGSLAFVDAWISSTVTPKMLVNFLAKNRMISLSECMIQFFSFAFGGTTECFLLATMAYDRY
VAICKPLLYPVIMNNSLCIRLLAFSFLGGFLHALIHEVLIFRLTFCNSNIIHHFYCDIIPLFMISCTD
PSINFLMVFILSGSIQVFTIVTVLNSYTFALFTILKKKSVRGVRKAFSTCGAHLLSVSLYYGPLIF
MYLRPASPQADDQDMIDSVFYTIIIPLLNPIIYSLRNKQVIDSFTKMVKRNV (SEQ ID NO: 235)

50

ATGTCGAATGAGGACATGGAACAGGATAATACAACATTGCTGACAGAGTTTGTTCTCACA
GGACTTACATATCAGCCAGAGTGGAAAATGCCCCTGTTCTTGGTGTTCTTGGTGATCTATC
TCATCACTATTGTGTGGAACCTTGGTCTGATTGCTCTTATCTGGAATGACCCACAACTTCAC
ATCCCCATGTACTTTTTTCTTGGGAGTTTAGCCTTTGTTGATGCTTGGATATCTTCCACAGT
55   AACTCCCAAAATGTTGGTTAATTTCTTGGCCAAAAACAGGATGATATCTCTGTCTGAATGC
ATGATTCAATTTTTTTCCTTTGCATTTGGTGGAACTACAGAATGTTTTCTCTTGGCAACAAT

GGCATATGATCGCTATGTAGCCATATGCAAACCTTTACTATATCCAGTGATTATGAACAAT
TCACTATGCATACGGCTGTTAGCCTTCTCATTTTTAGGTGGCTTCCTCCATGCCTTAATTCA
TGAAGTCCTTATATTCAGATTAACCTTCTGCAATTCTAACATAATACATCATTTTTACTGTG
ATATTATACCACTGTTTATGATTTCCTGTACTGACCCTTCTATTAATTTTCTAATGGTTTTTA

5   TTTTGTCTGGCTCAATTCAGGTATTCACCATTGTGACAGTTCTTAATTCTTACACATTTGCT
CTTTTCACAATCCTAAAAAAGAAGTCTGTTAGAGGCGTAAGGAAAGCCTTTTCCACCTGTG
GAGCCCATCTCTTATCGTCTCTTTATATTATGGCCCACTTATCTTCATGTATTTGCGCCCT
GCATCTCCACAAGCAGATGACCAAGATATGATAGACTCTGTCTTTTATACAATCATAATTC
CTTTGCTAAATCCCATTATCTACAGTCTGAGAAATAAACAAGTAATAGATTCATTCACAAA

10   AATGGTAAAAGAAATGTTTAG (SEQ ID NO: 236)

AOLFR128 sequences:

METQNLTVVTEFILLGLTQSQDAQLLVFVLVLIFYLIILPGNFLIIFTIKSDPGLTAPLYFFLGNLA
LLLDASYSFIVVPRMLVDFLSEKKVISYRSCITQLFFLHFLGAGEMFLLVVMAFDRYIAICRPLHY

15   STIMNPRACYALSLVLWLGGFIHSIVQVALILHLPFCGPNQLDNFFCDVPQVIKLACTNTFVVEL
LMVSNSGLLSLLCFLGLLASYAVILCRIREHSSEGKSKAISTCTTHIIIIFLMFGPAIFIYTCPFQAFP
ADKVVSLFHTVIFPLMNPVIYTLRNQEVKASMRKLLSQHMFC (SEQ ID NO: 237)

ATGGAAACACAGAACCTCACAGTGGTGACAGAATTCATTCTTCTTGGTCTGACCCAGTCTC

20   AAGATGCTCAACTTCTGGTCTTTGTGCTAGTCTTAATTTTCTACCTTATCATCCTCCCTGGA
AATTTCCTCATCATTTTCACCATAAAGTCAGACCCTGGGCTCACAGCCCCCCTCTATTTCTT
TCTGGGCAACTTGGCCTTACTGGATGCATCCTACTCCTTCATTGTGGTTCCCAGGATGTTG
GTGGACTTCCTCTCTGAGAAGAAGGTAATCTCCTATAGAAGCTGCATCACTCAGCTCTTTT
TCTTGCATTTTCTTGGAGCGGGAGAGATGTTCCTCCTCGTTGTGATGGCCTTTGACCGCTAC

25   ATCGCCATCTGCCGGCCTTTACACTATTCAACCATCATGAACCCTAGAGCCTGCTATGCAT
TATCGTTGGTTCTGTGGCTTGGGGGCTTTATCCATTCCATTGTACAAGTAGCCCTTATCCTG
CACTTGCCTTTCTGTGGCCCAAACCAGCTCGATAACTTCTTCTGTGATGTTCCACAGGTCAT
CAAGCTGGCCTGCACCAATACCTTTGTGGTGGAGCTTCTGATGGTCTCCAACAGTGGCCTG
CTCAGCCTCCTGTGCTTCCTGGGCCTTCTGGCCTCCTATGCAGTCATCCTCTGTCGTATAAG

30   GGAGCACTCCTCTGAAGGAAAGAGCAAGGCTATTTCCACATGCACCACCCATATTATCATT
ATATTTCTCATGTTTGGACCTGCTATTTTCATCTACACTTGCCCCTTCCAGGCTTTCCCAGC
TGACAAGGTAGTTTCTCTTTTCCATACTGTCATCTTTCCTTTGATGAACCCTGTTATTTATA
CGCTTCGCAACCAGGAGGTGAAAGCTTCCATGAGGAAGTTGTTAAGTCAACATATGTTTTG
CTGA (SEQ ID NO: 238)

35

AOLFR129 sequences:

MALYFSLILHGMSDLFFLSTGHPRASCRMEAMKLLNQSQVSEFILLGLTSSQDVEFLLFALFSVI
YVVTVLGNLLIIVTVFNTPNLNTPMYFLLGNLSFVDMTLASFATPKVILNLLKKQKVISFAGCFT
QIFLLHLLGGVEMVLLVSMAFDRYVAICKPLHYMTIMNKKVCVLLVVTSWLLGLLHSGFQIPF

40   AVNLPFCGPNVVDSIFCDLPLVTKLACIDIYFVQVVIVANSGIISLSCFIILLISYSLILITIKNHSPT
GQSKARSTLTAHITVVILFFGPCIFIYIWPFGNHSVDKFLAVFYTIITPILNPIIYTLRNKEMKISMK
KLWRAFVNSREDT (SEQ ID NO: 239)

ATGGCTCTTTATTTTTCACTCATACTCCATGGTATGAGTGATCTTTTCTTTCTCTCTACAGG

45   TCATCCAAGAGCGAGCTGTAGGATGGAGGCCATGAAACTATTAAATCAATCTCAAGTGTC
AGAATTCATTTTGCTGGGACTGACCAGCTCCCAGGATGTAGAGTTTCTTCTCTTTGCCCTCT
TCTCGGTTATCTATGTGGTCACAGTTTTGGGTAACCTTCTTATTATAGTCACAGTGTTTAAC
ACCCCTAACCTGAATACTCCCATGTATTTTCTCCTTGGTAATCTCTCTTTTGTAGATATGAC
CCTTGCTTCTTTTGCCACCCCTAAGGTGATTCTGAACTTGTTAAAAAAGCAGAAGGTAATT

50   TCTTTTGCTGGGTGCTTCACTCAGATATTTCTCCTTCACTTACTGGGTGGGGTTGAAATGGT
ACTGTTGGTCTCCATGGCTTTTGACAGATATGTGGCCATTTGTAAGCCCCTACACTACATG
ACCATCATGAACAAGAAGGTATGTGTTTTGCTTGTAGTGACCTCATGGCTCTTGGGTCTCC
TTCACTCAGGGTTTCAGATACCATTTGCTGTGAACTTGCCCTTTTGTGGTCCCAATGTGGTA
GACAGCATTTTTTGTGACCTCCCTTTGGTTACTAAGCTTGCCTGTATAGACATATATTTTGT

55   ACAGGTAGTCATTGTTGCCAACAGTGGCATAATCTCCCTGAGCTGTTTCATTATTTTGCTTA
TCTCCTACAGTCTGATCCTCATAACCATTAAGAACCACTCTCCTACTGGGCAATCTAAAGC

CCGTTCCACTTTGACTGCTCACATCACAGTGGTGATTCTCTTCTTTGGCCCATGCATCTTTA
TCTACATTTGGCCCTTCGGCAACCACTCTGTAGATAAGTTCCTTGCTGTGTTTTATACCATC
ATCACTCCTATCTTGAATCCAATTATCTATACTCTGAGAAACAAAGAAATGAAGATATCCA
TGAAAAAACTCTGGAGAGCTTTTGTGAATTCTAGAGAAGATACTTAG (SEQ ID NO: 240)

5

AOLFR131 sequences:

MASTSNVTELIFTGLFQDPAVQSVCFVVFLPVYLATVVGNGLIVLTVSISKSLDSPMYFFLSCLS
LVEISYSSTIAPKFIIDLLAKIKTISLEGCLTQIFFFHFFGVAEILLIVVMAYDCYVAICKPLHYMNI
ISRQLCHLLVAGSWLGGFCHSIIQILVIIQLPFCGPNVIDHYFCDLQPLFKLACTDTFMEGVIVLA
10   NSGLFSVFSFLILVSSYIVILVNLRNHSAEGRHKALSTCASHITVVILFFGPAIFLYMRPSSTFTED
KLVAVFYTVITPMLNPIIYTLRNAEVKIAIRRLWSKKENPGRE (SEQ ID NO: 241)

ATGGCCAGTACAAGTAATGTGACTGAGTTGATTTTCACTGGCCTTTTCCAGGATCCAGCTG
TGCAGAGTGTATGCTTTGTGGTGTTTCTCCCCGTGTACCTTGCCACGGTGGTGGGCAATGG
15   CCTCATCGTTCTGACGGTCAGTATCAGCAAGAGTCTGGATTCTCCCATGTACTTCTTCCTTA
GCTGCCTGTCCTTGGTGGAGATCAGTTATTCCTCCACTATCGCCCCTAAATTCATCATAGAC
TTACTTGCCAAGATTAAAACCATCTCTCTGGAAGGCTGTCTGACTCAGATATTCTTCTTCCA
CTTCTTTGGGGTTGCTGAGATCCTTTTGATTGTGGTGATGGCCTATGATTGCTACGTGGCC
ATTTGCAAGCCTCTTCATTATATGAACATTATCAGTCGTCAACTGTGTCACCTTCTGGTGGC
20   TGGTTCCTGGCTGGGGGGCTTTTGTCACTCCATAATTCAGATTCTCGTTATCATCCAATTGC
CCTTCTGTGGTCCCAATGTGATTGACCACTATTTCTGTGACCTCCAGCCTTTATTCAAGCTT
GCCTGCACTGACACCTTCATGGAGGGGGTTATTGTGTTGGCCAACAGTGGATTATTCTCTG
TCTTCTCCTTCCTCATCTTGGTGTCCTCTTATATTGTCATTCTGGTCAACTTGAGGAACCAT
TCTGCAGAGGGGAGGCACAAAGCCCTCTCCACCTGTGCTTCTCACATCACAGTGGTCATCT
25   TGTTTTTTGGACCTGCTATCTTCCTCTACATGCGACCTTCTTCCACTTTCACTGAAGATAAA
CTTGTGGCTGTATTCTACACGGTCATCACCCCCATGCTGAACCCCATCATTTACACACTCAG
GAATGCAGAGGTGAAAATCGCCATAAGAAGATTGTGGAGCAAAAAGGAGAATCCAGGGA
GGGAGTGA (SEQ ID NO: 242)

30   **AOLFR132 sequences:**

MVATNNVTEIIFVGFSQNWSEQRVISVMFLLMYTAVVLGNGLIVVTILASKVLTSPMYFFLSYL
SFVEICYCSVMAPKLIFDSFIKRKVISLKGCLTQMFSLHFFGGTEAFLLMVMAYDRYVAICKPL
HYMAIMNQRMCGLLVRIAWGGGLLHSVGQTFLIFQLPFCGPNIMDHYFCDVHPVLELACADT
FFISLLIITNGGSISVVSFFVLMASYLIILHFLRSHNLEGQHKALSTCASHVTVVDLFFIPCSLVYIR
35   PCVTLPADKIVAVFYTVVTPLLNPVIYSFRNAEVKNAMRRFIGGKVI (SEQ ID NO: 243)

ATGGTTGCTACAAACAATGTGACTGAAATAATTTTCGTGGGATTTTCCCAGAATTGGAGTG
AGCAGAGGGTCATTTCTGTGATGTTTCTCCTCATGTACACAGCTGTTGTGCTGGGCAATGG
CCTCATTGTGGTGACCATCCTGGCCAGCAAAGTGCTCACCTCCCCCATGTATTTCTTTCTCA
40   GCTACTTATCCTTTGTGGAGATCTGCTACTGTTCTGTCATGGCCCCCAAGCTTATCTTTGAC
TCCTTTATCAAGAGGAAAGTCATTTCTCTCAAGGGCTGCCTCACACAGATGTTTTCCCTCC
ATTTCTTTGGTGGCACTGAGGCCTTTCTCCTGATGGTGATGGCCTATGACCGCTATGTGGC
CATCTGCAAGCCCTTGCACTACATGGCCATCATGAACCAGCGAATGTGTGGTCTCCTCGTG
AGGATAGCATGGGGCGGGGGCCTGCTGCATTCTGTTGGGCAAACCTTCCTGATTTTCCAGC
45   TCCCGTTCTGTGGCCCCAACATCATGGACCACTACTTCTGTGATGTCCACCCAGTGCTGGA
GCTGGCCTGCGCAGACACCTTCTTCATTAGCCTGCTGATCATCACCAATGGCGGCTCCATC
TCCGTAGTCAGTTTCTTCGTGCTGATGGCTTCCTACCTGATCATCCTGCACTTCCTGAGAAG
CCACAACTTGGAGGGGCAGCACAAGGCCCTCTCCACCTGTGCCTCTCATGTCACAGTTGTC
GACCTGTTCTTCATACCTTGCTCCTTGGTCTATATTAGGCCCTGTGTCACCCTCCCTGCAGA
50   CAAGATAGTTGCTGTATTTTATACAGTGGTCACACCTCTCTTAAACCCTGTGATTTACTCCT
TCAGGAATGCTGAAGTGAAAAATGCCATGAGGAGATTTATTGGGGGAAAAGTAATTTGA
(SEQ ID NO: 244)

AOLFR133 sequences:

55   MTEFIFLVLSPNQEVQRVCFVIFLFLYTAIVLGNFLIVLTVMTSRSLGSPMYFFLSYLSFMEICYS
SATAPKLISDLLAERKVISWWGCMAQLFFLHFFGGTEIFLLTVMAYDHYVAICKPLSYTTIMN

111

WQVCTVLVGIAWVGGFMHSFAQILLIFHLLFCGPNVINHYFCDLVPLLKLACSDTFLIGLLIVAN
GGTLSVISFGVLLASYMVILLHLRTWSSEGWCKALSTCGSHFAVVILFFGPCVFNSLRPSTTLPI
DKMVAVFYTVITAILNPVTYSLRNAEMRKAMKRLWIRTLRLNEK (SEQ ID NO: 245)

5   ATGACTGAATTCATTTTTCTGGTACTTTCTCCCAACCAGGAGGTGCAGAGGGTTTGCTTTG
     TGATATTTCTGTTCTTGTACACAGCAATTGTGCTGGGGAATTTCCTCATTGTGCTCACTGTC
     ATGACCAGCAGAAGCCTTGGTTCCCCCATGTACTTCTTCCTCAGCTACCTCTCCTTCATGGA
     GATCTGCTACTCCTCCGCTACAGCCCCCAAACTCATCTCAGATCTGCTGGCTGAAAGGAAA
     GTCATATCTTGGTGGGGCTGCATGGCACAGCTTTTCTTCTTGCACTTCTTTGGTGGCACTGA
10   GATTTTCCTGCTCACTGTGATGGCCTATGACCACTATGTGGCCATCTGCAAGCCCCTCAGC
     TACACCACCATCATGAACTGGCAGGTGTGTACTGTCCTTGTAGGAATAGCATGGGTGGGA
     GGCTTCATGCATTCCTTTGCACAAATCCTTCTCATCTTCCACCTGCTCTTCTGTGGCCCCAA
     TGTGATCAATCACTATTTCTGTGACCTAGTTCCCCTTCTCAAACTTGCCTGCTCTGACACCT
     TCCTCATTGGTCTGCTGATTGTTGCCAATGGAGGCACCCTGTCTGTGATCAGTTTTGGGGT
15   CCTCTTAGCATCCTATATGGTCATCTTGCTCCATCTGAGAACCTGGAGCTCTGAAGGGTGG
     TGCAAAGCCCTCTCCACCTGTGGGTCCCATTTCGCTGTGGTTATCTTGTTCTTTGGGCCCTG
     CGTCTTCAACTCTCTGAGGCCTTCTACCACTCTGCCCATAGACAAGATGGTGGCTGTGTTCT
     ACACAGTGATAACCGCGATCCTGAACCCTGTCATCTACTCTCTGAGAAATGCTGAAATGAG
     GAAGGCCATGAAGAGGCTGTGGATTAGGACATTGAGACTAAATGAGAAATAG (SEQ ID
20   NO: 246)

AOLFR134 sequences:

MTTIILEVDNHTVTTRFILLGFPTRPAFQLLFFSIFLATYLLTLLENLLIILAIHSDGQLHKPMYFFL
SHLSFLEMWYVTVISPKMLVDFLSHDKSISFNGCMTQLYFFVTFVCTEYILLAIMAFDRYVAIC
25   NPLRYPVIMTNQLCGTLAGGCWFCGLMTAMIKMVFIAQLHYCGMPQINHYFCDISPLLNVSCE
     DASQAEMVDFFLALMVIAIPLCVVVASYAAILATILRIPSAQGRQKAFSTCASHLTVVILFYSMT
     LFTYARPKLMYAYNSNKVVSVLYTVIVPLLNPIIYCLRNHEVKAALRKTIHCRGSGPQGNGAFS
     S (SEQ ID NO: 247)

30   ATGACCACCATAATTCTGGAAGTAGATAATCATACAGTGACAACACGTTTCATTCTTCTGG
     GGTTTCCAACACGACCAGCCTTCCAGCTTCTCTTTTTCTCCATTTTCCTGGCAACCTATCTG
     CTGACACTGCTGGAGAATCTTCTTATCATCTTAGCTATCCACAGTGATGGGCAGCTGCATA
     AGCCCATGTACTTCTTCTTGAGCCACCTCTCCTTCCTGGAGATGTGGTATGTCACAGTCATC
     AGCCCCAAGATGCTTGTTGACTTCCTCAGTCATGACAAGAGTATTTCCTTCAATGGCTGCA
35   TGACTCAACTTTACTTTTTTGTGACCTTTGTCTGCACTGAGTACATCCTTCTTGCTATCATG
     GCCTTTGACCGCTATGTAGCCATTTGTAATCCACTACGCTACCCAGTCATCATGACCAACC
     AGCTCTGTGGCACACTGGCTGGAGGATGCTGGTTCTGTGGACTCATGACTGCCATGATTAA
     GATGGTTTTTATAGCACAACTTCACTACTGTGGCATGCCTCAGATCAATCACTACTTTTGTG
     ATATCTCTCCACTCCTTAACGTCTCCTGTGAGGATGCCTCACAGGCTGAGATGGTGGACTT
40   CTTCTTGGCCCTCATGGTCATTGCTATTCCTCTTTGTGTTGTGGTGGCATCCTACGCTGCTA
     TCCTTGCCACCATCCTCAGGATCCCTTCTGCTCAGGGCCGCCAAAAGGCATTCTCCACCTG
     TGCCTCCCACCTGACCGTCGTAATTCTCTTCTATTCCATGACACTTTTCACCTATGCCCGTC
     CCAAACTCATGTATGCCTACAATTCCAACAAAGTGGTATCTGTTCTCTACACTGTCATTGTT
     CCACTCCTCAACCCCATCATTTACTGTCTGAGGAACCATGAAGTAAAGGCAGCCCTCAGAA
45   AGACCATACATTGCAGAGGAAGTGGGCCCCAGGGAAATGGGGCTTTCAGTAGTTAA (SEQ
     ID NO: 248)

AOLFR135 sequences:

MIFPSHDSQAFTSVDMEVGNCTILTEFILLGFSADSQWQPILFGVFLMLYLITLSGNMTLVILIRT
50   DSHLHTPMYFFIGNLSFLDFWYTSVYTPKILASCVSEDKRISLAGCGAQLFFSCVVAYTECYLL
     AAMAYDRHAAICNPLLYSGTMSTALCTGLVAGSYIGGFLNAIAHTANTFRLHFCGKNIIDHFFC
     DAPPLVKMSCTNTRVYEKVLLGVVGFTVLSSILAILISYVNILLAILRIHSASGRHKAFSTCASHL
     ISVMLFYGSLLFMYSRPSSTYSLERDKVAALFYTVINPLLNPLIYSLRNKDIKEAFRKATQTIQPQ
     T (SEQ ID NO: 249)

55

ATGATTTTCCCTTCTCATGATAGTCAGGCTTTCACCTCCGTGGACATGGAAGTGGGAAATT
GCACCATCCTGACTGAATTCATCTTGTTGGGTTTCTCAGCAGATTCCCAGTGGCAGCCGAT
TCTATTTGGAGTGTTTCTGATGCTCTATTTGATAACCTTGTCAGGAAACATGACCTTGGTTA
TCTTAATCCGAACTGATTCCCACTTGCATACACCTATGTACTTTTTCATTGGCAATCTGTCT

5   TTTTTGGATTTCTGGTATACCTCTGTGTATACCCCCAAAATCCTGGCCAGTTGTGTCTCAGA
AGATAAGCGCATTTCCTTGGCTGGATGTGGGGCTCAGCTGTTTTTTTCCTGTGTTGTAGCCT
ACACTGAATGCTATCTCCTGGCAGCCATGGCATATGACCGCCATGCAGCAATTTGTAACCC
ATTGCTTTATTCAGGTACCATGTCCACCGCCCTCTGTACTGGGCTTGTTGCTGGCTCCTACA
TAGGAGGATTTTTGAATGCCATAGCCCATACTGCCAATACATTCCGCCTGCATTTTTGTGG

10   TAAAAATATCATTGACCACTTTTTCTGTGATGCACCACCATTGGTAAAAATGTCCTGTACA
AACACCAGGGTCTACGAAAAAGTCCTGCTTGGTGTGGTGGGCTTCACAGTACTCTCCAGCA
TTCTTGCTATCCTGATTTCCTATGTCAACATCCTCCTGGCTATCCTGAGAATCCACTCAGCT
TCAGGAAGACACAAGGCATTCTCCACCTGTGCTTCCCACCTCATCTCAGTCATGCTCTTCTA
TGGATCATTGTTGTTTATGTATTCAAGGCCTAGTTCCACCTACTCCCTAGAGAGGGACAAA

15   GTAGCTGCTCTGTTCTACACCGTGATCAACCCACTGCTCAACCCTCTCATCTATAGCCTGAG
AAACAAAGATATCAAAGAGGCCTTCAGGAAAGCAACACAGACTATACAACCACAAACATG
A (SEQ ID NO: 250)

AOLFR136 sequences:

20   MTMENYSMAAQFVLDGLTQQAELQLPLFLLFLGIYVVTVVGNLGMILLIAVSPLLHTPMYYFL
SSLSFVDFCYSSVITPKMLVNFLGKKNTILYSECMVQLFFFVVFVVAEGYLLTAMAYDRYVAIC
SPLLYNAIMSSWVCSLLVLAAFFLGFLSALTHTSAMMKLSFCKSHIINHYFCDVLPLLNLSCSNT
HLNELLLFIIAGFNTLVPTLAVAVSYAFILYSILHIRSSEGRSKAFGTCSSHLMAVVIFFGSITFMY
FKPPSSNSLDQEKVSSVFYTTVIPMLNPLIYSLRNKDVKKALRKVLVGK (SEQ ID NO: 251)

25

ATGACCATGGAAAATTATTCTATGGCAGCTCAGTTTGTCTTAGATGGTTTAACACAGCAAG
CAGAGCTCCAGCTGCCCCTCTTCCTCCTGTTCCTGGGAATCTATGTGGTCACAGTAGTGGG
CAACCTGGGCATGATTCTCCTGATTGCAGTCAGCCCTCTACTTCACACCCCCATGTACTATT
TCCTCAGCAGCTTGTCCTTCGTCGATTTCTGCTATTCCTCTGTCATTACTCCCAAAATGCTG

30   GTGAACTTCCTAGGAAAGAAGAATACAATCCTTTACTCTGAGTGCATGGTCCAGCTCTTTT
TCTTTGTGGTCTTTGTGGTGGCTGAGGGTTACCTCCTGACTGCCATGGCATATGATCGCTA
TGTTGCCATCTGTAGCCCACTGCTTTATAATGCGATCATGTCCTCATGGGTCTGCTCACTGC
TAGTGCTGGCTGCCTTCTTCTTGGGCTTTCTCTCTGCCTTGACTCATACAAGTGCCATGATG
AAACTGTCCTTTTGCAAATCCCACATTATCAACCATTACTTCTGTGATGTTCTTCCCCTCCT

35   CAATCTCTCCTGCTCCAACACACACCTCAATGAGCTTCTACTTTTTATCATTGCGGGGTTTA
ACACCTTGGTGCCCACCCTAGCTGTTGCTGTCTCCTATGCCTTCATCCTCTACAGCATCCTT
CACATCCGCTCCTCAGAGGGCCGGTCCAAAGCTTTTGGAACATGCAGCTCTCATCTCATGG
CTGTGGTGATCTTCTTTGGGTCCATTACCTTCATGTATTTCAAGCCCCCTTCAAGTAACTCC
CTGGACCAGGAGAAGGTGTCCTCTGTGTTCTACACCACGGTGATCCCCATGCTGAACCCTT

40   TAATATACAGTCTGAGGAATAAGGATGTGAAGAAAGCATTAAGGAAGGTCTTAGTAGGAA
AATGA (SEQ ID NO: 252)

AOLFR137 sequences:

MSPENQSSVSEFLLLGLPIRPEQQAVFFALFLGMYLTTVLGNLLIMLLIQLDSHLHTPMYFFLSH

45   LALTDISFSSVTVPKMLMNMQTQHLAVFYKGCISQTYFFIFFADLDSFLITSMAYDRYVAICHPL
HYATIMTQSQCVMLVAGSWVIACACALLHTLLLAQLSFCADHIIPHYFCDLGALLKLSCSDTSL
NQLAIFTAALTAIMLPFLCILVSYGHIGVTILQIPSTKGICKALSTCGSHLSVVTIYYRTIIGLYFLP
PSSNTNDKNIIASVIYTAVTPMLNPFIYSLRNKDIKGALRKLLSRSGAVAHACNLSTLGG (SEQ
ID NO: 253)

50

ATGAGCCCTGAGAACCAGAGCAGCGTGTCCGAGTTCCTCCTCCTGGGCCTCCCCATCCGGC
CAGAGCAGCAGGCCGTGTTCTTCGCCCTGTTCCTGGGCATGTACCTGACCACGGTGCTGGG
GAACCTGCTCATCATGCTGCTCATCCAGCTAGACTCTCACCTTCACACCCCCATGTACTTCT
TCCTTAGCCACTTGGCCCTCACTGACATCTCCTTTTCATCTGTCACTGTCCCTAAGATGCTG

55   ATGAACATGCAGACTCAGCACCTAGCCGTCTTTTACAAGGGATGCATTTCACAGACATATT
TTTTCATATTTTTTGCTGACTTAGACAGTTTCCTTATCACTTCAATGGCATATGACAGGTAT

113

GTGGCCATCTGTCATCCTCTACATTATGCCACCATCATGACTCAGAGCCAGTGTGTCATGC
TGGTGGCTGGGTCCTGGGTCATCGCTTGTGCGTGTGCTCTTTTGCATACCCTCCTCCTGGCC
CAGCTTTCCTTCTGTGCTGACCACATCATCCCTCACTACTTCTGTGACCTTGGTGCCCTGCT
CAAGTTGTCCTGCTCAGACACCTCCCTCAATCAGTTAGCAATCTTTACAGCAGCATTGACA
5   GCCATTATGCTTCCATTCCTGTGCATCCTGGTTTCTTATGGTCACATTGGGGTCACCATCCT
CCAGATTCCCTCTACCAAGGGCATATGCAAAGCCTTGTCCACTTGTGGATCCCACCTCTCA
GTGGTGACTATCTATTATCGGACAATTATTGGTCTCTATTTTCTTCCCCCATCCAGCAACAC
CAATGACAAGAACATAATTGCTTCAGTGATATACACAGCAGTCACTCCCATGTTGAACCCA
TTCATTTACAGTCTGAGAAATAAAGACATTAAGGGAGCCCTAAGAAAACTCTTGAGTAGG
10   TCAGGCGCAGTGGCTCATGCCTGTAATCTCAGCACTTTGGGAGGCTGA (SEQ ID NO: 254)

AOLFR138 sequences:

MLNFTDVTEFILLGLTSRREWQVLFFIVFLVVYIITVVGNIGMMLLIKVSPQLNSPMYFFLSHLS
FVDVWFSSNVTPKMLENLFSDKKTISYADCLAQCFFFIALVHVEIFILAAIAFDRYTVIGNPLLY
15   GSKMSRGVCIRLITFPYIYGFLTSLTATLWTYGLYFCGKIEINHFYCADPPLIKMACAGTFVKEY
TMLILAGINFTYSLTVIIISYLFILIAILRMRSAEGRQKAFSTCGSHPTAVIIFYGTLIFMYLRRPTE
ESVEQGKMVAVFYTTVIPMLNPMIYSLRNKDVKKAMMKVISRSC (SEQ ID NO: 255)

ATGCTCAATTTCACCGATGTGACAGAGTTCATTCTTTTGGGGCTAACGAGCCGTCGGGAAT
20   GGCAAGTTCTCTTCTTCATCGTTTTTCTTGTGGTCTACATTATCACCGTGGTGGGCAATATC
GGCATGATGTTGTTAATCAAGGTCAGTCCTCAGCTTAACAGCCCCATGTACTTTTTCCTCA
GTCACTTGTCATTTGTTGATGTGTGGTTTTCTTCCAATGTCACCCCTAAAATGTTGGaAAAT
CTGTTATCAGATAAAAAAACAATTTCTTATGCTGGCTGTTTAGCACAGTGTTTCTTCTTCAT
TGCTCTTGTCCATGTGGAAATTTTTATTCTTGCTGCGATTGCCTTTGATAGATACACAGTGA
·25   TTGGAAATCCTTTGCTTTATGGCAGCAAAATGTCAAGGGATGTCTGTATTCGACTGATTAC
TTTCCCTTACATTTATGGTTTTCTGACGAGTCTGACAGCAACATTATGGACTTATGGCTTGT
ACTTCTGTGGAAAAATTGAGATCAACCATTTCTACTGTGCAGATCCACCTCTCATCAAAAT
GGCCTGTGCCGGGACCTTTGTAAAAGAATATACAATGCTCATACTTGCCGGCATCAACTTC
ACATATTCCCTGACTGTAATTATCATCTCTTACTTATTCATCCTCATTGCCATTCTGCGAAT
30   GCGCTCAGCAGAAGGAAGGCAGAAGGCCTTTTCCACATGTGGGTCCCATCTGACAGCTGT
CATCATATTCTATGGTACTCTGATCTTCATGTATCTCAGACGTCCCACAGAGGAGTCTGTG
GAGCAGGGGAAGATGGTGGCTGTGTTCTATACCACAGTGATCCCCATGTTGAATCCCATGA
TCTACAGTCTGAGGAACAAGGATGTGAAAAAGGCCATGATGAAAGTGATCAGCAGATCAT
GTTAA (SEQ ID NO: 256)
35

AOLFR139 sequences:

MGFPGIHSWQHWLSLPLALLYLLALSANILILIIINKEAALHQPMYYFLGILAMADIGLATTIMP
KILAILWFNAKTISLLECFAQMYAIHCFVAMESSTFVCMAIDRYVAICRPLRYPSIITESFVFKAN
GFMALRNSLCLISVPLLAAQRHYCSQNQIEHCLCSNLGVTSLSCDDRRINSINQVLLAWTLMGS
40   DLGLIILSYALILYSVLKLNSPEAASKALSTCTSHLILILFFYTVIIVISITRSTGMRVPLIPVLLNVL
HNVIPPALNPMVYALKNKELRQGLYKVLRLGVKGT (SEQ ID NO: 257)

ATGGGATTCCCTGGCATTCACAGTTGGCAGCACTGGCTCTCCCTGCCCCTGGCTCTGCTCT
ACCTCTTAGCTCTCAGTGCCAACATCCTTATCCTGATCATCATCAACAAAGAGGCAGCACT
45   GCACCAGCCTATGTACTATTTCCTGGGCATCTTGGCTATGGCAGACATAGGCCTGGCTACC
ACCATCATGCCTAAGATTTTGGCCATCTTATGGTTCAATGCTAAGACCATCAGTCTCCTGG
AGTGCTTTGCTCAGATGTATGCCATACATTGCTTTGTGGCCATGGAATCAAGTACCTTTGT
CTGCATGGCTATTGATAGATATGTAGCCATTTGTCGACCGCTACGATATCCATCAATCATC
ACTGAATCTTTTGTTTTCAAAGCAAATGGGTTCATGGCACTGAGAAACAGCCTGTGTCTCA
50   TCTCAGTGCCTCTGTTGGCTGCCCAGAGGCATTACTGCTCCCAGAATCAAATTGAGCACTG
TCTTTGTTCTAACCTTGGAGTCACTAGCCTATCTTGTGATGATCGAAGAATCAATAGCATT
AACCAGGTCCTTTTGGCTTGGACACTCATGGGAAGTGACCTGGGTTTGATTATTTTATCAT
ATGCTCTAATACTTTACTCTGTCCTGAAGCTGAACTCTCCAGAAGCTGCATCCAAGGCCTT
AAGTACCTGCACCTCCCACCTCATCTTAATCCTTTTCTTCTACACAGTCATCATTGTGATTT
55   CCATTACTCGTAGTACAGGAATGAGAGTTCCCCCTTATTCCAGTTCTACTTAATGTGCTACA

CAATGTCATTCCCCCTGCCCTGAACCCCATGGTATATGCACTCAAGAACAAGGAACTCAGG
CAAGGCTTATACAAGGTACTTAGACTGGGAGTGAAGGGCACCTGA (SEQ ID NO: 258)

AOLFR140 sequences:

MLTLNKTDLIPASFILNGVPGLEDTQLWISFPFCSMYVVAMVGNCGLLYLIHYEDALHKPMYY
FLAMLSFTDLVMCSSTIPKALCIFWFHLKDIGFDECLVQMFFIHTFTGMESGVLMLMALDRYV
AICYPLRYSTILTNPVIAKVGTATFLRGVLLIIPFTFLTKRLPYCRGNILPHTYCDHMSVAKLSCG
NVKVNAIYGLMVALLIGGFDILCITISYTMILRAVVSLSSADARQKAFNTCTAHICAIVFSYTPAF
FSFFSHRFGEHIIPPSCHIIVANIYLLLPPTMNPIVYGVKTKQIRDCVIRILSGSKDTKSYSM (SEQ
ID NO: 259)

ATGCTAACACTGAATAAAACAGACCTAATACCAGCTTCATTTATTCTGAATGGAGTCCCAG
GACTGGAAGACACACAACTCTGGATTTCCTTCCCATTCTGCTCTATGTATGTTGTGGCTAT
GGTAGGGAATTGTGGACTCCTCTACCTCATTCACTATGAGGATGCCCTGCACAAACCCATG
TACTACTTCTTGGCCATGCTTTCCTTTACTGACCTTGTTATGTGCTCTAGTACAATCCCTAA
AGCCCTCTGCATCTTCTGGTTTCATCTCAAGGACATTGGATTTGATGAATGCCTTGTCCAG
ATGTTCTTCATCCACACCTTCACAGGGATGGAGTCTGGGGTGCTTATGCTTATGGCCCTGG
ATCGCTATGTGGCCATCTGCTACCCCTTACGCTATTCAACTATCCTCACCAATCCTGTAATT
GCAAAGGTTGGGACTGCCACCTTCCTGAGAGGGGTATTACTCATTATTCCCTTTACTTTCCT
CACCAAGCGCCTGCCCTACTGCAGAGGCAATATACTTCCCCATACCTACTGTGACCACATG
TCTGTAGCCAAATTGTCCTGTGGTAATGTCAAGGTCAATGCCATCTATGGTCTGATGGTTG
CCCTCCTGATTGGGGGCTTTGACATACTGTGTATCACCATCTCCTATACCATGATTCTCCGG
GCAGTGGTCAGCCTCTCCTCAGCAGATGCTCGGCAGAAGGCCTTTAATACCTGCACTGCCC
ACATTTGTGCCATTGTTTTCTCCTATACTCCAGCTTTCTTCTCCTTCTTTTCCCACCGCTTTG
GGGAACACATAATCCCCCCTTCTTGCCACATCATTGTAGCCAATATTTATCTGCTCCTACCA
CCCACTATGAACCCTATTGTCTATGGGGTGAAAACCAAACAGATACGAGACTGTGTCATAA
GGATCCTTTCAGGTTCTAAGGATACCAAATCCTACAGCATGTGA (SEQ ID NO: 260)

AOLFR141 sequences:

MSSTLGHNMESPNHTDVDPSVFFLLGIPGLEQFHLWLSLPVCGLGTATIVGNITILVVVATEPVL
HKPVYLFLCMLSTIDLAASVSTVPKLLAIFWCGAGHISASACLAQMFFIHAFCMMESTVLLAM
AFDRYVAICHPLRYATILTDTIIAHIGVAAVVRGSLLMLPCPFLIGRLNFCQSHVILHTYCEHMA
VVKLACGDTRPNRVYGLTAALLVIGVDLFCIGLSYALSAQAVLRLSSHEARSKALGTCGSHVC
VILISYTPALFSFFTHRFGHHVPVHIHILLANVYLLLPPALNPVVYGVKTKQIRKRVVRVFQSGQ
GMGIKASE (SEQ ID NO: 261)

ATGTCCAGCACTCTTGGCCACAACATGGAATCTCCTAATCACACTGATGTTGACCCTTCTG
TCTTCTTCCTCCTGGGCATCCCAGGTCTGGAACAATTTCATTTGTGGCTCTCACTCCCTGTG
TGTGGCTTAGGCACAGCCACAATTGTGGGCAATATAACTATTCTGGTTGTTGTTGCCACTG
AACCAGTCTTGCACAAGCCTGTGTACCTTTTTCTGTGCATGCTCTCAACCATCGACTTGGCT
GCCTCTGTCTCCACAGTTCCCAAGCTACTGGCTATCTTCTGGTGTGGAGCCGGACATATAT
CTGCCTCTGCCTGCCTGGCACAGATGTTCTTCATTCATGCCTTCTGCATGATGGAGTCCACT
GTGCTACTGGCCATGGCCTTTGATCGCTACGTGGCCATCTGCCACCCACTCCGCTATGCCA
CAATCCTCACTGACACCATCATTGCCCACATAGGGGTGGCAGCTGTAGTGCGAGGCTCCCT
GCTCATGCTCCCATGTCCCTTCCTTATTGGGCGTTTGAACTTCTGCCAAAGCCATGTGATCC
TACACACGTACTGTGAGCACATGGCTGTGGTGAAGCTGGCCTGTGGAGACACCAGGCCTA
ACCGTGTGTATGGGCTGACAGCTGCACTGTTGGTCATTGGGGTTGACTTGTTTTGCATTGG
TCTCTCCTATGCCCTAAGTGCACAAGCTGTCCTTCGCCTCTCATCCCATGAAGCTCGGTCCA
AGGCCCTAGGGACCTGTGGTTCCCATGTCTGTGTCATCCTCATCTCTTATACACCAGCCCTC
TTCTCCTTTTTTACACACCGCTTTGGCCATCACGTTCCAGTCCATATTCACATTCTTTTGGC
CAATGTTTATCTGCTTTTGCCACCTGCTCTTAATCCTGTGGTATATGGAGTTAAGACCAAAC
AGATCCGTAAAAGAGTTGTCAGGGTGTTTCAAAGTGGGCAGGGAATGGGCATCAAGGCAT
CTGAGTGA (SEQ ID NO: 262)

AOLFR143 sequences:

MLGLNGTPFQPATLQLTGIPGIQTGLTWVALIFCILYMISIVGNLSILTLVFWEPALHQPMYYFL
SMLALNDLGVSFSTLPTVISTFCFNYNHVAFNACLVQMFFIHTFSFMESGILLAMSLDRFVAICY
PLRYVTVLTHNRILAMGLGILTKSFTTLFPFPFVVKRLPFCKGNVLHHSYCLHPDLMKVACGDI
5   HVNNIYGLLVIIFTYGMDSTFILLSYALILRAMLVIISQEQRLKALNTCMSHICAVLAFYVPIIAVS
MIHRFWKSAPPVVHVMMSNVYLFVPPMLNPIIYSVKTKEIRKGILKFFHKSQA (SEQ ID NO:
263)

ATGCTGGGTCTCAATGGCACCCCCTTCCAGCCAGCAACACTCCAGCTGACAGGCATTCCTG
10   GGATACAAACAGGCCTCACCTGGGTTGCCCTGATTTTCTGCATCCTCTACATGATCTCCATT
GTAGGTAACCTCAGCATTCTCACTCTGGTGTTTTGGGAGCCTGCTCTGCATCAGCCCATGT
ACTACTTCCTCTCTATGCTCGCTCTCAATGATCTGGGAGTGTCCTTTTCTACACTTCCCACT
GTGATTTCTACTTTCTGCTTCAACTACAACCATGTTGCGTTTAATGCTTGCCTGGTCCAGAT
GTTCTTCATCCACACTTTCTCCTTCATGGAGTCAGGCATACTGCTGGCCATGAGCTTGGATC
15   GCTTTGTGGCTATTTGTTATCCATTACGCTATGTCACTGTGCTCACTCACAACCGTATATTG
GCTATGGGTCTGGGCATCCTTACCAAGAGTTTCACCACTCTCTTCCCTTTCCCTTTTGTGGT
GAAACGACTGCCCTTCTGCAAAGGCAATGTTTTGCATCACTCCTACTGTCTCCATCCAGAT
CTCATGAAAGTAGCATGTGGAGACATCCATGTTAACAACATTTATGGGCTCTTGGTGATCA
TTTTTACCTATGGTATGGACTCAACTTTCATCCTGCTTTCCTACGCATTGATCCTGAGAGCC
20   ATGCTGGTCATCATATCCCAGGAACAGCGGCTCAAGGCACTCAACACCTGCATGTCACACA
TCTGTGCAGTGCTGGCCTTTTATGTGCCCATAATTGCTGTCTCCATGATTCACCGCTTCTGG
AAAAGTGCTCCACCTGTTGTTCATGTCATGATGTCCAATGTCTACCTGTTTGTACCACCCAT
GCTCAACCCTATCATCTACAGTGTGAAAACCAAGGAGATCCGCAAAGGGATTCTCAAGTTC
TTCCATAAATCCCAGGCCTGA (SEQ ID NO: 264)

25

AOLFR144 sequences:

MGLFNVTHPAFFLLTGIPGLESSHSWLSGPLCVMYAVALGGNTVILQAVRVEPSLHEPMYYFL
SMLSFSDVAISMATLPTVLRTFCLNARNITFDACLIQMFLIHFFSMMESGILLAMSFDRYVAICD
PLRYATVLTTEVIAAMGLGAAARSFITLFPLPFLIKRLPICRSNVLSHSYCLHPDMMRLACADISI
30   NSIYGLFVLVSTFGMDLFFIFLSYVLILRSVMATASREERLKALNTCVSHILAVLAFYVPMIGVS
TVHRFGKHVPCYIHVLMSNVYLFVPPVLNPLIYSAKTKEIRRAIFRMFHHIKI (SEQ ID NO: 265)

ATGGGGTTGTTCAATGTCACTCACCCTGCATTCTTCCTCCTGACTGGTATCCCTGGTCTGGA
GAGCTCTCACTCCTGGCTGTCAGGGCCCCTCTGCGTGATGTATGCTGTGGCCCTTGGGGGA
35   AATACAGTGATCCTGCAGGCTGTGCGAGTGGAGCCCAGCCTCCATGAGCCCATGTACTACT
TCCTGTCCATGTTGTCCTTCAGTGATGTGGCCATATCCATGGCCACACTGCCCACTGTACTC
CGAACCTTCTGCCTCAATGCCCGCAACATCACTTTTGATGCCTGTCTAATTCAGATGTTTCT
TATTCACTTCTTCTCCATGATGGAATCAGGTATTCTGCTGGCCATGAGTTTTGACCGCTATG
TGGCCATTTGTGACCCCTTGCGCTATGCAACTGTGCTCACCACTGAAGTCATTGCTGCAAT
40   GGGTTTAGGTGCAGCTGCTCGAAGCTTCATCACCCTTTTCCCTCTTCCCTTTCTTATTAAGA
GGCTGCCTATCTGCAGATCCAATGTTCTTTCTCACTCCTACTGCCTGCACCCAGACATGATG
AGGCTTGCCTGTGCTGATATCAGTATCAACAGCATCTATGGACTCTTTGTTCTTGTATCCAC
CTTTGGCATGGACCTGTTTTTTATCTTCCTCTCCTATGTGCTCATTCTGCGTTCTGTCATGG
CCACTGCTTCCCGTGAGGAACGCCTCAAAGCTCTCAACACATGTGTGTCACATATCCTGGC
45   TGTACTTGCATTTTATGTGCCAATGATTGGGGTCTCCACAGTGCACCGCTTTGGGAAGCAT
GTCCCATGCTACATACATGTCCTCATGTCAAATGTGTACCTATTTGTGCCTCCTGTGCTCAA
CCCTCTCATTTATAGCGCCAAGACAAAGGAAATCCGCCGAGCCATTTTCCGCATGTTTCAC
CACATCAAAATATGA (SEQ ID NO: 266)

AOLFR145 sequences:

MSVQYSLSPQFMLLSNITQFSPIFYLTSFPGLEGIKHWIFIPFFFMYMVAISGNCFILIIIKTNPRLH
TPMYYLLSLLALTDLGLCVSTLPTTMGIFWFNSQSIYFGACQIQMFCIHSFSFMESSVLLMMSFD
RFVAICHPLRYSVIITGQQVVRAGLIVIFRGPVATIPIVLLLKAFPYCGSVVLSHSFCLHQEVIQLA

5   CTDTTFNNLYGLMVVVFTVMLDLVLIALSYGLILHTVAGLASQEEQRRAFQTCTAHLCAVLVF
FVPMMGLSLVHRFGKHAPPAIHLLMANVYLFVPPMLNPIIYSIKTKEIHRAIIKLLGLKKASK
(SEQ ID NO: 267)

ATGTCAGTCCAATATTCGCTCAGTCCTCAATTCATGCTGCTATCCAACATTACTCAGTTTAG

10   CCCCATATTCTATCTCACCAGCTTTCCTGGATTGGAAGGCATCAAACACTGGATTTTCATCC
CCTTTTTCTTTATGTACATGGTTGCCATCTCAGGCAATTGTTTCATTCTGATCATTATTAAG
ACCAACCCTCGTCTGCACACACCCATGTACTATCTACTATCCTTGCTGGCCCTCACTGACCT
GGGGCTGTGTGTGTCCACGTTGCCCACCACTATGGGGATCTTCTGGTTTAACTCCCAGAGT
ATCTACTTTGGAGCGTGTCAAATCCAGATGTTCTGCATCCACTCTTTTTCCTTCATGGAGTC

15   CTCAGTGCTCCTCATGATGTCCTTTGACCGCTTTGTGGCCATCTGCCACCCTCTGAGGTATT
CGGTCATTATCACTGGCCAGCAAGTGGTCAGAGCAGGCCTAATTGTCATCTTCCGGGGGACC
TGTGGCCACTATCCCTATTGTCCTCCTCCTGAAGGCTTTTCCCTACTGTGGATCTGTGGTCC
TCTCCCACTCATTTTGCCTGCACCAGGAAGTGATACAGCTGGCCTGCACAGATACCACCTT
CAATAATCTGTATGGACTGATGGTGGTAGTTTTCACTGTGATGCTGGACCTGGTGCTCATC

20   GCACTGTCCTATGGACTCATCCTGCACACAGTAGCAGGCCTGGCCTCCCAAGAGGAGCAGC
GCCGTGCCTTTCAGACATGCACCGCTCATCTCTGTGCTGTGCTAGTATTCTTTGTGCCCATG
ATGGGGCTGTCCCTGGTGCACCGTTTTGGGAAGCATGCCCCACCTGCTATTCATCTTCTTAT
GGCCAATGTCTACCTTTTTGTGCCTCCCATGCTTAACCCAATCATATACAGCATTAAGACC
AAGGAGATCCACCGTGCCATTATCAAACTCCTAGGTCTTAAAAAGGCCAGTAAATGA (SEQ

25   ID NO: 268

AOLFR146 sequences:

MSQVTNTTQEGIYFILTDIPGFEASHIWISIPVCCLYTISIMGNTTILTVIRTEPSVHQRMYLFLSM
LALTDLGLTLTTLPTVMQLLWFNVRRISSEACFAQFFFLHGFSFMESSVLLAMSVDCYVAICCP

30   LHYASILTNEVIGRTGLAIICCCVLAVLPSLFLLKRLPFCHSHLLSRSYCLHQDMIRLVCADIRLN
SWYGFALALLIIIVDPLLIVISYTLILKNILGTATWAERLRALNNCLSHILAVLVLYIPMVGVSMT
HRFAKHASPLVHVIMANTYLLAPPVMNPIIYSVKNKQIQWGMLNFLSLKNMHSR (SEQ ID NO:
269)

35   ATGTCCCAGGTGACTAACACCACACAAGAAGGCATCTACTTCATCCTCACGGACATCCCTG
GATTTGAGGCCTCCCACATCTGGATCTCCATCCCCGTCTGCTGTCTCTACACCATCTCCATC
ATGGGCAATACCACCATCCTCACTGTCATTCGCACAGAGCCATCTGTCCACCAGCGCATGT
ATCTGTTTCTCTCCATGCTGGCCCTGACGGACCTGGGTCTCACCCTCACCACCCTACCCACA
GTCATGCAGCTTCTCTGGTTCAACGTTCGTAGAATCAGCTCTGAGGCCTGTTTTGCTCAGTT

40   TTTCTTCCTTCATGGATTCTCCTTTATGGAGTCTTCTGTCCTCCTGGCTATGTCCGTTGACT
GCTATGTGGCCATCTGCTGTCCCCTCCATTATGCCTCCATCCTCACCAATGAAGTCATTGGT
AGAACTGGGTTAGCCATCATTTGCTGCTGTGTTCTGGCGGTTCTTCCCTCCCTTTTCTTACT
CAAGCGACTGCCTTTCTGCCACTCCCACCTTCTCTCTCGCTCCTATTGCCTCCACCAGGATA
TGATCCGCCTGGTCTGTGCTGACATCAGGCTCAACAGCTGGTATGGATTTGCTCTTGCCTT

45   GCTCATTATTATCGTGGATCCTCTGCTCATTGTGATCTCCTATACACTTATTCTGAAAAATA
TCTTGGGCACAGCCACCTGGGCTGAGCGACTCCGTGCCCTCAATAACTGCCTGTCCCACAT
TCTAGCTGTCCTGGTCCTCTACATTCCCATGGTTGGTGTATCTATGACTCATCGCTTTGCCA
AGCATGCCTCTCCACTGGTCCATGTTATCATGGCCAATATCTACCTGCTGGCACCCCCGGT
GATGAACCCCATCATTTACAGTGTAAAGAACAAGCAGATCCAATGGGGAATGTTAAATTTC

50   CTTTCCCTCAAAAATATGCATTCAAGATGA (SEQ ID NO: 270)

AOLFR147 sequences:

MPSASAMIIFNLSSYNPGPFILVGIPGLEQFHVWIGIPFCIIYIVAVVGNCILLYLIVVEHSLHEPMF
FFLSMLAMTDLILSTAGVPKALSIFWLGAREITFPGCLTQMFFLHYNFVLDSAILMAMAFDHYV

55   AICSPLRYTTILTPKTIIKSAMGISFRSFCIILPDVFLLTCLPFCRTRIIPHTYCEHIGVAQLACADISI
NFWYGFCVPIMTVISDVILIAVSYAHILCAVFGLPSQDACQKALGTCGSHVCVILMFYTPAFFSI

117

LAHRFGHNVSRTFHIMFANLYIVIPPALNPMVYGVKTKQIRDKVILLFSKGTG (SEQ ID NO: 271)

5
ATGCCATCTGCCTCTGCCATGATCATTTTCAACCTGAGCAGTTACAATCCAGGACCCTTCAT
TCTGGTAGGGATCCCAGGCCTGGAGCAATTCCATGTGTGGATTGGAATTCCCTTCTGTATC
ATCTACATTGTAGCTGTTGTGGGAAACTGCATCCTTCTCTACCTCATTGTGGTGGAGCATA
GTCTTCATGAACCCATGTTCTTCTTTCTCTCCATGCTGGCCATGACTGACCTCATCTTGTCC
ACAGCTGGTGTGCCTAAAGCACTCAGTATCTTTTGGCTAGGGGCTCGCGAAATCACATTCC
CAGGATGCCTTACACAAATGTTCTTCCTTCACTATAACTTTGTCCTGGATTCAGCCATTCTG
10
ATGGCCATGGCATTTGATCACTATGTAGCTATCTGTTCTCCCTTGAGATATACCACCATCTT
GACTCCCAAGACCATCATCAAGAGTGCTATGGGCATCTCCTTTCGAAGCTTCTGCATCATC
CTGCCAGATGTATTCTTGCTGACATGCCTGCCTTTCTGCAGGACACGCATCATACCCCACA
CATACTGTGAGCATATAGGTGTTGCCCAGCTCGCCTGTGCTGATATCTCCATCAACTTCTG
GTATGGCTTTTGTGTTCCCATCATGACGGTCATCTCAGATGTGATTCTCATTGCTGTTTCCT
15
ACGCACACATCCTCTGTGCTGTCTTTGGCCTTCCCTCCCAAGATGCCTGCCAGAAAGCCCT
CGGCACTTGTGGTTCTCATGTCTGTGTCATCCTCATGTTTTATACACCTGCCTTTTTCTCCA
TCCTCGCCCATCGCTTTGGACACAATGTCTCTCGCACCTTCCACATCATGTTTGCCAATCTC
TACATTGTTATCCCACCTGCACTCAACCCCATGGTTTACGGAGTGAAGACCAAGCAGATCA
GAGATAAGGTTATACTTTTGTTTTCTAAGGGTACAGGATGA (SEQ ID NO: 272)
20

AOLFR148 sequences:

MPTVNHSGTSHTVFHLLGIPGLQDQHMWISIPFFISYVTALLGNSLLIFIILTKRSLHEPMYLFLC
MLAGADIVLSTCTIPQALAIFWFRAGDISLDRCITQLFFIHSTFISESGILLVMAFDHYIAICYPLR
YTTILTNALIKKICVTVSLRSYGTIFPIIFLLKRLTFCQNNIIPHTFCEHIGLAKYACNDIRINIWYG
25 FSILMSTVVLDVVLIFISYMLILHAVFHMPSPDACHKALNTFGSHVCIIILFYGSGIFTILTQRFGR
HIPPCIHIPLANVCILAPPMLNPIIYGIKTKQIQEQVVQFLFIKQKITLV (SEQ ID NO: 273)

ATGCCTACTGTAAACCACAGTGGCACTAGCCACACAGTCTTCCACTTGCTGGGCATCCCTG
GCCTACAGGACCAGCACATGTGGATTTCTATCCCATTCTTCATTTCCTATGTCACCGCCCTT
30
CTTGGGAACAGCCTGCTCATCTTCATTATCCTCACAAAGCGCAGCCTCCATGAACCCATGT
ACCTCTTCCTCTGCATGCTGGCTGGAGCAGACATTGTCCTCTCCACGTGCACCATTCCTCAG
GCCTTAGCTATCTTCTGGTTCCGTGCTGGGGACATCTCCCTGGATCGTTGCATCACTCAGCT
CTTCTTCATCCATTCCACCTTCATCTCTGAGTCAGGGATCTTGCTGGTGATGGCCTTTGACC
ACTATATTGCCATATGCTACCCACTGAGGTACACCACCATTCTTACAAATGCTCTGATCAA
35
GAAAATTTGTGTGACTGTCTCTCTGAGAAGTTATGGTACAATTTTCCCTATCATATTTCTTT
TAAAAAGATTGACTTTCTGCCAGAATAATATTATTCCACACACCTTTTGTGAACACATTGG
CCTAGCCAAATATGCATGTAATGACATTCGAATAAACATTTGGTATGGGTTTTCCATTCTA
ATGTCGACGGTGGTCTTAGATGTTGTACTAATTTTTATTTCCTATATGCTGATTCTCCATGC
TGTCTTCCACATGCCTTCTCCAGATGCTTGCCACAAAGCTCTCAACACATTTGGCTCCCATG
40
TCTGCATCATCATCCTCTTTTATGGGTCTGGCATCTTCACAATCCTTACCCAGAGGTTTGGA
CGCCACATTCCACCTTGTATCCACATCCCGTTGGCTAATGTCTGCATTCTGGCTCCACCTAT
GCTGAATCCCATTATTTATGGGATCAAAACCAAGCAAATCCAGGAACAGGTGGTTCAGTTT
TTGTTTATAAAACAGAAAATAACTTTGGTTTAA (SEQ ID NO: 274)

45   **AOLFR149 sequences:**

MSNASLLTAFILMGLPHAPALDAPLFGVFLVVYVLTVLGNLLILLVIRVDSHLHTTMYYFLTNL
SFIDMWFSTVTVPKLLMTLVFPSGRAISFHSCMAQLYFFHFLGGTECFLYRVMSCDRYLAISYP
LRYTSMMTGRSCTLLATSTWLSGSLHSAVQAILTFHLPYCGPNWIQHYLCDAPPILKLACADTS
AIETVIFVTVGIVASGCFVLIVLSYVSIVCSILRIRTSEGKHRAFQTCASHCIVVLCFFGPGLFIYLR
50 PGSRKAVDGVVAVFYTVLTPLLNPVVYTLRNKEVKKALLKLKDKVAHSQSK (SEQ ID NO: 275)

ATGTCCAACGCCAGCCTACTGACAGCGTTCATCCTCATGGGCCTTCCCCATGCCCCAGCGC
TGGACGCCCCCCTCTTTGGAGTCTTCCTGGTGGTTTACGTGCTCACTGTGCTGGGGAACCT
55 CCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCACCATGTACTACTTCCTCA
CCAACCTGTCGTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCCAAATTGCTGATGAC

TTTGGTGTTCCCAAGTGGCAGGGCTATCTCCTTCCACAGCTGCATGGCTCAGCTCTATTTCT
TTCACTTCCTAGGGGGGCACCGAGTGTTTCCTCTACAGGGTCATGTCCTGTGATCGCTACCT
GGCCATCAGTTACCCGCTCAGGTACACCAGCATGATGACTGGGCGCTCGTGTACTCTTCTG
GCCACCAGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGGCCATATTGACTTTCC
ATTTGCCCTACTGTGGACCCAACTGGATCCAGCACTATTTGTGTGATGCACCGCCCATCCT
GAAACTGGCCTGTGCAGACACCTCAGCCATAGAGACTGTCATTTTTGTGACTGTTGGAATA
GTGGCCTCGGGCTGCTTTGTCCTGATAGTGCTGTCCTATGTGTCCATCGTCTGTTCCATCCT
GCGGATCCGCACCTCAGAGGGGAAGCACAGAGCCTTTCAGACCTGTGCCTCCCACTGTATC
GTGGTCCTTTGCTTCTTTGGCCCTGGTCTTTTCATTTACCTGAGGCCAGGCTCCAGGAAAGC
TGTGGATGGAGTTGTGGCCGTTTTCTACACTGTGCTGACGCCCCTTCTCAACCCTGTTGTGT
ACACCCTGAGGAACAAGGAGGTGAAGAAAGCTCTGTTGAAGCTGAAAGACAAAGTAGCAC
ATTCTCAGAGCAAATAG (SEQ ID NO: 276)

AOLFR150 sequences:

MELGNVTRVKEFIFLGLTQSQDQSLVLFLFLCLVYMTTLLGNLLIMVTVTCESRLHTPMYFLLR
NLAILDICFSSTTAPKVLLDLLSKKKTISYTSCMTQIFLFHLLGGADIFSLSVMAFDCYMAISKPL
HYVTIMSRGQCTALISASWMGGFVHSIVQISLLLPLPFCGPNVLDTFYCDVPQVLKLTCTDTFA
LEFLMISNNGLVTTLWFIFLLVSYTVILMTLRSQAGGGRRKAISTCTSPHHCGDPAFCALHLCLC
PALHCPPHRKGHLCHLHCHLPSAEPFDLHSEEPGNEVSHEKTEEKTRAF (SEQ ID NO: 277)

ATGGAGTTGGGAAATGTCACCAGAGTAAAAGAATTTATATTTCTGGGACTTACTCAATCCC
AAGACCAGAGTTTGGTCTTGTTTCTTTTTTTATGTCTTGTGTACATGACGACTCTGCTGGGA
AACCTCCTCATCATGGTCACCGTGACCTGTGAGTCTCGCCTTCACACCCCCATGTACTTCCT
GCTCCGCAATCTAGCCATCCTTGACATCTGCTTCTCCTCCACAACTGCTCCTAAAGTCTTGC
TGGACCTTCTGTCAAAGAAAAAGACCATATCCTATACAAGCTGCATGACACAGATATTTCT
CTTCCACCTCCTTGGTGGGGCAGACATTTTTTCTCTCTCTGTGATGGCGTTTGACTGCTACA
TGGCCATCTCCAAGCCCCTGCACTATGTGACCATCATGAGTAGAGGGCAATGCACTGCCCT
CATCTCTGCCTCTTGGATGGGGGGCTTTGTCCACTCCATCGTGCAGATCTCCCTGTTGCTGC
CTCTCCCTTTCTGTGGACCCAATGTTCTTGACACTTTCTACTGCGATGTCCCCCAGGTCCTC
AAACTCACTTGCACTGACACTTTTGCTCTTGAGTTCTTGATGATTTCCAACAATGGCCTGGT
CACTACCCTGTGGTTTATCTTCCTGCTTGTGTCCTACACAGTCATCCTAATGACGCTGAGGT
CTCAGGCAGGAGGGGGCAGGAGGAAAGCCATCTCCACTTGCACCTCCCCACATCACTGTG
GTGACCCTGCATTTTGTGCCCTGCATCTATGTCTATGCCCGGCCCTTCACTGCCCTCCCCAC
AGAAAAGGCCATCTCTGTCACCTTCACTGTCATCTCCCCTCTGCTGAACCCTTTGATCTACA
CTCTGAGGAACCAGGAAATGAAGTCAGCCATGAGAAGACTGAAGAGAAGACTCGTGCCTT
CTGA (SEQ ID NO: 278)

AOLFR151 sequences:

MFSPNHTIVTEFILLGLTDDPVLEKILFGVFLAIYLITLAGNLCMILLIRTNSHLQTPMYFFLGHLS
FVDICYSSNVTPNMLHNFLSEQKTISYAGCFTQCLLFIALVITEFYILASMALDRYVAICSPLHYS
SRMSKNICVCLVTIPYMYGFLSGFSQSLLTFHLSFCGSLEINHFYCADPPLIMLACSDTRVKKMA
MFVVAGFNLSSSLFIILLSYLFIFAAIFRIRSAEGRHKAFSTCASHLTIVTLFYGTLFCMYVRPPSE
KSVEESKITAVFYTFLSPMLNPLIYSLRNTDVILAMQQMIRGKSFHKIAV (SEQ ID NO: 279)

ATGTTCTCCCCAAAACCACACCATAGTGACAGAATTCATTCTCTTGGGACTGACAGACGACC
CAGTGCTAGAGAAGATCCTGTTTGGGGTATTCCTTGCGATCTACCTAATCACACTGGCAGG
CAACCTGTGCATGATCCTGCTGATCAGGACCAATTCCCACCTGCAAACACCCATGTATTTC
TTCCTTGGCCACCTCTCCTTTGTAGACATTTGCTATTCTTCCAATGTTACTCCAAATATGCT
GCACAATTTCCTCTCAGAACAGAAGACCATCTCCTACGCTGGATGCTTCACACAGTGTCTT
CTCTTCATCGCCCTGGTGATCACTGAGTTTTACATCCTTGCTTCAATGGCATTGGATCGCTA
TGTAGCCATTTGCAGCCCTTTGCATTACAGTTCCAGGATGTCCAAGAACATCTGTGTCTGT
CTGGTCACTATCCCTTACATGTATGGGTTTCTTAGTGGGTTCTCTCAGTCACTGCTAACCTT
TCACTTATCCTTCTGTGGCTCCCTTGAAATCAATCATTTCTACTGCGCTGATCCTCCTCTTA
TCATGCTGGCCTGCTCTGACACCCGTGTCAAAAAGATGGCAATGTTTGTAGTTGCAGGCTT
TAATCTCTCAAGCTCTCTCTTCATCATTCTTCTGTCCTATCTTTTCATTTTTGCAGCGATCTT
CAGGATCCGTTCTGCTGAAGGCAGGCACAAAGCCTTTTCTACGTGTGCTTCCCACCTGACA

ATAGTCACTTTGTTTTATGGAACCCTCTTCTGCATGTACGTAAGGCCTCCATCAGAGAAGT
CTGTAGAGGAGTCCAAAATAACTGCAGTCTTTTATACTTTTTTGAGCCCAATGCTGAACCC
ATTGATCTATAGCCTACGGAACACAGATGTAATCCTTGCCATGCAACAAATGATTAGGGGA
AAATCCTTTCATAAAATTGCAGTTTAG (SEQ ID NO: 280)

5

AOLFR152 sequences:

MDQINHTNVKEFFFLELTRSRELEFFLFVVFFAVYVATVLGNALIVVTITCESRLHTPMYFLLRN
KSVLDIVFSSITVPKFLVDLLSDRKTISYNDCMAQIFFFHFAGGADIFFLSVMAYDRYLAIAKPL
HYVTMMRKEVWVALVVASWVSGGLHSIIQVILMLPFPFCGPNTLDAFYCYVLQVVKLACTDT
FALELFMISNNGLVTLLWFLLLLLGSYTVILVMLRSHSGEGRNKALSTCTSHMLVVTLHFVPCV
YIYCRPFMTLPMDTTISINNTVITPMLNPIIYSLRNQEMKSAMQRLQRRLGPSESRKWG (SEQ ID
NO: 281)

10

15   ATGGACCAGATCAACCACACTAATGTGAAGGAGTTTTTCTTCCTGGAACTTACACGTTCCC
GAGAGCTGGAGTTTTTCTTGTTTGTGGTCTTCTTTGCTGTGTATGTAGCAACAGTCCTGGG
AAATGCACTCATTGTGGTCACTATTACCTGTGAGTCCCGCCTACACACTCCTATGTACTTTC
TCCTGCGGAACAAATCAGTCCTGGACATCGTTTTTTCATCTATCACCGTCCCCAAGTTCCTG
GTGGATCTTTTATCAGACAGGAAAACCATCTCCTACAATGACTGCATGGCACAGATCTTTT
TCTTCCACTTTGCTGGTGGGGCAGATATTTTTTTCCTCTCTGTGATGGCCTATGACAGATAC
20   CTTGCAATCGCCAAGCCCCTGCACTATGTGACCATGATGAGGAAAGAGGTGTGGGTGGCC
TTGGTGGTGGCTTCTTGGGTGAGTGGTGGTTTGCATTCAATCATCCAGGTAATTCTGATGC
TTCCATTCCCCTTCTGTGGCCCCAACACACTGGATGCCTTCTACTGTTATGTGCTCCAGGTG
GTAAAACTGGCCTGCACTGACACCTTTGCTTTGGAGCTTTTCATGATCTCTAACAACGGAC
TGGTGACCCTGCTCTGGTTCCTCCTGCTCCTGGGCTCCTACACTGTCATTCTGGTGATGCTG
25   AGATCCCACTCTGGGGAGGGGCGGAACAAGGCCCTCTCCACGTGCACGTCCCACATGCTG
GTGGTGACTCTTCACTTCGTGCCTTGTGTTTACATCTACTGCCGGCCCTTCATGACGCTGCC
CATGGACACAACCATATCCATTAATAACACGGTCATTACCCCCATGCTGAACCCCATCATC
TATTCCCTGAGAAATCAAGAGATGAAGTCAGCCATGCAGAGGCTGCAGAGGAGACTTGGG
CCTTCCGAGAGCAGAAAATGGGGGTGA (SEQ ID NO: 282)

30

AOLFR153 sequences:

MSKTSLVTAFILTGLPHAPGLDAPLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYYFLTNLS
FIDMWFSTVTVPKMLMTLVSPSGRAISFHSCVAQLYFFHFLGSTECFLYTVMSYDRYLAISYPL
RYTSMMSGSRCALLATSTWLSGSLHSAVQTILTFHLPYCGPNQIQHYLCDAPPILKLACADTSA
35   NEMVIFVDIGLVASGCFLLIVLSYVSIVCSILRIHTSEGRHRAFQTCASHCIVVLCFFVXCVFIYLR
PGSRDVVDGVVAIFYTVLTPLLNPVVYTLRNKEVKKAVLKLRDKVAHSQGE (SEQ ID NO:
283)

ATGTCCAAGACCAGCCTCGTGACAGCGTTCATCCTCACGGGCCTTCCCCATGCCCCAGGGC
40   TGGACGCCCCACTCTTTGGAATCTTCCTGGTGGTTTACGTGCTCACTGTGCTGGGGAACCT
CCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCCCCATGTACTACTTCCTCA
CCAACCTGTCCTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCCAAAATGCTGATGAC
CTTGGTGTCCCCAAGCGGCAGGGCTATCTCCTTCCACAGCTGCGTGGCTCAGCTCTATTTTT
TCCACTTCCTGGGGAGCACCGAGTGTTTCCTCTACACAGTCATGTCCTATGATCGCTACTTG
45   GCCATCAGTTACCCGCTCAGGTACACCAGCATGATGAGTGGGAGCAGATGTGCCCTCCTGG
CCACCAGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGACCATATTGACTTTCCAT
TTGCCCTACTGTGGACCCAACCAGATCCAGCACTATTTGTGTGATGCACCGCCCATCCTGA
AACTGGCCTGTGCAGACACCTCAGCCAACGAGATGGTCATCTTTGTGGACATTGGGCTAGT
GGCCTCGGGCTGCTTTCTCCTGATAGTGCTGTCTTATGTGTCCATCGTCTGTTCCATCCTGC
50   GGATCCACACCTCAGAGGGGAGGCACAGAGCCTTTCAGACCTGTGCCTCCCACTGCATCGT
GGTCCTTTGCTTTTTTGTNNCCTGTGTTTTCATTTACCTGAGACCAGGCTCCAGGGACGTCG
TGGATGGAGTTGTGGCCATTTTCTACACTGTGCTGACACCCCTTCTCAACCCTGTTGTGTAC
ACCCTGAGAAACAAGGAGGTGAAGAAAGCTGTGTTGAAACTGAGAGACAAAGTAGCACAT
TCTCAGGGAGAATAA (SEQ ID NO: 284)

55

AOLFR156 sequences:

MCWAMPSPFTGSSTRNMESRNQSTVTEFIFTGFPQLQDGSLLYFFPLLFIYTFIIIDNLLIFSAVRL
DTHLGNPMYNFISIFSFLEIWYTTATIPKMLSNLISEKKAISMTGCILQMYFFHSLENSEGILLTT
MAIDRYVAICNPLRYQMIMTPRLCAHLSAGSCLFGFLILLPEIVMISTLPFCGPNQIHQIFCDLVP
VLSLACTDTSMILIEDVIHAVTIIITFLIIALSYVRIVTVILRIPSSEGRQKAXSTCAGHLMVFLIFFG
SVSLMYLRFSNTYPPVLDTAIALMFTVLAPFFNPIIYSLRNKDMNNAIKKLFCLQKVLNKPGG
(SEQ ID NO: 285)

ATGTGCTGGGCTATGCCCTCTCCATTTACAGGTAGCTCTACTAGAAATATGGAGAGCAGAA
ACCAATCAACAGTGACTGAATTTATCTTCACTGGATTCCCTCAGCTTCAGGATGGTAGTCT
CCTGTACTTCTTTCCTTTACTTTTCATCTATACTTTTATTATCATTGATAACTTATTAATCTT
CTCTGCTGTAAGGCTGGACACCCATCTGGGCAACCCCATGTATAATTTTATCAGTATATTTT
CCTTTCTGGAGATCTGGTACACCACAGCCACCATTCCCAAGATGCTCTCCAACCTCATCAG
TGAAAAGAAGGCCATCTCAATGACTGGCTGCATCTTGCAGATGTATTTCTTCCACTCACTT
GAAAACTCAGAGGGGATCTTGCTGACCACCATGGCCATTGACAGATACGTTGCCATCTGCA
ACCCTCTTCGCTATCAAATGATCATGACCCCCCGGCTCTGTGCTCACCTCTCTGCAGGTTCC
TGCCTCTTCGGTTTCCTTATCCTGCTTCCCGAGATTGTGATGATTTCCACACTGCCTTTCTG
TGGGCCCAACCAAATCCATCAGATCTTCTGTGACTTGGTCCCTGTGCTAAGCCTGGCCTGT
ACAGACACGTCCATGATTCTGATTGAGGATGTGATTCATGCTGTGACCATCATCATTACCT
TCCTAATCATTGCCCTGTCCTATGTAAGAATTGTCACTGTGATATTGAGGATTCCCTCTTCT
GAAGGGAGGCAAAAGGCTNTTTCTACCTGTGCAGGCCACCTCATGGTCTTCCTGATATTCT
TTGGCAGTGTATCACTCATGTACTTGCGTTTCAGCAACACTTATCCACCAGTTTTGGACAC
AGCCATTGCACTGATGTTTACTGTACTTGCTCCATTCTTCAATCCCATCATTTATAGCCTGA
GAAACAAGGACATGAACAATGCAATTAAAAAACTGTTCTGTCTTCAAAAAGTGTTGAACA
AGCCTGGAGGTTAA (SEQ ID NO: 286)

AOLFR157 sequences:

MAMDNVTAVFQFLLIGISNYPQWRDTFFTLVLIIYLSTLLGNGFMIFLIHFDPNLHTPIYFFLSNL
SFLDLCYGTASMPQALVHCFSTHPYLSYPRCLAQTSVSLALATAECLLLAAMAYDRVVAISNP
LRYSVVMNGPVCVCLVATSWGTSLVLTAMLILSLRLHFCGANVINHFACEILSLIKLTCSDTSL
NEFMILITSIFTLLLPFGFVLLSYIRIAMAIIRIRSLQGRLKAFTTCGSHLTVVTIFYGSAISMYMKT
QSKSSPDQDKFISVFYGALTPMLNPLIYSLRKKDVKRAIRKVMLKRT (SEQ ID NO: 287)

ATGGCCATGGACAATGTCACAGCAGTGTTTCAGTTTCTCCTTATTGGCATTTCTAACTATCC
TCAATGGAGAGACACGTTTTTCACATTAGTGCTGATAATTTACCTCAGCACATTGTTGGGG
AATGGATTTATGATCTTTCTTATTCACTTTGACCCCAACCTCCACACTCCAATCTACTTCTT
CCTTAGTAACCTGTCTTTCTTAGACCTTTGTTATGGAACAGCTTCCATGCCCCAGGCTTTGG
TGCATTGTTTCTCTACCCATCCCTACCTCTCTTATCCCCGATGTTTGGCTCAAACGAGTGTC
TCCTTGGCTTTGGCCACAGCAGAGTGCCTCCTACTGGCTGCCATGGCCTATGACCGTGTGG
TTGCTATCAGCAATCCCCTGCGTTATTCAGTGGTTATGAATGGCCCAGTGTGTGTCTGCTT
GGTTGCTACCTCATGGGGGACATCACTTGTGCTCACTGCCATGCTCATCCTATCCCTGAGG
CTTCACTTCTGTGGGGCTAATGTCATCAACCATTTTGCCTGTGAGATTCTCTCCCTCATTAA
GCTGACCTGTTCTGATACCAGCCTCAATGAATTTATGATCCTCATCACCAGTATCTTCACCC
TGCTGCTACCATTTGGGTTTGTTCTCCTCTCCTACATACGAATTGCTATGGCTATCATAAGG
ATTCGCTCACTCCAGGGCAGGCTCAAGGCCTTTACCACATGTGGCTCTCACCTGACCGTGG
TGACAATCTTCTATGGGTCAGCCATCTCCATGTATATGAAAACTCAGTCCAAGTCCTCCCC
TGACCAGGACAAGTTTATCTCAGTGTTTTATGGAGCTTTGACACCCATGTTGAACCCCCTG
ATATATAGCCTGAGAAAAAAAGATGTTAAACGGGCAATAAGGAAAGTTATGTTGAAAAGG
ACATGA (SEQ ID NO: 288)

AOLFR158 sequences:

MKAGNFSDTPEFFLLGLSGDPELQPILFMLFLSMYLATMLGNLLIILAVNSDSHLHTPMYFLLSI
LSLVDICFTSTTMPKMLVNIQAQAQSINYTGCLTQICFVLVFVGLENGILVMMAYDRFVAICHP
LRYNVIMNPKLCGLLLLLLSFIVSVLDALLHTLMVLQLTFCIDLEIPHFFCELAHILKLACSDVLIN
NILVYLVTSLLGVVPLSGIIFSYTRIVSSVMKIPSAGGKYKAFSICGSHLIVVSLFYGTGFGVYLSS
GATHSSRKGAIASVMYTVVTPMLNPLIYSLRNKDMLKALRKLISRIPSFH (SEQ ID NO: 289)

ATGAAAGCAGGAAACTTCTCAGACACTCCAGAATTCTTTCTCTTGGGATTGTCAGGGGATC
CGGAGCTGCAGCCCATCCTCTTCATGCTGTTCCTGTCCATGTACCTGGCCACAATGCTGGG
GAACCTGCTCATCATCCTGGCCGTCAACTCTGACTCCCACCTCCACACCCCCATGTACTTCC
TCCTCTCTATCCTGTCCTTGGTCGACATCTGTTTCACCTCCACCACGATGCCCAAGATGCTG
GTGAACATCCAGGCACAGGCTCAATCCATCAATTACACAGGCTGCCTCACCCAAATCTGCT
TTGTCCTGGTTTTTGTTGGATTGGAAAATGGAATTCTGGTCATGATGGCCTATGATCGATT
TGTGGCCATCTGTCACCCACTGAGGTACAATGTCATCATGAACCCCAAACTCTGTGGGCTG
CTGCTTCTGCTGTCCTTCATCGTTAGTGTCCTGGATGCTCTGCTGCACACGTTGATGGTGCT
ACAGCTGACCTTCTGCATAGACCTGGAAATTCCCCACTTTTTCTGTGAACTAGCTCATATTC
TCAAGCTCGCCTGTTCTGATGTCCTCATCAATAACATCCTGGTGTATTTGGTGACCAGCCT
GTTAGGTGTTGTTCCTCTCTCTGGGATCATTTTCTCTTACACACGAATTGTCTCCTCTGTCA
TGAAAATTCCATCAGCTGGTGGAAAGTATAAAGCTTTTTCCATCTGCGGGTCACATTTAAT
CGTTGTTTCCTTGTTTTATGGAACAGGGTTTGGGGTGTACCTTAGTTCTGGGGCTACCCACT
CCTCCAGGAAGGGTGCAATAGCATCAGTGATGTATACCGTGGTCACCCCCATGCTGAACCC
ACTCATTTACAGCCTGAGAAACAAGGACATGTTGAAGGCTTTGAGGAAACTAATATCTAG
GATACCATCTTTCCATTGA (SEQ ID NO: 290)

AOLFR159 sequences:

MGPRNQTAVSEFLLMKVTEDPELKLIPFSLFLSMYLVTILGNLLILLAVISDSHLHTPMYFLLFN
LSFTDICLTTTTVPKILVNIQAQNQSITYTGCLTQICLVLVFAGLESCFLAVMAYDRYVAICHPL
RYTVLMNVHFWGLLILLSMFMSTMDALVQSLMVLQLSFCKNVEIPLFFCEVVQVIKLACSDTL
INNILIYFASSVFGAIPLSGIIFSYSQIVTSVLRMPSARGKYKAFSTCGCHLSVFSLFYGTAFGVYIS
SAVAESSRITAVASVMYTVVPQMMNPFIYSLRNKEMKKALRKLIGRLFPF (SEQ ID NO: 291)

ATGGGACCCAGAAACCAAACAGCTGTTTCAGAATTTCTTCTCATGAAAGTGACAGAGGAC
CCAGAACTGAAGTTAATCCCTTTCAGCCTGTTCCTGTCCATGTACCTGGTCACCATCCTGG
GGAACCTGCTCATTCTCCTGGCTGTCATCTCTGACTCCCACCTCCACACCCCCATGTACTTC
CTTCTCTTTAATCTCTCCTTTACTGACATCTGTTTAACCACAACCACAGTCCCAAAGATCCT
AGTGAACATCCAAGCTCAGAATCAGAGTATCACTTACACAGGCTGCCTCACCCAGATCTGT
CTTGTCTTGGTTTTTGCTGGCTTGGAAAGTTGCTTTCTTGCAGTCATGGCCTACGACCGCTA
TGTGGCCATTTGCCACCCACTGAGGTACACAGTCCTCATGAATGTCCATTTCTGGGGCTTG
CTGATTCTTCTCTCCATGTTCATGAGCACTATGGATGCCCTGGTTCAGAGTCTGATGGTATT
GCAGCTGTCCTTCTGCAAAAACGTTGAAATCCCTTTGTTCTTCTGTGAAGTCGTTCAGGTC
ATCAAGCTCGCCTGTTCTGACACCCTCATCAACAACATCCTCATATATTTTGCAAGTAGTGT
ATTTGGTGCAATTCCTCTCTCTGGAATAATTTTCTCTTATTCTCAAATAGTCACCTCTGTTC
TGAGAATGCCATCAGCAAGAGGAAAGTATAAAGCGTTTTCCACCTGTGGCTGTCACCTCTC
TGTTTTTTCCTTGTTCTATGGGACAGCTTTTGGGGTGTACATTAGTTCTGCTGTTGCTGAGT
CTTCCCGAATTACTGCTGTGGCTTCAGTGATGTACACTGTGGTCCCTCAAATGATGAACCC
CTTCATCTACAGCCTGAGAAATAAGGAGATGAAGAAAGCTTTGAGGAAACTTATTGGTAG
GCTGTTTCCTTTTTAG (SEQ ID NO: 292)

AOLFR160 sequences:

MPMQLLLTDFIIFSIRFIINSMEARNQTAISKFLLLGLIEDPELQPVLFSLFLSMYLVTILGNLLILL
AVISDSHLHTPMYFFLSNLSFLDICLSTTTIPKMLVNIQAQNRSITYSGCLTQICFVLFFAGLENC
LLAAMAYDRYVAICHPLRYTVIMNPRLCGLLILLSLLTSVVNALLLSLMVLRLSFCTDLEIPLFF
CELAQVIQLTCSDTLINNILIYFAACIFGGVPLSGIILSYTQITSCVLRMPSASGKHKAVSTCGSHL
SIVLLFYGAGLGVYISSVVTDSPRKTAVASVMYSVFPQMVNPFIYSLRNKDMKGTLRKFIGRIP
SLLWCAICFGFRFLE (SEQ ID NO: 293)

ATGCCGATGCAGCTGCTGCTTACAGATTTTATTATCTTTTCCATCAGATTCATCATCAACAG
CATGGAAGCGAGAAACCAAACAGCTATTTCAAAATTCCTTCTCCTGGGACTGATAGAGGAT
CCGGAACTGCAGCCCGTCCTTTTCAGCCTGTTCCTGTCCATGTACTTGGTCACCATCCTGGG
GAACCTGCTCATCCTCTTGGCTGTCATCTCTGACTCTCACCTCCACACCCCCATGTACTTCT
TCCTCTCCAATCTCTCCTTTTTGGACATTTGTTTAAGCACAACCACGATCCCAAAGATGCTG
GTGAACATCCAAGCTCAGAATCGGAGCATCACGTACTCAGGCTGCCTCACCCAGATCTGCT

TTGTCTTGTTTTTTGCTGGCTTGGAAAATTGTCTCCTTGCAGCAATGGCCTATGACCGCTAT
GTGGCCATTTGTCACCCCCTTAGATACACAGTCATCATGAACCCCCGCCTCTGTGGCCTGC
TGATTCTTCTCTCTCTGTTGACTAGTGTTGTGAATGCCCTTCTTCTCAGCCTGATGGTGTTG
AGGCTGTCCTTCTGCACAGACCTGGAAATCCCGCTCTTCTTCTGTGAACTGGCTCAGGTCA
TCCAACTCACCTGTTCAGACACCCTCATCAATAACATCCTGATATATTTTGCAGCTTGCATA
TTTGGTGGTGTTCCTCTGTCTGGAATCATTTTGTCTTACACTCAGATCACCTCCTGTGTTTT
GAGAATGCCATCAGCAAGTGGAAAGCACAAAGCAGTTTCCACCTGTGGGTCTCACCTCTCC
ATTGTTCTCTTGTTCTATGGGGCAGGTTTGGGGGTGTACATTAGTTCTGTGGTTACTGACTC
ACCTAGGAAGACTGCAGTGGCTTCAGTGATGTATTCTGTGTTCCCTCAAATGGTGAACCCC
TTTATCTATAGTCTGAGGAATAAGGACATGAAAGGAACCTTGAGGAAGTTCATAGGGAGG
ATACCTTCTCTTCTGTGGTGTGCCATTTGCTTTGGATTCAGGTTTCTAGAGTAA (SEQ ID
NO: 294)

AOLFR161 sequences:

MEPRNQTSASQFILLGLSEKPEQETLLFSLFFCMYLVMVVGNLLIILAISIDSHLHTPMYFFLANL
SLVDFCLATNTIPKMLVSLQTGSKAISYPCCLIQMYFFHFFGIVDSVIIAMMAYDRFVAICHPLH
YAKIMSLRLCRLLVGALWAFSCFISLTHILLMARLVFCGSHEVPHYFCDLTPILRLSCTDTSVNR
IFILIVAGMVIATPFVCILASYARILVAIMKVPSAGGRKKAFSTCSSHLSVVALFYGTTIGVYLCP
SSVLTTVKEKASAVMYTAVTPMLNPFIYSLRNRDLKGALRKLVNRKITSSS (SEQ ID NO: 295)

ATGGAACCAAGAAACCAAACCAGTGCATCTCAATTCATCCTCCTGGGACTCTCAGAAAAGC
CAGAGCAGGAGACGCTTCTCTTTTCCCTGTTCTTCTGCATGTACCTGGTCATGGTCGTGGG
GAACCTGCTCATCATCCTGGCCATCAGCATAGACTCCCACCTCCACACCCCCATGTACTTCT
TCCTGGCCAACCTGTCCCTGGTTGATTTCTGTCTGGCCACCAACACCATCCCTAAGATGCT
GGTGAGCCTTCAAACCGGGAGCAAGGCCATCTCTTATCCCTGCTGCCTGATCCAGATGTAC
TTCTTCCATTTCTTTGGCATCGTGGACAGCGTCATAATCGCCATGATGGCTTATGACCGGTT
CGTGGCCATCTGCCACCCATTGCACTACGCCAAGATCATGAGCCTACGCCTCTGTCGCCTG
CTGGTCGGCGCCCTCTGGGCGTTTTCCTGCTTCATCTCACTCACTCACATCCTCCTGATGGC
CCGTCTCGTTTTCTGCGGCAGCCATGAGGTGCCTCACTACTTCTGCGACCTCACTCCCATCC
TCCGACTTTCGTGCACGGACACCTCTGTGAATAGGATCTTCATCCTCATTGTGGCAGGGAT
GGTGATAGCCACGCCCTTTGTCTGCATCCTGGCCTCCTATGCTCGCATCCTTGTGGCCATCA
TGAAGGTCCCCTCTGCAGGCGGCAGGAAGAAAGCCTTCTCCACCTGCAGCTCCCACCTGTC
TGTGGTTGCTCTCTTCTATGGGACCACCATTGGCGTCTATCTGTGTCCCTCCTCGGTCCTCA
CCACTGTGAAGGAGAAAGCTTCTGCGGTGATGTACACAGCAGTCACCCCCATGCTGAATCC
CTTCATCTACAGCTTGAGGAACAGAGACCTGAAAGGGGCTCTCAGGAAGCTGGTCAACAG
AAAGATCACCTCATCTTCCTGA (SEQ ID NO: 296)

AOLFR162 sequences:

MMRLMKEVRGRNQTEVTEFLLLGLSDNPDLQGVLFALFLLIYMANMVGNLGMIVLIKIDLCLH
TPMYFFLSSLSFVDASYSSSVTPKMLVNLMAENKAISFHGCAAQFYFFGSFLGTECFLLAMMA
YDRYAAIWNPLLYPVLVSGRICFLLIATSFLAGCGNAAIHTGMTFRLSFCGSNRINHFYCDTPPL
LKLSCSDTHFNGIVIMAFSSFIVISCVMIVLISYLCIFIAVLKMPSLEGRHKAFSTCASYLMAVTIF
FGTILFMYLRPTSSYSMEQDKVVSVFYTVIIPVLNPLIYSLKNKDVKKALKKILWKHIL (SEQ ID
NO: 297)

ATGATGAGACTTATGAAAGAGGTTCGAGGCAGAAATCAAACAGAAGTAACAGAATTTCTC
CTCTTAGGACTTTCCGACAATCCAGATCTACAAGGAGTCCTCTTTGCATTGTTTCTGTTGAT
CTATATGGCAAACATGGTGGGCAATTTGGGGATGATTGTATTGATTAAGATTGATCTCTGT
CTCCACACCCCCATGTATTTCTTTCTCAGTAGCCTCTCTTTTGTAGATGCCTCTTACTCTTCT
TCCGTCACTCCCAAGATGCTGGTGAACCTCATGGCTGAGAATAAGGCCATTTCTTTTCATG
GATGTGCTGCCCAGTTCTACTTCTTTGGCTCCTTCCTGGGGACTGAGTGCTTCCTGTTGGCC
ATGATGGCATATGACCGCTATGCAGCCATTTGGAACCCCCTGCTCTACCCAGTTCTCGTGT
CTGGGAGAATTTGCTTTTTGCTAATAGCTACCTCCTTCTTAGCAGGTTGTGGAAATGCAGC
CATACATACAGGGATGACTTTTAGGTTGTCCTTTTGTGGTTCTAATAGGATCAACCATTTCT
ACTGTGACACCCCGCCACTGCTCAAACTCTCTTGCTCTGATACCCACTTCAATGGCATTGTG
ATCATGGCATTCTCAAGTTTTATTGTCATCAGCTGTGTTATGATTGTCCTCATTTCCTACCT

123

GTGTATCTTCATTGCCGTCTTGAAGATGCCTTCGTTAGAGGGCAGGCACAAAGCCTTCTCC
ACCTGTGCCTCTTACCTCATGGCTGTCACCATATTCTTTGGAACAATCCTCTTCATGTACTT
GCGCCCTACATCTAGCTACTCAATGGAGCAAGACAAGGTTGTCTCTGTCTTTTATACAGTA
ATAATCCCTGTGCTAAATCCCCTCATCTATAGTTTAAAAAATAAGGATGTAAAAAAGGCCC
5   TAAAGAAGATCTTATGGAAACACATCTTGTAG (SEQ ID NO: 298)

AOLFR163 sequences:

MQRSNHTVTEFILLGFTTDPGMQLGLFVVFLGVYSLTVVGNSTLIVLICNDSCLHTPMYFFTGN
LSFLDLWYSSVYTPKILVTCISEDKSISFAGCLCQFFFSAGLAYSECYLLAAVAYDRYVAISKPL
10   LYAQAMSIKLCALLVAVSYCGGFINSSIITKKTFSFNFCRENIIDDFFCDLLPLVELACGEKGGYK
IMMYFLLASNVICPAVLILASYLFIITSVLRISSSKGYLKAFSTCSSHLTSVTLYYGSILYIYALPRS
SYSFDMDKIVSTFYTVVFPMLNLMIYSLRNKDVKEALKKLLP (SEQ ID NO: 299)

ATGCAGAGGAGCAATCATACAGTGACTGAGTTTATACTGCTGGGCTTCACCACAGACCCA
15   GGAATGCAGCTGGGCCTCTTCGTGGTGTTCCTGGGCGTGTACTCTCTCACTGTGGTAGGAA
ATAGCACCCTCATCGTGTTGATCTGTAATGACTCCTGCCTCCACACACCCATGTATTTTTTC
ACTGGAAATCTGTCGTTTCTGGATCTCTGGTATTCTTCTGTCTACACCCCAAAGATCCTAGT
GACCTGCATCTCTGAAGACAAAAGCATCTCCTTTGCTGGCTGCCTGTGTCAGTTCTTCTTCT
CTGCAGGGCTGGCCTATAGTGAGTGCTACCTGCTGGCTGCCGTGGCTTATGACCGCTACGT
20   GGCCATCTCCAAGCCCCTGCTTTATGCCCAGGCCATGTCCATAAAGCTGTGTGCATTGCTG
GTAGCAGTCTCATATTGTGGTGGCTTTATTAACTCTTCAATCATCACCAAGAAAACGTTTTC
CTTTAACTTCTGCCGTGAAAACATCATTGATGACTTTTTCTGTGATTTGCTTCCCTTGGTGG
AGCTGGCCTGTGGCGAGAAGGGCGGCTATAAAATTATGATGTACTTCCTGCTGGCCTCCAA
TGTCATCTGCCCCGCAGTGCTCATCCTGGCCTCCTACCTCTTTATCATCACCAGTGTCTTGA
25   GGATCTCCTCCTCCAAGGGCTACCTCAAAGCCTTCTCCACATGCTCCTCCCACCTGACCTCT
GTCACTTTATACTATGGCTCCATTCTCTACATCTACGCTCTCCCCAGATCTAGCTATTCTTT
TGATATGGACAAAATAGTTTCTACATTTTACACTGTGGTATTCCCCATGTTGAATCTCATG
ATCTACAGCCTAAGGAATAAGGATGTGAAAGAGGCTCTGAAAAAACTTCTCCCATAA (SEQ
ID NO: 300)

30

AOLFR164 sequences:

MFLTERNTTSEATFTLLGFSDYLELQIPLFFVFLAVYGFSVVGNLGMIVIIKINPKLHTPMYFFLN
HLSFVDFCYSSIIAPMMLVNLVVEDRTISFSGCLVQFFFFCTFVVTELILFAVMAYDHFVAICNP
LLYTVAISQKLCAMLVVVLYAWGVACSLTLACSALKLSFHGFNTINHFFCELSSLISLSYPDSYL
35   SQLLLFTVATFNEISTLLIILTSYAFIIVTTLKMPSASGHRKVFSTCASHLTAITIFHGTILFLYCVP
NSKNSRHTVKVASVFYTVVIPLLNPLIYSLRNKDVKDAIRKIINTKYFHIKHRHWYPFNFVIEQ
(SEQ ID NO: 301)

ATGTTTCTGACAGAGAGAAATACGACATCTGAGGCCACATTCACTCTCTTGGGCTTCTCAG
40   ATTACCTGGAACTGCAAATTCCCCTCTTCTTTGTATTTCTGGCAGTCTACGGCTTCAGTGTG
GTAGGGAATCTTGGGATGATAGTGATCATCAAAATTAACCCAAAATTGCATACCCCCATGT
ATTTTTTCCTCAACCACCTCTCCTTTGTGGATTTCTGCTATTCCTCCATCATTGCTCCCATGA
TGCTGGTGAACCTGGTTGTAGAAGATAGAACCATTTCATTCTCAGGATGTTTGGTGCAATT
CTTTTTCTTTTGCACCTTTGTAGTGACTGAATTAATTCTATTTGCGGTGATGGCCTATGACC
45   ACTTTGTGGCCATTTGCAATCCTCTGCTCTACACAGTTGCCATCTCCCAGAAACTCTGTGCC
ATGCTGGTGGTTGTATTGTATGCATGGGGAGTCGCATGTTCCCTGACACTCGCGTGCTCTG
CTTTAAAGTTATCTTTTCATGGTTTCAACACAATCAATCATTTCTTCTGTGAGTTATCCTCC
CTGATATCACTCTCTTACCCTGACTCTTATCTCAGCCAGTTGCTTCTTTTCACTGTTGCCAC
TTTTAATGAGATAAGCACACTACTCATCATTCTGACATCTTATGCATTCATCATTGTCACCA
50   CCTTGAAGATGCCTTCAGCCAGTGGGCACCGCAAAGTCTTCTCCACCTGTGCCTCCCACCT
GACTGCCATCACCATCTTCCATGGCACCATCCTCTTCCTCTACTGTGTACCCAACTCCAAAA
ACTCCAGGCACACAGTCAAAGTGGCCTCTGTGTTTTACACCGTGGTGATCCCCTTGTTGAA
TCCCCTGATCTACAGTCTGAGAAATAAAGATGTTAAGGATGCAATCCGAAAAATAATCAAT
ACAAAATATTTTCATATTAAACATAGGCATTGGTATCCATTTAATTTTGTTATTGAACAATA
55   A (SEQ ID NO: 302)

AOLFR165 sequences:

MAVGRNNTIVTKFILLGLSDHPQMKIFLFMLFLGLYLLTLAWNLSLIALIKMDSHLHMPMYFFL
SNLSFLDICYVSSTAPKMLSDIITEQKTISFVGCATQYFVFCGMGLTECFLLAAMAYDRYAAICN
PLLYTVLISHTLCLKMVVGAYVGGFLSSFIETYSVYQHDFCGPYMINHFFCDLPPVLALSCSDTF
TSEVVTFIVSVVVGIVSVLVVLISYGYIVAAVVKISSATGRTKAFSTCASHLTAVTLFYGSGFFM
YMRPSSSYSLNRDKVVSIFYALVIPVVNPIIYSFRNKEIKNAMRKAMERDPGISHGGPFIFMTLG
(SEQ ID NO: 303)

ATGGCTGTAGGAAGGAACAACACAATTGTGACAAAATTCATTCTCCTGGGACTTTCAGACC
ATCCTCAAATGAAGATTTTCCTTTTCATGTTATTTCTGGGGCTCTACCTCCTGACGTTGGCC
TGGAACTTAAGCCTCATTGCCCTCATTAAGATGGACTCTCACCTGCACATGCCCATGTACT
TCTTCCTCAGTAACCTGTCCTTCCTGGACATCTGCTATGTGTCCTCCACCGCCCCTAAGATG
CTGTCTGACATCATCACAGAGCAGAAAACCATTTCCTTTGTTGGCTGTGCCACTCAGTACT
TTGTCTTCTGTGGGATGGGGCTGACTGAATGCTTTCTCCTGGCAGCTATGGCCTATGACCG
GTATGCTGCAATCTGCAACCCCTTGCTTTACACAGTCCTCATATCCCATACACTTTGTTTAA
AGATGGTGGTTGGCGCCTATGTGGGTGGATTCCTTAGTTCTTTCATTGAAACATACTCTGT
CTATCAGCATGATTTCTGTGGGCCCTATATGATCAACCACTTTTTCTGTGACCTCCCTCCAG
TCCTGGCTCTGTCCTGCTCTGATACCTTCACCAGCGAGGTGGTGACCTTCATAGTCAGTGTT
GTCGTTGGAATAGTGTCTGTGCTAGTGGTCCTCATCTCTTATGGTTACATTGTTGCTGCTGT
TGTGAAGATCAGCTCAGCTACAGGTAGGACAAAGGCCTTCAGCACTTGTGCCTCTCACCTG
ACTGCTGTGACCCTCTTCTATGGTTCTGGATTCTTCATGTACATGCGACCCAGTTCCAGCTA
CTCCCTAAACAGGGACAAGGTGGTGTCCATATTCTATGCCTTGGTGATCCCCGTGGTGAAT
CCCATCATCTACAGTTTTAGGAATAAGGAGATTAAAAATGCCATGAGGAAAGCCATGGAA
AGGGACCCCGGGATTTCTCACGGTGGACCATTCATTTTTATGACCTTGGGCTAA (SEQ ID
NO: 304)

AOLFR166 sequences:

MEMENCTRVKEFIFLGLTQNREVSLVLFLFLLLVYVTTLLGNLLIMVTVTCESRLHTPMYFLLH
NLSIADICFSSITVPKVLVDLLSERKTISFNHCFTQMFLFHLIGGVDVFSLSVMALDRYVAISKPL
HYATIMSRDHCIGLTVAAWLGGFVHSIVQISLLLPLPFCGPNVLDTFYCDVHRVLKLAHTDIFIL
ELLMISNNGLLTTLWFFLLLVSYIVILSLPKSQAGEGRRKAISTCTSHITVVTLHFVPCIYVYARP
FTALPMDKAISVTFTVISPLLNPLIYTLRNHEMKSAMRRLKRRLVPSDRK (SEQ ID NO: 305)

ATGGAGATGGAAAACTGCACCAGGGTAAAAGAATTTATTTTCCTTGGCCTGACCCAGAATC
GGGAAGTGAGCTTAGTCTTATTTCTTTTCCTACTCTTGGTGTATGTGACAACTTTGCTGGGA
AACCTCCTCATCATGGTCACTGTTACCTGTGAATCTCGCCTTCACACGCCCATGTATTTTTT
GCTCCATAATTTATCTATTGCCGATATCTGCTTCTCTTCCATCACAGTGCCCAAGGTTCTGG
TGGACCTTCTGTCTGAAAGAAAGACCATCTCCTTCAATCATTGCTTCACTCAGATGTTTCTA
TTCCACCTTATTGGAGGGGTGGATGTATTTTCTCTTTCGGTGATGGCATTGGATCGATATG
TGGCCATCTCCAAGCCCCTGCACTATGCGACTATCATGAGTAGAGACCATTGCATTGGGCT
CACAGTGGCTGCCTGGTTGGGGGGCTTTGTCCACTCCATCGTGCAGATTTCCCTGTTGCTC
CCACTCCCTTTCTGCGGACCCAATGTTCTTGACACTTTCTACTGTGATGTCCACCGGGTCCT
CAAACTGGCCCATACAGACATTTTCATACTTGAACTACTAATGATTTCCAACAATGGACTG
CTCACCACACTGTGGTTTTTCCTGCTCCTGGTGTCCTACATAGTCATATTATCATTACCCAA
GTCTCAGGCAGGAGAGGGCAGGAGGAAAGCCATCTCCACCTGCACCTCCCACATCACTGT
GGTGACCCTGCATTTCGTGCCCTGCATCTATGTCTATGCCCGGCCCTTCACTGCCCTCCCCA
TGGATAAGGCCATCTCTGTCACCTTCACTGTCATCTCCCCTCTGCTCAACCCCTTGATCTAC
ACTCTGAGGAACCATGAGATGAAGTCAGCCATGAGGAGACTGAAGAGAAGACTTGTGCCT
TCTGATAGAAAATAG *SEQ ID NO: 306)

AOLFR167 sequences:

MSITKAWNSSSVTMFILLGFTDHPELQALLFVTFLGIYLTTLAWNLALIFLIRGDTHLHTPMYFF
LSNLSFIDICYSSAVAPNMLTDFFWEQKTISFVGCAAQFFFFVGMGLSECLLLTAMAYDRYAAI
SSPLLYPTIMTQGLCTRMVVGAYVGGFLSSLIQASSIFRLHFCGPNIINHFFCDLPPVLALSCSDT
FLSQVVNFLVVVTVGGTSFLQLLISYGYIVSAVLKIPSAEGRWKACNTCASHLMVVTLLFGTAL

FVYLRPSSSYLLGRDKVVSVFYSLVIPMLNPLIYSLRNKEIKDALWKVLERKKVFS (SEQ ID NO: 307)

ATGTCCATAACCAAAGCCTGGAACAGCTCATCAGTGACCATGTTCATCCTCCTGGGATTCA
CAGACCATCCAGAACTCCAGGCCCTCCTCTTTGTGACCTTCCTGGGCATCTATCTTACCACC
CTGGCCTGGAACCTGGCCCTCATTTTTCTGATCAGAGGTGACACCCATCTGCACACACCCA
TGTACTTCTTCCTAAGCAACTTATCTTTCATTGACATCTGCTACTCTTCTGCTGTGGCTCCC
AATATGCTCACTGACTTCTTCTGGGAGCAGAAGACCATATCATTTGTGGGCTGTGCTGCTC
AGTTTTTTTTCTTTGTCGGCATGGGTCTGTCTGAGTGCCTCCTCCTGACTGCTATGGCATAC
GACCGATATGCAGCCATCTCCAGCCCCCTTCTCTACCCCACTATCATGACCCAGGGCCTCT
GTACACGCATGGTGGTTGGGGCATATGTTGGTGGCTTCCTGAGCTCCCTGATCCAGGCCAG
CTCCATATTTAGGCTTCACTTTTGCGGACCCAACATCATCAACCACTTCTTCTGCGACCTCC
CACCAGTCCTGGCTCTGTCTTGCTCTGACACCTTCCTCAGTCAAGTGGTGAATTTCCTCGTG
GTGGTCACTGTCGGAGGAACATCGTTCCTCCAACTCCTTATCTCCTATGGTTACATAGTGT
CTGCGGTCCTGAAGATCCCTTCAGCAGAGGGCCGATGGAAAGCCTGCAACACGTGTGCCT
CGCATCTGATGGTGGTGACTCTGCTGTTTGGGACAGCCCTTTTCGTGTACTTGCGACCCAG
CTCCAGCTACTTGCTAGGCAGGGACAAGGTGGTGTCTGTTTTCTATTCATTGGTGATCCCC
ATGCTGAACCCTCTCATTTACAGTTTGAGGAACAAAGAGATCAAGGATGCCCTGTGGAAG
GTGTTGGAAAGGAAGAAAGTGTTTCTTAG (SEQ ID NO: 308)

AOLFR168 sequences:

MEKINNVTEFIFWGLSQSPEIEKVCFVVFSFFYIIILLGNLLIMLTVCLSNLFKSPMYFFLSFLSFV
DICYSSVTAPKMIVDLLAKDKTISYVGCMLQLLGVHFFGCTEIFILTVMAYDRYVAICKPLHYM
TIMNRETCNKMLLGTWVGGFLHSIIQVALVVQLPFCGPNEIDHYFCDVHPVLKLACTETYIVG
VVVTANSGTIALGSFVILLISYSIILVSLRKQSAEGRRKALSTCGSHIAMVVIFFGPCTFMYMRPD
TTFSEDKMVAVFYTIITPMLNPLIYTLRNAEVKNAMKKLWGRNVFLEAKGK (SEQ ID NO: 309)

ATGGAAAAAATAAACAACGTAACTGAATTCATTTTCTGGGGTCTTTCTCAGAGCCCAGAGA
TTGAGAAAGTTTGTTTTGTGGTGTTTTCTTTCTTCTACATAATCATTCTTCTGGGAAATCTC
CTCATCATGCTGACAGTTTGCCTGAGCAACCTGTTTAAGTCACCCATGTATTTCTTTCTCAG
CTTCTTGTCTTTTGTGGACATTTGTTACTCTTCAGTCACAGCTCCCAAGATGATTGTTGACC
TGTTAGCAAAGGACAAAACCATCTCCTIATGTGGGGTGCATGTTGCAACTGCTTGGAGTAC
ATTTCTTTGGTTGCACTGAGATCTTCATCCTTACTGTAATGGCCTATGATCGTTATGTGGCT
ATCTGTAAACCCCTACATTATATGACCATCATGAACCGGGAGACATGCAATAAAATGTTAT
TAGGGACGTGGGTAGGTGGGTTCTTACACTCCATTATCCAAGTGGCTCTGGTAGTCCAACT
ACCCTTTTGTGGACCCAATGAGATAGATCACTACTTTTGTGATGTTCACCCTGTGTTGAAA
CTTGCCTGCACAGAAACATACATTGTTGGTGTTGTTGTGACAGCCAACAGTGGTACCATTG
CTCTGGGGAGTTTTGTTATCTTGCTAATCTCCTACAGCATCATCCTAGTTTCCCTGAGAAAG
CAGTCAGCAGAAGGCAGGCGCAAAGCCCTCTCCACCTGTGGCTCCCACATTGCCATGGTCG
TTATCTTTTTCGGCCCCTGTACTTTTATGTACATGCGCCCTGATACGACCTTTTCAGAGGAT
AAGATGGTGGCTGTATTTTACACCATTATCACTCCCATGTTAAATCCTCTGATTTATACACT
GAGAAATGCAGAAGTAAAGAATGCAATGAAGAAACTGTGGGGCAGAAATGTTTTCTTGGA
GGCTAAAGGGAAATAG (SEQ ID NO: 310)

AOLFR169 sequences:

MMDNHSSATEFHLLGFPGSQGLHHILFAIFFFFYLVTLMGNTVIIVIVCVDKRLQSPMYFFLSHL
STLEILVTTIIVPMMLWGLLFLGCRQYLSLHVSLNFSCGTMEFALLGVMAVDRYVAVCNPLRY
NIIMNSSTCIWVVIVSWVFGFLSEIWPIYATFQFTFRKSNSLDHFYCDRGQLLKLSCDNTLLTEFI
LFLMAVFILIGSLIPTIVSYTYIISTILKIPSASGRRKAFSTFASHFTCVVIGYGSCLFLYVKPKQTQ
GVEYNKIVSLLVSVLTPFLNPFIFTLRNDKVKEALRDGMKRCCQLLKD (SEQ ID NO: 311)

ATGATGGACAACCACTCTAGTGCCACTGAATTCCACCTTCTAGGCTTCCCTGGGTCCCAAG
GACTACACCACATTCTTTTTGCTATATTCTTTTTCTTCTATTTAGTGACATTAATGGGAAAC
ACGGTCATCATTGTGATTGTCTGTGTGGATAAACGTCTGCAGTCCCCCATGTATTTCTTCCT
CAGCCACCTCTCTACCCTGGAGATCCTGGTCACAACCATAATTGTCCCCATGATGCTTTGG

GGATTGCTCTTCCTGGGATGCAGACAGTATCTTTCTCTACATGTATCGCTCAACTTTTCCTG
TGGGACCATGGAGTTTGCATTACTTGGAGTGATGGCTGTGGACCGTTATGTGGCTGTGTGT
AACCCTTTGAGGTACAACATCATTATGAACAGCAGTACCTGTATTTGGGTGGTAATAGTGT
CATGGGTGTTTGGATTTCTTTCTGAAATCTGGCCCATCTATGCCACATTTCAGTTTACCTTC
CGCAAATCAAATTCATTAGACCATTTTTACTGTGACCGAGGGCAATTGCTCAAACTGTCCT
GCGATAACACTCTTCTCACAGAGTTTATCCTTTTCTTAATGGCTGTTTTTATTCTCATTGGT
TCTTTGATCCCTACGATTGTCTCCTACACCTACATTATCTCCACCATCCTCAAGATCCCGTC
AGCCTCTGGCCGGAGGAAAGCCTTCTCCACTTTTGCCTCCCACTTCACCTGTGTTGTGATTG
GCTATGGCAGCTGCTTGTTTCTCTACGTGAAACCCAAGCAAACACAGGGAGTTGAGTACAA
TAAGATAGTTTCCCTGTTGGTTTCTGTGTTAACCCCCTTCCTGAATCCTTTCATCTTTACTCT
TCGGAATGACAAAGTCAAAGAGGCCCTCCGAGATGGGATGAAACGCTGCTGTCAACTCCT
GAAAGATTAG (SEQ ID NO: 312)

AOLFR170 sequences:

MSFTSLIPSLCFSLTLPFLFCYLSLLPFLSAFLFITRWLLAFLSLFSVSVPVSSVSSSMVLCLYLSVS
ASPSVFCFSCMQGPILWIMANLSQPSEFVLLGFSSFGELQALLYGPFLMLYLLAFMGNTIIIVMVI
ADTHLHTPMYFFLGNFSLLEILVTMTAVPRMLSDLLVPHKVITFTGCMVQFYHFSLGSTSFLIL
TDMALDRFVAICHPLRYGTLMSRAMCVQLAGAAWAAPFLAMVPTVLSRAHLDYCHGDVINH
FFCDNEPLLQLSCSDTRLLEFWDFLMALTFVLSSFLVTLISYGYIVTTVLRIPSASSCQKAFSTCG
SHLTLVFIGYSSTIFLYVRPGKAHSVQVRKVVALVTSVLTPFLNPFILTFCNQTVKTVLQGQMQ
RLKGLCKAQ (SEQ ID NO: 313)

ATGTCTTTCACTTCTCTCATACCCTCACTCTGTTTCTCCTTGACTCTCCCATTCCTGTTTTGT
TATCTTTCTTTATTGCCGTTTCTTTCTGCTTTTCTGTTTATCACTCGCTGGCTACTTGCCTTT
CTCTCTCTATTCTCTGTCTCTGTCCCTGTTTCTTCTGTTTCAAGTTCAATGGTTCTCTGTCTC
TATCTCTCTGTTTCTGCCTCTCCGTCTGTCTTTTGTTTCTCTTGCATGCAGGGCCCCATACTG
TGGATCATGGCAAATCTGAGCCAGCCCTCCGAATTTGTCCTCTTGGGCTTCTCCTCCTTTGG
TGAGCTGCAGGCCCTTCTGTATGGCCCCTTCCTCATGCTTTATCTTCTCGCCTTCATGGGAA
ACACCATCATCATAGTTATGGTCATAGCTGACACCCACCTACATACACCCATGTACTTCTTC
CTGGGCAATTTTTCCCTGCTGGAGATCTTGGTAACCATGACTGCAGTGCCCAGGATGCTCT
CAGACCTGTTGGTCCCCCACAAAGTCATTACCTTCACTGGCTGCATGGTCCAGTTCTACTTC
CACTTTTCCCTGGGGTCCACCTCCTTCCTCATCCTGACAGACATGGCCCTTGATCGCTTTGT
GGCCATCTGCCACCCACTGCGCTATGGCACTCTGATGAGCCGGGCTATGTGTGTCCAGCTG
GCTGGGGCTGCCTGGGCAGCTCCTTTCCTAGCCATGGTACCCACTGTCCTCTCCCGAGCTC
ATCTTGATTACTGCCATGGCGACGTCATCAACCACTTCTTCTGTGACAATGAACCTCTCCTG
CAGTTGTCATGCTCTGACACTCGCCTGTTGGAATTCTGGGACTTTCTGATGGCCTTGACCTT
TGTCCTCAGCTCCTTCCTGGTGACCCTCATCTCCTATGGCTACATAGTGACCACTGTGCTGC
GGATCCCCTCTGCCAGCAGCTGCCAGAAGGCTTTCTCCACTTGCGGGTCTCACCTCACACT
GGTCTTCATCGGCTACAGTAGTACCATCTTTCTGTATGTCAGGCCTGGCAAAGCTCACTCT
GTGCAAGTCAGGAAGGTCGTGGCCTTGGTGACTTCAGTTCTCACCCCCTTTCTCAATCCCT
TTATCCTTACCTTCTGCAATCAGACAGTTAAAACAGTGCTACAGGGGCAGATGCAGAGGCT
GAAAGGCCTTTGCAAGGCACAATGA (SEQ ID NO: 314)

AOLFR171 sequences:

MVGNLLIWVTTIGSPSLGSLMYFFLAYLSLMDAIYSTAMSPKLMIDLLCDKIAISLSACMGQLFI
EHLLGGAEVFLLVVMAYDRYVAISKPLHYLNIMNRLVCILLLVVAMIGGFVHSVVQIVFLYSLP
ICGPNVIDHSVCDMYPLLELLCLDTYFIGLTVVANGGIICMVIFTFLLISCGVILNFLKTYSQEER
HKALPTCISHIIVVALVFVPCIFMYVRPVSNFPFDKLMTVFYSIITLMLNPLIYSLRQSEMKNAM
KNLWCEKLSIVRKRVSPTLNIFIPSSKATNRR (SEQ ID NO: 315)

ATGGTGGGAAACCTCCTCATTTGGGTGACTACTATTGGCAGCCCCTCCTTGGGCTCCCTAA
TGTACTTCTTCCTTGCCTACTTGTCACTTATGGATGCCATATATTCCACTGCCATGTCACCC
AAATTGATGATAGACTTACTCTGTGATAAAATCGCTATTTCCTTGTCAGCTTGCATGGGTC
AGCTCTTCATAGAACACTTACTTGGTGGTGCAGAGGTCTTCCTTTTGGTGGTGATGGCCTA
TGATCGCTATGTGGCTATCTCTAAGCCGCTGCACTATTTGAACATCATGAATCGACTGGTT
TGCATCCTTCTGTTGGTGGTGGCCATGATTGGAGGTTTTGTGCACTCTGTGGTTCAAATTGT

CTTTCTGTACAGTCTACCAATCTGTGGCCCCAATGTTATTGACCACTCTGTCTGTGACATGT
ACCCATTGTTGGAACTGTTGTGCCTTGACACCTACTTTATAGGACTCACTGTGGTTGCCAA
TGGTGGAATAATTTGTATGGTCATCTTTACCTTTCTGCTAATCTCCTGTGGAGTCATCCTAA
ACTTCCTTAAAACTTACAGTCAGGAAGAGAGGCATAAAGCCCTGCCTACCTGCATCTCCCA

5   CATCATTGTGGTTGCCCTCGTTTTTGTTCCCTGTATTTTTATGTATGTTAGACCCGTTTCCA
ACTTTCCCTTTGATAAATTAATGACTGTGTTTTATTCAATTATCACACTCATGTTGAATCCT
TTAATATACTCGTTGAGACAATCAGAGATGAAAAATGCTATGAAAAATCTCTGGTGTGAA
AAGTTAAGTATAGTTAGAAAAGAGTATCTCCCACACTGAACATATTTATTCCTAGTTCTA
AGGCAACAAATAGGCGGTAA (SEQ ID NO: 316)

10

AOLFR172 sequences:

MAETLQLNSTFLHPNFFILTGFPGLGSAQTWLTLVFGPIYLLALLGNGALPAVVWIDSTLHQPM
FLLLAILAATDLGLATSIAPGLLAVLWLGPRSVPYAVCLVQMFFVHALTAMESGVLLAMACDR
AAAIGRPLHYPVLVTKACVGYAALALALKAVAIVVPFPLLVAKFEHFQAKTIGHTYCAHMAV

15   VELVVGNTQATNLYGLALSLAISGMDILGITGSYGLIAHAVLQLPTREAHAKAFGTCSSHICVIL
AFYIPGLFSYLAHRFGHHTVPKPVHILLSNIYLLLPPALNPLIYGARTKQIRDRLLETFTFRKSPL
(SEQ ID NO: 317)

ATGGCAGAAACTCTACAACTCAATTCCACCTTCCTACACCCAAACTTCTTCATACTGACTG

20   GCTTTCCAGGGCTAGGAAGTGCCCAGACTTGGCTGACACTGGTCTTTGGGCCCATTTATCT
GCTGGCCCTGCTGGGCAATGGAGCACTGCCGGCAGTGGTGTGGATAGACTCCACACTGCA
CCAGCCCATGTTTCTACTGTTGGCCATCCTGGCAGCCACAGACCTGGGCTTAGCCACATCT
ATAGCCCCAGGGTTGCTGGCTGTGCTGTGGCTTGGGCCCCGATCTGTGCCATATGCTGTGT
GCCTGGTCCAGATGTTCTTTGTACATGCACTGACTGCCATGGAATCAGGTGTGCTTTTGGC

25   CATGGCCTGTGATCGTGCTGCGGCAATAGGGCGTCCACTGCACTACCCTGTCCTGGTCACC
AAAGCCTGTGTGGGTTATGCAGCCTTGGCCCTGGCACTGAAAGCTGTGGCTATTGTTGTAC
CTTTCCCACTGCTGGTGGCAAAGTTTGAGCACTTCCAAGCCAAGACCATAGGCCATACCTA
TTGTGCACACATGGCAGTGGTAGAACTGGTGGTGGGTAACACACAGGCCACCAACTTATA
TGGTCTGGCACTTTCACTGGCCATCTCAGGTATGGATATTCTGGGTATCACTGGCTCCTAT

30   GGACTCATTGCCCATGCTGTGCTGCAGCTACCTACCCGGGAGGCCCATGCCAAGGCCTTTG
GTACATGTAGTTCTCACATCTGTGTCATTCTGGCCTTCTACATACCTGGTCTCTTCTCCTAC
CTCGCACACCGCTTTGGTCATCACACTGTCCCAAAGCCTGTGCACATCCTTCTCTCCAACAT
CTACTTGCTGCTGCCACCTGCCCTCAACCCCCTCATCTATGGGCCCGCACCAAGCAGATC
AGAGACCGACTCCTGGAAACCTTCACATTCAGAAAAAGCCCGTTGTAA (SEQ ID NO: 318)

35

AOLFR173 sequences:

MSHTNVTIFHPAVFVLPGIPGLEAYHIWLSIPLCLIYITAVLGNSILIVVIVMERNLHVPMYFFLS
MLAVMDILLSTTTVPKALAIFWLQAHNIAFDACVTQGFFVHMMFVGESAILLAMAFDRFVAIC
APLRYTTVLTWPVVGRIALAVITRSFCIIFPVIFLLKRLPFCLTNIVPHSYCEHIGVARLACADITV

40   NIWYGFSVPIVMVILDVILIAVSYSLILRAVFRLPSQDARHKALSTCGSHLCVILMFYVPSFFTLL
THHFGRNIPQHVHILLANLYVAVPPMLNPIVYGVKTKQIREGVAHRFFDIKTWCCTSPLGS
(SEQ ID NO: 319)

ATGAGTCACACCAATGTTACCATCTTCCATCCTGCAGTTTTTGTCCTTCCTGGCATCCCTGG

45   GTTGGAGGCTTATCACATTTGGCTGTCAATACCTCTTTGCCTCATTTACATCACTGCAGTCC
TGGGAAACAGCATCCTGATAGTGGTTATTGTCATGGAACGTAACCTTCATGTGCCCATGTA
TTTCTTCCTCTCAATGCTGGCCGTCATGGACATCCTGCTGTCTACCACCACTGTGCCCAAGG
CCCTAGCCATCTTTTGGCTTCAAGCACATAACATTGCTTTTGATGCCTGTGTCACCCAAGGC
TTCTTTGTCCATATGATGTTTGTGGGGGAGTCAGCTATCCTGTTAGCCATGGCCTTTGATCG

50   CTTTGTGGCCATTTGTGCCCCACTGAGATATACAACAGTGCTAACATGGCCTGTTGTGGGG
AGGATTGCTCTGGCCGTCATCACCCGAAGCTTCTGCATCATCTTCCCAGTCATATTCTTGCT
GAAGCGGCTGCCCTTCTGCCTAACCAACATTGTTCCTCACTCCTACTGTGAGCATATTGGA
GTGGCTCGTTTAGCCTGTGCTGACATCACTGTTAACATTTGGTATGGCTTCTCAGTGCCCAT
TGTCATGGTCATCTTGGATGTTATCCTCATCGCTGTGTCTTACTCACTGATCCTCCGAGCAG

55   TGTTTCGTTTGCCCTCCCAGGATGCTCGGCACAAGGCCCTCAGCACTTGTGGCTCCCACCT
CTGTGTCATCCTTATGTTTTATGTTCCATCCTTCTTTACCTTATTGACCCATCATTTTGGGCG

128

TAATATTCCTCAACATGTCCATATCTTGCTGGCCAATCTTTATGTGGCAGTGCCACCAATGC
TGAACCCCATTGTCTATGGTGTGAAGACTAAGCAGATACGTGAGGGTGTAGCCCACCGGTT
CTTTGACATCAAGACTTGGTGCTGTACCTCCCCTCTGGGCTCATGA (SEQ ID NO: 320)

5   **AOLFR175 sequences:**

MHFLSQNDLNINLIPHLCLHRHSVIAGAFTIHRHMKIFNSPSNSSTFTGFILLGFPCPREGQILLFV
LFTVVYLLTLMGNGSIICAVHWDQRLHAPMYILLANFSFLEICYVTSTVPSMLANFLSDTKIISF
SGCFLQFYFFFSLGSTECFFLAVMAFDRYLAICRPLRYPTIMTRRLCTNLVVNCWVLGFIWFLIPI
VNISQMSFCGSRIIDHFLCDPAPLLTLTCKKGPVIELVFSVLSPLPVFMLFLFIVGSYALVVRAVL
10   RVPSAAGRRKAFSTCGSHLAVVSLFYGSVLVMYGSPPSKNEAGKQKTVTLFYSVVTPLLNPVI
YSLRNKDMRKALKKFWGT (SEQ ID NO: 321)

ATGCATTTTCTTTCCCAAAATGATTTAAATATAAATCTGATTCCCCATCTATGTTTGCACCG
TCATTCAGTAATTGCTGGTGCTTTTACAATTCACAGGCACATGAAAATCTTCAACAGCCCC
15   AGCAACTCCAGCACCTTCACTGGCTTCATCCTCCTGGGCTTCCCTTGCCCCAGGGAGGGGC
AGATCCTCCTCTTTGTGCTCTTCACTGTTGTTTACCTCCTGACCCTCATGGGCAATGGTTCC
ATCATCTGTGCTGTGCACTGGGATCAGAGACTCCACGCCCCCATGTACATCCTGCTCGCCA
ACTTCTCCTTCTTGGAGATATGTTATGTCACCTCCACAGTCCCCAGCATGCTGGCCAACTTC
CTCTCTGACACCAAGATCATCTCGTTCTCTGGCTGCTTCCTCCAGTTCTACTTTTTCTTCTCC
20   TTGGGCTCTACAGAATGCTTTTTCCTGGCAGTTATGGCATTTGATCGATACCTTGCCATCTG
TCGGCCTCTACGCTATCCAACCATTATGACCAGACGTCTCTGTACCAATCTTGTGGTCAATT
GCTGGGTACTTGGTTTCATCTGGTTCTTGATTCCTATCGTCAACATCTCCCAAATGTCCTTC
TGTGGATCTAGGATTATTGACCACTTCCTATGTGACCCAGCTCCTCTTCTAACTCTCACTTG
CAAAAAAGGCCCTGTGATAGAGCTTGTCTTTTCTGTCTTAAGTCCTCTGCCTGTCTTTATGC
25   TCTTTCTCTTCATTGTGGGGTCCTATGCTCTGGTCGTGAGAGCTGTGTTGAGGGTCCCTTCA
GCAGCTGGGAGAAGAAAGGCTTTCTCCACCTGTGGGTCTCACCTGGCTGTGGTTTCACTGT
TCTACGGCTCAGTACTGGTCATGTATGGGAGCCCACCATCTAAGAATGAAGCTGGAAAGC
AGAAGACTGTGACTCTGTTTTATTCTGTTGTTACCCCACTGCTTAACCCTGTGATATATAGT
CTTAGGAACAAAGATATGAGAAAGCTCTGAAGAAATTTTGGGGAACATAA (SEQ ID NO:
30   322)

AOLFR176 sequences:

MFFIIHSLVTSVFLTALGPQNRTMHFVTEFVLLGFHGQREMQSCFFSFILVLYLLTLLGNGAIVC
AVKLDRRLHTPMYILLGNFAFLEIWYISSTVPNMLVNILSEIKTISFSGCFLQFYFFFSLGTTECFF
35   LSVMAYDRYLAICRPLHYPSIMTGKFCIILVCVCWVGGFLCYPVPIVLISQLPFCGPNIIDHLVCD
PGPLFALACISAPSTELICYTFNSMIIFGPFLSILGSYTLVIRAVLCIPSGAGRTKAFSTCGSHLMV
VSLFYGTLMVMYVSPTSGNPAGMQKIITLVYTAMTPFLNPLIYSLRNKDMKDALKRVLGLTVS
QN (SEQ ID NO: 323)

40   ATGTTCTTTATTATTCATTCTTTGGTTACTTCTGTTTTTCTAACAGCTTTGGGACCCCAGAA
CAGAACAATGCATTTTGTGACTGAGTTTGTCCTCCTGGGTTTCCATGGTCAAAGGGAGATG
CAGAGCTGCTTCTTCTCATTCATCCTGGTTCTCTATCTCCTGACACTGCTAGGGAATGGAGC
TATTGTCTGTGCAGTGAAATTGGACAGGCGGCTCCACACACCCATGTACATCCTTCTGGGA
AACTTTGCCTTTCTAGAGATCTGGTACATTTCCTCCACTGTCCCAAACATGCTAGTCAATAT
45   CCTCTCTGAGATTAAAACCATCTCCTTCTCTGGTTGCTTCCTGCAATTCTATTTCTTTTTTTTC
ACTGGGTACAACAGAGTGTTTCTTTTTATCAGTTATGGCTTATGATCGGTACCTGGCCATC
TGTCGTCCATTACACTACCCCTCCATCATGACTGGGAAGTTCTGTATAATTCTGGTCTGTGT
ATGCTGGGTAGGCGGATTTCTCTGCTATCCAGTCCCTATTGTTCTTATCTCCCAACTTCCCT
TCTGTGGGCCCAACATCATTGACCACTTGGTGTGTGACCCAGGCCCATTGTTTGCACTGGC
50   CTGCATCTCTGCTCCTTCCACTGAGCTTATCTGTTACACCTTCAACTCGATGATTATCTTTG
GGCCCTTCCTCTCCATCTTGGGATCTTACACTCTGGTCATCAGAGCTGTGCTTTGTATTCCC
TCTGGTGCTGGTCGAACTAAAGCTTTCTCCACATGTGGGTCCCACCTAATGGTGGTGTCTC
TATTCTATGGAACCCTTATGGTGATGTATGTGAGCCCAACATCAGGGAACCCAGCAGGAAT
GCAGAAGATCATCACTCTGGTATACACAGCAATGACTCCATTCTTAAATCCCCTTATCTAT
55   AGTCTTCGAAACAAAGACATGAAAGATGCTCTAAAGAGAGTCCTGGGGTTAACAGTTAGC
CAAAACTGA (SEQ ID NO: 324)

129

AOLFR177 sequences:

MSFFFVDLRPMNRSATHIVTEFILLGFPGCWKIQIFLFSLFLVIYVLTLLGNGAIIYAVRCNPLLH
TPMYFLLGNFAFLEIWYVSSTIPNMLVNILSKTKAISFSGCFLQFYFFFSLGTTECLFLAVMAYD
RYLAICHPLQYPAIMTVRFCGKLVSFCWLIGFLGYPIPIFYISQLPFCGPNIIDHFLCDMDPLMAL
SCAPAPITECIFYTQSSLVLFFTSMYILRSYILLLTAVFQVPSAAGRRKAFSTCGSHLVVVSLFYG
TVMVMYVSPTYGIPTLLQKILTLVYSVTTPLFNPLIYTLRNKDMKLALRNVLFGMRIRQNS
(SEQ ID NO: 325)

ATGTCTTTCTTCTTTGTAGACTTAAGACCCATGAACAGGTCAGCAACACACATCGTGACAG
AGTTTATTCTCCTGGGATTCCCTGGTTGCTGGAAGATTCAGATTTTCCTCTTCTCATTGTTT
TTGGTGATTTATGTCTTGACCTTGCTGGGAAATGGAGCCATCATCTATGCAGTGAGATGCA
ACCCACTACTACACACCCCCATGTACTTTCTGCTGGGAAATTTTGCCTTCCTTGAGATCTGG
TATGTGTCCTCCACTATTCCTAACATGCTAGTCAACATTCTCTCCAAGACCAAGGCCATCTC
ATTTTCTGGGTGCTTCCTCCAGTTCTATTTCTTCTTTTCACTGGGAACAACTGAATGTCTCT
TTCTGGCAGTAATGGCTTATGATCGATACCTGGCCATCTGCCACCCACTGCAGTACCCTGC
CATCATGACTGTAAGGTTCTGTGGTAAGCTGGTGTCTTTCTGTTGGCTTATTGGATTCCTTG
GATACCCAATTCCCATTTTCTACATCTCCCAACTCCCCTTCTGTGGTCCTAATATCATTGAT
CACTTCCTGTGTGACATGGACCCATTGATGGCTCTATCCTGTGCCCCAGCTCCCATAACTG
AATGTATTTTCTATACTCAGAGCTCCCTTGTCCTCTTTTTCACTAGTATGTACATTCTTCGA
TCCTATATCCTGTTACTAACAGCTGTTTTTCAGGTCCCTTCTGCAGCTGGTCGGAGAAAAG
CCTTCTCTACCTGTGGTTCTCATTTGGTTGTGGTATCTCTTTTCTATGGGACAGTCATGGTA
ATGTATGTAAGTCCTACATATGGGATCCCAACTTTATTGCAGAAGATCCTCACACTGGTAT
ATTCAGTAACGACTCCTCTTTTTAATCCTCTGATCTATACTCTTCGTAATAAGGACATGAAA
CTCGCTCTGAGAAATGTCCTGTTTGGAATGAGAATTCGTCAAAATTCGTGA (SEQ ID NO:
326)

AOLFR178 sequences:

MVGANHSVVSEFVFLGLTNSWEIRLLLLVFSSMFYMASMMGNSLILLTVTSDPHLHSPMYFLL
ANLSFIDLGVSSVTSPKMIYDLFRKHEVISFGGCIAQIFFIHVIGGVEMVLLIAMAFDRYVAICKP
LQYLTIMSPRMCMFFLVAAWVTGLIHSVVQLVFVVNLPFCGPNVSDSFYCDLPRFIKLACTDSY
RLEFMVTANSGFISLGSFFILIISYVVIILTVLKHSSAGLSKALSTLSAHVSVVVLFFGPLIFVYTW
PSPSTHLDKFLAIFDAVLTPVLNPIIYTFRN (SEQ ID NO: 327)

ATGGTTGGGGCAAATCACTCCGTGGTGTCAGAGTTTGTGTTCCTGGGACTCACCAATTCCT
GGGAGATCCGACTTCTCCTCCTTGTGTTCTCCTCCATGTTTTACATGGCCAGTATGATGGGA
AACTCTCTCATTTTGCTCACTGTGACTTCTGACCCTCACTTGCACTCCCCCATGTATTTTCT
GTTAGCCAACCTCTCCTTCATTGACCTGGGTGTTTCCTCTGTCACTTCTCCCAAAATGATTT
ATGACCTGTTCAGAAAGCACGAAGTCATCTCCTTTGGAGGCTGCATCGCTCAAATCTTCTT
CATCCACGTCATTGGCGGTGTGGAGATGGTGCTGCTCATAGCCATGGCCTTTGACAGATAT
GTGGCCATATGTAAGCCCCTCCAGTACCTGACCATTATGAGCCCAAGAATGTGCATGTTCT
TCTTAGTGGCTGCCTGGGTGACCGGCCTTATCCACTCTGTAGTTCAATTGGTTTTTGTAGTA
AACTTGCCCTTCTGTGGTCCTAATGTATCGGACAGCTTTTACTGTGACCTTCCTCGGTTCAT
CAAACTTGCCTGCACAGACAGCTACCGACTGGAGTTCATGGTTACAGCCAACAGTGGATTC
ATCTCTCTGGGCTCCTTCTTCATACTGATCATTTCCTATGTGGTCATCATTCTCACTGTTCT
GAAACACTCTTCAGCTGGTTTATCCAAGGCTCTGTCCACCCTTTCAGCTCACGTCAGTGTG
GTAGTTTTGTTCTTTGGTCCTTTGATTTTTGTCTATACGTGGCCATCTCCCTCCACACACCT
GGATAAGTTTCTGGCCATCTTTGATGCAGTTCTCACTCCTGTTTTAAATCCTATCATCTACA
CATTCAGGAATTGA (SEQ ID NO: 328)

AOLFR179 sequences:

MNGMNHSVVSEFVFMGLTNSREIQLLLLFVFSLLFYFASMMGNLVIVFTVTMDAHLHSPMYFLL
ANLSIIDMAFCSITAPKMICDIFKKHKAISFRGCITQIFFSHALGGTEMVLLIAMAFDRYMAICKP
LHYLTIMSPRMCLYFLATSSIIGLIHSLVQLVFVVDLPFCGPNIFDSFYCDLPRLLRLACTNTQEL
EFMVTVNSGLISVGSFVLLVISYIFILFTVWKHSSGGLAKALSTLSAHVTVVILFFGPLMFFYTW
PSPTSHLDKYLAIFDAFITPFLNPVIYTFRNKDMKVAMRRLCSRLAHFTKIL (SEQ ID NO: 329)

ATGAATGGAATGAATCACTCTGTGGTATCAGAATTTGTATTCATGGGACTCACCAACTCAC
GGGAGATTCAGCTTCTACTTTTTGTTTTCTCTTGTTGTTCTACTTTGCGAGCATGATGGGA
AACCTTGTCATTGTATTCACTGTAACCATGGATGCTCATCTGCACTCCCCCATGTATTTCCT

5

CCTGGCTAACCTCTCAATCATTGATATGGCATTTTGCTCAATTACAGCCCCTAAGATGATTT
GTGATATTTTCAAGAAGCACAAGGCCATCTCCTTTCGGGGATGTATTACTCAGATCTTCTT
TAGCCATGCTCTTGGGGGCACTGAGATGGTGCTGCTCATAGCCATGGCCTTTGACAGATAC
ATGGCCATATGTAAACCTCTCCACTACCTGACCATCATGAGCCCAAGAATGTGTCTATACT
TTTTAGCCACTTCCTCTATCATTGGCCTTATCCACTCATTGGTCCAATTAGTTTTTGTGGTA

10

GATTTACCTTTTTGTGGTCCTAATATCTTTGACAGTTTTTACTGTGATCTCCCTCGGCTCCT
CAGACTTGCCTGTACCAACACCCAAGAACTGGAGTTCATGGTCACTGTCAATAGTGGACTC
ATTTCTGTGGGCTCCTTTGTCTTGCTGGTAATTTCCTACATCTTCATTCTGTTCACTGTTTG
GAAACATTCTTCTGGTGGTCTAGCCAAGGCCCTCTCTACCCTGTCAGCTCATGTCACTGTG
GTCATCTTGTTCTTTGGGCCACTGATGTTTTTCTACACATGGCCTTCTCCCACATCACACCT

15

GGATAAATATCTTGCTATTTTTGATGCATTTATTACTCCTTTTCTGAATCCAGTTATCTACA
CATTCAGGAACAAAGACATGAAAGTGGCAATGAGGAGACTGTGCAGTCGTCTTGCGCATT
TTACAAAGATTTTGTAA (SEQ ID NO: 330)

AOLFR180 sequences:

20

MTNKMYAIYIKNLNYFSFLIVQCLQPTMAIFNNTTSSSSNFLLTAFPGLECAHVWISIPVCCLYTI
ALLGNSMIFLVIITKRRLHKPMYYFLSMLAAVDLCLTITTLPTVLGVLWFHAREISFKACFIQMF
FVHAFSLLESSVLVAMAFDRFVAICNPLNYATILTDRMVLVIGLVICIRPAVFLLPLLVAINTVSF
HGGHELSHPFCYHPEVIKYTYSKPWISSFWGLFLQLYLNGTDVLFILFSYVLILRTVLGIVARKK
QQKALSTCVCHICAVTIFYVPLISLSLAHRLFHSTPRVLCSTLANIYLLLPPVLNPIIYSLKTKTIR

25

QAMFQLLQSKGSWGFNVRGLRGRWD (SEQ ID NO: 331)

ATGACTAATAAAATGTATGCTATATATATAAAGAATCTTAATTATTTTTCTTTCCTCATAGT
TCAGTGTCTTCAACCAACCATGGCAATATTCAATAACACCACTTCGTCTTCCTCAAACTTCC
TCCTCACTGCATTCCCTGGGCTGGAATGTGCTCATGTCTGGATCTCCATTCCAGTCTGCTGT

30

CTCTACACCATTGCCCTCTTGGGAAACAGTATGATCTTTCTTGTCATCATTACTAAGCGGA
GACTCCACAAACCCATGTATTATTTCCTCTCCATGCTGGCAGCTGTTGATCTATGTCTGACC
ATTACGACCCTTCCCACTGTGCTTGGTGTTCTCTGGTTTCATGCCCGGGAGATCAGCTTTAA
AGCTTGCTTCATTCAAATGTTCTTTGTGCATGCTTTCTCCTTGCTGGAGTCCTCGGTGCTGG
TAGCCATGGCCTTTGACCGCTTCGTGGCTATCTGTAACCCACTGAACTATGCTACTATCCTC

35

ACAGACAGGATGGTCCTGGTGATAGGGCTGGTCATCTGCATTAGACCAGCAGTTTTCTTAC
TTCCCCTTCTTGTAGCCATAAACACTGTGTCTTTTCATGGGGGTCACGAGCTTTCCCATCCA
TTTTGCTACCACCCAGAAGTGATCAAATACACATATTCCAAACCTTGGATCAGCAGTTTTT
GGGGACTGTTTCTTCAGCTCTACCTGAATGGCACTGACGTATTGTTTATTCTTTTCTCCTAT
GTCCTGATCCTCCGTACTGTTCTGGGCATTGTGGCCCGAAAGAAGCAACAAAAAGCTCTCA

40

GCACTTGTGTCTGTCACATCTGTGCAGTCACTATTTTCTATGTGCCACTGATCAGCCTCTCT
TTGGCACACCGCCTCTTCCACTCCACCCCAAGGGTGCTCTGTAGCACTTTGGCCAATATTTA
TCTGCTCTTACCACCTGTGCTGAACCCATCATTTACAGCTTGAAGACCAAGACAATCCGC
CAGGCTATGTTCCAGCTGCTCCAATCCAAGGGTTCATGGGGTTTTAATGTGAGGGGTCTTA
GGGGAAGATGGGATTGA (SEQ ID NO: 332)

45

AOLFR181 sequences:

MSVLNNSEVKLFLLIGIPGLEHAHIWFSIPICLMYLLAIMGNCTILFIIKTEPSLHEPMYYFLAML
AVSDMGLSLSSSLPTMLRVFLFNAMGISPNACFAQEFFIHGFTVMESSVLLIMSLDRFLAIHNPLR
YSSILTSNRVAKMGLILAIRSILLVIPFPFTLRRLKYCQKNLLSHSYCLHQDTMKLACSDNKTNV

50

IYGFFIALCTMLDLALIVLSYVLILKTILSIASLAERLKALNTCVSHICAVLTFYVPIITLAAMHHF
AKHKSPLVVILIADMFLLVPPLMNPIVYCVKTRQIWEKILGKLLNVCGR (SEQ ID NO: 333)

ATGTCTGTTCTCAATAACTCCGAAGTCAAGCTTTTCCTTCTGATTGGGATCCCAGGACTGG
AACATGCCCACATTTGGTTCTCCATCCCCATTTGCCTCATGTACCTGCTTGCCATCATGGGC

55

AACTGCACCATTCTCTTTATTATAAAGACAGAGCCCTCGCTTCATGAGCCCATGTATTATTT
CCTTGCCATGTTGGCTGTCTCTGACATGGGCCTGTCCCTCTCCTCCCTTCCTACCATGTTGA

GGGTCTTCTTGTTCAATGCCATGGGAATTTCACCTAATGCCTGCTTTGCTCAAGAATTCTTC
ATTCATGGATTCACTGTCATGGAATCCTCAGTACTTCTAATTATGTCTTTGGACCGCTTTCT
TGCCATTCACAATCCCTTAAGATACAGTTCTATCCTCACTAGCAACAGGGTTGCTAAAATG
GGACTTATTTTAGCCATTAGGAGCATTCTCTTAGTGATTCCATTTCCCTTCACCTTAAGGAG

5   ATTAAAATATTGTCAAAAGAATCTTCTTTCTCACTCATACTGTCTTCATCAGGATACCATGA
AGCTGGCCTGCTCTGACAACAAGACCAATGTCATCTATGGCTTCTTCATTGCTCTCTGTACT
ATGCTGGACTTGGCACTGATTGTTTTGTCTTATGTGCTGATCTTGAAGACTATACTCAGCAT
TGCATCTTTGGCAGAGAGGCTTAAGGCCCTAAATACCTGTGTCTCCCACATCTGTGCTGTG
CTCACCTTCTATGTGCCCATCATCACCCTGGCTGCCATGCATCACTTTGCCAAGCACAAAA

10   GCCCTCTTGTTGTGATCCTTATTGCAGATATGTTCTTGTTGGTGCCGCCCCTTATGAACCCC
ATTGTGTACTGTGTAAAGACTCGACAAATCTGGGAGAAGATCTTGGGGAAGTTGCTTAAT
GTATGTGGGAGATAA (SEQ ID NO: 334)

AOLFR182 sequences:

15   MTLGSLGNSSSSVSATFLLSGIPGLERMHIWISIPLCFMYLVSIPGNCTILFIIKTERSLHEPMYLFL
SMLALIDLGLSLCTLPTVLGIFWVGAREISHDACFAQLFFIHCFSFLESSVLLSMAFDRFVAICHP
LHYVSILTNTVIGRIGLVSLGRSVALIFPLPFMLKRFPYCGSPVLSHSYCLHQEVMKLACADMK
ANSIYGMFVIVSTVGIDSLLILFSYALILRTVLSIASRAERFKALNTCVSHICAVLLFYTPMIGLSV
IHRFGKQAPHLVQVVMGFMYLLFPPVMNPIVYSVKTKQIRDRVTHAFCY (SEQ ID NO: 335)

20
ATGACCCTGGGATCCCTGGGAAACAGCAGCAGCAGCGTTTCTGCTACCTTCCTGCTGAGTG
GCATCCCTGGGCTGGAGCGCATGCACATCTGGATCTCCATCCCACTGTGCTTCATGTATCT
GGTTTCCATCCCGGGCAACTGCACAATTCTTTTTATCATTAAAACAGAGCGCTCACTTCAT
GAACCTATGTATCTCTTCCTGTCCATGCTGGCTCTGATTGACCTGGGTCTCTCCCTTTGCAC

25   TCTCCCTACAGTCCTGGGCATCTTTTGGGTTGGAGCACGAGAAATTAGCCATGATGCCTGC
TTTGCTCAGCTCTTTTTCATTCACTGCTTCTCCTTCCTCGAGTCCTCTGTGCTACTGTCTATG
GCCTTTGACCGCTTTGTGGCTATCTGCCACCCCTTGCACTATGTTTCCATTCTCACCAACAC
AGTCATTGGCAGGATTGGCCTGGTCTCTCTGGGTCGTAGTGTAGCACTCATTTTTCCATTA
CCTTTTATGCTCAAAAGATTCCCCTATTGTGGCTCCCCAGTTCTCTCACATTCTTATTGTCT

30   CCACCAAGAAGTGATGAAATTGGCCTGTGCCGACATGAAGGCCAACAGCATCTACGGCAT
GTTTGTCATCGTCTCTACAGTGGGTATAGACTCACTGCTCATCCTCTTCTCTTATGCTCTGA
TCCTGCGCACCGTGCTGTCCATCGCCTCCAGGGCTGAGAGATTCAAGGCCCTTAACACCTG
TGTTTCCCACATCTGTGCTGTGCTGCTCTTCTACACTCCCATGATTGGCCTCTCTGTCATCC
ATCGCTTTGGAAAGCAGGCACCCCACCTGGTCCAGGTGGTCATGGGTTTCATGTATCTTCT

35   CTTTCCTCCTGTGATGAATCCCATTGTCTACAGTGTGAAGACCAAACAGATCCGGGATCGA
GTGACGCATGCCTTTTGTTACTAA (SEQ ID NO: 336)

AOLFR183 sequences:

MTNLNASQANHRNFILTGIPGTPDKNPWLAFPLGFLYTLTLLGNGTILAVIKVEPSLHEPTYYFL
40   SILALTDVSLSMSTLPSMLSIYWFNAPQIVFDACIMQMFFIHVFGIVESGVLVSMAFDRFVAIRN
PLHYVSILTHDVIRKTGISVLTRAVCVVFPVPFLIKCLPFCHSNVLSHSYCLHQNMMRLACASTR
INSLYGLIVVIFTLGLDVLLTLLSYVLTLKTVLGIVSRGERLKTLSTCLSHMSTVLLFYVPFMGA
ASMIHRFWEHLSPVVHMVMADIYLLLPPVLNPIVYSVKTKQI (SEQ ID NO: 337)

45   ATGACGAACTTGAATGCATCACAGGCCAACCACCGTAACTTCATTCTGACAGGTATCCCAG
GAACGCCAGACAAGAACCCATGGTTGGCCTTTCCCCTGGGATTTCTCTACACACTCACACT
CCTGGGAAATGGTACCATCCTAGCTGTCATCAAGGTGGAGCCAAGTCTCCATGAGCCCACG
TATTACTTCCTTTCTATCTTGGCTCTCACTGACGTTAGTCTCTCCATGTCCACCTTGCCCTCC
ATGCTCAGCATCTACTGGTTTAATGCCCCTCAGATTGTTTTTGATGCATGCATCATGCAGAT

50   GTTCTTCATCCATGTATTTGGAATAGTAGAATCAGGAGTCCTAGTGTCCATGGCCTTTGAC
AGATTTGTGGCCATCCGAAACCCATTACACTATGTTTCCATCCTCACTCACGATGTTATTCG
AAAGACTGGAATATCTGTCCTCACCCGGGCAGTCTGTGTGGTATTCCCTGTGCCCTTCCTT
ATAAAGTGCCTACCCTTCTGCCATTCCAATGTCTTGTCTCATTCATACTGTCTTCACCAAAA
CATGATGCGGCTAGCTTGTGCCAGCACCCGCATCAACAGCCTCTACGGCCTCATCGTCGTC

55   ATCTTCACACTGGGGCTCGATGTTCTCCTCACTCTACTGTCTTATGTACTCACCCTGAAGAC
TGTGCTGGGCATTGTCTCCAGAGGTGAAAGGCTGAAAACCCTCAGCACATGCCTCTCTCAC

ATGTCTACCGTGCTCCTCTTCTATGTTCCTTTTATGGGTGCTGCCTCCATGATCCACAGATT
TTGGGAGCATTTATCACCAGTAGTGCACATGGTCATGGCTGATATATACCTACTGCTCCCG
CCTGTGCTAAACCCCATTGTCTACAGTGTGAAGACCAAGCAAATTTGA (SEQ ID NO: 338)

5   **AOLFR184 sequences:**

MSTLPTQIAPNSSTSMAPTFLLVGMPGLSGAPSWWTLPLIAVYLLSALGNGTILWIIALQPALHR
PMHFFLFLLSVSDIGLVTALMPTLLGIALAGAHTVPASACLLQMVFIHVFSVMESSVLLAMSID
RALAICRPLHYPALLTNGVISKISLAISFRCLGLHLPLPFLLAYMPYCLPQVLTHSYCLHPDVARL
ACPEAWGAAYSLFVVLSAMGLDPLLIFFSYGLIGKVLQGVESREDRWKAGQTCAAHLSAVLLF
10   YIPMILLALINHPELPITQHTHTLLSYVHFLLPPLINPILYSVKMKEIRKRILNRLQPRKVGGAQ
(SEQ ID NO: 339)

ATGTCAACATTACCAACTCAGATAGCCCCCAATAGCAGCACTTCAATGGCCCCCACCTTCT
TGCTGGTGGGCATGCCAGGCCTATCAGGTGCACCCTCCTGGTGGACATTGCCCCTCATTGC
15   TGTCTACCTTCTCTCTGCACTGGGAAATGGCACCATCCTCTGGATCATTGCCCTGCAGCCC
GCCCTGCACCGCCCAATGCACTTCTTCCTCTTCTTGCTTAGTGTGTCTGATATTGGATTGGT
CACTGCCCTGATGCCCACACTGCTGGGCATCGCCCTTGCTGGTGCTCACACTGTCCCTGCC
TCAGCCTGCCTTCTACAGATGGTTTTTATCCATGTCTTTTCTGTCATGGAGTCCTCTGTCTT
GCTCGCCATGTCCATTGATCGGGCACTGGCCATCTGCCGACCTCTCCACTACCCAGCGCTC
20   CTCACCAATGGTGTAATTAGCAAAATCAGCCTGGCCATTTCTTTTCGATGCCTGGGTCTCC
ATCTGCCCCTGCCATTCCTGCTGGCCTACATGCCCTACTGCCTCCCACAGGTCCTAACCCAT
TCTTATTGCTTGCATCCAGATGTGGCTCGTTTGGCCTGCCCAGAAGCTTGGGGTGCAGCCT
ACAGCCTATTTGTGGTTCTTTCAGCCATGGGTTTGGACCCCCTGCTTATTTTCTTCTCCTAT
GGCCTGATTGGCAAGGTGTTGCAAGGTGTGGAGTCCAGAGAGGATCGCTGGAAGGCTGGT
25   CAAACCTGTGCTGCCCACCTCTCTGCAGTGCTCCTCTTCTATATCCCTATGATCCTCCTGGC
ACTGATTAACCATCCTGAGCTGCCAATCACTCAGCATACCCATACTCTTCTATCCTATGTCC
ATTTCCTTCTTCCTCCATTGATAAACCCTATTCTCTATAGTGTCAAGATGAAGGAGATTAGA
AAGAGAATACTCAACAGGTTGCAGCCCAGGAAGGTGGGTGGTGCTCAGTGA (SEQ ID NO:
340)
30

AOLFR185 sequences:

MFYPILNDISTKNNSNIMSCCNILFIKTVEIILVYNQTQSPWYPIVPSKSLVYNNNTCFDCYHLQR
VDCVPSRDHINQSMVLASGNSSSHPVSFILLGIPGLESFQLWIAFPFCATYAVAVVGNITLLHVIR
IDHTLHEPMYLFLAMLAITDLVLSSSTQPKMLAIFWFHAHEIQYHACLIQVFFIHAFSSVESGVL
35   MAMALDCYVATCFPLRHSSILTPSVVIKLGTIVMLRGLLWVSPFCFMVSRMPFCQHQAIPQSYC
EHMAVLKLVCADTSISRGYGLFVAFSVAGFDMIVIGMSYVMILRAVLQLPSGEARLKAFSTRA
SHICVILALYIPALFSFLTYRFGHDVPRVVHILFANLYLLIPPMLNPIIYGVRTKQIGDRVIQGCCG
NIP (SEQ ID NO: 341)

40   ATGTTCTACCCCATTTTGAATGACATAAGTACGAAAAACAACAGTAACATCATGTCATGTT
GTAACATATTATTTATTAAAACAGTTGAAATTATTCTAGTTTATAATCAAACCCAATCACC
CTGGTATCCAATAGTCCCATCCAAAAGCCTTGTATATAATAATAACACTTGTTTTGATTGTT
ATCATCTGCAGAGAGTAGATTGCGTTCCCAGCAGAGACCATATTAACCAGTCCATGGTGCT
GGCTTCAGGGAACAGCTCTTCTCATCCTGTGTCCTTCATCCTGCTTGGAATCCCAGGCCTG
45   GAGAGTTTCCAGTTGTGGATTGCCTTTCCGTTCTGTGCCACGTATGCTGTGGCTGTTGTTGG
AAATATCACTCTCCTCCATGTAATCAGAATTGACCACACCCTGCATGAGCCCATGTACCTC
TTTCTGGCCATGCTGGCCATCACTGACCTGGTCCTCTCCTCCTCCACTCAACCTAAGATGTT
GGCCATATTCTGGTTTCATGCTCATGAGATTCAGTACCATGCCTGCCTCATCCAGGTGTTCT
TCATCCATGCCTTTTCTTCTGTGGAGTCTGGGGTGCTCATGGCTATGGCCCTGGACTGCTAC
50   GTGGCTACCTGCTTCCCACTCCGACACTCTAGCATCCTGACCCCATCGGTCGTGATCAAAC
TGGGGACCATCGTGATGCTGAGAGGGCTGCTGTGGGTGAGCCCCTTCTGCTTCATGGTGTC
TAGGATGCCCTTCTGCCAACACCAAGCCATTCCCCAGTCATACTGTGAGCACATGGCTGTG
CTGAAGTTGGTGTGTGCTGATACAAGCATAAGTCGTGGGTATGGGCTCTTTGTGGCCTTCT
CTGTGGCTGGCTTTGATATGATTGTCATTGGTATGTCATACGTGATGATTTTGAGAGCTGT
55   GCTTCAGTTGCCCTCAGGTGAAGCCCGCCTCAAAGCTTTTAGCACACGTGCCTCCCATATC
TGTGTCATCTTGGCTCTTTATATCCCAGCCCTTTTTTCTTTCCTCACCTACCGCTTTGGCCAT

GATGTGCCCCGAGTTGTACACATCCTGTTTGCTAATCTCTATCTACTGATACCTCCCATGCT
CAACCCCATCATTTATGGAGTTAGAACCAAACAGATCGGGGACAGGGTTATCCAAGGATG
TTGTGGAAACATCCCCTGA (SEQ ID NO: 342)

5   **AOLFR186 sequences:**

MSNASLVTAFILTGLPHAPGLDALLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYYFLTNLS
FIDMWFSTVTVPKMLMTLVSPSGRAISFHSCVAQLYFFHFLGSTECFLYTVMSYDRYLAISYPL
RYTSMMSGSRCALLATGTWLSGSLHSAVQTILTFHLPYCGPNQIQHYFCDAPPILKLACADTSA
NVMVIFVDIGIVASGCFVLIVLSYVSIVCSILRIRTSDGRRRAFQTCASHCIVVLCFFVPCVVIYLR
10   PGSMDAMDGVVAIFYTVLTPLLNPVVYTLRNKEVKKAVLKLRDKVAHPQRK (SEQ ID NO:
343)

ATGTCCAACGCCAGCCTCGTGACAGCATTCATCCTCACAGGCCTTCCCCATGCCCCAGGGC
TGGACGCCCTCCTCTTTGGAATCTTCCTGGTGGTTTACGTGCTCACTGTGCTGGGGAACCT
15   CCTCATCCTGCTGGTGATCAGGGTGGATTCTCACCTCCACACCCCCATGTACTACTTCCTCA
CCAACCTGTCCTTCATTGACATGTGGTTCTCCACTGTCACGGTGCCCAAAATGCTGATGAC
CTTGGTGTCCCCAAGCGGCAGGGCTATCTCCTTCCACAGCTGCGTGGCTCAGCTCTATTTTT
TCCACTTCCTGGGGAGCACCGAGTGTTTCCTCTACACAGTCATGTCCTATGATCGCTACTTG
GCCATCAGTTACCCGCTCAGGTACACCAGCATGATGAGTGGGAGCAGGTGTGCCCTCCTGG
20   CCACCGGCACTTGGCTCAGTGGCTCTCTGCACTCTGCTGTCCAGACCATATTGACTTTCCAT
TTGCCCTACTGTGGACCCAACCAGATCCAGCACTACTTCTGTGACGCACCGCCCATCCTGA
AACTGGCCTGTGCAGACACCTCAGCCAACGTGATGGTCATCTTTGTGGACATTGGGATAGT
GGCCTCAGGCTGCTTTGTCCTGATAGTGCTGTCCTATGTGTCCATCGTCTGTTCCATCCTGC
GGATCCGCACCTCAGATGGGAGGCGCAGAGCCTTTCAGACCTGTGCCTCCCACTGTATTGT
25   GGTCCTTTGCTTCTTTGTTCCCTGTGTTGTCATTTATCTGAGGCCAGGCTCCATGGATGCCA
TGGATGGAGTTGTGGCCATTTTCTACACTGTGCTGACGCCCCTTCTCAACCCTGTTGTGTAC
ACCCTGAGAAACAAGGAGGTGAAGAAAGCTGTGTTGAAACTTAGAGACAAAGTAGCACAT
CCTCAGAGGAAATAA (SEQ ID NO: 344)

30   **AOLFR187 sequences:**

MAQVRALHKIMALFSANSIGAMNNSDTRIAGCFLTGIPGLEQLHIWLSIPFCIMYIAALEGNGILI
CVILSQAILHEPMYIFLSMLASADVLLSTTTMPKALANLWLGYSHISFDGCLTQKFFIHFLFIHSA
VLLAMAFDRYVAICSPLRYVTILTSKVIGKIVTATLSRSFIIMFPSIFLLEHLHYCQINIIAHTFCEH
MGIAHLSCSDISINVWYGLAAALLSTGLDIMLITVSYIHILQAVFRLLSQDARSKALSTCGSHICV
35   ILLFYVPALFSVFAYRFGGRSIPCYVHILLASLYVVIPPMLNPVIYGVRTKPILEGAKQMFSNLAK
GSK (SEQ ID NO: 345)

ATGGCACAGGTGAGGGCGCTGCATAAAATCATGGCCCTTTTTTCTGCTAACAGCATAGGTG
CTATGAACAACTCTGACACTCGCATAGCAGGCTGCTTCCTCACTGGCATCCCTGGGCTGGA
40   GCAACTACATATCTGGCTGTCCATCCCCTTCTGCATCATGTACATCGCTGCCCTGGAAGGC
AATGGCATCCTAATTTGTGTCATCCTCTCCCAGGCAATCCTGCATGAGCCCATGTACATAT
TCTTATCTATGCTGGCCAGTGCTGATGTCTTGCTCTCTACCACCACCATGCCTAAGGCCCTG
GCCAATTTGTGGCTAGGTTATAGCCACATTTCCTTTGATGGCTGCCTCACTCAAAAGTTCTT
CATTCACTTCCTCTTCATTCACTCTGCTGTCCTGCTGGCCATGGCCTTTGACCGCTATGTGG
45   CCATCTGCTCCCCCCTGCGATATGTCACAATCCTCACAAGCAAGGTCATTGGGAAGATCGT
CACTGCCACCCTGAGCCGCAGCTTCATCATTATGTTTCCATCCATCTTTCTCCTTGAGCACC
TGCACTATTGCCAGATCAACATCATTGCACACACATTTTGTGAGCACATGGGCATTGCCCA
TCTGTCCTGTTCTGATATCTCCATCAATGTCTGGTATGGGTTGGCAGCTGCTCTTCTCTCCA
CAGGCCTGGACATCATGCTTATTACTGTTTCCTACATCCACATCCTCCAAGCAGTCTTCCGC
50   CTCCTTTCTCAAGATGCCCGCTCCAAGGCCCTGAGTACCTGTGGATCCCATATCTGTGTCAT
CCTACTCTTCTATGTCCCTGCCCTTTTTCTGTCTTTGCCTACAGGTTTGGTGGGAGAAGCA
TCCCATGCTATGTCCATATTCTCCTGGCCAGCCTCTACGTTGTCATTCCTCCTATGCTCAAT
CCCGTTATTTATGGAGTGAGGACTAAGCCAATACTGGAAGGGGCTAAGCAGATGTTTTCA
AATCTTGCCAAAGGATCTAAATAA (SEQ ID NO: 346)

55

AOLFR188 sequences:

MFPSLCPCVLLVQLPLMNENMQCFVFCSCDSLLRMMVSRFIHVPFVKMKRIIVGGYSKHFFSN
ELLCVRPWSGKTWSIRHHIFDMELLTNNLKFITDPFVCRLRHLSPTPSEEHMKNKNNVTEFILL
GLTQNPEGQKVLFVTFLLIYMVTIMGNLLIIVTIMASQSLGSPMYFFLASLSFIDTVYSTAFAPK
MIVDLLSEKKTISFQGCMAQLFMDHLFAGAEVILLVVMAYDRYMAICKPLHELITMNRRVCVL
MLLAAWIGGFLHSLVQFLFIYQLPFCGPNVIDNFLCDLYPLLKLACTNTYVTGLSMIANGGAIC
AVTFFTILLSYGVILHSLKTQSLEGKRKAFYTCASHVTVVILFFVPCIFLYARPNSTFPIDKSMTV
VLTFITPMLNPLIYTLKNAEMKSAMRKLWSKKVSLAGKWLYHS (SEQ ID NO: 347)

ATGTTCCCCTCCCTGTGTCCATGTGTTCTCCTTGTTCAACTCCCACTTATGAATGAGAACAT
GCAGTGTTTTGTTTTCTGTTCTTGTGATAGTTTGCTGAGAATGATGGTTTCCCGCTTCATCC
ATGTCCCATTTGTAAAAATGAAAGGATAATTGTGGGAGGATATTCTAAACACTTCTTTTC
TAATGAGCTGCTCTGTGTGAGGCCCTGGTCAGGGAAAACGTGGTCGATAAGGCATCACAT
TTTTGACATGGAGCTTCTGACAAATAATCTCAAATTTATCACTGACCCTTTTGTTTGTAGGC
TCCGACACCTGAGTCCAACACCTTCAGAAGAACACATGAAAAATAAGAACAATGTGACTG
AATTTATCCTCTTAGGGCTCACACAGAACCCTGAGGGGCAAAAGGTTTTATTTGTCACATT
CTTACTAATCTACATGGTGACGATAATGGGCAACCTGCTTATCATAGTGACCATCATGGCC
AGCCAGTCCCTGGGTTCCCCCATGTACTTTTTTCTGGCTTCTTTATCATTCATAGATACCGT
CTATTCTACTGCATTTGCTCCCAAAATGATTGTTGACTTGCTCTCTGAGAAAAAGACCATTT
CCTTTCAGGGTTGTATGGCTCAACTTTTTATGGATCATTTATTTGCTGGTGCTGAAGTCATT
CTTCTGGTGGTAATGGCCTATGATCGATACATGGCCATCTGTAAGCCTCTTCATGAATTGA
TCACCATGAATCGTCGAGTCTGTGTTCTTATGCTGTTGGCGGCCTGGATTGGAGGCTTTCT
TCACTCATTGGTTCAATTTCTCTTTATTTATCAGCTCCCTTTCTGTGGACCCAATGTCATTG
ACAACTTCCTGTGTGATTTGTATCCCTTATTGAAACTTGCTTGCACCAATACCTATGTCACT
GGGCTTTCTATGATAGCTAATGGAGGAGCGATTTGTGCTGTCACCTTCTTCACTATCCTGC
TTTCCTATGGGGTCATATTACACTCTCTTAAGACTCAGAGTTTGGAAGGGAAACGAAAAGC
TTTCTACACCTGTGCATCCCACGTCACTGTGGTCATTTTATTCTTTGTCCCCTGTATCTTCTT
GTATGCAAGGCCCAATTCTACTTTTCCCATTGATAAATCCATGACTGTAGTTCTAACTTTTA
TAACTCCCATGCTGAACCCACTAATCTATACCCTGAAGAATGCAGAAATGAAAAGTGCCAT
GAGGAAACTTTGGAGTAAAAAAGTAAGCTTAGCTGGGAAATGGCTGTATCACTCATGA
(SEQ ID NO: 348)

AOLFR189 sequences:

MQQNNSVPEFILLGLTQDPLRQKIVFVIFLIFYMGTVVGNMLIIVTIKSSRTLGSPMYFFLFYLSF
ADSCFSTSTAPRLIVDALSEKKIITYNECMTQVFALHLFGCMEIFVLILMAVDRYVAICKPLRYP
TIMSQQVCIILIVLAWIGSLIHSTAQIILALRLPFCGPYLIDHYCCDLQPLLKLACMDTYMINLLL
VSNSGAICSSSFMILIISYIVILHSLRNHSAKGKKKALSACTSHIIVVILFFGPCIFIYTRPPTTFPMD
KMVAVFYTIGTPFLNPLIYTSEECRSEKCHEK (SEQ ID NO: 349)

ATGCAGCAAAATAACAGTGTGCCTGAATTCATACTGTTAGGATTAACACAGGATCCCTTGA
GGCAGAAAATAGTGTTTGTAATCTTCTTAATTTTCTATATGGGAACTGTGGTGGGGAATAT
GCTCATTATTGTGACCATCAAGTCCAGCCGGACACTAGGAAGCCCCATGTACTTCTTTCTA
TTTTATTTGTCCTTTGCAGATTCTTGCTTTTCAACTTCCACAGCCCCTAGATTAATTGTGGA
TGCTCTCTCTGAAAAGAAAATTATAACCTACAATGAGTGCATGACACAAGTCTTTGCACTA
CATTTATTTGGCTGCATGGAGATCTTTGTCCTCATTCTCATGGCTGTTGATCGCTATGTGGC
CATCTGTAAGCCCTTGCGTTACCCAACCATCATGAGCCAGCAGGTCTGCATCATCCTGATT
GTTCTTGCCTGGATAGGGTCTTTAATACACTCTACAGCTCAGATTATCCTGGCCTTAAGATT
GCCTTTCTGTGGACCCTATTTGATTGATCATTATTGCTGTGATTTGCAGCCCTTGTTGAAAC
TTGCCTGCATGGACACTTACATGATCAACCTGCTGTTGGTGTCTAACAGTGGGGCAATTTG
CTCAAGTAGTTTCATGATTTTGATAATTTCATATATTGTCATCTTGCATTCACTGAGAAACC
ACAGTGCCAAAGGGAAGAAAAAGGCTCTCTCCGCTTGCACGTCTCACATAATTGTAGTCAT
CTTATTCTTTGGCCCATGTATATTCATATATACACGCCCCCCGACCACTTTCCCCATGGACA
AGATGGTGGCAGTATTTTATACTATTGGAACACCCTTTCTCAATCCACTCATCTACACATCT
GAGGAATGCAGAAGTGAAAAATGCCATGAGAAAG (SEQ ID NO: 350)

AOLFR190 sequences:

MQRSNHTVTEFILLGFTTDPGMQLGLFVVFLGVYCLTVVGSSTLIVLICNDSRLHTPMYFVIGN
LSFLDLWYSSVHTPKILVTCISEDKSISFAGCLCQFFSARLAYSECYLLAAMAYDHYVAISKPLL
YAQTMPRRLCICLVLYSYTGGFVNAIILTSNTFTLDFCGDNVIDDFFCDVPPLVKLACSVRESYQ
AVLHFLLASNVISPTVLILASYLSIITTILRIHSTQGRIKVFSTCSSHLISVTLYYGSILYNYSRPSSS
YSLKRDKMVSTFYTMLFPMLNPMIYSLRSKDMKDALKKFFKSA (SEQ ID NO: 351)

ATGCAGAGGAGCAATCACACAGTGACTGAGTTCATCCTGCTGGGCTTCACCACAGATCCAG
GGATGCAACTGGGCCTCTTTGTGGTGTTCCTGGGTGTGTACTGTCTGACTGTGGTAGGAAG
TAGCACCCTCATCGTGTTGATCTGTAATGACTCCCGCCTACACACACCCATGTATTTTGTCA
TTGGAAATCTGTCATTTCTGGATCTCTGGTATTCTTCTGTCCACACCCCAAAGATCCTAGTG
ACCTGCATCTCTGAAGACAAAAGCATCTCCTTTGCTGGCTGCCTGTGTCAGTTCTTCTCTGC
CAGGCTGGCCTATAGTGAGTGCTACCTACTGGCTGCCATGGCTTATGACCACTACGTGGCC
ATCTCCAAGCCCCTGCTTTATGCTCAGACCATGCCAAGGAGATTGTGCATCTGTTTGGTTTT
ATATTCCTATACTGGGGGTTTTGTCAATGCAATAATATTAACCAGCAACACATTCACATTG
GATTTTGTGGTGACAATGTCATTGATGACTTTTTCTGTGATGTTCCACCCCTCGTGAAGCT
GGCATGCAGTGTGAGAGAGAGCTACCAGGCTGTGCTGCACTTCCTTCTGGCCTCCAATGTC
ATCTCCCCTACTGTGCTCATCCTTGCCTCTTACCTCTCCATCATCACCACCATCCTGAGGAT
CCACTCTACCCAGGGCCGCATCAAAGTCTTCTCCACATGCTCCTCCCACCTGATCTCCGTTA
CCTTATACTATGGCTCCATTCTCTACAACTACTCCCGGCCAAGTTCCAGCTACTCCCTCAAG
AGGGACAAAATGGTTTCTACCTTTTATACTATGCTGTTCCCCATGTTGAATCCCATGATCTA
CAGTCTGAGGAGTAAAGACATGAAAGACGCTCTGAAAAAATTCTTCAAGTCAGCATAA
(SEQ ID NO: 352)

AOLFR191 sequences:

MTGGGNITEITYFILLGFSDFPRIIKVLFTIFLVIYITSLAWNLSLIVLIRMDSHLHTPMYFFLSNLS
FIDVCYISSTVPKMLSNLLQEQQTITFVGCIIQYFIFSTMGLSESCLMTAMAYDRYAAICNPLLYS
SIMSPTLCVWMVLGAYMTGLTASLFQIGALLQLHFCGSNVIRHFFCDMPQLLILSCTDTFFVQV
MTAILTMFFGIASALVIMISYGYIGISIMKITSAKGSPKAFNTCASHLTAVSLFYTSGIFVYLRSSS
GGSSSFDRFASVFYTVVIPMLNPLIYSLRNKEIKDALKRLQKRKCC (SEQ ID NO: 353)

ATGACTGGGGGAGGAAATATTACAGAAATCACCTATTTCATCCTGCTGGGATTCTCAGATT
TTCCCAGGATCATAAAAGTGCTCTTCACTATATTCCTGGTGATCTACATTACATCTCTGGCC
TGGAACCTCTCCCTCATTGTTTTAATAAGGATGGATTCCCACCTCCATACACCCATGTATTT
CTTCCTCAGTAACCTGTCCTTCATAGATGTCTGCTATATCAGCTCCACAGTCCCCAAGATGC
TCTCCAACCTCTTACAGGAACAGCAAACTATCACTTTTGTTGGTTGTATTATTCAGTACTTT
ATCTTTTCAACGATGGGACTGAGTGAGTCTTGTCTCATGACAGCCATGGCTTATGATCGTT
ATGCTGCCATTTGTAACCCCCTGCTCTATTCATCCATCATGTCACCCACCCTCTGTGTTTGG
ATGGTACTGGGAGCCTACATGACTGGCCTCACTGCTTCTTTATTCCAAATTGGTGCTTTGCT
TCAACTCCACTTCTGTGGGTCTAATGTCATCAGACATTTCTTCTGTGACATGCCCCAACTGT
TAATCTTGTCCTGTACTGACACTTTCTTTGTACAGGTCATGACTGCTATATTAACCATGTTC
TTTGGGATAGCAAGTGCCCTAGTTATCATGATATCCTATGGCTATATTGGCATCTCCATCA
TGAAGATCACTTCAGCTAAAGGCAGTCCAAAGGCATTCAACACCTGTGCTTCTCATCTAAC
AGCTGTTTCCCTCTTCTATACATCAGGAATCTTTGTCTATTTGAGGTCCAGCTCTGGAGGTT
CTTCAAGCTTTGACAGATTTGCATCTGTTTTCTACACTGTGGTCATTCCCATGTTAAATCCC
TTGATTTACAGTTTGAGGAACAAAGAAATTAAAGATGCCTTAAAGAGGTTGCAAAAGAGA
AAGTGCTGCTGA (SEQ ID NO: 354)

AOLFR192 sequences:

MENNTEVTEFILVGLTDDPELQIPLFIVFLFIYLITLVGNLGMIELILLDSCLHTPMYFFLSNLSLV
DFGYSSAVTPKVMVGFLTGDKFILYNACATQFFFFVAFITAESFLLASMAYDRYAALCKPLHY
TTTMTTNVCACLAIGSYICGFLNASIHTGNTFRLSFCRSNVVEHFFCDAPPLLTLSCSDNYISEM
VIFFVVGFNDLFSILVILISYLFIFITIMKMRSPEGRQKAFSTCASHLTAVSIFYGTGIFMYLRPNSS
HFMGTDKMASVFYAIVIPMLNPLVYSLRNKEVKSAFKKTVGKAKASIGFIF (SEQ ID NO: 355)

ATGGAGAACAACACAGAGGTGACTGAATTCATCCTTGTGGGGTTAACTGATGACCCAGAA
CTGCAGATCCCACTCTTCATAGTCTTCCTTTTCATCTACCTCATCACTCTGGTTGGGAACCT
GGGGATGATTGAATTGATTCTACTGGACTCCTGTCTCCACACCCCCATGTACTTCTTCCTCA
GTAACCTCTCCCTGGTGGACTTTGGTTATTCCTCAGCTGTCACTCCCAAGGTGATGGTGGG
GTTTCTCACAGGAGACAAATTCATATTATATAATGCTTGTGCCACACAATTCTTCTTCTTTG
TAGCCTTTATCACTGCAGAAAGTTTCCTCCTGGCATCAATGGCCTATGACCGCTATGCAGC
ATTGTGTAAACCCCTGCATTACACCACCACCATGACAACAAATGTATGTGCTTGCCTGGCC
ATAGGCTCCTACATCTGTGGTTTCCTGAATGCATCCATTCATACTGGGAACACTTTCAGGC
TCTCCTTCTGTAGATCCAATGTAGTTGAACACTTTTTCTGTGATGCTCCTCCTCTCTTGACT
CTCTCATGTTCAGACAACTACATCAGTGAGATGGTTATTTTTTTTGTGGTGGGATTCAATG
ACCTCTTTTCTATCCTGGTAATCTTGATCTCCTACTTATTTATATTTATCACCATCATGAAG
ATGCGCTCACCTGAAGGACGCCAGAAGGCCTTTTCTACTTGTGCTTCCCACCTTACTGCAG
TTTCCATCTTTTATGGGACAGGAATCTTTATGTACTTACGACCTAACTCCAGCCATTTCATG
GGCACAGACAAAATGGCATCTGTGTTCTATGCCATAGTCATTCCCATGTTGAATCCACTGG
TCTACAGCCTGAGGAACAAAGAGGTTAAGAGTGCCTTTAAAAAGACTGTAGGGAAGGCAA
AGGCCTCTATAGGATTCATATTTTAA (SEQ ID NO: 356)

AOLFR193 sequences:

MENKTEVTQFILLGLTNDSELQVPLFITFPFIYIITLVGNLGIIVLIFWDSCLHNPMYFFLSNLSLV
DFCYSSAVTPIVMAGFLIEDKVISYNACAAQMYIFVAFATVENYLLASMAYDRYAAVCKPLHY
TTTMTTTVCARLAIGSYLCGFLNASIHTGDTFSLSFCKSNEVHHFFCDIPAVMVLSCSDRHISEL
VLIYVVSFNIFIALLVILISYTFIFITILKMHSASVYQKPLSTCASHFIAVGIFYGTIIFMYLQPSSSH
SMDTDKMAPVFYTMVIPMLNPLVYSLRNKEVKSAFKKVVEKAKLSVGWSV (SEQ ID NO:
357)

ATGGAAAATAAGACAGAAGTAACACAATTCATTCTTCTAGGACTAACCAATGACTCAGAA
CTGCAGGTTCCCCTCTTTATAACGTTCCCCTTCATCTATATTATCACTCTGGTTGGAAACCT
GGGAATTATTGTATTGATATTCTGGGATTCCTGTCTCCACAATCCCATGTACTTTTTTCTCA
GTAACTTGTCTCTAGTGGACTTTTGCTACTCTTCAGCTGTCACTCCCATCGTCATGGCTGGA
TTCCTTATAGAAGACAAGGTCATCTCTTACAATGCATGTGCTGCTCAAATGTATATCTTTGT
AGCTTTTGCCACTGTGGAAAATTACCTCTTGGCCTCAATGGCCTATGACCGCTATGCAGCA
GTGTGCAAACCCCTACATTACACCACAACCATGACAACAACTGTGTGTGCTCGTCTGGCCA
TAGGCTCCTACCTCTGTGGTTTCCTGAATGCCTCCATCCACACTGGGGACACATTTAGTCTC
TCTTTCTGTAAGTCCAATGAAGTCCATCACTTTTTCTGTGATATTCCAGCAGTCATGGTTCT
CTCTTGCTCTGATAGACATATTAGCGAGCTTGTTCTTATTTATGTTGTGAGCTTCAATATCT
TTATAGCTCTCCTGGTTATCTTGATATCCTACACATTCATTTTTATCACCATCCTAAAGATG
CACTCAGCTTCAGTATACCAGAAGCCTTTGTCCACCTGTGCCTCTCATTTCATTGCAGTCGG
CATCTTCTATGGGACTATTATCTTCATGTACTTACAACCCAGCTCCAGTCACTCCATGGACA
CAGACAAAATGGCACCTGTGTTCTATACAATGGTCATCCCCATGCTGAACCCTCTGGTCTA
TAGTCTGAGGAACAAGGAAGTGAAGAGTGCATTCAAGAAAGTTGTTGAGAAGGCAAAATT
GTCTGTAGGATGGTCAGTTTAA (SEQ ID NO: 358)

AOLFR194 sequences:
MERQNQSCVVEFILLGFSNYPELQGQLFVAFLVIYLVTLIGNAIIVIVSLDQSLHVPMYLFLLNL
SVVDLSFSAVIMPEMLVVLSTEKTTISFGGCFAQMYFILLFGGAECFLLGAMAYDRFAAICHPL
NYQMIMNKGVFMKLIIFSWALGFMLGTVQTSWVSSFPFCGLNEINHISCETPAVLELACADTFL
FEIYAFTGTFLIILVPFLLILLSYIRVLFAILKMPSTTGRQKAFSTCAAHLTSVTLFYGTASMTYLQ
PKSGYSPETKKVMSLSYSLLTPLLNLLIYSLRNSEMKRALMKLWRRRVVLHTI (SEQ ID NO:
359)

ATGGAAAGACAAAATCAAAGCTGTGTGGTTGAATTCATCCTCTTGGGCTTTTCTAACTATC
CTGAGCTCCAGGGGCAGCTCTTTGTGGCTTTCCTGGTTATTTATCTGGTGACCCTGATAGG
AAATGCCATTATTATAGTCATCGTCTCCCTAGACCAGAGCCTCCACGTTCCCATGTACCTGT
TTCTCCTGAACTTATCTGTGGTGGACCTGAGTTTCAGTGCAGTTATTATGCCTGAAATGCT
GGTGGTCCTCTCTACTGAAAAAACTACAATTTCTTTTGGGGGCTGTTTTGCACAGATGTAT
TTCATCCTTCTTTTTGGTGGGGCTGAATGTTTTCTTCTGGGAGCAATGGCTTATGACCGATT
TGCTGCAATTTGCCATCCTCTCAACTACCAAATGATTATGAATAAAGGAGTTTTTATGAAA
TTAATTATATTTTCATGGGCCTTAGGTTTTATGTTAGGTACTGTTCAAACATCATGGGTATC
TAGTTTTCCCTTTTGTGGCCTTAATGAAATTAACCATATATCTTGTGAAACCCCAGCAGTGT
TAGAACTTGCATGTGCAGACACGTTTTTGTTTGAAATCTATGCATTCACAGGCACCTTTTTG
ATTATTTTGGTTCCTTTCTTGTTGATACTCTTGTCTTACATTCGAGTTCTGTTTGCCATCCTG
AAGATGCCATCAACCACTGGGAGACAAAAGGCCTTTTCCACCTGTGCCGCTCACCTCACAT
CTGTGACCCTATTCTATGGCACAGCCAGTATGACTTATTTACAACCCAAATCTGGCTACTC
ACCGGAAACCAAGAAAGTGATGTCATTGTCTTACTCACTTCTGACACCACTGCTGAATCTG
CTTATCTACAGTTTGCGAAATAGTGAGATGAAGAGGGCTTTGATGAAATTATGGCGAAGG
CGAGTGGTTTTACACACAATCTGA (SEQ ID NO: 360)

AOLFR195 sequences:
MIVQLICTVCFLAVNTFHVRSSFDFLKADDMGEINQTLVSEFLLLGLSGYPKIEIVYFALILVMY
LVILIGNGVLIIASIFDSHFHTPMYFFLGNLSFLDICYTSSSVPSTLVSLISKKRNISFSGCAVQMFF
GFAMGSTECLLLGMMAFDRYVAICNPLRYPIILSKVAYVLMASVSWLSGGINSAVQTLLAMRL
PFCGNNIINHFACEILAVLKLACADISLNIITMVISNMAFLVLPLMVIFFSYMFILYTILQMNSATG
RRKAFSTCSAHLTVVIIFYGTIFFMYAKPKSQDLIGEEKLQALDKLISLFYGVVTPMLNPILYSLR
NKDVKAAVKYLLNKKPIH (SEQ ID NO: 361)

ATGATTGTTCAGTTAATTTGTACTGTTTGTTTCTTGGCAGTAAATACATTTCATGTTAGATC
TTCTTTTGATTTCCTGAAAGCAGATGACATGGGTGAGATTAACCAGACACTTGTGTCAGAA
TTTCTTCTTCTGGGTCTTTCTGGATACCCAAAGATTGAGATTGTTTACTTTGCTCTCATTCT
AGTTATGTACCTAGTGATTCTAATTGGCAATGGTGTTCTAATCATAGCCAGCATCTTTGATT
CTCATTTTCACACACCAATGTACTTCTTCCTGGGCAACCTCTCTTTCCTGGATATCTGCTAT
ACATCCTCCTCTGTTCCCTCAACATTGGTGAGCTTAATCTCAAAGAAAAGAAACATTTCCT

TCTCTGGATGTGCAGTGCAGATGTTCTTTGGGTTTGCAATGGGGTCAACAGAATGTCTGCT
TCTTGGCATGATGGCATTTGATCGTTATGTGGCCATCTGCAACCCACTGAGATACCCCATC
ATCCTGAGCAAGGTGGCGTATGTATTGATGGCTTCTGTGTCCTGGCTGTCCGGTGGAATAA
ATTCAGCTGTGCAAACATTACTTGCCATGAGACTGCCTTTCTGTGGGAATAATATTATCAA
TCATTTCGCATGTGAAATATTAGCTGTCCTCAAGCTGGCCTGTGCTGATATATCCCTCAATA
TTATCACCATGGTGATATCAAATATGGCCTTCCTGGTTCTTCCACTGATGGTCATTTTTTTC
TCCTATATGTTCATCCTCTACACCATCTTGCAAATGAATTCAGCCACAGGAAGACGCAAGG
CATTTTCCACGTGCTCAGCTCACCTGACTGTGGTGATCATATTTTACGGTACCATCTTCTTT
ATGTATGCGAAACCGAAGTCTCAAGACCTGATTGGGGAAGAAAAATTGCAAGCATTAGAC
AAGCTCATTTCTCTGTTTTATGGGGTAGTGACACCCATGCTGAATCCTATACTCTATAGCTT
GAGAAATAAGGATGTAAAAGCTGCTGTAAAATATTTGCTGAACAAAAAACCAATTCACTA
A (SEQ ID NO: 362)

AOLFR196 sequences:

MLESNYTMPTEFLFVGFTDYLPLRVTLFLVFLLVYTLTMVGNILLIILVNINSSLQIPMYYFLSNL
SFLDISCSTAITPKMLANFLASRKSISPYGCALQMFFFASFADAECLILAAMAYDRYAAICNPLL
YTTLMSRRVCVCFIVLAYFSGSTTSLVHVCLTFRLSFCGSNIVNHFFCDIPPLLALSCTDTQINQL
LLFALCSFIQTSTFVVIFISYFCILITVLSIKSSGGRSKTFSTCASHLIAVTLFYGALLFMYLQPTTS
YSLDTDKVVAVFYTVVFPMFNPIIYSFRNKDVKNALKKLLERIGYSNEWYLNRLRIVNI (SEQ
ID NO: 363)

ATGTTGGAGAGTAATTACACCATGCCAACTGAGTTCCTATTTGTTGGATTCACAGATTATC
TACCTCTCAGAGTCACACTGTTCTTGGTATTCCTTCTGGTATATACATTAACTATGGTCGGA
AATATACTCTTAATAATTCTAGTTAATATTAATTCAAGCCTTCAAATTCCCATGTATTATTT
TCTTAGCAACTTATCTTTCTTAGACATCAGCTGTTCTACAGCAATCACTCCTAAAATGCTGG
CAAACTTCTTGGCATCCAGGAAAAGCATCTCTCCTTATGGGTGTGCACTACAAATGTTTTT
CTTCGCTTCTTTTGCTGATGCTGAGTGCCTTATCCTGGCAGCAATGGCTTATGACCGCTATG
CAGCCATCTGCAACCCACTGCTCTATACTACACTGATGTCTAGGAGAGTCTGTGTCTGCTT
CATTGTGTTGGCATATTTCAGTGGAAGTACAACATCACTGGTCCATGTGTGCCTCACATTC
AGGCTGTCATTTTGTGGCTCCAATATCGTCAATCATTTTTTCTGTGATATCCCACCTCTTCT
GGCTTTATCATGTACAGACACTCAGATCAACCAGCTTCTGCTCTTTGCTTTGTGCAGCTTCA
TCCAGACCAGCACTTTTGTGGTAATATTTATTTCTTACTTCTGCATCCTCATCACTGTGTTG
AGCATCAAGTCCTCAGGTGGCAGAAGCAAAACATTCTCCACTTGTGCTTCCCACCTCATAG
CAGTCACCTTATTCTATGGAGCGCTCCTGTTTATGTACTTACAGCCCACCACTAGCTATTCC
CTAGACACTGATAAGGTGGTGGCAGTGTTTTATACTGTTGTATTTCCCATGTTTAATCCAA
TAATTTATAGTTTCAGAAACAAGGATGTGAAAAATGCTCTCAAAAAGCTATTAGAAAGAA
TTGGATATTCAAATGAATGGTATTTAAATCGTTTAAGAATAGTCAATATCTAA (SEQ ID NO:
364)

AOLFR197 sequences:

MCYLSQLCLSLGEHTLHMGMVRHTNESNLAGFILLGFSDYPQLQKVLFVLILILYLLTILGNTTI
ILVSRLEPKLHMPMYFFLSHLSFLYRCFTSSVIPQLLVNLWEPMKTIAYGGCLVHLYNSHALGS
TECVLLALMSCDRYVAVCRPLHYTVLMHIHLCMALASMAWLSGIATTLVQSTLTLQLPFCGH
RQVDHFICEVPVLIKLACVGTTFNEAELFVASILFLIVPVSFILVSSGYIAHAVLRIKSATRRQKAF
GTCFSHLTVVTIFYGTIIFMYLQPAKSRSRDQGKFVSLFYTVVTRMLNPLIYTLRIKEVKGALKK
VLAKALGVNIL (SEQ ID NO: 365)

ATGTGTTATCTTTCTCAGCTATGCCTCAGCCTTGGGGAACACACTTTACATATGGGGATGG
TGAGACATACCAATGAGAGCAACCTAGCAGGTTTCATCCTTTTAGGGTTTTCTGATTATCC
TCAGTTACAGAAGGTTCTATTTGTGCTCATATTGATTCTGTATTTACTAACTATTTTGGGGA
ATACCACCATCATTCTGGTTTCTCGTCTGGAACCCAAGCTTCATATGCCGATGTATTTCTTC
CTTTCTCATCTCTCCTTCCTGTACCGCTGCTTCACCAGCAGTGTTATTCCCCAGCTCCTGGT
AAACCTGTGGGAACCCATGAAAACTATCGCCTATGGTGGCTGTTTGGTTCACCTTTACAAC
TCCCATGCCCTGGGATCCACTGAGTGCGTCCTCTTGGCTCTGATGTCCTGTGACCGCTATGT
GGCTGTCTGCCGTCCTCTCCATTACACTGTCTTAATGCATATCCATCTCTGCATGGCCTTGG
CATCTATGGCATGGCTCAGTGGAATAGCCACCACCCTGGTACAGTCCACCCTCACCCTGCA

GCTGCCCTTCTGTGGGCATCGCCAAGTGGATCATTTCATCTGCGAGGTCCCTGTGCTCATC
AAGCTGGCTTGTGTGGGCACCACGTTTAACGAGGCTGAGCTTTTTGTGGCTAGTATCCTTT
TCCTTATAGTGCCTGTCTCATTCATCCTGGTCTCCTCTGGCTACATTGCCCACGCAGTGTTG
AGGATTAAGTCAGCTACCAGGAGACAGAAAGCATTCGGGACCTGCTTCTCCCACCTGACA

5   GTGGTCACCATCTTTTATGGAACCATCATCTTCATGTATCTGCAGCCAGCCAAGAGTAGAT
CCAGGGACCAGGGCAAGTTTGTTTCTCTCTTCTACACTGTGGTAACCCGCATGCTTAACCC
TCTTATTTATACCTTGAGGATCAAGGAGGTGAAAGGGGCATTAAAGAAAGTTCTAGCAAA
GGCTCTGGGAGTAAATATTTTATGA (SEQ ID NO: 366)

10   **AOLFR198 sequences:**

MENCTEVTKFILLGLTSVPELQIPLFILFTFIYLLTLCGNLGMMLILMDSCLHTPMYFFLSNLSL
VDFGYSSAVTPKVMAGFLRGDKVISYNACAVQMFFFVALATVENYLLASMAYDRYAAVCKP
LHYTTTMTASVGACLALGSYVCGFLNASFHIGGIFSLSFCKSNLVHHFFCDVPAVMALSCSDKH
TSEVILVFMSSFNIFFVLLVIFISYLFIFITILKMHSAKGHQKALSTCASHFTAVSVFYGTVIFIYLQ

15   PSSSHSMDTDKMASVFYAMIIPMLNPVVYSLRNREVQNAFKKVLRRQKFL (SEQ ID NO: 367)

ATGGAGAATTGTACGGAAGTGACAAAGTTCATTCTTCTAGGACTAACCAGTGTCCCAGAAC
TACAGATCCCCCTCTTTATCTTGTTCACCTTCATCTACCTCCTCACTCTGTGTGGGAACCTG
GGGATGATGTTGCTGATCCTGATGGACTCTTGTCTCCACACCCCCATGTACTTTTTCCTCAG

20   TAACCTGTCTCTGGTGGACTTTGGATACTCCTCAGCTGTCACTCCCAAGGTCATGGCTGGG
TTCCTTAGAGGAGACAAGGTCATCTCCTACAATGCATGTGCTGTTCAGATGTTCTTCTTTGT
AGCCTTGGCCACGGTGGAAAATTACTTGTTGGCCTCAATGGCCTATGACCGCTATGCAGCA
GTGTGCAAACCCCTACACTACACCACCACCATGACGGCCAGTGTAGGTGCCTGTCTGGCCC
TAGGCTCATATGTCTGTGGCTTCCTAAATGCCTCATTCCACATTGGGGGCATATTCAGTCTC

25   TCTTTCTGTAAATCCAATCTGGTACATCACTTTTTCTGTGATGTTCCAGCAGTCATGGCTCT
GTCTTGCTCTGATAAACACACTAGTGAGGTGATTCTGGTTTTTATGTCAAGCTTTAATATCT
TTTTTGTTCTTCTAGTTATCTTTATCTCCTACTTGTTCATATTCATCACCATCTTGAAGATGC
ATTCAGCTAAGGGACACCAAAAAGCATTGTCCACCTGTGCCTCTCACTTCACTGCAGTCTC
CGTCTTCTATGGGACAGTAATCTTCATCTACTTGCAGCCCAGCTCCAGCCACTCCATGGAC

30   ACAGACAAAATGGCATCTGTGTTCTATGCTATGATCATCCCCATGCTGAACCCTGTGGTCT
ACAGCCTGAGGAACAGAGAAGTCCAGAATGCATTCAAGAAAGTGTTGAGAAGGCAAAAAT
TTCTATAA (SEQ ID NO: 368)

AOLFR199 sequences:

35   MDTGNKTLPQDFLLLGFPGSQTLQLSLFMLFLVMYILTVSGNVAILMLVSTSHQLHTPMYFFLS
NLSFLEIWYTTAAVPKALAILLGRSQTISFTSCLLQMYFVFSLGCTEYFLLAAMAYDRCLAICYP
LHYGAIMSSLLSAQLALGSWVCGFVAIAVPTALISGLSFCGPRAINHFFCDIAPWIALACTNTQA
VELVAFVIAVVVILSSCLITFVSYVYIISTILRIPSASGRSKAFSTCSSHLTVVLIWYGSTVFLHVR
TSIKDALDLIKAVHVLNTVVTPVLNPFIYTLRNKEVRETLLKKWKGK (SEQ ID NO: 369)

40

ATGGACACAGGCAACAAAACTCTGCCCCAGGACTTTCTCTTACTGGGCTTTCCTGGTTCTC
AAACTCTTCAGCTCTCTCTCTTTATGCTTTTTCTGGTGATGTACATCCTCACAGTTAGTGGT
AATGTGGCTATCTTGATGTTGGTGAGCACCTCCCATCAGTTGCATACCCCCATGTACTTCTT
TCTGAGCAACCTCTCCTTCCTGGAGATTTGGTATACCACAGCAGCAGTGCCCAAAGCACTG

45   GCCATCCTACTGGGGAGAAGTCAGACCATATCATTTACAAGCTGTCTTTTGCAGATGTACT
TTGTTTTCTCATTAGGCTGCACAGAGTACTTCCTCCTGGCAGCCATGGCTTATGACCGCTGT
CTTGCCATCTGCTATCCTTTACACTACGGAGCCATCATGAGTAGCCTGCTCTCAGCGCAGC
TGGCCCTGGGCTCCTGGGTGTGTGGTTTCGTGGCCATTGCAGTGCCCACAGCCCTCATCAG
TGGCCTGTCCTTCTGTGGCCCCGTGCCATCAACCACTTCTTCTGTGACATTGCACCCTGGA

50   TTGCCCTGGCCTGCACCAACACACAGGCAGTAGAGCTTGTGGCCTTTGTGATTGCTGTTGT
GGTTATCCTGAGTTCATGCCTCATCACCTTTGTCTCCTATGTGTACATCATCAGCACCATCC
TCAGGATCCCCTCTGCCAGTGGCCGGAGCAAAGCCTTCTCCACGTGCTCCTCGCATCTCAC
CGTGGTGCTCATTTGGTATGGGTCCACAGTTTTCCTTCACGTCCGCACCTCTATCAAAGAT
GCCTTGGATCTGATCAAAGCTGTCCACGTCCTGAACACTGTGGTGACTCCAGTTTTAAACC

55   CCTTCATCTATACGCTTCGTAATAAGGAAGTAAGAGAGACTCTGCTGAAGAAATGGAAGG
GAAAATAA (SEQ ID NO: 370)

AOLFR200 sequences:

MTRKNYTSLTEFVLLGLADTLELQIILFLFFLVIYTLTVLGNLGMILLIRIDSQLHTPMYFFLANL
SFVDVCNSTTITPKMLADLLSEKKTISFAGCFLQMYFFISLATTECILFGLMAYDRYAAICRPLL
YSLIMSRTVYLKMAAGAFAAGLLNFMVNTSHVSSLSFCDSNVIHHFFCDSPPLFKLSCSDTILKE
SISSILAGVNIVGTLLVILSSYSYVLFSIFSMHSGEGRHRAFSTCASHLTAIILFYATCIYTYLRPSS
SYSLNQDKVASVFYTVVIPMLNPLIYSLRSKEVKKALANVISRKRTSSFL (SEQ ID NO: 371)

ATGACCAGAAAAAATTATACCTCACTGACTGAGTTCGTCCTATTGGGATTAGCAGACACGC
TGGAGCTACAGATTATCCTCTTTTTGTTTTTTCTTGTGATTTATACACTTACAGTACTGGGA
AATCTCGGGATGATCCTCTTAATCAGGATCGATTCCCAGCTTCACACACCCATGTATTTCTT
CCTGGCTAACCTGTCCTTTGTGGACGTTTGTAACTCAACTACCATCACCCCAAAGATGCTG
GCAGATTTATTATCAGAGAAGAAAACCATCTCTTTTGCTGGCTGCTTCCTACAGATGTACT
TCTTTATCTCCCTGGCGACAACCGAATGCATCCTCTTTGGGTTAATGGCCTATGACAGGTA
TGCGGCCATATGTCGCCCGCTGCTTTACTCCTTGATCATGTCCAGGACCGTCTACCTAAAA
ATGGCAGCCGGGGCTTTTGCTGCAGGGTTGCTGAACTTCATGGTCAACACAAGCCATGTCA
GCAGCTTGTCATTCTGTGACTCCAATGTCATCCATCACTTCTTCTGTGACAGTCCCCCACTT
TTCAAGCTCTCTTGTTCTGACACAATCCTGAAAGAAAGCATAAGTTCTATTTTGGCTGGTG
TGAATATTGTGGGGACTCTGCTTGTCATCCTCTCCTCCTACTCCTACGTTCTCTTCTCCATT
TTTTCTATGCATTCGGGGGAGGGGAGGCACAGAGCTTTCTCCACGTGTGCCTCTCACCTGA
CAGCCATAATTCTGTTCTATGCCACCTGCATCTATACTTACCTGAGACCTAGTTCCAGCTAC
TCCCTGAATCAGGACAAAGTGGCTTCTGTGTTCTACACAGTGGTGATTCCCATGTTGAATC
CTCTGATCTACAGCCTCAGGAGTAAGGAAGTAAAGAAGGCTTTAGCGAATGTAATTAGCA
GGAAAAGGACCTCTTCCTTTCTGTGA (SEQ ID NO: 372)

AOLFR201 sequences:

MEWENHTILVEFFLKGLSGHPRLELLFFVLIFIMYVVILLGNGTLILISILDPHLHTPMYFFLGNL
SFLDICYTTTSIPSTLVSFLSERKTISLSGCAVQMFLGLAMGTTECVLLGMMAFDRYVAICNPLR
YPIIMSKDAYVPMAAGSWIIGAVNSAVQSVFVVQLPFCRNNIINHFTCEILAVMKLACADISDN
EFIMLVATTLFILTPLLLIIVSYTLIIVSIFKISSSEGRSKASSTCSAHLTVVIIFYGTILFMYMKPKS
KETLNSDDLDATDKIISMFYGVMTPMMNPLIYSLRNKDVKEAVKHLLNRRFFSK (SEQ ID NO:
373)

ATGGAATGGGAAAACCACACCATTCTGGTGGAATTTTTTCTGAAGGGACTTTCTGGTCACC
CAAGACTTGAGTTACTCTTTTTTGTGCTCATCTTCATAATGTATGTGGTCATCCTTCTGGGG
AATGGTACTCTCATTTTAATCAGCATCTTGGACCCTCACCTTCACACCCCTATGTACTTCTT
TCTGGGGAACCTCTCCTTCTTGGACATCTGCTACACCACCACCTCTATTCCCTCCACGCTAG
TGAGCTTCCTTTCAGAAAGAAAGACCATTTCCCTTTCTGGCTGTGCAGTGCAGATGTTCCT
CGGCTTGGCCATGGGGACAACAGAGTGTGTGCTTCTGGGCATGATGGCCTTTGACCGCTAT
GTGGCTATCTGCAACCCTCTGAGATATCCCATCATCATGAGTAAGGATGCCTATGTACCCA
TGGCAGCTGGGTCCTGGATCATAGGAGCTGTCAATTCTGCAGTACAATCAGTGTTTGTGGT
ACAATTGCCTTTCTGCAGGAATAACATCATCAATCATTTCACCTGTGAAATTCTGGCTGTC
ATGAAACTGGCCTGTGCTGACATCTCAGACAATGAGTTCATCATGCTTGTGGCCACAACAT
TGTTCATATTGACACCTTTGTTATTAATCATTGTCTCTTACACGTTAATCATTGTGAGCATC
TTCAAAATTAGCTCTTCCGAGGGGAGAAGCAAAGCTTCCTCTACCTGTTCAGCCCATCTGA
CTGTGGTCATAATATTCTATGGGACCATCCTCTTCATGTACATGAAGCCCAAGTCTAAAGA
GACACTTAATTCGGATGACTTGGATGCTACCGACAAAATTATATCCATGTTCTATGGGGTG
ATGACTCCCATGATGAATCCTTTAATCTACAGTCTTAGAAACAAGGATGTGAAAGAGGCA
GTAAAACACCTACTGAACAGAAGGTTCTTTAGCAAGTGA (SEQ ID NO: 374)

AOLFR202 sequences:

MEWENHTILVEFFLKGLSGHPRLELLFFVLIFIMYVVILLGNGTLILISILDPHLHTPMYFFLGNL
SFLDICYTTTSIPSTLVSFLSERKTISLSGCAVQMFLSLAMGTTECVLLGVMAFDRYVAICNPLR
YPIIMSKDAYVPMAAGSWIIGAVNSAVQTVFVVQLPFCRNNIINHFTCEILAVMKLACADISGN
EFILLVTTTLFLLTPLLLIIVSYTLIILSIFKISSSEGRSKPSSTCSARLTVVITFCGTIFLMYMKPKSQ

ETLNSDDLDATDKLIFIFYRVMTPMMNPLIYSLRNKDVKEAVKHLLRRKNFNK (SEQ ID NO:
375)

ATGGAATGGGAAAACCACACCATTCTGGTGGAATTTTTTCTGAAGGGACTTTCTGGTCACC
CAAGACTTGAGTTACTCTTTTTTGTGCTCATCTTCATAATGTATGTGGTCATCCTTCTGGGG
AATGGTACTCTCATTTTAATCAGCATCTTGGACCCTCACCTTCACACCCCTATGTACTTCTT
TCTGGGGAACCTCTCCTTCTTGGACATCTGCTACACCACCACCTCTATTCCCTCCACGCTAG
TGAGCTTCCTTTCAGAAAGAAAGACCATTTCCCTTTCTGGCTGTGCAGTGCAGATGTTCCT
CAGCTTGGCCATGGGGACAACAGAGTGTGTGCTTCTGGGCGTGATGGCCTTTGACCGCTAT
GTGGCTATCTGCAACCCTCTGAGATATCCCATCATCATGAGTAAGGATGCCTATGTACCCA
TGGCAGCTGGGTCCTGGATCATAGGAGCTGTCAATTCTGCAGTACAAACAGTGTTTGTGGT
ACAATTGCCTTTCTGCAGGAATAACATCATCAATCATTTCACCTGTGAAATTCTAGCTGTC
ATGAAACTGGCCTGTGCTGACATCTCAGGCAATGAGTTCATCCTGCTTGTGACCACAACAT
TGTTCCTATTGACACCTTTGTTATTAATTATTGTCTCTTACACGTTAATCATTTTGAGCATC
TTCAAAATTAGCTCTTCGGAGGGGAGAAGCAAACCTTCCTCTACCTGCTCAGCTCGTCTGA
CTGTGGTGATAACATTCTGTGGGACCATCTTCCTCATGTACATGAAGCCCAAGTCTCAAGA
GACACTTAATTCAGATGACTTGGATGCCACTGACAAACTTATATTCATATTCTACAGGGTG
ATGACTCCCATGATGAATCCTTTAATCTACAGTCTTAGAAACAAGGATGTGAAGGAGGCA
GTAAAACACCTACTGAGAAGAAAAAATTTTAACAAGTAA (SEQ ID NO: 376)

AOLFR203 sequences:

MKRQNQSCVVEFILLGFSNFPELQVQLFGVFLVIYVVTLMGNAIITVIISLNQSLHVPMYLFLLN
LSVVEVSFSAVITPEMLVVLSTEKTMISFVGCFAQMYFILLFGGTECFLLGAMAYDRFAAICHPL
NYPVIMNRGVFMKLVIFSWISGIMVATVQTTWVFSFPFCGPNEINHLFCETPPVLELVCADTFLF
EIYAFTGTILIVMVPFLLILLSYIRVLFAILKMPSTTGRQKAFSTCASHLTSVTLFYGTANMTYLQ
PKSGYSPETKKLISLAYTLLTPLLNPLIYSLRNSEMKRTLIKLWRRKVILHTF (SEQ ID NO: 377)

ATGAAAAGACAAAATCAAAGCTGTGTGGTTGAATTCATCCTCCTGGGCTTTTCTAACTTTC
CTGAGCTCCAGGTGCAGCTCTTTGGGGTTTTTCCTAGTTATTTATGTGGTGACCCTGATGGGG
AAATGCCATCATTACAGTCATCATCTCCTTAAACCAGAGCCTCCACGTTCCCATGTACCTGT
TCCTCCTGAACCTATCTGTGGTGGAGGTGAGTTTCAGTGCAGTCATTACGCCTGAAATGCT
GGTGGTGCTCTCTACTGAGAAAACTATGATTTCTTTTGTGGGCTGTTTTGCACAGATGTAT
TTCATCCTTCTTTTTGGTGGGACTGAATGTTTTCTCCTGGGAGCGATGGCTTATGACCGATT
TGCTGCAATTTGCCATCCTCTGAACTACCCAGTGATTATGAACAGAGGGGTTTTTATGAAA
TTAGTAATATTCTCATGGATCTCAGGGATCATGGTGGCTACTGTGCAGACCACTTGGGTAT
TTAGTTTTCCATTTTGTGGCCCCAATGAAATTAATCATCTCTTCTGTGAGACTCCCCCGGTA
CTAGAGCTTGTGTGTGCAGACACCTTCTTATTTGAAATCTATGCCTTCACAGGCACCATTTT
GATTGTTATGGTTCCTTTCTTGTTGATCCTCTTGTCTTACATTCGAGTTCTGTTTGCCATCCT
GAAGATGCCATCAACTACTGGGAGACAAAAGGCCTTTTCCACCTGTGCCTCTCACCTCACA
TCTGTGACCCTGTTCTATGGCACAGCCAATATGACTTATTTACAACCCAAATCTGGCTACTC
ACCCGAAACCAAGAAACTGATCTCATTGGCTTACACGTTGCTTACCCCTCTGCTCAATCCG
CTCATCTATAGCTTACGAAACAGTGAGATGAAGAGGACTTTGATAAAACTATGGCGAAGA
AAAGTGATTTTACACACATTCTGA (SEQ ID NO: 378)

AOLFR204 sequences:

MEKKKNVTEFILIGLTQNPIMEKVTFVVFLVLYMITLSGNLLIVVTITTSQALSSPMYFFLTHLSL
IDTVYSSSSAPKLIVDSFQEKKIISFNGCMAQAYAEHIFGATEIILLTVMACDCYVAICKPLNYTT
IMSHSLCILLVAVAWVGGFLHATIQILFTVWLPFCGPNVIGHFMCDLYPLLKLVCIDTHTLGLFV
AVNSGFICLLNFLILVVSYVIILRSLKNNSLEGRCKALSTCISHIIVVVLFFVPCIFVYLRSVTTLPI
DKAVAVFYTMVVPMLNPVVYTLRNAEVKSAIRKLWRKKVTSDND (SEQ ID NO: 379)

ATGGAGAAGAAAAAGAATGTGACTGAATTCATTTTAATAGGTCTTACACAGAACCCCATA
ATGGAGAAAGTCACGTTTGTAGTATTTTTGGTTCTTTACATGATAACACTTTCAGGCAACC
TGCTCATTGTGGTTACCATTACCACCAGCCAGGCTCTGAGCTCCCCCATGTACTTCTTCCTG
ACCCACCTTTCTTTGATAGACACAGTTTATTCTTCTTCTTCAGCTCCTAAGTTGATTGTGGA
TTCCTTTCAAGAGAAGAAAATCATCTCCTTTAATGGGTGTATGGCTCAAGCCTATGCAGAA

CACATTTTTGGTGCTACTGAGATCATCCTGCTGACAGTGATGGCCTGTGACTGCTATGTGG
CCATCTGCAAACCTCTGAACTACACAACCATTATGAGCCACAGCCTGTGCATTCTCCTGGT
GGCAGTGGCCTGGGTGGGAGGATTTCTTCATGCAACTATTCAGATTCTCTTTACAGTATGG
CTGCCCTTCTGTGGCCCCAATGTCATAGGCCACTTCATGTGTGACTTGTACCCATTGTTAAA
5　　ACTTGTTTGCATAGACACTCATACCCTTGGTCTCTTTGTTGCTGTGAACAGTGGGTTTATCT
GCTTATTAAACTTCCTTATCTTGGTGGTATCCTATGTGATCATCTTGAGATCTTTAAAGAAC
AATAGCTTGGAGGGGAGGTGTAAAGCCCTCTCCACCTGTATTTCTCACATCATAGTAGTTG
TCTTATTCTTTGTGCCCTGTATATTTGTGTATCTGCGCTCAGTGACCACTCTGCCCATTGAT
AAAGCTGTTGCTGTATTTTATACTATGGTGGTCCCAATGTTAAATCCCGTGGTCTACACAC
10　　TCAGAAATGCTGAGGTAAAAAGTGCAATAAGGAAGCTTTGGAGAAAAAAGTGACTTCAG
ATAATGATTAA (SEQ ID NO: 380)

AOLFR205 sequences:

MESENRTVIREFILLGLTQSQDIQLLVFVLVLIFYFIILPGNFLIIFTIKSDPGLTAPLYFFLGNLAFL
15　　DASYSFTVAPRMLVDFLSAKKJISYRGCITQLFFLHFLGGGEGLLLVVMAFDRYIAICRPLHYPT
VMNPRTCYAMMLALWLGGFVHSIIQVVLILRLPFCGPNQLDNFFCDVPQVIKLACTDTFVVEL
LMVFNSGLMTLLCFLGLLASYAVILCRIRGSSSEAKNKAMSTCITHIIVIFFMFGPGIFIYTRPFRA
FPADKVVSLFHTVIFPLLNPVIYTLRNQEVKASMKKVFNKHIA (SEQ ID NO: 381)

20　　ATGGAAAGCGAGAACAGAACAGTGATAAGAGAATTCATCCTCCTTGGTCTGACCCAGTCT
CAAGATATTCAGCTCCTGGTCTTTGTGCTAGTTTTAATATTCTACTTCATCATCCTCCCTGG
AAATTTTCTCATTATTTTCACCATAAAGTCAGACCCTGGGCTCACAGCCCCCCTCTATTTCT
TTCTGGGCAACTTGGCCTTCCTGGATGCATCCTACTCCTTCACTGTGGCTCCCCGGATGTTG
GTGGACTTCCTCTCTGCGAAGAAGATAATCTCCTACAGAGGCTGCATCACTCAGCTCTTTT
25　　TCTTGCACTTCCTTGGAGGAGGGGAGGGATTACTCCTTGTTGTGATGGCCTTTGACCGCTA
CATCGCCATCTGCCGGCCTCTGCACTATCCTACTGTCATGAACCCTAGAACCTGCTATGCA
ATGATGTTGGCTCTGTGGCTTGGGGGTTTTGTCCACTCCATTATCCAGGTGGTCCTCATCCT
CCGCTTGCCTTTTTGTGGCCCAAACCAGCTGGACAACTTCTTCTGTGATGTCCCACAGGTC
ATCAAGCTGGCCTGCACCGACACATTTGTGGTGGAGCTTCTGATGGTCTTCAACAGTGGCC
30　　TGATGACACTCCTGTGCTTTCTGGGGCTTCTGGCCTCCTATGCAGTCATTCTTTGTCGCATA
CGAGGGTCTTCTTCTGAGGCAAAAAACAAGGCCATGTCCACGTGCATCACCCATATCATTG
TTATATTCTTCATGTTTGGACCTGGCATCTTCATCTACACGCGCCCCTTCAGGGCTTTCCCA
GCTGACAAGGTGGTTTCTCTCTTCCACACAGTGATTTTTCCTTTGTTGAATCCTGTCATTTA
TACCCTTCGCAACCAGGAAGTGAAAGCTTCCATGAAAAAGGTGTTTAATAAGCACATAGC
35　　CTGA (SEQ ID NO: 382)

AOLFR206 sequences:

MANRNNVTEFILLGLTENPKMQKIIFVVFSVIYINAMIGNVLIVVTITASPSLRSPMYFFLAYLSFI
DACYSSVNTPKLITDSLYENKTILFNGCMTQVFGEHFFRGVEVILLTVMAYDHYVAICKPLHYT
40　　TIMKQHVCSLLVGVSWVGGFLHATIQILFICQLPFCGPNVIDHFMCDLYTLINLACTNTHTLGLF
IAANSGFICLLNCLLLLVSCVVILYSLKTHSLEARHEALSTCVSHITVVILSFIPCIFVYMRPPATL
PIDKAVAVFYTMITSMLNPLIYTLRNAQMKNAIRKLCSRKAISSVK (SEQ ID NO: 383)

ATGGCGAATAGAAACAATGTGACAGAGTTTATTCTATTGGGGCTTACAGAGAATCCAAAA
45　　ATGCAGAAAATCATATTTGTTGTGTTTTCTGTCATCTACATCAACGCCATGATAGGAAATG
TGCTCATTGTGGTCACCATCACTGCCAGCCCATCACTGAGATCCCCCATGTACTTTTTCCTG
GCCTATCTCTCCTTTATTGATGCCTGCTATTCCTCTGTCAATACCCCTAAGCTGATCACAGA
TTCACTCTATGAAAACAAGACTATCTTATTCAATGGATGTATGACTCAAGTCTTTGGAGAA
CATTTTTTCAGAGGTGTTGAGGTCATCCTACTTACTGTAATGGCCTATGACCACTATGTGG
50　　CCATCTGCAAGCCCTTGCACTATACCACCATCATGAAGCAGCATGTTTGTAGCCTGCTAGT
GGGAGTGTCATGGGTAGGAGGCTTTCTTCATGCAACCATACAGATCCTCTTCATCTGTCAA
TTACCTTTCTGTGGTCCTAATGTCATAGATCACTTTATGTGTGATCTCTACACTTTGATCAA
TCTTGCCTGCACTAATACCCACACTCTAGGACTCTTCATTGCTGCCAACAGTGGGTTCATAT
GCCTGTTAAACTGTCTCTTGCTCCTGGTCTCCTGCGTGGTCATACTGTACTCCTTAAAGACC
55　　CACAGCTTAGAGGCAAGGCATGAAGCCCTCTCTACCTGTGTGTCTCCCACATCACAGTTGTCA
TCTTATCCTTTATACCCTGCATATTTGTGTACATGAGACCTCCAGCTACTTTACCCATTGAT

AAAGCAGTTGCTGTATTCTACACTATGATAACTTCTATGTTAAACCCCTTAATCTACACCTT
GAGGAATGCTCAAATGAAAAATGCCATTAGGAAATTGTGTAGTAGGAAAGCTATTTCAAG
TGTCAAATAA (SEQ ID NO: 384)

5   **AOLFR207 sequences:**
MERTNDSTSTEFFLVGLSAHPKLQTVFFVLILWMYLMILLGNGVLISVIIFDSHLHTPMYFFLCN
LSFLDVCYTSSSVPLILASFLAVKKKVSFSGCMVQMFISFAMGATECMILGTMALDRYVAICYP
LRYPVIMSKGAYVAMAAGSWVTGLVDSVVQTAFAMQLPFCANNVIKHFVCEILAILKLACADI
SINVISMTGSNLIVLVIPLLVISISYIFIVATILRIPSTEGKHKAFSTCSAHLTVVIIFYGTIFFMYAKP
10   ESKASVDSGNEDIIEALISLFYGVMTPMLNPLIYSLRNKDVKAAVKNILCRKNFSDGK (SEQ ID
NO: 385)

ATGGAAAGGACCAACGATTCCACGTCGACAGAATTTTTCCTGGTAGGGCTTTCTGCCCACC
CAAAGCTCCAGACAGTTTTCTTCGTTCTAATTTTGTGGATGTACCTGATGATCCTGCTTGGA
15   AATGGAGTCCTTATCTCAGTTATCATCTTTGATTCTCACCTGCACACCCCCATGTATTTCTT
CCTCTGTAATCTTTCCTTCCTCGACGTTTGCTACACAAGTTCCTCTGTCCCACTAATTCTTG
CCAGCTTTCTGGCAGTAAAGAAAAAGGTTTCCTTCTCTGGGTGTATGGTGCAAATGTTTAT
TTCTTTTGCCATGGGGGCCACGGAGTGCATGATCTTAGGCACGATGGCACTGGACCGCTAT
GTGGCCATCTGCTACCCACTGAGATACCCTGTCATCATGAGCAAGGGTGCCTATGTGGCCA
20   TGGCAGCTGGGTCCTGGGTCACTGGGCTTGTGGACTCAGTAGTGCAGACAGCTTTTGCAAT
GCAGTTACCATTCTGTGCTAATAATGTCATTAAACATTTTGTCTGTGAAATTCTGGCTATCT
TGAAACTGGCCTGTGCTGATATTTCAATCAATGTGATTAGTATGACAGGGTCGAATCTGAT
TGTTCTGGTTATTCCATTGTTAGTAATTTCCATCTCTTACATATTTATTGTTGCCACTATTCT
GAGGATTCCTTCCACTGAAGGAAAACATAAGGCCTTCTCCACCTGCTCAGCCCACCTGACA
25   GTGGTGATTATATTCTATGGAACCATCTTCTTCATGTACGCAAAGCCTGAGTCTAAAGCCT
CTGTTGATTCAGGTAATGAAGACATCATTGAGGCCCTCATCTCCCTTTTCTATGGAGTGAT
GACTCCCATGCTTAATCCTCTCATCTATAGTCTGCGAAACAAGGATGTAAAGGCTGCTGTC
AAAAACATACTGTGTAGGAAAAACTTTTCTGATGGAAAATGA (SEQ ID NO: 386)

30   **AOLFR208 sequences:**
MFPANWTSVKVFFFLGFFHYPKVQVIIFAVCLLMYLITLLGNIFLISITILDSHLHTPMYLFLSNL
SFLDIWYSSSALSPMLANFVSGRNTISFSGCATQMYLSLAMGSTECVLLPMMAYDRYVAICNP
LRYPVIMNRRTCVQIAAGSWMTGCLTAMVEMMSVLPLSLCGNSIINHFTCEILAILKLVCVDTS
LVQLIMLVISVLLLPMPMLLICISYAFILASILRISSVEGRSKAFSTCTAHLMVVVLFYGTALSMH
35   LKPSAVDSQEIDKFMALVYAGQTPMLNPIIYSLRNKEVKVALKKLLIRNHFNTAFISILK (SEQ
ID NO: 387)

ATGTTCCCGGCAAATTGGACATCTGTAAAAGTATTTTTCTTCCTGGGATTTTTTCACTACCC
CAAAGTTCAGGTCATCATATTTGCGGTGTGCTTGCTGATGTACCTGATCACCTTGCTGGGC
40   AACATTTTTCTGATCTCCATCACCATTCTAGATTCCCACCTGCACACCCCTATGTACCTCTT
CCTCAGCAATCTCTCCTTTCTGGACATCTGGTACTCCTCTTCTGCCCTCTCTCCAATGCTGG
CAAACTTTGTTTCAGGGAGAAACACTATTTCATTCTCAGGGTGCGCCACTCAGATGTACCT
CTCCCTTGCCATGGGCTCCACTGAGTGTGTGCTCCTGCCCATGATGGCATATGACCGGTAT
GTGGCCATCTGCAACCCCCTGAGATACCCTGTCATCATGAATAGGAGAACCTGTGTGCAGA
45   TTGCAGCTGGCTCCTGGATGACAGGCTGTCTCACTGCCATGGTGGAAATGATGTCTGTGCT
GCCACTGTCTCTCTGTGGTAATAGCATCATCAATCATTTCACTTGTGAAATTCTGGCCATCT
TGAAATTGGTTTGTGTGGACACCTCCCTGGTGCAGTTAATCATGCTGGTGATCAGTGTACT
TCTTCTCCCCATGCCAATGCTACTCATTTGTATCTCTTATGCATTTATCCTCGCCAGTATCC
TGAGAATCAGCTCAGTGGAAGGTCGAAGTAAAGCCTTTTCAACGTGCACAGCCCACCTGA
50   TGGTGGTAGTTTTGTTCTATGGGACGGCTCTCTCCATGCACCTGAAGCCCTCCGCTGTAGA
TTCACAGGAAATAGACAAATTTATGGCTTTGGTGTATGCCGGACAAACCCCCATGTTGAAT
CCTATCATCTATAGTCTACGGAACAAAGAGGTGAAAGTGGCCTTGAAAAAATTGCTGATTA
GAAATCATTTTAATACTGCCTTCATTTCCATCCTCAAATAA (SEQ ID NO: 388)

AOLFR209 sequences:

MDKINQTFVREFILLGLSGYPKLEIIFFALILVMYVVILIGNGVLIIASILDSRLHMPMYFFLGNLS
FLDICYTTSSIPSTLVSLISKKRNISFSGCAVQMFFGFAMGSTECFLLGMMAFDRYVAICNPLRY
PIIMNKVVYVLLTSVSWLSGGINSTVQTSLAMRWPFCGNNIINHFLCEILAVLKLACSDISVNIV
TLAVSNIAFLVLPLLVIFFSYMFILYTILRTNSATGRHKAFSTCSAHLTVVIIFYGTIFFMYAKPKS
QDLLGKDNLQATEGLVSMFYGVVTPMLNPIIYSLRNKDVKAAIKYLLSRKAINQ (SEQ ID NO:
389)

ATGGACAAGATAAACCAGACATTTGTGAGAGAATTCATTCTTCTGGGACTCTCTGGTTACC
CCAAACTTGAGATCATTTTCTTTGCTCTGATTCTAGTTATGTACGTAGTGATTCTAATTGGC
AATGGTGTTCTGATCATAGCAAGCATCTTGGATTCTCGTCTTCACATGCCCATGTACTTCTT
CCTGGGCAACCTCTCTTTCCTGGATATCTGCTATACAACCTCCTCCATTCCCTCAACACTGG
TGAGCTTAATCTCAAAGAAAAGAAACATTTCCTTCTCTGGATGTGCAGTGCAGATGTTCTT
TGGGTTTGCAATGGGGTCAACAGAATGTTTCCTCCTTGGCATGATGGCATTTGATCGTTAT
GTGGCCATCTGTAACCCTCTGAGATACCCCATCATCATGAACAAGGTGGTGTATGTACTGC
TGACTTCTGTATCATGGCTTTCTGGTGGAATCAATTCAACTGTGCAAACATCACTTGCCAT
GCGATGGCCTTTCTGTGGGAACAATATTATTAATCATTTCTTATGCGAGATCTTAGCTGTCC
TAAAATTAGCTTGTTCTGATATATCTGTCAATATTGTTACCCTAGCAGTGTCAAATATTGCT
TTCCTAGTTCTTCCTCTGCTCGTGATTTTTTTCTCCTATATGTTCATCCTCTACACCATCTTG
CGAACGAACTCGGCCACAGGAAGACACAAGGCATTTTCTACATGCTCAGCTCACCTGACTG
TGGTGATCATATTTTATGGTACCATCTTCTTTATGTATGCAAAACCTAAGTCCCAGGACCTC
CTTGGGAAAGACAACTTGCAAGCTACAGAGGGGCTTGTTTCCATGTTTTATGGGGTTGTGA
CCCCCATGTTAAACCCCATAATCTATAGCTTGAGAAATAAAGATGTAAAAGCTGCTATAAA
ATATTTGCTGAGCAGGAAAGCTATTAACCAGTAA (SEQ ID NO: 390)

AOLFR210 sequences:

MMGRRNDTNVADFILTGLSDSEEVQMALFMLFLLIYLITMLGNVGMLLIIRLDLQLHTPMYFFL
THLSFIDLSYSTVVTPKTLANLLTSNYISFTGCFAQMFCFVFLGTAECYLLSSMAYDRYAAICSP
LHYTVIMPKRLCLALITGPYVIGFMDSFVNVVSMSRLHFCDSNIIHHFFCDTSPILALSCTDTDN
TEMLIFIIAGSTLMVSLITISASYVSILSTILKINSTSGKQKAFSTCVSHLLGVTIFYGTMIFTYLKP
RKSYSLGRDQVAPVFYTIVIPMLNPLIYSLRNREVKNALIRVMQRRQDSR (SEQ ID NO: 391)

ATGATGGGTAGAAGGAATGACACAAATGTGGCTGACTTCATCCTTACGGGACTGTCAGAC
TCTGAAGAGGTCCAGATGGCTCTGTTTATGCTATTTCTCCTCATATACCTAATTACTATGCT
GGGGAATGTGGGGATGCTATTGATAATCCGCCTGGACCTCCAGCTTCACACTCCCATGTAT
TTTTTCCTTACTCACCTGTCATTTATTGACCTCAGTTACTCAACTGTCGTCACACCTAAAAC
CTTAGCGAACTTACTGACTTCCAACTATATTTCCTTCACGGGCTGCTTTGCCCAGATGTTCT
GTTTTGTCTTCTTGGGTACTGCTGAATGTTATCTTCTCTCCTCAATGGCCTATGATCGCTAT
GCAGCGATCTGCAGTCCTCTACACTACACAGTTATTATGCCCAAAAGGCTCTGCCTCGCTC
TCATCACTGGGCCTTATGTGATTGGCTTTATGGACTCCTTTGTCAATGTGGTTTCCATGAGC
AGATTGCATTTCTGTGACTCAAACATAATTCATCACTTTTTCTGTGACACTTCCCCAATTTT
AGCTCTGTCCTGCACTGACACAGACAACACTGAAATGCTGATATTCATTATCGCTGGTTCC
ACCCTGATGGTGTCCCTTATCACAATATCTGCATCCTATGTGTCCATTCTCTCTACCATCCT
GAAAATTAATTCCACTTCAGGAAAGCAGAAAGCTTTCTCTACTTGCGTCTCTCATCTCTTG
GGAGTCACCATCTTCTATGGAACTATGATTTTTACTTACTTAAAGCCAAGAAAGTCTTATT
CCTTGGGAAGAGATCAAGTGGCTCCTGTGTTTTATACTATTGTGATTCCCATGCTGAATCC
ACTCATTTATAGTCTTAGAAACAGAGAAGTGAAAAATGCTCTCATTAGAGTCATGCAGAG
AAGACAGGACTCCAGGTAG (SEQ ID NO: 392)

AOLFR211 sequences:

MMGRRNNTNVADFILMGLTLSEEIQMALFMLFLLIYLITMLGNVGMILIIRLDLQLHTPMYFFL
THLSFIDLSYSTVVTPKTLANLLTSNYISFTGCFAQMFFFAFLGTAECYLLSSMAHDRYAAICSP
LHYTVIMSKRLCLALITGPYVIGFIDSFVNVVSMSRLHFYDSNVIHHFFCDTSPILALSCTDTYNT
EILIFIIVGSTLMVSLFTISASYVFILFTILKINSTSGKQKAFSTCVSHLLGVTIFYSTLIFTYLKPRK
SYSLGRDQVASVFYTIVIPVLNPLIYSLRNKEVKNAVIRVMQRRQDSR (SEQ ID NO: 393)

ATGATGGGTAGAAGGAATAACACAAATGTGGCTGACTTCATCCTTATGGGACTGACACTTT
CTGAAGAGATCCAGATGGCTCTGTTTATGCTATTTCTCCTGATATACCTAATTACTATGCTG
GGGAATGTGGGGATGATATTGATAATCCGCCTGGACCTCCAGCTTCACACTCCCATGTATT
TTTTCCTTACTCACCTGTCATTTATTGACCTCAGTTACTCAACTGTCGTCACACCTAAAACC
TTAGCGAACTTACTGACTTCCAACTATATTTCCTTTACGGGCTGCTTTGCCCAGATGTTCTT
TTTTGCCTTCTTGGGTACTGCTGAATGTTACCTTCTCTCCTCAATGGCCCATGATCGCTATG
CAGCGATCTGCAGTCCTCTACACTACACAGTTATTATGTCCAAAAGGCTCTGCCTCGCTCT
CATCACTGGGCCTTATGTGATTGGCTTTATAGACTCCTTTGTCAACGTGGTTTCCATGAGCA
GATTGCATTTCTACGACTCAAACGTAATTCATCACTTTTTCTGTGACACTTCCCCAATTTTA
GCTCTGTCCTGCACTGATACATACAACACCGAAATCCTGATATTCATTATTGTTGGTTCCAC
CCTGATGGTGTCCCTTTTCACAATATCTGCATCCTATGTGTTCATTCTCTTTACCATCCTGA
AAATTAATTCCACTTCAGGAAAGCAGAAAGCTTTCTCTACTTGCGTCTCTCATCTCTTGGG
AGTCACCATCTTTTATAGCACTCTGATTTTTACTTATTTAAAACCAAGAAAGTCTTATTCCT
TGGGAAGAGATCAAGTGGCTTCTGTTTTTTATACTATTGTGATTCCCGTGCTGAATCCACT
CATTTATAGTCTTAGAAACAAAGAGGTGAAAAATGCTGTCATCAGAGTCATGCAGAGAAG
ACAGGACTCCAGGTAA (SEQ ID NO: 394)

AOLFR212 sequences:

MAGNNFTEVTVFILSGFANHPELQVSLFLMFLFIYLFTVLGNLGLITLIRMDSQLHTPMYFFLSN
LAFIDIFYSSTVTPKALVNFQSNRRSISFVGCFVQMYFFVGLVCCECFLLGSMAYNRYIAICNPL
LYSVVMSQKVSNWLGVMPYVIGFTSSLISVWVISSLAFCDSSINHFFCDTTALLALSCVDTFGT
EMVSFVLAGFTLLSSLLIITVTYIIIISAILRIQSAAGRQKAFSTCASHLMAVTIFYGSLIFTYLQPD
NTSSLTQAQVASVFYTIVIPMLNPLIYSLRNKDVKNALLRVIHRKLFP (SEQ ID NO: 395)

ATGGCTGGCAACAATTTCACTGAGGTTACCGTCTTCATCCTCTCTGGATTTGCAAATCACC
CTGAATTACAAGTCAGTCTTTTCTTGATGTTTCTCTTCATTTATCTATTCACTGTTTTGGGA
AACCTGGGACTGATCACGTTAATCAGAATGGATTCTCAGCTTCACACCCCTATGTACTTTT
TCCTGAGCAATTTAGCATTTATTGACATATTTTACTCCTCTACTGTAACACCTAAGGCATTG
GTGAATTTCCAATCCAATCGGAGATCCATCTCCTTTGTTGGCTGCTTTGTTCAAATGTACTT
TTTTGTTGGATTGGTGTGTTGTGAGTGTTTCCTTCTGGGATCAATGGCCTACAATCGCTACA
TAGCAATCTGCAATCCCTTACTGTATTCAGTAGTCATGTCCCAAAAAGTGTCCAACTGGCT
GGGAGTAATGCCATATGTGATAGGCTTCACAAGCTCGCTGATATCTGTCTGGGTGATAAGC
AGTTTGGCGTTCTGTGATTCCAGCATCAATCATTTTTTTTGTGACACCACAGCTCTTTTAGC
ACTCTCCTGTGTAGATACATTCGGCACAGAAATGGTGAGCTTTGTCTTAGCTGGATTCACT
CTTCTTAGCTCTCTCCTTATCATCACAGTCACTTATATCATCATCATCTCAGCCATCCTGAG
GATCCAGTCAGCAGCAGGCAGGCAGAAGGCCTTCTCCACCTGCGCATCCCACCTCATGGCT
GTAACTATCTTTTATGGGTCTCTGATTTTTCACCTATTTGCAACCTGATAACACATCATCGCT
GACCCAGGCGCAGGTGGCATCTGTATTCTATACGATTGTCATTCCCATGCTGAATCCACTC
ATCTACAGTCTGAGGAACAAAGATGTGAAAAATGCTCTTCTGAGAGTCATACATAGAAAA
CTTTTTCCATGA (SEQ ID NO: 396)

AOLFR213 sequences:

MNSLGKLVSMILSAHVFCYSKFNCFGCTHSIPALGADPPGGMGLGNESSLMDFILLGFSDHPRL
EAVLFVFVLFFYLLTLVGNFTIIIISYLDPPLHTPMYFFLSNLSLLDICFTTSLAPQTLVNLQRPKK
TITYGGCVAQLYISLALGSTECILLADMALDRYIAVCKPLHYVVIMNPRLCQQLASISWLSGLA
SSLIHATFTLQLPLCGNHRLDHFICEVPALLKLACVDTTVNELVLFVVSVLFVVIPPALISISYGFI
TQAVLRIKSVEARHKAFSTCSSHLTVVIIFYGTIIYVYLQPSDSYAQDQGKFISLFYTMVTPTLNP
IIYTLRNKDMKEALRKLLSGKL (SEQ ID NO: 397)

ATGAATAGTTTGGGAAAGTTGGTCTCCATGATCCTCTCAGCTCATGTGTTCTGTTATTCTAA
ATTTAATTGTTTTGGATGTACCCATTCCATTCCTGCCTTAGGTGCGGATCCCCCTGGAGGG
ATGGGATTGGGCAATGAGAGTTCCCTAATGGATTTCATCCTTCTAGGCTTCTCAGACCACC
CTCGTCTGGAGGCTGTTCTCTTTGTATTTGTCCTTTTCTTCTACCTCCTGACCCTTGTGGGA
AACTTCACCATAATCATCATCTCATATCTGGATCCCCCTCTTCATACCCCAATGTACTTTTT
TCTCAGCAACCTCTCTTTACTGGACATCTGCTTCACTACTAGCCTTGCTCCTCAGACCTTAG

TTAACTTGCAAAGACCAAAGAAGACGATCACTTACGGTGGTTGTGTGGCGCAACTCTATAT
TTCTCTGGCACTGGGCTCCACTGAATGTATCCTCTTGGCTGACATGGCCTTGGATCGGTAC
ATTGCTGTCTGCAAACCCCTCCACTATGTAGTCATCATGAACCCACGGCTTTGCCAACAGC
TGGCATCTATCTCCTGGCTCAGTGGTTTGGCTAGTTCCCTAATCCATGCAACTTTTACCTTG

5   CAATTGCCTCTCTGTGGCAACCATAGGCTGGACCATTTTATTTGCGAAGTACCAGCTCTTCT
CAAGTTGGCTTGTGTGGACACCACTGTCAATGAATTGGTGCTTTTTGTTGTTAGTGTTCTGT
TTGTTGTCATTCCACCAGCACTCATCTCCATCTCCTATGGCTTCATAACTCAAGCTGTGCTG
AGGATCAAATCAGTAGAGGCAAGGCATAAAGCCTTCAGCACCTGCTCCTCCCACCTTACAG
TGGTGATTATATTCTATGGCACCATAATCTACGTGTACCTGCAACCTAGTGACAGCTATGC

10   CCAGGACCAAGGGAAGTTTATCTCCCTCTTCTACACCATGGTGACCCCCACTTTAAATCCT
ATCATCTATACTTTAAGGAACAAGGATATGAAAGAGGCTCTGAGGAAACTTCTCTCGGGA
AAATTGTGA (SEQ ID NO: 398)

AOLFR214 sequences:

15   MDKSNSSVVSEFVLLGLCSSQKLQLFYFCFFSVLYTVIVLGNLLIILTVTSDTSLHSPMYFLLGN
LSFVDICQASFATPKMIADFLSAHETISFSGCIAQIFFIHLFTGGEMVLLVSMAYDRYVAICKPLY
YVVIMSRRTCTVLVMISWAVSLVHTLSQLSFTVNLPFCGPNVVDSFFCDLPRVTKLACLDSYIIE
ILIVVNSGILSLSTFSLLVSSYIIILVTVWLKSSAAMAKAFSTLASHIAVVILFFGPCIFIYVWPFTIS
PLDKFLAIFYTVFTPVLNPIIYTLRNRDMKAAVRKIVNHYLRPRRISEMSLVVRTSFH (SEQ ID

20   NO: 399)

ATGGATAAGTCCAATTCTTCAGTGGTGTCTGAATTTGTACTGTTGGGACTCTGTAGTTCTC
AAAAACTCCAGCTTTTCTATTTTTGTTTCTTCTCTGTGTTGTATACAGTCATTGTGCTGGGA
AATCTTCTCATTATCCTCACAGTGACTTCTGATACCAGCCTGCACTCCCCTATGTACTTTCT

25   CTTGGGAAACCTTTCCTTTGTTGACATTTGTCAGGCTTCTTTTGCTACCCCTAAAATGATTG
CAGATTTTCTGAGTGCACACGAGACCATATCTTTCAGTGGCTGCATAGCCCAAATTTTCTTT
ATTCACCTTTTTACTGGAGGGGAGATGGTGCTACTTGTTTCGATGGCCTATGACAGGTATG
TAGCCATATGCAAACCCTTATACTATGTGGTCATCATGAGCCGAAGGACATGCACTGTCTT
GGTAATGATCTCCTGGGCTGTGAGCTTGGTGCACACATTAAGCCAGTTATCATTTACTGTG

30   AACCTGCCTTTTGTGGACCTAATGTAGTAGACAGCTTTTTTGTGATCTTCCTCGAGTCAC
CAAACTTGCCTGCCTGGACTCTTACATCATTGAAATACTAATTGTGGTCAATAGTGGAATT
CTTTCCCTAAGCACTTTCTCTCTCTTGGTCAGCTCCTACATCATTATTCTTGTTACAGTTTG
GCTCAAGTCTTCAGCTGCAATGGCAAAGGCATTTTCTACGCTGGCTTCCCATATTGCAGTA
GTAATATTATTCTTTGGACCTTGCATCTTCATCTATGTGTGGCCCTTTACCATCTCTCCTTT

35   GGATAAATTTCTTGCCATATTTTACACTGTTTTCACCCCCGTCCTAAACCCCATTATTTATA
CACTAAGGAATAGGGATATGAAGGCTGCCGTAAGGAAAATTGTGAACCATTACCTGAGGC
CAAGGAGAATTTCTGAAATGTCACTAGTAGTGAGAACTTCCTTTCATTAA (SEQ ID NO:
400)

AOLFR215 sequences:

MAHTNESMVSEFVLLGLSNSWGLQLFFFAIFSIVYVTSVLGNVLIIVIISFDSHLNSPMYFLLSNL
SFIDICQSNFATPKMLVDFFIERKTISFEGCMAQIFVLHSFVGSEMMLLVAMAYDRFIAICKPLH
YSTIMNRRLCVIFVSISWAVGVLHSVSHLAFTVDLPFCGPNEVDSFFCDLPLVIELACMDTYEM
EIMTLTNSGLISLSCFLALIISYTIILIGVRCRSSSGSSKALSTLTAHITVVILFFGPCIYFYIWPFSRL

45   PVDKFLSVFYTVCTPLLNPIIYSLRNEDVKAAMWKLRNHHVNSWKN (SEQ ID NO: 401)

ATGGCTCACACAAATGAATCGATGGTGTCTGAGTTTGTACTTTTGGGACTCTCTAATTCCT
GGGGACTTCAACTTTTCTTTTTCGCCATCTTCTCTATAGTCTATGTGACATCAGTGCTAGGC
AATGTCTTAATTATTGTCATTATTTCTTTTGACTCCCATTTGAACTCTCCTATGTACTTCTTG

50   CTCAGTAATCTTTCTTTCATTGATATCTGTCAGTCTAACTTTGCCACCCCCAAGATGCTTGT
AGACTTTTTTATTGAGCGCAAGACTATCTCCTTTGAGGGTTGCATGGCCCAGATATTCGTT
CTTCACAGTTTTGTTGGGAGTGAGATGATGTTGCTTGTAGCTATGGCATATGACAGATTTA
TAGCCATATGTAAGCCTCTGCACTACAGTACAATTATGAACCGGAGGCTCTGTGTAATTTT
TGTGTCTATTTCCTGGGCGGTGGGCGTTCTTCATTCTGTGAGCCACTTGGCTTTTACAGTGG

55   ACCTGCCATTCTGTGGTCCCAATGAGGTGGATAGCTTCTTTTGTGACCTTCCCTTGGTGATA
GAGCTGGCTTGCATGGATACATATGAAATGGAAATTATGACCCTAACGAACAGTGGCCTG

147

ATATCATTGAGCTGTTTCCTGGCTTTAATTATTTCCTACACCATCATTTTGATCGGTGTCCG
ATGCAGGTCCTCCAGTGGGTCATCTAAGGCTCTTTCTACATTAACTGCCCACATCACAGTG
GTCATTCTTTTCTTCGGGCCTTGCATTTATTTCTATATATGGCCTTTTAGCAGACTTCCTGT
GGACAAATTTCTTTCTGTGTTCTACACTGTTTGTACTCCCTTGTTGAACCCCATCATCTACT
5   CTTTGAGGAATGAAGATGTTAAAGCAGCCATGTGGAAGCTGAGAAACCATCATGTGAACT
CCTGGAAAAACTAG (SEQ ID NO: 402)

AOLFR216 sequences:

MDVGNKSTMSEFVLLGLSNSWELQMFFFMVFSLLYVATMVGNSLIVITVIVDPHLHSPMYFLL
10   TNLSIIDMSLASFATPKMITDYLTGHKTISFDGCLTQIFFLHLFTGTEIILLMAMSFDRYIAICKPL
HYASVISPQVCVALVVASWIMGVMHSMSQVIFALTLPFCGPYEVDSFFCDLPVVFQLACVDTY
VLGLFMISTSGIIALSCFIVLFNSYVIVLVTVKHHSSRGSSKALSTCTAHFIVVFLFFGPCIFIYMW
PLSSFLTDKILSVFYTIFTPTLNPIIYTLRNQEVKIAMRKLKNRFLNFNKAMPS (SEQ ID NO: 403)

15   ATGGATGTGGGCAATAAGTCTACCATGTCTGAATTTGTTTTGCTGGGGCTCTCTAATTCCT
GGGAACTACAGATGTTTTTCTTTATGGTGTTTTCATTGCTTTATGTGGCAACAATGGTGGG
TAACAGCCTCATAGTCATCACAGTTATAGTGGACCCTCACCTACACTCTCCTATGTATTTCC
TGCTTACCAATCTTTCAATCATTGATATGTCTCTTGCTTCTTTCGCCACCCCAAAGATGATT
ACAGATTACCTAACAGGTCACAAAACCATCTCTTTTGATGGCTGCCTTACCCAGATATTCT
20   TTCTCCACCTTTTCACTGGAACTGAGATCATCTTACTCATGGCCATGTCCTTTGATAGGTAT
ATTGCAATATGCAAGCCCCTGCACTATGCTTCTGTCATTAGTCCCCAGGTGTGTGTTGCTCT
CGTGGTGGCTTCCTGGATTATGGGAGTTATGCATTCAATGAGTCAGGTCATATTTGCCCTC
ACGTTACCATTCTGTGGTCCCTATGAGGTAGACAGCTTTTTCTGTGACCTTCCTGTGGTGTT
CCAGTTGGCTTGTGTGGATACTTATGTTCTGGGCCTCTTTATGATCTCAACAAGTGGCATA
25   ATTGCGTTGTCCTGTTTTATTGTTTTATTTAATTCATATGTTATTGTCCTGGTTACTGTGAA
GCATCATTCTTCCAGAGGATCATCTAAGGCCCTTTCTACTTGTACAGCTCATTTCATTGTTG
TCTTCTTGTTCTTTGGGCCATGCATCTTCATCTACATGTGGCCACTAAGCAGCTTTCTCACA
GACAAGATTCTGTCTGTGTTTTATACCATCTTTACTCCCACTCTGAACCCAATAATCTATAC
TTTGAGGAATCAAGAAGTAAAGATAGCCATGAGGAAACTGAAAAATAGGTTTCTAAATTT
30   TAATAAGGCAATGCCTTCATAG (SEQ ID NO: 404)

AOLFR217 sequences:

MLESFQKSEQMAWSNQSAVTEFILRGLSSSLELQIFYFLFFSIVYAATVLGNLLIVVTIASEPHLH
SPTYFLLGNLSFIDMSLASFATPKMIADFLREHKAISFEGCMTQMFFLHLLGGAEIVLLISMSFD
35   RYVAICKPLHYLTIMSRRMCVGLVILSWIVGIFHALSQLAFTVNLPFCGPNEVDSFFCDLPLVIK
LACVDTYILGVFMISTSGMIALVCFILLVISYTIILVTVRQRSSGGSSKALSTCSAHFTVVTLFFGP
CTFIYVWPFTNFPIDKVLSVFYTIYTPLLNPVIYTVRNKDVKYSMRKLSSHIFKSRKTDHTP
(SEQ ID NO: 405)

40   ATGCTAGAGTCCTTCCAGAAATCAGAGCAAATGGCCTGGAGCAATCAGTCTGCGGTAACC
GAATTCATACTACGGGGTCTGTCCAGTTCTTTAGAACTCCAGATTTTCTACTTCCTGTTTTT
CTCCATAGTCTATGCAGCCACTGTGCTGGGGAACCTTCTTATTGTGGTCACCATTGCATCA
GAGCCACACCTTCATTCCCCTACGTACTTTCTGCTGGGCAATCTCTCCTTCATTGACATGTC
CCTGGCCTCATTTGCCACCCCCAAAATGATTGCAGACTTCCTTAGAGAACACAAAGCCATC
45   TCTTTTGAAGGCTGCATGACCCAGATGTTCTTCCTACATCTCTTAGGGGGTGCTGAGATTG
TACTGCTGATCTCCATGTCCTTTGATAGGTACGTGGCTATCTGTAAGCCTCTACATTACCTA
ACAATCATGAGCCGAAGAATGTGTGTTGGGCTTGTGATACTTTCCTGGATTGTCGGCATCT
TCCATGCTCTGAGTCAGTTAGCATTTACAGTGAATCTGCCCTTCTGTGGACCCAATGAAGT
AGACAGTTTCTTTTGTGACCTCCCTTTGGTGATTAAACTTGCTTGTGTCGACACATATATTC
50   TGGGGGTGTTCATGATCTCAACCAGTGGCATGATTGCCCTGGTGTGCTTCATCCTCTTGGT
GATCTCTTACACTATCATCCTGGTCACCGTTCGGCAGCGTTCCTCTGGTGGATCCTCCAAA
GCCCTCTCCACGTGCAGTGCCCACTTTACTGTTGTGACCCTTTTCTTTGGCCCATGCACTTT
CATTTATGTGTGGCCTTTCACAAATTTCCCAATAGACAAAGTACTCTCAGTATTTTATACCA
TATACACTCCCCTCTTGAATCCAGTGATCTATACCGTTAGGAATAAAGATGTCAAGTATTC
55   CATGAGGAAACTAAGCAGCCATATCTTTAAATCTAGGAAGACTGATCATACTCCTTAA
(SEQ ID NO: 406)

AOLFR218 sequences:

METANYTKVTEFVLTGLSQTREVQLVLFVIFLSFYLFILPGNILIICTIRLDPHLTSPMYFLLANLA
LLDIWYSSITAPKMLIDFFVERKIISFGGCIAQLFFLHFVGASEMFLLIVMAYDRYAAICRPLHYA
TIMNRRLCCILVALSWMGGFIHSIIQVALIVRLPFCGPNELDSYFCDITQVVRIACANTFPEELVM
ICSSGLISVVCFIALLMSYAFLLALLKKHSGSDENTNRAMSTCYSHITIVVLMFGPSIYTYARPFD
SFSLDKVVSVFHTVIFPLLNPIIYTLRNKEVKAAMRKVVTKYILCEEK (SEQ ID NO: 407)

ATGGAAACTGCAAATTACACCAAGGTGACAGAATTTGTTCTCACTGGCCTATCCCAGACTC
GGGAGGTCCAACTAGTCCTATTTGTTATATTTCTATCCTTCTATTTGTTCATCCTACCAGGA
AATATCCTTATCATTTGCACCATCAGGCTAGACCCTCATCTGACTTCTCCTATGTATTTCCT
GTTGGCTAATCTGGCCCTCCTTGATATTTGGTACTCTTCCATTACAGCCCCTAAAATGCTCA
TAGACTTCTTTGTGGAGAGGAAGATAATTTCCTTTGGTGGATGCATTGCACAGCTCTTCTT
CTTACACTTTGTTGGGGCTTCGGAGATGTTCTTGCTCATAGTGATGGCCTATGACCGCTAT
GCTGCTATCTGCCGACCCCTCCACTATGCTACCATCATGAATCGACGTCTCTGCTGTATCCT
GGTGGCTCTCCTGGATGGGGGGCTTCATTCATTCTATAATACAGGTGGCTCTCATTGTT
CGACTTCCTTTCTGTGGGCCCAATGAGTTAGACAGTTACTTCTGTGACATCACACAGGTTG
TCCGGATTGCCTGTGCCAACACCTTCCCAGAGGAGTTAGTGATGATCTGTAGTAGTGGTCT
GATCTCTGTGGTGTGTTTCATTGCTCTGTTAATGTCCTATGCCTTCCTTCTGGCCTTGCTCA
AGAAACATTCAGGCTCAGATGAGAATACCAACAGGGCCATGTCCACCTGCTATTCCCACAT
TACCATTGTGGTGCTAATGTTTGGGCCATCCATCTACATTTATGCTCGCCCATTTGACTCAT
TTTCCCTAGATAAAGTGGTGTCTGTGTTTCATACTGTAATATTCCCTTTACTTAATCCCATT
ATTTACACATTGAGAAACAAGGAAGTAAAGGCAGCCATGAGGAAGGTGGTCACCAAATAT
ATTTTGTGTGAAGAGAAGTGA (SEQ ID NO: 408).

AOLFR219 sequences:

MLTSLTDLCFSPIQVAEIKSLPKSMNETNHSRVTEFVLLGLSSSRELQPFLFLTFSLLYLAILLGNF
LIILTVTSDSRLHTPMYFLLANLSFIDVCVASFATPKMIADFLVERKTISFDACLAQIFFVHLFTGS
EMVLLVSMAYDRYVAICKPLHYMTVMSRRVCVVLVLISWFVGFIHTTSQLAFTVNLPFCGPN
KVDSFFCDLPLVTKLACIDTYVVSLLIVADSGFLSLSSFLLLVVSYTVILVTVRNRSSASMAKAR
STLTAHITVVTLFFGPCIFIYVWPFSSYSVDKVLAVFYTIFTLILNPVIYTLRNKEVKAAMSKLKS
RYLKPSQVSVVIRNVLFLETK (SEQ ID NO: 409).

ATGCTCACTTCATTAACTGATCTCTGTTTCTCTCCTATTCAGGTAGCTGAAATTAAGTCCCT
TCCAAAATCGATGAATGAGACAAATCATTCTCGGGTGACAGAATTTGTGTTGCTGGGACTG
TCTAGTTCAAGGGAGCTCCAACCTTTCTTGTTTCTTACATTTTCACTACTTTATCTAGCAAT
TCTGTTGGGCAACTTTCTCATCATCCTCACTGTGACCTCAGATTCCCGCCTTCACACCCCCA
TGTACTTTCTGCTTGCAAACCTGTCATTTATAGACGTATGTGTTGCCTCTTTTGCTACCCCT
AAAATGATTGCAGACTTTCTGGTTGAGCGCAAGACTATTTCTTTTGATGCCTGCCTGGCCC
AGATTTTCTTTGTTCATCTCTTCACTGGCAGTGAAATGGTGCTCCTAGTTTCCATGGCCTAT
GACCGTTATGTTGCTATATGCAAACCTCTCCACTACATGACAGTCATGAGCCGTCGTGTAT
GTGTTGTGCTCGTCCTCATTTCATGGTTTGTGGGCTTCATCCATACTACCAGCCAGTTGGCA
TTCACTGTTAATCTGCCATTTTGTGGTCCTAATAAGGTAGACAGTTTTTTCTGTGACCTTCC
TCTAGTGACCAAGTTAGCCTGCATAGACACTTATGTTGTCAGCTTACTAATAGTTGCAGAT
AGTGGCTTTCTTTCTCTGAGTTCCTTTCTCCTCTTGGTTGTCTCCTACACTGTAATACTTGTT
ACAGTTAGGAATCGCTCCTCTGCAAGCATGGCGAAGGCCCGCTCCACATTGACTGCTCACA
TCACTGTGGTCACTTTATTCTTTGGACCATGCATTTTCATCTATGTGTGGCCCTTCAGCAGT
TACTCAGTTGACAAAGTCCTTGCTGTATTCTACACCATCTTCACGCTTATTTTAAACCCTGT
AATCTACACGCTAAGAAACAAAGAAGTGAAGGCAGCTATGTCAAAACTGAAGAGTCGGTA
TCTGAAGCCTAGTCAGGTTTCTGTAGTCATAAGAAATGTTCTTTTCCTAGAAACAAAGTAA
(SEQ ID NO: 410).

AOLFR220 sequences:

MKQYSVGNQHSNYRSLLFPFLCSQMTQLTASGNQTMVTEFLFSMFPHAHRGGLLFFIPLLLIYG
FILTGNLIMFIVIQVGMALHTPLYFFISVLSFLEICYTTTTIPKMLSCLISEQKSISVAGCLLQMYFF
HSLGITESCVLTAMAIDRYIAICNPLRYPTIMIPKLCIQLTVGSCFCGFLLVLPEIAWISTLPFCGS

NQIHQIFCDFTPVLSLACTDTFLVVIVDAIHAAEIVASFLVIALSYIRIIIVILGMHSAEGHHKAFST
CAAHLAVFLLFFGSVAVMYLRFSATYSVFWDTAIAVTFVILAPFFNPIIYSLKNKDMKEAIGRLF
HYQKRAGWAGK (SEQ ID NO: 411).

5   ATGAAGCAATATTCAGTGGGTAATCAACATTCCAATTATAGGAGTCTCTTGTTTCCTTTTCT
GTGTTCACAGATGACACAGTTGACGGCCAGTGGGAATCAGACAATGGTGACTGAGTTCCT
CTTCTCTATGTTCCCGCATGCGCACAGAGGTGGCCTCTTATTCTTTATTCCCTTGCTTCTCA
TCTACGGATTTATCCTAACTGGAAACCTAATAATGTTCATTGTCATCCAGGTGGGCATGGC
CCTGCACACCCCTTTGTATTTCTTTATCAGTGTCCTCTCCTTCCTGGAGATCTGCTATACCA
10   CAACCACCATCCCCAAGATGCTGTCCTGCCTAATCAGTGAGCAGAAGAGCATTCCGTGGC
TGGCTGCCTCCTGCAGATGTACTTTTTCCACTCACTTGGTATCACAGAAAGCTGTGTCCTG
ACAGCAATGGCCATTGACAGGTACATAGCTATCTGCAATCCACTCCGTTACCCAACCATCA
TGATTCCCAAACTTTGTATCCAGCTGACAGTTGGATCCTGCTTTTGTGGCTTCCTCCTTGTG
CTTCCTGAGATTGCATGGATTTCCACCTTGCCTTTCTGTGGCTCCAACCAGATCCACCAGAT
15   ATTCTGTGATTTCACACCTGTGCTGAGCTTGGCCTGCACAGATACATTCCTAGTGGTCATT
GTGGATGCCATCCATGCAGCGGAAATTGTAGCCTCCTTCCTGGTCATTGCTCTATCCTACA
TCCGGATTATTATAGTGATTCTGGGAATGCACTCAGCTGAAGGTCATCACAAGGCCTTTTC
CACCTGTGCTGCTCACCTTGCTGTGTTCTTGCTATTTTTTGGCAGTGTGGCTGTCATGTATT
TGAGATTCTCAGCCACCTACTCAGTGTTTGGGACACAGCAATTGCTGTCACTTTTGTTATC
20   CTTGCTCCCTTTTTCAACCCCATCATCTATAGCCTGAAAAACAAGGACATGAAAGAGGCTA
TTGGAAGGCTTTTCCACTATCAGAAGAGGGCTGGTTGGGCTGGGAAATAG (SEQ ID NO:
412).

AOLFR221 sequences:

25   MRNLSGGHVEEFVLVGFPTTPPLQLLLFVLFFAIYLLTLLENALIVFTIWLAPSLHRPMYFFLGH
LSFLELWYINVTIPRLLAAFLTQDGRVSYVGCMTQLYFFIALACTECVLLAVMAYDRYLAICGP
LLYPSLMPSSLATRLAAASWGSGFFSSMMKLLFISQLSYCGPNIINHFFCDISPLLNLTCSDKEQA
ELVDFLLALVMILLPLLAVVSSYTAIIAAILRIPTSRGRHKAFSTCAAHLAVVVIYYSSTLFTYAR
PRAMYTFNHNKIISVLYTIIVPFFNPAIYCLRNKEVKEAFRKTVMGRCHYPRDVQD (SEQ ID
30   NO: 413).

ATGAGAAATTTGAGTGGAGGCCATGTCGAGGAGTTTGTCTTGGTGGGGTTTCCCTACCACGC
CTCCCCTCCAGCTGCTCCTCTTTGTCCTTTTTTTGCAATTTACCTTCTGACATTGTTGGAGA
ATGCACTTATTGTCTTCACAATATGGCTTGCTCCAAGCCTTCATCGTCCCATGTACTTTTTC
35   CTTGGCCATCTCTCTTTCCTGGAGCTATGGTACATCAATGTCACCATTCCTCGGCTCTTGGC
AGCCTTTCTTACCCAGGATGGTAGAGTCTCCTACGTAGGTTGCATGACCCAACTGTACTTC
TTTATTGCCTTAGCCTGTACTGAATGTGTGCTGTTGGCAGTTATGGCCTATGATCGCTACCT
GGCCATCTGTGGACCCCTCCTTTACCCTAGTCTCATGCCTTCCAGTCTGGCCACTCGCCTTG
CTGCTGCCTCTTGGGGCAGTGGCTTCTTCAGCTCCATGATGAAGCTTCTTTTTATTTCCCAA
40   TTGTCCTACTGTGGACCCAACATTATCAACCACTTTTTCTGTGATATTTCCCCACTACTCAA
CCTCACCTGCTCTGACAAGGAGCAAGCAGAGCTAGTAGACTTCCTTCTGGCCCTGGTGATG
ATTCTACTCCCTCTATTGGCTGTGGTTTCATCATACACTGCCATCATTGCAGCCATCCTGAG
GATCCCTACGTCCAGGGGACGCCACAAAGCCTTTTCCACTTGTGCCGCTCATCTGGCAGTG
GTTGTTATCTACTACTCCTCCACTCTCTTCACCTATGCACGGCCCCGGGCCATGTACACCTT
45   CAACCACAACAAGATTATCTCTGTGCTCTACACTATCATTGTACCATTCTTCAACCCAGCCA
TCTACTGCCTGAGGAACAAGGAGGTGAAGGAGGCCTTCAGGAAGACAGTGATGGGCAGAT
GTCACTATCCTAGGGATGTTCAGGACTGA (SEQ ID NO: 414).

AOLFR222 sequences:

50   MGQTNVTSWRDFVFLGFSSSGELQLLLFALFLSLYLVTLTSNVFIIIAIRLDSHLHTPMYLFLSFL
SFSETCYTLGIIPRMLSGLAGGDQAISYVGCAAQMFFSASWACTNCFLLAAMGFDRYVAICAPL
HYASHMNPTLCAQLVITSFLTGYLFGLGMTLVIFHLSFCSSHEIQHFFCDTPPVLSLACGDTGPS
ELRIFILSLLVLLVSFFFITISYAYILAAILRIPSAEGQKKAFSTCASHLTVVIIHYGCASFVYLRPK
ASYSLERDQLIAMTYTVVTPLLNPIVYSLRTRAIQTALRNAFRGRLLGKG (SEQ ID NO: 415).

55

ATGGGGCAGACCAACGTAACCTCCTGGAGGGATTTTGTCTTCCTGGGCTTCTCCAGTTCTG
GGGAGTTGCAGCTCCTTCTCTTTGCCTTGTTCCTCTCTCTGTATCTAGTCACTCTGACCAGC
AATGTCTTCATTATCATAGCCATCAGGCTGGATAGCCATCTGCACACCCCCATGTACCTCTT
CCTTTCCTTCCTATCCTTCTCTGAGACCTGCTACACTTTGGGCATCATCCCTAGAATGCTCT
CTGGCCTGGCTGGGGGGGACCAGGCTATCTCCTATGTGGGCTGTGCTGCCCAGATGTTCTT
TTCTGCCTCATGGGCCTGTACTAACTGCTTCCTTCTGGCTGCCATGGGCTTTGACAGATATG
TGGCCATCTGTGCTCCACTCCACTATGCCAGCCACATGAATCCTACCCTCTGTGCCCAGCT
GGTCATTACTTCCTTCCTGACTGGATACCTCTTTGGACTGGGAATGACACTAGTTATTTTCC
ACCTCTCATTCTGCAGCTCCCATGAAATCCAGCACTTTTTTTGTGACACGCCACCTGTGCTG
AGCCTAGCCTGTGGAGATACAGGCCCGAGTGAGCTGAGGATCTTTATCCTCAGTCTTTTGG
TCCTCTTGGTCTCCTTCTTCTTCATCACCATCTCCTACGCCTACATCTTGGCAGCAATACTG
AGGATCCCCTCTGCTGAGGGGCAGAAGAAGGCCTTCTCCACTTGTGCCTCGCACCTTACAG
TGGTCATTATTCATTATGGCTGTGCTTCCTTCGTGTACCTGAGGCCCAAAGCCAGCTACTCT
CTTGAGAGAGATCAGCTTATTGCCATGACCTATACTGTAGTGACCCCCCTCCTTAATCCCA
TTGTTTATAGTCTAAGGACTAGGGCTATACAGACAGCTCTGAGGAATGCTTTCAGAGGGAG
ATTGCTGGGTAAAGGATGA (SEQ ID NO: 416).

AOLFR223 sequences:

MEAANESSEGISFVLLGLTTSPGQQRPLFVLFLLLYVASLLGNGLIVAAIQASPALHAPMYFLLA
HLSFADLCFASVTVPKMLANLLAHDHSISLAGCLTQMYFFFALGVTDSCLLAAMAYDCYVAIR
HPLPYATRMSRAMCAALVGMAWLVSHVHSLLYILLMARLSFCASHQVPHFFCDHQPLLRLSC
SDTHHIQLLIFTEGAAVVVTPFLLILASYGAIAAAVLQLPSASGRLRAVSTCGSHLAVVSLFYGT
VIAVYFQATSRREAEWGRVATVMYTVVTPMLNPIIYSLWNRDVQGALRALLIGRRISASDS
(SEQ ID NO: 417).

ATGGAGGCTGCCAATGAGTCTTCAGAGGGAATCTCATTCGTTTTATTGGGACTGACAACAA
GTCCTGGACAGCAGCGGCCTCTCTTTGTGCTGTTCTTGCTCTTGTATGTGGCCAGCCTCCTG
GGTAATGGACTCATTGTGGCTGCCATCCAGGCCAGTCCAGCCCTTCATGCACCCATGTACT
TCCTGCTGGCCCACCTGTCCTTTGCTGACCTCTGTTTCGCCTCCGTCACTGTGCCCAAGATG
TTGGCCAACTTGTTGGCCCATGACCACTCCATCTCGCTGGCTGGCTGCCTGACCCAAATGT
ACTTCTTCTTTGCCCTGGGGGGTAACTGATAGCTGTCTTCTGGCGGCCATGGCCTATGACTG
CTACGTGGCCATCCGGCACCCCCTCCCCTATGCCACGAGGATGTCCCGGGCCATGTGCGCA
GCCCTGGTGGGAATGGCATGGCTGGTGTCCCACGTCCACTCCCTCCTGTATATCCTGCTCA
TGGCTCGCTTGTCCTTCTGTGCTTCCCACCAAGTGCCCCACTTCTTCTGTGACCACCAGCCT
CTCTTAAGGCTCTCGTGCTCTGACACCCACCACATCCAGCTGCTCATCTTCACCGAGGGCG
CCGCAGTGGTGGTCACTCCCTTCCTGCTCATCCTCGCCTCCTATGGGGCCATCGCAGCTGC
CGTGCTCCAGCTGCCCTCAGCCTCTGGGAGGCTCCGGGCTGTGTCCACCTGTGGCTCCCAC
CTGGCTGTGGTGAGCCTCTTCTATGGGACAGTCATTGCAGTCTACTTCCAGGCCACATCCC
GACGCGAGGCAGAGTGGGGCCGTGTGGCCACTGTCATGTACACTGTAGTCACCCCCATGC
TGAACCCCATCATCTACAGCCTCTGGAATCGCGATGTACAGGGGGCACTCCGAGCCCTTCT
CATTGGGCGAAGGATCTCAGCTAGTGACTCCTGA (SEQ ID NO: 418).

AOLFR224 sequences:

MGSFNTSFEDGFILVGFSDWPQLEPILFVFIFIFYSLTLFGNTIIIALSWLDLRLHTPMYFFLSHLSL
LDLCFTTSTVPQLLINLCGVDRTITRGGCVAQLFIYLALGSTECVLLVVMAFDRYAAVCRPLHY
MAIMHPHLCQTLAIASWGAGFVNSLIQTGLAMAMPLCGHRLNHFFCEMPVFLKLACADTEGT
EAKMFVARVIVVAVPAALILGSYVHIAHAVLRVKSTAGRRKAFGTCGSHLLVVFLFYGSAIYT
YLQSIHNYSEREGKFVALFYTIITPILNPLIYTLRNKDVKGALWKVLWRGRDSG (SEQ ID NO:
419).

ATGGGAAGTTTCAACACCAGTTTTGAAGATGGCTTCATTTTGGTGGGATTCTCAGATTGGC
CGCAACTGGAGCCCATCCTGTTTGTCTTTATTTTTATTTTCTACTCCCTAACTCTCTTTGGC
AACACCATCATCATCGCTCTCTCCTGGCTAGACCTTCGGCTGCACACACCTATGTACTTCTT
TCTCTCTCATCTGTCCCTCCTGGACCTCTGCTTCACCACCAGCACCGTGCCCCAGCTCCTGA
TCAACCTTTGCGGGGGTGGACCGCACCATCACCCGTGGAGGGTGTGTGGCTCAGCTCTTCAT
CTACCTAGCCCTGGGCTCCACAGAGTGTGTGCTCCTGGTGGTGATGGCCTTTGACCGCTAT

GCTGCTGTCTGTCGTCCACTCCACTACATGGCCATCATGCACCCCCATCTCTGCCAGACCCT
GGCTATCGCCTCCTGGGGGTGCGGGTTTCGTGAACTCTCTGATCCAGACAGGTCTCGCAATG
GCCATGCCTCTCTGTGGCCATCGACTGAATCACTTCTTCTGTGAGATGCCTGTATTTCTGAA
GTTGGCTTGTGCGGACACAGAAGGAACAGAGGCCAAGATGTTTGTGGCCCGAGTCATAGT
CGTGGCTGTTCCTGCAGCACTTATTCTAGGCTCCTATGTGCACATTGCTCATGCAGTGCTG
AGGGTGAAGTCAACGGCTGGGCGCAGAAAGGCTTTTGGGACTTGTGGGTCCCACCTCCTA
GTAGTTTTCCTTTTTTATGGCTCAGCCATCTACACATATCTCCAATCCATCCACAATTATTC
TGAGCGTGAGGGAAAATTTGTTGCCCTTTTTTATACTATAATTACCCCCATTCTCAATCCTC
TCATTTATACACTAAGAAACAAGGACGTGAAGGGGGCTCTGTGGAAAGTACTATGGAGGG
GCAGGGACTCAGGGTAG (SEQ ID NO: 420).

AOLFR225 sequences:

MENYNQTSTDFILLGLFPPSIIDLFFFILIVFIFLMALIGNLSMILLIFLDTHLHTPMYFLLSQLSLID
LNYISTIVPKMASDFLHGNKSISFTGCGIQSFFFLALGGAEALLLASMAYDRYIAICFPLHYLIRM
SKRVCVLMITGSWIIGSINACAHTVYVLHIPYCRSRAINHFFCDVPAMVTLACMDTWVYEGTV
FLSATIFLVFPFIGISCSYGQVLFAVYHMKSAEGRKKAYLTCSTHLTVVTFYYAPFVYTYLRPRS
LRSPTEDKVLAVFYTILTPMLNPIIYSLRNKEVMGALTRVSQRICSVKM (SEQ ID NO: 421).

ATGGAAAATTACAATCAAACATCAACTGATTTCATCTTATTGGGGCTGTTTCCACCATCAA
TAATTGACCTTTTCTTCTTCATTCTCATTGTTTTCATTTTCCTGATGGCTCTAATTGGAAACC
TGTCCATGATTCTTCTCATCTTCTTGGACACCCATCTCCACACACCCATGTATTTCCTACTG
AGTCAGCTCTCCCTCATTGACCTAAATTACATCTCCACCATTGTTCCTAAGATGGCATCTGA
TTTTCTGCATGGAAACAAGTCTATCTCCTTCACTGGGTGTGGGATTCAGAGTTTCTTCTTCT
TGGCATTAGGAGGTGCAGAAGCACTACTTTTGGCATCTATGGCCTATGATCGTTACATTGC
TATTTGCTTTCCTCTCCACTATCTCATCCGCATGAGCAAAAGAGTGTGTGTGCTGATGATA
ACAGGGTCTTGGATCATAGGCTCGATCAATGCTTGTGCTCACACTGTATATGTACTCCATA
TTCCTTATTGCCGATCCAGGGCCATCAATCATTTCTTCTGTGATGTCCCAGCAATGGTGACT
CTGGCCTGCATGGACACCTGGGTCTATGAGGGCACAGTGTTTTTGAGTGCCACCATCTTTC
TCGTGTTTCCCTTCATTGGTATTTCATGTTCCTATGGCCAGGTTCTCTTTGCTGTCTACCAC
ATGAAATCTGCAGAAGGGAGGAAGAAAGCCTATTTGACCTGCAGCACCCACCTCACTGTA
GTAACTTTCTACTATGCACCTTTTGTCTACACTTATCTACGTCCAAGATCCCTGCGATCTCC
AACAGAGGACAAGGTTCTGGCTGTCTTCTACACCATCCTCACCCCAATGCTCAACCCCATC
ATCTATAGCCTGAGGAACAAGGAGGTGATGGGGGCCCTGACACGAGTGAGTCAGAGAATC
TGCTCTGTGAAAATGTAG (SEQ ID NO: 422).

AOLFR226 sequences:

MEWRNHSGRVSEFVLLGFPAPAPLQVLLFALLLLAYVLVLTENTLIIMAIRNHSTLHKPMYFFL
ANMSFLEIWYVTVTIPKMLAGFVGSKQDHGQLISFEGCMTQLYFFLGLGCTECVLLAVMAYD
RYMAICYPLHYPVIVSGRLCVQMAAGSWAGGFGISMVKVFLISGLSYCGPNIINHFFCDVSPLL
NLSCTDMSTAELTDFILAIFILLGPLSVTGASYVAITGAVMHISSAAGRYKAFSTCASHLTVVIIF
YAASIFIYARPKALSAFDTNKLVSVLYAVIVPLLNPIIYCLRNQEVKRALCCTLHLYQHQDPDP

KKASRNV (SEQ ID NO: 423).

ATGGAGTGGCGGAACCATAGTGGGAGAGTGAGTGAGTTTGTGTTGCTGGGCTTCCCTGCT
CCTGCGCCACTACAGGTACTATTGTTTGCCCTTTTGCTGCTGGCCTATGTGTTGGTGCTGAC
TGAGAACACACTCATCATTATGGCAATTAGGAACCATTCTACCCTCCACAAACCCATGTAC
TTTTTTCTAGCTAATATGTCCTTTCTGGAGATCTGGTATGTCACTGTCACTATTCCCAAGAT
GCTTGCTGGCTTTGTTGGATCCAAACAGGATCATGGACAGCTAATCTCCTTTGAGGGATGC
ATGACACAGCTCTACTTTTTCCTTGGCTTGGGCTGCACTGAGTGTGTCCTTCTCGCTGTTAT
GGCCTATGATCGCTATATGGCCATCTGCTATCCTCTCCACTACCCAGTCATTGTCAGTGGCC
GGCTGTGTGTGCAGATGGCTGCTGGCTCTTGGGCTGGAGGTTTTGGCATCTCCATGGTCAA
AGTTTTTCTTATTTCTGGCCTCTCTTACTGTGGCCCCAACATCATCAACCACTTTTTCTGTG
ATGTCTCTCCATTGCTCAACCTCTCATGCACTGATATGTCCACAGCAGAGCTTACAGATTTC
ATCCTGGCCATTTTTATTCTTCTAGGGCCACTCTCTGTCACTGGGGCCTCCTATGTGGCCAT
TACTGGTGCTGTGATGCACATATCTTCGGCTGCTGGACGCTATAAGGCCTTTTCCACCTGT
GCCTCTCATCTCACTGTTGTGATAATCTTCTATGCAGCCAGTATCTTCATCTATGCTCGGCC

AAAGGCACTCTCAGCTTTTGACACCAACAAGTTGGTCTCTGTACTGTATGCTGTCATTGTA
CCATTGCTCAATCCCATCATTTACTGCCTGCGCAATCAAGAGGTCAAGAGAGCCCTATGCT
GTACTCTGCACCTGTACCAGCACCAGGATCCTGACCCCAAGAAAGCTAGCAGAAATGTATA
G (SEQ ID NO: 424).

5

AOLFR227 sequences:

MEPQNTSTVTNFQLLGFQNLLEWQALLFVIFLLIYCLTIIGNVVIITVVSQGLRLHSPMYMFLQH
LSFLEVWYTSTTVPLLLANLLSWGQAISFSACMAQLYFFVFLGATECFLLAFMAYDRYLAICSP
LRYPFLMHRGLCARLVVVSWCTGVSTGFLHSMMISRLDFCGRNQINHFFCDLPPLMQLSCSRV
YITEVTIFILSIAVLCICFFLTLGPYVFIVSSILRIPSTSGRRKTFSTCGSHLAVVTLYYGTMISMYV
CPSPHLLPEINKIISVFYTVVTPLLNPVIYSLRNKDFKEAVRKVMRRKCGILWSTSKRKF

LY (SEQ ID NO: 425).

ATGGAGCCCCAAAATACCTCCACTGTGACTAACTTTCAGCTGTTAGGATTCCAGAACCTTC
TTGAATGGCAGGCCCTGCTCTTTGTCATTTTCCTGCTCATCTACTGCCTGACCATTATAGGG
AATGTTGTCATCATCACCGTGGTGAGCCAGGGCCTGCGACTGCACTCCCCTATGTACATGT
TCCTCCAGCATCTCTCCTTTCTGGAGGTCTGGTACACGTCCACCACTGTGCCCCTTCTCCTA
GCCAACCTGCTGTCCTGGGGCCAAGCCATCTCCTTCTCTGCCTGCATGGCACAGCTCTACT
TCTTCGTATTCCTCGGCGCCACCGAGTGCTTTCTCCTGGCCTTCATGGCCTATGACCGTTAC
CTGGCCATCTGCAGCCCACTCCGCTACCCCTTTCTCATGCATCGTGGGCTATGTGCCAGGTT
GGTGGTGGTCTCATGGTGCACAGGGGTCAGCACAGGCTTTCTGCATTCCATGATGATTTCC
AGGTTGGACTTCTGTGGGCGCAATCAGATTAACCATTTCTTCTGCGACCTCCCGCCACTCA
TGCAGCTCTCCTGTTCCAGAGTTTATATCACCGAGGTGACCATCTTCATCCTGTCAATTGCC
GTGCTGTGCATTTGTTTTTTTCTGACACTGGGGCCCTATGTTTTCATTGTGTCCTCCATATT
GAGAATCCCTTCCACCTCTGGCCGGAGAAAGACCTTTTCCACATGTGGCTCCCACCTGGCT
GTTGTCACTCTCTACTACGGGACCATGATCTCCATGTATGTGTGTCCCAGTCCCCACCTGTT
GCCTGAAATCAACAAGATCATTTCTGTCTTCTACACTGTGGTCACACCACTGCTGAACCCA
GTTATCTACAGCTTGAGGAACAAAGACTTCAAAGAAGCTGTTAGAAAGGTCATGAGAAGG
AAATGTGGTATTCTATGGAGTACAAGTAAAAGGAAGTTCCTTTATTAG (SEQ ID NO: 426).

30

AOLFR229 sequences:

MFYVNQIPFQLYHISFVYPTELWSRAIIPCMPTLSFWVCSATPVSPGFFALILLVFVTSIASNVVK
IILIHIDSRLHTPMYFLLSQLSLRDILYISTIVPKMLVDQVMSQRAISFAGCTAQHFLYLTLAGAE
FFLLGLMSCDRYVAICNPLHYPDLMSRKICWLIVAAAWLGGSIDGFLLTPVTMQFPFCASREIN
HFFCEVPALLKLSCTDTSAYETAMYVCCIMMLLIPFSVISGSYTRILITVYRMSEAEGRRKAVAT
CSSHMVVVSLFYGAAMYTYVLPHSYHTPEQDKAVSAFYTILTPMLNPLIYSLRNKDVTGALQK
VVGRCVSSGKVTTF (SEQ ID NO: 427).

ATGTTTTATGTAAATCAGATACCTTTCCAACTTTATCATATCTCTTTCGTGTACCCTACAGA
GCTATGGAGCAGAGCAATTATTCCGTGTATGCCGACTTTATCCTTCTGGGTTTGTTCAGCA
ACGCCCGTTTCCCCTGGCTTCTTTGCCCTCATTCTCCTGGTCTTTGTGACCTCCATAGCCAG
CAACGTGGTCAAGATCATTCTCATCCACATAGACTCCCGCCTCCACACCCCCATGTACTTC
CTGCTCAGCCAGCTCTCCCTCAGGGACATCCTGTATATTTCCACCATTGTGCCCAAAATGCT
GGTCGACCAGGTGATGAGCCAGAGAGCCATTTCCTTTGCTGGATGCACTGCCCAACACTTC
CTCTACTTGACCTTAGCAGGGGCTGAGTTCTTCCTCCTAGGACTCATGTCCTGTGATCGCTA
CGTAGCCATCTGCAACCCTCTGCACTATCCTGACCTCATGAGCCGCAAGATCTGCTGGTTG
ATTGTGGCGGCAGCCTGGCTGGGAGGGTCTATCGATGGTTTCTTGCTCACCCCCGTCACCA
TGCAGTTCCCCTTCTGTGCCTCTCGGGAGATCAACCACTTCTTCTGCGAGGTGCCTGCCCTT
CTGAAGCTCTCCTGCACGGACACATCAGCCTACGAGACAGCCATGTATGTCTGCTGTATTA
TGATGCTCCTCATCCCTTTCTCTGTGATCTCGGGCTCTTACACAAGAATTCTCATTACTGTT
TATAGGATGAGCGAGGCAGAGGGGAGGCGAAAGGCTGTGGCCACCTGCTCCTCACACATG
GTGGTTGTCAGCCTCTTCTATGGGGCTGCCATGTACACATACGTGCTGCCTCATTCTTACCA
CACCCCTGAGCAGGACAAAGCTGTATCTGCCTTCTACACCATCCTCACTCCCATGCTCAAT
CCACTCATTTACAGCCTTAGGAACAAGGATGTCACGGGGGCCCTACAGAAGGTTGTTGGG
AGGTGTGTGTCCTCAGGAAAGGTAACCACTTTCTAA (SEQ ID NO: 428).

AOLFR230 sequences:

MGMEGLLQNSTNFVLTGLITHPAFPGLLFAIVFSIFVVAITANLVMILLIHMDSRLHTPMYFLLS
QLSIMDTIYICITVPKMLQDLLSKDKTISFLGCAVQIFLYLTLIGGEFFLLGLMAYDRYVAVCNP
LRYPLLMNRRVCLFMVVGSWVGGSLDGFMLTPVTMSFPFCRSREINHFFCEIPAVLKLSCTDTS
LYETLMYACCVLMLLIPLSVISVSYTHILLTVHRMNSAEGRRKAFATCSSHIMVVSVFYGAAFY
TNVLPHSYHTPEKDKVVSAFYTILTPMLNPLIYSLRNKDVAAALRKVLGRCGSSQSIRVATVIR
KG (SEQ ID NO: 429).

ATGGGCATGGAGGGTCTTCTCCAGAACTCCACTAACTTCGTCCTCACAGGCCTCATCACCC
ATCCTGCCTTCCCCGGGCTTCTCTTTGCAATAGTCTTCTCCATCTTTGTGGTGGCTATAACA
GCCAACTTGGTCATGATTCTGCTCATCCACATGGACTCCCGCCTCCACACACCCATGTACTT
CTTGCTCAGCCAGCTCTCCATCATGGATACCATCTACATCTGTATCACTGTCCCCAAGATGC
TCCAGGACCTCCTGTCCAAGGACAAGACCATTTCCTTCCTGGGCTGTGCAGTTCAGATCTT
CCTCTACCTGACCCTGATTGGAGGGGAATTCTTCCTGCTGGGTCTCATGGCCTATGACCGC
TATGTGGCTGTGTGCAACCCTCTACGGTACCCTCTCCTCATGAACCGCAGGGTTTGCTTATT
CATGGTGGTCGGCTCCTGGGTTGGTGGTTCCTTGGATGGGTTCATGCTGACTCCTGTCACT
ATGAGTTTCCCCTTCTGTAGATCCCGAGAGATCAATCACTTTTTCTGTGAGATCCCAGCCGT
GCTGAAGTTGTCTTGCACAGACACGTCACTCTATGAGACCCTGATGTATGCCTGCTGCGTG
CTGATGCTGCTTATCCCTCTATCTGTCATCTCTGTCTCCTACACGCACATCCTCCTGACTGT
CCACAGGATGAACTCTGCTGAGGGCCGGCGCAAAGCCTTTGCTACGTGTTCCTCCCACATT
ATGGTGGTGAGCGTTTTCTACGGGGCAGCCTTCTACACCAACGTGCTGCCCCACTCCTACC
ACACTCCAGAGAAAGATAAAGTGGTGTCTGCCTTCTACACCATCCTCACCCCCATGCTCAA
CCCACTCATCTACAGCTTGAGGAATAAAGATGTGGCTGCAGCTCTGAGGAAAGTACTAGG
GAGATGTGGTTCCTCCCAGAGCATCAGGGTGGCGACTGTGATCAGGAAGGGCTAG (SEQ ID
NO: 430).

AOLFR231 sequences:

MERANHSVVSEFILLGLSKSQNLQILFFLGFSVVFVGIVLGNLLILVTVTFDSLLHTPMYFLLSNL
SCIDMILASFATPKMIVDFLRERKTISWWGCYSQMFFMHLLGGSEMMLLVAMAIDRYVAICKP
LHYMTIMSPRVLTGLLLSSYAVGFVHSSSQMAFMLTLPFCGPNVIDSFFCDLPLVIKLACKDTYI
LQLLVIADSGLLSLVCFLLLLVSYGVIIFSVRYRAASRSSKAFSTLSAHITVVTLFFAPCVFIYVW
PFSRYSVDKILSVFYTIFTPLLNPIIYTLRNQEVKAAIKKRLCI (SEQ ID NO: 431).

ATGGAAAGAGCAAACCATTCAGTGGTATCGGAATTTATTTTGTTGGGACTTTCCAAATCTC
AAAATCTTCAGATTTTATTCTTCTTGGGATTCTCTGTGGTCTTCGTGGGGATTGTGTTAGGA
AACCTGCTCATCTTGGTGACTGTGACCTTTGATTCGCTCCTTCACACACCAATGTATTTTCT
GCTTAGCAACCTCTCCTGCATTGATATGATCCTGGCTTCTTTTGCTACCCCTAAGATGATTG
TAGATTTCCTCCGAGAACGTAAGACCATCTCATGGTGGGGATGTTATTCCCAGATGTTCTT
TATGCACCTCCTGGGTGGGAGTGAGATGATGTTGCTTGTAGCCATGGCAATAGACAGGTAT
GTTGCCATATGCAAACCCCTCCATTACATGACCATCATGAGCCCACGGGTGCTCACTGGGC
TACTGTTATCCTCCTATGCAGTTGGATTTGTGCACTCATCTAGTCAAATGGCTTTCATGTTG
ACTTTGCCCTTCTGTGGTCCCAATGTTATAGACAGCTTTTTCTGTGACCTTCCCCTTGTGAT
TAAACTTGCCTGCAAGGACACCTACATCCTACAGCTCCTGGTCATTGCTGACAGTGGGCTC
CTGTCACTGGTCTGCTTCCTCCTCTTGCTTGTCTCCTATGGAGTCATAATATTCTCAGTTAG
GTACCGTGCTGCTAGTCGATCCTCTAAGGCTTTCTCCACTCTCTCAGCTCACATCACAGTTG
TGACTCTGTTCTTTGCTCCGTGTGTCTTTATCTACGTCTGGCCCTTCAGCAGATACTCGGTA
GATAAAATTCTTTCTGTGTTTTACACAATTTTCACACCTCTCTTAAATCCTATTATTTATAC
ATTAAGAAATCAAGAGGTAAAAGCAGCCATTAAAAAAGACTCTGCATATAA (SEQ ID NO:
432).

AOLFR232 sequences:

MDNITWMASHTGWSDFILMGLFRQSKHPMANITWMANHTGWSDFILLGLFRQSKHPALLCV
VIFVVFLMALSGNAVLILLIHCDAHLHTPMYFFISQLSLMDMAYISVTVPKMLLDQVMGVNKIS
APECGMQMFFYVTLAGSEFFLLATMAYDRYVAICHPLRYPVLMNHRVCLFLSSGCWFLGSVD
GFTFTPITMTFPFRGSREIHHFFCEVPAVLNLSCSDTSLYEIFMYLCCVLMLLIPVVIISSSYLLILL

TIHGMNSAEGRKKAFATCSSHLTVVILFYGAAIYTYMLPSSYHTPEKDMMVSVFYTILTPVVNP
LIYSLRNKDVMGALKKMLTVEPAFQKAME (SEQ ID NO: 433).

5
ATGGACAACATCACCTGGATGGCCAGCCACACTGGATGGTCGGATTTCATCCTGATGGGAC
TCTTCAGACAATCCAAACATCCAATGGCCAATATCACCTGGATGGCCAACCACACTGGATG
GTCGGATTTCATCCTGTTGGGACTCTTCAGACAATCCAAACATCCAGCACTACTTTGTGTG
GTCATTTTTGTGGTTTTCCTGATGGCGTTGTCTGGAAATGCTGTCCTGATCCTTCTGATACA
CTGTGACGCCCACCTCCACACCCCCATGTACTTTTTCATCAGTCAATTGTCTCTCATGGACA
TGGCGTACATTTCTGTCACTGTGCCCAAGATGCTCCTGGACCAGGTCATGGGTGTGAATAA
10 GATCTCAGCCCCTGAGTGTGGGATGCAGATGTTCTTCTACGTGACACTAGCAGGTTCAGAA
TTTTTCCTTCTAGCCACCATGGCCTATGACCGCTACGTGGCCATCTGCCATCCTCTCCGTTA
CCCTGTCCTCATGAACCATAGGGTGTGTCTCTTCCTGTCATCAGGCTGCTGGTTCCTGGGCT
CAGTGGATGGCTTCACATTCACTCCCATCACCATGACCTTCCCCTTCCGTGGATCCCGGGA
GATTCATCATTTCTTCTGTGAAGTTCCTGCTGTATTGAATCTCTCCTGCTCAGACACCTCAC
15 TCTATGAGATTTTCATGTACTTGTGCTGTGTCCTCATGCTCCTCATCCCTGTGGTGATCATT
TCAAGCTCCTATTTACTCATCCTCCTCACCATCCACGGGATGAACTCAGCAGAGGGCCGGA
AAAAGGCCTTTGCCACCTGCTCCTCCCACCTGACTGTGGTCATCCTCTTCTATGGGGCTGCC
ATCTACACCTACATGCTCCCCAGCTCCTACCACACCCCTGAGAAGGACATGATGGTATCTG
TCTTCTATACCATCCTCACTCCAGTGGTGAACCCTTTAATCTATAGTCTTAGGAATAAGGAT
20 GTCATGGGGGCTCTGAAGAAAATGTTAACAGTGGAACCTGCCTTTCAAAAAGCTATGGAG
TAG (SEQ ID NO: 434).

AOLFR233 sequences:

MANITRMANHTGKLDFILMGLFRRSKHPALLSVVIFVVFLKALSGNAVLILLIHCDAHLHSPMY
25 FFISQLSLMDMAYISVTVPKMLLDQVMGVNKVSAPECGMQMFLYLTLAGSEFFLLATMAYDR
YVAICHPLRYPVLMNHRVCLFLASGCWFLGSVDGFMLTPITMSFPFCRSWEIHHFFCEVPAVTI
LSCSDTSLYETLMYLCCVLMLLIPVTIISSSYLLILLTVHRMNSAEGRKKAFATCSSHLTVVILFY
GAAVYTYMLPSSYHTPEKDMMVSVFYTILTPVLNPLIYSLRNKDVMGALKKMLTVRFVL
(SEQ ID NO: 435).

30
ATGGCCAACATCACCAGGATGGCCAACCACACTGGAAAGTTGGATTTCATCCTCATGGGAC
TCTTCAGACGATCCAAACATCCAGCTCTACTTAGTGTGGTCATCTTTGTGGTTTTCCTGAAG
GCGTTGTCTGGAAATGCTGTCCTGATCCTTCTGATACACTGTGACGCCCACCTCCACAGCC
CCATGTACTTTTTCATCAGTCAATTGTCTCTCATGGACATGGCGTACATTTCTGTCACTGTG
35 CCCAAGATGCTCCTGGACCAGGTCATGGGTGTGAATAAGGTCTCAGCCCCTGAGTGTGGG
ATGCAGATGTTCCTCTATCTGACACTAGCAGGTTCGGAATTTTTCCTTCTAGCCACCATGGC
CTATGACCGCTACGTGGCCATCTGCCATCCTCTCCGTTACCCTGTCCTCATGAACCATAGG
GTCTGTCTTTTCCTGGCATCGGGCTGCTGGTTCCTGGGCTCAGTGGATGGCTTCATGCTCAC
TCCCATCACCATGAGCTTCCCCTTCTGCAGATCCTGGGAGATTCATCATTTCTTCTGTGAAG
40 TCCCTGCTGTAACGATCCTGTCCTGCTCAGACACCTCACTCTATGAGACCCTCATGTACCTA
TGCTGTGTCCTCATGCTCCTCATCCCTGTGACGATCATTTCAAGCTCCTATTTACTCATCCT
CCTCACCGTCCACAGGATGAACTCAGCAGAGGGCCGGAAAAAGGCCTTTGCCACCTGCTC
CTCCCACCTGACTGTGGTCATCCTCTTCTATGGGGCTGCCGTCTACACCTACATGCTCCCCA
GCTCCTACCACACCCCTGAGAAGGACATGATGGTATCTGTCTTCTATACCATCCTCACTCC
45 GGTGCTGAACCCTTTAATCTATAGTCTTAGGAATAAGGATGTCATGGGGGCTCTGAAGAAA
ATGTTAACTGTGAGATTCGTCCTTTAG (SEQ ID NO: 436).

AOLFR234 sequences:

MPNSTTVMEFLLMRFSDVWTLQILHSASFFMLYLVTLMGNILIVTVTTCDSSLHMPMYFFLRN
50 LSILDACYISVTVPTSCVNSLLDSTTISKAGCVAQVFLVVFFVYVELLFLTIMAHDRYVAVCQPL
HYPVIVNSRICIQMTLASLLSGLVYAGMHTGSTFQLPFCRSNVIHQFFCDIPSLLKLSCSDTFSNE
VMIVVSALGVGGGCFIFIIRSYIHIFSTVLGFPRGADRTKAFSTCIPHILVVSVFLSSCSSVYLRPP
AIPAATQDLILSGFYSIMPPLFNPIIYSLRNKQIKVAIKKIMKRIFYSENV (SEQ ID NO: 437).

55 ATGCCCAATTCAACCACCGTGATGGAATTTCTCCTCATGAGGTTTTCTGATGTGTGGACAC
TACAGATTTTACATTCTGCATCCTTCTTTATGTTGTATTTGGTAACTCTAATGGGAAACATC

CTCATTGTGACCGTCACCACCTGTGACAGCAGCCTTCACATGCCCATGTACTTCTTCCTCAG
GAATCTGTCTATCTTGGATGCCTGCTACATTTCTGTTACAGTCCCTACCTCATGTGTCAATT
CCCTACTGGACAGCACCACCATTTCTAAGGCGGGATGTGTAGCTCAGGTCTTCCTCGTGGT
TTTTTTTGTATATGTGGAGCTTCTGTTTCTCACCATTATGGCTCATGACCGCTATGTGGCTG
5   TCTGCCAGCCACTTCACTACCCTGTGATCGTGAACTCTCGAATCTGCATCCAGATGACACT
GGCCTCCCTACTCAGTGGTCTTGTCTATGCAGGCATGCACACTGGCAGCACATTCCAGCTG
CCCTTCTGTCGGTCCAACGTTATTCATCAATTCTTCTGTGACATCCCCTCTCTGCTGAAGCT
CTCTTGCTCTGACACCTTCAGCAATGAGGTCATGATTGTTGTCTCTGCTCTGGGGGTAGGT
GGCGGCTGTTTCATCTTTATCATCAGGTCTTACATTCACATCTTTTCGACCGTGCTCGGGTT
10   TCCAAGAGGAGCAGACAGAACAAAGGCCTTTTCCACCTGCATCCCTCACATCCTGGTGGTG
TCAGTCTTCCTCAGTTCATGCTCTTCTGTGTACCTCAGGCCACCTGCGATACCTGCAGCCAC
CCAGGATCTGATCCTTTCTGGTTTTTATTCCATAATGCCTCCCCTCTTTAACCCTATTATTTA
CAGTCTTAGAAATAAGCAAATAAAGGTGGCCATCAAGAAAATCATGAAGAGAATTTTTTA
TTCAGAAAATGTGTAA (SEQ ID NO: 438).

15

AOLFR235 sequences:

MDGVNDSSLQGFVLMGISDHPQLEMIFFIAILFSYLLTLLGNSTILLLSRLEARLHTPMYFFLSNL
SSLDLAFATSSVPQMLINLWGPGKTISYGGCITQLYVFLWLGATECILLVVMAFDRYVAVCRPL
RYTAIMNPQLCWLLAVIACLGGLGNSVIQSTFTLQLPLCGHRRVEGFLCEVPAMIKLACGDTSL
20   NQAVLNGVCTFFTAVPLSIIVISYCLIAQAVLKIRSAEGRRKAFNTCLSHLLVVFLFYGSASYGY
LLPAKNSKQDQGKFISLFYSLVTPMVNPLIYTLRNMEVKGALRRLLGKGREVG (SEQ ID NO:
439).

ATGGACGGGGTGAATGATAGCTCCTTGCAGGGCTTTGTTCTGATGGGCATATCAGACCATC
25   CCCAGCTGGAGATGATCTTTTTTATAGCCATCCTCTTCTCCTATTTGCTGACCCTACTTGGG
AACTCAACCATCATCTTGCTTTCCCGCCTGGAGGCCCGGCTCCATACACCCATGTACTTCTT
CCTCAGCAACCTCTCCTCCTTGGACCTTGCTTTCGCTACTAGTTCAGTCCCCCAAATGCTGA
TCAATTTATGGGGACCAGGCAAGACCATCAGCTATGGTGGCTGCATAACCCAGCTCTATGT
CTTCCTTTGGCTGGGGGCCACCGAGTGCATCCTGCTGGTGGTGATGGCATTTGACCGCTAC
30   GTGGCAGTGTGCCGGCCCCTCCGCTACACCGCCATCATGAACCCCCAGCTCTGCTGGCTGC
TGGCTGTGATTGCCTGCCTGGGTGGCTTGGGCAACTCTGTGATCCAGTCAACATTCACTCT
GCAGCTCCCATTGTGTGGGCACCGGAGGGTGGAGGGATTCCTCTGCGAGGTGCCTGCCAT
GATCAAACTGGCCTGTGGCGACACAAGTCTCAACCAGGCTGTGCTCAATGGTGTCTGCACC
TTCTTCACTGCAGTCCCACTAAGCATCATCGTGATCTCCTACTGCCTCATTGCTCAGGCAGT
35   GCTGAAAATCCGCTCTGCAGAGGGGAGGCGAAAGGCGTTCAATACGTGCCTCTCCCATCT
GCTGGTGGTGTTCCTCTTCTATGGCTCAGCCAGCTATGGGTATCTGCTTCCGGCCAAGAAC
AGCAAACAGGACCAGGGCAAGTTCATTTCCCTGTTCTACTCGTTGGTCACACCCATGGTGA
ATCCCCTCATCTACACGCTGCGGAACATGGAAGTGAAGGGCGCACTGAGGAGGTTGCTGG
GGAAAGGAAGAGAAGTTGGCTGA (SEQ ID NO: 440).

40

AOLFR236 sequences:

MTSQERDTAIYSINVSFVAKGMTSRSVCEKMTMTTENPNQTVVSHFFLEGLRYTAKHSSLFFL
LFLLIYSITVAGNLLILLTVGSDSHLSLPMYHFLGHLSFLDACLSTVTVPKVMAGLLTLDGKVIS
FEGCAVQLYCFHFLASTECFLYTVMAYDRYLAICQPLHYPVAMNRRMCAEMAGITWAIGATH
45   AAIHTSLTFRLLYCGPCHIAYFFCDIPPVLKLACTDTTINELVMLASIGIVAAGCLILIVISYIFIVA
AVLRIRTAQGRQRAFSPCTAQLTGVLLYYVPPVCIYLQPRSSEAGAGAPAVFYTIVTPMLNPFIY
TLRNKEVKHALQRLLCSSFRESTAGSPPP (SEQ ID NO: 441).

ATGACATCTCAGGAAAGGGATACAGCTATTTATTCCATTAATGTCAGTTTTGTTGCAAAGG
50   GGATGACTAGCCGCTCTGTGTGTGAGAAGATGACCATGACAACGGAGAACCCCAACCAGA
CTGTGGTGAGCCACTTCTTCCTGGAGGGTTTGAGGTACACCGCTAAACATTCTAGCCTCTT
CTTCCTCCTCTTCCTCCTCATCTACAGCATCACTGTGGCTGGGAATCTCCTCATCCTCCTAA
CTGTGGGCTCTGACTCTCACCTCAGCTTACCCATGTACCACTTCCTGGGGCACCTCTCCTTC
CTGGATGCCTGTTTGTCTACAGTGACAGTGCCCAAGGTCATGGCAGGCCTGCTGACTCTGG
55   ATGGGAAGGTGATCTCCTTTGAGGGCTGTGCCGTACAGCTTTATTGCTTCCACTTTCTGGC
CAGCACTGAGTGCTTCCTGTACACAGTCATGGCCTATGACCGCTATCTGGCTATCTGTCAA

CCCCTGCACTACCCAGTGGCCATGAACAGAAGGATGTGTGCAGAAATGGCTGGAATCACC
TGGGCCATAGGTGCCACGCACGCTGCAATCCACACCTCCCTCACCTTCCGCCTGCTCTACT
GTGGGCCTTGCCACATTGCCTACTTCTTCTGCGACATACCCCCTGTCCTAAAGCTCGCCTGT
ACAGACACCACCATTAATGAGCTAGTCATGCTTGCCAGCATTGGCATCGTGGCTGCAGGCT
5   GCCTCATCCTCATCGTTATTTCCTACATCTTCATCGTGGCAGCTGTGTTGCGCATCCGCACA
GCCCAGGGCCGGCAGCGGGCCTTCTCCCCCTGCACTGCCCAGCTCACTGGGGTGCTCCTGT
ACTACGTGCCACCTGTCTGTATCTACCTGCAGCCTCGCTCCAGTGAGGCAGGAGCTGGGGC
CCCTGCTGTCTTCTACACAATCGTAACTCCAATGCTCAACCCATTCATTTACACTTTGCGGA
ACAAGGAGGTGAAGCATGCTCTGCAAAGGCTTTTGTGCAGCAGCTTCCGAGAGTCTACAG
10   CAGGCAGCCCACCCCCATAG (SEQ ID NO: 442).

AOLFR237 sequences:

MDQRNYTRVKEFTFLGITQSRELSQVLFTFLFLV.YMTTLMGNFLIMVTVTCESHLHTPMYFLL
RNLSILDICFSSITAPKVLIDLLSETKTISFSGCVTQMFFFHLLGGADVFSLSVMAFDRYIAISKPL
15   HYMTIMSRGRCTGLIVGFLGGGLVHSIAQISLLLPLPVCGPNVLDTFYCDVPQVLKLACTDTFT
LELLMISNNGLVSWFVFFFLLISYTVILMMLRSHTGEGRRKAISTCTSHITVVTLHFVPCIYVYA
RPFTALPTDTAISVTFTVISPLLNPIIYTLRNQEMKLAMRKLKRRLGQSERILIQ (SEQ ID NO:
443).

20   ATGGATCAGAGAAATTACACCAGAGTGAAAGAATTTACCTTCCTGGGAATTACTCAGTCCC
GAGAACTGAGCCAGGTCTTATTTACCTTCCTGTTTTTGGTGTACATGACAACTCTAATGGG
AAACTTCCTCATCATGGTTACAGTTACCTGTGAATCTCACCTTCATACGCCCATGTACTTCC
TGCTCCGCAACCTGTCTATTCTTGACATCTGCTTTTCCTCCATCACAGCTCCTAAGGTCCTG
ATAGATCTTCTATCAGAGACAAAAACCATCTCCTTCAGTGGCTGTGTCACTCAAATGTTCT
25   TCTTCCACCTTCTGGGGGGAGCAGACGTTTTTTCTCTCTCTGTGATGGCGTTTGACCGCTAT
ATAGCCATCTCCAAGCCCCTGCACTATATGACCATCATGAGTAGGGGGCGATGCACAGGCC
TCATCGTGGGCTTCCTGGGTGGGGGGCTTGTCCACTCCATAGCGCAGATTTCTCTATTGCT
CCCACTCCCTGTCTGTGGACCCAATGTTCTTGACACTTTCTACTGCGATGTCCCCCAGGTCC
TCAAACTTGCCTGCACTGACACCTTCACTCTGGAGCTCCTGATGATTTCAAATAATGGGTT
30   AGTCAGTTGGTTTGTATTCTTCTTTCTCCTCATATCTTACACGGTCATCTTGATGATGCTGA
GGTCTCACACTGGGGAAGGCAGGAGGAAAGCCATCTCCACCTGCACCTCCCACATCACCG
TGGTGACCCTGCATTTCGTGCCCTGCATCTATGTCTATGCCCGGCCCTTCACTGCCCTCCCC
ACAGACACTGCCATCTCTGTCACCTTCACTGTCATCTCCCCTTTGCTCAATCCTATAATTTA
CACGCTGAGGAATCAGGAAATGAAGTTGGCCATGAGGAAACTGAAGAGACGGCTAGGAC
35   AATCAGAAAGGATTTTAATTCAATAA (SEQ ID NO: 444).

AOLFR238 sequences:

MAPENFTRVTEFILTGVSSCPELQIPLFLVFLVLYVLTMAGNLGIITLTSVDSRLQTPMYFFLRHL
AIINLGNSTVIAPKMLMNFLVKKKTTSFYECATQLGGFLFFIVSEVMMLAVMAYDRYVAICNP
40   LLYMVVVSRRLCLLLVSLTYLYGFSTAIVVSPCIFSVSYCSSNIINHFYCDIAPLLALSCSDTYIPE
TIVFISAATNLFFSMITVLVSYFNIVLSILRIRSPEGRKKAFSTCASHMIAVTVFYGTMLFMYLQP
QTNHSLDTDKMASVFYTLVIPMLNPLIYSLRNNDVNVALKKFMENPCYSFKSM (SEQ ID NO:
445).

45   ATGGCTCCTGAAAATTTCACCAGGGTCACTGAGTTTATTCTCACAGGTGTCTCTAGCTGTC
CAGAGCTCCAGATTCCCCTCTTCCTGGTCTTCCTAGTGCTCTATGTGCTGACCATGGCAGG
GAACCTGGGCATCATCACCCTCACCAGTGTTGACTCTCGACTTCAAACCCCCATGTACTTTT
TCCTGAGACATCTAGCTATCATCAATCTTGGCAACTCTACTGTCATTGCCCCTAAAATGCTG
ATGAACTTTTTAGTAAAGAAGAAAACTACCTCATTCTATGAATGTGCCACCCAACTGGGAG
50   GGTTCTTGTTCTTTATTGTATCGGAGGTAATGATGCTGGCTGTGATGGCCTATGACCGCTA
TGTGGCCATTTGTAACCCTCTGCTCTACATGGTGGTGGTGTCTCGGCGGCTCTGCCTCCTGC
TGGTGTCCCTCACGTACCTCTATGGCTTTTCTACAGCTATTGTGGTTTCACCTTGTATATTC
TCTGTGTCTTATTGCTCTTCTAATATAATCAATCATTTTTACTGTGATATTGCACCTCTGTT
AGCATTATCTTGCTCTGATACTTACATACCAGAAACAATAGTCTTTATATCTGCAGCAACA
55   AATTTGTTTTTTTCCATGATTACAGTTCTAGTATCTTATTTCAATATTGTTTTGTCCATTCTA
AGGATACGTTCACCAGAAGGAAGGAAAAAAGCCTTTTCCACCTGCGCTTCGCATATGATA

GCAGTCACGGTTTTCTATGGGACAATGCTATTTATGTATTTGCAGCCCCAAACCAACCACT
CACTGGATACTGATAAGATGGCTTCTGTGTTTTACACATTGGTGATTCCTATGCTGAATCC
CTTGATCTACAGCCTGAGGAATAATGATGTAAATGTTGCCTTAAAGAAATTCATGGAAAAT
CCATGTTACTCCTTTAAATCAATGTAA (SEQ ID NO: 446).

5

AOLFR239 sequences:

MDPQNYSLVSEFVLHGLCTSRHLQNFFFIFFFGVYVAIMLGNLLILVTVISDPCLHSSPMYFLLG
NLAFLDMWLASFATPKMIRDFLSDQKLISFGGCMAQIFFLHFTGGAEMVLLVSMAYDRYVAIC
KPLHYMTLMSWQTCIRLVLASWVVGFVHSISQVAFTVNLPYCGPNEVDSFFCDLPLVIKLACM
10   DTYVLGIIMISDSGLLSLSCFLLLLLISYTVILLAIRQRAAGSTSKALSTCSAHIMVVTLFFGPCIFV
YVRPFSRFSVDKLLSVFYTIFTPLLNPIIYTLRNEEMKAAMKKLQNRRVTFQ (SEQ ID NO: 447).

ATGGACCCACAGAACTATTCCTTGGTGTCAGAATTTGTGTTGCATGGACTCTGCACTTCAC
GACATCTTCAAAATTTTTTCTTTATATTTTTCTTTGGGGTCTATGTGGCCATTATGCTGGGT
15   AACCTTCTCATTTTGGTCACTGTAATTTCTGATCCCTGCCTGCACTCCTCCCCTATGTACTT
CCTGCTGGGGAACCTAGCTTTCCTGGACATGTGGCTGGCCTCATTTGCCACTCCCAAGATG
ATCAGGGATTTCCTTAGTGATCAAAAACTCATCTCCTTTGGAGGATGTATGGCTCAAATCT
TCTTCTTGCACTTTACTGGTGGGGCTGAGATGGTGCTCCTGGTTTCCATGGCCTATGACAG
ATATGTGGCCATATGCAAACCCTTGCATTACATGACTTTGATGAGTTGGCAGACTTGCATC
20   AGGCTGGTGCTGGCTTCATGGGTCGTTGGATTTGTGCACTCCATCAGTCAAGTGGCTTTCA
CTGTAAATTTGCCTTACTGTGGCCCCAATGAGGTAGACAGCTTCTTCTGTGACCTCCCTCTG
GTGATCAAACTTGCCTGCATGGACACCTATGTCTTGGGTATAATTATGATCTCAGACAGTG
GGTTGCTTTCCTTGAGCTGTTTTCTGCTCCTCCTGATCTCCTACACCGTGATCCTCCTCGCT
ATCAGACAGCGTGCTGCCGGTAGCACATCCAAAGCACTCTCCACTTGCTCTGCACATATCA
25   TGGTAGTGACGCTGTTCTTTGGCCCTTGCATTTTTGTTTATGTGCGGCCTTTCAGTAGGTTC
TCTGTGGACAAGCTGCTGTCTGTGTTTTATACCATTTTTACTCCACTCCTGAACCCCATTAT
CTACACATTGAGAAATGAGGAGATGAAAGCAGCTATGAAGAAACTGCAAAACCGACGGGT
GACTTTTCAATGA (SEQ ID NO: 448).

30   **AOLFR240 sequences:**

MAGENHTTLPEFLLLGFSDLKALQGPLFWVVLLVYLVTLLGNSLIILLTQVSPALHSPMYFFLR
QLSVVELFYTTDIVPRTLANLGSPHPQAISFQGCAAQMYVFIVLGISECCLLTAMAYDRYVAIC
QPLRYSTLLSPRACLAMVGSSWLTGIITATTHASLIFSLPFRSHPIIPHFLCDILPVLRLASAGKHR
SEISVMTATIVFIMIPFSLIVTSYIRILGAILAMASTQSRRKVFSTCSSHLLVVSLFFGTASITYIRPQ
35   AGSSVTTDRVLSLFYTVITPMLNPIIYTLRNKDVRRALRHLVKRQRPSP (SEQ ID NO: 449).

ATGGCTGGGGAAAACCATACTACACTGCCTGAATTCCTCCTTCTGGGATTCTCTGACCTCA
AGGCCCTGCAGGGCCCCCTGTTCTGGGTGGTGCTTCTGGTCTACCTGGTCACCTTGCTGGG
TAACTCCCTGATCATCCTCCTCACACAGGTCAGCCCTGCCCTGCACTCCCCCATGTACTTCT
40   TCCTGCGCCAACTCTCAGTGGTGGAGCTCTTCTACACCACTGACATCGTGCCCAGGACCCT
GGCCAATCTGGGCTCCCCGCATCCCCAGGCCATCTCTTTCCAGGGCTGTGCAGCCCAGATG
TACGTCTTCATTGTCCTGGGCATCTCGGAGTGCTGCCTGCTCACGGCCATGGCCTATGACC
GATATGTTGCCATCTGCCAGCCCCTACGCTATTCCACCCTCTTGAGCCCACGGGCCTGCTT
GGCCATGGTGGGGTCCTCCTGGCTCACAGGCATCATCACGGCCACCACCCATGCCTCCCTC
45   ATCTTCTCTCTACCTTTTCGCAGCCACCCGATCATCCCGCACTTTCTCTGTGACATCCTGCC
AGTACTGAGGCTGGCAAGTGCTGGGAAGCACAGGAGCGAGATCTCCGTGATGACAGCCAC
CATAGTCTTCATTATGATCCCCTTCTCTCTGATTGTCACCTCTTACATCCGCATCCTGGGTG
CCATCCTAGCAATGGCCTCCACCCAGAGCCGCCGCAAGGTCTTCTCCACCTGCTCCTCCCA
TCTGCTCGTGGTCTCTCTCTTCTTTGGAACAGCCAGCATCACCTACATCCGGCCGCAGGCA
50   GGCTCCTCTGTTACCACAGACCGCGTCCTCAGTCTCTTCTACACAGTCATCACACCCATGCT
CAACCCCATCATCTACACCCTTCGGAACAAGGACGTGAGGAGGGCCCTGCGACACTTGGT
GAAGAGGCAGCGCCCCTCACCCTGA (SEQ ID NO: 450).

AOLFR241 sequences:

55   MPQILIFTYLNMFYFFPPLQILAENLTMVTEFLLLGFSSLGEIQLALFVVFLFLYLVILSGNVTIIS
VIHLDKSLHTPMYFFLGILSTSETFYTFVILPKMLINLLSVARTISFNCCALQMFFFLGFAITNCLL

LGVMGYDRYAAICHPLHYPTLMSWQVCGKLAAACAIGGFLASLTVVNLVFSLPFCSANKVNH
YFCDISAVILLACTNTDVNEFVIFICGVLVLVVPFLFICVSYLCILRTILKIPSAEGRRKAFSTCAS
HLSVVIVHYGCASFIYLRPTANYVSNKDRLVTVTYTIVTPLLNPMVYSLRNKDVQLAIRKVLG
KKGSLKLYN (SEQ ID NO: 451).

ATGCCCCAAATTCTTATATTCACATACCTGAATATGTTTTACTTCTTTCCCCCTTTGCAGAT
CTTGGCAGAAAACCTCACCATGGTCACCGAATTCCTGTTGCTGGGTTTTTCCAGCCTTGGT
GAAATTCAGCTGGCCCTCTTTGTAGTTTTTCTTTTTCTGTATCTAGTCATTCTTAGTGGCAA
TGTCACCATTATCAGTGTCATCCACCTGGATAAAAGCCTCCACACACCAATGTACTTCTTCC
TTGGCATTCTCTCAACATCTGAGACCTTCTACACCTTTGTCATTCTACCCAAGATGCTCATC
AATCTACTTTCTGTGGCCAGGACAATCTCCTTCAACTGTTGTGCTCTTCAAATGTTCTTCTT
CCTTGGTTTTGCCATTACCAACTGCCTGCTATTGGGTGTGATGGGTTATGATCGCTATGCTG
CCATTTGTCACCCTCTGCATTACCCCACTCTTATGAGCTGGCAGGTGTGTGGAAAACTGGC
AGCTGCCTGTGCAATTGGTGGCTTCTTGGCCTCTCTTACAGTAGTAAATTTAGTTTTCAGCC
TCCCTTTTTGTAGCGCCAACAAAGTCAATCATTACTTCTGTGACATCTCAGCAGTCATTCTT
CTGGCTTGTACCAACACAGATGTTAACGAATTTGTGATATTCATTTGTGGAGTTCTTGTAC
TTGTGGTTCCCTTTCTGTTTATCTGTGTTTCTTATCTCTGCATTCTGAGGACTATCCTGAAG
ATTCCCTCAGCTGAGGGCAGACGGAAAGCGTTTTCCACCTGCGCCTCTCACCTCAGTGTTG
TTATTGTTCATTATGGCTGTGCTTCCTTCATCTACCTGAGGCCTACAGCAAACTATGTGTCC
AACAAAGACAGGCTGGTGACGGTGACATACACGATTGTCACTCCATTACTAAACCCCATG
GTTTATAGCCTCAGAAACAAGGATGTCCAACTTGCTATCAGAAAAGTGTTGGGCAAGAAA
GGTTCTCTAAAACTATATAATTGA (SEQ ID NO: 452).

AOLFR242 sequences:

MNTTLFHPYSFLLLLGIPGLESMHLWVGFPFFAVFLTAVLGNITILFVIQTDSSLHHPMFYFLAILS
SIDPGLSTSTIPKMLGTFWFTLREISFEGCLTQMFFIHLCTGMESAVLVAMAYDCYVAICDPLCY
TLVLTNKVVSVMALAIFLRPLVFVIPFVLFILRLPFCGHQIIPHTYGEHMGIARLSCASIRVNIIYG
LCAISILVFDIIAIVISYVQILCAVFLLSSHDARLKAFSTCGSHVCVMLTFYMPAFFSFMTHRFGR
NIPHFIHILLANFYVVIPPALNSVIYGVRTKQIRAQVLKMFFNK (SEQ ID NO: 453).

ATGAATACCACTCTATTTCATCCTTACTCTTTCCTTCTTCTGGGAATTCCTGGGCTGGAAAG
TATGCATCTCTGGGTTGGTTTTTCCTTTCTTTGCTGTGTTCCTGACAGCTGTCCTTGGGAATA
TCACCATCCTTTTTGTGATTCAGACTGACAGTAGTCTCCATCATCCCATGTTCTACTTCCTG
GCCATTCTGTCATCTATTGACCCGGGCCTGTCTACATCCACCATCCCTAAAATGCTTGGCAC
CTTCTGGTTTACCCTGAGAGAAATCTCCTTTGAAGGATGCCTTACCCAGATGTTCTTCATCC
ACCTGTGCACTGGCATGGAATCAGCTGTGCTTGTGGCCATGGCCTATGATTGCTATGTGGC
CATCTGTGACCCTCTTTGCTACACGTTGGTGCTGACAAACAAGGTGGTGTCAGTTATGGCA
CTGGCCATCTTTCTGAGACCCTTAGTCTTTGTCATACCCTTTGTTCTATTTATCCTAAGGCT
TCCATTTTGTGGACACCAAATTATTCCTCATACTTATGGTGAGCACATGGGCATTGCCCGC
CTGTCTTGTGCCAGCATCAGGGTTAACATCATCTATGGCTTATGTGCCATCTCTATCCTGGT
CTTTGACATCATAGCAATTGTCATTTCCTATGTACAGATCCTTTGTGCTGTATTTCTACTCT
CTTCACATGATGCACGACTCAAGGCATTCAGCACCTGTGGCTCTCATGTGTGTGTCATGTT
GACTTTCTATATGCCTGCATTTTTCTCATTCATGACCCATAGGTTTGGTCGGAATATACCTC
ACTTTATCCACATTCTTCTGGCTAATTTCTATGTAGTCATTCCACCTGCTCTCAACTCTGTA
ATTTATGGTGTCAGAACCAAACAGATTAGAGCACAAGTGCTGAAAATGTTTTTCAATAAAT
AA (SEQ ID NO: 454).

AOLFR243 sequences:

MEQVNKTVVREFVVLGFSSLARLQQLLFVIFLLLYLFTLGTNAIIISTIVLDRALHTPMYFFLAIL
SCSEICYTFVIVPKMLVDLLSQKKTISFLGCAIQMFSFLFFGSSHSFLLAAMGYDRYMAICNPLR
YSVLMGHGVCMGLMAAACACGFTVSLVTTSLVFHLPFHSSNQLHHFFCDISPVLKLASQHSGF
SQLVIFMLGVFALVIPLLLILVSYIRIISAILKIPSSVGRYKTFSTCASHLIVVTVHYSCASFIYLRPK
TNYTSSQDTLISVSYTILTPLFNPMIYSLRNKEFKSALRRTIGQTFYPLS (SEQ ID NO: 455).

ATGGAGCAAGTCAATAAGACTGTGGTGAGAGAGTTCGTCGTCCTCGGCTTCTCATCCCTGG
CCAGGCTGCAGCAGCTGCTCTTTGTTATCTTCCTGCTCCTCTACCTGTTCACTCTGGGCACC

AATGCAATCATCATTTCCACCATTGTGCTGGACAGAGCCCTTCATACTCCCATGTACTTCTT
CCTTGCCATCCTTTCTTGCTCTGAGATTTGCTATACCTTTGTCATTGTACCCAAGATGCTGG
TTGACCTGCTGTCCCAGAAGAAGACCATTTCTTTCCTGGGCTGTGCCATCCAAATGTTTTCC
TTCCTCTTCTTTGGCTCCTCTCACTCCTTCCTGCTGGCAGCCATGGGCTATGATCGCTATAT

5 GGCCATCTGTAACCCACTGCGCTACTCAGTGCTCATGGGACATGGGGTGTGTATGGGACTA
ATGGCTGCTGCCTGTGCCTGTGGCTTCACTGTCTCCCTGGTCACCACCTCCCTAGTATTTCA
TCTGCCCTTCCACTCCTCCAACCAGCTCCATCACTTCTTCTGTGACATCTCCCCTGTCCTTA
AACTGGCATCTCAGCACTCCGGCTTCAGTCAGCTGGTCATATTCATGCTTGGTGTATTTGC
CTTGGTCATTCCTCTGCTACTTATCCTAGTCTCCTACATCCGCATCATCTCTGCCATTCTAA

10 AAATCCCTTCCTCCGTTGGAAGATACAAGACCTTCTCCACCTGTGCCTCCCATCTCATTGTG
GTAACTGTTCACTACAGTTGTGCCTCTTTCATCTACTTAAGGCCCAAGACTAATTACACTTC
AAGCCAAGACACCCTAATATCTGTGTCATACACCATCCTTACCCCATTGTTCAATCCAATG
ATTTATAGTCTGAGAAATAAGGAATTCAAATCAGCCCTACGAAGAACAATCGGCCAAACT
TTCTATCCTCTTAGTTAA (SEQ ID NO: 456).   ....

15

AOLFR244 sequences:

MWQEYYFLNVFFPLLKVCCLTINSHVVILLPWECYHLIWKILPYIGTTVGSMEEYNTSSTDFTF
MGLFNRKETSGLIFAIISIIFFTALMANGVMIFLIQTDLRLHTPMYFLLSHLSLIDMMYISTIVPKM
LVNYLLDQRTISFVGCTAQHFLYLTLVGAEFFLLGLMAYDRYVAICNPLRYPVLMSRRVCWMI

20 IAGSWFGGSLDGFLLTPITMSFPFCNSREINHFFCEAPAVLKLACADTALYETVMYVCCVLMLL
IPFSVVLASYARILTTVQCMSSVEGRKKAFATCSSHMTVVSLFYGAAMYTYMLPHSYHKPAQ
DKVLSVFYTILTPMLNPLIYSLRNKDVTGALKRALGRFKGPQRVSGGVF (SEQ ID NO: 457).

ATGTGGCAAGAATACTATTTTTTAAATGTTTTCTTCCCACTTTTAAAAGTTTGCTGCCTAAC
25 AATTAATTCACATGTTGTTATTTTACTGCCCTGGGAATGCTATCATCTTATTTGGAAGATAT
TACCTTATATCGGCACAACTGTAGGATCAATGGAAGAGTACAACACATCCTCTACAGACTT
CACTTTCATGGGGCTGTTCAACAGAAAGGAAACCTCAGGTCTTATTTTTGCCATCATCTCT
ATCATCTTCTTCACCGCACTGATGGCCAATGGGGTTATGATCTTCCTGATCCAAACAGATT
TGCGCCTTCATACACCCATGTACTTCCTCCTCAGCCACCTTTCCTTAATTGACATGATGTAT

30 ATTTCCACTATTGTGCCTAAGATGCTGGTTAATTACCTGCTGGATCAAAGGACCATTTCCTT
TGTGGGGTGCACAGCTCAACACTTCCTCTACCTTACCCTTGTGGGAGCTGAATTCTTCCTG
CTGGGCCTCATGGCCTATGACCGCTATGTGGCCATTTGCAACCCTCTGAGATACCCTGTCC
TCATGAGCCGCCGGGTCTGTTGGATGATTATAGCAGGTTCCTGGTTTGGGGGCTCTTTGGA
TGGCTTCCTCCTAACCCCCATCACCATGAGCTTTCCCTTCTGCAATTCCCGGGAGATTAACC

35 ACTTCTTCTGTGAGGCACCAGCAGTCCTGAAGTTGGCATGTGCAGACACAGCCCTCTACGA
GACAGTGATGTATGTGTGCTGTGTTTTGATGCTGCTGATTCCTTTCTCTGTAGTCCTTGCTT
CCTATGCCCGAATCCTGACTACAGTTCAGTGCATGAGCTCAGTGGAGGGCAGGAAGAAGG
CATTTGCCACTTGCTCATCCCACATGACTGTGGTGTCCTTGTTCTACGGGGCTGCCATGTAC
ACCTACATGCTGCCACATTCTTACCACAAGCCAGCCCAGGACAAAGTCCTCTCTGTGTTTT

40 ACACCATTCTCACACCCATGCTGAACCCCCTCATCTACAGCCTTAGAAACAAGGATGTGAC
TGGAGCTCTGAAGAGGGCCTTGGGGAGGTTCAAGGGTCCTCAAAGGGTGTCAGGAGGTGT
CTTTTGA (SEQ ID NO: 458).

AOLFR245 sequences:

45 MDLKNGSLVTEFILLGFFGRWELQIFFFVTFSLIYGATVMGNILIMVTVTCRSTLHSPLYFLLGN
LSFLDMCLSTATTPKMIIDLLTDHKTISVWGCVTQMFFMHFFGGAEMTLLIIMAFDRYVAICKP
LHYRTIMSHKLLKGFAILSWIIGFLHSISQIVLTMNLPFCGHNVINNIFCDLPLVIKLACIETYTLE
LFVIADSGLLSFTCFILLLVSYIVILVSVPKKSSHGLSKALSTLSAHIIVVTLFFGPCIFIYVWPFSSL
ASNKTLAVFYTVITPLLNPSIYTLRNKKMQEAIRKLRFQYVSSAQNF (SEQ ID NO: 459).

50

ATGGATCTTAAAAATGGATCTCTAGTGACCGAGTTTATTTTACTAGGATTTTTTGGACGAT
GGGAACTTCAAATTTTCTTCTTTGTGACATTTTCCCTGATCTACGGTGCTACTGTGATGGGA
AACATTCTCATTATGGTCACAGTGACATGTAGGTCAACCCTTCATTCTCCCTTGTACTTTCT
CCTTGGAAATCTCTCTTTTTTGGACATGTGTCTCTCCACTGCCACAACACCCAAGATGATCA

55 TAGATTTGCTCACTGACCACAAGACCATCTCTGTGTGGGGCTGCGTGACCCAGATGTTCTT
CATGCACTTCTTTGGGGGTGCTGAGATGACTCTTCTGATAATCATGGCCTTTGACAGGTAT

GTAGCCATATGTAAACCCCTGCACTATAGGACAATCATGAGCCACAAGCTGCTAAAGGGG
TTTGCGATACTTTCATGGATAATTGGTTTTTTACACTCCATAAGCCAGATAGTTTTAACAAT
GAACTTGCCTTTCTGTGGCCACAATGTCATAAACAACATATTTTGTGATCTTCCCCTTGTGA
TCAAGCTTGCTTGCATTGAAACATACACCCTGGAATTATTTGTCATTGCTGACAGCGGGCT
5   GCTCTCTTTCACCTGTTTCATCCTCTTGCTTGTTTCTTACATTGTCATCCTGGTCAGTGTACC
AAAAAAATCATCACATGGGCTCTCCAAGGCGCTGTCCACATTGTCTGCCCACATCATTGTG
GTCACTCTGTTCTTTGGACCTTGTATTTTTATCTATGTTTGGCCATTCAGTAGTTTGGCAAG
CAATAAAACTCTTGCCGTATTTTATACAGTTATCACACCCTTACTGAATCCGAGTATTTATA
CCCTGAGAAATAAGAAAATGCAAGAGGCCATAAGAAAATTACGGTTCCAATATGTTAGTT
10   CTGCACAGAATTTCTAG (SEQ ID NO: 460).

AOLFR246 sequences:

MSPENQSSVSEFLLLGLPIRPEQQAVFFTLFLGMYLTTVLGNLLIMLLIQLDSHLHTPMYFFLSH
LALTDISFSSVTVPKMLMDMRTKYKSILYEECISQMYFFIFFTDLDSFLITSMAYDRYVAICHPL
15   HYTVIMREELCVFLVAVSWILSCASSLSHTLLLTRLSFCAANTIPHVFCDLAALLKLSCSDIFLNE
LVMFTVGVVVITLPFMCILVSYGYIGATILRVPSTKGIHKALSTCGSHLSVVSLYYGSIFGQYLF
PTVSSSIDKDVIVALMYTVVTPMLNPFIYSLRNRDMKEALGKLFSRATFFSW (SEQ ID NO:
461).

20   ATGAGCCCTGAGAACCAGAGCAGCGTGTCCGAGTTCCTCCTTCTGGGCCTCCCCATCCGGC
CAGAGCAGCAGGCTGTGTTCTTCACCCTGTTCCTGGGCATGTACCTGACCACGGTGCTGGG
GAACCTGCTCATCATGCTGCTCATCCAGCTGGACTCTCACCTTCACACCCCCATGTACTTCT
TCCTCAGCCACTTGGCTCTCACTGACATCTCCTTTTCATCTGTCACTGTCCCTAAGATGCTG
ATGGACATGCGGACTAAGTACAAATCGATCCTCTATGAGGAATGCATTTCTCAGATGTATT
25   TTTTTATAtTTTTTACTGACCTGGACAGCTTCCTTATTACATCAATGGCATATGACCGATAT
GTTGCCATATGTCACCCTCTCCACTACACTGTCATCATGAGGGAAGAGCTCTGTGTCTTCTT
AGTGGCTGTATCTTGGATTCTGTCTTGTGCCAGCTCCCTCTCTCACACCCTTCTCCTGACCC
GGCTGTCTTTCTGTGCTGCGAACACCATCCCCCATGTCTTCTGTGACCTTGCTGCCCTGCTC
AAGCTGTCCTGCTCAGATATCTTCCTCAATGAGCTGGTCATGTTCACAGTAGGGGTGGTGG
30   TCATTACCCTGCCATTCATGTGTATCCTGGTATCATATGGCTACATTGGGGCCACCATCCTG
AGGGTCCCTTCAACCAAAGGGATCCACAAAGCATTGTCCACATGTGGCTCCCATCTCTCTG
TGGTGTCTCTCTATTATGGGTCAATATTTGGCCAGTACCTTTTCCCGACTGTAAGCAGTTCT
ATTGACAAGGATGTCATTGTGGCTCTCATGTACACGGTGGTCACACCCATGTTGAACCCCT
TTATCTACAGCCTTAGGAACAGGGACATGAAAGARGCCCTTGGGAAACTCTTCAGTAGAG
35   CAACATTTTTCTCCTTGGTGACATCTGACTTTTTAAAAAATTAG (SEQ ID NO: 462).

AOLFR247 sequences:

MGQHNLTVLTEFILMELTRRPELQIPLFGVFLVIYLITVVGNLTMIILTKLDSHLHTPMYFSIRHL
ASVDLGNSTVICPKVLANFVVDRNTISYYACAAQLAFFLMFIISEFFILSAMAYDRYVAICNPLL
40   YYVIMSQRLCHVLVGIQYLYSTFQALMFTIKIFTLTFCGSNVISHFYCDDVPLLPMLCSNAQEIE
LLSILFSVFNLISSFLIVLVSYMLILLAICQMHSAEGRKKAFSTCGSHLTVVVVFYGSLLFMYMQ
PNSTHFFDTDKMASVFYTLVIPMLNPLIYSLRNEEVKNAFYKLFEN (SEQ ID NO: 463).

ATGGGCCAACACAATCTAACAGTGCTAACTGAATTCATTCTGATGGAACTCACAAGGCGGC
45   CTGAGCTGCAGATTCCCCTTTTTGGAGTCTTCCTCGTCATCTACCTAATCACAGTGGTGGGC
AACCTAACTATGATCATTTTGACCAAACTGGACTCCCACTTACATACACCTATGTACTTTTC
TATCAGACATTTGGCTTCTGTTGATCTTGGTAATTCTACTGTCATTTGTCCCAAGGTGCTGG
CAAATTTTGTTGTGGATCGAAATACTATTTCCTATTATGCATGTGCTGCACAGCTGGCATTC
TTCCTTATGTTCATTATCAGTGAATTTTTCATCCTGTCAGCCATGGCCTATGACCGCTATGT
50   GGCCATTTGTAACCCTCTGCTCTATTATGTTATTATGTCTCAGCGACTGTGTCATGTACTGG
TGGGCATTCAATATCTCTACAGCACATTTCAGGCTCTGATGTTCACTATTAAGATTTTTACA
TTGACCTTCTGTGGCTCTAATGTCATCAGTCATTTTTACTGTGATGATGTTCCTTTGCTACC
TATGCTTTGCTCAAATGCACAGGAAATAGAATTGTTGAGCATACTATTTTCTGTATTTAATT
TGATCTCCTCCTTTCTGATAGTCTTAGTGTCCTACATGTTGATTTTGTTAGCTATATGTCAA
55   ATGCATTCTGCAGAGGGCAGGAAAAAGGCTTTCTCCACATGTGGTTCCCATTTGACAGTGG
TGGTTGTGTTCTATGGGTCTCTACTCTTCATGTACATGCAGCCCAATTCCACTCACTTCTTT

GATACTGATAAAATGGCTTCTGTGTTTTACACTTTAGTAATCCCCATGCTTAACCCTTTGAT
TTACAGCTTAAGAAACGAAGAGGTGAAAAATGCCTTCTATAAGCTCTTTGAGAATTGA
(SEQ ID NO: 464).

AOLFR248 sequences:

MPCMPCALPTGGLLPHPQHTMMEIANVSSPEVFVLLGFSTRPSLETVLFIVVLSFYMVSILGNGI
IILVSHTDVHLHTPMYFFLANLPFLDMSFTTSIVPQLLANLWGPQKTISYGGCVVQFYISHWLG
ATECVLLATMSYDRYAAICRPLHYTVIMHPQLCLGLALASWLGGLTTSMVGSTLTMLLPLCG
NNCIDHFFCEMPLIMQLACVDTSLNEMEMYLASFVFVVLPLGLILVSYGHIARAVLKIRSAEGR
RKAFNTCSSHVAVVSLFYGSIIFMYLQPAKSTSHEQGKFIALFYTVVTPALNPLIYTLRNTEVKS
ALRHMVLENCCGSAGKLAQI (SEQ ID NO: 465).

ATGCCCTGTATGCCCTGTGCTCTTCCCACAGGTGGCCTTTTGCCCCACCCCCAGCATACAAT
GATGGAAATAGCCAATGTGAGTTCTCCAGAAGTCTTTGTCCTCCTGGGCTTCTCCACACGA
CCCTCACTAGAAACTGTCCTCTTCATAGTTGTCTTGAGTTTTACATGGTATCGATCTTGGG
CAATGGCATCATCATTCTGGTCTCCCATACAGATGTGCACCTCCACACACCTATGTACTTCT
TTCTTGCCAACCTCCCCTTCCTGGACATGAGCTTCACCACGAGCATTGTCCCACAGCTCCTG
GCTAACCTCTGGGGACCACAGAAAACCATAAGCTATGGAGGGTGTGTGGTCCAGTTCTAT
ATCTCCCATTGGCTGGGGGCAACCGAGTGTGTCCTGCTGGCCACCATGTCCTATGACCGCT
ACGCTGCCATCTGCAGGCCACTCCATTACACTGTCATTATGCATCCACAGCTTTGCCTTGG
GCTAGCTTTGGCCTCCTGGCTGGGGGGTCTGACCACCAGCATGGTGGGCTCCACGCTCACC
ATGCTCCTACCGCTGTGTGGGAACAATTGCATCGACCACTTCTTTTGCGAGATGCCCCTCA
TTATGCAACTGGCTTGTGTGGATACCAGCCTCAATGAGATGGAGATGTACCTGGCCAGCTT
TGTCTTTGTTGTCCTGCCTCTGGGGCTCATCCTGGTCTCTTACGGCCACATTGCCCGGGCCG
TGTTGAAGATCAGGTCAGCAGAAGGGCGGAGAAAGGCATTCAACACCTGTTCTTCCCACG
TGGCTGTGGTGTCTCTGTTTTACGGGAGCATCATCTTCATGTATCTCCAGCCAGCCAAGAG
CACCTCCCATGAGCAGGGCAAGTTCATAGCTCTGTTCTACACCGTAGTCACTCCTGCGCTG
AACCCACTTATTTACACCCTGAGGAACACGGAGGTGAAGAGCGCCCTCCGGCACATGGTA
TTAGAGAACTGCTGTGGCTCTGCAGGCAAGCTGGCGCAAATTTAG (SEQ ID NO: 466).

AOLFR249 sequences:

MKSQIEKSDLKYRAILLQKVTRMFLLFWVLLLVLSRLLVVMGRGNSTEVTEFHLLGFGVQHEF
QHVLFIVLLLIYVTSLIGNIGMILLIKTDSRLQTPMYFFPQHLAFVDICYTSAITPKMLQSFTEEN
NLITFRGCVIQFLVYATFATSDCYLLAIMAMDCYVAICKPLRYPMIMSQTVYIQLVAGSYIIGSI
NASVHTGFTFSLSFCKSNKINHFFCDGLPILALSCSNIDINIILDVVFVGFDLMFTELVIIFSYIYIM
VTILKMSSTAGRKKSFSTCASHLTAVTIFYGTLSYMYLQPQSNNSQENMKVASIFYGTVIPMLN
PLIYSLRNKEGK (SEQ ID NO: 467).

ATGAAAAGTCAAATTGAAAAAAGTGACTTAAAATATAGAGCCATTTTATTGCAAAAAGTC
ACAAGGATGTTCCTGCTTTTCTGGGTCCTTCTCTTGGTCCTTTCTAGACTTTTGGTAGTCAT
GGGTCGAGGAAACAGCACTGAAGTGACTGAATTCCATCTTCTGGGATTTGGTGTCCAACAC
GAATTTCAGCATGTCCTTTTCATTGTACTTCTTCTTATCTATGTGACCTCCCTGATAGGAAA
TATTGGAATGATCTTACTCATCAAGACCGATTCCAGACTTCAAACACCCATGTACTTTTTTC
CACAACATTTGGCTTTTGTTGATATCTGTTATACTTCTGCTATCACTCCCAAGATGCTCCAA
AGCTTCACAGAAGAAAATAATTTGATAACATTTCGGGGCTGTGTGATACAATTCTTAGTTT
ATGCAACATTTGCAACCAGTGACTGTTACCTCCAGCTATTATGGCAATGGATTGTTATGT
TGCCATCTGTAAGCCCCTTCGCTATCCCATGATCATGTCCCAAACAGTCTACATCCAACTCG
TAGCTGGCTCATATATTATAGGCTCAATAAATGCCTCTGTACATACAGGTTTTACATTTTCA
CTGTCCTTCTGCAAGTCTAATAAAATCAATCACTTTTTCTGTGATGGTCTCCCAATTCTTGC
CCTTTCATGCTCCAACATTGACATCAACATCATTCTAGATGTTGTCTTTGTGGGATTTGACT
TGATGTTCACTGAGTTGGTCATCATCTTTTCCTACATCTACATTATGGTCACCATCCTGAAG
ATGTCTTCTACTGCTGGGAGGAAAAAATCCTTCTCCACATGTGCCTCCCACCTGACAGCAG
TAACCATTTTCTATGGGACACTCTCTTACATGTACTTACAGCCTCAGTCTAATAATTCTCAG
GAGAATATGAAAGTAGCCTCTATATTTTATGGCACTGTTATTCCCATGTTGAATCCTTTAAT
CTATAGCTTGAGAAATAAGGAAGGAAAATAA (SEQ ID NO: 468).

AOLFR250 sequences:

MENQSSISEFFLRGISAPPEQQQSLFGIFLCMYLVTLTGNLLIILAIGSDLHLHTPMYFFLANLSFV
DMGLTSSTVTKMLVNIQTRHHTISYTGCLTQMYFFLMFGDLDSFFLAAMAYDRYVAICHPLCY
STVMRPQVCALMLALCWVLTNIVALTHTFLMARLSFCVTGEIAHFFCDITPVLKLSCSDTHINE
MMVFVLGGTVLIVPFLCIVTSYIHIVPAILRVRTRGGVGKAFSTCSSHLCVVCVFYGTLFSAYLC
PPSIASEEKDIAAAAMYTIVTPMLNPFIYSLRNKDMKGALKRLFSHRSIVSS (SEQ ID NO: 469).

ATGGAAAACCAATCCAGCATTTCTGAATTTTTCCTCCGAGGAATATCAGCGCCTCCAGAGC
AACAGCAGTCCCTCTTCGGAATTTTCCTGTGTATGTATCTTGTCACCTTGACTGGGAACCTG
CTCATCATCCTGGCCATTGGCTCTGACCTGCACCTCCACACCCCCATGTACTTTTTCTTGGC
CAACCTGTCTTTTGTTGACATGGGTTTAACGTCCTCCACAGTTACCAAGATGCTGGTGAAT
ATACAGACTCGGCATCACACCATCTCCTATACGGGTTGCCTCACGCAAATGTATTTCTTTCT
GATGTTTGGTGATCTAGACAGCTTCTTCCTGGCTGCCATGGCGTATGACCGCTATGTGGCC
ATTTGCCACCCCCTCTGCTACTCCACAGTCATGAGGCCCCAAGTCTGTGCCCTAATGCTTGC
ATTGTGCTGGGTCCTCACCAATATCGTTGCCCTGACTCACACGTTCCTCATGGCTCGGTTGT
CCTTCTGTGTGACTGGGGAAATTGCTCACTTTTTCTGTGACATCACTCCTGTCCTGAAGCTG
TCATGTTCTGACACCCACATCAACGAGATGATGGTTTTTGTCTTGGGAGGCACCGTACTCA
TCGTCCCCTTTTTATGCATTGTCACCTCCTACATCCACATTGTGCCAGCTATCCTGAGGGTC
CGAACCCGTGGTGGGGTGGGCAAGGCCTTTTCCACCTGCAGTTCCCACCTCTGCGTTGTTT
GTGTGTTCTATGGGACCCTCTTCAGTGCCTACCTGTGTCCTCCCTCCATTGCCTCTGAAGAG
AAGGACATTGCAGCAGCTGCAATGTACACCATAGTGACTCCCATGTTGAACCCCTTTATCT
ATAGCCTAAGGAACAAGGACATGAAGGGGGCCCTAAAGAGGCTCTTCAGTCACAGGAGTA
TTGTTTCCTCTTAG (SEQ ID NO: 470).

AOLFR251 sequences:

MEGNKTWITDITLPRFQVGPALEILLCGLFSAFYTLTLLGNGVIFGIICLDCKLHTPMYFFLSHLA
IVDISYASNYVPKMLTNLMNQESTISFFPCIMQTFLYLAFAHVECLILVVMSYDRYADICHPLRY
NILMSWRVCTVLAVASWVFSFLLALVPLVLILRLPFCGPHEINHFCEILSVLKLACADTWLNQV
VIFAACVFILVGPLCLVLVSYLRILAAILRIQSGEGRRKAFSTCSSHLCVVGLFFGSAIVTYMAPK
SRHPEEQQKVLSLFYSLFNPMLNPLIYSLRNAEVKGALRRALRKERLT (SEQ ID NO: 471).

ATGGAAGGCAACAAGACATGGATCACAGACATCACCTTGCCGCGATTCCAGGTTGGTCCA
GCACTGGAGATTCTCCTCTGTGGACTTTTCTCTGCCTTCTATACACTCACCCTGCTGGGGAA
TGGGGTCATCTTTGGGATTATCTGCCTGGACTGTAAGCTTCACACACCCATGTACTTCTTCC
TCTCACACCTGGCCATTGTTGACATATCCTATGCTTCCAACTATGTCCCCAAGATGCTGACG
AATCTTATGAACCAGGAAAGCACCATCTCCTTTTTTCCATGCATAATGCAGACATTCTTGT
ATTTGGCTTTTGCTCACGTAGAGTGTCTGATTTTGGTGGTGATGTCCTATGATCGCTATGCG
GACATCTGCCACCCCTTACGTTACAATATCCTCATGAGCTGGAGAGTGTGCACTGTCCTGG
CTGTGGCTTCCTGGGTGTTCAGCTTCCTCCTGGCTCTGGTCCCTTTAGTTCTCATCCTGAGG
CTGCCCTTCTGCGGGCCTCATGAAATCAACCACTTCTGTGAAATCCTGTCTGTCCTCAAGTT
GGCCTGTGCTGACACCTGGCTCAACCAGGTGGTCATCTTTGCAGCCTGCGTGTTCATCCTG
GTGGGGCCACTCTGCCTGGTGCTGGTCTCCTACTTGCGCATCCTGGCCGCCATCTTGAGGA
TCCAGTCTGGGGAGGGCCGCAGAAAGGCCTTCTCCACCTGCTCCTCCCACCTTTGCGTGGT
GGGACTCTTCTTTGGCAGCGCCATTGTCACGTACATGGCCCCCAAGTCCCGCCATCCTGAG
GAGCAGCAGAAAGTTCTTTCCCTGTTTTACAGCCTTTTCAATCCAATGCTGAACCCCCTGA
TATATAGCCTAAGGAATGCAGAGGTCAAGGGCGCCCTGAGGAGGGCACTGAGGAAGGAG
AGGCTGACGTGA (SEQ ID NO: 472).

AOLFR252 sequences:

MRLANQTLGGDFFLLGIFSQISHPGRLCLLIFSIFLMAVSWNITLILLIHIDSSLHTPMYFFINQLSL
IDLTYISVTVPKMLVNQLAKDKTISVLGCGTQMYFYLQLGGAECCLLAAMAYDRYVAICHPLR
YSVLMSHRVCLLLASGCWFVGSVDGFMLTPIAMSFPFCRSHEIQHFFCEVPAVLKLSCSDTSLY
KIFMYLCCVIMLLIPVTVISVSYYYIILTIHKMNSVEGRKKAFTTCSSHITVVSLFYGAAIYNYML
PSSYQTPEKDMMSSFFYTILTPVLNPIIYSFRNKDVTRALKKMLSVQKPPY (SEQ ID NO: 473).

ATGCGGCTGGCCAACCAGACCCTGGGTGGTGACTTTTTCCTGTTGGGAATCTTCAGCCAGA
TCTCACACCCTGGCCGCCTCTGCTTGCTTATCTTCAGTATATTTTTGATGGCTGTGTCTTGG
AATATTACATTGATACTTCTGATCCACATTGACTCCTCTCTGCATACTCCCATGTACTTCTT
TATAAACCAGCTCTCACTCATAGACTTGACATATATTTCTGTCACTGTCCCCAAAATGCTG
5   GTGAACCAGCTGGCCAAAGACAAGACCATCTCGGTCCTTGGGTGTGGCACCCAGATGTAC
TTCTACCTGCAGTTGGGAGGTGCAGAGTGCTGCCTTCTAGCCGCCATGGCCTATGACCGCT
ATGTGGCTATCTGCCATCCTCTCCGTTACTCTGTGCTCATGAGCCATAGGGTATGTCTCCTC
CTGGCATCAGGCTGCTGGTTTGTGGGCTCAGTGGATGGCTTCATGCTCACTCCCATCGCCA
TGAGCTTCCCCTTCTGCAGATCCCATGAGATTCAGCACTTCTTCTGTGAGGTCCCTGCTGTT
10   TTGAAGCTCTCTTGCTCAGACACCTCACTTTACAAGATTTTCATGTACTTGTGCTGTGTCAT
CATGCTCCTGATACCTGTGACGGTCATTTCAGTGTCTTACTACTATATCATCCTCACCATCC
ATAAGATGAACTCAGTTGAGGGTCGGAAAAAGGCCTTCACCACCTGCTCCTCCCACATTAC
AGTGGTCAGCCTCTTCTATGGAGCTGCTATTTACAACTACATGCTCCCCAGCTCCTACCAA
ACTCCTGAGAAAGATATGATGTCATCCTTTTTCTACACTATCCTTACACCTGTCTTGAATCC
15   TATCATTTACAGTTTCAGGAATAAGGATGTCACAAGGGCTTTGAAAAAAATGCTGAGCGT
GCAGAAACCTCCATATTAA (SEQ ID NO: 474).

AOLFR253 sequences:

MTFFSSGGNCEPVMCSGNQTSQNQTASTDFTLTGLFAESKHAALLYTVTFLLFLMALTGNALL
20   ILLIHSEPRLHTPMYFFISQLALMDLMYLCVTVPKMLVGQVTGDDTISPSGCGIQMFFHLTLAG
AEVFLLAAMAYDRYAAVCRPLHYPLLMNQRVCQLLVSACWVLGMVDGLLLTPITMSFPFCQS
RKILSFFCETPALLKLSCSDVSLYKMLTYLCCILMLLTPIMVISSSYTLILHLIHRMNSAAGRRKA
LATCSSHMIIVLLLFGASFYTYMLRSSYHTAEQDMMVSAFYTIFTPVLNPLIYSLRNKDVTRAL
RSMMQSRMNQEK (SEQ ID NO: 475).

25

ATGACTTTTTTTTCCTCAGGGGGGAAACTGTGAGCCAGTCATGTGCTCAGGGAATCAGACTT
CTCAGAATCAAACAGCAAGCACTGATTTCACCCTCACGGGACTCTTTGCTGAGAGCAAGCA
TGCTGCCCTCCTCTACACCGTGACCTTCCTTCTTTTCTTGATGGCCCTCACTGGGAATGCCC
TCCTCATCCTCCTCATCCACTCAGAGCCCCGCCTCCACACCCCCATGTACTTCTTCATCAGC
30   CAGCTCGCGCTCATGGATCTCATGTACCTATGCGTGACTGTGCCCAAGATGCTTGTGGGCC
AGGTCACTGGAGATGATACCATTTCCCCGTCAGGCTGTGGGATCCAGATGTTCTTCCACCT
GACCCTGGCTGGAGCTGAGGTTTTCCTCCTGGCTGCCATGGCCTATGACCGATATGCTGCT
GTTTGCAGACCTCTCCATTACCCACTGCTGATGAACCAGAGGGTGTGCCAGCTCCTGGTGT
CAGCCTGCTGGGTTTTGGGAATGGTTGATGGTTTGTTGCTCACCCCCATTACCATGAGCTT
35   CCCCTTTTGCCAGTCTAGGAAAATCCTGAGTTTTTTCTGTGAGACTCCTGCCCTGCTGAAGC
TCTCCTGCTCTGACGTCTCCCTCTATAAGATGCTCACGTACCTGTGCTGCATCCTCATGCTT
CTCACCCCCATCATGGTCATCTCCAGCTCATACACCCTCATCCTGCATCTCATCCACAGGAT
GAATTCTGCCGCCGGCCGCAGGAAGGCCTTGGCCACCTGCTCCTCCCACATGATCATAGTG
CTGCTGCTCTTCGGTGCTTCCTTCTACACCTACATGCTCCGGAGTTCCTACCACACAGCTGA
40   GCAGGACATGATGGTGTCTGCCTTTTACACCATCTTCACTCCTGTGCTGAACCCCCTCATTT
ACAGTCTCCGCAACAAAGATGTCACCAGGGCTCTGAGGAGCATGATGCAGTCAAGAATGA
ACCAAGAAAAGTAG (SEQ ID NO: 476).

AOLFR254 sequences:

45   MTNTSSSDFTLLGLLVNSEAAGIVFTVILAVFLGAVTANLVMIFLIQVDSRLHTPMYFLLSQLSI
MDTLFICTTVPKLLADMVSKEKIISFVACGIQIFLYLTMIGSEFFLLGLMAYDCYVAVCNPLRYP
VLMNRKKCLLLAAGAWFGGSLDGFLLTPITMNVPYCGSRSINHFFCEIPAVLKLACADTSLYET
LMYICCVLMLLIPISIISTSYSLILLTIHRMPSAEGRKKAFTTCSSHLTVVSIFYGAAFYTYVLPQS
FHTPEQDKVVSAFYTIVTPMLNPLIYSLRNKDVIGAFKKVFACCSSAQKVATSDA (SEQ ID NO:
50   477).

ATGACGAACACATCATCCTCTGACTTCACCCTCCTGGGGCTTCTGGTGAACAGTGAGGCTG
CCGGGATTGTATTTACAGTGATCCTTGCTGTTTTCTTGGGGGCCGTGACTGCAAATTTGGT
CATGATATTCTTGATTCAGGTGGACTCTCGCCTCCACACCCCCATGTACTTTCTGCTCAGTC
55   AGCTGTCCATCATGGACACCCTTTTCATCTGTACCACTGTCCCAAAACTCCTGGCAGACAT
GGTTTCTAAAGAGAAGATCATTTCCTTTGTGGCCTGTGGCATCCAGATCTTCCTCTACCTG

ACCATGATTGGTTCTGAGTTCTTCCTCCTGGGCCTCATGGCCTATGACTGCTACGTGGCTGT
CTGTAACCCTCTGAGATACCCAGTCCTGATGAACCGCAAGAAGTGTCTTTTGCTGGCTGCT
GGTGCCTGGTTTGGGGGCTCCCTCGATGGCTTTCTGCTCACTCCCATCACCATGAATGTCC
CTTACTGTGGCTCCCGAAGTATCAACCATTTTTTCTGTGAGATCCCAGCAGTTCTGAAACT

5   GGCCTGTGCAGACACGTCCTTGTATGAAACTCTGATGTACATCTGCTGTGTCCTCATGTTG
CTCATCCCCATCTCTATCATCTCCACTTCCTACTCCCTCATCTTGTTAACCATCCACCGCAT
GCCCTCTGCTGAAGGTCGCAAAAAGGCCTTCACCACTTGTTCCTCCCACTTGACTGTAGTT
AGCATCTTCTATGGGGCTGCCTTCTACACATACGTGCTGCCCCAGTCCTTCCACACCCCCG
AGCAGGACAAAGTAGTGTCAGCCTTCTATACCATTGTCACGCCCATGCTTAATCCTCTCAT

10   CTACAGCCTCAGAAACAAGGACGTCATAGGGGCATTTAAAAAGGTATTTGCATGTTGCTCA
TCTGCTCAGAAAGTAGCAACAAGTGATGCTTAG (SEQ ID NO: 478).

AOLFR255 sequences:

MEQSNYSVYADFILLGLFSNARFPWLLFALILLVFLTSIASNVVKIILIHIDSRLHTPMYFLLSQLS

15   LRDILYISTIVPKMLVDQVMSQRAISFAGCTAQHFLYLTLAGAEFFLLGLMSYDRYVAICNPLH
YPVLMSRKICWLIVAAAWLGGSIDGFLLTPVTMQFPFCASREINHFFCEVPALLKLSCTDTSAY
ETAMYVCCIMMLLIPFSVISGSYTRILITVYRMSEAEGRGKAVATCSSHMVVVSLFYGAAMYT
YVLPHSYHTPEQDKAVSAFYTILTPMLNPLIYSLRNKDVTGALQKVVGRCVSSGKVTTF (SEQ
ID NO: 479).

20

ATGGAGCAGAGCAATTATTCCGTGTATGCCGACTTTATCCTTCTGGGTTTGTTCAGCAACG
CCCGTTTCCCCTGGCTTCTCTTTGCCCTCATTCTCCTGGTCTTTTTGACCTCCATAGCCAGC
AACGTGGTCAAGATCATTCTCATCCACATAGACTCCCGCCTCCACACCCCCATGTACTTCCT
GCTCAGCCAGCTCTCCCTCAGGGACATCCTGTATATTTCCACCATTGTGCCCAAAATGCTG

25   GTCGACCAGGTGATGAGCCAGAGAGCCATTTCCTTTGCTGGATGCACTGCCCAACACTTCC
TCTACTTGACCTTAGCAGGGGCTGAGTTCTTCCTCCTAGGACTCATGTCCTATGATCGCTAC
GTAGCCATCTGCAACCCTCTGCACTATCCTGTCCTCATGAGCCGCAAGATCTGCTGGTTGA
TTGTGGCGGCAGCCTGGCTGGGAGGGTCTATCGATGGTTTCTTGCTCACCCCCGTCACCAT
GCAGTTCCCCTTCTGTGCCTCTCGGGAGATCAACCACTTCTTCTGCGAGGTGCCTGCCCTTC

30   TGAAGCTCTCCTGCACGGACACATCAGCCTACGAGACAGCCATGTATGTCTGCTGTATTAT
GATGCTCCTCATCCCTTTCTCTGTCATCTCGGGCTCTTACACAAGAATTCTCATTACTGTTT
ATAGGATGAGCGAGGCAGAGGGGAGGGGAAAGGCTGTGGCCACCTGCTCCTCACACATGG
TGGTTGTCAGCCTCTTCTATGGGGCTGCCATGTACACATACGTGCTGCCTCATTCTTACCAC
ACCCCTGAGCAGGACAAAGCTGTATCTGCCTTCTACACCATCCTTACTCCCATGCTCAATC

35   CACTCATTTACAGCCTTAGGAACAAGGATGTCACAGGGGCCCTACAGAAGGTTGTGGGGA
GGTGTGTGTCCTCAGGAAAGGTAACCACTTTCTAA (SEQ ID NO: 480).

AOLFR256 sequences:

MGGKQPWVTEFILVGFQVGPALAILLCGLFSVFYTLTLLGNGVIFGIICLDSKLHTPMYFFLSHL

40   AIIDMSYASNNVPKMLANLMNQKSTISFVPCIMQTFLYLAFAVTECLILVVMSYDRYVAICHPF
QYTVIMSWRVCTILASTCWIISFLMALVHITHILRPPFCGPQKINHFICQIMSVFKLACAGPRLNQ
VVLYAGSAFIVEGPLCLELVSNLHILSRHLEDPVMGRAADRLTLPAPSHLCMVGLLFGSTMVM
YMAPKSRHPEEQQKVLSLFYSLFNPMLNPLIYSLRNAEVKGALKRVLWKQRSK (SEQ ID NO:
481).

45

ATGGGAGGCAAGCAGCCCTGGGTCACAGAATTCATCCTGGTGGGATTCCAGGTTGGTCCA
GCACTGGCGATTCTCCTCTGTGGACTCTTCTCTGTCTTCTATACACTCACCCTGCTGGGGAA
TGGGGTCATCTTTGGGATTATCTGCCTGGACTCTAAGCTTCACACACCCATGTACTTCTTCC
TCTCACACCTGGCCATCATTGACATGTCCTATGCTTCCAACAATGTTCCCAAGATGTTGGC

50   AAACCTAATGAACCAGAAAAGCACCATCTCCTTTGTTCCATGCATAATGCAGACTTTTTTG
TATTTGGCTTTTGCTGTTACAGAGTGCCTGATTTTGGTGGTGATGTCCTATGATAGGTATGT
GGCCATCTGCCACCCTTTCCAGTACACTGTCATCATGAGCTGGAGAGTGTGCACGATCCTG
GCCTCAACATGCTGGATAATTAGCTTTCTCATGGCTCTGGTCCATATAACTCATATTCTGAG
GCCGCCTTTTTGTGGCCCACAAAAGATCAACCACTTTATCTGTCAAATCATGTCCGTATTCA

55   AATTGGCCTGTGCTGGCCCTAGGCTCAACCAGGTGGTCCTATATGCGGGTTCTGCGTTCAT
CGTAGAGGGGCCGCTCTGCCTGGAGCTGGTCTCCAACTTGCACATCCTGTCGCGCCATCTT

GAGGATCCAGTAATGGGGAGGGCCGCAGACCGACTTACTCTTCCTGCTCCTTCCCACCTTT
GCATGGTGGGACTCCTTTTTGGCAGCACCATGGTCATGTACATGGCCCCCAAGTCCCGCCA
CCCTGAGGAGCAGCAGAAGGTCCTTTCCCTGTTTTACAGCCTTTTCAACCCGATGCTGAAC
CCCTTGATCTACAGCCTGAGGAACGCAGAGGTCAAGGGTGCCCTGAAAAGAGTGTTGTGG
5   AAACAGAGATCAAAGTGA (SEQ ID NO: 482).

AOLFR257 sequences:

MESNQTWITEVILLGFQVDPALELFLFGFFLLFYSLTLMGNGIILGLIYLDSRLHTPMYVFLSHL
AIVDMSYASSTVPKMLANLVMHKKVISFAPCILQTFLYLAFAITECLILVMMCYDRYVAICHPL
10   QYTLIMNWRVCTVLASTCWIFSFLLALVHITLILRLPFCGPQKINHFFCQIMSVFKLACADTRLN
QVVLFAGSAFILVGPLCLVLVSYLHILVAILRIQSGEGRRKAFSTCSSHLCVVGLFFGSAIVMYM
APKSSHSQERRKILSLFYSLFNPILNPLIYSLRNAEVKGALKRVLWKQRSM (SEQ ID NO: 483).

ATGGAAAGCAATCAGACCTGGATCACAGAAGTCATCCTGTTGGGATTCCAGGTGGACCCA
15   GCTCTGGAGTTGTTCCTCTTTGGGTTTTTCTTGCTATTCTACAGCTTAACCCTGATGGGAAA
TGGGATTATCCTGGGGCTCATCTACTTGGACTCTAGACTGCACACACCCATGTATGTCTTC
CTGTCACACCTGGCCATTGTGGACATGTCCTATGCCTCGAGTACTGTCCCTAAGATGCTAG
CAAATCTTGTGATGCACAAAAAAGTCATCTCCTTTGCTCCTTGCATACTTCAGACTTTTTTG
TATTTGGCGTTTGCTATTACAGAGTGTCTGATTTTGGTGATGATGTGCTATGATCGGTATG
20   TGGCAATCTGTCACCCCTTGCAATACACCCTCATTATGAACTGGAGAGTGTGCACTGTCCT
GGCCTCAACTTGCTGGATATTTAGCTTTCTCTTGGCTCTGGTCCATATTACTCTTATTCTGA
GGCTGCCTTTTGTGGCCCACAAAAGATCAACCACTTTTTCTGTCAAATCATGTCCGTATTC
AAATTGGCCTGTGCTGACACTAGGCTCAACCAGGTGGTCCTATTTGCGGGTTCTGCGTTCA
TCTTAGTGGGGCCGCTCTGCCTGGTGCTGGTCTCCTACTTGCACATCCTGGTGGCCATCTTG
25   AGGATCCAGTCTGGGGAGGGCCGCAGAAAGGCCTTCTCTACCTGCTCCTCCCACCTCTGCG
TGGTGGGGCTTTTCTTTGGCAGCGCCATTGTCATGTACATGGCCCCCAAGTCAAGCCATTC
TCAAGAACGGAGGAAGATCCTTTCCCTGTTTTACAGCCTTTTCAACCCGATCCTGAACCCC
CTCATCTACAGCCTTAGGAATGCAGAGGTGAAAGGGGCTCTAAAGAGAGTCCTTTGGAAA
CAGAGATCAATGTGA (SEQ ID NO: 484).
30

AOLFR259 sequences:

MGDNQSRVTEFILVGFQLSVEMEVLLFWIFSLLYLFSLLANGMILGLICLDPRLRTPMYFFLSHL
AVIDIYYASSNLLNMLENLVKHKKTISFISCIMQMALYLTFAAAVCMILVVMSYDRFVAICHPL
HYTVIMNWRVCTVLAITSWACGFSLALINLILLLRLPFCGPQEVNHFFGEILSVLKLACADTWIN
35   EIFVFAGGVFVLVGPLSLMLISYMRILLAILKIQSKEGRKKAFSTCSSHLCVVGLYFGMAMVVY
LVPDNSQRQKQQKILTLFYSLFNPLLNPLIYSLRNAQVKGALYRALQKKRTM (SEQ ID NO:
485).

ATGGGGGACAACCAATCACGGGTCACAGAATTCATCCTGGTTGGATTCCAGCTCAGTGTG
40   GAGATGGAAGTGCTCCTCTTCTGGATCTTCTCCCTGTTATATCTCTTCAGCCTGCTGGCAAA
TGGCATGATCTTGGGGCTCATCTGTCTGGATCCCAGACTGCGCACCCCCATGTACTTCTTCC
TGTCACACTTGGCCGTCATTGACATATACTATGCTTCCAGCAATTTGCTCAACATGCTGGA
AAACCTAGTGAAACACAAAAAAACTATCTCGTTCATCTCTTGCATTATGCAGATGGCTTTG
TATTTGACTTTTGCTGCTGCAGTGTGCATGATTTTGGTGGTGATGTCCTATGACAGATTTGT
45   GGCGATCTGCCATCCCCTGCATTACACTGTCATCATGAACTGGAGAGTGTGCACAGTACTG
GCTATTACTTCCTGGGCATGTGGATTTTCCCTGGCCCTCATAAATCTAATTCTCCTTCTAAG
GCTGCCCTTCTGTGGGCCCCAGGAGGTGAACCACTTCTTCGGTGAAATTCTGTCTGTCCTC
AAACTGGCCTGTGCAGACACCTGGATTAATGAAATTTTTGTCTTTGCTGGTGGTGTGTTTG
TCTTAGTCGGGCCCCTTTCCTTGATGCTGATCTCCTACATGCGCATCCTCTTGGCCATCCTG
50   AAGATCCAGTCAAAGGAGGGCCGCAAAAAAGCCTTTTCCACCTGCTCCTCCCACCTCTGTG
TGGTTGGGCTTTACTTTGGCATGGCCATGGTGGTTTACCTGGTCCCAGACAACAGTCAACG
ACAGAAGCAGCAGAAAATTCTCACCCTGTTTTACAGCCTTTTCAACCCATTGCTGAACCCC
CTCATCTACAGCCTGCGGAATGCTCAAGTGAAGGGTGCCTTATACAGAGCACTGCAGAAA
AAGAGGACCATGTGA (SEQ ID NO: 486).
55

166

AOLFR24B sequences:

MPSINDTHFYPPFFLLLGIPGLDTLHIWISFPFCIVYLIAIVGNMTILFVIKTEHSLHQPMFYFLAM
LSMIDLGLSTSTIPKMLGIFWFNLQEISFGGCLLQMFFIHMFTGMETVLLVVMAYDRFVAICNP
LQYTMILTNKTISILASVVVGRNLVLVTPFVFLILRLPFCGHNIVPHTYCEHRGLAGLACAPIKIN
IIYGLMVISYIIVDVILIASSYVLILRAVFRLPSQDVRLKAFNTCGSHVCVMLCFYTPAFFSFMTH
RFGQNIPHYIHILLANLYVVVPPALNPVIYGVRTKQIREQIVKIFVQKE (SEQ ID NO: 487)

ATGCCTTCTATCAATGACACCCACTTCTATCCCCCCTTCTTCCTCCTGCTAGGAATACCAGG
ACTGGACACTTTACATATCTGGATTTCTTTCCCATTCTGTATTGTGTACCTGATTGCCATTG
TGGGGAATATGACCATTCTCTTTGTGATCAAAACTGAACATAGTCTACACCAGCCCATGTT
CTACTTCCTGGCCATGTTGTCTATGATTGATCTGGGTCTGTCCACATCCACTATCCCCAAAA
TGCTAGGAATCTTCTGGTTCAACCTCCAAGAGATCAGCTTTGGGGGATGCCTTCTTCAGAT
GTTCTTTATTCACATGTTTACAGGCATGGAGACTGTTCTGTTGGTGGTCATGGCTTATGACC
GCTTTGTTGCCATCTGCAACCCTCTCCAGTACACCATGATCCTCACCAATAAAACCATCAG
TATCCTAGCTTCTGTGGTTGTTGGAAGAAATTTAGTTCTTGTAACCCCATTTGTGTTTCTCA
TTCTGCGTCTGCCATTCTGTGGGCATAACATCGTACCTCACACATACTGTGAGCACAGGGG
TCTGGCCGGGTTGGCCTGTGCACCCATTAAGATCAACATAATCTATGGGCTCATGGTGATT
TCTTATATTATTGTGGATGTGATCTTAATTGCCTCTTCCTATGTGCTTATCCTTAGAGCTGT
TTTTCGCCTTCCCTCTCAAGATGTCCGACTAAAGGCCTTCAATACCTGTGGTTCTCATGTCT
GTGTTATGCTGTGCTTTTACACACCAGCATTTTTTTCTTTTATGACACATCGTTTTGGCCAA
AACATTCCCCACTATATCCATATTCTTTTGGCTAACCTGTATGTGGTTGTCCCACCTGCCCT
TAACCCTGTCATTTATGGAGTCAGGACCAAGCAGATCCGAGAGCAAATTGTGAAAATATTT
GTACAGAAAGAATAA (SEQ ID NO: 488)

AOLFR33B sequences:

MLHTNNTQFHPSTFLVVGVPGLEDVHVWIGFPFFAVYLTALLGNIIILFVIQTEQSLHQPMFYFL
AMLAGTDLGLSTATIPKMLGIFWFNLGEIAFGACITQMYTIHICTGLESVVLTVTGIDRYIAICNP
LRYSMILTNKVIAILGIVIIVRTLVFVTPFTFLTLRLPFCGVRIIPHTYCEHMGLAKLACASINVIY
GLIAFSVGYIDISVIGFSYVQILRAVFHLPAWDARLKALSTCGSHVCVMLAFYLPALFSFMTHRF
GHNIPHYIHILLANLYVVFPPALNSVIYGVKTKQIREQVLRILNPKSFWHFDPKRIFHNNSVRQ
(SEQ ID NO: 489)

ATGCTTCATACCAACAATACACAGTTTCACCCTTCCACCTTCCTCGTAGTGGGGGGTCCCAG
GGCTGGAAGATGTGCATGTATGGATTGGCTTCCCCTTCTTTGCGGTGTATCTAACAGCCCT
TCTAGGGAACATCATTATCCTGTTTGTGATACAGACTGAACAGAGCCTCCACCAACCCATG
TTTTACTTCCTAGCCATGTTGGCCGGCACTGATCTGGGCTTGTCTACAGCAACCATCCCCA
AGATGCTGGGAATTTTCTGGTTTAATCTTGGAGAGATTGCATTTGGTGCCTGCATCACACA
GATGTATACCATTCATATATGCACTGGCCTGGAGTCTGTGGTACTGACAGTCACGGGCATA
GATCGCTATATTGCCATCTGCAACCCCCTGAGATATAGCATGATCCTTACCAACAAGGTAA
TAGCCATTCTGGGCATAGTCATCATTGTCAGGACTTTGGTATTTGTGACTCCATTCACATTT
CTCACCCTGAGATTGCCTTTCTGTGGTGTCCGGATTATCCCTCATACCTATTGTGAACACAT
GGGCTTGGCAAAGTTAGCTTGTGCCAGTATTAATGTTATATATGGATTGATTGCCTTCTCA
GTGGGATACATTGACATTTCTGTGATTGGATTTTCCTATGTCCAGATCCTCCGAGCTGTCTT
CCATCTCCCAGCCTGGGATGCCCGGCTTAAGGCACTCAGCACATGTGGCTCTCACGTCTGT
GTTATGTTGGCTTTCTACCTGCCAGCCCTCTTTTCCTTCATGACACACCGCTTTGGCCACAA
CATCCCTCATTACATCCACATTCTTCTGGCCAATCTGTATGTGGTTTTTCCCCCTGCTCTTA
ACTCTGTTATCTATGGGGTCAAAACAAAACAGATACGAGAGCAGGTACTTAGGATACTCA
ACCCTAAAAGCTTTTGGCATTTTGACCCCAAGAGGATCTTCCACAACAATTCAGTTAGACA
ATAA (SEQ ID NO: 490)

AOLFR112B sequences:

MKNKTVLTEFILLGLTDVPELQVAVFTFLFLAYLLSILGNLTILILTLLDSHLQTPMYFFLRNFSF
LEISFTNIFIPRVLISITTGNKSISFAGCFTQYFFAMFLGATEFYLLAAMSYDRYVAICKPLHYTTI
MSSRICIQLIFCSWLGGLMAIIPTITLMSQQDFCASNRLNHYFCDYEPLLELSCSDTSLIEKVVFL
VASVTLVVTLVLVILSYAFIIKTILKLPSAQQRTKAFSTCSSHMIVISLSYGSCMFMYINPSAKEG
DTFNKGVALLITSVAPLLNPFIYTLRNQQVKQPFKDMVKKLLNL (SEQ ID NO: 491)

167

ATGAAAAATAAAACCGTGTTAACTGAGTTTATCCTTCTGGGTCTAACAGATGTCCCTGAAC
TCCAGGTGGCAGTTTTCACCTTTCTTTTCCTTGCGTATTTACTCAGCATCCTTGGAAATCTG
ACTATCCTCATCCTCACCTTGCTGGACTCCCACCTTCAGACTCCCATGTATTTCTTTCTCCG
GAACTTCTCCTTCTTGGAAATTTCCTTCACAAACATCTTCATTCCAAGGGTCCTGATTAGCA
TCACAACAGGGAACAAGAGTATCAGCTTTGCTGGCTGCTTCACTCAGTATTTCTTTGCCAT
GTTCCTTGGGGCTACAGAGTTTTACCTTCTGGCTGCCATGTCCTATGACCGCTATGTGGCC
ATCTGCAAACCTCTGCATTACACCACCATCATGAGCAGCAGAATCTGCATCCAGCTGATTT
TCTGCTCTTGGCTGGGTGGGCTAATGGCTATTATCCAACAATCACCCTGATGAGTCAGCA
GGACTTTGTGCATCCAACAGACTGAATCATTACTTCTGTGACTATGAGCCTCTTCTGGAA
CTCTCATGTTCAGACACAAGCCTCATAGAGAAGGTTGTCTTTCTTGTGGCATCTGTGACCC
TGGTGGTCACTCTGGTGCTAGTGATTCTCTCCTATGCATTCATTATCAAGACTATTCTGAAG
CTCCCCTCTGCCCAACAAAGGACAAAGCCTTTTCCACATGTTCTTCCCACATGATTGTCAT
CTCCCTCTCTTACGGAAGCTGCATGTTTATGTACATTAATCCCTCTGCAAAAGAAGGGGAT
ACATTCAACAAGGGAGTAGCTCTACTCATTACTTCAGTTGCTCCTTTGTTGAACCCCTTTAT
TTACACCCTAAGGAACCAACAGGTAAAACAACCCTTCAAGGATATGGTCAAAAAGCTTCT
GAATCTTTAA (SEQ ID NO: 492)

AOLFR130B sequences:

MEGKNQTAPSEFIILGFDHLNELQYLLFTIFFLTYICTLGGNVFIIVVTIADSHLHTPMYYFLGNL
ALIDICYTTTNVPQMMVHLLSEKKIISYGGCVTQLFAFIFFVGSECLLLAAMAYDRYIAICKPLR
YSFIMNKALCSWLAASCWTCGFLNSVLHTVLTFHLPFCGNNQINYFFCDIPPLLILSCGDTSLNE
LALLSIGILISWTPFLCIILSYLYIISTILRIRSSEGRHKAFSTCASHLLIVILYYGSAIFTYVRPISSYS
LEKDRLISVLYSVVTPMLNPVIYTLRNKDIKEAVKAIGRKWQPPVFSSDI (SEQ ID NO: 493)

ATGGAAGGAAAGAATCAAACAGCTCCATCTGAATTCATCATCTTGGGGTTCGACCACCTGA
ATGAATTGCAGTATTTACTCTTCACCATCTTCTTTCTGACCTACATATGCACTTTAGGAGGC
AATGTTTTTATCATTGTGGTGACCATAGCTGATTCCCACCTACACACACCCATGTATTATTT
CCTAGGAAATCTTGCCCTTATTGACATCTGCTACACTACTACTAATGTCCCCCAGATGATG
GTGCATCTTCTGTCAGAGAAGAAAATCATTTCCTATGGAGGCTGTGTGACCCAGCTCTTTG
CATTCATTTTCTTTGTTGGCTCAGAGTGTCTCCTCCTGGCAGCAATGGCATATGATCGATAT
ATTGCTATCTGTAAGCCGTTAAGGTACTCATTTATTATGAACAAGGCCCTGTGCAGCTGGT
TAGCAGCCTCATGCTGGACATGTGGGTTTCTCAACTCAGTGTTGCACACCGTTCTGACCTT
CCACCTGCCCTTCTGTGGTAACAATCAGATCAATTATTTCTTCTGTGACATACCTCCCTTGC
TCATCTTGTCTTGTGGTGATACTTCCCTCAATGAACTGGCTTTGCTGTCCATTGGGATCCTC
ATAAGCTGGACTCCTTTCCTGTGCATCATCCTTTCCTACCTTTACATCATCTCCACCATCCT
GAGGATCCGTTCCTCTGAGGGGAGGCACAAAGCCTTTTCCACCTGTGCCTCCCACCTGCTC
ATTGTTATTCTCTATTATGGCAGTGCTATCTTCACGTATGTGAGGCCCATCTCATCTTACTC
TCTAGAGAAAGATAGATTGATCTCAGTGCTGTATAGTGTTGTCACACCCATGCTGAATCCT
GTAAATTTATACGCTAAGGAATAAGGACATCAAAGAGGCTGTGAAGGCCATAGGGAGAAAG
TGGCAGCCACCAGTTTTCTCTTCTGATATATAA (SEQ ID NO: 494)

AOLFR142B sequences:

MARKDMAHINCTQATEFILVGLTDHQELKMPLFVLFLSIYLFTVVGNLGLILLIRADTSLNTPM
YFFLSNLAFVDFCYSSVITPKMLGNFLYKQNVISFDACATQLGCFLTFMISESLLLASMAYDRY
VAICNPLLYMVVMTPGICIQLVAVPYSYSFLMALFHTILTFRLSYCHSNIVNHFYCDDMPLLRL
TCSDTRFKQLWIFACAGIMFISSLLIVFVSYMFIISAILRMHSAEGRQKAFSTCGSHMLAVTIFYG
TLIFMYLQPSSSHALDTDKMASVFYTVIIPMLNPLIYSLQNKEVKEALKKIIINKN (SEQ ID NO:
495)

ATGGCCAGAAAAGATATGGCTCACATCAATTGCACCCAGGCGACAGAGTTTATTCTTGTGG
GCCTCACAGACCATCAGGAGTTGAAGATGCCCCTCTTTGTGCTATTCTTATCCATCTACCTC
TTCACAGTGGTAGGCAACTTGGGTTTGATCCTACTCATTAGAGCGGATACAAGTCTCAACA
CACCAATGTACTTCTTTCTTAGCAACCTAGCTTTTGTGGATTTCTGTTACTCTTCTGTCATT
ACACCCAAAATGCTTGGGAATTTCTTGTACAAACAAAATGTTATATCCTTTGATGCATGTG
CTACTCAACTGGGCTGCTTTCTCACCTTCATGATATCAGAATCCTTGCTACTGGCTTCCATG

GCCTATGACCGATATGTGGCCATTTGTAACCCTCTATTGTATATGGTTGTAATGACTCCAG
GAATCTGCATTCAACTTGTAGCAGTTCCTTATAGCTATAGCTTCCTAATGGCACTATTTCAC
ACCATCCTCACCTTCCGCCTCTCCTATTGCCACTCCAACATTGTCAACCATTTCTATTGTGA
TGACATGCCTCTCCTCAGGCTAACTTGCTCAGACACTCGCTTCAAACAGCTCTGGATCTTT
5   GCCTGTGCTGGTATCATGTTCATTTCCTCCCTTCTGATTGTCTTTGTCTCCTACATGTTCATC
ATTTCTGCCATCCTGAGGATGCATTCAGCTGAGGGAAGACAGAAGGCTTTCTCGACGTGTG
GCTCTCACATGCTGGCAGTCACCATATTCTATGGGACCCTCATTTTTATGTACTTACAGCCT
AGCTCTAGCCATGCCCTGGACACAGACAAGATGGCCTCTGTCTTCTACACAGTGATCATTC
CCATGTTGAATCCCTTAATCTATAGCCTCCAGAATAAGGAGGTGAAAGAAGCTCTGAAGA
10   AAATCATTATCAATAAAAACTAG (SEQ ID NO: 496)

AOLFR171C sequences:

MAEVNIIYVTVFILKGITNRPELQAPCFGVFLVIYLVTVLGNLGLITLIKIDTRLHTPMYYFLSHL
AFVDLCYSSAITPKMMVNFVVERNTIPFHACATQLGCFLTFMITECFLLASMAYDCYVAICSPL
15   HYSTLMSRRVCIQLVAVPYIYSFLVALFHTVITFRLTYCGPNLINHFYCDDLPFLALSCSDTHMK
EILIFAFAGFDMISSSSIVLTSYIFIIAAILRIRSTQGQHKAISTCGSHMVTVTIFYGTLIFMYLQPKS
NHSLDTDKMASVFYTVVIPMLNPLIYSLRNKEVKDASKKALDKGCENLQILTFLKIRKLY (SEQ
ID NO: 497)

20   ATGGCTGAAGTTAATATCATTTATGTCACTGTATTCATTCTGAAAGGAATTACCAACCGGC
CAGAGCTTCAGGCCCCGTGCTTTGGGGTGTTTTTAGTTATCTATCTGGTCACAGTGCTGGG
CAATCTTGGGTTGATTACTTTAATCAAGATTGATACTCGACTCCACACACCTATGTACTATT
TCCTCAGCCACCTGGCCTTTGTTGACCTTTGTTACTCCTCTGCTATTACACCGAAGATGATG
GTGAATTTTGTTGTGGAACGCAACACCATTCCTTTCCATGCTTGTGCAACCCAACTGGGTT
25   GTTTTCTCACCTTCATGATCACTGAGTGTTTCCTTCTAGCCTCCATGGCCTACGATTGCTAT
GTCGCCATCTGTAGTCCCCTGCATTATTCAACACTGATGTCAAGAAGAGTCTGCATTCAAC
TGGTGGCAGTTCCATATATATACAGCTTCCTGGTTGCCCTCTTCCACACCGTTATCACTTTC
CGTCTGACTTACTGTGGCCCAAACTTAATTAACCATTTCTATTGTGATGACCTCCCCTTCTT
AGCTCTGTCCTGCTCAGACACACACATGAAGGAAATTCTGATATTTGCCTTTGCTGGCTTT
30   GATATGATCTCTTCCTCTTCCATTGTCCTCACCTCCTACATCTTTATTATTGCCGCTATCCTA
AGGATCCGCTCTACTCAGGGGCAACACAAAGCCATTTCCACCTGTGGCTCCCATATGGTGA
CTGTCACTATTTTCTATGGCACACTGATCTTTATGTACCTACAGCCCAAATCAAATCACTCC
TTGGACACAGACAAGATGGCTTCTGTATTTTACACAGTGGTGATCCCCATGTTAAACCCCC
TAATCTATAGTCTAAGGAACAAAGAAGTGAAAGATGCCTCAAAGAAAGCCTTGGATAAAG
35   GTTGTGAAAACTTACAGATATTAACATTTTTAAAAATAAGAAAACTTTATTAA (SEQ ID NO:
498)

AOLFR225B sequences:

MKNRTMFGEFILLGLTNQPELQVMIFIFLFLTYMLSILGNLTIITLTLLDPHLQTPMYFFLRNFSF
LEISFTSIFIPRFLTSMTTGNKVISFAGCLTQYFFAIFLGATEFYLLASMSYDRYVAICKPLHYLTI
40   MSSRVCIQLVFCSWLGGFLAILPPIILMTQVDFCVSNILNHYYCDYGPLVELACSDTSLLELMVI
LLAVVTLMVTLVLVTLSYTYIIRTILRIPSAQQRTKAFSTCSSHMIVISLSYGSCMFMYINPSAKE
GGAFNKGIAVLITSVTPLLNPFIYTLRNQQVKQAFKDSVKKIVKL (SEQ ID NO: 499)

45   ATGAAAAACAGAACCATGTTTGGTGAGTTTATTCTACTGGGCCTTACAAATCAACCTGAAC
TCCAAGTGATGATATTCATCTTTCTGTTCCTCACCTACATGCTAAGTATCCTAGGAAATCTG
ACTATTATCACCCTCACCTTACTAGACCCCCACCTCCAGACCCCCATGTATTTCTTCCTCCG
GAATTTCTCCTTCTTAGAAATTTCCTTCACATCCATTTTTATTCCCAGATTTCTGACCAGCA
TGACAACAGGAAATAAAGTTATCAGCTTTGCTGGCTGCTTGACTCAGTATTTTTTTGCTAT
50   ATTTCTTGGAGCTACCGAGTTTTACCTCCTGGCCTCCATGTCTTATGATCGTTATGTGGCCA
TCTGCAAACCCTTGCATTACCTGACTATTATGAGCAGCAGAGTCTGCATACAACTAGTGTT
CTGCTCCTGGTTGGGGGGATTCCTAGCAATCTTACCACCAATCATCCTGATGACCCAGGTA
GATTTCTGTGTCTCCAACATTCTGAATCACTATTACTGTGACTATGGGCCTCTCGTGGAGCT
TGCCTGCTCAGACACAAGCCTCTTAGAACTGATGGTCATCCTCTTGGCCGTTGTGACTCTC
55   ATGGTTACTCTGGTGCTGGTGACACTTTCTTACACATACATTATCAGGACTATTCTGAGGA
TCCCTTCTGCCCAGCAAAGGACAAAGGCCTTTTCCACTTGTTCCTCCCACATGATTGTCATC

TCCCTCTCTTATGGCAGCTGCATGTTTATGTACATTAATCCTTCTGCAAAAGAAGGAGGTG
CTTTCAACAAAGGAATAGCTGTACTCATTACTTCGGTTACTCCCTTACTGAATCCCTTCATA
TATACTTTAAGAAATCAGCAAGTGAAACAAGCTTTCAAGGACTCAGTCAAAAGATTGTG
AAACTTTAA (SEQ ID NO: 500)

5

AOLFR274B sequences:

MEFVFLAYPSCPELHILSFLGVSLVYGLIITGNILIVVSIHTETCLCTSMYYFLGSLSGIEICYTAV
VVPHILANTLQSEKTITLLGCATQMAFFIALGSADCFLLAAMAYDRYVAICHPLQYPLLMTLTL
CVHLVVASVISGLFLSLQLVAFIFSLPFCQAQGIEHFFCDVPPVMHVVCAQSHIHEQSVLVAAIL
10   AIAVPFFLITTSYTFIVAALLKIHSAAGRHRAFSTCSSHLTVVLLQYGCCAFMYLCPSSSYNPKQ
DRFISLVYTLGTPLLNPLIYALRNSEMKGAVGRVLTRNCLSQNS (SEQ ID NO: 501)

ATGGAATTTGTGTTCCTGGCCTATCCCTCCTGCCCAGAACTGCATATTCTGTCCTTCCTTGG
GGTCAGCCTGGTTTATGGTTTGATCATCACTGGGAACATTCTCATTGTGGTGTCCATTCAC
15   ACAGAAACCTGTCTATGCACATCCATGTACTATTTCCTGGGCAGCCTTTCTGGGATTGAAA
TATGCTACACTGCAGTGGTGGTGCCCCATATCCTGGCCAACACCCTACAGTCAGAGAAGAC
CATCACTCTCCTGGGCTGTGCCACCCAGATGGCTTTCTTCATTGCACTGGGCAGTGCTGAT
TGCTTCCTCTTGGCTGCCATGGCCTATGACCGCTATGTGGCCATTTGCCACCCGTTGCAGTA
CCCTCTCCTCATGACATTGACTCTTTGTGTCCACTTGGTTGTGGCATCAGTCATCAGTGGTC
20   TGTTCCTGTCCTTACAACTGGTGGCCTTCATCTTCTCTCTGCCATTCTGCCAGGCTCAGGGC
ATTGAGCACTTCTTTTGTGATGTGCCACCAGTCATGCATGTTGTTTGTGCTCAGAGTCACAT
TCATGAGCAGTCAGTGCTGGTGGCAGCCATACTAGCCATTGCTGTGCCTTTCTTCCTCATC
ACCACCTCCTACACCTTCATAGTGGCTGCTCTGCTCAAGATCCACTCGGCTGCTGGCCGCC
ACCGGGCCTTCTCCACCTGCTCTTCCCACCTCACTGTGGTGCTGCTGCAGTATGGCTGCTGT
25   GCCTTCATGTACCTGTGCCCCAGCTCCAGCTACAACCCCAAGCAAGATCGGTTCATCTCAC
TGGTGTACACATTGGGAACCCCACTGCTCAACCCACTTATCTATGCCCTGAGGAACAGTGA
GATGAAAGGGGCCGTAGGGAGAGTTCTTACCAGGAACTGCCTTTCCCAGAACAGCTAG
(SEQ ID NO: 502)

30   **AOLFR276B sequences:**

MGGFGTNISSTTSFTLTGFPEMKGLEHWLAALLLLLYAISFLGNILILFIIKEEQSLHQPMYYFLS
LFSVNDLGVSFSTLPTVLAAVCFHAPETTFDACLAQMFFIHFSSWTEFGILLAMSFDHYVAICNP
LRYATVLTDVRVAHNGISIVIRSFCMVFPLPFLLKRLPFCKASVVLAHSYCLHADLIRLPWGDT
TINSMYGLFIVISAFGVDSLLILLSYVLILHSVLAIASRGERLKTLNTCVSHIYAVLIFYVPMVSVS
35   MVHRFGRHAPEYVHKFMSLCTSNALPNYLFHQD (SEQ ID NO: 503)

ATGGGGGGCTTTGGGACTAACATCTCAAGTACTACCAGCTTCACTCTAACAGGCTTCCCTG
AGATGAAGGGTCTGGAGCACTGGCTGGCTGCCCTTCTGCTGCTGCTTTATGCTATTTCCTT
CCTGGGCAACATCCTCATCCTCTTTATCATAAAGGAAGAGCAGAGCTTGCACCAGCCAATG
40   TACTACTTCCTGTCTCTTTTTTCTGTTAATGACCTGGGTGTGTCCTTTTCTACATTGCCCACT
GTACTGGCTGCTGTGTGTTTTCATGCCCCAGAGACAACTTTTGATGCCTGCCTGGCCCAGA
TGTTCTTCATCCACTTTTCCTCCTGGACAGAGTTTGGCATCCTACTGGCCATGAGTTTTGAC
CACTATGTGGCCATCTGTAACCCGCTGCGCTATGCCACAGTGCTCACTGATGTCCGTGTGG
CCCACAATGGCATATCCATTGTCATCCGCAGCTTCTGCATGGTATTCCCACTTCCCTTCCTC
45   CTGAAGAGACTGCCTTTCTGTAAGGCCAGTGTGGTACTGGCCCATTCCTACTGTCTGCATG
CAGACCTGATTCGGCTGCCCTGGGGAGACACTACCATCAACAGCATGTATGGCCTGTTCAT
TGTCATCTCTGCCTTTGGTGTAGATTCACTGCTCATCCTCCTCTCCTATGTGCTCATTCTAC
ATTCTGTGCTGGCCATTGCCTCCAGGGGTGAGAGGCTTAAGACACTCAACACATGTGTGTC
ACATATCTATGCAGTGCTGATCTTCTATGTGCCTATGGTTAGTGTGTCCATGGTTCATCGAT
50   TTGGGAGGCATGCTCCTGAATATGTGCACAAGTTCATGTCTCTTTGTACCTCCAATGCTCT
ACCCAATTATCTATTCCATCAAGACTAA (SEQ ID NO: 504)

AOLFR311B sequences:

MDWENCSSLTDFFLLGITNNPEMKVTLFAVFLAVYIINFSANLGMIVLIRMDYQLHTPMYFFLS
55   HLSFCDLCYSTATGPKMLVDLLAKNKSIPFYGCALQFLVFCIFADSECLLLSVMAFDRYKAIINP
LLYTVNMSSRVCYLLLTGVYLVGIADALIHMTLAFRLCFCGSNEINHFFCDIPPLLLLSRSDTQV

170

NELVLFTVFGFIELSTISGVFISYCYIILSVLEIHSAEGRFKALSTCTSHLSAVAIFQGTLLFMYFRP
SSSYSLDQDKMTSLFYTLVVPMLNPLIYSLRNKDVKEALKKLKNKILF (SEQ ID NO: 505)

ATGGACTGGGAAAATTGCTCCTCATTAACTGATTTTTTTCTCTTGGGAATTACCAATAACCC
AGAGATGAAAGTGACCCTATTTGCTGTATTCTTGGCTGTTTATATCATTAATTTCTCAGCAA
ATCTTGGAATGATAGTTTTAATCAGAATGGATTACCAACTTCACACACCAATGTATTTCTT
CCTCAGTCATCTGTCTTTCTGTGATCTCTGCTATTCTACTGCAACTGGGCCCAAGATGCTGG
TAGATCTACTTGCCAAGAACAAGTCAATACCCTTCTATGGCTGTGCTCTGCAATTCTTGGT
CTTCTGTATCTTTGCAGATTCTGAGTGTCTACTGCTGTCAGTGATGGCCTTTGATCGGTACA
AGGCCATCATCAACCCCCTGCTCTATACAGTCAACATGTCTAGCAGAGTGTGCTATCTACT
CTTGACTGGGGTTTATCTGGTGGGAATAGCAGATGCTTTGATACATATGACACTGGCCTTC
CGCCTATGCTTCTGTGGGTCTAATGAGATTAATCATTTCTTCTGTGATATCCCTCCTCTCTT
ATTACTCTCTCGCTCAGATACACAGGTCAATGAGTTAGTGTTATTCACCGTCTTTGGTTTTA
TTGAACTGAGTACCATTTCAGGAGTTTTCATTTCTTATTGTTATATCATCCTATCAGTCTTG
GAGATACACTCTGCTGAGGGGAGGTTCAAAGCTCTCTCTACATGCACTTCCCACTTATCTG
CGGTTGCAATTTTCCAGGGAACTCTGCTCTTTATGTATTTCCGGCCAAGTTCTTCCTATTCT
CTAGATCAAGATAAAATGACCTCATTGTTTTACACCCTTGTGGTTCCCATGTTGAACCCCCT
GATTTATAGCCTGAGGAACAAGGATGTGAAAGAGGCCCTGAAAAAACTGAAAAATAAAT
TTTATTTTAA (SEQ ID NO: 506)

AOLFR314 sequences:

MEVKNCCMVTEFILLGIPHTEGLEMTLFVLFLPFYACTLLGNVSILVAVMSSARLHTPMYFFLG
NLSVFDMGFSSVTCPKMLLYLMGLSRLISYKDCVCQLFFFHFLGSIECFLFTVMAYDRFTAICY
PLRYTVIMNPRICVALAVGTWLLGCIHSSILTSLTFTLPYCGPNEVDHFFCDIPALLPLACADTSL
AQRVSFTNVGLISLVCFLLILLSYTRITISILSIRTTEGRRRAFSTCSAHLIAILCAYGPIITVYLQPT
PNPMLGTVVQILMNLVGPMLNPLIYTLRNKEVKTALKTILHRTGHVPES (SEQ ID NO: 507)

ATGGAGGTGAAGAACTGCTGCATGGTGACAGAGTTCATCCTTTTGGGAATCCCACACACA
GAGGGGCTGGAGATGACACTTTTTGTCTTATTCTTGCCCTTCTATGCCTGCACTCTACTGGG
AAATGTGTCTATCCTTGTTGCTGTTATGTCTTCTGCTCGCCTTCACACACCTATGTATTTCT
TCCTGGGAAACTTGTCTGTGTTTGACATGGGTTTCTCCTCAGTGACTTGTCCCAAAATGCT
GCTCTACCTTATGGGGCTGAGCCGACTCATCTCCTACAAAGACTGTGTCTGCCAGCTTTTCT
TCTTCCATTTCCTCGGGAGCATTGAGTGCTTCTTGTTTACGGTGATGGCCTATGACCGCTTC
ACTGCCATCTGTTATCCTCTGCGATACACAGTCATCATGAACCCAAGGATCTGTGTGGCCC
TGGCTGTGGGCACATGGCTGTTAGGGTGCATTCATTCCAGTATCTTGACCTCCCTCACCTTC
ACCTTGCCATACTGTGGTCCCAATGAAGTGGATCACTTCTTCTGTGACATTCCAGCACTGTT
GCCCTTGGCCTGTGCTGACACATCCTTAGCCCAGAGGGTGAGCTTCACCAACGTTGGCCTC
ATATCTCTTGTCTGCTTTCTGCTAATTCTTTTATCCTACACTAGAATCACAATATCTATCTT
AAGCATTCGTACAACTGAGGGCCGTCGCCGTGCCTTCTCCACCTGCAGTGCTCACCTCATT
GCCATCCTCTGTGCCTATGGGCCCATCATCACTGTCTACCTGCAGCCCACACCCAACCCCA
TGCTGGGAACCGTGGTACAAATTCTCATGAATCTGGTAGGACCAATGCTGAACCCTTTGAT
CTATACCTTGAGGAATAAGGAAGTAAAAACAGCCCTGAAAACAATATTGCACAGGACAGG
CCATGTTCCTGAGAGTTAG (SEQ ID NO: 508)

AOLFR324B sequences:

MPIANDTQFHTSSFLLLGIPGLEDVHIWIGFPFFSVYLIALLGNAAIFFVIQTEQSLHEPMYYCLA
MLDSIDLSLSTATIPKMLGIFWFNIKEISFGGYLSQMFFIHFFTVMESIVLVAMAFDRYIAICKPL
WYTMILTSKIISLIAGIAVLRSLYMVIPLVFLLLRLPFCGHRIIPHTYCEHMGIARLACASIKVNIM
FGLGSISLLLLDVLLIILSHIRILYAVFCLPSWEARLKALNTCGSHIGVILAFSTPAFFSFFTHCFGH
DIPQYIHIFLANLYVVVPPTLNPVIYGVRTKHIRETVLRIFFKTDH (SEQ ID NO: 509)

ATGCCTATAGCTAACGACACCCAGTTCCATACTTCTTCATTCCTACTGCTGGGTATCCCAGG
GCTAGAAGATGTGCACATCTGGATTGGATTCCCTTTTTTCTCTGTGTATCTTATTGCACTCC
TGGGAAATGCTGCTATCTTCTTTGTGATCCAAACTGAGCAGAGTCTCCATGAGCCCATGTA
CTACTGCCTGGCCATGTTGGATTCCATTGACCTGAGCTTGTCTACGGCCACCATTCCCAAA
ATGCTGGGCATCTTCTGGTTCAATATCAAGGAAATATCTTTTGGAGGCTACCTTTCTCAGA

TGTTCTTCATCCATTTCTTCACTGTCATGGAGAGCATCGTATTGGTGGCCATGGCCTTTGAC
CGCTACATTGCCATTTGCAAACCTCTTTGGTACACCATGATCCTCACCAGCAAAATCATCA
GCCTCATTGCAGGCATTGCTGTCCTGAGGAGCTTGTACATGGTCATTCCACTGGTGTTTCT
CCTCTTAAGGTTGCCCTTCTGTGGACATCGTATCATCCCTCATACTTACTGTGAGCACATGG
5   GCATTGCCCGTCTGGCCTGTGCCAGCATCAAAGTCAACATTATGTTTGGTCTTGGCAGTAT
TTCTCTCTTGTTATTGGATGTGCTCCTTATTATTCTCTCCCATATCAGGATCCTCTATGCTGT
CTTCTGCCTGCCCTCCTGGGAAGCTCGACTCAAAGCTCTCAACACCTGTGGCTCTCACATT
GGTGTTATCTTAGCCTTTTCTACACCAGCATTTTTCTCTTTCTTTACACACTGCTTTGGCCAT
GATATTCCCCAATATATCCACATTTTCTTGGCTAATCTATATGTGGTTGTTCCTCCCACCCT
10 CAATCCTGTAATCTATGGGGTCAGAACCAAACATATTAGGGAGACAGTGCTGAGGATTTTC
TTCAAGACAGATCACTAA (SEQ ID NO: 510)

AOLFR328 sequences:

MALGNHSTITEFLLLGLSADPNIRALLFVLFLGIYLLTIMENLMLLLVIRADSCLHKPMYFFLSH
15 LSFVDLCFSSVIVPKMLENLLSQRKTISVEGCLAQVFFVFVTAGTEACLLSGMAYDRHAAIRRP
LLYGQIMGKQLYMHLVWGSWGLGFLDALINVLLAVNMVFCEAKIIHHYSYEMPSLLPLSCSDI
SRSLIVLLCSTLLHGLGNFLLVFLSYTRIISTILSISSTSGRSKAFSTCSAHLTAVTLYYGSGLLRHL
MPNSGSPIELIFSVQYTVVTPMLNSLIYSLKNKEVKVALKRTLEKYLQYTRR (SEQ ID NO: 511)

20 ATGGCCTTGGGGAATCACAGCACCATCACCGAGTTCCTCCTCCTTGGGCTGTCTGCCGACC
CCAACATCCGGGCTCTGCTCTTTGTGCTGTTCCTGGGGATTTACCTCCTGACCATAATGGA
AAACCTGATGCTGCTGCTCGTGATCAGGGCTGATTCTTGTCTCCATAAGCCCATGTATTTCT
TCCTGAGTCACCTCTCTTTTGTTGATCTCTGCTTCTCTTCAGTCATTGTGCCCAAGATGCTG
GAGAACCTCCTGTCACAGAGGAAAACCATTTCAGTAGAGGGCTGCCTGGCTCAGGTCTTCT
25 TTGTGTTTGTCACTGCAGGGACTGAAGCCTGCCTTCTCTCAGGGATGGCCTATGACCGCCA
TGCTGCCATCCGCCGCCCACTACTTTATGGACAGATCATGGGTAAACAGCTGTATATGCAC
CTTGTGTGGGGCTCATGGGGACTGGGCTTTCTGGACGCACTCATCAATGTCCTCCTAGCTG
TAAACATGGTCTTTTGTGAAGCCAAAATCATTCACCACTACAGCTATGAGATGCCATCCCT
CCTCCCTCTGTCCTGCTCTGATATCTCCAGAAGCCTCATCGTTTTGCTCTGCTCCACTCTCC
30 TACATGGGCTGGGAAACTTCCTTTTGGTCTTCTTATCCTACACCCGTATAATCTCTACCATC
CTAAGCATCAGCTCTACCTCGGGCAGAAGCAAGGCCTTCTCCACCTGCTCTGCCCACCTCA
CTGCAGTGACACTTTACTATGGCTCAGGTTTGCTCCGCCATCTCATGCCAAACTCAGGTTC
CCCCATAGAGTTGATCTTCTCTGTGCAGTATACTGTAGTCACTCCCATGCTGAATTCCCTCA
TCTATAGCCTGAAAAATAAGGAAGTGAAGGTAGCTCTGAAAAGAACTTTGGAAAAATATT
35 TGCAATATACCAGACGTTGA (SEQ ID NO: 512)

Claims:

1.   A method for representing sensory perception of one or more odorants
comprising:

5   (a)   providing a representative class of n olfactory receptors or ligand-
        binding domains thereof;

        (b)   measuring values X_1 to X_n representative of at least one activity of the
        one or more odorants selected from the group consisting of binding of the one
        or more odorants to the ligand-binding domain of at least one of the n

10   olfactory receptors, activating at least one of the n olfactory receptors with the
        one or more odorants, and blocking at least one of the n olfactory receptors
        with the one or more odorants; and

        (c)   generating a representation of sensory perception from the values X_1 to
        X_n;

15 wherein at least one of the n olfactory receptors has an amino acid sequence selected
    from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID
    NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID
    NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID
    NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID
20 NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID
    NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID
    NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID
    NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID
    NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID
25 NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID
    NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ
    ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115,
    SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID
    NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133,
30 SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID
    NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151,
    SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID
    NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169,

SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID
NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187,
SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID
NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205,

5   SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID
NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223,
SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID
NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241,
SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID

10   NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259,
SEQ ID NO: 261, SEQ ID NO:, 263, SEQ ID NO:, 265, SEQ ID NO: 267, SEQ ID
NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277,
SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID
NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295,

15   SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID
NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313,
SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID
NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331,
SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID

20   NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349,
SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID
NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367,
SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID
NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385,

25   SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID
NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403,
SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID
NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421,
SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID

30   NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439,
SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID
NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457,
SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID

NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475,

SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID

NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493,

SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID

5   NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO:

511.

2.   The method of Claim 1, wherein at least one of the olfactory receptors

specifically recognizes the odorant, and there are between 5 and 350 of the n olfactory

10   receptors selected from the listed amino acid sequences.

3.   The method of Claim 1, wherein at least two different activities are measured

to provide the values X_1 to X_n.

15   4.   The method of Claim 1, wherein each odorant receptor is expressed in cells,

and the cells expressing each odorant receptor are located at an identifiable position.

5.   The method of Claim 1, wherein at least one olfactory receptor is soluble, and

binding of odorant to a ligand-binding domain of the soluble olfactory receptor is

20   measured in solution.

6.   The method of Claim 1, wherein at least one olfactory receptor is in solid state,

and binding of odorant to a ligand-binding domain of the solid-state olfactory receptor

is measured on a substrate.

25

7.   The method of Claim 1, wherein the value measured for binding is above a

preset limit for specific binding to olfactory receptors.

8.   The method of Claim 1, wherein the value measured for activating an olfactory

30   receptor is derived from a signal selected from the group consisting of intracellular

Ca^{2+}, cAMP, cGMP and IP3.

9.   The method of Claim 1, wherein the value measured for activating an olfactory receptor is above a preset limit for specific activation.

10.   The method of Claim 1, wherein the value measured for blocking an olfactory receptor is at least a reduction in binding of the odorant or activation by the odorant.

11.   The method of Claim 1, wherein the representation of sensory perception is generated with a neural network.

12.   A biosensor comprised of the n ligand-binding domains or olfactory receptors of Claim 1.

13.   A method for producing a database of odorant representations comprising:

(a)   providing one or more known odorants and

(b)   generating a representation of the one or more known odorants in accordance with the method of Claim 1 to produce the database.

14.   A database produced by Claim 13.

15.   A method of identifying an unknown odorant comprising:

(a)   measuring values X_1 to X_n representative of at least one activity selected from the group consisting of binding the unknown odorant to a ligand-binding domain of at least one of n olfactory receptors, activating at least one of n olfactory receptors with the unknown odorant, and blocking at least one of n olfactory receptors with the unknown odorant;

(b)   generating a representation of the unknown odorant from the values X_1 to X_n; and

(c)   comparing the unknown odorant's representation to the database of Claim 14 to identify the known odorant which is most similar in representation.

16.   A method of producing an artificial odorant comprising:

(a)   measuring values X_1 to X_n representative of at least one activity selected from the group consisting of binding a desirable odorant to a ligand-binding domain of at least one of n olfactory receptors, activating at least one of n olfactory receptors with a desirable odorant, and blocking at least one of n

5   olfactory receptors with a desirable odorant;

(b)   generating a representation of the desirable odorant from the values X_1 to X_n;

(c)   decomposing the desirable odorant's representation into representations of known odorants from the database of Claim 14 or

10   superposing known odorants' representations from the database to reproduce the desirable odorant; and

(d)   formulating the known odorants to reproduce sensory perception of the desirable odorant and thereby produce the artificial odorant.

15   17.   An artificial odorant produced by Claim 16.

18.   A method of identifying a primary odorant related to sensory perception comprising:

(a)   providing a representative class of n olfactory receptors or ligand-

20   binding domains thereof;

(b)   measuring at least one activity of a odorant selected from the group consisting of binding of the candidate odorant to the ligand-binding domain of at least one of the n olfactory receptors and activating with the candidate odorant at least one of the n olfactory receptors, and

25   (c)   identifying the candidate odorant as a primary odorant if only one or less than 10% of the representative class of n olfactory receptors is bound or activated;

wherein at least one of the n olfactory receptors has an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID

30   NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID

NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID

NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID

NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID

NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID

5　　NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID

NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ

ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115,

SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID

NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133,

10　　SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID

NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151,

SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID

NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169,

SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID

15　　NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187,

SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID

NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205,

SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID

NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223,

20　　SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID

NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241,

SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID

NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259,

SEQ ID NO: 261, SEQ ID NO:, 263, SEQ ID NO:, 265, SEQ ID NO: 267, SEQ ID

25　　NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277,

SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID

NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295,

SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID

NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313,

30　　SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID

NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331,

SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID

NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349,

SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID
NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367,
SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID
NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385,

5   SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID
NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403,
SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID
NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421,
SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID

10   NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439,
SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID
NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457,
SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID
NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475,

15   SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID
NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493,
SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID
NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO:
511.

20

19.   A primary odorant identified by Claim 18.

20.   A method of identifying a compound which blocks activation by a odorant of
at least one olfactory receptor comprising:

25   (a)   producing a structurally-related candidate compound from a ligand of
the at least one olfactory receptor,

(b)   measuring activation by the odorant of the at least one olfactory
receptor with the candidate compound, and

(c)   identifying the candidate compound as a compound which blocks

30   activation if activation of the at least one olfactory receptor is reduced or
inhibited;

wherein at least one of the olfactory receptors has an amino acid sequence selected
from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID

179

NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID

NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID

NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID

NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID

5   NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID

NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID

NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID

NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID

NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID

10   NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ

ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115,

SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID

NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133,

SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID

15   NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151,

SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID

NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169,

SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID

NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187,

20   SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID

NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205,

SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID

NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223,

SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID

25   NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241,

SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID

NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259,

SEQ ID NO: 261, SEQ ID NO:, 263, SEQ ID NO:, 265, SEQ ID NO: 267, SEQ ID

NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277,

30   SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID

NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295,

SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID

NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313,

SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331, SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349, SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439, SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475, SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493, SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO: 511.

21.	The method of Claim 20, wherein the ligand is a primary odorant.

22.	A compound which blocks activation of an olfactory receptor identified by Claim 20.